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Abstract 
 
Modern targeted cancer therapeutics are directed against components of cell signalling 
pathways, responsible for driving tumour progression. In this thesis, chemical tools and 
inhibitors of two enzymes involved in cell signalling, namely sulfatase 2 (Sulf-2) and 
extracellular signal-regulated kinase 5 (ERK5), have been investigated. 
Sulfatase 2 is a heparan sulfate (HS) processing enzyme, which has been implicated in the 
progression of several cancers including hepatocellular carcinoma (HCC). In HCC 
patients, high Sulf-2 mRNA expression correlates with a poor prognosis. The first 
published small-molecule Sulf-2 inhibitors were monosaccharide glucosamine derivatives, 
bearing a sulfamate at the O
6
-position. The most potent analogue from this series, was 5, 
having a reported IC50 against Sulf-2 of 130 µM. Although 5 was not sufficiently potent 
for use in target validation studies, its discovery provided encouragement that viable Sulf-2 
inhibition was possible with low molecular weight compounds. 
 
 
In the absence of a published crystal structure and of a biological assay suitable for a high-
throughput screening campaign, the structure of the endogenous substrate was considered 
as a potential starting point for identification of probe compounds, for use in target 
validation studies. Biphenyl A and biphenyl ether B sulfamates were designed in an 
attempt to identify a non-saccharide scaffold, which could mimic the spatial arrangements 
of groups believed to be important for binding of the endogenous substrate to Sulf-2. 
Access to these targets was facilitated by the development of a sulfamate protecting group 
strategy, which enabled a more flexible approach to the synthesis of phenolic 
O-sulfamates. 
 
v 
Preliminary sulfatase inhibition data have been generated, indicating that biphenyl 162 and 
biphenyl ether sulfamates 197 exhibited better potency against Sulf-2 than monosaccharide 
glucosamine 5 in our assay format. 
 
 
Extracellular signal-regulated kinase 5 (ERK5) is a member of the protein kinase 
superfamily, which plays an essential role in the transduction of extracellular signals to 
intracellular effectors. Activation of the ERK5 signalling pathway is associated with cell 
survival, proliferation, and differentiation, and ERK5 over-expression has been implicated 
in tumour development. An ERK5 inhibitor, XMD8-92 218, which was reported in the 
literature, displayed selectivity for ERK5 when tested against a panel of 402 kinases in an 
ATP-site competition binding assay (ERK5 IC50 = 300 nM) and showed reasonable activity 
in HeLa cells (GI50 = 1.5 μM). This compound also inhibited the growth of two human 
tumour xenograft models (HeLa cells and Lewis lung cells), highlighting that ERK5 is a 
valid target for anti-cancer therapy. 
 
 
A pyrrole carboxamide series of ERK5 inhibitors was optimised from lead compounds 
such as 318, which had good absorption in the Caco-2 assay but suffered from low 
solubility and medium clearance in mouse liver microsomes in vitro, and translated to poor 
oral bioavailability in vivo. The objective of the optimisation studies was to improve ERK5 
inhibitory activity, both in the biochemical and cellular assays, and improve 
pharmacokinetic parameters to deliver compounds suitable for in vivo efficacy studies. 
Three areas were identified for investigation i.e. alkylation of the amide nitrogen; 
replacement of the meta-chloro on the aroyl ring; and substitution on the heteroaromatic 
amide ring at the ortho and para positions. 
vi 
 
 
Docking of compounds into a recently published co-crystal structure of an analogue of 
XMD8-92 bound to ERK5 has provided information on the possible binding mode of the 
pyrrole carboxamide series and was used to guide the design of inhibitors (Figure 1). 
Extension of the carboxamide heteroaromatic amine at the para position, with aliphatic 
and cyclic aliphatic side-chains bearing a basic centre, resulted in significantly improved 
ERK5 inhibitory activity (IC50 < 30 nM) as exemplified by 406, which achieved a 3-fold 
improvement in cellular inhibitory activity, and combined excellent microsomal stability 
with high solubility. However all the compounds with a basic centre suffered from a high 
efflux ratio and low membrane permeability in the Caco-2 assay, and as a result, had poor 
in vivo oral bioavailability in mouse PK studies. The work presented in this thesis has 
extended the SARs around the pyrrole carboxamide core but did not allow to deliver a new 
in vivo tool. 
 
 
Figure 1: Possible binding pose of 318 modelled in the active site of ERK5 (PDB code 
4b99) 
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Chapter 1. Introduction to Cancer and Modern Drug Discovery 
 
1.1. The Genetic Origin of Cancer 
Cancer is a genetic disease at the cellular level that results from alterations in DNA, and is 
responsible of one in eight deaths worldwide.
1, 2
 Each cancer is the consequence of a 
process of a Darwinian selective evolution at a cellular level: the continuous acquisition of 
genetic mutations in a cell confers the capability to proliferate and survive more efficiently 
than its neighbours.
2
 Normal cells evolve progressively into cancer cells and acquire, in a 
multistep process, characteristics that guide their tumorigenic and malignant phenotype.
3
 In 
2000, following an analysis of different cancer types, Hanahan and Weinberg defined six 
hallmarks of cancers that normal cells acquire from accumulated genetic damage as they 
become cancerous (Figure 1.1).
4
 In a recent update, two further emerging hallmarks were 
suggested: the avoidance of immune destruction and the reprogramming of energy 
metabolism.
3
 
 
 
Figure 1.1: The six hallmark of cancers
4
 
 
It is estimated that each cell of a human organism typically undergoes more than twenty 
thousands DNA damaging events and more than ten thousands replication errors per day.
5
 
Under normal circumstances, DNA repair mechanisms act on the mutated cells before the 
beginning of cellular replication. However, damaged DNA that escapes repair processes 
can lead to incorporation of altered genetic material, which is passed on to subsequent 
generations of cells. Genetic defects may be further accumulated with age following 
prolonged exposure to mutagens such as ultra-violet radiation or tobacco smoke.
1
 
2 
Endogenous DNA damage is mainly caused by reactive oxygen species and related 
reactive molecules.
5
 The nature of DNA alteration of tumour cells has been shown to be 
diverse, ranging from subtle mutations such as a single DNA base pair change (transitions, 
transversions, insertions or deletions) to more significant mutations such as chromosomal 
translocation.
1
 Chromosome rearrangement and gene deletions are less common than 
single-base substitution but may have a more profound effect by inactivating multiple 
contiguous genes.
5
 
Examination of The Cancer Genome Atlas indicates that each tumour is unique and 
contains tens to hundreds of thousands of mutations, supporting the hypothesis of a 
mutator phenotype of cancer cells.
5
 Each mutation in a cancer cell genome can be 
classified according to its consequences for cancer development.
6
 Mutations conferring a 
growth advantage are classified as ‘drivers’ and located in a subset of genes known as 
‘cancer genes’. Mutations that confer little phenotypic advantage are named ‘passengers’.6 
Most somatic mutations in cancer genomes are passengers.
2
 The number of driver 
mutations required for a cell to display a cancer phenotype varies. Tumours are complex 
tissues, composed of largely heterogeneous cells, suggesting that they may derive from 
different mutations in the cancer genome. 
Specific and recurrent genomic abnormalities are associated with particular cancer types.
2
 
The presence of abnormal cancer genes now dictates the classification and treatment 
protocols for some cancers.
2
 
 
1.2. Targeted Therapies 
Most cancers are treated with a combination of surgery, radiation therapy and/or 
chemotherapy. While surgery and radiation are used to treat cancer locally, chemotherapy 
also treats distant sites in the body.
7
 Until the end of the twentieth century, chemotherapy 
consisted mainly of cytotoxic drugs that kill rapidly dividing cells, both carcinogenic and 
healthy, resulting in significant non-tumour toxicity.
7, 8
 In order to achieve their effect, 
these drugs, which work by interfering with essential cellular events such as DNA 
replication, require high doses, resulting in narrow therapeutic windows where efficacy is 
maximised and adverse toxicity minimised.
9, 10
 
In the 1960s, a research program studying genes identified oncogenes, suppressor 
oncogenes, and signalling pathways essential for cancer development, marking the 
3 
transition to the age of ‘targeted therapy’.11 This work also contributed to the development 
of new technologies which facilitated the sequencing of the human genome.
12
 Analogous 
to antimicrobial drug discovery, identification and modulation of targets uniquely present 
in cancer cells should reduce adverse effects in healthy tissues and produce anticancer 
agents with enhanced therapeutic index.
13
 Targeted therapeutic agents, composed of small-
molecule drugs and monoclonal antibodies, alter the function of cancer-specific proteins, 
that play a critical role in tumour growth, progression and survival.
10, 14
 In cells where the 
target is a ‘driver’, these therapies have similar efficacy to classical chemotherapy and 
radiotherapy, but are less harmful to normal cells, inducing fewer undesired side-effects.
15
 
Although cancer cells typically contain multiple mutations, some develop dependence on a 
single mutation for growth and survival, rendering them susceptible to targeted 
inhibition.
16
 
 
 
Figure 1.2: Representation of some complex signalling networks
17
 
 
The genomic era and progress in molecular biology have led to an improved understanding 
of cancer cell biology, and discovery of entirely new signalling networks responsible for 
the regulation of cellular processes such as cell proliferation and survival.
18
 More than two 
hundred cell signalling pathways have been identified (Figure 1.2).
17
 These cascades 
transduce extracellular signals through the cell membrane and cytosol and cause an 
intracellular response.
19
 Dysregulation of signalling pathways, leading to uncontrolled cell 
growth, proliferation and survival, is a common feature in tumours and modulation of these 
4 
cascades with small-molecules has expanded the scope for possible targeted therapies.
10
 
Specific components of these signalling networks, such as growth factors and their 
receptors or cell cycle modulators, have been recognised as promising biological targets. 
Dependence of a cancer to the targeted signalling pathway is decisive to the success of a 
treatment.
20
 Selection of the pathway component to target with a small-molecule inhibitor 
is a complex decision. Targeting a protein early in a pathway, such as an extracellular 
receptor, may lead to enhanced efficacy by affecting multiple downstream outcomes, but 
may also cause unwanted side-effects.
21
 Although safer, inhibition of a downstream protein 
may have limited efficacy with cell developing alternative mechanisms to bypass the 
inhibition.
21
 
 
 
 
The first targeted chemotherapeutic agent to reach the market was imatinib 1 (Glivec
®
), an 
inhibitor of the Bcr-Abl fusion protein kinase, used for the treatment of chronic myeloid 
leukaemia (CML).
13
 Imatinib was designed to block sustained proliferative signalling in 
CML caused by a gene translocation, also known as the Philadelphia chromosome.
22
 This 
genetic defect produces the Bcr-Abl fusion protein, which is only present in tumour cells 
and provides an opportunity for selective inhibition. Imatinib induces complete 
hematologic and cytogenetic remissions in most CML patients.
20
 The clinical success of 
imatinib has established a paradigm for cancer targeted therapies. In 2014, over 30 targeted 
agents have been approved for clinical use in the treatment of a broad range of human 
cancers.
15
 
 
1.3. Resistance to Targeted Therapies 
The emergence of drug resistance prevents molecular targeted therapies from eliciting 
lasting clinical benefit.
16, 23
 Resistance to chemotherapy can be caused by primary 
unresponsiveness of a small number of cells prior to drug treatment, which is called 
intrinsic resistance, or can be acquired over time by the tumour in response to the treatment 
(acquired resistance).
14, 24
 Existing unresponsiveness generally results from the presence of 
pre-existing redundant signalling pathways. These resistant clones, originally present in a 
small proportion, become predominant over time under the selective pressure of 
5 
chemotherapy.
15
 There are many mechanisms whereby tumours may acquire resistance to 
targeted therapies. Alterations in the driving pathway have been observed in several 
patients and include constitutive activation of downstream effectors.
25
 Bypass mechanisms 
such as activation and up-regulation of parallel signalling pathways or gain of stem cell-
like functions can also drive acquired resistance (Figure 1.3).
7
 
The development of additional mutations is another resistance mechanism, common for 
kinase targeted therapies (Figure 1.3).
23
 This includes single-point mutation, gene deletion 
and amplification of genomic areas.
25
 Mutation of the gatekeeper residue in a kinase target 
may confer resistance, by abrogating drug binding while maintaining high catalytic 
activity.
7
 For instance, 40% of patients treated with imatinib have developed resistance 
through point mutations that change the conformation of the c-Abl kinase.
25
 The genomic 
pressure of selective inhibition can lead to amplification of the target gene and reduce the 
efficacy of drug treatment.
26
 Similarly, protein expression can be upregulated to overcome 
inhibition. 
 
 
Figure 1.3: Schematic representation of three mechanisms of resistance to targeted 
therapies. RTK: receptor tyrosine kinase. STK: serine/threonine kinase. Red star: 
mutation.
23
 
 
Overexpression of transporter efflux pumps, such as P-gp, MRP1 or BCRP, may prevent 
drugs from getting into cells, leading to low intracellular drug concentrations and resulting 
in chemoresistance.
16, 25
 Altered expression of active uptake transporters can have a similar 
effect. Drug sequestration away from the intended intracellular site of action via pH 
variation is another mechanism leading to reduced efficacy.
16
 Acquired resistance can also 
be mediated by pharmacokinetic and pharmacodynamics factors, such as enhanced 
6 
metabolism of the drug and high protein binding of the inhibitor.
24
 An increased 
understanding of the biological processes underlying intrinsic and acquired resistance is 
required to guide subsequent treatment selection.
24
  
The full potential from molecularly targeted cancer agents might arise from the use of 
intelligent drug combinations, which should allow the problems of intertumour genetic 
heterogeneity and drug resistance in cancers to be tackled.
7
 Recently, heterogeneity in the 
tumour microenvironment has also been associated with variable responses to targeted 
therapy, introducing a more complex level of intertumour heterogeneity.
15
 New 
technologies and methods are still required to evaluate and prioritise the best potential 
combinations.
7
 Drug combinations of cytotoxic agents, which work by different molecular 
mechanisms, have been defined and proved more effective than single agent therapy, by 
achieving additive or synergistic effects. The major limitation of this strategy is the high 
level of induced undesired side-effects.
7
 Combinations of molecularly targeted therapeutics 
with cytotoxic chemotherapy or radiation are already used in the clinic but without 
compelling biology rationale supporting them. For instance, paclitaxel (Taxol
®
) is used in 
combination with trastuzumab (Herceptin
®
), a monoclonal antibody, for the treatment of 
breast cancer.
7
 Different strategies for the combination of molecular targeted agents can be 
envisaged, including inhibition of parallel signalling pathways. Targeting a single 
signalling pathway at different levels using two agents is another combinatorial option.
7
 
Both approaches are expected to increase activity and overcome resistance. 
 
1.4. Personalised Medicine 
The clinical benefit achieved with targeted therapies varies greatly.
16, 27
 Indeed, such 
therapies are highly effective in patients where the targeted mutation drives tumour growth 
but their effect can be modest and transient when the carcinogenicity is driven by multiple 
mutations.
27
 The average response rate to targeted therapy across an unselected patient 
population is between 10 and 20%. This has emphasised the importance of identifying 
molecular signatures, also called predictive biomarkers for patient selection.
24
 Biomarkers 
are also used to define the best treatment regimen and identify patients with high risks for 
adverse effects.
28
 This approach of proactively selecting populations for specific treatments 
is called ‘personalised’ or ‘stratified’ medicine.29 Personalised medicine adds a step to 
traditional diagnosis, with a biomarker-assessment required to associate a patient with a 
specific therapy (Figure 1.4). Personalised medicine aims to eliminate the “one size fit all” 
7 
model of medicine.
30
 A different set of biomarkers, ‘response’ biomarkers enable the 
response to be monitored during the course of treatment and can be used to guide further 
decision-making.
15
 
 
 
Figure 1.4: Stratified medicine in the clinical context (adapted from ref 29) 
 
Molecular analyses at the protein, DNA, RNA or micro RNA levels have contributed to the 
identification of novel tumour subclasses, each with unique prognosis outcome or response 
to treatment.
30
 These classifications are expected to significantly improve patient 
management. Incorporation of new, advanced technologies, that will provide detailed 
prognosis for each individual, will have a significant cost. 
Predictive biomarkers, for defining potentially responsive patients, are also increasingly 
integrated into early clinical development of targeted therapies and guide clinical trial 
design. This has significantly accelerated drug development and approval.
15
 For instance, 
clinical studies with crizotinib (Xalkori
®
) lasted just 4 years before the drug was approved 
by the FDA. 
 
1.5. The Drug Discovery Process 
‘Omic’ technologies are used during the initiation of a drug discovery program to identify 
novel molecular targets, whose modulation is likely to be beneficial in a given disease.
31
 
Validation of the target follows and is an essential step in the drug discovery process to 
ensure low attrition rate.
32
 Complementary approaches, such as biochemical, genetic, in 
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Stratified medicine 
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vivo and bioinformatics studies are used to provide functional information on the target in 
the disease phenotype.
31, 33
 Modulating target expression at the protein and mRNA levels is 
frequently used in cellular validation studies to examine the effects on the phenotype of 
cells.
32
 In complement of these biological studies, identification of chemical probes for use 
in experiments in vitro is essential for rigorous preclinical target validation.
34
 These 
molecules support the interpretation of biological experiments and give an understanding 
of the function of proteins and their role in physiology and pathology.
35
 Molecular probes 
provide a proof of concept for the druggability of a target by small-molecule inhibitors.
35
 
Once evidence for the role of a target in a disease has been established in vitro, chemical 
tools are optimised for in vivo evaluation. Several recent reviews provide interesting 
discussions on the design of efficient tool compounds for in vivo studies (Figure 1.5).
34-37
 
 
 
Figure 1.5: Important criteria for quality chemical probes
34
 
 
A full drug discovery program is initiated when biological experiments have demonstrated 
that modulation of the target in the treatment of the disease is likely to be beneficial 
(Figure 1.6).
38
 Hit identification is the first stage of a project and followed by a hit-to-lead 
phase which may use chemical tools from the target validation studies or alternative 
chemical hits.
39
 High-throughput screening (HTS) of large libraries of chemically diverse 
templates is the most widely applicable technology for the identification of hits.
40, 41
 
However, it is now recognised that the high molecular weight and poor physicochemical 
9 
properties of compounds identified by HTS can render them unsuitable for further 
medicinal chemistry exploration.
42, 43
 Alternative strategies, such as fragment-based 
approaches, de novo design or virtual screening may be employed.
44-47
 
 
 
Figure 1.6: Phases in the pre-clinical drug discovery process (adapted from ref 43) 
 
In the hit-to-lead phase, the structure-activity relationships of initial hits are explored to 
identify functional groups required for activity, and those that may be varied to improve 
potency. In vitro surrogate assays are also used for evaluation of pharmacokinetics 
parameters (plasma protein binding, microsomal stability, permeability) and off-target 
pharmacology properties (hERG inhibition, CYP inhibition). The lead optimisation process 
involves combining all of the desired properties into a single agent suitable for progression into 
clinical trials. A candidate molecule must achieve good potency against the primary target and 
selectivity over relevant secondary targets. In addition, the selected compound must 
demonstrate in vivo pharmacokinetics, safety, and pharmaceutical properties suitable for 
entering clinical evaluation studies.43 
Despite increased investments in research and development activities, attrition rates for 
small-molecule drug candidates have remained high, leading to the perception that the 
pharmaceutical industry has low productivity.
38, 48, 49
 In recent years, high molecular 
weight and lipophilicity, also termed “molecular obesity”, have caused the failure of many 
drug candidates.
49
 Defining physicochemical properties that predict long-term viability of 
drug candidates has been of interest for the medicinal chemistry community and was 
achieved via retrospective analysis of the physicochemical properties of marketed drugs. 
The pioneering study of Christopher Lipinski, regarding the physicochemical properties 
required to achieve good solubility and absorption, established a set of guidelines known as 
the “rule of 5”.50 Additional examinations of compound collections have since been 
conducted, with the objective to provide deeper and broader perspectives on this landmark 
assessment.
51, 52
 These studies have raised the awareness of the importance of controlling 
physicochemical properties in the design of drug candidates and parametric guidelines 
have now been established to facilitate decision making.
48
 Several binding indexes, 
including ligand efficiency (L.E.) and lipophilic ligand efficiency (LLE or LipE), relating 
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properties of a compound to potency, have been introduced to guide medicinal chemists 
during lead optimisation.
53, 54
 
 
1.6. The Sulfatase-2 and ERK5 Projects 
The advent of targeted therapies has provided novel efficacious treatment but only for a 
limited number of cancer types. A continuing effort is still required for the identification of 
new cancer treatments. Modulation of components of cell signalling pathways is currently 
an area of focus for novel anti-cancer drug discovery therapies. 
The two projects described in this thesis concentrate on the development of small-
molecules that modulate oncogenic signalling cascades. However, the approaches taken are 
significantly different. Inhibition of sulfatase-2 (Sulf-2) occurs early in the signalling 
sequence and is likely to affect multiple signalling pathways via reduction in the 
availability of several growth factors. In contrast, inhibition of ERK5 affects a single non-
classical MAP kinase pathway at a late point in the signalling cascade. 
The two projects cover different stages of the drug discovery process. The Sulf-2 project is 
at the target validation stage and focuses on the design of chemical tools for in vitro and in 
vivo model experiments. The ERK5 project is in the lead optimisation stage and focus on 
the optimisation of ADMET properties and pharmacology. 
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Chapter 2. Sulfatase-2 and Reported Small-Molecule Inhibitors 
 
2.1. The Sulfatase Enzyme Family 
The sulfation state of many physiological molecules has been associated with the 
regulation of important processes, including embryogenesis, inflammation, blood 
coagulation and drug metabolism.
55
 Protein phosphorylation within cells is crucial for the 
regulation of most intracellular events. Sulfation of carbohydrates plays a similar role 
outside the cell and mediates a variety of extracellular communication events. 
Two classes of enzyme modulate the degree of sulfation of proteins, lipids and saccharides: 
the sulfotransferases and the sulfatases.
55
 Whereas sulfotransferases have been intensively 
studied and were thought for a long time to be the only regulators of the sulfation state of 
biomolecules, the sulfatases only became a subject of interest in the last 20 years when it 
was discovered that they were associated with lysosomal disorders.
56
 
The human sulfatase family is a large protein family which comprises seventeen members 
(Table 2.1).
57
 These proteins hydrolyse sulfate esters from diverse sulfated substrates, 
ranging from steroids to carbohydrates and lipids.
58
 Regardless of their substrate, the 
sulfatases have highly conserved amino acid sequences and are structurally and 
mechanistically closely related. A number of sulfatases were discovered for their ability to 
hydrolyse phenolic sulfate esters, and have therefore been named aryl sulfatase. The 
endogenous physiological substrates were identified retrospectively and are in some cases 
still unknown (Table 2.1).
59
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Table 2.1: Substrate and subcellular location of human sulfatases
57
 
Enzyme Abbreviation 
Subcellular 
location 
Endogenous substrate 
Aryl sulfatase A ARSA Lysosome Sulfatide 
Aryl sulfatase B ARSB Lysosome 
Dermatan sulfate, 
chondroitin sulfate 
Aryl sulfatase C 
or Steroid sulfatase 
ARSC 
STS 
ER Steroid sulfates 
Aryl sulfatase D ARSD ER Unknown 
Aryl sulfatase E ARSE Golgi apparatus Unknown 
Aryl sulfatase F ARSF ER Unknown 
Aryl sulfatase G ARSG ER Unknown 
Aryl sulfatase H ARSH Unknown Unknown 
Aryl sulfatase I ARSI ER Unknown 
Aryl sulfatase J ARSJ ER Unknown 
Aryl sulfatase K ARSK Unknown Unknown 
Galactosamine-6-
sulfatase 
GalN6S Lysosome 
Chondroitin sulfate, 
keratin sulfate 
Glucosamine-6-
sulfatase 
GlcN6S Lysosome 
Heparin sulfate, keratin 
sulfate 
Iduronate-2-sulfatase IdoA2S Lysosome 
Heparan sulfate, 
dermatan sulfate 
Heparin-N-sulfatase GlcNS Lysosome Heparan sulfate 
Sulfatase 1 Sulf-1 ECM Heparan sulfate 
Sulfatase 2 Sulf-2 ECM Heparan sulfate 
ER = endoplasmic reticulum; ECM = extracellular matrix 
 
In human, sulfatases are part of the secretory pathway and can be found either in 
subcellular compartments - lysosome, Golgi network, endoplasmic reticulum (ER) - or in 
the extracellular matrix (ECM). Owing to these different localisations, the optimum pH for 
activity varies between members of the family, with lysosomal sulfatases active at acidic 
pH, whereas ER, Golgi apparatus and ECM sulfatases are active at neutral pH.
57
 
Lysosomal sulfatases have been well characterised and play an important role in the 
catabolism of sulfated metabolites.
56
 For instance, ARSB, GalN6S, GlcN6S, GlcNS and 
13 
IdoA2S participate in the degradation of glycosaminoglycans, which consist of long chains 
of unbranched repeating disaccharide units. The lysosomal sulfatases are exoenzymes that 
act at the non-reducing end of polysaccharides.
56
 The other sulfatase to have been widely 
studied is ARSC, also known as steroid sulfatase (STS), which is an endoplasmic 
reticulum-bound protein. ARSC hydrolyses sulfate esters from steroid precursors such as 
oestrone, cholesterol, pregnenolone and dehydroepiandrosterone sulfates (Figure 2.1).
59
 
This enzyme has been associated with hormone-dependent diseases. Less is known about 
the recently discovered extracellular sulfatases, Sulfatase 1 and Sulfatase 2 which 
hydrolyse the O
6
-sulfate of glucosamine residues in heparan sulfate proteoglycan (HSPG) 
chains.
56
 
 
 
Figure 2.1: Hydrolysis of oestrone sulfate by ARSC 
 
Several human disorders, such as mucopolysaccharidose, X-linked ichthyosis or 
chondrodysplacia, have been associated with a single sulfatase deficiency. Deficiency in 
all human sulfatases has also been observed, resulting in a rare and severe genetic disease, 
termed multiple sulfatase deficiency.
58
 
 
2.2. Structure of Sulfatases 
All sulfatases have a similar size ranging from 500 to 800 amino acids. The sequence 
homology among the seventeen members of the family ranges between 20% and 60%. The 
degree of similarity is higher in the N-terminal region which contains the catalytic site. The 
high degree of similarity suggests that sulfatases may result from the evolution of a 
common ancestral gene.
56
 
The X-ray crystal structures of three human sulfatases (ARSA, ARSB and ARSC) and one 
bacterial sulfatase have been solved. The four structures are very similar and exhibit a 
globular domain composed of α-helices and -sheets. In addition to this spherical domain, 
ARSC has a unique membrane-anchoring domain (Figure 2.2).
60
 An overlay of the four 
crystal structures has revealed that the polar catalytic domains superimpose on each other, 
14 
with only minor spatial differences. No crystal structures of a sulfatase bound to its 
substrate has been published to date. 
 
 
Figure 2.2: Overlay of the four sulfatase crystal structures: ARSA (blue), ARSB 
(magenta), ARSC (green) and Pseudomonas Aeruginosas Sulfatase (yellow)
60
 
 
All sulfatases possess within their catalytic site a conserved cysteine residue which is post-
translationally modified into a formylglycine (FGly), residue essential for the enzymatic 
activity of sulfatases (Figure 2.3).
58
 The post-translational modification is performed by an 
enzyme named formylglycine-generating enzyme (FGE), which is encoded by the sulfatase 
modifying factor 1 gene.
57
 The cysteine oxidation occurs within the ER when the 
polypeptide is still unfolded. A peptide segment of 11 amino acid residues, starting with 
the cysteine to be modified, is required to direct the FGly modification.
61
 A core motif, 
C(X/T)P(X/S)R was revealed to be essential to obtain modest amounts of oxidation.
62
 This 
motif is conserved across all human sulfatases. The molecular mechanism by which the 
FGE oxidises the cysteine residue is still unknown.
56, 57
 Hydration of the aldehyde gives an 
activated hydroxyformylglycine (HFGly) (Figure 2.3). 
 
 
Figure 2.3: The post-translational modification mediated by FGE  
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The active site of sulfatases is situated in the N-terminal region and comprises ten polar 
residues and a divalent metal cation, identified as a calcium or magnesium ion by structural 
biology studies. The HFGly residue is located at the bottom of the catalytic cleft 
(Figure 2.4). The members of the sulfatase family share a common catalytic mechanism, 
highlighted by the conserved sequence of residues in the catalytic domain.
60
 The proposed 
function of each residue is detailed in Table 2.2. 
 
 
Figure 2.4: Schematic representation of the active site of the sulfatase enzymes (adapted 
from ref 56) 
 
Table 2.2: Proposed function of amino acids and metal cation in the active site
56
 
Residue Proposed function 
HFGly Catalytic nucleophile 
M Substrate binding and activation, stabilisation of HFGly 
AsnA Metal coordination, activation of HFGly 
AspA Metal coordination 
AspB Metal coordination 
AspC Metal coordination 
ArgA Stabilisation of HFGly 
HisA Stabilisation of HFGly, elimination of HFGly sulfate 
HisB Substrate binding and activation, alcohol protonation 
LysA Substrate binding and activation, stabilisation of HFGly 
LysB Substrate binding and activation, alcohol protonation 
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Although the residues acting on substrate recognition have not been identified, it is 
assumed that recognition must occur outside the narrow cleft containing the highly-
conserved active site. The C-terminal region, which is less conserved among the sulfatases, 
may act as a substrate discerning unit.
56, 60
 
 
2.3. The Mechanism of Desulfation by Sulfatase Enzymes 
Until the identification of the post-translational modification of the cysteine residue in 
1995, the mechanism of sulfate ester hydrolysis remained unknown. The original proposed 
mechanism was an addition-hydrolysis mechanism based on the electrophilic nature of the 
formylglycine residue (Figure 2.5).
56
 Nucleophilic attack of the negatively charged sulfate 
oxygen on the FGly moiety gives a sulfate diester. A water molecule then releases the 
alcohol conjugate and the formylglycine is regenerated via sulfate -elimination. 
 
 
Figure 2.5: Addition-hydrolysis mechanism
56
 
 
The crystal structure of ARSA provided the first piece of evidence, suggesting that the 
FGly residue may exist in its hydrated form in the resting state of the enzyme. A second 
potential mechanism is a transesterification-elimination mechanism, and was proposed 
following this discovery (Figure 2.6).
56, 63
 In this instance, nucleophilic attack of the 
hydroxylformylglycine (HFGly) on the sulfate sulfur atom releases the alcohol conjugate. 
Geminal elimination of the sulfate group is followed by hydration of the FGly moiety 
intermediate. 
 
 
Figure 2.6: Transesterification-elimination mechanism
56
 
 
A number of pieces of evidence supporting the transesterification-elimination mechanism 
have accumulated. However, the nature of sulfate ester hydrolysis is still unclear and could 
be either associative (SN2 like) or dissociative (SN1 like).
56
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2.4. Sulf-1 and Sulf-2: the Endosulfatases 
Sulfatase 1 was discovered serendipitously during a study of the quail embryo.
64
 The 
mammalian versions of the enzyme were identified shortly after in rat, mouse and 
human.
65, 66
 During the course of a study aiming to clone a full-length Sulf-1 c-DNA, a 
closely related protein was identified and designated as sulfatase 2.
65
 
Sulf-1 and Sulf-2 are the largest proteins of the sulfatase family, around 870 amino acids in 
length, and are the only two localised in the extracellular matrix. The Sulfs have a high 
degree of similarity (63-65%) and display the same conserved catalytic residues as the 
other members of the family.
67
 A cysteine residue, present in the catalytic domain, needs to 
be oxidized into a FGly for the enzyme to be active.
57
 
The Sulfs are divided into four domains. Starting from the N-terminal domain, there is first 
a promoter region, followed by the catalytic domain of 374 amino acids, then a basic 
hydrophilic domain of 346/366 amino acids, and finally a C-terminal domain of 109/127 
amino acids (Figure 2.7) .
68
 The central hydrophilic domain is a feature of the Sulfs which 
does not exist in other members of the family.
69
 
 
 
Figure 2.7: Post-translational processing of the Sulfs (adapted from ref 67) 
 
Sulf-1 and Sulf-2 consist of a heterodimer of 75 and 50 kDa subunits, linked via disulfide 
bonds (Figure 2.7). The cleavage of the pro-protein is believed to occur in the Golgi 
apparatus under the action of a furin type protease. Although, the catalytic domain is 
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located in the N-terminal 75 kDa subunit, the C-terminal fragment is important since its 
deletion induces the loss of both endosulfatase and arylsulfatase activity.
69
 The unique 
hydrophilic domain of about 320 amino acids is largely positively charged. Its deletion 
prevents endosulfatase activity but not hydrolysis of phenolic sulfates, suggesting that the 
hydrophobic domain might be involved in the binding of the Sulfs to their natural 
substrates, heparin and heparan sulfate proteoglycan.
68
 In addition, this domain is also 
involved in the binding of the Sulfs to the cell surface.
67
 
HSPGs are major components of the extracellular matrix and the cell surface. These 
macromolecules are a subtype of proteoglycans, where heparan sulfate chains are attached 
to a restricted set of core proteins. The heparan sulfate chains are linear polysaccharides 
composed of repeating and alternating disaccharide units of N-acetylated or N-sulfated 
glucosamines and uronic acids (glucuronic acid or iduronic acid).
70
 The polysaccharides 
are heterogenous in terms of length, space between modified segments and extent of 
sulfation and epimerization.
71
 The extent of sulfation of heparan sulfate is crucial for its 
biological functions.
72
 Four different sites of sulfation exits in heparan sulfate: the N
2
-, O
3
-, 
and O
6
-positions of glucosamine and the O
2
-position of iduronic acid (Figure 2.8).
73
 
 
 
Figure 2.8: A trisulfated disaccharide unit (IdoA2S-GlcNS6S) of heparan sulfate 
 
Heparan sulfate chains are heterogenous in their sulfation pattern, with region of high 
sulfation separated by regions of lower sulfation.
67
 As one of the body’s most negatively 
charged macromolecules, HSPGs bind to a variety of different proteins, such as 
morphogens and growth factors, and regulate important physiological processes including 
cell proliferation, cell migration and coagulation (Figure 2.9).
69, 71
 An additional function 
attributed to HSPGs is to act as co-receptors for cell surface receptor tyrosine kinases. The 
sulfation and epimerisation of heparan sulfate chains are dynamically and strictly regulated 
under normal philological conditions. 
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Figure 2.9: Roles of heparan sulfate proteoglycan in cell physiology
71
 
 
The Sulfs hydrolyse O
6
-sulfate from glucosamine in highly sulfated regions of HSPG and 
preferably on trisulfated disaccharide units (IdoA2-GlcNS6S).
65, 72, 74, 75
 The O
6
-sulfation 
of glucosamine has been identified as a key regulator of HSPG interactions with growth 
factors, morphogens and chemokines.
70
 Therefore, the Sulfs can reverse ligand interaction 
with HSPG and increase ligand concentration in the extracellular matrix.
73
 Although the 
Sulfs have some functional redundancy, biological studies have demonstrated that their 
effects on heparan sulfate structure are different. In addition to their endosulfatase activity, 
it has now been established that Sulf-1 and Sulf-2 also hydrolyse intra-chain sulfates.
65,
 
76
  
 
2.5. Sulf-2: An Attractive Target for Cancer Therapy 
Depending on their activating or inhibitory effects upon cell signalling, deregulation of the 
Sulfs has been associated with either tumour progression or suppression.
68
 Sulf-1 and 
Sulf-2 are overexpressed in a number of cancers including breast, central nervous system, 
colon, lung, hepatocellular carcinoma and pancreatic cancer.
77-84
 To understand the 
significance of upregulated Sulfs expression, a case-by-case analysis needs to be 
performed. 
20 
Sulf-2 expression has been correlated with aggressive tumour phenotype and poorer patient 
survival in HCC.
81
 An analysis of 139 resected HCC tissues revealed that Sulf-2 
expression was increased in 57% of the samples. Sulf-2 is also highly expressed in 73% of 
HCC cell lines.
81
 In vitro overexpression of Sulf-2 promoted HCC cell growth and 
migration, whereas Sulf-2 knockdown abrogated HCC cell proliferation
81
. In vivo 
experiments have proven that Sulf-2 knockdown using shRNA resulted in reduced growth 
of HCC tumour xenograft models.
67, 80
 Similarly, in vivo silencing of Sulf-2 in pancreatic 
adenocarcinoma inhibited tumour growth.
77
 
Sulf-2 has been demonstrated to promote carcinogenesis through activation of the Wnt 
pathway.
77, 78, 85
 Overexpression of Sulf-2 liberates Wnt ligands such as Wnt1, Wnt3, 
Wnt3a and Wnt4 from HSPG.
77
 These free ligands then bind to the Frizzled receptor and 
activate signal transduction pathways resulting in accumulation of non-phosphorylated 
-catenin in the cytoplasm. After its translocation to the nucleus, -catenin binds to 
members of the TFC/LEF family of transcription factors, and activates target genes 
promoting cell growth.
77, 86
 For instance in pancreatic adenocarcinoma cell lines, 
expression of Sulf-2 contributes to in vitro cell growth and tumourigenicity via promoting 
autocrine Wnt signaling.
87
 The Wnt/Frizzled/-catenin pathway is activated in 
approximately half of HCCs, a cancer type where Sulf-2 is overexpressed.
78
 
 
 
Figure 2.10: The canonical Wnt signalling pathway
88
 
 
Sulf-2 has been shown to possess pro-angiogenic activity and could therefore contribute to 
tumourigenesis.
79
 The pro-angiogenic effects could be explained by the release of VEGF 
ligands sequestration by HSPGs. 
21 
The release of binding proteins from HSPGs by the action of Sulf-2 increases the 
availability of HSPGs to interact with tyrosine kinase receptors, such as the FGF receptor. 
Interactions between HSPGs and the FGF receptor induce dimerization of the receptor into 
its active form, increasing affinity of the receptor for its FGF ligand. However, 
controversial data have been reported, showing that Sulf-2 could have an inhibitory effect 
on the FGF pathway. 
67
 It now appears that the effect of Sulf-2 on the classical MAP 
kinase pathway could be cancer-type specific.
75, 80, 81, 89
 
Despite their structural similarity, Sulf-1 and Sulf-2 have been shown to have opposite 
effects on liver cancer cells in vitro and in vivo. Sulf-1 acts as a tumour suppressor through 
inhibition of receptor tyrosine kinase signalling whereas Sulf-2 has been shown to exert an 
oncogenic effect through activation of diverse signalling pathways such APK, Akt and 
Wnt.
80
 The contradictory findings on the effect of the Sulfs come from distinct cellular 
contexts, and it can be hypothesised that their effect will differ depending on cancer-types 
and the signalling pathways driving carcinogenesis. 
 
2.6. Reported Sulfatases Small-Molecule Inhibitors 
Among the seventeen human sulfatases, ARSC is the only member which has been the 
target of some drug discovery programs. ARSC inhibitors have been developed to provide 
novel therapies for the treatment of hormone-dependent breast cancer.
90
 ARSC expression 
is upregulated in a large number of breast cancer patients and is a source of active 
oestrogens.
91
 EMATE 2 was the first potent ARSC inhibitor to be developed.
92
 This steroid 
derivative inhibits ARSC irreversibly with an IC50 value of 80 nM. The development of 
EMATE as a drug was stopped at the preclinical stage, since the inhibitor was found to 
exert a strong oestrogenic effect.
93
 To develop xenobiotics deprived of oestrogenic effects, 
non-steroidal sulfamate inhibitors have been investigated, leading to the identification of 
667COUMATE 3.
91
 This potent irreversible inhibitor of ARSC was found to be 3-fold 
more active than EMATE 2 in vitro and is currently in phase II clinical trial for the 
treatment of hormone-dependent breast cancer.
93-95
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The majority of agents modulating ARSC activity possess a sulfamate warhead which was 
found to be critical for their pharmacological effect.
90
 Replacement of the oxygen atom of 
the sulfamate by a nitrogen, a sulfur or a carbon completely abolished ARSC inhibition.
56, 
87, 96
 Primary sulfamates have also been used for the irreversible inhibition of other 
sulfatases. Unlike their primary counterparts, secondary and tertiary sulfamates are 
reversible inhibitors and usually possess a less pronounced pharmacological effect.
97
 
Four possible mechanisms have been proposed for the irreversible inhibition of sulfatases 
by primary sulfamates (Figure 2.11).
98, 99
 The first mechanism (Figure 2.11, a)) involves 
nucleophilic attack of the HFGly on the sulfamate sulfur atom. Following elimination of 
sulfamic acid, a FGly moiety is obtained. The electrophilic FGly then reacts with sulfamic 
acid to form an imine, which irreversibly inhibits the enzyme activity. The second 
mechanism (Figure 2.11, b)) proceeds in a similar fashion up to generation of the FGly 
unit. In this instance a lysine residue, activated by the eliminated sulfamic acid, reacts with 
the FGly residue to form an imine. In the third and fourth proposed mechanisms 
(Figure 2.11, c) and d)) irreversible sulfatase inhibition is caused by the formation of a 
sulfamide. These mechanisms are hypothetical and only limited evidence have been 
identified in support of each. 
 
 
Figure 2.11: Postulated mechanisms for the irreversible inhibition of sulfatase enzymes by 
primary sulfamates
56, 99
 
 
The accumulation of evidence demonstrating that Sulf-2 is contributing to carcinogenesis 
makes it an attractive target for the development of new anticancer drugs. In 2010, Hossain 
et al. reported the sulfated oligosaccharide PI-88 (Figure 2.12) to be a dual Sulf-1 and 
23 
Sulf-2 inhibitor.
100
 This heparin mimic, derived from yeast, is under evaluation in several 
clinical trials as an inhibitor of the heparin sulfate-degrading enzyme heparanase.
101
 PI-88 
has also been shown to block the interactions of heparin sulfate with different growth 
factors, reducing the downstream activities of the affected pathways. The measured Sulf-2 
inhibition by PI-88 was 1.6 µg/mL, an IC50 value very close to that reported for heparanase 
(2.0 µg/mL).
100
 
 
 
Figure 2.12: Chemical structure of PI-88. PI-88 is composed predominantly (≈ 90%) of 
(a) phosphomonopentaose and (b) phosphomonotetraose sulfates (adapted from ref 101) 
 
More recently Wong et al. reported monosaccharide sulfamate inhibitors of Sulf-1 and 
Sulf-2 (Figure 2.13).
102
 These compounds were derived from the monosaccharide 
glucosamine substrate, bearing a sulfamate at the O
6
-position. Two of these 
monosaccharide inhibitors (5 and 8) had activity in the micromolar range and were 
equipotent for Sulf-1 and Sulf-2.
102
 Primary and tertiary sulfamate derivatives were 
assessed and both were found to be reversible inhibitors. Sulfation of the amino group of 
glucosamine significantly improved Sulf-2 inhibition, suggesting that polar functionalities 
might be required to enhance the interaction between the inhibitor and the enzyme.
102
 
Although these compounds were not sufficiently potent for use in target validation studies, 
their discovery provided encouragement that viable Sulf-2 inhibition was possible with low 
molecular weight compounds. In the same paper, Sulf-1 and Sulf-2 inhibition by two 
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simple phenyl sulfamates was found to be significantly weaker than with monosaccharides 
5 and 8.
102
 
 
Figure 2.13: Monosaccharide sulfamate inhibitors of Sulf-1 and Sulf-2 and their reported 
Sulf-2 inhibitory activity.
102
 
 
In 2013, Roberts et al. reported 2,4-disulfonylphenyl-tert-butylnitrone (OKN-007 10) as a 
Sulf-2 inhibitor.
103
 OKN-007 promoted tumour cell apoptosis and inhibited cell 
proliferation, viability, and migration of Huh7 cells overexpressing Sulf-2. However, no 
inhibition data against isolated Sulf-2 have been reported, suggesting that the cellular 
effects observed might be caused by alternative mechanisms than Sulf-2 modulation. 
OKN-007, also known as NXY-059, was originally developed as a free radical 
neuroprotectant for the treatment of acute ischemic stroke.
104
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Chapter 3. Development of Novel O-Aryl Sulfamate Protecting Groups 
for the Synthesis of Potential Non-Saccharide Sulf-2 Inhibitors 
 
3.1. Design of Potential Chemical Probes for Sulf-2 Inhibition 
3.1.1. Rationale 
Chemical probes or tools are used to establish the relationship between a specific target 
and broader biological mechanisms, allowing a link between target perturbation and 
disease-related pharmacology to be established.
34, 37
 Probe compounds are essential to 
support cell-based preclinical target validation, and in identification of molecular targets 
involved in disease modulation. A good chemical probe should have high potency and 
selectivity for the assigned primary target, to confidently associate biological response with 
target modulation.
36
 
The initial aim of the Sulf-2 project was to identify chemical tools for use in experiments 
in vitro with the objective to determine whether IC50 values against Sulf-2 below 100 μM 
were achievable with small-molecule inhibitors, whether selectivity over other members of 
the human sulfatase family was achievable and whether Sulf-2 perturbation with a small-
molecule inhibits cancer cell growth in vitro. In parallel, the reported Sulf-1/Sulf-2 dual 
inhibitors 5 and 8, were resynthesised by a colleague and used for the development of a 
Sulf-2 primary pharmacology assay.
105
 
In the absence of a published crystal structure and of a biological assay suitable for a high-
throughput screening campaign, the structure of the endogenous HSPG substrate was 
considered as a potential starting point for identification of probe compounds. Although no 
crystal structure of an HSPG was available, modelled structures of the related 
macromolecule heparin, which is likely to reflect the structure of the highly sulfated 
regions of HSPGs, were utilised to gain an understanding of the structural features 
governing interactions between heparin and its protein binding partners.
106
 Negatively 
charged sulfate and carboxylate groups cover most of the accessible surface of the 
polymer, and have been shown to regulate the binding of heparin to the enzyme 
3-O-sulfotransferase.
106, 107
 X-ray crystal structures of FGF-1 and FGF-2 in complex with 
heparin oligosaccharides also revealed the importance of the sulfate and carboxylate 
groups for binding.
108
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These studies demonstrated that interactions of the charged sulfate and carboxylate groups 
on the heparin oligosaccharide with basic amino acids on protein binding partners are often 
key contributors to tight and specific binding. Mimicking these ionic interactions was 
considered important for de novo design of potential non-saccharide based Sulf-2 
inhibitors. 
Several approaches were pursued in parallel for the identification of improved tool 
compounds, relative to 5. Analogues of monosaccharide 5 and simplified cyclic aliphatic 
scaffolds were synthesised by a colleague working on the project to generate Sulf-1 and 
Sulf-2 SARs, and to understand structural changes affecting selectivity.
105
 Since phenyl 
sulfamate has been reported to be a weak Sulf-2 inhibitor, a set of phenol-derived primary 
and dimethyl sulfamates was also prepared to examine the electronic and steric effect of 
substituents on Sulf-2 inhibition.
102, 105
 
A second generation of aromatic sulfamate inhibitors was subsequently designed, to 
attempt to position the sulfamate and a second polar moiety in similar regions of space to 
those occupied by sulfate and carboxylate groups in heparin. This series could provide hit 
compounds with improved physicochemical properties compared with the monosaccharide 
scaffold and is more amenable to large scale and rapid analogue synthesis. 
The first template designed using this strategy was based on a biphenyl sulfamate core, 
with polar groups on the second aromatic ring (B-ring). The biphenyl targets were energy 
minimised in the gas phase and overlaid onto a trisaccharide heparin fragment taken from 
the reducing end of the modelled heparin structure (Figure 3.1). A primary sulfamate group 
at the 3-position of the first phenyl ring (A-ring) was overlaid with the 6-O sulfate of 
glucosamine, enabling substituents on the second phenyl ring to overlay the N-sulfate of 
glucosamine or the O-sulfate of iduronic acid in the heparin-derived template structure. 
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Figure 3.1: Representative overlays of biphenyl targets (cyan) with a heparin-derived 
trisaccharide template (green) 
 
In addition to the rationally designed derivatives, the biphenyl core was used to probe 
additional polar and ionic interactions through incorporation of polar functional groups 
into the ortho, meta and para position of the B-ring. 
A biphenyl ether sulfamate scaffold was the second template designed using a similar 
strategy (Figure 3.2). This template incorporates an oxygen linker which may mimic that 
found in polysaccharides and has lower energy barriers to conformational changes. 
 
 
Figure 3.2: Representative overlays of biphenyl ether targets (cyan) with a heparin-derived 
trisaccharide template (green) 
 
3.1.2. Requirements for a Novel Sulfamate Protecting Group 
In order to explore the effect of substitution on the B-ring of a biphenyl template 
efficiently, it was necessary to introduce the primary sulfamate moiety early in the 
synthesis. Initial retrosynthetic analysis suggested that 3-bromophenylsulfamate (11) could 
be a versatile coupling partner in Suzuki-Miyaura cross-coupling reactions to access 
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biphenyl sulfamates, which could then undergo further chemical modifications (R
1
 to R
2
) 
to provide the desired targets (Figure 3.3). 
 
 
Figure 3.3: Initial retrosynthetic analysis for the biphenyl sulfamate series 
 
However, the sensitivity of primary sulfamates to basic conditions limited the efficiency of 
Suzuki cross-couplings on 3-bromophenyl sulfamate (11), with low product yields and a 
mixture of desulfamoylated product and starting material obtained (Scheme 3.1). An array 
of conditions was explored in which the base component was varied, the best results being 
obtained with weak bases such as sodium carbonate and Pd(dppf)Cl2 as catalyst. However, 
despite extensive optimisation efforts, the highest product yield was only 22%.
109
 The 
instability of primary phenol O-sulfamates under basic conditions is due to an E1Cb 
mechanism in which deprotonation of one of the primary sulfamate protons precedes 
elimination of the phenol.
110, 111
 Thus a protecting group was required for the synthesis of 
these primary sulfamate targets. 
 
 
Scheme 3.1: Reagents and conditions: (i) NH2SO2Cl, DMA/toluene, 0 °C to RT, 24 h, 
87%; (ii) PhB(OH)2, 2 M aq. Na2CO3, Pd(dppf)Cl2, DME, 80 °C, μW, 20 min, 22%. 
 
Reported protecting groups for sulfamates include N-alkyloxycarbonyl (alkyl = t-butyl-
112
, 
benzyl-
113
 or methyl-
114
) and the N-t-butyl group.
115
 However, these groups all retain one 
proton on the sulfamate nitrogen and the sulfamate is therefore still vulnerable to E1Cb 
degradation. A protecting group that masks both NH2 protons would be expected to confer 
the sulfamate with improved base stability. Bis-benzyl protection of the NH2 group of 
sulfonamides has been reported, but this protecting group can be difficult to remove.
116
 
Electron-releasing groups on the aryl ring of benzyl protecting groups allow the stability 
and deprotection conditions to be tuned.
117
 Thus, bis-(benzyl) (reference standard), 
bis-(4-methoxybenzyl), bis-(2,4-dimethoxybenzyl) and bis-(3,4-dimethoxybenzyl) were 
selected for investigation as potential dual protecting groups for sulfamates. Bis-protection 
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of the sulfamate would be carried out early in the synthesis of the biphenyl inhibitors while 
the deprotection would be the final step (Figure 3.4). 
 
 
Figure 3.4: Second retrosynthetic analysis for the biphenyl sulfamate series 
(PG = protecting group) 
 
3.2. Development of Novel Sulfamate Protecting Groups 
3.2.1. Identification of a Synthetic Route for the Incorporation of bis-
Benzyl Sulfamates 
Initially, the reaction of dibenzylamine (16) with sulfuryl chloride (15) in the presence of 
pyridine or triethylamine was investigated, but gave a complex mixture of products and 
afforded N,N-bis-benzylsulfamoyl chloride (17) in poor yield (Scheme 3.2). The 
subsequent reaction of 17 with 4-bromophenol also proceeded in disappointing yield. 
 
 
Scheme 3.2: Reagents and conditions: (i) NEt3 or pyridine, Et2O, -78 °C to RT, 4 h, 10%; 
(ii) 4-bromophenol, Cs2CO3, THF, 67 °C, 40%. 
 
An alternative synthetic route utilising a sulfonyl-diimidazole derivative 19 was designed. 
Sulfonyl-diimidazoles have been used as sulfonyl transfer reagents for the preparation of 
sulfonates, sulfonamides and sterically congested unsymmetrical sulfonyl ureas.
118-120
 
Compound 19 has recently been identified as the optimal reagent of this class, and was 
selected for investigation.
119, 121
 This compound was obtained by reacting an excess of 
2-methylimidazole with sulfuryl chloride (15) (Scheme 3.3).
119
 Reaction of 19 with 
dibenzylamine under a range of reaction conditions failed to displace the imidazole and 
attempts to activate sulfonyl-diimidazole 19 by methylation using Meerwein’s salt 
(trimethyloxonium tetrafluoroborate) were unsuccessful.  
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Scheme 3.3: Reagents and conditions: (i) 2-methylimidazole, DCM, 0 °C to RT, 24 h, 
73%; (ii) Several conditions investigated – all failed. 
 
The reported preparation of phenyl imidazolylsulfonates entailed the reaction of 
commercially available 1,1’-sulfonyldiimidazole with a phenoxide in THF at room 
temperature.
122, 123
 As an alternative approach, this method was applied to the preparation 
of 4-bromophenyl 2-methyl-1H-imidazole-1-sulfonate (21), resulting in slow conversion, 
with heating being required to complete the reaction (67 °C, 24 h) (Scheme 3.4). This 
confirmed the hypothesis made by Shirbin et al. that this procedure had limited efficacy 
with electron deficient phenols.
123 
To accelerate this reaction, a microwave assisted 
procedure was developed and afforded 4-bromophenyl 2-methyl-1H-imidazole-1-sulfonate 
(21) in 92% yield in 30 min. 
 
 
Scheme 3.4: Reagents and conditions: (i) 4-bromophenol, Cs2CO3, THF, 80 °C, μW, 
30 min, 92%; (ii) Me3O·BF4, DCM, 0 °C to RT, 8 h, 90%; (iii) Bn2NH (16), MeCN, RT, 
16 h, 77%; (iv) K2CO3, PhB(OH)2, Pd(PPh3)4, MeCN, 120 °C, μW, 20 min, 72%; (v) conc. 
H2SO4, 200 °C, μW, 30 min; (vi) TFA, 100 °C, μW, 30 min. 
 
Attempted reaction of imidazolylsulfonate 21 directly with dibenzylamine (16) under 
various conditions failed to displace the imidazole moiety. Activation of imidazole-
sulfonates to nucleophilic attack by methylation with methyl triflate has been utilised for 
the synthesis of protected sulfates.
124-126
 Owing to the extremely hazardous nature of 
methyl triflate, Meerwein’s salt was used to effect the methylation of 21 in high yield to 
give tetrafluoroborate salt 22 (Scheme 3.4). 
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Reaction of 22 with dibenzylamine (16) at room temperature now proceeded in high yields 
to give fully protected sulfamate 18. This compound was subjected to Suzuki cross-
coupling conditions in the presence of potassium carbonate, to afford the desired biphenyl 
23, with no desulfamoylation being observed. Deprotection of bis-benzylsulfonamides is 
precedented under strongly acidic conditions.
127, 128
 However, subjecting 
bis-benzylsulfamate 23 to concentrated sulfuric acid (200 °C, μW, 30 min) or neat 
trifluoroacetic acid (100 °C, μW, 30 min) resulted in exclusive recovery of starting 
material. Palladium-catalysed hydrogenation of the benzyl groups was also unsuccessful 
(Scheme 3.4). 
The effect of electron-donating groups on the aryl ring of the benzyl moiety was then 
investigated. Methoxy-substituted dibenzylamines 31 - 33 were readily obtained by 
reductive amination (Table 3.1).
129
 Substituted bis-benzylsulfamates 37 - 39 were prepared 
using a similar reaction sequence to that described for analogue 23 above. 
 
Table 3.1: Summary of yields for the four step synthesis of 24; Reagents and conditions: 
(i) a) EtOH, 78 °C, 4 h; b) NaBH4, RT 16 h; (ii) 22, MeCN, RT, 16 h; (iii) K2CO3, 
PhB(OH)2, Pd(PPh3)4, MeCN, 120 °C, μW, 20 min; (iv) TFA, DCM, for ratio, time and 
temp. see Table 3.4. 
 
R R’ Step 1 Step 2 Step 3 
4-OMe 4-OMe 31, 75% 34, 84% 37, 83% 
2,4-OMe 2,4-OMe 32, 85% 35, 86% 38, 83% 
3,4-OMe 3,4-OMe 33, 70% 36, 85% 39, 86% 
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As expected, incorporation of the methoxy functionality at the 4-, 2,4- and 3,4-positions of 
the benzyl groups facilitated deprotection to [1,1'-biphenyl]-4-yl sulfamate (24) (Tables 3.1 
and 3.2), resulting in high yields of 24 under mild to moderate acidic conditions. As the 
conditions required for removing 3,4-dimethoxybenzyl were similar to those employed for 
4-methoxybenzyl, but the reaction proceeded in poorer yield, 3,4-dimethoxybenzyl 
protection was not studied further. 
 
Table 3.2: Reaction conditions and yields for deprotection of N-protected [1,1'-biphenyl]-
4-yl sulfamates 37, 38 and 39 
Compound TFA:DCM ratio Temperature (°C) Time (h) Yield of 24 
37 1:0 50 12 85% 
37 1:1 42 24 90% 
38 1:1 RT 0.2 95% 
38 1:9 RT 2 95% 
38 1:19 RT 7 90% 
39 1:0 50 24 50% 
39 4:1 42 30 63% 
 
3.2.2. Scope and Limitations of the bis-(2,4-Dimethoxybenzyl) and 
bis-(4-Methoxybenzyl) Protecting Groups 
To investigate the scope and limitations of this methodology, a range of phenols with 
diverse steric and electronic properties was progressed through the synthetic sequence. For 
the reaction of phenols with 19, the time required for completion of the reaction for 
phenols with no ortho-substituent was found to be consistent with the pKa value of the 
phenol, electron-poor phenols requiring extended reaction times (Table 3.3). Sterically 
hindered phenols such as 2,6-dimethylphenol also required prolonged reaction times. 
However, very electron poor (4-nitrophenol) and/or sterically hindered phenols 
(2,6-dichlorophenol), failed to yield any product (Table 3.3). 
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Table 3.3: Summary of reaction time for the preparation of substituted phenyl 2-methyl-
1H-imidazole-1-sulfonate 21 and 48 - 54; Reagents and conditions: (i) 19, Cs2CO3, THF, 
80 °C, μW. 
 
Compound R 
Time for completion 
(min) 
pKa
130
 
48 4-OMe 15 10.4 
21 4-Br 30 9.7 
49 4-Cl 50 9.5 
50 3-Cl 65 9.3 
51 2,6-Me 75 10.2 
52 2-Cl 240 7.7 
53 2,6-Cl No reaction 7.1 
54 4-NO2 No reaction 6.8 
 
To determine conditions of general applicability for diverse phenols, the two least reactive 
phenols, 4-nitrophenol and 2,6-dichlorophenol, were selected for further optimisation. Four 
parameters were investigated: time, temperature (microwave heating), solvent and the 
stoichiometry of 19. 
 
 
Scheme 3.5: Reagents and conditions: (i) 19 (1.05 mol equiv.), Cs2CO3, MeCN or DMF, 
150 °C, μW, 10 min. 
 
Employing THF as solvent and increasing the temperature of the reaction to 150 C did not 
significantly improve conversion for these phenols. For 4-nitrophenol (47), the use of 
either DMF or acetonitrile in place of THF greatly enhanced the rate of the reaction, and 
after 10 min at 150 °C no starting material remained. However, a major by-product was 
4,4'-oxybis(nitrobenzene) (55), presumably resulting from SNAr attack of the unreacted 
phenol 47 on the desired product 54, with subsequent elimination of 2-methyl-1H-
imidazole-1-sulfonic acid (56) which may decompose to sulfur trioxide and 
2-methylimidazole (Scheme 3.5). The conversion was also improved for 
2,6-dichlorophenol (46) in these solvents, although unreacted 2,6-dichlorophenol was the 
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major component after heating for 10 min. Raising the reaction temperature to 180 C did 
not improve conversion to the product. However, increasing the molar equivalents of 19 
led to reduced formation of 55, and gave excellent yields of the substituted phenyl 2-
methyl-1H-imidazole-1-sulfonates 53 and 54 (Table 3.4). 
 
Table 3.4: Effect of molar equivalent of 19 on the formation of 53 and 54; Reagents and 
conditions: (i) 19, Cs2CO3, MeCN, 180 °C, μW, 10 min. 
 
Starting material Molar equiv. of 19 
% of product 
observed by LC-MS 
47 1.05 22 
47 5 35 
47 10 75 
46 1.05 20 
46 5 59 
46 10 80 * 
* Reaction complete after 15 min 
 
Additional optimisation studies were performed for phenols with pKa > 7.1 and/or 
sterically demanding phenols. It was determined that high conversions could routinely be 
achieved under relatively mild conditions (15 min, microwave heating at 120 C, 2 mol 
equiv. of 19, MeCN) (Table 3.5). Thus, two methods have been identified, which allow 
reactive phenols (Method 1) and less reactive phenols (Method 2) to be utilised. 
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Table 3.5: Optimised conditions for microwave heating of substituted phenols with 
1,1'-sulfonylbis(2-methyl-1H-imidazole) (19); Reagents and conditions: Method 1 
(i) 19 (2 mol equiv.), Cs2CO3, MeCN, 120 °C, μW, 15 min; Method 2 (ii) 19 (10 mol 
equiv.), Cs2CO3, MeCN, 180 °C, μW, 15 min. 
 
R pKa 
Method 1 
(isolated yield) 
Method 2 
(isolated yield) 
4-OMe 10.4 48, 97% n.d. 
4-Br 9.7 21, 93% n.d. 
4-Cl 9.5 49, 93% n.d. 
3-Cl 9.3 50, 83% n.d. 
2-Cl 7.7 52, 90% n.d. 
2,6-Me 10.2 51, 92% n.d. 
2,6-Cl 7.1 53, 0% 53, 84% 
4-NO2 6.8 54, 0% 54, 82% 
3-NO2 9.3 57, 72% n.d. 
2-NO2 6.9 58, 0% 58, 70% 
4-CN 7.7 59, 59% 59, 80% 
2-CN 7.0 60, 0% 60, 72% 
4-CF3 8.5 61, 80% n.d. 
n.d. = not determined 
 
One-pot methylation of imidazolylsulfonates 21, 48 - 54 and 57 - 61 followed by 
substitution with 32 to give the bis-(2,4-dimethoxybenzyl) sulfamates proceeded in similar 
yield for all phenols studied and deprotection with 10% TFA in DCM was also clean and 
high yielding (Table 3.6). The optimised conditions were applied to the protection of a set 
of phenol O-sulfamates, bis-N-protected by 4-methoxybenzyl. For these compounds, 
deprotection with 50% TFA in dichloromethane proceeded in high yield to the 
corresponding phenol O-sulfamate (Table 3.6). These results demonstrated that the 
sulfamate protection methodology was applicable to a range of phenols with diverse steric 
and electronic properties.  
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Table 3.6: Summary of yields for methylation/substitution with bis-(4-methoxybenzyl) 
amine (31) or bis-(2,4-dimethoxybenzyl)amine (32) of aryl 2-methyl-1H-imidazole-1-
sulfamates followed by deprotection; Reagents and conditions: (i) a) Me3O·BF4, DCM, 
0 °C to RT, 8 h; b) 31 or 32, MeCN, 42 °C, 24 h; (ii) 10% TFA/DCM, RT, 2 h (for 
R = dmb); (iii) 50% TFA/DCM, 42 C, 24 h (for R = PMB). 
 
Step 1 Step 2 
R R’ Yield R Yield 
4-MeO dmb 62, 65% 4-MeO 79, 90% 
2,6-Me dmb 63, 61% 2,6-Me 80, 90% 
4-Cl dmb 64, 63% 4-Cl 81, 84% 
3-Cl dmb 65, 61% 3-Cl 82, 90% 
2-Cl dmb 66, 68% 2-Cl 83, 81% 
2,6-Cl dmb 67, 63% 2,6-Cl 84, 89% 
4-NO2 dmb 68, 62% 4-NO2 85, 80% 
3-NO2 dmb 69, 57% 3-NO2 86, 87% 
2-NO2 dmb 70, 61% 2-NO2 87, 40% 
4-CN dmb 71, 63% 4-CN 88, 92% 
2-CN dmb 72, 60% 2-CN 89, 86% 
4-CF3 dmb 73, 66% 4-CF3 90, 90% 
4-MeO PMB 74, 80% 4-MeO 79, 93% 
2,6-Me PMB 75, 62% 2,6-Me 80, 92% 
4-Cl PMB 76, 81% 4-Cl 81, 90% 
3-Cl PMB 77, 72% 3-Cl 82, 86% 
2-Cl PMB 78, 78% 2-Cl 83, 92% 
dmb = 2,4-dimethoxybenzyl; PMB = 4-methoxybenzyl 
 
3.2.3. Chemical Stability of Sulfamates N-Protected with bis-(2,4-
Dimethoxybenzyl) 
To assess the chemical stability of bis-(2,4-dimethoxybenzyl) protected sulfamates, a set of 
compounds was prepared to determine the robustness of this group to some common 
transformations. Compound 93, synthesised following the reaction sequence optimised in 
section 3.2.2., was subjected to palladium-catalysed hydrogenation, resulting in cleavage 
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of the O-benzyl group while the N-2,4-dimethoxybenzyl groups were retained 
(Scheme 3.6). Deprotection of 94 with dilute trifluoroacetic acid provided 95 in 86% yield. 
 
 
Scheme 3.6: Reagents and conditions: (i) 19, Cs2CO3, MeCN, 120 °C, μW, 15 min, 96%; 
(ii) a) Me3O·BF4, DCM, 0 °C to RT, 8 h; b) 32, MeCN, 42 °C, 24 h, 61%; (iii) H2, 
10% Pd/C, MeOH, 50 °C, 24 h, 85%; (iv) 10% TFA/DCM, RT, 2 h, 86%. 
 
Analogous reactions to those described above were utilised for the preparation of 
compound 98 (Scheme 3.7). Basic hydrolysis of methyl ester 98 was achieved in high yield 
without affecting the bis-N-protected sulfamate. Mild acidic cleavage of the 
2,4-dimethoxybenzyl groups afforded 100 in 89% yield. 
 
 
Scheme 3.7: Reagents and conditions: (i) 19, Cs2CO3, MeCN, 120 °C, μW, 15 min, 92%; 
(ii) a) Me3O·BF4, DCM, 0 °C to RT, 8 h; b) 32, MeCN, 42 °C, 24 h, 64%; (iii) LiOH, 
H2O/THF, 60 °C, 24 h, 85%; (iv) 10% TFA/DCM, RT, 2 h, 89%. 
 
Template 98 was further elaborated to investigate stability to reduction, oxidation and 
anionic nucleophilic conditions. Lithium aluminium hydride reduction of methyl ester 98 
gave benzyl alcohol 101, which was oxidised with manganese dioxide (Scheme 3.8). 
Nucleophilic attack of phenylmagnesium bromide on the carbonyl group of 102 led to 
isolation of 103 in 88% yield. A second manganese dioxide oxidation followed by TFA 
deprotection of the sulfamate functionality of 104 were employed to access 105. 
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Scheme 3.8: Reagents and conditions: (i) LiAlH4 (2 M in THF), THF, 0 °C, 2 h , 84%; 
(ii) MnO2, DCM, RT, 16 h, 89%; (iii) PhMgBr (1 M in THF), THF, 0 °C to RT, 2 h , 88%; 
(iv) MnO2, DCM, RT, 16 h, 84%; (v) 10% TFA/DCM, RT, 2 h, 87%. 
 
To investigate orthogonality with the Boc protecting group, intermediates 108 and 109 
were prepared according to a similar reaction sequence to that descripted in section 3.2.2. 
(Scheme 3.9). Deprotection of the N-t-butyloxycarbonyl (Boc)-aniline 108 occurred with 
simultaneous removal of bis-N-2,4-dimethoxybenzyl from the sulfamate group to afford 
3-aminophenyl sulfamate 110. However, when 4-methoxybenzyl was used to protect the 
sulfamate moiety in 109, the Boc group could be removed without affecting the sulfamate 
protecting group and afforded 111 (Scheme 3.9). 
 
 
Scheme 3.9: Reagents and conditions: (i) 19, Cs2CO3, MeCN, 120 °C, μW, 15 min, 84%; 
(ii) a) Me3O·BF4, DCM, 0 °C to RT, 8 h; b) 32, MeCN, 42 °C, 24 h (R = dmb, 57%; 
R = PMB, 70%); (iii) 10% TFA/DCM, RT, 2 h, (110 from 108, 70%; 111 from 109, 94%); 
(iv) 50% TFA/DCM, 42 °C, 24 h, 88%. 
 
In summary, it has been demonstrated that sulfamates bis-N-protected with 
2,4-dimethoxybenzyl were stable to hydrogen/palladium catalyst, aqueous lithium 
hydroxide, lithium aluminium hydride, manganese dioxide and phenylmagnesium 
bromide. The bis-(4-methoxybenzyl) protection also enabled selective deprotection of a 
Boc group over the sulfamate.  
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3.2.4. Extension to the Protection of Secondary O-Aryl Sulfamates 
The methodology was extended to the protection of secondary aryl 
sulfamates. Secondary benzyl amines 115 - 118 were obtained via 
reductive amination in moderate to good yields (Table 3.7). 
Nucleophilic displacement of the imidazolium of 22 proceeded in 
high yields and was followed by Suzuki-Miyaura cross-coupling 
with phenylboronic acid to afford fully protected biphenyl 
secondary sulfamates 123 - 126. Deprotection of secondary 
sulfamates occurred under similar conditions to those employed for 
the deprotection of primary sulfamates (Table 3.7). 
Table 3.7: Summary of yields for the four step synthesis of secondary sulfamates; 
Reagents and conditions: (i) a) EtOH, 78 °C, 4 h; b) NaBH4, RT 16 h; (ii) 22, MeCN, RT, 
16 h; (iii) K2CO3, PhB(OH)2, Pd(PPh3)4, MeCN, 120 °C, μW, 20 min; 
(iv) 10% TFA/DCM, RT, 2 h; (v) 50% TFA/DCM, 42 °C, 24 h. 
 
R R’ Step 1 Step 2 Step 3 Step 4 
Me 
dmb 115, 25% 119, 95% 123, 90% 127, 95% 
PMB 116, 24% 120, 96% 124, 87% 127, 96% 
i
Bu dmb 117, 69% 121, 85% 125, 85% 128, 93% 
Bn dmb 118, 67% 122, 89% 126, 87% 129, 96% 
 
3.2.5. Summary 
Two new protecting groups for primary and secondary sulfamates have been developed 
and shown to be stable to a wide range of conditions used in standard functional group 
interconversions. These protecting groups are easily removed under mild acidic conditions. 
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3.3. The Biphenyl Sulfamate Series 
The protecting group methodology was applied to the synthesis of a library of 13 biphenyl 
sulfamates. In order to explore the substitution of the B-ring efficiently, a synthetic route 
based on the retrosynthetic analysis presented in section 3.1.2. was established 
(Scheme 3.10). Key intermediate 132 was prepared on a large scale following the reaction 
sequence previously described. 
 
 
Scheme 3.10: Reagents and conditions: (i) 19, Cs2CO3, MeCN, 120 °C, μW, 15 min, 76%; 
(ii) Me3O·BF4, DCM, 0 °C to RT, 8 h, 85%; (iii) 32, MeCN, RT, 16 h, 71%. 
 
Microwave-assisted Suzuki-Miyaura cross-coupling of 132 in presence of potassium 
carbonate and Pd(PPh3)4 afforded 133 in 75% yield (Table 3.8). These conditions were 
unsuccessful for the preparation of 134 and 135, but alternative Suzuki conditions, which 
had previously been used successfully on other substrates in the Sulf-2 project, provided 
these compounds in good yields. The same conditions were utilised for the synthesis of 
aniline derivatives 136 - 138. All deprotections proceeded at room temperature in dilute 
TFA, resulting in high yields of the desired primary sulfamates 139 - 144. 
 
Table 3.8: Summary of yields for the two step synthesis of biphenyl sulfamate derivatives; 
Reagents and conditions: (i) K2CO3, R-PhB(OH)2, Pd(PPh3)4, MeCN, 120 °C, μW, 
20 min; (ii) R-PhB(pin), 2 M aq. Na2CO3, Pd(dppf)Cl2, dioxane, 80 °C, μW, 20 min; 
(iii) 10% TFA/DCM, RT, 2 h. 
 
R 
Step 1 Step 2 
Method Yield Yield 
2’-CO2Me i 133, 75% 139, 88% 
3’-CO2H ii 134, 79% 140, 82% 
4’-CO2H ii 135, 77% 141, 90% 
2’-NH2 ii 136, 82% 142, 83% 
3’-NH2 ii 137, 77% 143, 82% 
4’-NH2 ii 138, 72% 144, 82% 
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Methyl ester 133 was hydrolysed under basic conditions and the resulting carboxylic acid 
145 was deprotected to give 149 (Table 3.9). Acetylation of aniline derivatives 136 - 138 
with acetic anhydride in presence of triethylamine afforded acetamidobiphenyls 146 - 148. 
Acid-mediated cleavage of 2-4-dimethoxybenzyl groups resulted in isolation of 150 - 152 
in high yields. 
 
Table 3.9: Summary of yields for the two step functionalisation/deprotection of protected 
biphenyl sulfamates; Reagents and conditions: (i) LiOH, H2O/THF, 60 °C, 24 h, 80%; 
(ii) Ac2O, NEt3, DCM, RT, 24 h; (iii) 10% TFA/DCM, RT, 2 h. 
 
R’ 
Step 1 Step 2 
Method Yield Yield 
2’-CO2H i 145, 80% 149, 89% 
2’-NHAc ii 146, 87% 150, 86% 
3’-NHAc ii 147, 89% 151, 91% 
4’-NHAc ii 148, 88% 152, 84% 
 
Preparation of amino-sulfate derivative 154 by reaction of aniline 152 with sulfur trioxide 
pyridine complex was unsuccessful (Scheme 3.11). This methodology is a two-step 
process, whereby the initial pyridinium salt 153 is converted into a stable sodium 
derivative 154 under basic conditions. A range of mild bases were explored but were either 
incompatible with the sulfamate moiety or ineffective at displacing the pyridinium ion. Ion 
exchange chromatography was also attempted but resulted in exclusive recovery of 142. 
 
 
Scheme 3.11: Reagents and conditions: (i) Sulfur trioxide pyridine complex, pyridine, 
DMF, RT, 3 h; (ii) 1 M aq. NaOH, RT, 1 h. 
 
In 2004, Taylor et al. reported the 2,2,2-trichloroethyl (TCE) group as an effective 
protection of arylsulfate esters.
131
 The protecting group is introduced by reacting a phenol 
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with 2,2,2-trichloroethyl chlorosulfate (156) in the presence of triethylamine and DMAP, 
and is cleaved under mild conditions using zinc or palladium.
131
 Although ammonium 
formate was originally reported as an important component for the deprotection, recent 
reports have indicated that it could be replaced by alternative reagents, such as a phosphate 
buffer at pH = 7.4.
131-134
 These neutral conditions were of interest, since they would allow 
deprotection of the sulfate after deprotection of the sulfamate. The imidazolium salt 
derivative of 156 was reported in a subsequent paper and found to be a superior reagent for 
the synthesis of TCE-protected sulfate esters.
126
 This reagent has since been used for the 
sulfation of a variety of phenols and carbohydrates, but also been successfully utilised for 
the synthesis of aliphatic protected amino-sulfates.
121, 124, 125, 135
 For these reasons, 
imidazolium salt 158 was selected for investigation. 
TCE chlorosulfate (156) was obtained by reacting one equivalent of 2,2,2-trichloroethanol 
(155) with sulfuryl chloride (Scheme 3.12). Displacement of the chloride of 156 with 
2-methylimidazole gave alkyl imidazole-1-sulfonate 157, which was methylated with 
Meerwein’s salt to give 158 in excellent yields. 
 
 
Scheme 3.12: Reagents and conditions: (i) SO2Cl2, pyridine, Et2O, -78 °C, 4 h, 83%; 
(ii) 2-methylimidazole, THF, 0 °C to RT, 16 h, 95 %; (iii) Me3O·BF4, DCM, 0 °C to RT, 
20 h, 86%. 
 
As there was no literature precedent for reaction of imidazolium salt 158 with anilines, a 
model system was used for the optimisation of their reaction. It was found that high 
conversion could be achieved using 3 molar equivalents of 158 at reflux in THF over 30 h. 
In an attempt to shorten the reaction time, it was determined that microwave irradiation in 
acetonitrile at 120 °C for 20 min provided similar results. Interestingly, the use of a base 
was detrimental to the sulfation and led to the formation of several by-products. 
These conditions were successfully applied to the synthesis of para- and meta-derivatives 
160 and 161, but no conversion was observed for ortho-aniline 136, suggesting that steric 
hindrance might limit the applicability of the reaction (Table 3.10). The trichloroethyl 
group was stable under the acidic conditions used for sulfamate deprotection. Cleavage of 
the trichloroethyl group was achieved using zinc in a mixture of methanol and acetate 
buffer (pH = 4.65) with no desulfamoylation. The resulting sulfamic acids were converted 
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to sodium salts using ion exchange chromatography, affording targets 164 and 165 in high 
yields. 
 
Table 3.10: Summary of yields for the three step synthesis of amino-sulfate derivatives; 
Reagents and conditions: (i) 158, THF, 67 °C, 30 h; (ii) 10% TFA/DCM, RT, 2 h; 
(iii) a) Zn powder, MeOH, acetate buffer pH = 4.65, 60 °C, 2 h; b) Dowex 50W8X2 Na
+
 
form, H2O. 
 
Position Step 1 Step 2 Step 3 
2’- 159, 0% - - 
3’- 160, 75% 162, 86% 164, 84% 
4’- 161, 82% 163, 91% 165, 80% 
 
Protection of 2-aminobiphenyl 136 with TCE chlorosulfate (156) was not found to be 
affected by steric hindrance but produced bis-N,N-sulfated aminobiphenyl 166 
(Scheme 3.13). In an attempt to prevent double addition of the TCE chlorosulfate group, a 
variety of conditions was explored in which the base component was varied. The best 
results were obtained with 2,6-lutidine, but despite extensive optimisation efforts, the 
major product was always bis-N-sulfated aminobiphenyl 166. As a result, 166 was taken 
forward in the synthesis. Acidic deprotection of the sulfamate protecting group afforded 
167 in 90% yield. Deprotection of the sulfate groups of 167 following the procedure used 
for the synthesis of 164 and 165 afforded bis-N,N-sulfamic acid 168. Interestingly, under 
mild acidic conditions one of the two sulfate groups could be hydrolysed leading to 
isolation of 154. Using a model system for the optimisation of this reaction sequence, it 
was found that a one-pot deprotection/mono-sulfate hydrolysis could be achieved by 
addition of acetic acid to the reaction mixture. Applying these conditions to the synthesis 
of 154 led to isolation of the desired target in moderate yield (Scheme 3.13). 
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Scheme 3.13: Reagents and conditions: (i) 156, NEt3, DMAP, THF, 0 °C to RT, 24 h, 
70%; (ii) 10% TFA/DCM, RT, 2 h, 90%; (iii) Zn powder, MeOH, acetate buffer 
pH = 4.65, AcOH, RT, 24 h; (iv) Dowex 50W8X2 Na
+
 form, H2O, 50%. 
 
3.4. The Biphenyl Ether Sulfamate Series 
Retrosynthetic analysis for the biphenyl ether series indicated that the use of the bis-(2,4-
dimethoxylbenzyl) protecting group would again be beneficial (Figure 3.5). Protected 
sulfamate B would be a key intermediate in the synthesis and could be engaged in SNAr 
reactions with a variety of activated fluorobenzenes. This would afford biphenyl ether 
scaffold C, which could then be further modified (R
1
 to R
2
), before deprotection of the 
sulfamate moiety at the last step to give the desired biphenyl targets D. 
 
 
Figure 3.5: Retrosynthetic analysis for the biphenyl ether series 
 
Key intermediate 173 was initially prepared following a four step synthesis starting with 
mono-benzylation of resorcinol (169) (Scheme 3.14).
136
 Compound 170 was converted into 
bis-protected sulfamate 172 by applying the reaction sequence developed in section 3.2.2. 
The final step involved palladium-catalysed hydrogenation of the O-benzyl protecting 
group. All the reactions proceeded in good yield and 173 was isolated in 27% overall yield. 
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Scheme 3.14: Reagents and conditions: (i) BnBr, K2CO3, MeCN, 80 °C , 24 h, 72%; 
(ii) 19, Cs2CO3, MeCN, 120 °C, μW, 15 min, 95%; (iii) a) Me3O·BF4, DCM, 0 °C to RT, 
8 h; b) 32, MeCN, 42 °C, 24 h, 55%; (iv) H2, 10% Pd/C, MeOH:THF (4:1), 50 °C, 24 h, 
75%. 
 
Concurrently, a shorter reaction sequence to access 173 was 
developed and optimised (Scheme 3.15). The use of an excess of 
resorcinol (169) and an equimolar ratio of caesium carbonate and 
sulfonyl-diimidazole 19 allowed isolation of 174 in 80% yield. 
Excess resorcinol was removed by repeated aqueous washes. The 
use of low temperature and a dilute reaction mixture (0.08 M) 
prevented side-reactions during the methylation/imidazolium 
displacement step. This shorter synthetic scheme provided key 
intermediate 173 in 48% overall yield. 
 
 
Scheme 3.15: Reagents and conditions: (i) 19, Cs2CO3, MeCN, 120 °C, μW, 15 min, 80%; 
(ii) a) Me3O·BF4, DCM:THF (8:1), 0 °C to RT, 9 h; b) 32, MeCN, 42 °C, 24 h, 60%. 
 
SNAr reaction of fluoronitrobenzenes 175 - 177 with 173 in the presence of potassium 
carbonate gave biphenyl ether intermediates 178 - 180, which were cleanly reduced via 
palladium-catalysed flow hydrogenation (Table 3.11). Deprotection of 181 - 183 was 
achieved in a 10% TFA solution in DCM, resulting in high yields of the desired primary 
sulfamates 184 - 186. 
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Table 3.11: Summary of yields for the three step synthesis of aminobiphenyl ether 
derivatives; Reagents and conditions: (i) 173, K2CO3, DMF, 150 °C, μW, 20 min; (ii) H2, 
10% Pd/C, MeOH:THF (3:1), RT, 24 h; (iii) 10% TFA/DCM, RT, 2 h. 
 
Position Step 1 Step 2 Step 3 
2’- 178, 80% 181, 85% 184, 90% 
3’- 179, 75% 182, 87% 185, 82% 
4’- 180, 85% 183, 86% 186, 65% 
 
The acetamido-targets 190 - 192 were prepared in an analogous manner to the biphenyl 
derivatives discussed in the previous section (Table 3.12). 
 
Table 3.12: Summary of yields for the two step synthesis of acetamidobiphenyl ether 
derivatives; Reagents and conditions: (i) Ac2O, NEt3, DCM, RT, 24 h; (ii) 10% 
TFA/DCM, RT, 2 h. 
 
Position Step 1 Step 2 
2’- 187, 87% 190, 85% 
3’- 188, 88% 191, 94% 
4’- 189, 86% 192, 92% 
 
Sulfation of aniline intermediates 181 - 183 with imidazolium salt 
158 proceeded in high yields for para- and meta-derivatives 194 
and 195, but ortho-substitution resulted in a disappointing 15% 
yield of 193 (Table 3.13). Deprotection of the sulfamate and sulfate 
groups was achieved following the procedure previously described 
in section 3.3. 
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Table 3.13: Summary of yields for the three step synthesis of amino-sulfate derivatives; 
Reagents and conditions: (i) 158, THF, 67 °C, 30 h; (ii) 10% TFA/DCM, RT, 2 h; 
(iii) a) Zn powder, MeOH, acetate buffer pH = 4.65, 60 °C, 2 h; b) Dowex 50W8X2 Na
+
 
form, H2O. 
 
Position Step 1 Step 2 Step 3 
2’- 193, 15% - - 
3’- 194, 78% 196, 86% 198, 75% 
4’- 195, 90% 197, 89% 199, 70% 
 
Ortho-aminosulfate target 202 was therefore synthesised using analogous synthetic 
transformations to those employed for the preparation of 154 (Scheme 3.16). Noticeably, 
the sulfation and deprotection steps proceeded in lower yield with the biphenyl ether 
scaffold. 
 
 
Scheme 3.16: Reagents and conditions: (i) 156, NEt3, DMAP, THF, 0 °C to RT, 24 h, 
55%; (ii) 10% TFA/DCM, RT, 2 h, 86%; (iii) a) Zn powder, MeOH, acetate buffer 
pH = 4.65, AcOH, RT, 24 h; b) Dowex 50W8X2 Na
+
 form, H2O 33%. 
 
SNAr reactions of 173 with 2-fluorobenzoic acid or methyl 2-fluorobenzoate, under a 
variety of conditions, resulted in exclusive recovery of starting material. Due to this lack of 
success, the SNAr reaction was conducted on fluorobenzonitriles 203 - 205 (Table 3.14). 
The resulting cyanobiphenyl ethers 206 - 208 were hydrolysed to the corresponding 
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benzoic acids 209 - 211 under basic conditions with prolonged microwave heating. Acidic 
deprotection of the sulfamate moiety afforded targets 212 - 214 in excellent yields. 
 
Table 3.14: Summary of yields for the three step synthesis of benzoic acid derivatives; 
Reagents and conditions: (i) 173, K2CO3, DMF, 150 °C, μW, 20 min; (ii) 2 M aq. NaOH, 
dioxane, 130 °C, μW, 2 h; (iii) 10% TFA/DCM, RT, 2 h. 
 
Position Step 1 Step 2 Step 3 
2’- 206, 81% 209, 45% 212, 90% 
3’- 207, 61% 210, 80% 213, 94% 
4’- 208, 72% 211, 65% 214, 92% 
 
Thus, a set of 13 substituted biphenyl and 12 biphenyl ether sulfamates were prepared. 
 
3.5. Biological Evaluation of the Biphenyl and Biphenyl Ether Sulfamate Series 
In parallel with the synthesis of potential Sulf-2 inhibitors, Dr Gary Beale and Dr Sari 
Alhasan worked on the development of a Sulf-2 primary pharmacology assay. Isolation of 
active Sulf-2 enzyme was challenging and preliminary sulfatase inhibitory activity data 
have only recently been generated for these compounds. To determine the selectivity of the 
compounds, aryl sulfatases A (ARSA) and B (ARSB) inhibition was also assessed. 
Compounds were assayed for their ability to inhibit the desulfation of 
4-methylumbelliferyl sulfate (4-MUS) (Figure 3.6) to the fluorescent phenol, 
4-methylumbelliferone (MU), at a single concentration of 1 mM. 
 
 
Figure 3.6: The action of sulfatases in converting 4-MUS to 4-MU 
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In this assay format, the reported Sulf-1/Sulf-2 inhibitors 5 and 8 exhibited no inhibition of 
Sulf-2, ARSA or ARSB. The measured Sulf-2 inhibition of 5 was considerably different to 
the reported literature value (IC50 = 130 μM).
102
 This can be rationalised by a significant 
difference with the reported assay protocol, where Sulf-2 was incubated with the inhibitors 
at concentrations ranging from 3.75 mM to 1 mM for 10 min and then diluted into assay 
buffer. Hence, it would be expected that the IC50 values of 5 and 8 would be greater than 
the reported ones (i.e. compound 5 IC50 = 128-140 μM; compound 8 IC50 = 214-258 μM). 
The Sulf-2 inhibitory activity of a set of simple monocyclic phenol-derived primary 
sulfamates, prepared by a colleague, was determined (data not included in this thesis). 
Although, these compounds did not inhibit Sulf-2, introduction of a phenyl ring at the 
3-position started to show some inhibition. This was encouraging since this template had 
been selected for further elaboration. 
The Sulf-2 inhibitory activity data for biphenyl inhibitors are presented in Table 3.15 and 
should be compared to compound 13, which showed moderate Sulf-2 inhibition at 1 mM 
and was not selective over ARSB. Carboxylic acid 140, 141, 149 and methyl ester 139 
derivatives retained Sulf-2 inhibition. The amino and aminosulfate functionalities were 
tolerated at the ortho and meta positions (142, 143, 154, 164) but not at the para position 
(144, 165). These polar groups appear to be tolerated in certain positions of the B-ring but 
do not appear to be making significant interactions to improve potency. Alternatively, it 
can be hypothesised that any advantages that are gained, are offset by other factors, such as 
desolvation penalty. 
Introduction of the aminoacetate group (150 - 152) induced a reduction in Sulf-2 inhibitory 
activity. Trichloroethyl protected sulfates derivatives 162 and 163 were also assayed and 
showed a significant improvement in potency against Sulf-2, with more than 90% 
inhibition at 1 mM. Unfortunately these compounds were also potent inhibitors of ARSA 
and ARSB. The increased inhibitory activity of derivatives 162 and 163, which have the 
highest clogP in this series, might suggest the presence of a lipophilic pocket in the enzyme 
active site. 
With the exception of three compounds (142, 143, 164), the biphenyl sulfamate inhibitors 
had superior or similar potency against ARSA than Sulf-2. Interestingly, these three 
compounds were also selective over ARSB. Unlike biphenyl sulfamate 13, the majority of 
substituted biphenyl sulfamates did not inhibit ARSB at 1 mM.  
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Table 3.14: Preliminary sulfatase inhibition data for the biphenyl sulfamates inhibitors. 
The % inhibition are the mean of two independent determinations. 
 
Compound R 
Sulf-2 
% inhibition 
@ 1 mM 
ARSA 
% inhibition 
@ 1 mM 
ARSB 
% inhibition 
@ 1 mM 
13 H 38 14 65 
139 2’-CO2Me 20 86 0 
149 2’-CO2H 31 98 0 
140 3’-CO2H 12 59 0 
141 4’-CO2H 22 85 0 
142 2’-NH2 21 0 0 
143 3’-NH2 20 0 0 
144 4’-NH2 6 61 0 
150 2’-NHAc 4 33 0 
151 3’-NHAc 8 52 33 
152 4’-NHAc 3 0 0 
154 2’-NHSO3Na 37 26 0 
164 3’-NHSO3Na 31 0 0 
165 4’-NHSO3Na 4 0 0 
167 2’-N(SO3CH2CCl3)2 10 63 0 
162 3’-NHSO3CH2CCl3 98 87 59 
163 4’-NHSO3CH2CCl3 92 100 71 
 
The Sulf-2 inhibitory activity data for biphenyl ether inhibitors are presented in Table 3.15. 
Compound 215 is the reference compound, with no substituent on the B-ring, which 
similarly to biphenyl sulfamate 13 showed moderate Sulf-2 inhibition at 1 mM. 
Interestingly, the Sulf-2 SAR of the biphenyl ether series was very similar to the SAR of 
the biphenyl series (Table 3.14) i.e. the carboxylate, the ortho- and meta-amino and 
aminosulfate functionalities are tolerated, whereas the aminoacetate, the para-amino and 
aminosulfate groups induced a reduction in potency. The trichoethyl protected sulfate 
derivatives 196 and 197 were again the most potent derivatives of the series. These two 
molecules were also potent inhibitors of ARSA and ARSB. 
All the biphenyl ether derivatives were moderate to good inhibitors of ARSA. Introduction 
of amino and substituted amino groups at the ortho position of the B-ring increased 
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inhibition of ARSB. This trend was not observed in the biphenyl series. Interestingly, 
incorporation of aminosulfate or trichloroethyl aminosulfate groups also induced a 
significant increase in ARSB inhibition. In general, the biphenyl ether derivatives were less 
selective for Sulf-2 over ARSB than the biphenyl series. 
 
Table 3.15: Preliminary sulfatase inhibition data for the biphenyl sulfamates inhibitors. 
The % inhibition are the mean of two independent determinations. 
 
Compound R 
Sulf-2 
% inhibition 
@ 1 mM 
ARSA 
% inhibition 
@ 1 mM 
ARSB 
% inhibition 
@ 1 mM 
215 H 32 n.d. n.d. 
212 2’-CO2H 10 44 0 
213 3’-CO2H 30 49 0 
214 4’-CO2H 23 33 0 
184 2’-NH2 28 75 13 
185 3’-NH2 31 75 0 
186 4’-NH2 14 75 0 
187 2’-NHAc 11 29 47 
188 3’-NHAc 10 57 0 
189 4’-NHAc 14 45 0 
202 2’-NHSO3Na 56 54 93 
198 3’-NHSO3Na 58 95 85 
199 4’-NHSO3Na 13 34 76 
201 2’-N(SO3CH2CCl3)2 18 82 39 
196 3’-NHSO3CH2CCl3 96 100 97 
197 4’-NHSO3CH2CCl3 95 99 87 
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Figure 3.7: IC50 curves for inhibitor 162, 163 and 197 
 
Sulf-2 IC50 values were determined for three of the most potent inhibitors (162, 163 and 
197) (Figure 3.7). Compound 163 had the highest Sulf-2 inhibitory activity with an IC50 
value of 156 μM. ARSA and ARSB IC50 values were also determined for these three 
compounds, which were not selective for Sulf-2 over ARSA or ARSB (Table 3.16). 
 
Table 3.16: ARSA and ARSB potency of inhibitors 162, 163 and 197 
Compound ARSA IC50 (μM) ARSB IC50 (μM) 
162 76 239 
163 84 222 
197 94 123 
 
  
163, IC
50
 = 393 μM 
162, IC
50
 = 156 μM 
197, IC
50
 = 409 μM 
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3.6. Summary 
In order to attempt to identify tool compounds for use in biological target validation 
studies, a de novo design strategy was employed, based on an analysis of functional groups 
in the endogenous substrate HSPGs, which may be important for binding of Sulf-2. 
Biphenyl and biphenyl ether scaffolds were selected and a set of 31 inhibitors was 
prepared. The aim was to identify a non-saccharide template, with improved 
physicochemical properties compared with 5 and more amenable to large scale and rapid 
analogue synthesis. Preliminary sulfatase inhibition data indicated that biphenyl and 
biphenyl ether sulfamates had superior potency against Sulf-2 compared with 
monosaccharide 5. Incorporation of polar functionalities around the B-ring did not improve 
inhibitory activity. Unexpectedly, trichloroethyl protected sulfates had improved Sulf-2 
inhibition, with compound 162 having an IC50 value of 156 μM. This derivative is the most 
potent Sulf-2 inhibitor identified to date. However, 162 was also a potent inhibitor of 
ARSA and ARSB. 
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Chapter 4. The Extracellular Signal-Regulated Kinase 5 (ERK5) 
and Reported Small-Molecule Inhibitors 
 
4.1. Protein Kinases: Attractive Targets for Cancer Therapy 
Protein phosphorylation, a very common post-translational modification with 500,000 
potential phosphorylation sites in the human proteome, is a central mechanism for 
biological regulation of most eukaryotic cellular processes and cell signalling pathways.
137, 
138
 Upon phosphorylation, the special characteristics of the dianionic phosphate group 
induce critical and distinct biological effects, such as enzyme activation, enzyme 
inhibition, protein localisation, protein degradation, protein-protein interactions and 
transitions in protein state.
137
 
Protein kinases are enzymes that catalyse the transfer of a terminal -phosphoryl group of 
adenosine triphosphate (ATP) to the hydroxyl group of a serine, threonine or tyrosine 
residue in a protein. Phosphorylation on serine, threonine and tyrosine is approximately 
86.4, 11.8 and 1.8% respectively.
139
 Since they account for almost all protein 
phosphorylation, protein kinases mediate most important biological processes, including 
signal transduction but also metabolism, transcription, cell cycle progression, cytoskeletal 
rearrangement and cell movement, apoptosis and differentiation.
140
 The conserved 
sequence of protein kinases has allowed the identification of over five hundred human 
protein kinases by analysis of the human genome.
140, 141
 These represent approximately 2% 
of all human genes and constitute the third largest protein family. Typical protein kinases 
are classified by the residues that they phosphorylate and divided into two families, namely 
serine/threonine kinases and tyrosine kinases. 
The catalytic domain of protein kinases consists of approximately 290 amino acid residues. 
In 1991, the first crystal structure of a protein kinase catalytic domain was solved.
142
 There 
is now over 1,500 structures of approximately 200 kinases in the PDB. The conserved 
secondary structure of the catalytic domain is arranged into twelve subdomains which fold 
into a bi-lobed catalytic core structure.
143
 The small N-terminal lobe is composed of five 
-strands and a single -helix (the regulatory C-helix). The large C-terminal lobe has a 
predominant -helical character and includes the activation loop, located between a 
conserved DFG motif and an APE motif (Figure 4.1).
138
 The cleft formed between the two 
sub-domains, which are connected by the hinge segment, constitutes the active site.
137
 ATP 
binds in the active site and makes the kinase catalytically active. 
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Figure 4.1: Ribbon representation of phosphorylase kinase (PDB code 2phk) showing the 
main features of a kinase catalytic domain
137
 
 
Protein kinases can adopt an active or an inactive state, which have different structural 
conformations.
138
 Whereas a common catalytically competent conformation has been 
established with active kinases, structural diversity is observed with inactive kinases.
138
 In 
the inactive form, the activation segment blocks the active site, preventing ATP from 
binding. Different regularity mechanisms, such as phosphorylation on the activation 
segment or at other sites, removal of inhibitory sequences, or association of other domains 
induce a conformational change, which enables ATP to access the active site, resulting in 
the enzyme to be catalytically active.
139
 The mode of ATP binding is largely consistent 
across kinase families, with the N
1
- and N
6
-positions of the adenine ring system forming 
hydrogen bonds with the peptide backbone of the kinase hinge region.
138
 Van der Vaals 
interactions between the purine heterocycle and apolar aliphatic groups enhance the 
binding affinity. The triphosphate group points out of the adenosine pocket in direction of 
the peptide substrate. The non-transferable - and -phosphate groups form ionic 
interactions with three conserved glycine residues from a flexible N-terminal loop.
137
 A 
second network of interactions mediated by a magnesium ion cofactor ensure correct 
positioning of the -phosphate for transfer (Figure 4.2). The substrate has a low affinity for 
the kinase and its binding is mediated by residues in the vicinity of the phosphorylation 
site. The hydroxyl group to be phosphorylated is oriented toward an aspartate residue on 
the catalytic loop. 
56 
 
Figure 4.2: Simplified illustration of the molecular contacts between ATP and conserved 
active site residues and cofactors involved in catalysis of phosphate transfer (adapted from 
ref 137) 
 
Most protein kinases are organised in a network of kinases, regulated by 
autophosphorylation and phosphorylation by other kinases. Receptor tyrosine kinases are 
cell-surface receptors integrated into the cell membrane which are activated by binding of 
growth factors and transduce extracellular signals.
144
 Non-receptor tyrosine kinases are 
found in the cytoplasm and generally function downstream of receptor tyrosine kinases.
145
 
Commensurate with their prominent role in normal physiology, protein kinase mutations 
and dysregulations play an important role in disease state.
137
 Indeed, approximately half of 
all kinases map with genes associated with major diseases, including cancer, diabetes, 
inflammation and neurodegeneration.
140
 Accordingly, the development of agonists and 
antagonists for this class of enzyme has been a major focus of drug development in the past 
two decades and has afforded new therapeutic opportunities.
146
 In a disease state, 
deregulation of protein kinases occurs through mutation to constitutively active or inactive 
forms, loss of negative regulators or chromosomal rearrangements, leading to the 
formation of active fusion proteins.
138
 This leads to aberrantly regulated signalling 
pathways which in cancer promote tumourigenesis.
147
 The development of large scale 
ribonucleic acid interference (RNAi) screens and phosphoproteomic analyses has 
accelerated the identification of disease-associated kinase targets.
147
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4.2. Kinase Inhibitors in Clinical Use 
Since the primary sequence and three-dimensional structures of kinases share a high degree 
of similarity, the discovery of selective inhibitors with minimum off-target activity has 
been and is still a real challenge.
148
 In 2014, the early scepticism in the drug discovery 
community about kinases as drug targets has now disappeared with the original problems 
being solved or found to be less problematic. In the past 15 years, 27 drugs targeting 
kinases have been approved for clinical use and close to two hundreds are being evaluated 
in clinical trials (Table 4.1).
149
 The most recently approved small-molecule kinase inhibitor 
(Ceritinib) was registered in April 2014 after a Phase I clinical trial for the treatment of 
lung cancer.
150
 Protein kinases are estimated to represent more than 25% of all 
pharmaceutical drug targets.
151
 
Imatinib was the first kinase inhibitor approved for clinical use in 2001.
152
 Imatinib is a 
tyrosine kinase inhibitor originally developed for the treatment of chronic myelogenous 
leukaemia (CML). A reciprocal translocation of genetic material from chromosomes 9 and 
22 results the generation the Bcr-Abl protein kinase, which leads the unregulated 
proliferation of white blood cells.
1
 Imatinib binds to the ATP-binding pocket of the 
Bcr-Abl protein in its inactive form, resulting in a decreased activity of the tyrosine kinase. 
Imatinib demonstrated impressive results in the clinic and validated the targeted therapy 
paradigm.
22
 
Most kinase targeted drug discovery programs are for application in the oncology area, 
where a lack of specificity has not proved to be a barrier to clinical approval.
146
 Due to the 
simultaneous inhibition of several kinases, the majority of approved small-molecule kinase 
inhibitors is used to treat one or more cancer.
149
 Protein kinase inhibitors constitute the 
most important drug class in cancer with 50 to 70% of current cancer drug discovery 
programmes focussing on the development of protein kinase inhibitors.
149
 However, the 
number of kinase inhibitors undergoing clinical trials for the treatment of other diseases, 
such as hypertension, Parkinson’s disease or autoimmune diseases, is rising, and the first 
protein kinase inhibitor for the treatment of inflammatory diseases has recently been 
approved.
149
 
Protein kinase structural studies have guided drug design and explained the mechanism of 
inhibition by identification of the interactions of kinase inhibitor with the kinase ATP-
binding site.
145
 Kinase inhibitors are classified according to the kinase state they inhibit 
and their binding mode. They have been classified into four categories (Types I, II, III and 
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IV) (Figure 4.3).
148
 Type I are ATP-competitive inhibitors targeting the kinase in its active 
conformation and comprise the majority of reported kinase inhibitors. Although the ATP-
binding domain is common to all protein kinases, potent ATP-competitive inhibitors with 
high selectivity for a few kinases have been developed by targeting adjacent hydrophobic 
pockets which are less conserved.
139
 Type II inhibitors target the inactive conformation of 
the kinase and do not compete directly with ATP binding. Targeting the inactive 
conformation of a kinase, which is more diverse, allowed the design of more selective 
inhibitors with an improved therapeutic window. In the inactive state, the DFG motif has 
an ‘out’ conformation which opens a large allosteric binding pocket which has been 
exploited for the tight binding of inhibitors.
146
 Type III inhibitors bind to a site adjacent to 
the ATP-binding site known as the ‘back pocket’ and don’t make any interaction with the 
hinge segment of the kinase. Type IV kinase inhibitors bind to a site remote from the ATP-
binding pocket.
151
 These inhibitors are known as allosteric inhibitors and act by inducing a 
conformational change that make the kinase inactive.
148
 Since they exploit binding sites 
and regulatory mechanisms which are unique to a particular kinase, Type III and IV 
inhibitors exhibit the highest degree of kinase selectivity.
146
 The first allosteric inhibitor, 
Trametinib, was approved for the treatment of melanoma in May 2013.
153, 154
 
 
 
Figure 4.3: Examples of type III and IV kinase inhibitor binding sites. The cMET crystal 
structure in DFG-in, α-C-helix-out conformation (PDB code 3eqg) is to used highlight 
these pockets. The protein kinase is shown in grey, with the hinge region connecting the N- 
and the C-loops in green. Type III inhibitor (PD-325089) binding at the allosteric pocket, 
adjacent to the ATP pocket, is represented by magenta van der Waals surface. The region 
where the Type IV inhibitor GNF-2 binds, the myristoyl pocket in cAbl, is shown in this 
cartoon representation using a russet surface. The activation loop between the DFG and PE 
sequences are colored in red, and the α-C-helix is represented in blue.151  
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Table 4.1: Small-molecule kinase inhibitors approved for clinical use by the FDA 
Name Structure 
Reported 
target 
Approved for clinical 
use 
Afatinib 
 
Her2; EGFR 2013; NSCLC 
Axitinib 
 
VEGFRs; 
PDGFRB; c-Kit 
2012; Renal cell 
carcinoma 
Bosutinib 
 
Bcr-Abl; Src; 
Lyn; Hck 
2012; CML 
Cabozantinib 
 
VEGFRs; Kit; 
Axl; Met; 
TrkB; Flt3; 
Tie2 
2012; Metastatic 
medullary thyroid 
cancer 
Ceritinib 
 
ALK; IGF-1R; 
InsR; ROS1 
2014; NSCLC 
Crizotinib 
 
ALK; c-Met; 
Ros 
2011; NSCLC 
Dabrafenib 
 
B-Raf 
2013; Metastatic 
melanoma 
Dasatinib 
 
Multiple 
tyrosine kinases 
2006; CML, ALL 
Erlotinib 
 
ErbB1 
2004; NSCLC, 
pancreatic cancer 
Gefitinib 
 
EGFR 2003; NSCLC 
Ibrutinib 
 
Bruton’s kinase 
2013; Mantle cell 
lymphoma, CLL 
Imatinib 
 
Bcr-Abl 
c-Kit 
PDGFR 
2001; CML, ALL, 
GIST 
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Name Structure 
Reported 
target 
Approved for clinical 
use 
Lapatinib 
 
ErbB2 
EGFR 
2007; Breast cancer 
Nilotinib 
 
Bcr-Abl 
PDGFR 
2007; CML 
Pazopanib 
 
VEGFR2 
PDGFR 
c-Kit 
2009; Renal cell 
carcinoma, soft tissue 
sarcomas 
Ponatinib 
 
Multiple 
tyrosine kinases 
2012; CML, ALL 
Regorafenib 
 
Multiple 
tyrosine kinases 
2012; Colorectal 
cancer 
Ruxolitinib 
 
JAKs 2011; Myelofibrosis 
Sorafenib 
 
Multiple 
tyrosine kinases 
2005; HCC, renal cell 
carcinoma 
Sunitinib 
 
Multiple 
tyrosine kinases 
2006; Renal cell 
carcinoma, GIST 
Tofacitinib 
 
JAKs 
2012; Rheumatoid 
arthritis 
Trametinib 
 
MEK1/2 
2013; Metastatic 
melanoma 
Vandetanib 
 
Multiple 
tyrosine kinases 
2011; Thyroid cancer 
Vemurafenib 
 
B-Raf 2011; Melanoma 
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An emerging field in kinase drug discovery is the development of ATP-competitive 
irreversible inhibitors, which covalently bind to a nucleophilic cysteine residue in the 
active site. This irreversible binding allows to overcome competition with the high 
millimolar concentration of ATP.
151
 Initially pharmaceutical companies were concerned 
with the high reactivity of these covalent inhibitors that could irreversibly modify 
undesired targets and lead to potential toxicities.
143
 The first irreversible kinase inhibitor, 
Afatinib, was recently approved by the FDA for the treatment of metastatic non-small cell 
lung cancer in July 2013.
155, 156
 A second irreversible kinase inhibitor, Ibrutinib, was 
approved a short time after in November 2013 for the treatment of mantle cell lymphoma 
and chronic lymphocytic leukaemia.
157, 158
 These recent approvals highlight the emergence 
of this type of inhibitor. 
Because kinases have essential roles in cell metabolism, survival and function, their 
inhibition induces a loss of function which cell compensates using extrinsic and intrinsic 
mechanisms leading to drug-resistance.
159
 The development of acquired resistance to 
kinase inhibitors has limited the duration of treatment with kinase inhibitor drugs. 
Resistance occurs through mutations in the targeted kinase gene, reducing drug binding 
affinity. Mutation of the gate-keeper residue which controls the access to the hydrophobic 
pocket located adjacent to the ATP-binding site is the most common mutation. Non-
mutation mediated resistance mechanisms have also been identified and include 
upregulation of alternative kinase pathways or cross-talks between signalling pathways.
137, 
143
 An understanding of acquired resistance to kinase inhibitors will help to overcome the 
problem. One strategy under investigation is to inhibit the resistant kinase with an inhibitor 
that binds at an alternative binding site. Combination of therapeutic agents is currently 
used to overcome resistance in the clinic.  
Despite the recent success of novel kinase inhibitors, the scope of the therapeutic area 
needs to be extended. Basic kinase research is focussed on less than 10% of the human 
kinome, with only 50 protein kinases having been studied in detail. There are still 100 
kinases with unknown functions and half of all kinases are largely uncharacterised.
137
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4.3. The MAP Kinase Signalling Pathways 
The mitogen-activated protein kinase (MAPK) pathways are important cell signalling 
pathways in which alteration of constituent proteins has been implicated in many human 
diseases, including Alzheimer’s disease, Parkinson’s disease and various types of 
cancers.
160
 The MAP kinases are a family of serine/threonine kinases organised in a 
signalling sequence that transduces mainly extracellular signals, leading to changes in the 
cellular environment which modulate gene transcription.
161
 In eukaryotes, 14 MAP kinases 
have been identified and are categorised as conventional MAP kinases or atypical MAP 
kinases.
162
 Extracellular signal-related kinase (ERK) 1/2/5, c-Jun amino (N)-terminal 
kinase (JNK) 1/2/3, and the p38 isoforms (, ,  and ) are classified as conventional 
MAP kinases, whereas ERK3/4/7 and Nemo-like kinase (NLK) are classified as atypical. 
The conventional MAP kinases are characterised by having a conserved tripeptide motif T-
X-Y in their activation loop, which is not conserved in the atypical MAP kinases. Dual 
phosphorylation of the conserved threonine and tyrosine residues is required for their full 
activation.
163
 
 
 
Figure 4.4: General representation of a MAP kinase signalling pathway 
 
A conventional MAP kinase pathway involves three sequentially activated protein kinases 
(Figure 4.4).
164
 The MAP kinase is activated by phosphorylation by a MAP kinase kinase 
(MAPKK), which in turn is activated by a MAP kinase kinase kinase (MAPKKK). The 
MAPKKK is itself activated in response to an extracellular or intracellular stimulus such as 
an increase in growth factor levels, cytokines, or as a stress response.
160
 The MAP kinases 
phosphorylate key cytoplasmic and nuclear regulatory proteins such as transcription 
factors, co-activators and repressors, and chromatin-remodelling molecules.
165
 The 
specificity of each MAP kinase is controlled by docking sites on the targeted substrate.
166
 
MAP kinases control fundamental cellular processes, including growth, proliferation, 
angiogenesis, differentiation, migration and apoptosis.
164
 MAP kinase signalling is 
relatively complex and diverse since one MAPKKK can phosphorylate more than one 
MAPKK and current studies suggest there may be some redundancies and cross-talk 
among members of the MAP kinase family.
166, 167
 Efficient signal transduction in the MAP 
Stimulus MAPKKK MAPKK MAPK 
Downstream 
Response 
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kinase pathways is maintained by adaptor/scaffold proteins through formation of multi-
enzyme complexes.
166
 These adaptor/scaffold proteins temporally bring at close proximity 
multiple members of a MAP kinase pathway to facilitate efficient phosphorylation and 
signal transduction. 
Four MAP kinase pathways have been identified (Figure 4.5).
160
 The pathway involving 
Raf, MEK1/2 and ERK1/2 was the first to be discovered and is referred to as the classical 
MAPK pathway.
162
 Of the MAP kinase pathways, the classical pathway has received the 
most attention as a target for modulation in cancer chemotherapy as it is deregulated in 
approximately one-third of all human cancers and particularly in pancreatic cancers (90%), 
melanoma (63%) and colon cancers (50%).
164, 168
 
 
 
Figure 4.5: Schematic representation of the classical and non-classical MAP kinase 
pathways 
 
The classical MAP kinase pathway is activated by growth factor binding to a receptor 
tyrosine kinase in the plasma membrane such as the fibroblast growth factor receptor 
(FGFR), the platelet-derived growth factor receptor (PDGFR) or the nerve growth factor 
Growth 
Factors Raf MEK1/2 ERK1/2 
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Growth 
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receptor (NGFR).
162
 The phosphorylated receptor tyrosine kinase, in combination with co-
factors, activates a member of the Ras family of proteins (H-Ras, K-Ras or N-Ras) 
(Figure 4.6). The Ras protein then recruits and activates a MAPKKK of the Raf kinase 
family (A-Raf, B-Raf or C-Raf), which in turn phosphorylates one of the MAPKK 
proteins, MEK1 or MEK2, which themselves phosphorylate the MAP kinase ERK1/2 
proteins.
162
 MEK1/2 phosphorylate ERK1/2 on threonine and tyrosine residues in a 
conserved TEY amino acid motif of the activation loop. This dual phosphorylation results 
in activation of ERK1/2, leading to phosphorylation of downstream substrates such as 
protein kinases, including ribosomal S6 kinase (RSK), and transcription factors, including 
Elk-1 and c-Myc.
169
 This ultimately leads to changes in gene expression. The ERK1/2 
cascade plays a central role in the control of cell proliferation and a sustained activation of 
this pathway is required in normal cells.
164
 The ERK1/2 signalling sequence also plays 
important roles in regulating cell shape and motility.
170
 
 
 
Figure 4.6: The classical MAP kinase pathway
105
 
 
Constitutive activation of this pathway can occur through several mechanisms, including 
overexpression of receptor tyrosine kinases, sustained production of growth factor ligands, 
or mutations conferring increased constitutive activity of a member of the pathway, 
allowing signalling to occur in the absence of growth factors.
164
 The ERK1/2 signalling 
pathway is also a key downstream effector of the Ras small GTPase which is the most 
frequently mutated oncogene in human cancers.
171
 The significant contribution of this 
pathway in oncogenic cells development is emphasised by the fact that deregulation can 
occur at several levels. In cancer cells, this pathway promotes cell proliferation, cell 
survival and metastasis. This has triggered intensive research by the pharmaceutical 
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industry to develop inhibitors of the classical MAP kinase pathway for the treatment of 
cancer.
171
 Several inhibitors of this signalling pathway have now been approved for 
clinical use.
143
 This encompasses the B-Raf inhibitors Sorafenib and Vemurafenib, and the 
MEK1/2 inhibitor Trametinib. To date no inhibitors of ERK1 or ERK2 have entered 
clinical trials. 
 
4.4. ERK5 and the ERK5 MAP Kinase Signalling Pathway 
While the conventional MAP kinase pathway is one of the most studied signal transduction 
sequence, less is known about the ERK5 signalling pathway.
166
 ERK5 was simultaneously 
discovered by two independent research groups in 1995.
172, 173
 ERK5 is ubiquitously 
expressed in many tissues but more significantly in the heart, skeletal muscle, placenta, 
lungs and kidneys.
167
 ERK5 double knock-out mice suffered from defects in normal 
cardiac development, maturation of vasculature and angiogenesis, resulting in embryonic 
lethality after 10 days. ERK5 deletion in adult mice leads to lethality within 2-4 weeks. 
ERK5 has also been shown to be a facilitator of neuronal cell survival.
167
 These findings 
demonstrate that ERK5 plays a critical role in normal cell growth cycles, survival and 
differentiations. 
The ERK5 protein kinase is composed of 816 amino acids and has a molecular weight of 
approximately 102 kDa, which is more than double that of the other MAP kinases 
(Figure  4.7). Because of its large size, ERK5 is also known as Big Map Kinase-1 
(BMK-1).
172
 The kinase domain (a.a. 78-406) shares 66% sequence identity to the kinase 
domain of ERK2 and resides in the N-terminal domain. 
 
 
Figure 4.7: Structure of ERK5 and functional domains
167
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The large carboxy-terminal tail of ERK5 makes it distinct from the other typical MAP 
kinases. The C-terminus has an auto-inhibitory function, as truncation leads to increased 
kinase activity. A nuclear localisation signal (NLS) domain (a.a. 505-539), two proline-
rich domains (PR1, 434-465 and PR2, 578-701), a myocyte enhancer factor 2 (MEF2) 
interacting region (a.a. 440-501) and a transcriptional activation domain (a.a. 664-789) are 
localised within the C-terminal domain.
167
 The transcriptional activation domain is 
believed to undergo autophosphorylation which allows it to directly regulate gene 
transcription. This property of ERK5 is unique among the typical MAP kinases.
167
 
In its unphosphorylated state, ERK5 is considered to exist in a folded conformation where 
the N- and C-terminals are interacting (Figure 4.8). The folded conformation leads to 
ERK5 sequestering in the cytoplasm. Dual phosphorylation by MEK5 on Thr218 and 
Tyr220 in the conserved TEY motif of the activation loop triggers a conformational change 
and translocation to the nucleus.
167
 Upon dephosphorylation ERK5 reverts to a folded 
conformation and relocates to the cytoplasm. 
 
 
Figure 4.8: Schematic representation of the process of ERK5 activation for nuclear 
localisation
167
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The ERK5 MAP kinase pathway is the most recently identified MAP kinase module and 
has been associated with cellular proliferation, migration, survival and angiogenesis. This 
pathway can be stimulated by a wide range of signals, including vascular endothelial 
growth factor (VEGF), epidermal growth factor (EGF), fibroblast growth factor (FGF2), 
platelet derived growth factor (PDGF), nerve growth factor (NGF), inflammatory 
cytokines such as interleukin 6 (IL6) and osmotic and hypoxic stress.
167
 Upon activation by 
the extracellular stimuli, the closely related MEKK2 and MEKK3 phosphorylate MEK5 at 
Ser
311
 and Thr
315
. The activator of MEK5 varies depending on the stimuli and the cell 
type.
166
 In turn, MEK5, the sole MAPKK of this signalling cascade, phosphorylates ERK5 
on Thr218 and Tyr220 leading to activation of the protein kinase. Activated ERK5 
translocates to the nucleus where it undergoes autophosphorylation of numerous residues 
on its C-terminal domain, resulting in enhanced transcriptional activity.
167
 
Phosphorylated ERK5 associates with, phosphorylates and activates a number of 
downstream transcription factors, such as the myocyte enhancer factor (MEF) family, 
c-Myc, RSK, c-Fos, c-Jun and Sap1a. Members of the MEF family of transcription factors 
are involved in the modulation of apoptosis. MEF2A and MEF2C are activated by both 
ERK5 and p38 MAP kinases, whereas MEF2D appears to be a specific substrate of 
ERK5.
167
 The MEF2-interaction region and the transcriptional activation domain of the 
C-terminus are crucial for regulating MEF2 activity. In addition, ERK5 is able to 
phosphorylate MEK5 at different Serine residues. All the transcription factors activated by 
ERK5 have been implicated in tumour development.
174
 
 
4.5. ERK5 and Cancer 
A complete understanding of the role of ERK5 in cancer, and the effect of its inhibition on 
tumourigenesis has still to be established. However some key data support the inhibition of 
ERK5 as a potential cancer therapeutic strategy. 
 
The ERK5 Pathway and Prognosis 
ERK5 is overexpressed in tumour cells of a number of breast cancer patients. Patients with 
high levels of ERK5 have a lower median disease-free survival (DFS) time of 14 months 
compared with 34 months for patients with low ERK5 levels (Figure 4.9).
175
 A similar 
correlation of high MEK5 expression and poor prognosis is also detected in prostate cancer 
patients.
176
 Elevated cytoplasmic and nuclear levels of ERK5 serve as an independent 
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prognostic marker for advanced prostate cancer, with nuclear ERK5 expression present 
only in malignant cells.
177
 
 
 
Figure 4.9: Kaplan-Meier plot of disease-free survival (DFS) with respect to ERK5 levels in 
84 early stage breast cancer patients. Patients with high levels of ERK5 (n = 17) had a worse 
disease-free survival time (14.13 months; 95% CI: 3.78-24.48) compared with patients (n = 67) 
with low levels (34.33 months; 95% CI: 18.52-50.14).175 
 
ERK5 Amplification and Overexpression 
Amplification of the MAPK7 gene encoding for ERK5 is observed in approximately 50% 
of HCC tumours.
178
 ERK5 expression was also found to be significantly upregulated in 
breast and prostate cancer patients.
175, 177
 
 
ERK5 and In Vitro Cell Proliferation 
HeLa cells proliferation has been shown to be ERK5-dependent, with dysfunctional ERK5 
blocking entry into S-phase.
179
 Proliferation of MCF7 and BT474 breast cancer cell lines is 
controlled by ERK5 activity.
174
 The expression of the p21 proliferation modulator is 
controlled by ERK5 via suppression of the promyelocytic leukaemia protein (PML).
180
 
PML acts as a tumour suppressor by activating p21 expression leading to tumour 
suppression. Upon phosphorylation by ERK5, PML is inactivated and p21 expression 
ceased (Figure 4.10). ERK5 knockdown via siRNA resulted in increased p21 levels and 
tumour regression.
181
 A recent study has also demonstrated that high ERK5 levels reduce 
p53 expression, increasing cell proliferation.
182
 
Proliferation of the prostate cancer cell line LNCap and the T24 bladder cancer cells is 
affected by RNAi knockdown.
183, 184
 However RNAi techniques have not confirmed the 
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requirement for ERK5 in cell proliferation of the prostate cancer cell line PC3, where 
overexpression of ERK5 increased proliferation. It demonstrates that ERK5 might only 
sustain proliferation in some specific cancer cell lines.
174
  
 
 
Figure 4.10: Regulation of p21 expression via phosphorylation of PML by ERK5 
 
ERK5 and Apoptosis 
Overexpression of wild type ERK5 protects multiple myeloma cells from induced 
apoptosis, whereas overexpression of a catalytically inactive mutant of ERK5 leads to 
increased sensitivity to induced apoptosis.
185
 ERK5 also has a pro-survival role in 
T-lymphocytes which were sensitised to induced apoptosis by ERK5 small hairpin RNA 
knockdown.
186
  
 
The ERK5 Pathway and Metastatic Potential 
ERK5 has been shown to play a role in cellular invasion and metastatic spread, affecting 
cell migration, and attachment to the extracellular matrix, through interactions with the 
vβ3 integrin and focal adhesion kinase (FAK) in breast cancer cells.
167
 FAK signalling 
plays an important role in the regulation of cell adhesion and motility. Overexpression of 
MEK5 in prostate cancer induces expression of matrix metalloproteases-2 and -9 through 
induction of expression of activator protein-1.
176
 The matrix metalloproteases assist the 
migration of cancer cells via degradation of the extracellular matrix. High ERK5 
expression correlates with high levels of bone metastases and poor prognosis in prostate 
70 
cancer patients. In prostate cancer patients, MEK5 overexpression also correlates with 
higher metastatic potential (Figure 4.11).
177
 
 
 
Figure 4.11: MEK5 expression level and presence of metastases
177
; White bars - 
high/moderate MEK5 expression, Black bars - low MEK5 expression 
 
The ERK5 Pathway and Angiogenesis 
In human xenograft models, ERK5 deletion reduced tumour growth in mice and inhibited 
development of tumour blood vessels.
187
 VEGF-stimulated tubular morphogenesis in 
endothelial cells is mediated by ERK5, and VEGF and FGF pro-angiogenic factors have been 
shown to stimulate ERK5 activation in HUVEC cells.188, 189 Activation of Id1 (inhibitor of 
differentiation 1) is triggered under specific conditions by ERK5. Id1 is a negative regulator of 
TSP1 (thrombospondin-1), an angiogenesis inhibitor. Hence, ERK5 might induce angiogenesis 
by constitutional activation of Id1.169 
 
Constitutive Activation of ERK5 
Out of 900 samples sequenced, only one somatic mutation of ERK5 has been reported, 
suggesting that mutation of ERK5 into a constitutively active form is rare in cancer. 
Deregulation of this pathway is therefore likely to occur through altered protein levels, as seen 
in HCC, with the 17p11 amplification being present in 50% of cases.174 Sustained activation of 
upstream signalling, such as Src, may also result in dysregulation of ERK5 signalling.174 
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4.6. Published ERK5 Inhibitors 
Two classes of inhibitors of the MEK5/ERK5 pathway have been described in the 
literature; an oxindole series and a diazepinone series.
190, 191
 Both classes are selective for 
the MEK5/ERK5 pathway over the classical MAP kinase pathway. 
4.6.1. The Oxindole Series 
The oxindole inhibitors 216 and 217 were developed by Boehringer Ingelheim 
Pharmaceuticals and reported in 2008.
191
 Compounds 216 and 217 inhibit both ERK5 and 
MEK5, with 40- to 200-fold greater activity against MEK5 than ERK5 (Table 4.2). 
Significant selectivity for MEK5 over MEK1, MEK2 and ERK1 (IC50 > 6 μM) was 
measured, and both compounds were over 100-fold selective for MEK5 against a panel of 
85 kinases.
191
 
 
Table 4.2: Published MEK5 and ERK5 inhibitory potency of oxindole inhibitors 
Compound R MEK5 IC50 (nM) ERK5 IC50 (nM) 
216 H 4.3 810 
217 M 1.5 59 
 
In Hela cells, the phosphorylation of ERK1/2, p38 or Jnk1/2 MAP kinases was not affected 
by 216 and 217. Cell proliferation was reduced through inhibition of the transcriptional 
activity of MEF2C, a downstream substrate of the MEK5/ERK5 pathway, supporting the 
hypothesis that the oxindole inhibitors affect this pathway. 
 
4.6.2. The Diazepinone Series 
In 2010, the Scripps Research Institute reported XMD8-92 218 as a selective ERK5 
inhibitor.
181
 This compound was discovered serendipitously, following screening of a 
library of compounds initially designed as polo-like kinase (PLK) inhibitors. SARs around 
the polar aliphatic heterocycle of this series was reported in a follow-up communication, 
showing that variation at this position had little effect on activity (Table 4.3).
190
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Table 4.3: Selected ERK5 inhibition data for the diazepinone series
190, 192
 
Compound R
1
 R
2
 ERK5 IC50 (nM) 
219 
 
Me 190 
220 
 
Me 230 
222 
 
Me 260 
223 
 
Me 240 
224 
 
Me 200 
225 
 
Me 130 
226 
 
c-Pent 200 
227 
 
c-Pent 82 
 
A co-crystal structure of 227 bound to ERK5, determined at a resolution of 2.8 Å, was later 
published (Figure 4.12).
193
 Crystals were obtained from a kinase domain construct 
(residues 1-397), which was not phosphorylated on the activation loop. The structure 
confirms the key binding interaction between the 2-aminopyrimidine of 227 and the hinge 
region of the kinase, as previously observed with this inhibitor scaffold. The core has a 
non-planar shape with the N-cyclopentyl group pointing towards the glycine-rich loop and 
the carbonyl of the diazepinone forming a hydrogen bond via a water molecule to the 
backbone nitrogen of the DFG motif Asp200 and the C helix Glu102 (Figure 4.12 B).193 
The aliphatic heterocycle ring system points out of the ATP-binding site towards the 
solvent exposed surface of the kinase and lies adjacent to the glycine-rich loop. This 
position is consistent with the flat SARs reported for analogues incorporating diverse 
water-solubilising groups in this region of the template.
190
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Figure 4.12: Co-crystal structure of compound 227 bound to ERK5 (PDB code 4b99).
193, 
194
 The N-terminal is colored blue. The C-terminal is colored green. The activation loop 
and C helix are colored red, and compound 227 is colored yellow. 
 
XMD8-92 218 displayed high selectivity for ERK5 over a panel of 402 kinases in an in 
vitro ATP-site competition binding assay. In an enzymatic assay, the dissociation constant 
of 218 for ERK5 was 80 nM and no significant MEK5 inhibition was detected with doses 
of up to 50 μM. Compound 218 has been profiled in an in vivo rat pharmacokinetic study, 
demonstrating acceptable half-life, moderate clearance and good bioavailability 
(Table 4.4). XMD8-92 had an anti-proliferative effect in HeLa cells and exhibited in vivo 
growth inhibitory activity in tumour xenograft models, demonstrating the efficacy and 
tolerability of ERK5-targeted cancer treatment in animals.
181
 In a separate in vivo study, 
XMD8-92 prevented the formation of new vasculature. 
 
Table 4.4: In vivo pharmacokinetic parameters for XMD8-92 218. Dose 1 mg/kg i.v. and 
2 mg/kg p.o.
181
 
Cl 
mL/min/kg 
Vd 
L/kg 
t1/2 
h 
F 
% 
37.0 3.4 3.4 69 
 
The discovery of diazepinone inhibitor 218 provided further evidence that inhibition of the 
MEK5/ERK5 pathway may be a valid cancer therapy. This compound was used as a 
benchmark in diverse ‘in house’ biological assays and assisted the development of novel 
ERK5 inhibitors in Newcastle. 
 
A B 
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Chapter 5. Development of Novel ERK5 Inhibitors: the Pyrrole 
Carboxamide Series 
 
5.1. Identification of the Pyrrole Carboxamide Series by HTS 
The pyrrole carboxamide chemotype was identified from a HTS of 48,500 compounds 
from a diverse library and 9,000 compounds from a kinase focussed library using an 
Immobilised Metal Affinity Polarisation (IMAP
TM
) assay.
195
 Three distinct chemical series 
were identified from this screening as having moderate to good ERK5 inhibitory activity: 
the benzothiazoles A, the cyanopyridines B and the pyrrole carboxamides C. 
 
Seventeen members of the pyrrole carboxamide series demonstrated moderate to good 
ERK5 inhibition (IC50 < 33 μM), with seven compounds having an IC50 of less than 10 μM 
and the most potent hit 228 having an IC50 of 0.7 μM. To validate this series, the four most 
potent compounds were re-synthesised and re-tested against ERK5. Two of the 
resynthesised compounds failed to inhibit ERK5, while compound 228 only showed a low 
reduction in potency, having an IC50 of 3.7 μM. 
 
 
5.2. Preliminary SARs in the Pyrrole Carboxamide Series 
Initial SARs were conducted by Dr Sandrine Vidot, Dr Ruth Bawn, Dr Stephanie Myers 
and Dr Lauren Molyneux and led to the identification of functionalities required for 
activity.
196-198
 The key SARs which had been generated at the commencement of the work 
described in this thesis are summarised in Figure 5.1. 
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Figure 5.1: Summary of key SARs for ERK5 inhibition 
 
The pyrrole NH and the amide carbonyl are essential for activity and it is assumed that 
these might interact with key residues in the hinge region of the kinase. 
Introduction of a heteroatom in the benzylic amide side-chain afforded equipotent 
inhibitors, such as compound 229. Truncation of the benzylic amide to heteroaryl amides 
and aliphatic heterocyclic amides conferred a significant and consistent improvement in 
selectivity over p38 (Figure 5.2). 
 
 
Figure 5.2: Hit-to-lead optimisation in the pyrrole carboxamide series 
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Deletion of the aryl ketone resulted in ERK5 IC50 of over 120 μM, demonstrating that this 
fragment is required for ERK5 inhibition. Replacing the benzoyl by a benzyl and reduction 
of the ketone to the corresponding alcohol both resulted in loss of inhibitory activity 
(ERK5 IC50 > 120 µM), suggesting that the carbonyl is crucial for activity and could be 
acting as a hydrogen bond acceptor. Replacement of the 2,3-dichlorophenyl ring with 
heteroaromatic and saturated rings was not tolerated. Incorporation of para-substituents, 
including Me, F, Cl, OMe, O
i
Pr, OCF3 and NO2, gave inactive compounds. Double ortho-
substitution with halogens, such as 2-bromo-6-fluorophenyl 231 or 2-chloro-6-
fluorophenyl 232, was optimal and provided a significant gain of activity. Substitution at 
both meta positions was still an area under investigation. 
 
5.3. Structure-Guided Drug Design 
At the start of the project in 2008, no ERK5 crystal structure had been released in the 
public domain. As a result, homology models were developed and used to guide design. 
Dr Suzan Boyd, on behalf of CRT-DL, developed a first generation homology model based 
on the crystal structure of ERK2 which was identified by BLAST (Basic Local Alignment 
Search Tool) as the closest homologue of ERK5, with 51% sequence similarity in the 
kinase domain region and 78% in the ATP-binding domain. In 2010, a second generation 
homology model of ERK5, based on the crystal structure of the second closest homologue 
of ERK5, namely p38, was developed at Newcastle University by Prof Martin Noble. 
The p38 crystal structure was retrieved from the protein data bank (PDB code 3mpt)199, 
200
 and computationally mutated using MODELLER software to express the amino acid 
residues present in ERK5. Pyrrole carboxamide inhibitors were then built into the ERK5 
model using GROMACS software (Figure 5.3). 
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Figure 5.3: Docking model of 234 in the p38-derived homology model 
 
More recently, the co-crystal structure of ERK5 bound to an analogue of competitor 
compound XMD8-92 was deposited in the protein data bank (PDB code 4b99).
193, 194
 This 
crystal structure was used by Dr Susan Boyd to model some pyrrole carboxamide 
compounds in the ATP-binding site of ERK5 using the GOLD docking program 
(Figure 5.4). 
 
 
Figure 5.4: Putative binding mode of compound 231 in the ATP-binding site of ERK5 
(PDB code 4b99) 
 
The pyrrole carboxamide series is assumed to inhibit ERK5 in an ATP-competitive 
manner, with the pyrrole NH and the amide carbonyl binding to the hinge region of the 
kinase (Figure 5.5). The ketone and the amide carbonyl are coplanar with the pyrrole ring, 
with the 2-bromo-6-fluorophenyl ring orthogonal to this plane and located in a 
hydrophobic pocket with limited amount of space around it. This phenyl ring could be 
making a -stacking interaction with Lys62. The pyridyl side-chain is pointing towards the 
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outside of the binding pocket, probably into solvent. The orientation of the phenyl and 
pyridyl rings was difficult to predict accurately. 
 
 
Figure 5.5: Proposed binding mode of inhibitor 231 in the ERK5 binding site 
 
5.4. Screening Cascade in the ERK5 Project 
The screening sequence starts with the generation of cell free IC50 data for ERK5 using an 
IMAP
TM
 format assay (Figure 5.6).
195
 This assay assesses the potency of compounds by 
measuring fluorescence polarisation. A fluorescent labelled peptide, substrate for ERK5, is 
phosphorylated by the kinase in presence of ATP. The phosphorylation results in the 
formation of a complex between the phospho-group of the peptide and metal-containing 
nanoparticles within the IMAP
TM
 binding agent. This binding leads to a detectable increase 
fluorescence polarisation. In presence of a potent inhibitor, phosphorylation of the labelled 
substrate is impeded and the polarisation readout is reduced. This biochemical assay was 
performed by Ms Ai Ching Wong at Cancer Research Technology Discovery research 
Laboratories (London). 
 
 
Figure 5.6: IMAP
TM
 assay format 
 
Compounds with encouraging primary potency data (IC50  100 nM) were progressed to 
ERK5 cellular activity assays and counter-screened against the closely related p38 
MAPK (Figure 5.7). The ERK5 cellular activity was measured in a MEF2D reporter gene 
A B 
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assay in HEK293 cells. In parallel ERK5 inhibition in an EGF-stimulated HeLa cell-line 
was determined by assessing ERK5 autophosphorylation using Western blotting. These 
preliminary cell-based studies were conducted by Lan-Zhen Wang, Dr Noel Edwards and 
Dr Pamela Lochhead. 
Compounds with encouraging cellular potencies and selectivity data were progressed to a 
panel of in vitro pharmacokinetic screens (plasma protein binding, mouse liver 
microsomes, Caco-2 permeability and solubility) that would inform the selection of 
compounds for studies in mouse. Human liver microsomal (HLM) clearance, inhibition of 
the hERG ion channel and inhibition of cytochrome P450 (Cyp) were not considered to be 
critical for selection of a compound for in vivo studies. The in vitro assays used to assess 
the pharmacokinetics and physicochemical properties in the pyrrole carboxamide series 
were outsourced to Cyprotex, and are summarised in Table 5.1.  
The in vivo pharmacokinetic profile of promising compounds was studied in mice and 
performed by Huw Thomas at the Paul O-Gorman Building, Newcastle Cancer Centre. 
Details of the protocols for ERK5 biochemical and cell-based assays, and for the p38 
selectivity assay are provided in Chapter 10. 
 
 
Figure 5.7: Screening sequence for the evaluation of ERK5 inhibitors  
ERK5 IC
50
 
IMAP assay 
p38  
counter-screen 
ERK5 cellular 
assays 
In vitro PK 
(Ppb, solubility, MLM, Caco-2) 
In vivo mouse PK 
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Table 5.1: Summary of Cyprotex physicochemical and in vitro ADMET assays used for 
the ERK5 inhibitor optimisation 
Assay Explanation 
Solubility 
Assessment of kinetic solubility was performed using a turbidimetric method, 
which entails diluting a test compound solution prepared in DMSO with 
aqueous buffer, and determining precipitation as the end-point by measuring 
absorbance at 620 nm. An estimated precipitation range in M is reported, and 
when this value is less than 1 µM, a compound is considered highly insoluble. 
In cases where the lower solubility limit is between 1 and 100 µM, a compound 
can be considered to be moderately soluble, and above 100 µM denotes high 
solubility. 
Ppb 
Ppb represents the extent of binding to plasma proteins in blood. It is reported as 
fraction unbound (Fu) and is a value between 0 and 1. An Fu of 0.1 indicates 
that, in the blood, 90% of the compound is bound to proteins with 10% free. 
HLM and MLM  
A measure of the vulnerability of a compound to metabolism by cytochrome 
P450 in human or mouse. Figures are quoted as intrinsic clearance (Clint) in units 
of μL/min/mg protein, with lower figures representing low liability to cyp-
mediated metabolism. 
Caco-2 
A measure of the rate of permeation of a compound across a monolayer of a 
Caco-2 cancer cell line, which contain efflux pumps. Intrinsic flux is measured 
by the B2A measurement, with recognition by efflux transporters being implied 
from the ratio of B2A over A2B. Two figures are quoted: apparent permeability 
(Papp) is quoted as a rate in units of 10
-6
 cm/s; efflux ratio (ER) is a ratio with no 
units. A high B2A figure and low ER reflect that a compound is highly 
permeable with low propensity for efflux. 
Cyp inhibition 
Inhibition of cytochrome P450s can lead to drug-drug interactions, or a 
compound inhibiting its own metabolism leading to unpredictable accumulation. 
Inhibition of four isoforms of cytochrome P450 (2D6, 3A4, 2C9 and 2C19) were 
assessed, initially at a single concentration with results presented as per cent 
inhibition (% inh.). Ki values are generated on compounds showing evidence of 
Cyp inhibition. 
hERG inhibition 
The hERG (human ether-a-go-go-related gene product) ion channel is linked to 
cardiac arrhythmias leading to life-threatening Torsades de Pointes. A 
significant therapeutic window over hERG inhibition is required.  
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5.5. Lead Compounds in the Pyrrole Carboxamide Series 
The most promising compounds in this series prior to the work described in this thesis can 
be classified in two categories according to the amide substituent. 
5.5.1. Class 1: Aliphatic Heterocyclic Amides 
 
The most potent analogue in this class of compounds was aminopiperidyl amide 233, 
prepared by Dr Stephanie Myers (ERK5 IC50 = 0.20  0.07 μM, LE = 0.37; p38 
IC50 = 8.5  0.2 μM). The basic centre of the amide substituent has an estimated pKa of 9.5 
and is expected to be protonated under physiological conditions. 
 
Table 5.2: Physicochemical and in vitro ADME properties of 233 
MW clogP clogD HLM Clint
a
 MLM Clint
a 
Caco-2 AB
b
 (ER) 
363 2.6 1.3  5 8 3.8 (9) 
a L/min/mg protein; b Papp 10
-6
 cm.s
-1 
 
Surprisingly compound 233 had high metabolic stability in human and mouse liver 
microsomes but exhibited low apical to basolateral permeability and a high efflux 
ratio (ER) in the Caco-2 assay (Table 5.2). This suggests that the compound might be 
recognised by an efflux transporter, such as P-glycoproteins. 
 
Table 5.3: In vivo pharmacokinetic parameters for 233. Dose 10 mg/kg i.v. and p.o. 
Fu 
Cl 
mL/min/kg 
Clu 
mL/min/kg 
Vd 
L/kg 
t1/2 
min 
F 
% 
0.32 91 284 3.4 61  10 
 
The in vivo pharmacokinetic parameters for compound 233 in mouse are summarised in 
Table 5.3. The compound had low plasma protein binding and a very high total plasma 
clearance, likely caused by metabolism of the high unbound fraction in plasma. The 
unbound clearance was moderate, consistent with low in vitro mouse microsomal 
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clearance. The low bioavailability was consistent with the high total plasma clearance and 
the problems of absorption indicated by the high efflux in the Caco-2 assay. 
The objective for this class of target was to improve potency against ERK5 (IC50  10 nM), 
decrease in vivo plasma clearance, and reduce efflux in the Caco-2 assay.
105
 Optimisation 
of leads with cyclic aliphatic amide substituent was not part of the work described in this 
thesis. 
 
5.5.2. Class 2: Heteroaromatic Amides 
Table 5.4: Biochemical inhibitory activity and Cyp inhibition profiles for key compounds 
in the second class of leads 
 
Compound R
1 
R
2 ERK5 IC50 
(µM)
a 
p38α IC50 
(µM)
b Cyp inhibition 
234 Br 
 
0.67 ± 0.15
 
> 120 Strong (IC50  2 μM) 
231 Br 
 
0.82 ± 0.07 > 120 No Cyp inhibition 
235 Cl 
 
0.60 ± 0.27 > 120 Strong (IC50  2 μM) 
232 Cl 
 
0.58 ± 0.24 93 ± 12 Weak (IC50 > 6 μM) 
236 Cl 
 
0.40 ± 0.09 > 120 Weak (IC50 > 11 μM) 
237 Cl 
 
1.1 ± 0.8
c 
111 ± 1 Strong (IC50  1 μM) 
a
 Determinations ± standard deviation (mean of n = 4 unless otherwise stated); 
b
 n = 2; 
c
 n = 6
 
 
In this class of compounds, similar potencies had been obtained with different 
heteroaromatic amide substituents (4-aminopyridyl, 3-aminopyridyl and 
5-aminopyrimidyl). Compounds had been prioritised for in vitro pharmacokinetic studies 
depending on their cytochrome P450 enzyme inhibition profile (Table 5.4). Unflanked 
4-aminopyridyl analogues 234 and 235 were found to be potent Cyp inhibitors. The 
pyrimidyl ring of compound 236 was an alternative to the pyridyl substituent with no 
inhibition of cytochrome P450s but with a low flux and moderate efflux in the Caco-2 assay. 
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Introduction of methyl groups in ortho position of the pyridyl nitrogen reduced Cyp 
inhibition but significantly decreased the solubility. Replacement of the 4-aminopyridyl 
substituent by the 3-aminopyridyl group afforded compounds with retained ERK5 
inhibitory activity and no cytochrome P450s inhibition. 
 
Table 5.5: Physicochemical and in vitro ADME properties of 231 
MW clogP HLM Clint
a
 MLM Clint
a Caco-2 AB
b
 
(ER) 
hERG 
inhibition 
(μM) 
388 3.1  5 26 34 (0.82) > 25 
a L/min/mg protein; b Papp 10
-6
 cm.s
-1 
 
In the EGF-stimulated HeLa cellular assay, compound 231 showed only a 3-fold reduction 
in potency, having an IC50 of 1.9 μM. This inhibitor was then selected for in vitro ADME 
studies and showed low clearance in mouse and human liver microsomes, high flux and no 
efflux in the Caco-2 assay, and no hERG inhibition (Table 5.5). It was progressed to an in 
vivo pharmacokinetic study in mouse to provide information on leads with heteroaromatic 
amide substituents and study whether the compound could be used in target validation 
studies in vivo. The compound had moderate plasma protein binding and total plasma 
clearance (Table 5.6). The volume of distribution is moderate and the half-life acceptable. 
The good bioavailability of the compound is consistent with the high absorption predicted 
in the Caco-2 assay and the moderate total plasma clearance. 
 
Table 5.6: In vivo pharmacokinetic parameters for 231. Dose 10 mg/kg i.v. and p.o. 
Fu 
Cl 
mL/min/kg 
Clu 
mL/min/kg 
Vd 
L/kg 
t1/2 
min 
F 
% 
0.06 27 459 1.2 65 68 
 
The selectivity profile of inhibitor 231 was determined at the International Center for 
Kinase Profiling in Dundee against a panel of 130 diverse protein kinases. The compound 
was found to be a selective ERK5 kinase inhibitor, with CDK2 being the only kinase with 
over 50% inhibition at 1 M. Independently, 231 was found to inhibit MEK5, the upstream 
activator of ERK5, with an IC50 of 3.4 M. 
Efficacy of compound 231 was assessed in an in vivo tumour xenograft model in CD1 
mice transplanted with A2780 human ovarian carcinoma cells, and compared to the 
efficacy of competitor compound XMD8-92 (218). Following subcutaneous inoculation, 
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the tumours were allowed to grow for 7 days to an average volume of 72 mm
3
. The mice 
were then randomised to receive either vehicle, compound 231 (100 mg/kg p.o.) or 
XMD8-92 218 (50 mg/kg i.p.) twice daily for 11 days. Tumour volumes were measured at 
days 0, 2, 4, 7, 9 and 11, and body weight was also assessed as an indicator for toxicity. No 
weight loss was observed in animals dosed with pyrrole carboxamide inhibitor 231. 
Similar tumour growth regression was observed in mouse treated with 231 or XMD8-92, 
compared with the vehicle control group (Figure 5.8). The results of this study were 
encouraging and demonstrated that an ERK5 inhibitor could be used as an anti-
proliferative agent. 
 
 
Figure 5.8: Treatment of CD1 mice bearing A280 xenograft with 231 (100 mg/kg p.o.) or 
XMD8-92 218 (50 mg/kg i.p.) 
 
With this class of leads, the target for the optimisation program was to improve ERK5 
inhibitory activity, both in the biochemical and cellular assays, whist maintaining the 
attractive pharmacokinetic profile. 
The overall objective in this drug discovery program was to identify in vivo tool 
compounds with improved potency relative to 231 and to identify compounds with the 
potential for pre-clinical development, having sub-ten nanomolar potency against ERK5, 
selectivity over p38 and a suitable ADMET profile. 
  
Control 
218 
231 
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5.6. Development Criteria for Pyrrole Carboxamide Inhibitors Optimisation 
The desired criteria identified for an orally available ERK5 inhibitor pre-clinical candidate 
are outlined in Table 5.7. 
 
Table 5.7: Desired development criteria for a pre-clinical candidate in the ERK5 pyrrole 
carboxamide series. 
Category Parameter Pre-clinical candidate 
Physicochemical 
properties  
Molecular weight (MW) 
sLogP 
TPSA (Å
2
) 
H bond donors 
H bond acceptors 
< 500 
< 5 
75-100 
< 5 
< 10 
In Vitro pharmacology 
ERK5; IC50 (nM) 
LE * 
Selectivity  
Cellular ERK5; IC50 (nM) 
hERG; IC50 (µM) 
< 10 
> 0.3 
> 100-fold 
< 100 
> 25 
In Vitro ADME 
Solubility L/U (µM) ** > 50/50 
PPB (%) *** < 99 
Mouse liver microsomal (MLM) 
clearance (µL/min/mg) 
< 48 
Human liver microsomal (HLM) 
clearance (µL/min/mg) 
< 48 
Caco-2 A2B Papp (x 10
-6
 cm/s) / 
Efflux Ratio 
> 10 /< 2 
CYP1A, CYP2C19, CYP2C9, 
CYP2D6, CYP3A4; IC50 (µM) 
All >10 
In Vivo DMPK 
Clearance (mL/mg/kg) 
Vdss (L/kg) 
Bioavailability (F) (%) 
t1/2 Mouse (h) 
< 30 
> 1 
> 30 
> 1 
* LE = ∆G/HAC (where ∆G = -1.4 logIC50); ** L/U = Lower bound/Upper bound solubility 
range; *** PPB in human 
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Chapter 6. Accessing a Lipophilic Pocket Identified from 
the p38-Derived Homology Model 
 
6.1. Rationale 
A small lipophilic pocket, close to the ribose pocket, was identified in the p38α-derived 
homology model (Figure 6.1). Small alkyl substituents have been used in other drug 
discovery projects to exploit pockets located in a similar region of space.
201, 202
 
 
 
Figure 6.1: Potential lipophilic pocket circled in red, in the p38-derived homology model 
 
In the pyrrole carboxamide series, it was postulated that alkyl substituents at the 3-position 
of the pyrrole core could access this pocket and confer increased inhibitory activity. 
However, substitution at this position was not tolerated and resulted in complete loss of 
ERK5 inhibition and selectivity over p38 (Table 6.1), indicating that the binding site of 
ERK5 could not accommodate substituent at this position.
198
 This 70-fold reduction of 
activity could also be explained by a conformational change of the inhibitor caused by the 
alkyl groups at the 3-position. 
The model suggested that this pocket could also be accessed by two alternative 
modifications, namely alkylation of the amide nitrogen and appending ortho-substituents 
on the heteroaromatic amide side-chain. Exploration of these regions of the template had 
not previously been undertaken.  
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Table 6.1: ERK5 and p38 inhibitory activities of 3-substituted pyrroles 
 
Compound R
1 
R
2 ERK5 IC50 
(µM)
a 
p38α IC50 
(µM)
a 
232 
 
H 0.58 ± 0.24
b 
93 ± 12 
238 Me 40 ± 1 43 ± 2 
239 Et 38 ± 1 50 ± 1 
236 
 
H 0.40 ± 0.09
b 
> 120 
240 Me 69 ± 1 13 ± 2 
a
 Determinations ± standard deviation (mean of n = 2 unless otherwise 
stated); 
b
 n = 4 
 
Initially small alkyl substituted amides were selected for investigation in order to 
determine whether tertiary amides would be tolerated and retain ERK5 inhibition. The 
N-methylpiperidine and 3-aminopyridine amide substituents which adopt a different spatial 
orientation when docked in the ERK5 active site were chosen for investigation. The 
2-bromo-6-fluorobenzoyl and the 2-chloro-6-fluorobenzoyl which provide good ERK5 
inhibitory activity and selectivity over p38 were incorporated in the target molecules 
(Figure 6.2). In parallel with this work, Dr Lauren Molyneux identified 3,6-dichloro-2-
fluorobenzoyl as an alternative substituent at the pyrrole 4-position which conferred 
improved ERK5 inhibition relative to the 2,6-dihalogenatedbenzoyl group. A small set of 
compounds with this new aroyl moiety was then added to the initial list of targets. 
 
 
Figure 6.2: Tertiary amides to be synthesised 
 
The orientation of the pyridyl amide ring in the ERK5 binding site being uncertain, 
substitution of this ring was envisaged at both ortho positions. Alkyl, alkoxy and 
alkylamine substituents were selected for investigation. The variation of the linker should 
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introduce different flexibility and orientation for these substituents, resulting in a slightly 
different occupation of space. This should maximise the chance to access the lipophilic 
pocket. The 2-chloro-6-fluoro and 3,6-dichloro-2-fluoroaroyl rings were incorporated in 
the target molecules (Figure 6.3). 
 
 
Figure 6.3: Ortho-substituted heteroaromatic amides to be synthesised 
 
6.2. Synthesis of N-alkylated 4-Amino-1-methylpiperidyl and 3-Aminopyridyl 
Amides 
Carboxylic acids 244, 249 and 250 were key building blocks for the synthesis of amide 
derivatives. These were prepared in excellent yields following a two step procedure, 
starting with a Friedel-Crafts acylation of commercially available reagents, followed by 
basic hydrolysis of the methyl ester (Scheme 6.1 and 6.2). This two step procedure, which 
had been previously developed within the ERK5 project, was carried out on a large scale. 
 
 
Scheme 6.1: Reagents and conditions: (i) SOCl2, DMF, THF, 0 °C to RT, 5 h; (ii) AlCl3, 
methyl 1H-pyrrole-2-carboxylate, 0 °C to RT, 20 h, 96%, (iii) LiOH, H2O/THF, 67 °C, 
18 h, 98%. 
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Scheme 6.2: Reagents and conditions: (i) AlCl3, methyl 1H-pyrrole-2-carboxylate, 0 °C to 
RT, 20 h (247, X = H, 96%; 248, X = Cl, 97%); (ii) LiOH, H2O/THF, 67 °C, 18 h (249, 
X = H, 93%; 250, X = Cl, 95%). 
 
Exploration of the amide substitution was achieved through the preparation of secondary 
4-aminopiperidine and 3-aminopyridine. N-Alkylated 1-methylpiperidines-4-amine can be 
synthesised by reductive amination from 1-methyl-4-piperidone (251).
203
 This literature 
procedure, which uses sodium cyanoborohydride as reducing agent, was implemented 
(Scheme 6.3). Although the reactions were proceeding well when monitored by LC-MS, 
the desired amines were only obtained in low to moderate yields. The difficult isolation 
was caused by the high aqueous solubility and high volatility of these small secondary 
aliphatic amines. 
 
 
Scheme 6.3: Reagents and conditions: (i) AcOH, MgSO4, methyl-, ethyl-, or isopropyl-
amine, MeOH, 30 min, RT; (ii) sodium cyanoborohydride, MeOH, 0 °C to RT, 24 h (252, 
R = Me, 9%; 253, R = Et, 24%, 254, R = 
i
Pr, 40%); (iii) 244 or 249, EDCI.HCl, DMAP, 
DCM, 0 °C to RT, 24 h (255, R = Me, X = Cl, 18%; 256, R = Et, X = Cl, 20%; 257, 
R = Et, X = Br, 22%). 
 
Coupling of 4-amino-1-methylpiperidine has routinely been achieved in the ERK5 project 
using carbonyldiimidazole (CDI) as the coupling reagent.
197, 198
 However, these conditions 
were unsuccessful with N-alkylated 1-methylpipepirines-4-amine 252 - 254 and an array of 
different coupling conditions had to be investigated (Table 6.2). Among these conditions, 
only the EDCI-mediated coupling in presence of catalytic DMAP afforded the desired 
amide targets in high purity.
204
 This coupling was low yielding and limited to small alkyl 
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groups. Indeed, no desired product was isolated using N-isopropyl-1-methylpiperidin-4-
amine 254, suggesting that alternative conditions will have to be employed with bulky 
amines. At this point, biological evaluation of the first set of compounds 255 - 257 
indicated that ERK5 inhibitory activity was not retained with tertiary piperidine amides, 
and, as a result, the synthesis of the remaining targets was ceased. 
 
Table 6.2: Exploration of conditions for the coupling of N-alkylated 1-methylpipepirines-
4-amine 252 - 254 
# Conditions Observation 
1 Microwave-assisted PCl3 coupling 
5% of product detected by 
LC-MS in complex mixture 
2 Cyanuric fluoride 
Acyl fluoride was formed but 
did not react with the amine 
3 T3P No reaction 
4 EDCI and 2-hydroxypyridine N-oxide No reaction 
5 EDCI and HOBt Complex mixture of products 
6 EDCI and DMAP 
40% of product detected by 
LC-MS 
 
Ullman coupling of 3-bromopyridine (258) with methylamine, following literature 
conditions, afforded N-methylpyridin-3-amine (259) in a good 80% yield.
205
 The same 
reaction conditions produced N-isopropylpyridin-3-amine (260) only in 22% yield, 
emphasising the limitation of this ‘green’ Ullman coupling methodology developed by Jiao 
et al. (Scheme 6.4).
205
 Synthesis of N-ethylpyridin-3-amine (263) was achieved via 
reductive amination of 3-aminopyridine (261) with acetaldehyde in trifluoroethanol 
(Scheme 6.4).
206
 
 
 
Scheme 6.4: Reagents and conditions: (i) methyl- or isopropyl-amine, H2O, Cu, 100 °C, 
24 h (259, R = Me, 80%; 260, R = 
i
Pr, 22%); (ii) acetaldehyde, MgSO4, trifluoroethanol, 
1 h, RT; (iii) NaBH4, trifluoroethanol, 0 °C to RT, 1 h, 67%.  
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A previous investigation of amide coupling conditions of aromatic heterocyclic amines to 
carboxylic acids 244 and 249 conducted in the ERK5 project led to the identification of a 
PCl3 microwave-assisted coupling as optimal.
198
 This methodology was originally 
developed by Colombo et al. for the coupling of electron-poor amines.
207
 The PCl3-
mediated coupling was successfully implemented with N-alkylated 3-aminopyridines 259, 
260, 263 and afforded the target compounds in good yields (Table 6.3). 
 
Table 6.3: Summary of yields for the PCl3-mediated amide coupling; Reagents and 
conditions: (i) N-alkylated 3-aminopyridine, PCl3, MeCN, 150 °C, µW, 7 min. 
 
R
1 
R
2 
Yield 
 
Me 264, 62% 
Et 265, 50% 
i
Pr 266, 55% 
 
Me 267, 60% 
Et 268, 40% 
i
Pr 269, 50% 
 
Me 270, 42% 
Et 271, 60% 
i
Pr 272, 62% 
 
6.3. Synthesis of 3-Aminopyridyl Amides Bearing Substituent at the 2- or 
4-Position 
The strategy employed for the synthesis of ortho-substituted amides was to prepare the 
requisite aminopyridines from 2-chloro-3-nitropyridine (273) or 4-chloro-3-nitropyridine 
(293). When the desired 3-aminopyridine was commercially available at an acceptable 
price, the reagent was purchased and directly coupled to pyrrole carboxylate 249 and 250. 
Suzuki-Miyaura cross-coupling was used to introduce alkyl substituents at the 2-position 
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of the pyridyl ring (Scheme 6.5).
208
 Interestingly, the allyl group isomerised during the 
reaction to form the more substituted and conjugated alkene (E)-bond of compound 275. 
SNAr reactions were performed to obtain 276 and 277 in high yields.
209
 The 2-substituted-
3-nitropyridines 274 - 277 were cleanly reduced via palladium-catalysed flow 
hydrogenation (Scheme 6.5). 
 
 
Scheme 6.5: Reagents and conditions: (i) K2CO3, ethylboronic acid or allylboronic acid 
pinacol ester, tetrakis(triphenylphosphine)palladium(0), dioxane, 100 °C, 48 h (274, 56%; 
275, 53%); (ii) sodium ethoxide, EtOH, RT, 17 h, 62%; (iii) K2CO3, pyrrolidine, RT, 17 h, 
83%; (iv) H2, 10% Pd/C, MeOH, 40 °C, 8 h (278, 93%; 279, 90%; 280, 76%; 281, 92%). 
 
Coupling of the aminopyridines to pyrrole carboxylate 249 and 250 was achieved using 
three different methodologies (Table 6.4). The PCl3-mediated amide coupling was optimal 
for alkyl substituted 3-aminopyridines but resulted in oxygen dealkylation when employed 
for the coupling of 2-ethoxy- and 2-methoxypyridine-3-amines. For these amines, coupling 
using cyanuric fluoride allowed isolation of the desired product in moderate to good 
yields.
210
 Coupling of 2-(pyrrolidine-1-yl)pyridine-3-amine (281) proved challenging with 
the acidic PCl3 and cyanuric fluoride coupling, producing a complex mixture of products. 
Non acidic conditions using the Mukaiyama pyridinium coupling reagent to activate the 
acid were applied and led to the isolation of 286 and 292 in moderate yields (Table 6.4).
211
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Table 6.4: Summary of yields for the amide coupling; Reagents and conditions: (i) amine, 
PCl3, MeCN, 150 °C, µW, 7 min; (ii) pyridine, cyanuric fluoride, MeCN, RT, 30 min then 
amine, 40 °C, 24 h; (iii) 2-chloro-1-methylpyridinium, NEt3, side-chain, DCM, 42 °C, 
24 h. 
 
R
1 
R
2 
Coupling conditions Yield 
 
Et PCl3 282, 35% 
n
Pr PCl3 283, 24% 
OMe Cyanuric fluoride 284, 62% 
OEt Cyanuric fluoride 285, 41% 
 
Mukaiyama 286, 31% 
 
Me PCl3 287, 63% 
Et PCl3 288, 41% 
n
Pr PCl3 289, 32% 
OMe Cyanuric fluoride 290, 27% 
OEt Cyanuric fluoride 291, 62% 
 
Mukaiyama 292, 30% 
 
Compounds incorporating the same substituents at 4-position of the pyridyl ring were also 
prepared. A similar reaction sequence to that described for the preparation of 2-substituted-
3-aminopyridine was employed (Scheme 6.6). Suzuki-Miyaura cross-couplings on 
4-chloro-3-nitropyridine (293) produced more complicated mixtures of products with 
dehalogenation being observed. However, this did not prevent the isolation of the target 
products in high purity and moderate yields. Displacement of the 4-chloro group with 
sodium methoxide, sodium ethoxide and pyrrolidine proceeded at room temperature to 
give 297, 298 and 299. Hydrogenation was achieved in an analogous manner as previously 
described. Reduction of the nitro group and the alkene bound of 295 and 296 was achieved 
in a single process (Scheme 6.6). 
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Scheme 6.6: Reagents and conditions: (i) K2CO3, ethylboronic acid, vinyl boronic acid or 
allylboronic acid pinacol ester, tetrakis(triphenylphosphine)palladium(0), dioxane, 100 °C, 
48 h (294, 50%; 295, 41%; 296, 35%); (ii) NaOMe, MeOH, RT, 17 h, 84%; (iii) NaOEt, 
EtOH, RT, 17 h, 76%; (iv) K2CO3, pyrrolidine, RT, 17 h, 91%; (v) H2, 10% Pd/C, MeOH, 
40 °C, 8 h (300, 80 - 82%; 301, 87%; 302, 91%; 303, 93%; 304, 97%). 
 
To complete the synthesis of the ortho-substituted pyridyl amide targets, aminopyridine 
intermediates 300 - 304 were coupled to pyrrole carboxylic acids 249 and 250. The 
PCl3-mediated protocol was employed for the alkyl substituted aminopyridines whereas an 
amended Mukaiyama procedure, free of base, was required for the other amines 
(Table 6.5). This alternative procedure significantly reduced the amount of side reactions 
detected under a range of other coupling conditions. It is assumed that electron-donating 
groups at the 4-position of the pyridyl ring increased the reactivity of the pyridyl nitrogen, 
which competed with the amino group in the coupling. In the absence of base, the pyridyl 
nitrogen gets protonated and the coupling takes place via the amino group. 
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Table 6.5: Summary of yields for the coupling step; Reagents and conditions: (i) amine, 
PCl3, MeCN, 150 °C, µW, 7 min; (ii) 2-chloro-1-methylpyridinium, amine, DCM, 42 °C, 
24 h. 
 
R
1 
R
2 
Coupling conditions Yield 
 
Me PCl3 305, 65% 
Et PCl3 306, 61% 
n
Pr PCl3 307, 48% 
OMe Amended Mukaiyama 308, 14% 
OEt Amended Mukaiyama 309, 21% 
 
Amended Mukaiyama 310, 23% 
 
Me PCl3 311, 62% 
Et PCl3 312, 48% 
n
Pr PCl3 313, 41% 
OMe Amended Mukaiyama 314, 5% 
OEt Amended Mukaiyama 315, 13% 
 
Amended Mukaiyama 316, 34% 
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6.4. SARs and Biological Evaluation of N-Alkylated Amides and 
3-Aminopyridyl Amides with Substituent at the 2- or 4-Position 
The ERK5 inhibitory activity and p38 counterscreening data for compounds 255 - 257 
are presented in Table 6.6 and should be compared to the secondary amide derivatives 233 
and 317. In each case, ERK5 inhibition was reduced by at least 10-fold, with the largest 
alkyled amides being the least active. Substitution of the amide NH in this series did not 
produce compounds with improved selectivity for ERK5 over p38 (Table 6.6). 
In the pyridyl series, alkylation of the amide NH also reduced ERK5 binding affinity, 
independently of the aroyl substituents (Table 6.7). Interestingly, compounds 266 and 269 
retained good ERK5 inhibitory activity, suggesting that inhibitors with large amide 
substituents maintain good affinity for ERK5 with a possible alternative binding mode. 
However, compound 269 inhibited p38 with an IC50 value of 5.5 μM, demonstrating that 
ERK5 selectivity would be difficult to achieve with such tertiary amides. 
Table 6.6: ERK5 and p38 inhibitory activities of N-alkylated 1-methylpiperidyl amides 
 
Compound X R ERK5 IC50 (µM)
a
 p38α IC50 (µM)
a
 
233 * 
Cl 
H 0.19 ± 0.07
b 
8.5 ± 0.2 
255 Me 2.5 ± 0.4 n.d. 
256 Et 3.7 ± 0.8 22.0 ± 1.4 
317 * 
Br 
H 0.29 ± 0.12
c 
11.2 ± 0.2 
257 Et 4.9 ± 0.9 38.5 ± 5.2 
a
 Determinations ± standard deviation (mean of n = 2 unless otherwise stated); 
b
 n = 4; 
c
 n = 8; 
* compound prepared by Dr Stephanie Myers; n.d. = not determined  
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Table 6.7: ERK5 and p38 inhibitory activities of N-alkylated 3-aminopyridyl amides 
 
Compound R
1 
R
2 
ERK5 IC50 (µM)
a p38α IC50 (µM)
a 
231 * 
 
H 0.82 ± 0.01
b 
> 120 
264 Me 4.5 ± 1.0 > 120 
265 Et 2.1 ± 0.1 34.2 ± 0.1 
266 
i
Pr 1.1 ± 0.5
d 
n.d. 
232 * 
 
H 0.58 ± 0.24
b 
93.2 ± 12.5 
267 Me 3.3 ± 1.0 54.7 ± 3.3 
268 Et 1.3 ± 0.4 17.0 ± 1.1 
269 
i
Pr 0.98 ± 0.25
b
 5.5 ± 0.2 
318 ** 
 
H 0.066 ± 0.033
c
 >120 
270 Me 4.4 ± 0.1 n.d. 
271 Et 1.8 ± 0.1 n.d. 
272 
i
Pr 2.2 ± 0.1 n.d. 
a
 Determinations ± standard deviation (mean of n = 2 unless otherwise stated); 
b
 n = 4; 
c
 n = 7; 
d
 n = 8; * compound prepared by Dr Stephanie Myers; ** compound prepared by Dr Lauren 
Molyneux; n.d. = not determined 
 
In both series, independently of the aroyl substitution pattern, the best results were always 
obtained with a non-alkylated amide. These results demonstrate that alkyl groups on the 
amide nitrogen might not access the pocket identified in the p38α-derived homology 
model. These groups probably clash with the protein ATP-binding domain wall, leading to 
a significant loss of inhibitory activity. These alkyl groups might also induce a twist of the 
amide-pyrrole bond and lead to a reduced interaction between the amide carbonyl and the 
hinge region of the kinase. 
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Table 6.8: ERK5 inhibitory activity of 2-substituted 3-aminopyridyl amides 
Compound R
1 
R
2 
ERK5 IC50 (µM)
a 
232 * 
 
H 0.58 ± 0.24
b 
319 Me 0.96 ± 0.16
b
 
282 Et 1.6 ± 0.2 
283 
n
Pr 5.3 ± 1.5 
284 OMe 2.8 ± 0.7 
285 OEt 5.9 ± 0.1 
286 
 
8.0 ± 1.4 
318 ** 
 
H 0.066 ± 0.033
c
 
287 Me 0.39 ± 0.20
d 
288 Et 1.0 ± 0.2 
289 
n
Pr 3.5 ± 1.6 
290 OMe 1.2 ± 0.1 
291 OEt 6.1 ± 1.8 
292 
 
12.2 ± 2.7 
a
 Determinations ± standard deviation (mean of n = 2 unless otherwise 
stated); 
b
 n = 4; 
c
 n = 7; 
d
 n = 6; * compound prepared by Dr Stephanie 
Myers; ** compound prepared by Dr Lauren Molyneux 
 
The ERK5 inhibitory activity data for compounds 282 - 292 and 300 - 316 are presented in 
Table 6.8 and 6.9, and should be compared to the unsubstituted pyridyl amides 232 and 
318. All the substituents introduced at the ortho positions of the pyridyl ring induced a 
significant reduction of ERK5 inhibition. In the 2-chloro-6-fluorobenzoyl series, although 
the methyl group was tolerated, any larger substituent led to a significant reduction of 
ERK5 binding affinity. Inhibitory activity data are similar for compounds with identical 
substituents at the 2- or the 4-position of the pyridyl ring. 
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Table 6.9: ERK5 inhibitory activity of 4-substituted 3-aminopyridyl amides 
Compound R
1 
R
2 
ERK5 IC50 (µM)
a 
232 * 
 
H 0.58 ± 0.24
b 
305 Me 1.3 ± 0.5
d 
306 Et 2.1 ± 0.5 
307 
n
Pr 3.3 ± 0.6 
308 OMe 2.2 ± 0.1 
309 OEt 2.3 ± 0.5 
310 
 
16.5 ± 6.6 
318 ** 
 
H 0.066 ± 0.033
c
 
311 Me 0.41 ± 0.22
d 
312 Et 1.2 ± 0.8 
313 
n
Pr 2.8 ± 0.8 
314 OMe 1.0 ± 0.1 
315 OEt 1.4 ± 0.4 
316 
 
8.7 ± 2.9 
a
 Determinations ± standard deviation (mean of n = 2 unless otherwise 
stated); 
b
 n = 4; 
c
 n = 7; 
d
 n = 6; * compound prepared by Dr Stephanie 
Myers; ** compound prepared by Dr Lauren Molyneux 
 
Independently of the aroyl substitution pattern, the best ERK5 inhibition values were 
observed with an unsubstituted pyridyl ring. These results demonstrate that substituents at 
the ortho position of the heteroaromatic ring might not access the pocket identified in the 
p38α-derived homology model. Ortho-substituents probably clash with the protein ATP-
binding cleft wall, leading to a significant loss of inhibitory activity. The relatively modest 
potency of compounds 282 - 292 and 300 - 316 compared with the parent unsubstituted 
ERK5 inhibitors 232 and 318 militate against further optimisation at these positions of the 
pyrrole carboxamide scaffold. 
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Chapter 7. Structure-Activity Relationship Studies around the Meta 
Position of the Benzoyl Ring 
 
7.1. Rationale 
Examination of compound 234 modelled in the ERK5 ATP-binding site from the 
p38-derived homology model led to the identification of a putative pocket highlighted in 
Figure 7.1. This resulted in the design of a new set of potential ERK5 inhibitors, 
incorporating a third substituent at the 3-position of the aroyl ring, which could improve 
binding interactions with the ATP-binding domain of ERK5. 
 
 
Figure 7.1: Docking of compound 234 in the p38-derived homology model with 
potential pocket to be exploited in red. 
 
Exploration of this area of the template had been previously explored by other members of 
the ERK5 project (Dr Stephanie Myers, Dr Lauren Molyneux and Amy Heptinstall).
197, 198
 
To initially test the hypothesis, a variety of small meta-substituents (F, Cl, Me, Et and 
vinyl) were introduced on a 2,6-difluoroaroyl motif to target the putative hydrophobic 
pocket. The preliminary results indicated that addition of a substituent at the 3-position of 
the benzoyl ring was tolerated and in most cases improved potency (Table 7.1).
197, 198
 For 
instance, introduction of a meta-chlorine resulted in a 3.5-fold inhibition improvement, 
with compound 322 having an IC50 of 0.29 μM. These positive results suggested that 
further SARs around the 3-position of the aroyl ring could be beneficial. 
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Table 7.1: ERK5 inhibitory activity of meta-substituted difluoroaroyl pyrroles 
Compound R
1 
ERK5 IC50 (µM)
a 
320 H 1.1 ± 0.27
b 
321 F 0.40 ± 0.11 
322 Cl 0.29 ± 0.11
 
323 Me 0.66 ± 0.27
b 
324 Et 1.3 ± 0.15 
325 vinyl 1.6 ± 0.34
c
 
a
 Determinations ± standard deviation (mean of n = 4 unless 
otherwise stated); 
b
 n = 6; 
c
 n = 2 
 
With the hypothesis validated, it was then decided to incorporate the best meta-substituents 
identified from the initial study on the 2-chloro-6-fluorobenzoyl motif, which exhibited 
improved potency relative to the 2,6-difluorobenzoyl moiety, as discussed in section 5.2. 
Since the position of the two halogens on the aroyl ring was difficult to predict using 
docking software, two series of analogues were prepared for each meta-substituent 
(Table 7.2). Direct matched pair analysis of these inhibitors was expected to reveal 
whether the group at the 3-position had to be introduced adjacent to the fluorine or to the 
chlorine. 
 
Table 7.2: ERK5 inhibitory activity of meta-substituted 2-chloro-6-fluoroaroyl pyrroles 
Compound R
1 
R
2
 ERK5 IC50 (µM)
a 
232 H H 0.58 ± 0.24
 
326 F H 0.71 ± 0.31 
318 Cl H 0.066 ± 0.033
b 
327 Me H 0.51 ± 0.28
c 
328 Br H 0.066 ± 0.026
 
329 H F 1.0 ± 0.28 
330 H Cl 0.26 ± 0.10
d 
331 H Me 0.65 ± 0.37
e
 
a
 Determinations ± standard deviation (mean of n = 4 unless otherwise 
stated); 
b
 n = 7; 
c
 n = 8; 
d
 n = 9; 
e
 n = 6 
 
Interestingly, modification of the meta position of inhibitor 232 mainly produced 
compounds with similar activities, with the exception of compounds 318 and 330 which 
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incorporate a meta-chlorine (Table 7.2). Inhibitor 318 exhibited a sharp increase in ERK5 
inhibitory activity with an almost 9-fold improvement relative to 232. It was the first 
pyrrole carboxamide inhibitor with an IC50 value below 100 nM. Comparison of the 
inhibitory activities of 318 and 330 suggested that the meta-substitution was more 
beneficial when introduced adjacent to the fluorine. 
To explain the increase in ERK5 inhibition, Dr Susan Boyd at Cancer Research 
Technology Discovery Laboratories docked compound 318 in the ATP-binding site of 
ERK5 from the published protein co-crystal structure (PDB code 4b99) using the GOLD 
docking program (Figure 7.2 A). The model shows that the trihalogenated ring fits nicely 
in the back pocket of the ATP-binding domain and that the pyrrole NH and the amide 
carbonyl form two hydrogen bonds with the hinge region of the kinase (Figure 7.2 B). The 
meta-chlorine is positioned ideally to make a halogen bond with the backbone carbonyl 
oxygen of Asn189 (Figure 7.2 B). The chlorine-oxygen distance is 3.6 Å with the two 
atoms positioned in a “head on” fashion, which could lead to a low affinity halogen bond. 
Optimal halogen-oxygen distance in classical halogen bonds is about 3.0 Å and deviations 
from it reduce the attractive overlap of the electron-deficient σ-hole with the lone-pair of 
the carbonyl.
212
 
 
 
Figure 7.2: A) Modelling of 318 in the ATP-binding site of ERK5 (PDB code 4b99); 
B) Potential interactions between the inhibitor and the kinase. 
 
To confirm the hypothesis that the meta-chlorine could form a halogen bonding interaction 
with a backbone carbonyl, the matched pair analogue of 318 incorporating a bromine at the 
3-position of the benzoyl moiety was synthesised. Bromines have a larger σ-hole and 
classically lead to an increase in halogen bond strength.
213
 Compound 328 retained ERK5 
inhibition with an IC50 of 66 nM. The identical ERK5 inhibition of 328 relative to 318 did 
not allow to conclude whether the meta-halogen was involved in halogen bonding 
ASP 
MET 
ASN 
A B 
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interactions with the protein. A co-crystal structure of inhibitor 318 and ERK5 will be 
required to answer this question. 
In the EGF-stimulated HeLa cellular assay, compound 318 showed only a 3-fold reduction 
in potency, having a mean IC50 value of 0.19 μM from three independent experiments. This 
inhibitor was then selected for in vitro ADME assessment and showed medium clearance 
in mouse and human liver microsomes, high flux and no efflux in the Caco-2 assay, and 
poor solubility (Table 7.3). Incorporation of the meta-chlorine increased the clogP and 
reduced the topological polar surface area (tPSA), resulting in lower solubility.
214
 
Oxidative dehalogenation by cytochrome P450s might cause the medium metabolic 
turnover of compound 318.
215
 
 
Table 7.3: Physicochemical and in vitro ADME data for 318 
MW clogP 
tPSA 
Å
2
 
Sol 
(μM) 
HLM 
Clint
a
 
MLM 
Clint
a 
Caco-2 AB
b
 
(ER) 
378 3.8 75 10-65 32 47 25 (0.7) 
a L/min/mg protein; b Papp 10
-6
 cm.s
-1 
 
Despite these non-optimal ADMET properties, 318 was progressed to an in vivo 
pharmacokinetic study in mouse (Table 7.4). The compound had high plasma protein 
binding and low total plasma clearance, with a hepatic extraction ratio of approximately 
10%. The unbound clearance was high, consistent with the metabolic instability detected in 
mouse liver microsomes. The volume of distribution was low for a compound with a 
weakly basic centre, and the half-life was acceptable. The moderate oral bioavailability of 
the compound is not consistent with the good absorption predicted in the Caco-2 assay and 
the low total plasma clearance. This implies that 318 suffered impairment of absorption 
(Fabs ≈ 30%) probably due to the poor solubility of the compound. 
 
Table 7.4: In vivo pharmacokinetic parameters for 318. Dose 10 mg/kg i.v. and p.o. 
Fu 
Cl 
mL/min/kg 
Clu 
mL/min/kg 
Vd 
L/kg 
t1/2 
min 
F 
% 
0.02 11 550 0.3 103 24 
 
The data presented in Table 7.3 and 7.4 demonstrated the necessity to identify an 
alternative meta-substituent which could retain the high biochemical and cellular inhibitory 
activities of 318, and improve the physicochemical and pharmacokinetic properties of the 
compound.  
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7.2. Introduction of a Methoxy Group at the Meta Positions of the 2-Chloro-6-
fluorobenzoyl Moiety 
7.2.1. Rationale 
Introduction of the ethyl group on the difluoro benzoyl moiety did not lead to any potency 
gain. Simple ethylbenzene favours a conformation where the ethyl group is twisted at 90 
degrees to the plane of the ring.
216
 For this group to twist out of this orientation by more 
than 30 degrees, there is a calculated 2 kcal/mol energy penalty which could equate to a 
significant potency loss and might offset any gain from lipophilic binding. Small-molecule 
crystal structures in the Cambridge Structural Database also support the out of plane 
arylethyl conformation as being favoured. The methoxy group of anisole has a strong 
preference for sitting in the plane of the ring, positioning the methyl group in a different 
region of space to the methyl in ethylbenzene.
217
 The preferred conformation of ortho-
substituted anisoles is a planar anti form, whereas the minor conformation is a non-planar 
form with the methyl group rotated toward the ortho-substituent.
218-220
 This alternative 
minor conformer is only formed under UV irradiation and only small amount of it is 
expected to exist under normal conditions. Incorporation of a meta-methoxy group would 
therefore allow exploration of a different direction to that explored with the ethyl analogue 
and would provide further information regarding the torsion angle and the size of groups 
tolerated at this position. 
It was decided to incorporate the 3-methoxy substituent on the 2-chloro-6-fluoroaroyl 
moiety with 3-aminopyridyl, 5-aminopyrimidyl and 4-amino-N-methylpiperidyl amide 
side-chains (Figure 7.3). At the time of synthesis, these side-chains combined optimal 
properties in terms of potency, aqueous solubility and reduced CYP450 inhibitory activity. 
 
 
Figure 7.3: 3-Methoxy-substituted aroyl targets to be synthesised 
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7.2.2. Synthesis 
Preparation of the meta-methoxyaroyl carboxylic acid intermediates was achieved using 
procedures previously developed and optimised in the ERK5 project. The synthesis started 
with the thionyl chloride mediated conversion of commercially available carboxylic acids 
332 and 333 to the corresponding acyl chlorides 334 and 335, which were engaged in a 
Friedel-Crafts acylation with methyl pyrrole-2-carboxylate to give 336 and 337 in good 
yields, with minimum demethylation observed. Methyl ester hydrolysis was achieved 
under basic conditions and afforded pure carboxylic acids 338 and 339 in excellent yields 
(Scheme 7.1). 
 
 
Scheme 7.1: Reagents and conditions: (i) SOCl2, DMF, THF, 0 °C to RT, 5 h; (ii) AlCl3, 
methyl 1H-pyrrole-2-carboxylate, 0 °C to RT, 20 h (336, R
1
 = H, R
2
 = OMe, 81%; 337, 
R
1
 = OMe, R
2
 = H, 60%), (iii) LiOH, H2O/THF, 67 °C, 18 h (338, R
1
 = H, R
2
 = OMe, 
97%; 339, R
1
 = OMe, R
2
 = H, 93%). 
 
Coupling of 4-amino-1-methylpiperidine has routinely been achieved in the ERK5 project 
using carbonyldiimidazole (CDI) as the coupling reagent and was successfully employed 
in this instance (Table 7.5).
197, 198
 PCl3-mediated coupling was used with electron-poor 
heteroaromatic amines and afforded compounds 341, 342, 344 and 345 in low to good 
yield (17 - 72%). The yields were relatively low for the pyrimidyl amides due to 
difficulties in isolating the product from close-running impurities. 
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Table 7.5: Summary of yields for the amide coupling; Reagents and conditions: (i) CDI, 
4-amino-1-methylpiperidine, THF, 70 °C, 3 h; (ii) 3-aminopyridine or 5-aminopyrimidine, 
PCl3, MeCN, 150 °C, µW, 7 min. 
R
1 
R
2 
Yield 
 
 
340, 64% 
 
341, 56% 
 
342, 17% 
 
 
343, 51% 
 
344, 72% 
 
345, 22% 
 
7.2.3. SARs and Biological Evaluation 
The ERK5 inhibitory activity data for compounds 340 - 345 are presented in Table 7.6 and 
should be compared to the 2-chloro-6-fluoroaroyl inhibitors 232, 233 and 236. 
 
Table 7.6: ERK5 inhibitory activity of meta-methoxyaroyl inhibitors 
Compound R
1 
R
2 
ERK5 IC50 (µM)
a
 
233 
 
 
0.20 ± 0.07 
232 
 
0.58 ± 0.24 
236 
 
0.40 ± 0.09 
340 
 
 
0.058 ± 0.019
b
 
341 
 
0.091 ± 0.037
c
 
342 
 
0.20 ± 0.07
b 
343 
 
 
0.17 ± 0.05 
344 
 
0.25 ± 0.05 
345 
 
0.43 ± 0.14
b
 
a
 Determinations ± standard deviation (mean of n = 4 unless otherwise 
stated); 
b
 n = 6; 
c
 n = 8 
 
107 
Compounds with the methoxy adjacent to fluorine atom exhibited a sharp increase in 
ERK5 inhibition, with compounds 340 and 341 having sub-100 nM ERK5 IC50 values. 
Introduction of the methoxy next to the chlorine seemed to be less effective and mainly 
gave compounds with activities similar to their unsubstituted matched pair. Importantly, all 
of the compounds in this series retained selectivity for ERK5 over p38. These results 
suggested that the conformation of the meta-substituent was crucial to observe a potency 
gain. The difference of activity of 340 vs. 343, and 341 vs. 344 also confirmed the trend 
observed with the meta-chlorine group, i.e. the meta-substitution was more beneficial when 
introduced adjacent to the fluorine. 
Despite 340 being the most active of this subset of compounds, it was anticipated that this 
inhibitor would suffer from high efflux, as previously observed with inhibitors 
incorporating the N-methylpiperidine side-chain. As a result, the second most active 
compound, inhibitor 341 was selected for in vitro ADME studies and showed excellent 
solubility, low clearance in human liver microsomes, and high flux with no efflux in the 
Caco-2 assay (Table 7.7). Reduction of the clogP by 0.7 units compared with 
trihalogenated inhibitor 318 and an increased tPSA contributed to enhance the solubility. 
However, the meta-methoxy introduced another metabolic liability, namely oxygen-
demethylation, and compound 341 was very highly cleared in mouse liver microsomes.
221
 
Interestingly, the microsomal stability of 341 was species-dependent. Owing to its high 
metabolic turnover, 341 was not progressed to an in vivo pharmacokinetic study. 
 
Table 7.7: Physicochemical and in vitro ADME data for 341 
MW clogP 
Sol 
(μM) 
tPSA 
Å
2
 
HLM Clint
a
 MLM Clint
a Caco-2 AB
b
 
(ER) 
374 3.1 > 100 84 19 137 18 (1.5) 
a L/min/mg protein; b Papp 10
-6
 cm.s
-1 
 
The positive results obtained with the 6-chloro-2-fluoro-3-methoxyaroyl pattern provided 
encouragement, that further elaboration at this position could be beneficial. The objective 
was to incorporate groups on the oxygen linker with reduced metabolic liability, which 
could maintain the favourable pharmacokinetic properties of compound 318. Introduction 
of larger groups should determine the size of the optimal substituent to fill the lipophilic 
pocket. 
A small set of 3-alkoxy-6-chloro-2-fluoroaroyl targets was proposed (Figure 7.4). Groups 
of different polarity bearing various spatial conformations were selected. During the course 
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of the program to optimise the aroyl meta-substituent, work in the research group was also 
being undertaken to investigate the SARs of the amide substituent. A colleague identified 
4-amino-1-methylpyrazole as an alternative amide substituent which conferred improved 
ERK5 inhibition relative to 5-aminopyrimidine and improved ADME properties relative to 
4-amino-1-methylpiperidine.
105
 This improved amide substituent was therefore selected to 
be incorporated in the target compounds. 
 
 
Figure 7.4: 3-Alkoxysubstituted aroyl targets to be synthesised 
 
7.3. Synthesis of Inhibitors Incorporating 3-Alkoxy-6-chloro-2-fluorobenzoyl at 
the Pyrrole 4-Position 
4-Amino-1-methylpyrazole (348) was a key building block in the synthesis of this series of 
compounds. It was prepared on a large scale following a two-step procedure, starting with 
methylation of commercially available 4-nitropyrazole 346 using dimethyl oxalate under 
basic conditions as the methylating reagent (Scheme 7.2).
222
 This high yielding alkylation 
procedure prevented the use of classical carcinogenic methylating reagents. Amine 348 
was then obtained by catalytic flow hydrogenation of 1-methyl-4-nitropyrazole (347). 
 
 
Scheme 7.2: Reagents and conditions: (i) Dimethyl oxalate, KOtBu, DMF, 140 °C, 4 h, 
85%; (ii) H2, 10% Pd/C, MeOH, 40 °C, 8 h, 99%. 
 
In order to explore the meta position efficiently, a synthetic route, which would allow late-
stage diversification of the meta position, was established. Retrosynthetic analysis 
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suggested that compound C was a versatile intermediate, which could be utilised in 
alkylations or Mitsunobu reactions with alkyl alcohols, giving access to the desired 
alkoxyaroyl B (Figure 7.5). Intermediate B could then be converted to the target molecule 
in two steps, namely ester hydrolysis and amide coupling. This synthetic strategy was 
expected to be relatively high-throughput and give access to the library of targets in a 
minimum number of steps. 
 
 
Figure 7.5: Retrosynthetic analysis for the alkoxyaroyl series 
 
Key intermediate C was prepared in 4 steps (Scheme 7.3). Protection of 4-chloro-2-
fluorophenol (349) with a tert-butyldimethylsilyl group was achieved in a very high yield 
and followed by a lithium-mediated carbonylation.
223
 Unexpectedly, during the basic 
work-up of the reaction, the silyl protecting group was cleaved and compound 351 was 
isolated in 92% yield. Transformation of carboxylic acid 351 to the corresponding acyl 
chloride 352 was carried out under dilute conditions to prevent side-reactions. An excess of 
aluminium trichloride was required for the Friedel-Crafts acylation to occur and 353 was 
isolated in a moderate 45% yield. Ester hydrolysis was followed by PCl3-mediated 
coupling to afford 355 and 356 in moderate yields. 
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Scheme 7.3: Reagents and conditions: (i) TBDMSCl, imidazole, DMF, 0 °C to RT, 18 h, 
92%; (ii) a) nBuLi (2.4 M in hexane), THF, -78 °C, 30 min; b) CO2 (dry ice), -78 °C to 
RT, 1 h; c) 2 M aq. NaOH, RT, 30 min, 92%; (iii) SOCl2, DMF, THF, 0 °C to RT, 5 h; 
(iv) AlCl3, methyl 1H-pyrrole-2-carboxylate, 0 °C to RT, 20 h, 45%; (v) LiOH, H2O/THF, 
67 °C, 18 h, 93%; (vi) 3-aminopyridine or 4-amino-1-methylpyrazole, PCl3, MeCN, 
150 °C, µW, 7 min (355, 55%; 356, 45%). 
 
Ethylation of the hydroxyl group of compound 353 was attempted using iodoethane and 
potassium carbonate as a base (Scheme 7.4).
224
 Unfortunately, these conditions exclusively 
led to the formation of a dialkylated product, suggesting that the pKa of the pyrrole NH was 
lower than predicted. The pKa of an unsubstituted pyrrole is close to 17.
225
 Addition of 
electron withdrawing groups at the 2- and 4-position of the ring might have reduced the 
pKa by 4 or 5 units, allowing partial deprotonation by potassium carbonate. Selective 
dealkylation of the pyrrole nitrogen was attempted following a literature procedure but 
proved unsuccessful.
226
 When the oxygen alkylation was attempted using milder bases, 
such as DABCO and pyridine, no conversion was observed. 
Attempted Mitsunobu reaction of 353 with 2-methoxyethanol led to a complex mixture of 
products, with evidence by LC-MS analysis of unprotected pyrrole participating in 
undesired side-reactions (Scheme 7.4).
227
 Owing to the lack of success with this initial 
strategy, an alternative approach had to be considered. 
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Scheme 7.4: Reagents and conditions: (i) K2CO3, iodoethane, MeCN, 65 °C, 18 h; 
(ii) PPh3, DEAD, 2-methoxyethanol, THF, 0 °C to RT, 24 h; (iii) LiOH, H2O/THF, 67 °C, 
18 h; (iv) 3-aminopyridine or 4-amino-1-methylpyrazole, PCl3, MeCN, 150 °C, µW, 
7 min. 
 
One possible strategy was to repeat the scheme with the pyrrole nitrogen protected. This 
implied a long synthetic route, with orthogonal protecting groups manipulation and 
introduction of the diversification after six steps. Mitsunobu reactions are known to be 
unpredictable on large substrates and its success was still uncertain in this case. A second 
strategy was to introduce diversification at the first step on 4-chloro-2-fluorophenol (349), 
and then use a 4-steps sequence of previously optimised reactions to access the desired 
targets (Table 7.8). Although this second approach would have a lower throughput, it 
appeared to be more robust and reliable, and was subsequently selected for the synthesis of 
a first set of derivatives. The five steps scheme was applied to the synthesis of a small 
library of analogues. The yields for each step are summarised in Table 7.8. 
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Table 7.8: Summary of yields for the five steps synthesis of meta-alkoxy derivatives; 
Reagents and conditions: (i) K2CO3, iodoethane, MeCN, 65 °C, 18 h; (ii) PPh3, DEAD, 
R-OH, THF, 0 °C to RT, 24 h; (iii) a) nBuLi (2.4 M in hexane), THF, -78 °C, 30 min; 
b) CO2 (dry ice), -78 °C to RT, 1 h; (iv) a) SOCl2, DMF, THF, 0 °C to RT, 5 h; b) AlCl3, 
methyl 1H-pyrrole-2-carboxylate, 0 °C to RT, 20 h; (v) LiOH, H2O/THF, 67 °C, 18 h; 
(vi) 3-aminopyridine or 4-amino-1-methylpyrazole, PCl3, MeCN, 150 °C, µW, 7 min. 
 
R Step 1 Step 2 Step 3 Step 4 Step 5 
 357, 82% 363, 97% 368, 78% 372, 96% 
376, 60% 
380, 62% 
 358, 96% 364, 84% 369, 72% 373, 95% 
377, 66% 
381, 62% 
 
359, 0% - - - - 
 
360, 96% 365, 86% 370, 82% 374, 96% 
378, 62% 
382, 38% 
 
361, 95% 366, 94% 371, 81% 375, 96% 
379, 70% 
383, 59% 
 
362, 83% 367, 92% 0% - - 
 
As expected, the five step scheme enabled rapid preparation of eight analogues. Mitsunobu 
reaction of 349 with a range of commercially available alcohols proceeded in very high 
yields. An array of synthetic transformations was then employed to obtain the desired 
products, including: carbonylation, Friedel-Crafts acylation, basic ester hydrolysis and 
PCl3 coupling with microwave irradiation. All reactions proceeded in good to excellent 
yields (Table 7.8). 
Friedel-Crafts acylation failed with benzoic acid 367. The t-butyl carbamate protecting 
group was cleaved under the reaction conditions, leading to the formation of multiple by-
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products. Targets incorporating a basic heterocycle will have to be prepared via an 
alternative route. 
Reaction of 4-chloro-2-fluorophenol (349) with 3-hydroxyoxetane, using the standard 
Mitsunobu conditions, failed to produce 359, but intermediate 359 was successfully obtained 
by increasing the temperature to 67 °C (Scheme 7.5). The oxetane ring of 384 opened in 
presence of aluminum trichloride during the Friedel-Crafts acylation, leading to the 
formation of 385 in 68% yield. Interestingly, partial ring closing of the 1-chloro-3-
hydroxypropane moiety of 385 was observed under the basic conditions used for the 
methyl ester hydrolysis. A prolonged reaction time allowed complete conversion to the 
oxetane ring, resulting in a 74% isolated yield of 386. Coupling of 386 with 
3-aminopyridine using PCl3 with microwave irradiation led to the formation of two major 
by-products 387 and 388, which were isolated in sufficient high purity for biological 
evaluation (Scheme 7.5). 
 
 
Scheme 7.5: Reagents and conditions: (i) PPh3, DEAD, 3-hydroxyoxetane, THF, 0 °C to 
reflux, 24 h, 97%; (ii) a) nBuLi (2.4 M in hexane), THF, -78 °C, 30 min; b) CO2 (dry ice), 
-78 °C to RT, 1 h, 94%; (iii) a) SOCl2, DMF, THF, 0 °C to RT, 5 h; b) AlCl3, methyl 
1H-pyrrole-2-carboxylate, 0 °C to RT, 20 h, 68%; (iv) LiOH, H2O/THF, 67 °C, 72 h, 74%; 
(v) 3-aminopyridine, PCl3, MeCN, 150 °C, µW, 7 min (387, 23%; 388, 25%). 
 
The milder Mukaiyama coupling conditions allowed isolation of 389 and 390 
(Scheme 7.6). However, the overall yield was relatively low due to difficulties in isolating 
the product from close-running impurities. 
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Scheme 7.6: Reagents and conditions: (i) 2-chloro-1-methylpyridinium, NEt3, 
3-aminopyridine or 4-amino-1-methylpyrazole, DCM, 42 °C, 24 h (389, 21%; 390, 27%). 
 
Synthesis of the targets incorporating the (methylsulfonyl)ethane moiety was achieved 
using a similar reaction sequence to that described for the synthesis of compounds 
376 - 383 (Scheme 7.7). To prevent side-reactions during the carbonylation step, the side-
chain was introduced as a thioether, which was subsequently oxidised using Oxone
®
 to 
give 393 in 89% yield. Friedel-Crafts acylation was followed by acidic hydrolysis of 
methyl ester 394. These conditions prevented a retro-Michael addition, observed under the 
classical basic hydrolysis conditions. PCl3-mediated coupling led to isolation in moderate 
yield of the desired products 396 and 397 (Scheme 7.7). 
 
 
Scheme 7.7: Reagents and conditions: (i) PPh3, DEAD, 2-(methylthio)ethanol, THF, 0 °C 
to RT, 24 h, 95%; (ii) a) nBuLi (2.4 M in hexane), THF, -78 °C, 30 min; b) CO2 (dry 
ice), -78 °C to RT, 1 h, 88%; (iii) Oxone
®
, MeOH, H2O, RT, 24 h, 89%; (iv) a) SOCl2, 
DMF, THF, 0 °C to RT, 5 h; b) AlCl3, methyl 1H-pyrrole-2-carboxylate, 0 °C to RT, 20 h, 
69%; (v) dioxane, 4 M aq. HCl, 65 °C, 70 h, 83%; (vi) 3-aminopyridine or 4-amino-1-
methylpyrazole, PCl3, MeCN, 150 °C, µW, 7 min (396, 40%; 397, 35%). 
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7.4. SARs and Biological Evaluation of 4-(3-Alkoxy-6-chloro-
2-fluorobenzoyl)pyrrole Carboxamide Derivatives 
The ERK5 inhibitory activity data of 4-(3-alkoxy-6-chloro-2-fluorobenzoyl)pyrrole 
carboxamide derivatives are presented in Table 7.9 and should be compared to the 
2-chloro-6-fluoroaroyl inhibitors 232 and 398. The results confirmed that the 4-amino-1-
methylpyrazole and 3-aminopyridine amide substituent endowed similar ERK5 activity. 
Diverse substitution of the aroyl hydroxyl group was found to have little effect on ERK5 
inhibitory potency, with the majority of O-substituted derivatives having an IC50 within 
3-fold of 232 and 398. The (methylsulfonyl)ethoxy moiety (396 and 397) was not tolerated 
and completely abolished binding affinity for ERK5. Smaller groups, such as ethyl (376 
and 380) or oxetane (389 and 390) exhibited improved ERK5 inhibition, similar to the 
potency of meta-methoxy derivatives 340 and 399. However, these compounds had 
reduced ligand efficiency relative to 340 and 399, and did not achieve the IC50 threshold of 
100 nM, required to trigger generating in vitro ADME assessment. 
 
Table 7.9: ERK5 inhibitory activity of meta-alkoxyaroyl inhibitors 
R
1 
ERK5 IC50 (µM)
a
 
  
H 232, 0.58 ± 0.24 398, 1.0 ± 0.3 
OH 355, 1.2 ± 0.4
c 
356, 0.74 ± 0.33
c
 
 340, 0.091 ± 0.037
e
 399, 0.11 ± 0.03 
 376, 0.12 ± 0.01
c
 380, 0.20 ± 0.07
c 
 377, 1.5 ± 0.9
d 
381, 1.9 ± 1.1
e 
 
396, > 30 397, > 30 
 
389, 0.12 ± 0.06 390, 0.19 ± 0.11
b 
 
378, 0.48 ± 0.16
c
 382, 0.55 ± 0.18
c 
 
379, 1.7 ± 0.1 383, 3.6 ± 1.4 
 
387, 0.67 ± 0.25 - 
 
388, 1.3 ± 0.3 - 
a
 Determinations ± standard deviation (mean of n = 4 unless otherwise 
stated); 
b
 n = 6; 
c
 n = 3; 
d
 n = 7; 
e
 n = 8 
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A significant reduction of ERK5 inhibitory activity was apparent for compounds 379 and 
383, suggesting that large meta-substituents might not be tolerated. Future work in this 
series should investigate small basic meta-substituents, such as methylazitidine or 
dimethylethylamine. These groups have a different polarity and could be involved in other 
types of binding interactions. The meta-methoxy group (340 and 399) remains the most 
potent substituent in this series and close analogues, such as OCHF2 or OCF3, are of 
interest. Indeed, in addition to an increased metabolic stability, these groups also have low 
energy barriers to rotation and can therefore access a wide range of conformations.
228, 229
 
This would allow exploration of different directions to those explored by the methoxy and 
ethoxy analogues. 
A co-crystal structure of ERK5 with key inhibitors (318, 340 and 399) will be required to 
get a better understanding of the binding interactions involved and guide the next round of 
SARs. 
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Chapter 8. Structure-Activity Relationship Studies Around the 2-Position 
of 5-Aminoheteroaromatic Amides 
 
The results presented in this chapter have been focusing on the optimisation of the 
physicochemical properties of the inhibitors whilst maintaining low nanomolar potencies. 
Throughout this investigation, the SARs of an initial set of targets have guided the design 
of the following generation of analogues. Hence, to facilitate the reading and avoid several 
subdivisions, the SARs and biological evaluation sections will precede the synthesis of the 
compounds. 
 
8.1. Rationale 
 
 
As discussed in section 7.1. introduction of the 3,6-dichloro-2-fluorobenzoyl moiety at the 
pyrrole 4-position conferred improved ERK5 inhibition relative to the 2-chloro-6-
fluorobenzoylbenzoyl group. Incorporation of a third halogen on the scaffold increased the 
lipophilicity and decreased the tPSA, resulting in reduced solubility and low 
bioavailability.
198
 Examination of 318 modelled in the ERK5 ATP-binding site from the 
literature co-crystal structure suggested that substituents at the para position of the pyridyl 
amide may project towards the solvent-exposed surface of ERK5. Introduction of water-
solubilising groups at this position should be tolerated and improve the solubility of the 
inhibitors. These substituents would also hinder the pyridyl nitrogen and might therefore 
reduce the moderate metabolic liability observed with compound 318 in mouse liver 
microsomes. Extensive SARs were conducted at this position by Dr Duncan Miller and 
resulted in the identification of 400 and 401, two compounds with sub-40 nM ERK5 
inhibitory activity (Table 8.1).
105
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Table 8.1: ERK5 inhibitory activity and in vitro ADME properties of 400 and 401 
 
Compound R 
ERK5 
IC50 (nM)
a 
Sol 
(μM) 
HLM 
Clint
b
 
MLM 
Clint
b 
Caco-2 
AB
c
 (ER) 
hERG 
IC50 (μM) 
400 H 13 ± 5 > 100 31 13 0.6 (35) > 25 
401 Me 37 ± 17 30-100 252 75 n.d. 2.63 
a
 Determinations ± standard deviation (mean of n = 4) ; 
b L/min/mg protein; c Papp 10
-6
 cm.s
-1
; 
n.d. = not determined 
 
The SAR studies revealed that the low potency observed for 400 and 401 was due to the 
basic nature of the terminal piperazine nitrogen. The solubility was increased for both 
compounds relative to 318 (Table 8.1). In vitro human and mouse liver microsomal data 
for 400 and 401 were dissimilar with the NH-piperazine analogue being five times more 
stable, supporting the possibility of N-demethylation as a major route of metabolism for 
401 (Table 8.1). Compound 401 was found to inhibit hERG with an IC50 value of 2.63 μM 
whereas the hERG IC50 value for 400 was greater than 25 μM, indicating the presence of 
subtle hERG SAR in this series. In the Caco-2 membrane permeability assay, 400 was 
found to exhibit high efflux and low permeability, suggesting significant recognition by 
active transporters (Table 8.1). 
 
 
Figure 8.1: Docking of 400 in the ATP-binding site of ERK5 (PDB code 4b99)
194
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Modelling of 400 in the ATP-binding site of ERK5 from the literature co-crystal structure 
suggested that the piperazine could adopt a conformation that would allow the protonated 
basic centre to participate in an ionic interaction with a glutamate residue on the exit of the 
binding-site (Figure 8.1). 
To investigate tolerance to variation of the position of the basic centre, an analogue of 400, 
displaying an amino spacer between the pyrimidyl and the piperidinyl rings, was prepared 
by a colleague.
105
 Compound 402 retained good ERK5 potency (Table 8.2). The metabolic 
stability of 402 was significantly improved relative to 401, indicating that N-dealkylation 
was a slower metabolic process in this template. Compound 402 did not inhibit the hERG 
cardiac ion channel with concentration of up to 25 μM. In the Caco-2 assay, 402 had a 
similar high efflux and low flux relative to 400. The focus for further investigation thus 
turned to reducing efflux liability while maintaining ERK5 inhibitory potency. 
 
Table 8.2: ERK5 inhibitory activity and in vitro ADME properties of 402 
 
Compound 
ERK5 IC50 
(nM)
a 
Sol 
(μM) 
HLM 
Clint
b
 
MLM 
Clint
b 
Caco-2 
AB
c
 (ER) 
hERG 
IC50 (μM) 
402 14 ± 3 10 - 100 6 19 0.3 (99) > 25 
a
 Determinations ± standard deviation (mean of n = 4) ; 
b L/min/mg protein; c Papp 10
-6
 cm.s
-1 
 
8.2. Intestinal Absorption of Xenobiotics 
8.2.1. The Caco-2 in vitro Assay 
Oral delivery is the most convenient form of drug administration for patients. For this 
reason, the majority of drug discovery programs aims at designing pharmaceutical agents 
for oral administration.
230
 Intestinal absorption restricts the oral bioavailability of 
compounds and a variety of in vitro assays, including the Caco-2 assay, have been 
developed to evaluate intestinal permeability.
230
 Originally, lipophilicity was used to 
predict membrane permeability but was later found to be too simplistic and not always 
predictable. 
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Caco-2 cells are a human colon epithelial cancer cell line and are cultured as a monolayer 
to be used as a model of human intestinal absorption of drugs.
231
 The Caco-2 cell 
monolayer mimics the human intestinal epithelium of the small intestine by expressing 
uptake carriers, efflux transporters and Phase II conjugation enzymes.
230
 This model 
enables to study both paracellular and transcellular absorptions.
232
 Three pathways 
mediating the intestinal absorption of orally administered pharmaceutical agents have been 
identified and are covered by the Caco-2 assay: passive diffusion, carrier-mediated 
or -limited transport, and vesicular transport.
230
 Influx transporters, such as PEPT1 or 
OATP, and efflux transporters, such as P-gp or BCRP, are expressed on the apical or 
basolateral membrane of Caco-2 cells and play a crucial role in the transport of compounds 
across the monolayer.
233
 
The apical and basolateral chambers represent the luminal and blood/mesenteric lymph 
sides of the gastrointestinal tract (Figure 8.2).
230
 The xenobiotic to be assessed is added to 
either the apical or basolateral side of the Caco-2 monolayer. The concentration of the 
compound in the recipient compartment is measured at various time points and a transport 
rate determined. It is expressed as the apparent permeability coefficient Papp.
231
 In the 
absence of active transport involvement, the apical to basolateral and basolateral to apical 
apparent permeability are similar.
231
 Carrier-mediated efflux on the apical membrane 
enhances drug transport in the basolateral to apical direction, while attenuation the apical 
to basolateral absorption.
231
 
 
 
Figure 8.2: Schematic depiction of the Cacco-2 cell transporter system (adapted from 
ref 231) 
 
In summary, the Caco-2 monolayer assay is a standard tool for the prediction of intestinal 
drug absorption and for mechanistic studies of drug transport.
231, 232
 It provides valuable 
information for drug development in an efficient and reproducible manner and is widely 
used in pharmaceutical companies.
230, 233
  
 
  
 
  
Apical 
(A) 
Basolateral (B) 
 
 
Caco-2 cell monolayer 
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8.2.2. Molecular Properties Controlling Membrane Permeability 
Although many biological processes regulate the absorption of pharmaceutical agents 
through the intestine, passive transport and active efflux have been identified as the key 
impeding mechanisms. 
A range of molecular properties facilitating passive transport by the transcellular route 
through the intestinal epithelial cells has been identified.
234
 A molecular weight below 500 
and a tPSA below 140 have been associated with good passive absorption.
214, 235
 The 
molecular rigidity of compounds influences the intestinal permeability. An increased 
molecular rigidity often results in superior bioavailability.
236
 Its impact can be assessed by 
looking at the number of rotatable bonds, and it has been observed that for compounds 
with a molecular weight in the range 400 to 500, less than 10 rotatable bonds are 
associated with good passive absorption.
235, 236
 A decrease in hydrogen bond count also 
improves passive permeability. A recent study from AstraZeneca has advised to maintain 
clogD values above 3.4 for compounds with a molecular weight in the range 450 to 500, in 
order to achieve high apical to basolateral Papp in the Caco-2 assay.
237
 The ionisation state 
of a drug influences its rate of absorption from the small intestine. Basic compounds tend 
to be protonated in the gastrointestinal tract, resulting in high polarity and reduced 
lipophilicity. Such properties limit passive absorption across biomembranes. Reduction of 
an amine pKa can lead to improved absorption.
238
 
P-gp and BCPR are the most impactful efflux transporters and display a considerable 
overlap in their substrates.
234
 Their involvement in drug absorption is more pronounced if 
the drug has a poor passive permeability.
231, 239
 An understanding of transport mechanisms 
and structural activity relationship responsible for the influx and efflux of a pharmaceutical 
agent often allows medicinal chemists to take advantage of these processes. However, the 
molecular properties that confer P-gp efflux remain poorly understood.
240
 P-gp transports 
structurally unrelated agents out of the cell, such as anthracyclines, alkaloids or steroid 
hormones.
241
 Several tyrosine kinase inhibitors have also been identified as P-gp 
substrates.
242
 There is little correlation between clogP and P-gp efflux liability, with a large 
range of clogP being tolerated to avoid P-gp efflux.
240
 
Relatively modest structural changes have been successfully utilised in diverse medicinal 
chemistry programs to modulate P-gp recognition.
240
 Consideration of tPSA and 
HBA/HBD values is important. Indeed, maintaining tPSA below 90 Å
2
 and hydrogen 
bound donor count below 2 usually maximizes the chance of evading P-gp efflux.
240
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Masking HBD groups via intramolecular hydrogen bonding has enabled to reduce P-gp 
substrate recognition. Replacement of a NH with a methylene unit was successfully 
employed to reduce P-gp affinity of an GPR139 antagonist.
243
 Repositioning of HBD 
groups in a scaffold can also diminish P-gp recognition. This strategy is valuable for 
compounds with low tPSA where a lower tPSA might introduce off-target activity and 
undesired safety profile.
240
 The presence of a strongly basic amine can often induce P-gp 
efflux and tend to lower the threshold for tPSA tolerance. 
241
 Removal of the basic centre 
or reduction of its pKa is a proven strategy to reduce P-gp affinity.
240
 
Drugs substrate of active transporters, with moderate to high passive permeability, can still 
have high oral bioavailability. The high drug concentration in the gastrointestinal lumen 
saturates efflux transporters, enabling absorption through passive diffusion.
235
 Parallel 
artificial membrane permeability assay (PAMPA) can be used as a filter to select 
compounds with sufficient passive permeability to test in P-gp efflux assays, such as the 
Caco-2 assay.
240
 In the field of central nervous system drug discovery, the MDR-MDCK 
cell monolayer assay is employed to detect P-gp substrate.
244
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8.3. Investigation of 5-Aminoheteroaromatic Amides Introducing Piperidine 
and Piperazine Side-Chains via a Variety of Spacers at the 2-Position 
8.3.1. SARs and Biological Evaluation of Pyrimidyl-Amide Linked 
Analogues 
Pyrrole carboxamide 402 has a high tPSA (103 Å) and contains three hydrogen bond 
donors (Table 8.3). The pyrrole NH is essential for ERK5 activity and the amide NH 
cannot easily be replaced, since methylation of the amide nitrogen of 318 resulted in a 
65-fold reduction of ERK5 potency (see section 6.4). Replacement of the NH-spacer had 
not previously been investigated and variations of this part of the template could 
favourably modulate the molecular properties of the inhibitors. 
 
Table 8.3: Structure and molecular properties of 2-substituted 5-pyrimidyl amides 
403 - 409 
 
Compound R MW clogP clogD 
tPSA 
(Å
2
) 
HBA HBD 
402 
 
491 3.8 2.4 103 8 3 
403 
 
505 4.2 2.5 94 8 2 
404 
 
491 3.7 2.1 103 8 3 
405 
 
491 3.3 2.3 94 8 2 
406 
 
477 3.0 1.9 103 8 3 
407 
 
490 4.8 2.5 91 7 2 
408 
 
476 4.2 2.1 100 7 3 
409 
 
478 3.5 2.4 100 8 2 
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The compounds in table 8.3 were designed and synthesised with the aim of addressing the 
issues of membrane permeability. Methylation of the NH-spacer (403 and 404) or its 
replacement by a methylene group (407 and 408) removed one hydrogen bond donor and 
reduced the tPSA. The nitrogen spacer was also moved in the piperidine ring to give a 
piperazine (405 and 406). Although this modification was not modulating the number of 
HBAs or the tPSA, it would reduce the basicity of the terminal basic centre by a minimum 
of 1 unit and would introduce a second basic centre closer to the pyrimidyl ring. The basic 
centre in compound 409 was moved closer to the heteroaromatic ring and had a 
significantly lower pKa (≈ 8). All these structural modifications were made to establish 
further SARs and to change the pattern of HBDs and HBAs in the inhibitors, with the 
objective to reduce transporter recognition. 
 
Table 8.4: ERK5 inhibitory activity of 2-substituted 5-pyrimidyl amides 403 - 409 
Compound R ERK5 IC50 (nM)
a
 L.E. LipE 
402 
 
14 ± 3 0.33 5.5 
403 
 
21 ± 7 0.31 5.2 
404 
 
20 ± 5 0.32 5.6 
405 
 
7 ± 4 0.34 5.9 
406 
 
8 ± 2 0.35 6.2 
407 
 
7 ± 3 0.34 5.7 
408 
 
7 ± 3 0.35 6.0 
409 
 
53 ± 16 0.31 4.9 
a
 Determinations ± standard deviation (mean of n = 4) 
 
Methylation of the NH-spacer (403 and 404) retained ERK5 binding affinity (Table 8.4). 
Replacement of the amino spacer with a methylene group (407 and 408) resulted in a 
2-fold increase in potency relative to 402. Replacement of the piperidine (407 and 408) 
with a piperazine (405 and 406) was tolerated and gave equipotent compounds. For each 
matched pair, methylated and non-methylated compounds had comparable potency 
(Table 8.4). Interestingly the ERK5 inhibitory activity of morpholine analogue 409 was 
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only reduced by 4-fold, suggesting that an alternative position of the basic centre might be 
tolerated and that a HBA at this position might interact with a HBD in the protein. All the 
compounds had good ligand and lipophilic ligand efficiency. 
 
Table 8.5: Structure and molecular properties of 2-substituted 5-pyrimidyl amides 
410 - 413 
 
Compound R MW clogP clogD 
tPSA 
(Å
2
) 
HBA HBD 
410 
 
487 2.7 1.6 103 9 2 
411 
 
473 2.4 1.3 112 9 3 
412 
 
486 4.1 1.9 100 8 2 
413 
 
472 3.7 1.5 109 8 3 
 
In parallel of this work, the 6-chloro-2-fluoro-3-methoxybenzoyl group was identified as 
an alternative substituent at the pyrrole 4-position conferring similar ERK5 inhibition 
relative to the 3,6-dichloro-2-fluorobenzoyl group (see section 7.2). A selection of the best 
amide substituent was therefore prepared in combination with the 6-chloro-2-fluoro-3-
methoxybenzoyl group (Table 8.5). This alternative substitution pattern lowered the logD 
relative to the trihalogenated aroyl and gave compounds with similar molecular weight and 
higher tPSA. 
 
Table 8.6: ERK5 inhibitory activity of 2-substituted 5-pyrimidyl amides 410 - 413 
Compound R ERK5 IC50 (nM)
a
 L.E. LipE 
410 
 
13 ± 4 0.32 6.2 
411 
 
16 ± 2 0.32 6.5 
412 
 
18 ± 8 0.31 5.8 
413 
 
12 ± 5 0.33 6.4 
a
 Determinations ± standard deviation (mean of n = 4) 
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Analogues 410 - 413 incorporating the meta-methoxybenzoyl group maintained excellent 
sub-20 nM potency against ERK5 (Table 8.6). Although the ERK5 inhibitory activity was 
slightly reduced compared with the trihalogenated matched pairs 405 - 408, these 
inhibitors 410 - 413 had similar ligand efficiency and superior lipophilic ligand efficiency 
(Table 8.6 and Figure 8.3). 
 
 
Figure 8.3: Bar diagram displaying the ERK5 inhibitory activity of the meta-methoxy vs 
the meta-chloro derivatives 
 
The most potent compounds with the fewest HBAs and HBDs, and the lowest tPSA were 
selected for in vitro ADME studies (Table 8.7). All compounds showed excellent solubility 
and moderate plasma protein binding consistent with the presence of a basic centre in the 
molecules. In mouse liver microsomes in vitro, 406 and 408 had excellent stability with no 
metabolism being observed. Derivatives 405 and 407 suffered from moderate metabolic 
turnover, possibility through N-demethylation. All the compounds exhibited low apical to 
basolateral apparent permeability and high efflux in the Caco-2 assay, suggesting that they 
are slow to cross the intestine membrane and are likely to be recognised by efflux 
transporters. Methylated compounds 405 and 407 had significantly higher basolateral to 
apical apparent permeability than the non-methylated derivatives 406 and 408.  
0
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Table 8.7: ERK5 inhibitory activity and in vitro ADME properties for 405 - 408 
 
Compound Y R 
ERK5 IC50 
(nM)
a 
Sol 
(μM) 
Ppb 
Fu 
MLM 
Clint
b 
Caco-2 
AB
c
 (ER) 
405 N Me 7 ± 4 > 100 0.167 28 0.9 (20) 
406 N H 8 ± 2 > 100 0.143 < LOD 0.3 (3.7) 
407 C Me 7 ± 3 > 100 0.141 31 0.4 (40) 
408 C H 7 ± 3 > 100 0.116 < LOD 0.2 (8.7) 
a
 Determinations ± standard deviation (mean of n = 4) ; 
b L/min/mg protein; c Papp 10
-6
 cm.s
-1 
 
The cellular activity of the most active compounds was measured in HeLa cells. An IC50 
value was generated from a seven point concentration response curve, using a densitometry 
measurement of the phospho-ERK5 band. As Western blotting is a semi-quantitative 
technique and the experiment was only conducted once, a high degree of experimental 
variation might have impacted on the IC50 values generated using this assay. All the 
compounds with the trihalogenated aroyl at the pyrrole 4-position (405 - 408) had IC50 
values close to or below 100 nM, independently of their efflux ratio in the Caco-2 assay 
(Table 8.8). The meta-methoxybenzoyl compounds 410 - 413 were less active relative to 
their meta-chloro matched pairs 405 - 408. The low logD and high tPSA of the non-
methylated compounds 411 and 413 might have impaired their cellular permeability and 
resulted in lower ERK5 inhibitory activities close to 1 μM. 
The cellular activity of some compounds was also assessed using a MEF2D reporter gene 
assay in HEK293 cells (Table 8.8). Measurement of MEF2D phosphorylation, a 
downstream substrate of ERK5, allows determination of ERK5 IC50 values. The ERK5 
inhibitory activities of the trihalogenated compounds were consistent with the activities 
measured in HeLa cells. Although the compounds were slightly less active in the 
HEK293T assay, 405 was still the most potent with an IC50 value of 100 nM. Interestingly, 
the meta-methoxybenzoyl compounds 410, 411 and 413 were again less active than their 
meta-chloro matched pairs. The consistency observed between the two assays conferred 
confidence in the semi-quantitative HeLa densitometry assay and provided confirmation 
that this series of compounds is able to inhibit ERK5 in cells.  
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Table 8.8: Comparison of ERK5 inhibitory activity in the IMAP cell-free assay with 
ERK5 inhibition in the HeLa and HEK293T cellular assays 
 
Compound X Y R 
ERK5 IC50 
(nM)*
a 
Caco-2 
AB
d
 (ER) 
HeLa IC50 
(μM)b 
HEK293T 
IC50 (μM)
c
 
405 Cl N Me 7 ± 4 0.9 (20) 0.02 0.10 ± 0.02 
406 Cl N H 8 ± 2 0.35 (3.7) 0.06 0.24 ± 0.05 
407 Cl C Me 7 ± 3 0.4 (40) 0.11 n.d. 
408 Cl C H 7 ± 3 0.2 (8.7) 0.05 0.24 ± 0.04 
410 OMe N Me 13 ± 4 n.d. 0.10 0.46 ± 0.10 
411 OMe N H 16 ± 2 n.d. 1.1 0.57 ± 0.39 
412 OMe C Me 18 ± 8 n.d. 0.19 n.d. 
413 OMe C H 12 ± 5 n.d. 0.74 0.62 ± 0.28 
* ERK5 inhibitory activity in the cell-free IMAP assay; 
a
 Determinations ± standard deviation (mean of 
n = 4) ; 
b 
Data from a single determination; 
c
 n = 2; 
d 
Papp 10
-6
 cm.s
-1
; n.d. = not determined 
 
Compound 406 which had the lowest efflux ratio in the Caco-2 assay, excellent metabolic 
stability in MLM, high ligand and lipophilic efficiency, and was potent in both cellular 
assays, was selected for in vivo pharmacokinetic evaluation in mouse. The compound had 
low total plasma clearance and unbound clearance, consistent with the low in vitro mouse 
microsomal clearance (Table 8.9). However, 406 had no oral bioavailability indicating that 
the oral dose was not absorbed. This is consistent with the low membrane permeability and 
moderate efflux observed in the Caco-2 assay. The low volume of distribution was 
unexpected for a compound with a basic centre. 
 
Table 8.9: In vivo pharmacokinetic parameters for 406. Dose 10 mg/kg i.v. and p.o. 
Cl 
mL/min/kg 
Clu 
mL/min/kg 
Vd 
L/kg 
t1/2 
min 
F 
% 
17 119 0.5 61 0 
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8.3.2. Synthesis of the Pyrimidyl-Amide Linked Analogues 
Exploration of the pyrimidyl 2-position was achieved through preparation of 2-substituted 
5-aminopyrimidines via various synthetic routes. SNAr displacement of the chlorine of 
2-chloro-5-nitropyrimidine (414) afforded 415, which was cleanly reduced using 
palladium-catalysed flow hydrogenation to give t-butyl 4-((5-aminopyrimidin-2-
yl)(methyl)amino) piperidine-1-carboxylate (416) in high yields (Scheme 8.1). The 
Mukaiyama coupling conditions, which only require a low number of equivalents of the 
amine coupling component (1.25 equivalents), were utilised for the coupling of 416 with 
250, and led to the isolation of 417 in 48% yield. t-Butyl carbamate 417 was deprotected 
using TFA in DCM in the presence of triethylsilane, which acted as a scavenger for the 
liberated t-butyl cation, preventing side-reactions with this reactive intermediate such as 
alkylation of the pyrrole ring.245 Secondary amine target 404 was obtained in a good 75% yield 
(Scheme 8.1). 
 
 
Scheme 8.1: Reagents and conditions: (i) tert-butyl 4-(methylamino)piperidine-1-
carboxylate, NEt3, THF, 0 °C to RT, 3 h, 94%; (ii) H2, 10% Pd/C, MeOH:THF (1:1), 
40 °C, 8 h, 96%; (iii) 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250), 
2-chloro-1-methylpyridinium iodide, NEt3, DCM, 42 °C, 24 h, 48%; (iv) DCM, TFA, 
Et3SiH, RT, 2 h, 75%. 
 
Intermediate 415 was converted to 418 in high yield using an in situ 
deprotection/Eschweiler-Clarke methylation procedure (Scheme 8.2).
246
 A similar reaction 
sequence to that described for the preparation of 404 was then employed, leading to 
N-methylated piperidine target 403. 
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Scheme 8.2: Reagents and conditions: (i) formic acid, formaldehyde (37 % wt. in water), 
95 °C, 3 h, 94%; (ii) H2, 10% Pd/C, MeOH:THF (1:1), 40 °C, 8 h, 96%; 
(iii) 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250), 2-chloro-1-
methyl pyridinium iodide, NEt3, DCM, RT, 24 h, 45%. 
 
Dihexafluorophosphate salt 421 is a versatile intermediate towards the synthesis of 
2-functionalised 5-aminopyrimidines. It reacts readily with functionalised amidines in 
presence of sodium methoxide to give dimethylaminomethylene protected 
5-aminopyrimidines. It was easily prepared on a large scale following a literature 
procedure (Scheme 8.3).
247
  
 
 
Scheme 8.3: Reagents and conditions: (i) a) POCl3, 10 °C to RT, 20 min; b) glycine 
hydrochloride, 5 °C to 80 °C, 4 h; c) H2O, 5 °C, 5 min; d) 60% aq. HPF6, -5 °C, 40%. 
 
The synthesis of the targets 405 and 406 displaying a piperidine side-chain began with a 
Horner-Wadsworth-Emmons reaction between diethyl(cyanomethyl)phosphonate and 
piperidone 422 (Scheme 8.4).
248
 Subsequent hydrogenation of cyanoacrylate 423 provided 
424, which was converted into an amidoxime using aqueous hydroxylamine. Acetylation 
followed by hydrogenation of the resulting O-acetylamidoxime afforded amidine 426 in an 
excellent yield.
249
 Condensation of 426 with dihexafluorophosphate salt 421 followed by 
basic hydrolysis of the resulting amino protecting group were utilised for the synthesis of 
2-substituted 5-aminopyrimidine 428. Amine 428 was coupled to pyrrole carboxylic acids 
250 and 338 using the Mukaiyama coupling protocol. The Boc-protected amines 429 and 
430 were deprotected to give secondary amine targets 408 and 413 in good yields. The 
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Eschweiler-Clarke methylation procedure was also employed as the final step to access the 
N-methylated targets 407 and 412 (Scheme 8.4). 
 
 
Scheme 8.4: Reagents and conditions: (i) diethyl cyanomethylphosphonate, LiHMDS 
(1 M in THF), THF, -78 °C, 1 h, 92%; (ii) H2, 10% Pd/C, EtOAc, RT, 24 h, quantitative; 
(iii) a) 50% aq. hydroxylamine, EtOH, 80 °C, 5 h; b) Ac2O, NEt3, dioxane, RT, 18 h, 79% 
(over 2 steps); (iv) H2, 10% Pd/C, EtOAc:DCM (5:1), RT, 16 h, 95%; (v) hydrogen 
dihexafluorophosphate salt 421, NaOMe (1 M in MeOH), EtOH, 78 °C, 2.5 h; (vi) 5% aq. 
K2CO3, dioxane, 100 °C, 18 h, 79% (over 2 steps); (vii) 4-(3,6-dichloro-2-fluorobenzoyl)-
1H-pyrrole-2-carboxylic acid (250) or 4-(6-chloro-2-fluoro-3-methoxybenzoyl)-1H-
pyrrole-2-carboxylic acid (338), 2-chloro-1-methylpyridinium iodide, NEt3, DCM, 42 °C, 
24 h, (429, X = Cl, 51%; 430, X = OMe, 37%); (viii) DCM, TFA, Et3SiH, RT, 2 h, (408, 
X
 
= Cl, R = H, 63%; 413, X = OMe, R = H, 65%); (ix) formic acid, formaldehyde (37 % 
wt. in water), 95 °C, 3 h, (407, X = Cl, R = Me, 72%; 412, X = OMe, R = Me, 72%). 
 
Nucleophilic addition of methoxide on diethoxyacetonitrile 431 gave methyl 
diethoxyacetimidate which was converted to amidine 432 by treatment with ammonium 
chloride (Scheme 8.5).
250
 Condensation of dihexafluorophosphate salt 421 with 432, 
followed by basic hydrolysis of the dimethylaminomethylene protecting group afforded 
2-substituted 5-aminopyrimidine 434 in 49% yield.
247
 The amino group of 434 was 
subsequently protected as a benzyl carbamate and the acetal hydrolysed under dilute acidic 
conditions, providing 436.
251
 Compound 437 was prepared via reductive amination of 436 
with Boc-protected piperazine in trifluoroethanol.
206
 The Cbz protecting group was 
removed in excellent yield using flow hydrogenation over 10% palladium on carbon to 
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afford 438, which was engaged in a sequence of reactions analogous to those used for the 
synthesis of piperidine targets 405 and 406, and provided final derivatives 405, 406, 410 
and 411 in good yields (Scheme 8.5). 
 
 
Scheme 8.5: Reagents and conditions: (i) a) NaOMe, MeOH, RT, 16 h; b) NH4Cl, MeOH, 
RT, 18 h, 89%; (ii) hydrogen dihexafluorophosphate salt 421, NaOMe (1 M in MeOH), 
EtOH, 78 °C, 2.5 h; (iii) 5% aq. K2CO3, dioxane, 100 °C, 18 h, 49% (over 2 steps); 
(iv) benzyl chloroformate, K2CO3, THF:H2O (1:1), RT, 24 h, 80%; (v) 1 M aq. HCl, 
MeCN, RT, 8 h, 89%; (vi) a) tert-butyl piperazine-1-carboxylate, MgSO4, trifluoroethanol, 
1 h, RT; b) NaBH4, trifluoroethanol, 0 °C to RT, 1 h, 42%; (vii) H2, 10% Pd/C, EtOAc, 
RT, 24 h, 99%; (viii) 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250) 
or 4-(6-chloro-2-fluoro-3-methoxybenzoyl)-1H-pyrrole-2-carboxylic acid (338), 2-chloro-
1-methylpyridinium iodide, NEt3, DCM, 42 °C, 24 h, (439, X = Cl, 42%; 440, X = OMe, 
31%); (ix) DCM, TFA, Et3SiH, RT, 2 h, (406, X = Cl, R = H, 70%; 411, X = OMe, R = H, 
73%); (x) formic acid, formaldehyde (37 % wt. in water), 95 °C, 3 h, (405, X = Cl, 
R = Me, 71%; 410, X = OMe, R = Me, 76%). 
 
Intermediate 436 was amenable to functionalisation via reductive amination. It enabled the 
introduction of the morpholine side-chain to give 441, which was converted to final 
derivative 409, using a two-step sequence (Scheme 8.6). Final derivative 409 was isolated 
in only 16% yield due to difficulties in isolating the product from close-running impurities. 
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Scheme 8.6: Reagents and conditions: (i) a) morpholine, MgSO4, trifluoroethanol, 1 h, 
RT; b) NaBH4, trifluoroethanol, 0 °C to RT, 1 h, 68%; (ii) H2, 10% Pd/C, EtOAc, RT, 
24 h, 97%; (iii) 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250), 
2-chloro-1-methylpyridinium iodide, NEt3, DCM, 42 °C, 24 h, 16%. 
 
8.3.3. SARs and Biological Evaluation of Pyridyl-Amide Linked Analogues 
During the course of the optimisation of the pyrimidyl spacer, Dr Duncan Miller 
demonstrated that ERK5 inhibitory potency for 2-substituted 5-pyridyl and 5-pyrimidyl 
amides was broadly similar (Table 8.10).
105
 
 
Table 8.10: Comparison of ERK5 inhibitory activity of 2-substituted 5-pyridyl and 
2-substituted 5-pyrimidyl amides 
Compound Y R ERK5 IC50 (nM)
a
 
400 N 
 
13 ± 5 
443 C 13 ± 6
b 
402 N 
 
14 ± 3 
444 C 24 ± 20
b 
a
 Determinations ± standard deviation (mean of n = 4); 
b
 n = 6 
 
Incorporation of a pyridyl ring in place of the pyrimidyl removes a hydrogen bond 
acceptor, inducing a reduction in the tPSA which could be beneficial to increase membrane 
permeability. This modification was investigated in combination with different spacers and 
the trihalogenated pyrrole 4-substituent.  
The compounds in Table 8.11 were designed and synthesised with the aim of reducing 
efflux liability and building further SARs in this position. The oxygen spacer which was 
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synthetically more accessible with a pyridyl linker was added to the list of spacers used in 
the pyrimidyl series (see section 8.3.1.). 
 
Table 8.11: Structure and molecular properties of 2-substituted 5-pyridyl amides 445 - 452 
 
Compound R MW clogP clogD 
tPSA 
(Å
2
) 
HBA HBD 
444 
 
490 3.6 2.6 90 7 3 
445 
 
504 4.0 2.7 81 7 2 
446 
 
490 3.5 2.3 90 7 3 
447 
 
491 4.0 2.7 87 7 2 
448 
 
477 3.5 2.3 96 7 3 
449 
 
490 3.1 2.5 81 7 2 
450 
 
476 2.7 2.2 90 7 3 
451 
 
489 4.5 2.8 78 6 2 
452 
 
475 4.0 2.3 87 6 3 
 
The ERK5 inhibitory activity of the pyridyl-amide linked analogues are presented in 
Table 8.12. The modifications of the spacer all yielded compounds with similar or superior 
potency against ERK5, relative to 444. Independently of the terminal aliphatic heterocycle 
and the nature of the spacer, the methylated and non-methylated matched pairs had 
identical ERK5 inhibition (Figure 8.4). Methylation of the NH-spacer in compounds 445 
and 446 had little effect on ERK5 inhibitory activity whereas replacement with an oxygen 
(447 and 448) conferred a 2-fold improvement in potency. Introduction of a methylene 
group in place of the amino spacer resulted in a significant improvement in the binding 
interaction, with 449, 450, 451 and 452 having a 4-fold increase in potency compared with 
444. ERK5 inhibition was found to be comparable for the pyridyl and pyrimidyl matched 
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pair analogues (see section 8.3.1.), confirming that these heterocycles were 
interchangeable. All compounds retained good ligand and lipophilic efficiencies (Table 
8.12). 
 
Table 8.12: ERK5 inhibitory activity of 2-substituted 5-pyridyl amides 445 - 452 
Compound R ERK5 IC50 (nM)
a
 L.E. LipE 
444 
 
24 ± 20
b
 0.32 5.0 
445 
 
22 ± 9
b 
0.31 4.9 
446 
 
25 ± 7
b 
0.32 5.3 
447 
 
14 ±1 0.33 5.2 
448 
 
11 ± 1 0.34 5.7 
449 
 
5 ±2 0.34 5.7 
450 
 
5 ± 1
b 
0.35 6.1 
451 
 
6 ± 1 0.34 5.5 
452 
 
5 ± 1 0.35 6.0 
a
 Determinations ± standard deviation (mean of n = 4); 
b
 n = 6 
 
 
Figure 8.4: Bar diagram showing ERK5 inhibitory activity of 2-substituted 5-pyridyl 
amides 445 - 452  
0
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Table 8.13: Structure and molecular properties of 2-substituted 5-pyridyl amides 453 - 456 
 
Compound R MW clogP clogD 
tPSA 
(Å
2
) 
HBA HBD 
453 
 
486 2.6 2.0 91 8 2 
454 
 
472 2.2 1.7 99 8 3 
455 
 
485 3.9 2.2 87 7 2 
456 
 
471 3.4 1.8 96 7 3 
 
Compounds with ERK5 inhibitory potencies below 10 nM were also prepared with the 
meta-methoxy benzoyl pyrrole 4-substituent, leading to inhibitors with reduced logD but 
increased tPSA (Table 8.13). The meta-methoxybenzoyl analogues 453 - 456 retained 
sub-10 nM potencies comparable with the trihalogenated inhibitors (Table 8.14). These 
compounds had improved lipophilic efficiency. 
 
Table 8.14: ERK5 inhibitory activity of 2-substituted 5-pyrimidyl amides 453 - 456 
Compound R ERK5 IC50 (nM)
a
 L.E. LipE 
453 
 
8 ± 3
b 
0.33 6.1 
454 
 
8 ± 2 0.34 6.4 
455 
 
10 ± 3 0.32 5.8 
456 
 
9 ± 1 0.33 6.2 
a
 Determinations ± standard deviation (mean of n = 4); 
b
 n = 5 
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Most of the pyridyl derivatives were progressed to in vitro ADME profiling (Table 8.15) 
with a view to establish an efflux SAR around the template. All compounds had excellent 
solubility. Plasma protein binding of the trihalogenated compounds 447 and 449 - 452 was 
moderate. Replacement of the meta-chlorine with the methoxy (454, 456) notably 
increased the free fraction of the drug. All of the methylated piperidines 445, 447 and 451 
or piperazine 449 had moderate to high turnover in mouse liver microsomes in vitro. Their 
non-methylated matched pairs 446, 448, 450 and 452 had much improved metabolic 
stability, indicating that N-demethylation may take place. Interestingly, the microsomal 
turnover of 447 and 451 was species-dependent, with higher stability observed in human 
than in mouse liver microsomes. All compounds retained undesirable high efflux ratios and 
apical to basolateral apparent permeability in the Caco-2 assay, suggesting that the pyridyl 
amides were still substrates for transporter pumps and that variation of the spacer had little 
influence on the permeability. The Caco-2 efflux ratio of 456 (ER = 2.5) was significantly 
reduced compared to 402 (ER = 99). However the apical to basolateral permeability across 
the Caco-2 monolayer was still low (Papp = 0.5 × 10
-6
 cm/s). Although 447 had a moderate 
Caco-2 efflux (ER = 8) some apical to basolateral permeability was observed (Papp = 2.5 × 
10
-6
 cm/s). In the carbon spacer series, all compounds had a similar apical to basolateral 
Papp, comprised between 0.5 and 1 × 10
-6
 cm/s. However the basolateral to apical Papp was 
significantly different between methylated and non-methylated derivatives (449 vs. 450, 
451 vs. 452), with higher apparent permeability for the methylated inhibitors. This could 
be rationalised by the increased lipophilicity of the alkylated compounds 449 and 451, 
which could also be substrates for an active uptake transporter on the basolateral 
membrane. Overall the results indicate that disappointingly reduction of the tPSA and the 
number of HBA and HBD had not abrogated transporter recognition. 
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Table 8.15: ERK5 inhibitory activity and in vitro ADME properties for 445 - 456 
 
Cmpd X R 
ERK5 
IC50 (nM)
a 
Sol 
(μM) 
Ppb 
Fu 
MLM 
Clint
c 
HLM 
Clint
c
 
Caco-2 
AB
d
 (ER) 
445 Cl 
 
22 ± 9
b 
> 100 n.d. 110 n.d. 2.0 (14) 
446 Cl 
 
25 ± 7
b 
> 100 n.d. 20 n.d. 0.2 (38) 
447 Cl 
 
14 ± 1 > 100 0.048 50 16 2.5 (8) 
448 Cl 
 
11 ± 1 > 100 n.d. 1 n.d. 0.2 (74) 
449 Cl 
 
5 ± 2 > 100 0.099 59 n.d. 1.0 (30) 
450 Cl 
 
5 ± 1
b 
> 100 0.091 7 n.d. 0.6 (6) 
451 Cl 
 
6 ± 1 > 100 0.083 34 8 0.7 (28) 
452 Cl 
 
5 ± 1 > 100 0.062 4 3 0.6 (5) 
454 OMe 
 
8 ± 2 > 100 0.182 7 n.d. 0.6 (4) 
456 OMe 
 
9 ± 1 > 100 0.115 14 n.d. 0.5 (2.5) 
a
 Determinations ± standard deviation (mean of n = 4) ; 
b
 n = 6; 
c L/min/mg protein; d Papp 10
-6
 cm.s
-1
; 
n.d. = not determined 
 
The cellular activity of the compounds whose ADME properties had been determined, was 
assessed in HeLa cells (Table 8.16). Compounds with the N-methyl spacer were 
moderately potent. Introduction of the oxygen and methylene spacer in the trihalogenated 
series (447 - 452), resulted in sub-100 nM cellular ERK5 inhibitory activity with the 
exception of 450 for whom a second IC50 value determination would be required to 
confirm the low potency initially measured. Similarly to the SARs observed with the 
pyrimidyl linker (see section 8.3.1.), compounds 454 and 456 with the meta-
methoxybenzoyl pyrrole 4-substituent were less active compared with their meta-chloro 
matched pairs 450 and 452. 
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Table 8.16: Comparison of ERK5 inhibitory activity in the IMAP cell-free assay, with 
ERK5 inhibition in the HeLa cellular assay 
 
Compound X R 
ERK5 IC50 
(nM)*
a 
Caco-2 AB
c
 
(ER) 
HeLa IC50 
(μM)d 
445 Cl 
 
22 ± 9
b 
2.0 (14) 0.48 
446 Cl 
 
25 ± 7
b 
0.2 (38) 0.44 ± 0.32
e 
447 Cl 
 
14 ± 1 2.5 (8) 0.06 ± 0.04
f 
448 Cl 
 
11 ± 1 0.2 (74) 0.05 
449 Cl 
 
5 ± 2 1.0 (30) 0.07 
450 Cl 
 
5 ± 1
b 
0.6 (6) 1.5 
451 Cl 
 
6 ± 1 0.7 (28) 0.03 ± 0.02
f
 
452 Cl 
 
5 ± 1 0.6 (5) 0.04 ± 0.03
e
 
454 OMe 
 
8 ± 2 0.6 (4) 0.18 
456 OMe 
 
9 ± 1 0.5 (2.5) 0.44 
* ERK5 inhibitory activity in the cell-free IMAP assay; 
a
 Determinations ± standard deviation 
(mean of n = 4); 
b
 n = 6; 
c 
Papp 10
-6
 cm.s
-1
; 
d
 n = 1; 
e
 n = 2; 
f
 n = 3 
 
Compounds with the best combination of in vitro ADME properties and good cellular 
potencies were progressed to an in vivo pharmacokinetic study in mouse (Table 8.17). 
Compounds with a methylated terminal aliphatic heterocycle, such as 447 and 451 had 
moderate total plasma clearance and high unbound clearance, in agreement with the high 
turnover observed in in vitro mouse liver microsomes. These compounds had a moderate 
volume of distribution and low bioavailability, reflecting the poor absorption predicted in 
the Caco-2 assay (447, ER = 8; 451, ER = 28). 
Although compounds 450, 452 and 456 had low total plasma clearance and unbound 
clearance, they had no bioavailability. This suggests that the oral dose was not absorbed 
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and that all compounds in this chemical series with an efflux ratio above 2 in the Caco-2 
assay are unlikely to achieve good oral bioavailability. Surprisingly, these secondary 
aliphatic amines had a low volume of distribution despite their basic nature. Overall the 
high efflux in the Caco-2 assay translated to poor in vivo bioavailability. However, 
methylated compounds 447 and 451, which had the higher efflux ratio, showed some 
bioavailability, suggesting that an increased lipophilicity might improve absorption of this 
chemical class. 
 
Table 8.17: In vivo pharmacokinetic parameters for selected compounds. Dose 10 mg/kg 
i.v. and p.o. 
 
Compound X R 
Cl 
mL/min/kg 
Clu 
mL/min/kg 
Vd 
L/kg 
t1/2 
min 
F 
% 
447 Cl 
 
25 521 1.1 80 13 
450 Cl 
 
11 121 0.2 99 0 
451 Cl 
 
20 241 1 263 9 
452 Cl 
 
6 97 0.4 80 0 
456 OMe 
 
4 38 0.2 74 0 
 
8.3.4. Synthesis of the Pyridyl-Amide Linked Analogues 
Exploration of the pyridyl 2-position was achieved through preparation of 2-substituted 
5-aminopyridines from 2-chloro-5-nitropyridine (459). 
A four step strategy, where diversification of the pyridyl 2-substituent was introduced at 
the first step, was applied to the synthesis of a small library of eight derivatives, 
incorporating nitrogen-, oxygen- and carbon-linked piperidines (Table 8.19). SNAr 
reactions on 2-chloro-5-nitropyridine (459) were utilised for the synthesis of heteroatom-
linked piperidines 460 and 461.  
141 
Hydroboration of 1-Boc-4-methylidenepiperidine (457) followed by Suzuki-Miyaura 
cross-coupling with 2-chloro-5-nitropyridine (459), using a literature procedure developed 
for the synthesis of 4-benzyl piperidines, led to isolation of 458 in only 10% yield 
(Table 8.18, entry 1).
252
 To improve the outcome of this transformation, alternative 
palladium catalysts, bases and solvents were investigated but all produced 458 in 
disappointing yields. Use of 2-bromo-5-nitropyridine as coupling partner was also 
unsuccessfully attempted. Isolation of 458 in a low yield was primarily due to the 
formation of 5-nitropyridin-2-ol as a major by-product. Thus, increasing the number of 
equivalents of 2-chloro-5-nitropyridine improved conversion, with 2 equivalents proving 
optimal (Table 8.18, entry 3). Although the yield of the reaction was still moderate, it was 
deemed sufficient for the first step of a short synthetic route. 
 
Table 8.18: Investigation of the effect of 2-chloro-5-nitropyridine equivalents on the 
conversion of 457 into 458; Reagents and conditions: (i) a) 9-BBN (0.5 M in THF), 67 °C, 
3 h; b) 2-chloro-5-nitropyridine (459), K2CO3, PdCl2dppf, DMF:H2O (10:1), 60 °C, 18 h. 
 
# 
2-Chloro-5-nitropyridine 
Equiv. 
Yield 
1 1 10% 
2 1.5 30% 
3 2 40% 
4 2.5 35% 
 
The 2-substituted 5-nitropyridines 458, 460 and 461 were subsequently reduced using 
palladium-catalysed hydrogenation to give aminopyridines 462, 463 and 464, which were 
converted into the desired final products following a similar reaction sequence to that 
described for the pyrimidyl analogues in section 8.3.2., namely Mukaiyama amide 
coupling, acid mediated-Boc deprotection and in situ deprotection/Eschweiler-Clarke 
methylation (Table 8.19). All target compounds were isolated in good yields and high 
purity. 
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Table 8.19: Summary of yields for the four steps synthesis of 2-sustituted 5-pyridyl-
amides; Reagents and conditions: (i) tert-butyl 4-(methylamino)piperidine-1-carboxylate, 
NEt3, THF, RT to 67 °C, 18 h, 75%; (ii) a) NaH (60% dispersion in mineral oil), 1-Boc-4-
hydroxypiperidine, THF, 0 °C to RT, 1 h; b) 2-chloro-5-nitropyridine (459), 0 °C to RT, 
20 h, 78%; (iii) a) tert-butyl 4-methylidenepiperidine-1-carboxylate, 9-BBN (0.5 M in 
THF), 67 °C, 3 h; b) 2-chloro-5-nitropyridine (459), K2CO3, PdCl2dppf, DMF:H2O (10:1), 
60 °C, 18 h, 40%; (iv) H2, 10% Pd/C, MeOH:THF (1:1), 40 °C, 8 h; (v) 4-(3,6-dichloro-2-
fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250) or 4-(6-chloro-2-fluoro-3-
methoxybenzoyl)-1H-pyrrole-2-carboxylic acid (338), 2-chloro-1-methylpyridinium 
iodide, NEt3, DCM, 42 °C, 24 h; (vi) DCM, TFA, Et3SiH, RT, 2 h; (vii) formic acid, 
formaldehyde (37 % wt. in water), 95 °C, 3 h. 
 
Y 
Step 1 Step 2 Step 3 Step 4 
R Yield R Yield X R Yield X R Yield 
NMe Boc 460, 
75% 
Boc 
462, 
95% 
Cl Boc 
465, 
49% 
Cl 
H 
446, 
77% 
Me 
445, 
74% 
O Boc 461, 
78% 
Boc 
463, 
96% 
Cl Boc 
466, 
48% 
Cl 
H 
448, 
77% 
Me 
447, 
71% 
C Boc 458, 
40% 
Boc 
464, 
96% 
Cl Boc 
467, 
42% 
Cl 
H 
452, 
70% 
Me 
451, 
75% 
OMe Boc 
468, 
39% 
OMe 
H 
456, 
76% 
Me 
455, 
71% 
 
The synthesis of the targets incorporating a piperazine side-chain (449, 450, 453 and 454) 
began with displacement of the 2-chloro group of 459 with the anion of diethyl malonate to 
give 469 in 64% yield (Scheme 8.7).
253
 A tandem ester hydrolysis/decarboxylation was 
then carried out in boiling aqueous sulphuric acid to provide 2-methyl-5-nitropyridine 
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(470), which was subsequently N-oxidised using m-CPBA.
254
 A Polonovki reaction was 
utilised to convert N-oxide 471 to pyridylmethanol 472, which was oxidised to aldehyde 
473 by manganese dioxide.
255
 Intermediate 474 was prepared via reductive amination of 
473 with Boc-protected piperazine in trifluoroethanol.
206
 Hydrogenation of 474 followed 
by amide coupling and Boc cleavage/methylation were achieved as described for the 
pyrimidyl analogues. The yields of all these reactions were consistent with previous 
observations (Scheme 8.7). 
 
 
Scheme 8.7: Reagents and conditions: (i) a) NaH (60% dispersion in mineral oil), diethyl 
malonate, THF, 0 °C to RT, 1 h; b) 2-chloro-5-nitropyridine (459), 0 °C to RT, 20 h, 64%; 
(ii) 20% aq. H2SO4, 100 °C, 2 h, 95%; (iii) m-CPBA (74%), DCM, 0 °C to RT, 16 h, 96%; 
(iv) a) TFAA, DCM, 0 °C to RT, 16 h; b) MeOH, 0 °C to RT, 8 h, 50%; (v) MnO2, DCM, 
RT, 16 h, 61%; (vi) a) tert-butyl piperazine-1-carboxylate, MgSO4, trifluoroethanol, 1 h, 
38 °C; b) NaBH4, trifluoroethanol, 0 °C to RT, 1 h, 51%; (vii) H2, 10% Pd/C, MeOH:THF 
(1:1), 40 °C, 8 h, 95%; (viii) 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic 
acid (250) or 4-(6-chloro-2-fluoro-3-methoxybenzoyl)-1H-pyrrole-2-carboxylic acid (338), 
2-chloro-1-methylpyridinium iodide, NEt3, DCM, 42 °C, 24 h, (476, X = Cl, 28%; 
477, X = OMe, 33%); (ix) DCM, TFA, Et3SiH, RT, 2 h, (450, X = Cl, R = H, 73%; 
454, X = OMe, R = H, 71%); (x) formic acid, formaldehyde (37 % wt. in water), 95 °C, 3 
h, (449, X = Cl, R = Me, 66%; 453, X = OMe, R = Me, 76%). 
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8.4. Investigation of 2-Substituents with a Different Spatial Conformation 
8.4.1. SARs and Biological Evaluation of Inhibitors Bearing Basic 
Substituents 
Subtle modifications of the molecular properties of 402 did not allow to access ERK5 
inhibitors with low efflux and high permeability in the in vitro Caco-2 assay, suggesting 
that introduction of a basic aliphatic heterocycle at the 2-position of the heteroaromatic 
conferred affinity for one or more efflux transporters. To address the efflux liability, 
another approach investigated, was to append alternative 2-substituents with significant 
structural diversity which might reduce transporter recognition, whilst maintaining low 
ERK5 inhibitory activity. 
 
Table 8.20: Structure and molecular properties of 5-pyridyl/pyrimidyl amides bearing 
alternative basic amines at the 2-position (478 - 486) 
 
Compound R Y MW clogP clogD 
tPSA 
(Å
2
) 
HBA HBD 
444 
 
C 490 3.6 2.6 90 7 3 
402 N 491 3.8 2.4 103 8 3 
478 
 
N 465 3.6 1.9 103 8 3 
479 
 
C 492 4.1 2.6 90 7 3 
480 N 493 4.3 2.4 103 8 3 
481 
 
C 490 3.7 2.7 90 7 3 
482 N 491 3.9 2.5 103 8 3 
483 
 
C 504 4.2 2.9 90 7 3 
484 N 505 4.5 2.7 103 8 3 
485 
 
C 506 3.0 2.7 99 8 3 
486 N 507 3.3 2.5 112 9 3 
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A set of structurally diverse derivatives, incorporating basic side-chains at the 2-position of 
the 5-pyridyl/pyrimidyl amide, was therefore prepared (Table 8.20). This library of 
compounds, which place the basic centre at a different position relative to 402 and 444, 
would allow further SARs to be established. All compounds retained high tPSA and a 
similar number of HBA and HBD compared with 402 and 444 (Table 8.20). 
ERK5 inhibitory activity for these pyridyl- and pyrimidyl-linked analogues was 
comparable with 402 and 444 (Table 8.21), indicating that a broad range of substituents 
incorporating a basic amine was tolerated in this position. Interestingly, the increased 
conformational flexibility of the side-chains did not lead to an entropic penalty for binding. 
Modulation of the basicity of the basic centre appeared to affect ERK5 inhibition with 
analogues 485 and 486, suffering from a 3- to 4-fold reduction in potency. 
 
Table 8.21: ERK5 inhibitory activity of 5-pyridyl/pyrimidyl amides bearing alternative 
basic amines at the 2-position (478 - 486) 
Compound R Y 
ERK5 IC50 
(nM)
a
 
L.E. LipE 
444 
 
C 24 ± 20
b
 0.32 5.0 
402 N 14 ± 3 0.33 5.5 
478 
 
N 17 ± 3 0.34 5.9 
479 
 
C 24 ± 15
c 
0.32 5.0 
480 N 19 ± 2 0.32 5.3 
481 
 
C 24 ± 13
b 
0.32 4.9 
482 N 18 ± 2 0.32 5.3 
483 
 
C 11 ± 3
b 
0.32 5.1 
484 N 12 ± 2 0.32 5.3 
485 
 
C 108 ± 60 0.28 4.2 
486 N 49 ± 15 0.29 4.8 
a
 Determinations ± standard deviation (mean of n = 4); 
b
 n = 6; 
c
 n = 8 
 
Compounds 480, 483, 484 and 486 were progressed to in vitro ADME profiling 
(Table 8.22). The diethylamine and morpholine moieties improved solubility relative to 
402. All the compounds had moderate plasma protein binding and moderate to high 
metabolic instability in mouse liver microsomes in vitro, indicating that long aliphatic 
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chains at the heteroaromatic 2-position might introduce a metabolic liability. Interestingly, 
the clearance of pyrimidyl derivative 484 was twice lower than the clearance of its pyridyl 
matched pair 483. The Caco-2 efflux ratio of these inhibitors was still very high, with low 
apical to basolateral apparent permeability, indicating that variation in the structure of the 
inhibitors did not abrogate transporter recognition. 
 
Table 8.22: ERK5 inhibitory activity and in vitro ADME properties for selected inhibitors 
 
Compound R Y 
ERK5 
IC50 
(nM)
a 
Sol 
(μM) 
Ppb 
Fu 
MLM 
Clint
c 
Caco-2 AB
d
 
(ER) 
402 
 
N 14 ± 3
 
10 - 100 0.067 19 0.3 (99) 
480 
 
N 19 ± 2
 
> 100 n.d. 41 0.4 (88) 
483 
 
C 11 ± 3
b 
30 - 100 0.058 62 0.5 (64) 
484 N 12 ± 2 30 - 100 0.113 32 0.5 (60) 
486 
 
N 49 ± 15 > 100 0.039 129 0.5 (97) 
a
 Determinations ± standard deviation (mean of n = 4); 
b
 n = 6; 
c L/min/mg protein; d Papp 10
-6
 cm.s
-1
; 
n.d. = not determined 
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The cellular activity of this series of compounds was also determined in HEK293 cells 
(Table 8.23). All the compounds had IC50 value between 80 and 150 nM, with derivative 
482 being the most active. Compounds 485 and 486, which were slightly less active in the 
enzymatic assay retained similar activity in cells relative to the other compounds of the 
series. The pyridyl and pyrimidyl matched pair had similar activity. 
 
Table 8.23: Comparison of ERK5 inhibitory activity in the IMAP cell-free assay, with 
ERK5 inhibition in the HeLa and HEK293T cellular assays 
Compound R Y 
ERK5 IC50 
(nM)*
a 
HeLa IC50 
(μM)b 
HEK293T 
IC50 (μM)
c
 
478 
 
N 17 ± 3 n.d. 0.12 ± 0.03 
479 
 
C 24 ± 15
e 
n.d. 0.15 ± 0.10 
480 N 19 ± 2 0.49 0.15 ± 0.02 
481 
 
C 24 ± 13
d 
n.d. 0.12 ± 0.02 
482 N 18 ± 2 n.d. 0.08 ± 0.03 
483 
 
C 11 ± 3
d 
n.d. 0.14 ± 0.01 
484 N 12 ± 2 0.07 0.09 ± 0.02 
485 
 
C 108 ± 60 n.d. 0.13 ± 0.01 
486 N 49 ± 15 0.35 0.14 ± 0.02 
* ERK5 inhibitory activity in the cell-free IMAP assay; 
a
 Determinations ± standard 
deviation (mean of n = 4); 
b 
Data from a single determination; 
c
 n = 2; 
d
 n = 6; 
e
 n = 8; 
n.d. = not determined 
 
8.4.2. SARs and Biological Evaluation of Inhibitors Bearing Neutral 
Substituents 
The high efflux ratio and low permeability of all the compounds incorporating a basic 
amine in the pyridyl/pyrimidyl 2-position suggested that the basicity of the side-chain was 
driving transporter recognition. Previous SAR had established that the basic centre was 
providing a potency advantage and molecular modelling suggested that it might be 
interacting with a glutamate residue on the exit of the active site (Figure 8.5). 
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Figure 8.5: Docking of 402 in the ATP-binding site of ERK5 (PDB code 4b99) 
194
 
 
Only a small set of alternative non-basic pyrimidine 2-substituents had previously been 
investigated and resulted in a significant reduction of ERK5 potency for 488 and 490 
(Table 8.24).
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 The 4-hydroxypiperidine moiety in inhibitor 489, which places a hydrogen 
bond donor group in the vicinity of the glutamate residue, was tolerated, and 489 was 
equipotent with 487. This encouraging result suggested that incorporation of neutral 
aliphatic substituents, which could mimic the interaction of the basic nitrogen or 
participate in alternative binding interactions, might improve ERK5 binding affinity. 
 
Table 8.24: ERK5 inhibitory activity of 2-substituted 5-pyrimidyl amides 
Compound R 
ERK5 IC50 
(μM)a 
487 H 0.32 ± 37
b 
488 
 
1.5 ± 0.2
 
489 
 
0.53 ± 0.09
c 
490 
 
9.7 ± 7.3
 
a
 Determinations ± standard deviation (mean of n = 2); 
b
 n = 9; 
c
 n = 4 
 
A small library of compounds introducing (methylsulfonyl)ethyl, methoxyethyl, oxetane or 
hydroxyethyl groups at the 2-position of pyridyl or pyrimidyl amides was synthesised. 
These side-chains were linked to the pyridyl/pyrimidyl ring via an amine or an ether group. 
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These compounds retained high tPSA and a similar number of HBD and HBA compared 
with the basic analogues (Table 8.25). 
 
Table 8.25: Structure and molecular properties of 5-pyridyl/pyrimidyl amides bearing a 
neutral side-chain at the 2-position (491 - 496) 
 
Compound R Y MW clogP clogD 
tPSA 
(Å
2
) 
HBA HBD 
318 
H 
C 378 3.8 3.8 75 5 2 
487 N 379 4.0 4.0 88 6 2 
491 
 
C 499 2.6 2.0 121 8 3 
492 N 500 3.0 1.8 134 9 3 
493 
 
C 500 2.8 2.8 118 8 2 
494  C 452 3.7 3.7 93 7 2 
495  C 438 3.1 3.1 104 7 3 
496 
 
C 450 3.6 3.6 93 7 2 
 
A significant reduction in ERK5 inhibitory activity was apparent in the pyridyl series, 
indicating that introduction of neutral flexible substituents might induce an entropic 
penalty for binding (Table 8.26). Compound 495 which displays a terminal hydrogen bond 
donor was the most potent compound of the pyridyl series. Introduction of the 
(methylsulfonyl)ethyl group in pyrimidyl amide 492 conferred a 2-fold improvement in 
ERK5 inhibition compared with 487, suggesting that incorporation of neutral substituents 
might have an opposite effect in the pyridyl and pyrimidyl series. None of these 
compounds achieved the IC50 threshold of 100 nM, required to be progressed in the 
cascade and submitted for in vitro ADME evaluation. 
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Table 8.26: ERK5 inhibitory activity of 5-pyridyl/pyrimidyl amides bearing a neutral side-
chain at the 2-position (491 - 496) 
Compound R Y 
ERK5 IC50 
(μM)a 
L.E. LipE 
318 
H 
C 0.066 ± 0.033
c
 0.39 3.4 
487 N 0.32 ± 37
d
 0.36 2.5 
491 
 
C 0.21 ± 0.04
b 
0.28 4.6 
492 N 0.15 ± 0.04 0.29 5.0 
493 
 
C 0.43 ± 0.17 0.27 3.5 
494  C 1.2 ± 0.4 0.27 2.2 
495  C 0.32 ± 0.09 0.31 3.4 
496 
 
C 1.1 ± 0.3 0.27 2.4 
a
 Determinations ± standard deviation (mean of n = 4); 
b
 n = 6; 
c
 n = 7; 
d
 n = 9 
 
8.4.3. Synthesis 
Pyridyl derivatives with oxygen-linked substituents were prepared following a three step 
sequence of previously optimised reactions (Table 8.27). Sodium hydride was utilised to 
generate alkoxides from commercially available alcohols, which were engaged in SNAr 
reactions with 2-chloro-5-nitropyridine (459). The resulting 2-alkoxy-5-nitropyridines 
498 - 500 were reduced using palladium-catalysed flow hydrogenation and coupled to 
pyrrole carboxylic acid 250 using the Mukaiyama procedure. All reactions proceeded in 
moderate to excellent yields (Table 8.27). 
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Table 8.27: Summary of yields for the three step synthesis of 2-alkoxy 5-pyridyl-amides; 
Reagents and conditions: (i) a) NaH (60% dispersion in mineral oil), R-OH, THF, 0 °C to 
RT, 1 h; b) 2-chloro-5-nitropyridine (459), 0 °C to RT, 20 h; (ii) H2, 10% Pd/C, 
MeOH:THF (1:1), 40 °C, 8 h; (iii) 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-
carboxylic acid (250), 2-chloro-1-methylpyridinium iodide, NEt3, DCM, 42 °C, 24 h. 
 
R Step 1 Step 2 Step 3 
 
497, 0% / / 
 498, 69% 501, 96% 494, 51% 
 499, 41% 502, 95% 495, 20% 
 
500, 86% 503, 93% 496, 28% 
 
The first step of this reaction sequence failed with 2-(methylsulfonyl)ethanol due to a 
retro-Michael reaction taking place and leading exclusively to the formation of 5-nitro-
pyridin-2-ol. To prevent this side-reaction, the SNAr was conducted with the anion of 
2-(methylthio)ethanol to form 504, which was subsequently oxidised using Oxone
®
 to give 
505 in 57% yield (Scheme 8.8). The nitro reduction and amide coupling were conducted as 
previously described. 
 
Scheme 8.8: (i) a) NaH (60% dispersion in mineral oil), 2-(methylthio)ethanol, THF, 0 °C 
to RT, 1 h; b) 2-chloro-5-nitropyridine, 0 °C to RT, 20 h, 88%; (ii) Oxone
®
, MeOH, H2O, 
RT, 24 h, 57%; (iii) H2, 10% Pd/C, MeOH, 40 °C, 8 h, 95%; (iv) 4-(3,6-dichloro-2-
fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250), 2-chloro-1-methylpyridinium iodide, 
NEt3, DCM, 42 °C, 24 h, 24%.  
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Derivatives with NH-linked side-chains were also prepared following a three step reaction 
sequence using a similar array of synthetic transformations, namely SNAr reaction, 
palladium-catalysed nitro hydrogenation and Mukaiyama amide coupling (Table 8.28). A 
complex mixture of tertiary and secondary amides was obtained for the final coupling step, 
resulting in low to moderate yields. 
 
Table 8.28: Summary of yields for the three step synthesis of 2-alkylamine 
5-pyridyl/pyrimidyl-amides; Reagents and conditions: (i) R-NH2, NEt3, THF, 0 °C to RT, 
3 h; (ii) R-NH2, NEt3, THF, 67 °C, 16 h; (iii) H2, 10% Pd/C, MeOH:THF (1:1), 40 °C, 8 h; 
(iv) 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250), 2-chloro-1-
methylpyridinium iodide, NEt3, DCM, 42 °C, 24 h. 
 
R Y Step 1 Step 2 Step 3 
 
N 507, 74% 518, 96% 478, 11% 
 
C 508, 59%
 
519, 98%
 
479, 27%
 
N 509, 93% 520, 95% 480, 34% 
 
C 510, 63%
 
521, 93%
 
481, 20%
 
N 511, 87% 522, 92% 482, 29% 
 
C 512, 96%
 
523, 97%
 
483, 22%
 
N 513, 93% 524, 91% 484, 41% 
 
C 514, 65% 525, 95% 485, 14% 
N 515, 91% 526, 93% 486, 36% 
 
C 516, 63% 527, 95% 491, 17% 
N 517, 46% 528, 55% 492, 45% 
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8.5. Investigation of Alternative Methylene Linked Amines at the 2-Position of 
5-Aminopyridyl Amides 
8.5.1. SARs and Biological Evaluation 
During the course of the optimisation of the pyrimidyl spacer (see section 8.3.1.), 
compound 409 was identified as a sub-100 nM ERK5 inhibitor (Table 8.29). This positive 
result was really unexpected since all previously synthesised inhibitors missing the 
terminal basic nitrogen had failed to achieve low nanomolar potency. Introduction of the 
methylene spacer resulted in a 28-fold increase in potency relative to 488. The significant 
improvement in ERK5 inhibition, emerging from the addition of the methylene group, was 
confirmed by the 0.13 μM IC50 value of 529, the meta-methoxybenzoyl matched pair of 
409. 
 
Table 8.29: ERK5 inhibitory activity of 2-substituted 5-pyrimidyl amides 
Compound X R 
ERK5 IC50 
(μM)a 
487 Cl H 0.32 ± 37
b 
488 Cl 
 
1.5 ± 0.2
 
489 Cl 
 
0.53 ± 0.09
c 
409 Cl 
 
0.053 ± 0.016
 
529 OMe 
 
0.13 ± 0.03 
a
 Determinations ± standard deviation (mean of n = 2); 
b
 n = 9; 
c
 n = 4 
 
The pyridyl amide analogues of 409 and 529 were also synthesised. Compounds 530 and 
531 retained low nanomolar ERK5 inhibitory activity (Table 8.30). Inhibitor 530 had high 
protein plasma binding and moderate solubility, despite the presence of the water-
solubilising morpholine moiety. Inhibitor 530 was subject to rapid metabolism in mouse 
liver microsomes in vitro. The Caco-2 efflux for this compound was high, but moderate 
apparent permeability (Papp = 3.7 × 10
-6
 cm/s) across the Caco-2 monolayer was observed. 
This result was encouraging since several kinase inhibitors approved for clinical use are 
substrates of efflux transporters but retained good oral bioavailability owing to their 
moderate to high permeability.
256
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Table 8.30: ERK5 inhibitory activity and in vitro ADME properties of 530 and 531 
 
Compound X 
ERK5 IC50 
(nM)
a Ppb Fu 
Sol 
(μM) 
MLM 
Clint
b 
Caco-2 
AB
c
 (ER) 
530 Cl 31 ± 6 0.047 30-100 92 3.7 (9) 
531 OMe 43 ± 21 n.d. n.d. n.d. n.d. 
a
 Determinations ± standard deviation (mean of n = 4); 
b L/min/mg protein; c Papp 10
-6
 cm.s
-1
; 
n.d. = not determined 
 
In order to determine the origin of potency gain, a small set of inhibitors incorporating 
methylene-linked amines was prepared (Table 8.31). Dimethylamine analogue 532 
retained low nanomolar ERK5 inhibitory activity and achieved a high ligand efficiency of 
0.36. Replacement of the dimethyl amine with a piperidine in inhibitor 533 led to a 2-fold 
improvement in potency. These data demonstrate that the morpholine oxygen of 530 was 
not contributing to potency. Ring opening of the morpholine to an aliphatic side-chain was 
tolerated, with 534 having similar potency to 530. A slight reduction in ERK5 inhibition 
was apparent for compound 535, suggesting that the flexibility of the aliphatic chains 
might lead to an entropic penalty for binding. The morpholine oxygen was also moved 
outside of the ring to give 4-hydroxypiperidine derivative 536, which had sub-10 nM 
ERK5 inhibitory activity. Overall, these results demonstrated that the basicity of the 
benzylic nitrogen is driving potency. Indeed, compounds with higher basicity relative to 
530, all had superior ERK5 binding affinity, whereas compounds 534 and 535 had a 
marginal decrease in activity (Table 8.31).  
Inhibitors 532 and 536 had excellent solubility and moderate plasma protein binding 
(Table 8.31). Unsurprisingly, 532 had high metabolic instability in mouse liver 
microsomes, with N-demethylation suspected to be the major route of metabolism. 
Compound 536 had good in vitro microsomal stability. Derivative 532 retained undesired 
high efflux in the Caco-2 assay and similar apparent permeability relative to 530, 
indicating that reduction of the molecular weight had not abrogated efflux pump 
recognition. Inhibitor 536 had the lowest apical to basolateral apparent permeability 
observed in the pyrrole carboxamide series and a very high efflux ratio (ER = 132) 
compared with 530, suggesting that incorporation of an additional HBD increases affinity 
for efflux transporters. These results demonstrate that substitution at the 2-position of 
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5-pyridyl/pyrimidyl amides with basic side-chains leads to low permeability and high 
efflux independently of the position, the shape or the size of the basic substituent. 
 
Table 8.31: ERK5 inhibitory activity and in vitro ADME properties of 532 - 536 
 
Compound R 
ERK5 IC50 
(nM)
a Ppb Fu 
Sol 
(μM) 
MLM 
Clint
b 
Caco-2 
AB
c
 (ER) 
532 
 
21 ± 2 0.0132 > 100 52 2.7 (17) 
533 
 
9 ± 1 n.d. n.d. n.d. n.d. 
534 
 
38 ± 6 n.d. n.d. n.d. n.d. 
535 
 
115 ± 18 n.d. n.d. n.d. n.d. 
536 
 
8 ± 2 0.099 > 100 17 0.2 (132) 
a
 Determinations ± standard deviation (mean of n = 4); 
b L/min/mg protein; c Papp 10
-6
 cm.s
-1
; n.d. = not 
determined 
 
The cellular activity of the compounds with IC50 values below 100 nM in the biochemical 
assay was determined in HEK293 cells (Table 8.32). With the exception of compound 536, 
all compounds had low nanomolar activity in cells similar to the activity determined in the 
biochemical assay. The difference of potency for inhibitor 536 could be explained by its 
poor cellular permeability as determined in the Caco-2 assay. It appears the introduction of 
methylene linked amine at the 2-position of 5-pyridyl amide conferred improved cellular 
activity relative to all the side-chains previously investigated. Indeed, all the other 
inhibitors tested in the HEK293 assay suffered from a significant reduction of potency 
compared with their biochemical activity (see section 8.3.1. Table 8.8 and section 8.4.1. 
Table 8.23). 
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Table 8.32: Comparison of ERK5 inhibitory activity in the IMAP cell-free assay, with 
ERK5 inhibition in the HEK293T cellular assay 
Compound R 
ERK5 IC50 
(nM)*
a 
HEK293T 
IC50 (nM)
b
 
530 
 
31 ± 6 31 ± 9 
532 
 
21 ± 2 25 ± 10 
533 
 
9 ± 1 13 ± 2 
534 
 
38 ± 6 40 ± 14 
536 
 
8 ± 2 44 ± 7 
* ERK5 inhibitory activity in the cell-free IMAP assay; 
a
 Determinations ± standard deviation (mean of n = 4); 
b
 n = 3 
 
8.5.2. Synthesis 
Table 8.33: Summary of yields for the three step synthesis of 2-methylamine 5-pyridyl-
amides; Reagents and conditions: (i) R-NH2, NaBH(OAc)3, DCE, RT, 16 h; (ii) H2, 10% 
Pd/C, MeOH:THF (1:1), 40 °C, 8 h; (iii) 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-
carboxylic acid (250), 2-chloro-1-methylpyridinium iodide, NEt3, DCM, 42 °C, 24 h. 
 
R Step 1 Step 2 Step 3 
 
537, 68% 543, 90% 530, 44% 
 
538, 63% 544, 93% 532, 8% 
 
539, 59% 545, 95% 533, 27% 
 
540, 69% 546, 95% 534, 18% 
 
541, 79% 547, 95% 535, 20% 
 
542, 75% 548, 96% 536, 23% 
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Compound 473 was a versatile intermediate in the synthesis of methylene-linked amines. It 
was prepared following the synthetic route described in section 8.3.4. Reductive amination 
of 473 with a range of commercially available amines was achieved in 1,2-dichloroethane 
using sodium triacetoxyborohydride as reducing reagent (Table 8.33). Nitro reduction and 
amide coupling were performed using the standard methodology previously described. 
 
8.6. Summary 
Exploration of the SAR around the para position of the heteroaromatic amide substituent 
has led to the identification of compounds with improved potency against ERK5 relative to 
402, in both biochemical and cellular assays. Incorporation of a methylene spacer between 
the heteroaromatic and the basic aliphatic heterocycle has provided a set of compounds 
with sub-10 nM ERK5 inhibitory activities. Replacement of the basic side-chain with 
neutral substituents was not tolerated with respect to ERK5 potency. 
All ERK5 inhibitors, containing a basic centre, suffered from high efflux and low 
permeability in the Caco-2 assay, translating to poor in vivo bioavailability for several 
compounds. It is assumed that the basic centre increases their propensity for recognition by 
efflux transporters, such as P-gp or BCRP. A range of strategies to address the efflux 
liability has been investigated without success. This work illustrates the challenge in 
balancing potency and permeability. 
A co-crystal structure of ERK5 with inhibitors 318 and 406 will be required to identify 
potential binding interactions via substituents at the 2-position of 5-aminoheteroaromatic 
amides and guide the next round of SARs. 
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Chapter 9. Conclusions and Future Directions 
 
The two medicinal chemistry programs described in this thesis encompassed diverse 
chemistry, biology and stages of the drug discovery process. 
 
9.1. Design of Small-Molecule Inhibitors of Sulfatase-2 
Sulf-2 has been implicated in the progression of several cancers including hepatocellular 
carcinoma (HCC). The aim of the Sulf-2 project was to identify chemical tools for use in 
experiments in vitro to determine whether low micromolar Sulf-2 inhibitors could be 
selective over other members of the human sulfatase family and block cancer cell growth. 
The Sulf-2 project was in the early target validation phase and the only known series of 
inhibitors were monosaccharide sulfamate mimics of the endogenous substrate HSPGs. 
In an attempt to identify non-saccharide Sulf-2 inhibitors, a de novo design strategy was 
employed, based on an analysis of functional groups in the endogenous substrate HSPGs 
believed to be important for binding of Sulf-2. Biphenyl and biphenyl ether sulfamates, 
positioning a polar moiety in similar regions of space to those occupied by sulfate and 
carboxylate groups in heparin were prepared. Novel sulfamate protecting groups were 
developed to enable a more flexible approach to the synthesis of biphenyl and biphenyl 
ether O-sulfamates. 
 
 
 
Preliminary sulfatase inhibition data have been generated, indicating that biphenyl and 
biphenyl ether sulfamates exhibit superior potency against Sulf-2 than monosaccharide 
glucosamine 5. Incorporation of polar functionalities around the B-ring did not improve 
inhibitory activity, challenging the initial design hypothesis. Unexpectedly, the non-polar 
trichloroethyl protected sulfates had improved Sulf-2 inhibition, with compound 162 
having an IC50 value of 156 μM. This compound was significantly more active than 
monosaccharide 5, which did not inhibit Sulf-2 in our biochemical assay. Selectivity over 
other members of the sulfatase family was not achieved with these aromatic sulfamates. 
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Potential future design options include replacement of trichloroethyl protected sulfates 
with sulfonamides. Libraries of such derivatives could easily be prepared and would 
provide further SARs in this region of the scaffold. Isolation of Sulf-2 is very challenging 
and a more robust isolation/biochemical assay will be required for this project to become a 
full drug discovery program. The limitations of the de novo design strategy suggested that 
alternative methods for hit identification might need to be employed. 
 
9.2. Design of Small-Molecule Inhibitors of ERK5 
The ERK5 project was a more advanced program, in the lead optimisation phase. 
Extensive ERK5 potency SARs around the pyrrole carboxamide core A had previously 
been established. In this thesis, optimisations of the aroyl and the amide substituents were 
attempted, with the aim to improve both potency and ADMET properties. 
 
 
Introduction of meta-alkoxy substituents on the aroyl ring was investigated with the 
objective to improve the binding affinity via interaction with residues of a lipophilic pocket 
identified in the p38-derived homology model. The meta-methoxy group in 341 led to a 
6-fold improvement in potency against ERK5, and provided inhibitors equipotent with 
those incorporating the trihalogenated aroyl pattern. 
 
 
Obtaining a co-crystal structure of ERK5 with selected pyrrole carboxamide inhibitors, 
such as 341, will guide the future work around the benzoyl substituents. The SAR studies 
presented in this thesis have shown that groups larger than methoxy were detrimental to the 
ERK5 inhibition. Preparation of close analogues, incorporating a meta-OCHF2 or OCF3 
group would be of interest. 
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Attempts to access a lipophilic pocket in the ERK5 binding site via alkylation of the amide 
was attempted. All tertiary amides suffered from a significant decrease in ERK5 inhibitory 
activity (ERK5 IC50 > 1 μM) and reduced selectivity over p38. Substitution at the 2- or 
4-position of 3-aminopyridine amides also failed to improve potency against ERK5 
through interaction with this putative lipophilic pocket.  
Introduction of substituents bearing a basic centre at the 2-position of 5-aminopyrimidyl 
amides resulted in significant improvement of ERK5 inhibition, leading to the 
identification of compounds with sub-20 nanomolar IC50 values, such as piperazine 
derivative 406. Although, this compound had good cellular activity, it suffered from a high 
efflux ratio and low membrane permeability in the Caco-2 assay, and as a result, suffered 
from poor oral bioavailability in an in vivo mouse PK study. 
 
 
Reducing the tPSA and minimising the number of hydrogen bond donor and acceptor 
groups in the molecule through replacement of the pyrimidine with a pyridine led to 
compounds with similar pharmacological and in vitro ADME profiles. All compounds with 
an efflux ratio above 2 in the Caco-2 assay had poor in vivo oral bioavailability. 
Introduction of basic side-chains with a different spatial conformation provided 
compounds, such as 483, which retained low nanomolar ERK5 inhibitory activity. 
However, all of these derivatives had very high efflux ratio and poor apical to basolateral 
permeability in the Caco-2 assay. Inhibitors bearing a neutral substituent at the 2-position 
had reduced potency against ERK5. 
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Introduction of a methylene spacer in 488, resulted in a 28-fold increase in potency and 
provided compound with a basic centre in a different position. Related analogue 530 
retained low nanomolar ERK5 inhibition and had improved permeability in the Caco-2 
assay despite a high efflux ratio. A small library of derivatives was prepared, leading to the 
identification of compound 536 which had improved ERK5 inhibitory activity but a higher 
efflux ratio and reduced permeability relative to 530. 
 
 
The work presented in this thesis has extended the SARs around the pyrrole carboxamide 
core, and has highlighted structural modifications which improve potency against ERK5 
and affect ADMET properties. Principally, introduction of basic substituents at the 
2-position of 5-aminoheteroaromatic amides significantly improved ERK5 binding affinity 
but was detrimental to the permeability of the compounds, leading to inhibitors with poor 
oral bioavailability. Past SAR studies have demonstrated the limitations of the different 
homology models used to guide compound design in the pyrrole carboxamide series. A 
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co-crystal structure of ERK5 with key inhibitors is now required to guide the next round of 
SARs. 
 
 
Figure 9.1: Summary of SARs for the pyrrole carboxamide series developed or confirmed 
by the work contained in this thesis 
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Chapter 10. Experimental 
 
10.1. Summary of Generic Reactions, Analytical and Chromatographic 
Conditions 
10.1.1. Chemicals and Solvents 
All commercial reagents were purchased from Sigma-Aldrich Chemical Company, Alfa 
Aesar, Apollo Scientific or Tokyo Chemical Industry UK Ltd. The chemicals were of the 
highest available purity. Unless otherwise stated, chemicals were used as supplied without 
further purification. Anhydrous solvents were obtained from AcroSeal
TM
 or Aldrich 
SureSeal™ bottles and were stored under nitrogen. Petrol refers to the fraction with a 
boiling point between 40 and 60 °C. 
 
10.1.2. Chromatography 
Thin layer chromatography utilised to monitor reaction progress was conducted on plates 
pre-coated with silica gel Merck 60F254 or Merck NH2F254S. The eluent was as stated 
(where this consisted of more than one solvent, the ratio is stated as volume:volume) and 
visualisation was either by short wave (254 nm) ultraviolet light, or by treatment with the 
visualisation reagent stated followed by heating. ‘Flash’ medium pressure liquid 
chromatography (MPLC) was carried out either on a Biotage SP4 automated purification 
system or a Varian 971-FP automated purification system, using pre-packed Varian or 
Grace silica or amino-bonded silica cartridges. 
 
10.1.3. Microwave Reactions 
All reactions carried out in a microwave were performed in a Biotage Initiator with Sixty 
robot. 
 
10.1.4. Analytical Techniques 
Melting points were determined using a VWR Stuart SMP40 apparatus and are 
uncorrected. 
1
H, 
13
C and 
19
F nuclear magnetic resonance (NMR) spectra were obtained as either CDCl3, 
CD3OD or DMSO-d6 solutions and recorded at 500 MHz, 126 MHz and 471 MHz, 
respectively, on a Bruker Avance III 500 spectrometer. Where 
13
C NMR data are not 
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quoted, insufficient material was available or problems obtaining high resolution spectra 
were encountered. Chemical shifts are quoted in parts per million (δ) referenced to the 
appropriate deuterated solvent employed. Multiplicities are indicated by s (singlet), 
d (doublet), t (triplet), q (quartet), quin (quintet), m (multiplet), br (broad) or combinations 
thereof. Coupling constant values are given in Hz. Homonuclear and heteronuclear two 
dimensional NMR experiments were used where appropriate to facilitate assignment of 
chemical shifts. 
LC-MS was carried out on a Waters Acquity UPLC system with PDA and ELSD 
employing positive or negative electrospray modes as appropriate to the individual compound. 
Where LRMS data is not quoted, the mass was not recognised for that compound. High 
resolution mass spectrometry was performed by the EPSRC UK National Mass 
Spectrometry Facility, University of Wales Swansea, Singleton Park, Swansea, SA2 8PP. 
FTIR spectra were recorded on either a Bio-Rad FTS 3000MX diamond ATR or an 
Agilent Cary 630 FTIR as a neat sample. 
UV spectra were obtained using a U-2001 Hitachi Spectrophotometer with the sample 
dissolved in ethanol. 
Data were compared with literature data for compounds which had been previously 
reported. 
 
10.2. Sulf-2 Inhibitors - Experimental Procedures 
10.2.1. Sulfatase Biological Assay Protocols 
The sulfatase biological assays were performed by Dr Gary Beale and Dr Sari Alhasan. 
 
Sulf-2 assay protocol 
Compounds were screened using 4-MUS as a substrate for Sulf-2 according to a protocol 
described by Morimoto-Tomita et al.
65
 Briefly 293T cells were transiently transfected with 
pcDNA3.1/Myc-His(-)-HSulf-2 DNA (Addgene) and TransIT-LT1 Transfection Reagent 
(Mirus) using a transfection mixture at the ratio 1:3 (µg DNA: µL transfection reagent) in 
Opti-MEM I reduced serum medium (Gibco). Conditioned medium containing Sulf-2 was 
collected after 3 days and bound to HIS-Select Nickel affinity gel (Sigma) overnight at 
4 °C. Beads were washed three times with washing buffer containing 50 mM HEPES 
(pH 7.5), 300 mM NaCl, 0.05% Tween 20, followed by washing once with washing buffer 
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containing no tween. Beads were suspended in 50 mM Hepes (pH 7.5) and used in 
inhibition assays. 20 μL of bead slurry was incubated with 1 mM compound (in DMSO) 
plus 10X reaction buffer (500 mM HEPES pH 7.5, 100 mM CaCl2) for 1 h at 37 °C. The 
reaction was started by the addition of 20 μL of 20 mM 4-MUS (final concentration of 
8 mM) and incubated at 37 °C for 1 h. The reaction was stopped with 100 μL 1 M Tris 
buffer (pH 10.4) and read at 460 nm following excitation at 355 nm in FLUOstar Omega 
plate reader (BMG Labtech) using Omega data analysis software. 
 
ARSA and ARSB assay protocols 
Compounds were screened in a 96-well black plate (Sterilin) using 4-MUS as a substrate, 
using 50 μL reaction mixture containing 40 ng of the commercially available enzymes 
(ARSA or ARSB from R & D Systems), 50 mM HEPES (pH = 4.5), 10 mM CaCl2, 1 mM 
test compound (dissolved in DMSO; final concentration of DMSO in reaction = 2%), and 
H2O (45 μL). The assay mixture was incubated for 1 h at 37 °C, followed by addition of 
5 μL of 4-MUS (Km = 1.6 mM for ARSA and 612 μM for ARSB), and incubation for a 
further 1 h at 37 °C. The reaction was stopped with 100 μL of 1 M Tris (pH = 10.5) and 
read at 460 nm following excitation at 355 nm in FLUOstar Omega plate reader (BMG 
Labtech) using Omega data analysis software. 
 
10.2.2. Synthesis of Sulf-2 Inhibitors: General Procedures 
Except where water was included in the reaction mixture, all reactions were carried out 
under strict anhydrous conditions with glassware oven-dried and cooled under nitrogen. 
Temperatures quoted refer to bath temperatures. 
 
General procedure A: To the appropriate 1-((phenoxy)sulfonyl)-2,3-dimethyl-1H-
imidazol-3-ium tetrafluoroborate (1 mol equiv.) in acetonitrile (8 mL/mmol of 
tetrafluoroborate salt) was added the appropriate benzylamine (1 mol equiv.). The reaction 
mixture was stirred for 16 h. Upon completion, the solvent was removed in vacuo to yield 
a crude product. The crude product was purified by column chromatography. 
 
General procedure B: To 1,1'-sulfonylbis(2-methyl-1H-imidazole) (19) (2 mol equiv.) 
and caesium carbonate (1.1 mol equiv.) in acetonitrile was added the appropriate phenol 
(1 mol equiv.). The resulting mixture was heated at 120 °C for 15 min under microwave 
irradiation. After cooling, the mixture was concentrated in vacuo. The resulting residue 
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was dissolved in saturated aq. NH4Cl (15 mL) and the mixture extracted with EtOAc 
(3 × 15 mL). The combined organic extracts were washed with water (20 mL) and brine 
(20 mL), dried over MgSO4 and concentrated in vacuo. The crude product was purified by 
column chromatography. 
 
General procedure C: A solution of the appropriate protected bromophenyl sulfamate 
(1 mol equiv.) in acetonitrile (20 mL/mmol of 4-bromophenyl sulfamate) was sparged with 
nitrogen for 15 min. To this solution, potassium carbonate (3 mol equiv.), phenyl boronic 
acid (1.5 mol equiv.) and tetrakis(triphenylphosphine)palladium(0) (0.1 mol equiv.) were 
added. The resulting mixture was heated at 120 °C for 20 min under microwave irradiation. 
Upon completion, the solvent was removed in vacuo. The crude residue was dissolved in a 
mixture of EtOAc and water (20 mL, respectively), and extracted with EtOAc (3 × 25 mL). 
The pooled organic extracts were washed with water (30 mL) and brine (30 mL), dried 
over MgSO4 and concentrated in vacuo. The crude product was purified by column 
chromatography. 
 
General procedure D: The appropriate 2,4-dimethoxybenzyl protected sulfamate (1 mol 
equiv.) was solubilised in a 10% TFA/DCM mixture (10 mL/mmol of sulfamate). The 
resulting solution was stirred at RT for 2 h. Upon completion, the solvent was removed in 
vacuo. The crude residue was dissolved in EtOAc (20 mL), washed with 10% aq. NaHCO3 
(20 mL) and extracted with EtOAc (3 × 25 mL). The combined organic extracts were 
washed with water (30 mL) and brine (30 mL), dried over MgSO4 and concentrated in 
vacuo. The crude product was purified by column chromatography. 
 
General procedure E: The appropriate 4-methoxybenzyl protected sulfamate (1 mol 
equiv.) was solubilised in a 50% TFA/DCM mixture (10 mL/mmol of sulfamate). The 
resulting solution was heated at 42 °C for 24 h. Upon completion, the solvent was removed 
in vacuo. The crude residue was dissolved in EtOAc (20 mL), washed with 10% aq. 
NaHCO3 (20 mL) and extracted with EtOAc (3 × 25 mL). The pooled organic extracts 
were washed with water (30 mL) and brine (30 mL), dried over MgSO4 and concentrated 
in vacuo. The crude product was purified by column chromatography. 
 
General procedure F: To the appropriate amine (1 mol equiv.) in ethanol (0.5 mL/mmol 
of benzylamine) were added the appropriate benzaldehyde (1 mol equiv.) and MgSO4 
(300 mg). The resulting mixture was stirred at 78 °C for 4 h. Once cooled to RT, sodium 
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borohydride (1.1 mol equiv.) was carefully added to the reaction mixture. The resulting 
mixture was then stirred overnight at RT. Upon completion, the solvent was removed in 
vacuo. The crude residue was dissolved in EtOAc (60 mL), neutralised by washing with 
saturated aq. NH4Cl (30 mL), washed with water and brine (30 mL, respectively), dried 
over MgSO4 and concentrated in vacuo. The crude product was purified by column 
chromatography. 
 
General procedure G: To 1,1'-sulfonylbis(2-methyl-1H-imidazole) (19) (10 mol equiv.) 
and caesium carbonate (1.1 mol equiv.) in acetonitrile was added the appropriate phenol 
(1 mol equiv.). The resulting mixture was heated at 180 °C for 15 min under microwave 
irradiation. After cooling, the mixture was concentrated in vacuo. The resulting residue 
was dissolved in saturated aq. NH4Cl (15 mL) and the mixture extracted with EtOAc 
(3 × 15 mL). The pooled organic extracts were washed with water (20 mL) and brine 
(20 mL), dried over MgSO4 and concentrated in vacuo. The crude product was purified by 
column chromatography. 
 
General procedure H: To the appropriate phenyl 2-methyl-1H-imidazole-1-sulfonate 
(1 mol equiv.) in DCM (10 mL/mmol of sulfonate), cooled at 0 °C, was added 
trimethyloxonium tetrafluoroborate (1 mol equiv.). The resulting solution was stirred at 
0 °C for 1 h and allowed to warm to RT. After 8 h, the reaction was diluted with 
acetonitrile (5 mL/mmol of sulfonate) and the appropriate benzylamine (1 mol equiv.) was 
added. The resulting reaction mixture was heated at 42 °C for 24 h. Upon completion, the 
solvent was removed in vacuo to yield a crude product. The crude product was purified by 
column chromatography. 
 
General procedure I: To 3-bromophenyl bis(2,4-dimethoxybenzyl)sulfamate (132) in 
dimethoxyethane (7 mL/mmol of 3-bromophenyl sulfamate) was added a 2 M aq. solution 
of sodium bicarbonate (2 mol equiv.). The resulting solution was sparged with nitrogen for 
15 min. The appropriate phenylboronic acid (1.2 mol equiv.) and 
[1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with DCM 
(0.05 mol equiv.) were then added. The resulting mixture was heated at 80 °C for 20 min 
under microwave irradiation. Upon completion, the reaction mixture was diluted with 
water and EtOAc (10 mL, respectively), filtered through Celite and extracted with EtOAc 
(3 × 25 mL). The pooled organic extracts were washed with water and brine (30 mL, 
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respectively), dried over MgSO4 and concentrated in vacuo. The crude product was 
purified by column chromatography. 
 
General procedure J: To the appropriate aniline (1 mol equiv.) in DCM (10 mL/mmol of 
aniline) were added triethylamine (2 mol equiv.) and acetic anhydride (1.2 mol equiv.). 
The resulting solution was stirred at RT overnight. Upon completion, the reaction mixture 
was diluted with DCM (10 mL), washed with saturated aq. NaHCO3 (20 mL) and extracted 
with DCM (3 × 20 mL). The combined organic extracts were washed with water (30 mL) 
and brine (30 mL), dried over MgSO4 and concentrated in vacuo. The crude product was 
purified by column chromatography. 
 
General procedure K: To the appropriate aniline (1 mol equiv.) in THF (10 mL/mmol of 
aniline) was added 2,3-dimethyl-1-((2,2,2-trichloroethoxy)sulfonyl)-1H-imidazol-3-ium 
tetrafluoroborate (158) (3 mol equiv.). The resulting reaction mixture was heated at 67 °C 
for 30 h. Upon completion, the solvent was removed in vacuo to yield a crude product. The 
crude product was purified by column chromatography. 
 
General procedure L: To the appropriate aniline (1 mol equiv.) in THF (10 mL/mmol of 
aniline), cooled in an ice bath, were added 4-(dimethylamino)pyridine (2.2 mol equiv.) and 
triethylamine (4 mol equiv.). The resulting solution was stirred at 0 °C for 10 min, and then 
a solution 2,2,2-trichloroethyl chlorosulfate (156) (4 mol equiv.) in THF (5 mL/mmol of 
aniline) was added dropwise over 15 min. The resulting solution was stirred in an ice bath 
for 1 h and allowed to warm to RT. The reaction mixture was left stirring for an additional 
24 h. Upon completion, the mixture was diluted with EtOAc (20 mL), quenched by the 
cautious addition of saturated aq. NaHCO3 (20 mL) and extracted with EtOAc 
(3 × 20 mL). The pooled organic extracts were washed with water and brine (40 mL, 
respectively), dried over MgSO4 and concentrated in vacuo. The crude product was 
subjected to column chromatography. 
 
General procedure M: To the appropriate 2,2,2-trichloroethylsulfamoyloxyphenyl in 
MeOH (10 mL/mmol of phenyl) were added acetate buffer pH 4.65 (10 mL/mmol of 
protected aminophenyl) and zinc (10 mol equiv.). The resulting reaction mixture was 
heated at 60 °C for 2 h. Upon completion, the heterogeneous mixture was filtered through 
Celite and washed with MeOH (10 mL). The filtrate was concentrated in vacuo to give a 
crude oil, which was dissolved in water (10 mL) and washed with ether (10 mL). The 
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crude product was converted to the sodium salt by ion-exchange chromatography 
(DOWEX 50WX2 - Na
+
 form). The crude product was then subjected to column 
chromatography. 
 
General procedure N: To 3-hydroxyphenyl bis(2,4-dimethoxybenzyl)sulfamate (173) 
(1 mol equiv.) and potassium carbonate (1.2 mol equiv.) in N,N-dimethylformamide was 
added the appropriate fluorobenzene (2 mol equiv.). The resulting mixture was heated at 
180 °C for 30 min under microwave irradiation. After cooling, the mixture was 
concentrated in vacuo. The resulting residue was dissolved in saturated aq. NaHCO3 
(20 mL) and extracted with EtOAc (3 × 20 mL). The pooled organic extracts were washed 
with water (20 mL) and brine (20 mL), dried over MgSO4 and concentrated in vacuo. The 
crude product was purified by column chromatography. 
 
General procedure O: The appropriate nitrobenzene in MeOH (15 mL/mmol of 
nitrobenzene) and THF (5 mL/mmol of nitrobenzene) was subjected to palladium-
catalysed hydrogenation using an H-Cube

 reactor and a 10% Pd/C CatCart under a full 
pressure of hydrogen. The reaction was conducted at RT for 24 h. Upon completion, the 
solvents were removed in vacuo and the crude product was purified by column 
chromatography. 
 
10.2.3. Sulf-2 Inhibitors Synthetic Procedures 
Dibenzylsulfamoyl chloride, (17) 
 
To sulfuryl chloride (15) (0.41 mL, 0.68 g, 5.06 mmol) in Et2O (10 mL), cooled at -78 °C, 
was added dropwise over 35 min a solution of dibenzylamine (16) (0.97 mL, 1.0 g, 
5.06 mmol) and pyridine (0.41 mL, 0.40 g, 5.06 mmol) in Et2O (10 mL). The resulting 
mixture was stirred at -78 °C for 3 h and for an additional 2 h at RT. The mixture was then 
filtered through Celite and concentrated in vacuo. The crude solid was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  98:2) to yield the title compound as a 
white solid (150 mg, 10%); Rf = 0.58 (petrol:EtOAc, 97:3; KMnO4); m.p. 65.5-67.5 °C; 
No λmax (EtOH)/nm; IR (neat) νmax/cm
-1
 1494, 1451, 1383, 1173, 1039; 
1
H NMR 
(500 MHz, CDCl3) δ 4.40 (4H, s, 2 × ArCH2), 7.23 – 7.16 (4H, m, 4 × ArH), 7.30 – 7.24 
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(6H, m, 6 × ArH); 
13
C NMR (126 MHz, CDCl3)  53.1 (ArCH2), 128.7 (CH Ar), 128.9 
(CH Ar), 129.4 (CH Ar), 133.15 (Cq Ar). 
 
4-Bromophenyl dibenzylsulfamate, (18) 
 
Compound 18 was synthesised following two different procedures. 
1
st
 procedure: To 4-bromophenol (41) (29 mg, 0.17 mmol) and caesium carbonate (60 mg, 
0.18 mmol) in THF was added dibenzylsulfamoyl chloride (17) (54 mg, 0.18 mmol). The 
resulting mixture was heated at 67 °C for 16 h. After cooling, the mixture was concentrated 
in vacuo. The resulting residue was dissolved in saturated aq. NH4Cl (10 mL) and 
extracted with EtOAc (3 × 10 mL). The pooled organic extracts were washed with water 
(20 mL) and brine (20 mL), dried over MgSO4 and concentrated in vacuo. The crude 
product was purified by column chromatography (silica gel, petrol:EtOAc, 1:0  97:3) to 
yield the title compound as a white solid (29 mg, 40%). 
2
nd
 procedure: Compound 18 was synthesised according to general procedure A, using the 
following reagents: 1-((4-bromophenoxy)sulfonyl)-2,3-dimethyl-1H-imidazol-3-ium 
tetrafluoroborate (22) (400 mg, 0.96 mmol), dibenzylamine (16) (184 µL, 189 mg, 
0.96 mmol) and acetonitrile (7.7 mL). The crude product was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  97:3) to yield the title compound as a 
white solid (320 mg, 77%); Rf = 0.34 (petrol:EtOAc, 96:4); m.p. 86.5-88.5 °C; 
λmax (EtOH)/nm 258.0; IR (neat) νmax/cm
-1
 1481, 1452, 1369, 1154, 1061; 
1
H NMR 
(500 MHz, CDCl3) δ 4.39 (4H, s, 2 × ArCH2), 6.99 (2H, d, J = 8.8 Hz, H-2, 6), 7.31 – 7.27 
(4H, m, 4 × ArH), 7.39 – 7.32 (6H, m, 6 × ArH), 7.44 (2H, d, J = 8.8 Hz, H-3, 5); 
13
C NMR (126 MHz, CDCl3)  51.3 (ArCH2), 120.2 (C-4), 123.8 (C-2, 6), 128.5 (CH Ar), 
128.9 (CH Ar), 129.2 (CH Ar), 132.9 (C-3, 5), 134.7 (C-1'), 149.4 (C-1); HRMS (ESI) 
calcd for C20H19BrNO3S [M(
79
Br)+H]
+
 432.0264, found 432.0272. 
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1,1'-sulfonylbis(2-methyl-1H-imidazole), (19) 
 
To 2-methylimidazole (20.3 g, 247 mmol) in DCM (100 mL), cooled at 0 °C, was added 
dropwise over 30 min sulfuryl chloride (15) (5 mL, 8.32 g, 61.7 mmol) in DCM (40 mL). 
The resulting solution was stirred at 0 °C for 1 h and allowed to warm to RT. After 24 h, 
the reaction was quenched by the cautious addition of water (100 mL) and extracted with 
DCM (2 × 50 mL). The pooled organic extracts were washed with brine (100 mL), dried 
over MgSO4 and concentrated in vacuo. The crude yellow solid was purified by column 
chromatography (silica gel, DCM:MeOH, 1:0  93:7) to yield the title compound as an 
off-white solid (10.2 g, 73%); Rf = 0.32 (DCM:MeOH, 93:7; KMnO4); m.p. 86.0-88.0 °C 
(lit. 90.0-91.0 °C)
119
; No λmax (EtOH)/nm; IR (neat) νmax/cm
-1
 3116, 1553, 1419, 1147, 
1052; 
1
H NMR (500 MHz, CDCl3) δ 2.52 (6H, s, 2 × CH3), 6.95 (2H, d, J = 1.7 Hz, H-4 or 
H-5), 7.37 (2H, d, J = 1.7 Hz, H-4 or H-5); 
13
C NMR (126 MHz, CDCl3)  15.1 (CH3), 
120.2 (C-4 or C-5), 128.6 (C-4 or C-5), 146.1 (C-2); LRMS (ES
+
) m/z 227.2 [M+H]
+
; 
HRMS (ESI) calcd for C8H11N4O2S [M+H]
+
 227.0597, found 227.0597; 
1
H NMR and IR 
data were identical to literature data.
119
 
 
4-Bromophenyl 2-methyl-1H-imidazole-1-sulfonate, (21) 
 
Compound 21 was synthesised according to general procedure B, using the following 
reagents: 1,1'-sulfonylbis(2-methyl-1H-imidazole) (19) (262 mg, 1.16 mmol), caesium 
carbonate (207 mg, 0.64 mmol), 4-bromophenol (41) (100 mg, 0.58 mmol) and acetonitrile 
(5 mL). The crude yellow oil was purified by column chromatography (silica gel, 
petrol:EtOAc, 1:0  8:2) to yield the title compound as a clear oil (169 mg, 93%); 
Rf = 0.35 (petrol:EtOAc, 8:2; KMnO4); No λmax (EtOH)/nm; IR (neat) νmax/cm
-1
 1553, 
1480, 1422, 1207, 1147, 1043, 1012; 
1
H NMR (500 MHz, CDCl3) δ 2.50 (3H, s, CH3), 
6.81 (2H, d, J = 8.9 Hz, H-2, 6), 6.89 (1H, d, J = 1.7 Hz, H-4' or H-5'), 7.12 (1H, d, 
J = 1.7 Hz, H-4' or H-5'), 7.49 (2H, d, J = 8.9 Hz, H-3, 5); 
13
C NMR (126 MHz, CDCl3) 
 15.1 (CH3), 120.5 (C-4' or C-5'), 122.4 (C-4), 123.4 (C-2, 6), 128.2 (C-4' or C-5'), 133.6 
(C-3, 5), 146.8 (C-1 or C-2'), 148.0 (C-1 or C-2'); LRMS (ES
+
) m/z 317.1 [M(
79
Br)+H]
+
, 
319.1 [M(
81
Br)+H]
+
; HRMS (ESI) calcd for C10H10BrN2O3S [M(
79
Br)+H]
+
 316.9590, 
found 316.9598. 
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1-((4-Bromophenoxy)sulfonyl)-2,3-dimethyl-1H-imidazol-3-ium tetrafluoroborate, 
(22) 
 
To 4-bromophenyl 2-methyl-1H-imidazole-1-sulfonate (21) (4.18 g, 13.2 mmol) in DCM 
(60 mL), cooled at 0 °C, was added trimethyloxonium tetrafluoroborate (1.96 g, 
13.2 mmol). The resulting solution was stirred at 0 °C for 1 h and allowed to warm to RT. 
After 8 h, the reaction was cooled in an ice bath and petrol (120 mL) was added to the 
mixture. A white precipitate formed and was filtered off, washed with cold petrol (60 mL) 
and dry under high vacuum. The white fluffy solid (4.97 g, 90%) was used in the next step 
without further purification; m.p. 131.0-133.0 °C; No λmax (EtOH)/nm; IR (neat) νmax/cm
-1
 
3139, 1605, 1479, 1449, 1235, 1212 1149, 1023; 
1
H NMR (500 MHz, MeOD)  2.90 (3H, 
s, CH3), 3.96 (3H, s, NCH3), 7.26 (2H, d, J = 9.1 Hz, H-2, 6), 7.68 (2H, d, J = 9.1 Hz, H-3, 
5), 7.70 (1H, d, J = 2.4 Hz, H-4' or H-5'), 7.83 (1H, d, J = 2.4 Hz, H-4' or H-5'); 
13
C NMR 
(126 MHz, MeOD)  11.9 (CH3), 36.9 (NCH3), 122.4 (C-4' or C-5'), 124.2 (C-4), 124.6 (C-
2, 6), 125.1 (C-4' or C-5'), 135.2 (C-3, 5), 149.6 (C-1 or C-2'), 150.2 (C-1 or C-2'); LRMS 
(ES
+
) m/z 331.1 [M(
79
Br)-BF4]
+
, 333.2 [M(
81
Br)-BF4]
+
; HRMS (ESI) calcd for 
C11H12BrN2O3S [M(
79
Br)-BF4]
+
 330.9747, found 330.9749. 
 
[1,1'-Biphenyl]-4-yl dibenzylsulfamate, (23) 
 
Compound 23 was synthesised according to general procedure C, using the following 
reagents: 4-bromophenyl dibenzylsulfamate (18) (250 mg, 0.58 mmol), potassium 
carbonate (240 mg, 1.73 mmol), phenyl boronic acid (106 mg, 0.87 mmol), 
tetrakis(triphenylphosphine)palladium(0) (67 mg, 0.06 mmol) and acetonitrile (11.5 mL). 
The crude product was purified by column chromatography (silica gel, petrol:EtOAc, 
1:0  97:3) to yield the title compound as a white solid (320 mg, 72%); Rf = 0.42 
(petrol:EtOAc, 96:4); m.p. 131.5-133.5 °C; λmax (EtOH)/nm 251.0; IR (neat) νmax/cm
-1
 
1483, 1455, 1363, 1187, 1149, 1051; 
1
H NMR (500 MHz, CDCl3) δ 4.43 (4H, s, 
2 × ArCH2), 7.21 (2H, d, J = 8.7 Hz, H-3, 5), 7.39 – 7.27 (11H, m, 11 × ArH), 7.45 (2H, t, 
J = 7.6 Hz, H-4'), 7.58 – 7.52 (4H, m, 4 × ArH); 13C NMR (126 MHz, CDCl3)  51.3 
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(ArCH2), 122.3 (C-3, 5), 127.3 (CH Ar), 127.7 (CH Ar), 128.4 (CH Ar), 128.5 (CH Ar), 
128.8 (CH Ar), 129.0 (CH Ar), 129.2 (CH Ar), 134.9 (C-1''), 140.0 (C-1 or C-1'), 140.2 
(C-1 or C-1'), 149.8 (C-4); HRMS (ESI) calcd for C26H24NO3S [M+H]
+
 430.1471, found 
430.1478. 
 
[1,1'-Biphenyl]-4-yl sulfamate, (24) 
 
Compound 24 was synthesised following two different procedures. 
1
st
 procedure: Compound 24 was synthesised according to general procedure D, using the 
following reagents: [1,1'-biphenyl]-4-yl bis(2,4-dimethoxybenzyl)sulfamate (38) (180 mg, 
0.33 mmol), DCM (3.0 mL) and TFA (0.33 mL). The crude product was purified by 
column chromatography (silica gel, petrol:EtOAc, 1:0  7:3) to yield the title compound 
as an off-white solid (77 mg, 95%). 
2
nd
 procedure: Compound 24 was synthesised according to general procedure E, using the 
following reagents: [1,1'-biphenyl]-4-yl bis(4-methoxybenzyl)sulfamate (37) (100 mg, 
0.20 mmol), DCM (1.0 mL) and TFA (1.0 mL). The crude product was purified by column 
chromatography (silica gel, petrol:DCM, 1:0  0:1) to yield the title compound as an off-
white solid (45 mg, 90%); Rf = 0.34 (petrol:EtOAc, 7:3); m.p. 156.5-158.5 °C 
(lit. 146.0-149.0 °C)
257; λmax (EtOH)/nm 250.0; IR (neat) νmax/cm
-1
 3421, 3301, 1545, 1516, 
1484, 1363, 1176, 1155; 
1
H NMR (500 MHz, DMSO-d6) δ 7.42 – 7.34 (3H, m, H-3, 5 and 
H-4'), 7.48 (2H, dd, J = 7.7, 7.7 Hz, H-3', 5'), 7.66 (2H, dd, J = 7.7, 1.1 Hz, H-2', 6'), 7.75 
(2H, d, J = 8.7 Hz, H-2, 6), 8.04 (2H, s, ArOSO2NH2); 
13
C NMR (126 MHz, DMSO-d6) 
δ 122.6 (C-3, 5), 126.7 (C-2', 6'), 127.6 (C-4'), 128.0 (C-2, 6), 129.0 (C-3, 5), 138.5 (C-1 or 
C-1'), 139.2 (C-1 or C-1'), 149.6 (C-4); LRMS (ES
-
) m/z 248.2 [M-H]
-
; HRMS (ESI) calcd 
for C12H10NO3S [M-H]
-
 248.0387, found 248.0376; 
1
H NMR, 
13
C NMR and IR data were 
identical to literature data.
257, 258
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bis(4-Methoxybenzyl)amine, (31) 
 
Compound 31 was synthesised according to general procedure F, using the following 
reagents: 4-methoxybenzylamine (3.22 mL, 3.38 g, 24.6 mmol), 4-methoxybenzaldehyde 
(3.0 mL, 3.36 g, 24.6 mmol), sodium borohydride (1.03 g, 27.1 mmol) and ethanol 
(12.3 mL). The crude product was purified by column chromatography (silica gel, 
DCM:MeOH, 1:0  94:6) to yield the title compound as an orange solid (4.81 g, 75%); 
Rf = 0.28 (DCM:MeOH, 94:6; ninhydrin); m.p. 33.0-35.0 °C (lit. 35.0-37.0°C)
259
; 
λmax (EtOH)/nm 275.0; IR (neat) νmax/cm
-1
 1611, 1509, 1463, 1239, 1171, 1031; 
1
H NMR 
(500 MHz, CDCl3) δ 3.73 (4H, s, 2 × ArCH2), 3.81 (6H, s, 2 × ArOCH3), 6.87 (4H, d, 
J = 8.7 Hz, H-3, 5), 7.25 (4H, d, J = 8.7 Hz, H-2, 6); 
13
C NMR (126 MHz, CDCl3)  52.6 
(ArCH2), 55.4 (ArOCH3), 113.9 (C-3, 5), 129.4 (C-2, 6), 132.7 (C-1), 158.7 (C-4); 
LRMS (ES
+
) m/z 258.4 [M+H]
+
; IR, 
1
H NMR, 
13
C NMR and LRMS data were identical to 
literature data.
260, 261
 
 
bis(2,4-Dimethoxybenzyl)amine, (32) 
 
Compound 32 was synthesised according to general procedure F, using the following 
reagents: 2,4-dimethoxybenzylamine (2.72 mL, 3.03 g, 18.0 mmol), 2,4-dimethoxy 
benzaldehyde (3.0 g, 18.0 mmol), sodium borohydride (0.75 g, 19.9 mmol) and ethanol 
(9 mL). The crude product was purified by column chromatography (silica gel, 
DCM:MeOH, 1:0  9:1) to yield the title compound as a pale yellow oil (4.91 g, 85%); 
Rf = 0.34 (DCM:MeOH, 9:1; ninhydrin); λmax (EtOH)/nm 276.5; IR (neat) νmax/cm
-1
 1611, 
1586, 1505, 1454, 1287, 1205, 1154, 1031; 
1
H NMR (500 MHz, CDCl3) δ 3.73 (4H, s, 
2 × ArCH2), 3.79 (6H, s, 2 × ArOCH3), 3.79 (6H, s, 2 × ArOCH3), 6.46 – 6.41 (4H, m, H-3 
and 5), 7.17 (2H, d, J = 8.6 Hz, H-6); 
13
C NMR (126 MHz, CDCl3)  48.2 (ArCH2), 55.4 
(ArOCH3), 55.5 (ArOCH3), 98.5 (C-3), 103.7 (C-5), 120.6 (C-1), 130.6 (C-6), 158.7 (C-2 
or C-4), 160.2 (C-2 or C-4); LRMS (ES
+
) m/z 318.4 [M+H]
+
; HRMS (ESI) calcd for 
C18H24NO4 [M+H]
+
 318.1700, found 318.1703; 
1
H NMR and 
13
C NMR data were identical 
to literature data.
262, 263
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bis(3,4-Dimethoxybenzyl)amine, (33) 
 
Compound 33 was synthesised according to general procedure F, using the following 
reagents: 3,4-dimethoxybenzylamine (2.72 mL, 3.02 g, 18.0 mmol), 3,4-dimethoxy 
benzaldehyde (3.0 g, 18.0 mmol), sodium borohydride (0.75 g, 19.9 mmol) and ethanol 
(9 mL). The crude product was purified by column chromatography (silica gel, 
DCM:MeOH, 1:0  9:1) to yield the title compound as a pale yellow solid (3.91 g, 68%); 
Rf = 0.33 (DCM:MeOH, 9:1; ninhydrin); m.p. 68.5-70.5 °C (lit. 69.0-71.0 °C)
129
; 
λmax (EtOH)/nm 278.5; IR (neat) νmax/cm
-1
 1589, 1513, 1464, 1448, 1232, 1134, 1021; 
1
H NMR (500 MHz, CDCl3) δ 3.74 (4H, s, 2 × ArCH2), 3.87 (6H, s, 2 × ArOCH3), 3.89 
(6H, s, 2 × ArOCH3), 6.82 (2H, d, J = 8.2 Hz, H-5), 6.86 (2H, dd, J = 8.2, 1.8 Hz, H-6), 
6.90 (2H, d, J = 1.8 Hz, H-2); 
13
C NMR (126 MHz, CDCl3)  53.0 (ArCH2), 56.0 
(ArOCH3), 56.0 (ArOCH3), 111.0 (C-5), 111.4 (C-2), 120.3 (C-6), 133.0 (C-1), 148.1 (C-3 
or C-4), 149.0 (C-3 or C-4); LRMS (ES
+
) m/z 318.4 [M+H]
+
; HRMS (ESI) calcd for 
C18H24NO4 [M+H]
+
 318.1700, found 318.1699; 
1
H NMR and IR data were identical to 
literature data.
129
 
 
4-Bromophenyl bis(4-methoxybenzyl)sulfamate, (34) 
 
Compound 34 was synthesised according to general procedure A, using the following 
reagents: 1-((4-bromophenoxy)sulfonyl)-2,3-dimethyl-1H-imidazol-3-ium 
tetrafluoroborate (22) (600 mg, 1.43 mmol), bis(4-methoxybenzyl)amine (31) (370 mg, 
1.43 mmol) and acetonitrile (11.5 mL). The crude product was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  95:5) to yield the title compound as a 
pale orange solid (595 mg, 84%); Rf = 0.34 (petrol:EtOAc, 95:5); m.p. 61.5-63.5 °C; 
λmax (EtOH)/nm 274.5; IR (neat) νmax/cm
-1
 1614, 1513, 1479, 1456, 1361, 1249, 1169, 
1033; 
1
H NMR (500 MHz, CDCl3) δ 3.82 (6H, s, 2 × ArOCH3), 4.30 (4H, s, 2 × ArCH2), 
6.88 (4H, d, J = 8.7 Hz, H-3', 5'), 7.00 (2H, d, J = 8.9 Hz, H-2, 6), 7.20 (4H, d, J = 8.7 Hz, 
H-2', 6'), 7.45 (2H, d, J = 8.9 Hz, H-3, 5); 
13
C NMR (126 MHz, CDCl3)  50.4 (ArCH2), 
55.5 (ArOCH3), 114.2 (C-3', 5'), 120.1 (C-4 or C-1'), 123.9 (C-2, 6), 126.8 (C-4 or C-1'), 
176 
130.5 (C-2', 6'), 132.9 (C-3, 5), 149.5 (C-1), 159.7 (C-4'); HRMS (ESI) calcd for 
C22H26BrN2O5S [M(
79
Br)+NH4]
+
 509.0740, found 509.0740. 
 
4-Bromophenyl bis(2,4-dimethoxybenzyl)sulfamate, (35) 
 
Compound 35 was synthesised according to general procedure A, using the following 
reagents: 1-((4-bromophenoxy)sulfonyl)-2,3-dimethyl-1H-imidazol-3-ium 
tetrafluoroborate (22) (600 mg, 1.43 mmol), bis(2,4-dimethoxybenzyl)amine (32) (456 mg, 
1.43 mmol) and acetonitrile (11.5 mL). The crude product was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  85:15) to yield the title compound as a 
clear oil (680 mg, 86%); Rf = 0.30 (petrol:EtOAc, 85:15); λmax (EtOH)/nm 277.0; IR (neat) 
νmax/cm
-1
 1613, 1588, 1507, 1481, 1370, 1208, 1156, 1035; 
1
H NMR (500 MHz, CDCl3) 
δ 3.73 (6H, s, 2 × ArOCH3), 3.80 (6H, s, 2 × ArOCH3), 4.44 (4H, s, 2 × ArCH2), 6.39 (2H, 
d, J = 2.4 Hz, H-3'), 6.43 (2H, dd, J = 8.4, 2.4 Hz, H-5'), 6.92 (2H, d, J = 8.9 Hz, H-2, 6), 
7.24 (2H, d, J = 8.4 Hz, H-6'), 7.39 (2H, d, J = 8.9 Hz, H-3, 5); 
13
C NMR (126 MHz, 
CDCl3)  47.1 (ArCH2), 55.2 (ArOCH3), 55.5 (ArOCH3), 98.3 (C-3'), 104.1 (C-5'), 116.6 
(C-4 or C-1'), 119.7 (C-4 or C-1'), 123.8 (C-2, 6), 131.1 (C-6'), 132.6 (C-3, 5), 149.5 (C-1), 
158.6 (C-2'or C-4'), 160.8 (C-2'or C-4'); HRMS (ESI) calcd for C24H27BrNO7S 
[M(
79
Br)+H]
+
 552.0686, found 552.0676. 
 
4-Bromophenyl bis(3,4-dimethoxybenzyl)sulfamate, (36) 
 
Compound 36 was synthesised according to general procedure A, using the following 
reagents: 1-((4-bromophenoxy)sulfonyl)-2,3-dimethyl-1H-imidazol-3-ium 
tetrafluoroborate (22) (600 mg, 1.43 mmol), bis(3,4-dimethoxybenzyl)amine (33) (456 mg, 
1.43 mmol) and acetonitrile (11.5 mL). The crude product was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  65:35) to yield the title compound as an 
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off-white solid (675 mg, 85%); Rf = 0.32 (petrol:EtOAc, 65:35); m.p. 99.5-101.5 °C; 
λmax (EtOH)/nm 278.0; IR (neat) νmax/cm
-1
 1595, 1518, 1464, 1358, 1259, 1238, 1141, 
1024; 
1
H NMR (500 MHz, CDCl3) δ 3.82 (6H, s, 2 × ArOCH3), 3.89 (6H, s, 2 × ArOCH3), 
4.33 (4H, s, 2 × ArCH2), 6.77 (2H, dd, J = 8.1, 1.9 Hz, H-6'), 6.82 (2H, d, J = 8.1 Hz, 
H-5'), 6.84 (2H, d, J = 1.9 Hz, H-2'), 7.05 (2H, d, J = 8.9 Hz, H-2, 6), 7.47 (2H, d, 
J = 8.9 Hz, H-3, 5); 
13
C NMR (126 MHz, CDCl3)  51.1 (ArCH2), 56.0 (ArOCH3), 56.1 
(ArOCH3), 111.0 (C-5'), 112.2 (C-2'), 120.2 (C-4 or C-1'), 121.7 (C-6'), 123.7 (C-2, 6), 
127.2 (C-4 or C-1'), 133.0 (C-3, 5), 149.3 (Cq Ar), 149.4 (Cq Ar), 149.5 (Cq Ar); 
HRMS (ESI) calcd for C24H30BrN2O7S [M(
79
Br)+NH4]
+
 569.0952, found 569.0947. 
 
[1,1'-Biphenyl]-4-yl bis(4-methoxybenzyl)sulfamate, (37) 
 
Compound 37 was synthesised according to general procedure C, using the following 
reagents: 4-bromophenyl bis(4-methoxybenzyl)sulfamate (34) (400 mg, 0.81 mmol), 
potassium carbonate (337 mg, 2.44 mmol), phenyl boronic acid (149 mg, 1.22 mmol), 
tetrakis(triphenylphosphine)palladium(0) (94 mg, 0.08 mmol) and acetonitrile (16 mL). 
The crude product was purified by column chromatography (silica gel, petrol:EtOAc, 
1:0  95:5) to yield the title compound as a pale yellow oil (330 mg, 83%); Rf = 0.38 
(petrol:EtOAc, 95:5); λmax (EtOH)/nm 251.0; IR (neat) νmax/cm
-1
 1610, 1511, 1484, 1379, 
1248, 1178, 1153, 1052, 1031; 
1
H NMR (500 MHz, CDCl3) δ 3.81 (6H, s, 2 × ArOCH3), 
4.34 (4H, s, 2 × ArCH2), 6.87 (4H, d, J = 8.7 Hz, H-3'', 5''), 7.24 – 7.19 (6H, m, H-3, 5 and 
H-2'', 6''), 7.39 – 7.34 (1H, m, H-4'), 7.45 (2H, dd, J = 7.6, 7.6 Hz, H-3', 5'), 7.58 – 7.52 
(4H, m, H-2, 6 and H-2', 6'); 
13
C NMR (126 MHz, CDCl3)  50.4 (ArCH2), 55.4 
(ArOCH3), 114.2 (C-3'', 5''), 122.3 (C-3, 5), 126.9 (C-1''), 127.2 (C-2, 6 or C-2', 6'), 127.7 
(C-4'), 128.5 (C-2, 6 or C-2', 6'), 129.0 (C-3', 5'), 130.6 (C-2'', 6''), 140.0 (C-1 or C-1'), 
140.2 (C-1 or C-1'), 149.9 (C-4), 159.7 (C-4''); HRMS (ESI) calcd for C28H31N2O5S 
[M+NH4]
+
 507.1948, found 507.1945. 
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[1,1'-Biphenyl]-4-yl bis(2,4-dimethoxybenzyl)sulfamate, (38) 
 
Compound 38 was synthesised according to general procedure C, using the following 
reagents: 4-bromophenyl bis(2,4-dimethoxybenzyl)sulfamate (35) (450 mg, 0.81 mmol), 
potassium carbonate (337 mg, 2.44 mmol), phenyl boronic acid (149 mg, 1.22 mmol), 
tetrakis(triphenylphosphine)palladium(0) (94 mg, 0.08 mmol) and acetonitrile (16 mL). 
The crude product was purified by column chromatography (silica gel, petrol:EtOAc, 
1:0  85:15) to yield the title compound as a yellow oil (375 mg, 83%); Rf = 0.32 
(petrol:EtOAc, 85:15); λmax (EtOH)/nm 250.5; IR (neat) νmax/cm
-1
 1612, 1590, 1507, 1469, 
1369, 1206, 1154, 1042, 1034; 
1
H NMR (500 MHz, CDCl3) δ 3.73 (6H, s, 2 × ArOCH3), 
3.78 (6H, s, 2 × OCH3), 4.48 (4H, s, 2 × ArCH2), 6.39 (2H, d, J = 2.4 Hz, H-3''), 6.43 (2H, 
dd, J = 8.4, 2.4 Hz, H-5''), 7.15 (2H, d, J = 8.7 Hz, H-3, 5), 7.27 (2H, d, J = 8.4 Hz, H-6''), 
7.38 – 7.33 (1H, m, H-4'), 7.44 (2H, dd, J = 7.6, 7.6 Hz, H-3', 5'), 7.51 (2H, d, J = 8.7 Hz, 
H-2, 6), 7.55 (2H, dd, J = 7.6, 1.2 Hz, H-2', 6'); 
13
C NMR (126 MHz, CDCl3)  47.0 
(ArCH2), 55.2 (ArOCH3), 55.5 (ArOCH3), 98.3 (C-3''), 104.1 (C-5''), 116.8 (C-1''), 122.3 
(C-3, 5), 127.2 (C-2', 6'), 127.6 (C-4'), 128.3 (C-2, 6), 129.0 (C-3', 5'), 131.1 (C-6''), 139.6 
(C-1 or C-1'), 140.3 (C-1 or C-1'), 150.0 (C-4), 158.6 (C-2'' or C-4''), 160.7 (C-2'' or C-4''); 
HRMS (ESI) calcd for C30H32NO7S [M+H]
+
 550.1894, found 550.1887. 
 
[1,1'-Biphenyl]-4-yl bis(3,4-dimethoxybenzyl)sulfamate, (39) 
 
Compound 39 was synthesised according to general procedure C, using the following 
reagents: 4-bromophenyl bis(3,4-dimethoxybenzyl)sulfamate (36) (450 mg, 0.81 mmol), 
potassium carbonate (337 mg, 2.44 mmol), phenyl boronic acid (149 mg, 1.22 mmol), 
tetrakis(triphenylphosphine)palladium(0) (94 mg, 0.08 mmol) and acetonitrile (16 mL). 
The crude product was purified by column chromatography (silica gel, petrol:EtOAc, 
1:0  65:35) to yield the title compound as a yellow solid (385 mg, 86%); Rf = 0.35 
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(petrol:EtOAc, 65:35); m.p. 120.5-122.5 °C; λmax (EtOH)/nm 237.5; IR (neat) νmax/cm
-1
 
1593, 1518, 1450, 1370, 1261, 1237, 1140, 1019; 
1
H NMR (500 MHz, CDCl3) δ 3.82 (6H, 
s, 2 × ArOCH3), 3.87 (6H, s, 2 × ArOCH3), 4.36 (4H, s, 2 × ArCH2), 6.78 (2H, dd, J = 8.2, 
1.8 Hz, H-6''), 6.81 (2H, d, J = 8.2 Hz, H-5''), 6.87 (2H, d, J = 1.8 Hz, H-2''), 7.25 (2H, d, 
J = 8.6 Hz, H-3, 5), 7.39 – 7.32 (1H, m, H-4'), 7.44 (2H, dd, J = 7.6 , 7.6 Hz, H-3', 5'), 
7.59 – 7.51 (4H, m, H-2, 6 and H-2', 6'); 13C NMR (126 MHz, CDCl3)  51.1 (ArCH2), 
56.0 (ArOCH3), 56.1 (ArOCH3), 111.0 (C-5''), 112.2 (C-2''), 121.7 (C-6''), 122.1 (C-3, 5), 
127.2 (C-2, 6 or C-2', 6'), 127.4 (C-1''), 127.8 (C-4'), 128.6 (C-2, 6 or C-2', 6'), 129.0 (C-3', 
5'), 140.0 (C-1 and C-1'), 149.2 (Cq Ar), 149.4 (Cq Ar), 149.9 (Cq Ar); HRMS (ESI) calcd 
for C30H35N2O7S [M+NH4]
+
 567.2159, found 567.2155. 
 
4-Methoxyphenyl 2-methyl-1H-imidazole-1-sulfonate, (48) 
 
Compound 48 was synthesised according to general procedure B, using the following 
reagents: 1,1'-sulfonylbis(2-methyl-1H-imidazole) (19) (364 mg, 1.61 mmol), caesium 
carbonate (289 mg, 0.89 mmol), 4-methoxyphenol (100 mg, 0.81 mmol) and acetonitrile 
(5 mL). The crude yellow oil was purified by column chromatography (silica gel, 
petrol:EtOAc, 1:0  8:2) to yield the title compound as a clear oil (210 mg, 97%); 
Rf = 0.26 (petrol:EtOAc, 8:2; KMnO4); λmax (EtOH)/nm 273.5; IR (neat) νmax/cm
-1
 1595, 
1552, 1500, 1416, 1206, 1141, 1029; 
1
H NMR (500 MHz, CDCl3) δ 2.44 (3H, s, CH3), 
3.78 (3H, s, ArOCH3), 6.82 (4H, s, H-2, 3, 4, 5), 6.88 (1H, d, J = 1.7 Hz, H-4’ or H-5’), 
7.13 (1H, d, J = 1.7 Hz, H-4’ or H-5’); 13C NMR (126 MHz, CDCl3)  15.0 (CH3), 55.8 
(ArOCH3), 115.1 (C-2, 6 or C-3, 5), 120.5 (C-4’ or C-5’), 122.7 (C-2, 6 or C-3, 5), 128.0 
(C-4’ or C-5’), 142.4 (C-1 or C-2’), 147.0 (C-1 or C-2’), 159.3 (C-4); LRMS (ES+) m/z 
269.2 [M+H]
+
; HRMS (ESI) calcd for C11H13N2O4S [M+H]
+
 269.0591, found 269.0591. 
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4-Chlorophenyl 2-methyl-1H-imidazole-1-sulfonate, (49) 
 
Compound 49 was synthesised according to general procedure B, using the following 
reagents: 1,1'-sulfonylbis(2-methyl-1H-imidazole) (19) (218 mg, 0.96 mmol), caesium 
carbonate (173 mg, 0.53 mmol), 4-chlorophenol (62 mg, 0.48 mmol) and acetonitrile 
(5 mL). The crude yellow oil was purified by column chromatography (silica gel, 
petrol:EtOAc, 1:0  8:2) to yield the title compound as a clear oil (123 mg, 93%); 
Rf = 0.35 (petrol:EtOAc, 8:2; KMnO4); λmax (EtOH)/nm 264.5; IR (neat) νmax/cm
-1
 1553, 
1483, 1422, 1207, 1145, 1044, 1014; 
1
H NMR (500 MHz, CDCl3) δ 2.49 (3H, s, CH3), 
6.87 (2H, d, J = 9.0 Hz, H-2, 6), 6.89 (1H, d, J = 1.7 Hz, H-4’ or H-5’), 7.12 (1H, d, 
J = 1.7 Hz, H-4’ or H-5’), 7.33 (2H, d, J = 9.0 Hz, H-3, 5); 13C NMR (126 MHz, CDCl3) 
 15.1 (CH3), 120.5 (C-4’ or C-5’), 123.1 (C-2, 6), 128.2 (C-4’ or C-5’), 130.5 (C-3, 5), 
134.6 (C-4), 146.8 (C-1 or C-2’), 147.4 (C-1 or C-2’); LRMS (ES+) m/z 272.9 
[M(
35
Cl)+H]
+
, 275.1 [M(
37
Cl)+H]
+
; HRMS (ESI) calcd for C10H10ClN2O3S [M(
35
Cl)+H]
+
 
273.0095, found 273.0101. 
 
3-Chlorophenyl 2-methyl-1H-imidazole-1-sulfonate, (50) 
 
Compound 50 was synthesised according to general procedure B, using the following 
reagents: 1,1'-sulfonylbis(2-methyl-1H-imidazole) (19) (429 mg, 1.89 mmol), caesium 
carbonate (340 mg, 1.04 mmol), 3-chlorophenol (100 µL, 122 mg, 0.48 mmol) and 
acetonitrile (5 mL). The crude yellow oil was purified by column chromatography (silica 
gel, petrol:EtOAc, 1:0  8:2) to yield the title compound as a clear oil (214 mg, 83%); 
Rf = 0.33 (petrol:EtOAc, 8:2; KMnO4); λmax (EtOH)/nm 265.0; IR (neat) νmax/cm
-1
 1583, 
1554, 1423, 1207, 1152, 1044; 
1
H NMR (500 MHz, CDCl3) δ 2.51 (3H, s, CH3), 6.79 (1H, 
ddd, J = 8.1, 2.3 and 1.0 Hz, H-6), 6.90 (1H, d, J = 1.7 Hz, H-4’ or H-5’), 7.03 (1H, dd, 
J = 2.3, 2.1 Hz, H-2), 7.14 (1H, d, J = 1.7 Hz, H-4’ or H-5’), 7.29 (1H, dd, J = 8.1, 8.1 Hz, 
H-5), 7.38 – 7.32 (1H, m, H-4); 13C NMR (126 MHz, CDCl3)  15.1 (CH3), 119.8 (C-6), 
120.5 (C-4’ or C-5’), 122.5 (C-2), 128.2 (C-4’ or C-5’), 129.1 (C-4), 131.1 (C-5), 135.8 
(C-3), 146.8 (C-1 or C-2’), 149.2 (C-1 or C-2’); LRMS (ES+) m/z 273.4 [M(35Cl)+H]+, 
181 
275.1 [M(
37
Cl)+H]
+
; HRMS (ESI) calcd for C10H10ClN2O3S [M(
35
Cl)+H]
+
 273.0095, 
found 273.0101. 
 
2,6-Dimethylphenyl 2-methyl-1H-imidazole-1-sulfonate, (51) 
 
Compound 51 was synthesised according to general procedure B, using the following 
reagents: 1,1'-sulfonylbis(2-methyl-1H-imidazole) (19) (370 mg, 1.64 mmol), caesium 
carbonate (293 mg, 0.90 mmol), 2,6-dimethylphenol (100 mg, 0.82 mmol) and acetonitrile 
(5 mL). The crude yellow oil was purified by column chromatography (silica gel, 
petrol:EtOAc, 1:0  8:2) to yield the title compound as a white solid (203 mg, 93%); 
Rf = 0.30 (petrol:EtOAc, 8:2; KMnO4); m.p. 55.0-57.0 °C; λmax (EtOH)/nm 262.5; 
IR (neat) νmax/cm
-1
 1551, 1473, 1419, 1205, 1046; 
1
H NMR (500 MHz, CDCl3) δ 2.07 (6H, 
s, 2 × ArCH3), 2.55 (3H, s, CH3 imidazole), 6.93 (1H, d, J = 1.6 Hz, H-4’ or H-5’), 7.06 (2H, 
d, J = 7.4 Hz, H-3, 5), 7.16 – 7.10 (1H, m, H-4), 7.21 (1H, d, J = 1.6 Hz, H-4’ or H-5’); 
13
C NMR (126 MHz, CDCl3)  15.2 (ArCH3), 16.3 (CH3 imidazole), 120.1 (C-4’ or C-5’), 
127.9 (C-4), 128.1 (C-4’ or C-5’), 129.8 (C-3, 5), 131.7 (C-2, 6), 146.6 (C-1 or C-2’), 
147.9 (C-1 or C-2’); LRMS (ES+) m/z 267.2 [M+H]+; HRMS (ESI) calcd for C12H15N2O3S 
[M+H]
+
 267.0798, found 267.0803. 
 
2-Chlorophenyl 2-methyl-1H-imidazole-1-sulfonate, (52) 
 
Compound 52 was synthesised according to general procedure B, using the following 
reagents: 1,1'-sulfonylbis(2-methyl-1H-imidazole) (19) (218 mg, 0.96 mmol), caesium 
carbonate (173 mg, 0.53 mmol), 2-chlorophenol (50 µL, 62 mg, 0.48 mmol) and 
acetonitrile (5 mL). The crude yellow oil was purified by column chromatography (silica 
gel, petrol:EtOAc, 1:0  8:2) to yield the title compound as a clear oil (119 mg, 90%); 
Rf = 0.33 (petrol:EtOAc, 8:2; KMnO4); λmax (EtOH)/nm 264.5; IR (neat) νmax/cm
-1
 1555, 
1474, 1424, 1193, 1170, 1043; 
1
H NMR (500 MHz, CDCl3) δ 2.56 (3H, s, CH3), 6.89 (1H, 
d, J = 1.9 Hz, H-4’ or H-5’), 7.09 – 7.07 (1H, m, ArH), 7.10 (1H, d, J = 1.9 Hz, H-4’ or 
H-5’), 7.36 – 7.26 (2H, m, 2 × ArH), 7.52 – 7.40 (1H, m, ArH); 13C NMR (126 MHz, 
CDCl3)  15.3 (CH3), 120.4 (C-4’ or C-5’), 123.8 (CH Ar), 127.5 (C-2), 128.2 (C-4’ or 
182 
C-5’), 128.4 (CH Ar), 129.3 (CH Ar), 131.4 (CH Ar), 145.3 (C-1 or C-2’), 147.0 (C-1 or 
C-2’); LRMS (ES+) m/z 272.9 [M(35Cl)+H]+, 275.2 [M(37Cl)+H]+; HRMS (ESI) calcd for 
C10H10ClN2O3S [M(
35
Cl)+H]
+
 273.0095, found 273.0101. 
 
2,6-Dichlorophenyl 2-methyl-1H-imidazole-1-sulfonate, (53) 
 
Compound 53 was synthesised according to general procedure G, using the following 
reagents: 1,1'-sulfonylbis(2-methyl-1H-imidazole) (19) (3.47 g, 15.3 mmol), caesium 
carbonate (550 mg, 1.69 mmol), 2,6-dichlorophenol (250 mg, 1.53 mmol) and acetonitrile 
(20 mL). The crude yellow oil was purified by column chromatography (silica gel, 
petrol:EtOAc, 1:0  85:15) to yield the title compound as a clear oil (396 mg, 84%); 
Rf = 0.34 (petrol:EtOAc, 8:2; KMnO4); λmax (EtOH)/nm 271.0, 278.0; IR (neat) νmax/cm
-1
 
1573, 1556, 1429, 1201, 1177, 1044; 
1
H NMR (500 MHz, CDCl3) δ 2.68 (3H, s, CH3), 
6.92 (1H, d, J = 1.8 Hz, H-4’ or H-5’), 7.19 (1H, d, J = 1.9 Hz, H-4’ or H-5’), 7.26 – 7.20 
(1H, m, H-4), 7.39 (2H, d, J = 8.1 Hz, H-3, 5); 
13
C NMR (126 MHz, CDCl3)  15.3 (CH3), 
120.2 (C-4’ or C-5’), 128.1 (C-4’ or C-5’), 129.2 (C-4), 129.7 (C-3, 5), 129.8 (C-2, 6), 
143.1 (C-1 or C-2’), 146.8 (C-1 or C-2’); LRMS (ES+) m/z 307.1 [M(35Cl35Cl)+H]+, 309.1 
[M(
35
Cl
37
Cl)+H]
+
; HRMS (ESI) calcd for C10H9Cl2N2O3S [M(
35
Cl
35
Cl)+H]
+
 306.9705, 
found 306.9709. 
 
4-Nitrophenyl 2-methyl-1H-imidazole-1-sulfonate, (54) 
 
Compound 54 was synthesised according to general procedure G, using the following 
reagents: 1,1'-sulfonylbis(2-methyl-1H-imidazole) (19) (4.07 g, 18.0 mmol), caesium 
carbonate (644 mg, 1.98 mmol), 4-nitrophenol (250 mg, 1.80 mmol) and acetonitrile 
(20 mL). The crude brawn oil was purified by column chromatography (silica gel, 
petrol:EtOAc, 1:0  8:2) to yield the title compound as an off-white solid (418 mg, 82%); 
Rf = 0.29 (petrol:EtOAc, 3:1; KMnO4); m.p. 113.0-115.0 °C; λmax (EtOH)/nm 253.5; 
IR (neat) νmax/cm
-1
 1618, 1588, 1553, 1525, 1424, 1346, 1208, 1145, 1045; 
1
H NMR 
(500 MHz, CDCl3) δ 2.57 (3H, s, CH3), 6.92 (1H, d, J = 1.7 Hz, H-4’ or H-5’), 7.13 (1H, d, 
J = 1.7 Hz, H-4’ or H-5’), 7.16 (2H, d, J = 9.2 Hz, H-2, 6), 8.27 (2H, d, J = 9.2 Hz, H-3, 
183 
5); 
13
C NMR (126 MHz, CDCl3)  15.2 (CH3), 120.5 (C-4’ or C-5’), 122.9 (C-2, 6), 126.1 
(C-3, 5), 128.5 (C-4’ or C-5’), 146.8 (Cq Ar), 147.3 (Cq Ar), 152.8 (Cq Ar); LRMS (ES
+
) 
m/z 284.4 [M+H]
+
; HRMS (ESI) calcd for C10H10N3O5S [M+H]
+
 284.0336, found 
284.0341. 
 
3-Nitrophenyl 2-methyl-1H-imidazole-1-sulfonate, (57) 
 
Compound 57 was synthesised according to general procedure B, using the following 
reagents: 1,1'-sulfonylbis(2-methyl-1H-imidazole) (19) (651 mg, 2.87 mmol), caesium 
carbonate (515 mg, 1.58 mmol), 3-nitrophenol (200 mg, 1.44 mmol) and acetonitrile 
(20 mL). The crude yellow oil was purified by column chromatography (silica gel, 
petrol:EtOAc, 1:0  3:1) to yield the title compound as a yellow solid (294 mg, 72%); 
Rf = 0.27 (petrol:EtOAc, 3:1; KMnO4); m.p. 70.5-72.5 °C; λmax (EtOH)/nm 249.0; 
IR (neat) νmax/cm
-1
 1557, 1522, 1418, 1351, 1193, 1160, 1045; 
1
H NMR (500 MHz, 
CDCl3) δ 2.57 (3H, s, CH3), 6.93 (1H, d, J = 1.8 Hz, H-4’ or H-5’), 7.14 (1H, d, 
J = 1.8 Hz, H-4’ or H-5’), 7.26 (1H, ddd, J = 8.3, 2.3 and 0.9 Hz, H-6), 7.60 (1H, dd, 
J = 8.3, 8.3 Hz, H-5), 7.92 (1H, dd, J = 2.3, 2.3 Hz, H-2), 8.26 (1H, ddd, J = 8.3, 2.3 and 
0.9 Hz, H-4); 
13
C NMR (126 MHz, CDCl3)  15.2 (CH3), 117.8 (C-2), 120.4 (C-4’ or 
C-5’), 123.5 (C-4), 127.7 (C-6), 128.6 (C-4’ or C-5’), 131.3 (C-5), 146.8 (Cq Ar), 149.0 
(Cq Ar), 149.1 (Cq Ar); LRMS (ES
+
) m/z 284.4 [M+H]
+
; HRMS (ESI) calcd for 
C10H10N3O5S [M+H]
+
 284.0336, found 284.0337. 
 
2-Nitrophenyl 2-methyl-1H-imidazole-1-sulfonate, (58) 
 
Compound 58 was synthesised according to general procedure G, using the following 
reagents: 1,1'-sulfonylbis(2-methyl-1H-imidazole) (19) (4.88 g, 21.6 mmol), caesium 
carbonate (773 mg, 2.37 mmol), 2-nitrophenol (300 mg, 2.16 mmol) and acetonitrile 
(20 mL). The crude brawn oil was purified by column chromatography (silica gel, 
DCM:MeOH, 1:0  99:1) to yield the title compound as a yellow solid (428 mg, 70%); 
Rf = 0.20 (DCM:MeOH, 99:1; KMnO4); m.p. 55.5-57.5 °C; λmax (EtOH)/nm 245.0; 
IR (neat) νmax/cm
-1
 1600, 1532, 1425, 1339, 1208, 1151, 1045; 
1
H NMR (500 MHz, 
184 
CDCl3) δ 2.56 (3H, s, CH3), 6.93 (1H, d, J = 1.8 Hz, H-4’ or H-5’), 7.11 (1H, dd, J = 8.2, 
1.3 Hz, H-6), 7.12 (1H, d, J = 1.8 Hz, H-4’ or H-5’), 7.59 – 7.51 (1H, m, H-4), 7.66 (1H, 
ddd, J = 8.2, 7.5 and 1.7 Hz, H-5), 8.08 (1H, dd, J = 8.2, 1.7 Hz, H-3); 
13
C NMR 
(126 MHz, CDCl3)  15.2 (CH3), 120.3 (C-4’ or C-5’), 124.4 (C-6), 126.8 (C-3), 128.6 
(C-4’ or C-5’), 129.2 (C-4), 135.0 (C-5), 141.2 (Cq Ar), 142.4 (Cq Ar), 147.1 (Cq Ar); 
LRMS (ES
+
) m/z 284.1 [M+H]
+
; HRMS (ESI) calcd for C10H10N3O5S [M+H]
+
 284.0336, 
found 284.0340. 
 
4-Cyanophenyl 2-methyl-1H-imidazole-1-sulfonate, (59) 
 
Compound 59 was synthesised following two different procedures. 
1
st
 procedure: Compound 59 was synthesised according to general procedure B, using the 
following reagents: 1,1'-sulfonylbis(2-methyl-1H-imidazole) (19) (760 mg, 3.36 mmol), 
caesium carbonate (602 mg, 1.85 mmol), 4-cyanophenol (200 mg, 1.68 mmol) and 
acetonitrile (20 mL). The crude yellow solid was purified by column chromatography 
(silica gel, petrol:EtOAc, 1:0  7:3) to yield the title compound as a white solid (261 mg, 
59%). 
2
nd
 procedure: Compound 59 was synthesised according to general procedure G, using the 
following reagents: 1,1'-sulfonylbis(2-methyl-1H-imidazole) (19) (950 mg, 4.20 mmol), 
caesium carbonate (150 mg, 0.46 mmol), 4-cyanophenol (50 mg, 042 mmol) and 
acetonitrile (5 mL). The crude yellow solid was purified by column chromatography (silica 
gel, petrol:EtOAc, 1:0  7:3) to yield the title compound as a white solid (88 mg, 80%); 
Rf = 0.28 (petrol:EtOAc, 7:3; KMnO4); m.p. 102.5-104.5 °C; λmax (EtOH)/nm 268.5; 
IR (neat) νmax/cm
-1
 2239, 1601, 1555, 1498, 1417, 1206, 1144, 1048; 
1
H NMR (500 MHz, 
CDCl3) δ 2.54 (3H, s, CH3), 6.91 (1H, d, J = 1.8 Hz, H-4’ or H-5’), 7.09 (2H, d, 
J = 8.7 Hz, H-2, 6), 7.12 (1H, d, J = 1.8 Hz, H-4’ or H-5’), 7.70 (2H, d, J = 8.7 Hz, 
H-3, 5); 
13
C NMR (126 MHz, CDCl3)  15.1 (CH3), 113.1 (ArCN), 117.2 (C-4), 120.4 
(C-4’ or C-5’), 123.0 (C-2, 6), 128.5 (C-4’ or C-5’), 134.6 (C-3, 5), 146.8 (C-1 or C-2’), 
151.6 (C-1 or C-2’); LRMS (ES+) m/z 264.4 [M+H]+; HRMS (ESI) calcd for C11H10N3O3S 
[M+H]
+
 264.0437, found 264.0442. 
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2-Cyanophenyl 2-methyl-1H-imidazole-1-sulfonate, (60) 
 
Compound 60 was synthesised according to general procedure G, using the following 
reagents: 1,1'-sulfonylbis(2-methyl-1H-imidazole) (19) (4.75 g, 21.0 mmol), caesium 
carbonate (752 mg, 2.31 mmol), 2-cyanophenol (250 mg, 2.10 mmol) and acetonitrile 
(20 mL). The crude brawn oil was purified by column chromatography (silica gel, 
DCM:MeOH, 1:0  99:1) to yield the title compound as a yellow solid (398 mg, 72%); 
Rf = 0.18 (DCM:MeOH, 99:1; KMnO4); m.p. 96.5-98.5 °C; λmax (EtOH)/nm 271.5; 
IR (neat) νmax/cm
-1
 1608, 1555, 1510, 1487, 1424, 1207, 1151, 1045; 
1
H NMR (500 MHz, 
CDCl3) δ 2.60 (3H, s, CH3), 6.93 (1H, d, J = 1.8 Hz, H-4’ or H-5’), 7.14 (1H, d, 
J = 1.8 Hz, H-4’ or H-5’), 7.25 (1H, dd, J = 8.6, 1.1 Hz, H-6), 7.49 (1H, ddd, J = 7.6, 7.6 
and 1.1 Hz, H-4), 7.67 (1H, ddd, J = 8.6, 7.6 and 1.7 Hz, H-5), 7.71 (1H, dd, J = 7.6, 
1.7 Hz, H-3); 
13
C NMR (126 MHz, CDCl3)  15.3 (CH3), 108.0 (C-2), 113.6 (ArCN), 
120.4 (C-4’ or C-5’), 123.1 (C-6), 128.6 (C-4’ or C-5’), 128.9 (C-4), 134.4 (C-3), 134.8 
(C-5), 147.2 (C-1 or C-2’), 149.5 (C-1 or C-2’); LRMS (ES+) m/z 264.4 [M+H]+; 
HRMS (ESI) calcd for C11H10N3O3S [M+H]
+
 264.0437, found 264.0442. 
 
4-(Trifluoromethyl)phenyl 2-methyl-1H-imidazole-1-sulfonate, (61) 
 
Compound 61 was synthesised according to general procedure B, using the following 
reagents: 1,1'-sulfonylbis(2-methyl-1H-imidazole) (19) (837 mg, 3.70 mmol), caesium 
carbonate (663 mg, 2.04 mmol), 4-(trifluoromethyl)phenol (300 mg, 1.85 mmol) and 
acetonitrile (20 mL). The crude orange oil was purified by column chromatography (silica 
gel, petrol:EtOAc, 1:0  8:2) to yield the title compound as a clear oil (454 mg, 80%); 
Rf = 0.32 (petrol:EtOAc, 8:2; KMnO4); λmax (EtOH)/nm 259.5; IR (neat) νmax/cm
-1
 1613, 
1555, 1508, 1427, 1323, 1211, 1173, 1127; 
1
H NMR (500 MHz, CDCl3) δ 2.52 (3H, s, 
CH3), 6.91 (1H, d, J = 1.8 Hz, H-4’ or H-5’), 7.08 (2H, d, J = 8.4 Hz, H-2, 6), 7.13 (1H, d, 
J = 1.8 Hz, H-4’ or H-5’), 7.66 (2H, d, J = 8.4 Hz, H-3, 5); 13C NMR (126 MHz, CDCl3) 
 15.1 (CH3), 120.5 (C-4’ or C-5’), 122.4 (C-2, 6), 123.3 (d, J = 272.5 Hz, ArCF3), 127.9 
(q, J = 3.7 Hz, C-3, 5), 128.4 (C-4’ or C-5’), 131.1 (q, J = 33.4 Hz, C-4), 146.8 (C-2’), 
186 
151.2 (C-1); 
19
F NMR(471 MHz, CDCl3) -62.6 (CF3); LRMS (ES
+
) m/z 308.1 [M+H]
+
; 
HRMS (ESI) calcd for C11H10F3N2O3S [M+H]
+
 307.0359, found 307.0358. 
 
4-Methoxyphenyl bis(2,4-dimethoxybenzyl)sulfamate, (62) 
 
Compound 62 was synthesised according to general procedure H, using the following 
reagents: 4-methoxyphenyl 2-methyl-1H-imidazole-1-sulfonate (48) (350 mg, 1.30 mmol), 
trimethyloxonium tetrafluoroborate (193 mg, 1.30 mmol), DCM (13 mL), acetonitrile 
(6.5 mL) and bis(2,4-dimethoxybenzyl)amine (32) (414 mg, 1.30 mmol). The crude 
product was purified by column chromatography (silica gel, petrol:EtOAc, 1:0  3:1) to 
yield the title compound as a pale yellow oil (428 mg, 65%); Rf = 0.30 (petrol:EtOAc, 3:1; 
KMnO4); λmax (EtOH)/nm 277.0; IR (neat) νmax/cm
-1
 1613, 1589, 1502, 1463, 1367, 1208, 
1156, 1032; 
1
H NMR (500 MHz, CDCl3) δ 3.72 (6H, s, 2 × ArOCH3), 3.78 (3H, s, 
ArOCH3), 3.79 (6H, s, 2 × ArOCH3), 4.43 (4H, s, 2 × ArCH2), 6.37 (2H, d, J = 2.4 Hz, 
H-3’), 6.42 (2H, dd, J = 8.4, 2.4 Hz, H-5’), 6.79 (2H, d, J = 9.1 Hz, H-3, 5), 7.00 (2H, d, 
J = 9.1 Hz, H-2, 6), 7.26 (2H, d, J = 8.4 Hz, H-6’); 13C NMR (126 MHz, CDCl3)  47.0 
(ArCH2), 55.2 (ArOCH3), 55.5 (ArOCH3), 55.7 (ArOCH3), 98.2 (C-3’), 104.1 (C-5’), 
114.5 (C-3, 5), 116.8 (C-1’), 123.2 (C-2, 6), 131.0 (C-6’), 143.9 (C-1), 157.9 (Cq Ar), 
158.5 (Cq Ar), 160.6 (Cq Ar); HRMS (ESI) calcd for C25H30NO8S [M+H]
+
 504.1687, found 
504.1677. 
 
2,6-Dimethylphenyl bis(2,4-dimethoxybenzyl)sulfamate, (63) 
 
Compound 63 was synthesised according to general procedure H, using the following 
reagents: 2,6-dimethylphenyl 2-methyl-1H-imidazole-1-sulfonate (51) (300 mg, 
1.13 mmol), trimethyloxonium tetrafluoroborate (167 mg, 1.13 mmol), DCM (11.5 mL), 
acetonitrile (5.5 mL) and bis(2,4-dimethoxybenzyl)amine (32) (358 mg, 1,13 mmol). The 
187 
crude product was purified by column chromatography (silica gel, petrol:EtOAc, 
1:0  85:15) to yield the title compound as a white solid (345 mg, 61%); Rf = 0.25 
(petrol:EtOAc, 85:15; KMnO4); m.p. 92.5-94.5 °C; λmax (EtOH)/nm 277.0; IR (neat) 
νmax/cm
-1
 1612, 1608, 1510, 1466, 1364, 1289, 1204, 1027; 
1
H NMR (500 MHz, CDCl3) 
δ 2.35 (6H, s, 2 × ArCH3), 3.72 (6H, s, 2 × ArOCH3), 3.79 (6H, s, 2 × ArOCH3), 4.60 (4H, 
s, 2 × ArCH2), 6.37 (2H, d, J = 2.4 Hz, H-3’), 6.43 (2H, dd, J = 8.4, 2.4 Hz, H-5’), 7.02 
(3H, s, H-3 and H-4 and H-5), 7.33 (2H, d, J = 8.4 Hz, H-6’); 13C NMR (126 MHz, CDCl3) 
 17.6 (ArCH3), 46.8 (ArCH2), 55.2 (ArOCH3), 55.5 (ArOCH3), 98.2 (C-3’), 104.1 (C-5’), 
116.8 (C-1’), 126.4 (C-3, 5 or C-4), 129.3 (C-3, 5 or C-4), 130.7 (C-6’), 132.5 (C-2, 6), 
147.9 (C-1), 158.5 (C-2’ or C-4’), 160.6 (C-2’ or C-4’); HRMS (ESI) calcd for 
C26H32NO7S [M+H]
+
 502.1894, found 502.1894. 
 
4-Chlorophenyl bis(2,4-dimethoxybenzyl)sulfamate, (64) 
 
Compound 64 was synthesised according to general procedure H, using the following 
reagents: 4-chlorophenyl 2-methyl-1H-imidazole-1-sulfonate (49) (300 mg, 1.10 mmol), 
trimethyloxonium tetrafluoroborate (163 mg, 1.10 mmol), DCM (11.0 mL), acetonitrile 
(5.5 mL) and bis(2,4-dimethoxybenzyl)amine (32) (349 mg, 1,10 mmol). The crude 
product was purified by column chromatography (silica gel, petrol:EtOAc, 1:0  8:2) to 
yield the title compound as a clear oil (352 mg, 63%); Rf = 0.32 (petrol:EtOAc, 8:2; 
KMnO4); λmax (EtOH)/nm 277.0; IR (neat) νmax/cm
-1
 1613, 1589, 1508, 1484, 1370, 1208, 
1156, 1035; 
1
H NMR (500 MHz, CDCl3) δ 3.73 (6H, s, 2 × ArOCH3), 3.80 (6H, s, 
2 × ArOCH3), 4.44 (4H, s, 2 × ArCH2), 6.39 (2H, d, J = 2.4 Hz, H-3’), 6.43 (2H, dd, 
J = 8.3, 2.4 Hz, H-5’), 6.98 (2H, d, J = 9.0 Hz, H-2, 6), 7.24 (4H, d, J = 9.0 Hz, H-3, 5 and 
H-6’); 13C NMR (126 MHz, CDCl3)  47.1 (ArCH2), 55.2 (ArOCH3), 55.5 (ArOCH3), 98.3 
(C-3’), 104.1 (C-5’), 116.6 (C-1’), 123.5 (C-2, 6), 129.6 (C-3, 5), 131.1 (C-6’), 148.9 
(C-1), 158.6 (C-2’ or C-4’), 160.8 (C-2’ or C-4’); HRMS (ESI) calcd for C24H27ClNO7S 
[M+H]
+
 508.1191, found 508.1181 
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3-Chlorophenyl bis(2,4-dimethoxybenzyl)sulfamate, (65) 
 
Compound 65 was synthesised according to general procedure H, using the following 
reagents: 3-chlorophenyl 2-methyl-1H-imidazole-1-sulfonate (50) (300 mg, 1.10 mmol), 
trimethyloxonium tetrafluoroborate (163 mg, 1.10 mmol), DCM (11.0 mL), acetonitrile 
(5.5 mL) and bis(2,4-dimethoxybenzyl)amine (32) (349 mg, 1,10 mmol). The crude 
product was purified by column chromatography (silica gel, petrol:EtOAc, 1:0  8:2) to 
yield the title compound as a clear oil (341 mg, 61%); Rf = 0.31 (petrol:EtOAc, 8:2; 
KMnO4); λmax (EtOH)/nm 277.0; IR (neat) νmax/cm
-1
 1613, 1587, 1508, 1467, 1371, 1208, 
1156, 1034; 
1
H NMR (500 MHz, CDCl3) δ 3.75 (6H, s, 2 × ArOCH3), 3.81 (6H, s, 
2 × ArOCH3), 4.45 (4H, s, 2 × ArCH2), 6.41 (2H, d, J = 2.4 Hz, H-3’), 6.45 (2H, dd, 
J = 8.4, 2.4 Hz, H-5’), 6.91 (1H, dd, J = 2.2, 2.0 Hz, H-2), 7.03 (1H, ddd, J = 7.9, 2.2 and 
1.4 Hz, H-6), 7.20 – 7.16 (1H, m, H-4), 7.22 (1H, dd, J = 8.0, 7.9 Hz, H-5), 7.26 (2H, d, 
J = 8.4 Hz, H-6’); 13C NMR (126 MHz, CDCl3)  47.3 (ArCH2), 55.3 (ArOCH3), 55.5 
(ArOCH3), 98.4 (C-3’), 104.1 (C-5’), 116.6 (C-1’), 120.4 (C-6), 122.6 (C-2), 126.7 (C-4), 
130.3 (C-5), 131.2 (C-6’), 134.7 (C-3), 150.8 (C-1), 158.6 (C-2’ or C-4’), 160.8 (C-2’ or 
C-4’); HRMS (ESI) calcd for C24H27ClNO7S [M+H]
+
 508.1191, found 508.1187. 
 
2-Chlorophenyl bis(2,4-dimethoxybenzyl)sulfamate, (66) 
 
Compound 66 was synthesised according to general procedure H, using the following 
reagents: 2-chlorophenyl 2-methyl-1H-imidazole-1-sulfonate (52) (350 mg, 1.28 mmol), 
trimethyloxonium tetrafluoroborate (190 mg, 1.28 mmol), DCM (13 mL), acetonitrile 
(6.5 mL) and bis(2,4-dimethoxybenzyl)amine (32) (407 mg, 1,28 mmol). The crude 
product was purified by column chromatography (silica gel, petrol:EtOAc, 1:0  8:2) to 
yield the title compound as a clear oil (444 mg, 68%); Rf = 0.30 (petrol:EtOAc, 8:2; 
KMnO4); λmax (EtOH)/nm 276.5; IR (neat) νmax/cm
-1
 1614, 1589, 1508, 1473, 1372, 1207, 
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1157, 1034; 
1
H NMR (500 MHz, CDCl3) δ 3.71 (6H, s, 2 × ArOCH3), 3.78 (6H, s, 
2 × ArOCH3), 4.56 (4H, s, 2 × ArCH2), 6.35 (2H, d, J = 2.4 Hz, H-3’), 6.40 (2H, dd, 
J = 8.4, 2.4 Hz, H-5’), 7.16 (1H, ddd, J = 7.8, 7.8 and 1.7 Hz, H-4 or H-5), 7.23 (1H, ddd, 
J = 7.8, 7.8 and 1.7 Hz, H-4 or H-5), 7.27 (2H, d, J = 8.4 Hz, H-6’), 7.40 (1H, dd, J = 7.8, 
1.7 Hz, H-3 or H-6), 7.43 (1H, dd, J = 7.8, 1.7 Hz, H-3 or H-6); 
13
C NMR (126 MHz, 
CDCl3)  47.1 (ArCH2), 55.2 (ArOCH3), 55.5 (ArOCH3), 98.2 (C-3’), 104.1 (C-5’), 116.5 
(C-1’), 123.6 (C-3 or C-6), 127.2 (C-4 or C-5), 127.2 (C-2), 127.9 (C-4 or C-5), 130.8 (C-3 
or C-6), 130.9 (C-6’), 146.7 (C-1), 158.5 (C-2’ or C-4’), 160.6 (C-2’ or C-4’); HRMS 
(ESI) calcd for C24H27ClNO7S [M+H]
+
 508.1191, found 508.1183. 
 
2,6-Dichlorophenyl bis(2,4-dimethoxybenzyl)sulfamate, (67) 
 
Compound 67 was synthesised according to general procedure H, using the following 
reagents: 2,6-dichlorophenyl 2-methyl-1H-imidazole-1-sulfonate (53) (350 mg, 
1.14 mmol), trimethyloxonium tetrafluoroborate (169 mg, 1.14 mmol), DCM (11.4 mL), 
acetonitrile (5.7 mL) and bis(2,4-dimethoxybenzyl)amine (32) (362 mg, 1.14 mmol). The 
crude product was purified by column chromatography (silica gel, petrol:EtOAc, 
1:0  8:2) to yield the title compound as a yellow oil (389 mg, 63%); Rf = 0.31 
(petrol:EtOAc, 8:2; KMnO4); λmax (EtOH)/nm 277.5; IR (neat) νmax/cm
-1
 1613, 1589, 1508, 
1440, 1382, 1207, 1157, 1035; 
1
H NMR (500 MHz, CDCl3) δ 3.71 (6H, s, 2 × ArOCH3), 
3.78 (6H, s, 2 × ArOCH3), 4.60 (4H, s, 2 × ArCH2), 6.35 (2H, d, J = 2.4 Hz, H-3’), 6.40 
(2H, dd, J = 8.4, 2.4 Hz, H-5’), 7.10 (1H, dd, J = 8.1, 8.1 Hz, H-4), 7.30 (2H, d, J = 8.4 Hz, 
H-6’), 7.33 (2H, d, J = 8.1 Hz, H-3, 5); 13C NMR (126 MHz, CDCl3)  47.2 (ArCH2), 55.2 
(ArOCH3), 55.5 (ArOCH3), 98.1 (C-3’), 104.0 (C-5’), 116.5 (C-1’), 127.3 (C-4), 129.4 
(C-3, 5), 130.2 (C-2, 6), 131.0 (C-6’), 144.3 (C-1), 158.5 (C-2’ or C-4’), 160.6 (C-2’ or 
C-4’); HRMS (ESI) calcd for C24H26Cl2NO7S [M+H]
+
 542.0802, found 542.0793. 
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4-Nitrophenyl bis(2,4-dimethoxybenzyl)sulfamate, (68) 
 
Compound 68 was synthesised according to general procedure H, using the following 
reagents: 4-nitrophenyl 2-methyl-1H-imidazole-1-sulfonate (54) (300 mg, 1.06 mmol), 
trimethyloxonium tetrafluoroborate (157 mg, 1.06 mmol), DCM (10.5 mL), acetonitrile 
(5.3 mL) and bis(2,4-dimethoxybenzyl)amine (32) (337 mg, 1,06 mmol). The crude 
product was purified by column chromatography (silica gel, petrol:EtOAc, 1:0  8:2) to 
yield the title compound as a yellow oil (340 mg, 62%); Rf = 0.29 (petrol:EtOAc, 8:2; 
KMnO4); λmax (EtOH)/nm 275.0; IR (neat) νmax/cm
-1
 1613, 1589, 1507, 1374, 1346, 1206, 
1156, 1033; 
1
H NMR (500 MHz, CDCl3) δ 3.75 (6H, s, 2 × ArOCH3), 3.81 (6H, s, 
2 × ArOCH3), 4.48 (4H, s, 2 × ArCH2), 6.40 (2H, d, J = 2.4 Hz, H-3’), 6.44 (2H, dd, 
J = 8.3, 2.4 Hz, H-5’), 7.16 (2H, d, J = 9.2 Hz, H-2, 6), 7.24 (2H, d, J = 8.3 Hz, H-6’), 8.15 
(2H, d, J = 9.2 Hz, H-3, 5); 
13
C NMR (126 MHz, CDCl3)  47.4 (ArCH2), 55.3 (ArOCH3), 
55.6 (ArOCH3), 98.4 (C-3’), 104.1 (C-5’), 116.3 (C-1’), 122.4 (C-2, 6), 125.4 (C-3, 5), 
131.2 (C-6’), 145.5 (Cq Ar), 155.1 (Cq Ar), 158.6 (C-2’ or C-4’), 161.0 (C-2’ or C-4’); 
HRMS (ESI) calcd for C24H27N2O9S [M+H]
+
 519.1432, found 519.1413. 
 
3-Nitrophenyl bis(2,4-dimethoxybenzyl)sulfamate, (69) 
 
Compound 69 was synthesised according to general procedure H, using the following 
reagents: 3-nitrophenyl 2-methyl-1H-imidazole-1-sulfonate (57) (200 mg, 0.71 mmol), 
trimethyloxonium tetrafluoroborate (104 mg, 0.71 mmol), DCM (7.1 mL), acetonitrile 
(3.5 mL) and bis(2,4-dimethoxybenzyl)amine (32) (225 mg, 0.71 mmol). The crude 
product was purified by column chromatography (silica gel, petrol:EtOAc, 1:0  8:2) to 
yield the title compound as a yellow oil (208 mg, 57%); Rf = 0.27 (petrol:EtOAc, 8:2; 
KMnO4); λmax (EtOH)/nm 273.0; IR (neat) νmax/cm
-1
 1612, 1589, 1530, 1507, 1351, 1206, 
1157, 1033; 
1
H NMR (500 MHz, CDCl3) δ 3.78 (6H, s, 2 × ArOCH3), 3.82 (6H, s, 
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2 × ArOCH3), 4.49 (4H, s, 2 × ArCH2), 6.43 (2H, d, J = 2.3 Hz, H-3’), 6.45 (2H, dd, 
J = 8.3, 2.3 Hz, H-5’), 7.26 (2H, d, J = 8.3 Hz, H-6’), 7.46 (1H, dd, J = 8.1, 7.6 Hz, H-5), 
7.51 – 7.48 (1H, m, H-6), 7.65 (1H, dd, J = 2.2, 2.1 Hz, H-2), 8.06 (1H, ddd, J = 7.7, 2.2 
and 1.5 Hz, H-4); 
13
C NMR (126 MHz, CDCl3)  47.5 (ArCH2), 55.3 (ArOCH3), 55.5 
(ArOCH3), 98.4 (C-3’), 104.2 (C-5’), 116.4 (C-1’), 117.7 (C-2), 121.3 (C-4), 128.6 (C-6), 
130.2 (C-5), 131.3 (C-6’), 148.7 (Cq Ar), 150.6 (Cq Ar), 158.7 (C-2’ or C-4’), 161.0 (C-2’ 
or C-4’); HRMS (ESI) calcd for C24H27N2O9S [M+H]
+
 519.1432, found 519.1409. 
 
2-Nitrophenyl bis(2,4-dimethoxybenzyl)sulfamate, (70) 
 
Compound 70 was synthesised according to general procedure H, using the following 
reagents: 2-nitrophenyl 2-methyl-1H-imidazole-1-sulfonate (58) (250 mg, 0.88 mmol), 
trimethyloxonium tetrafluoroborate (131 mg, 0.88 mmol), DCM (8.8 mL), acetonitrile 
(4.4 mL) and bis(2,4-dimethoxybenzyl)amine (32) (281 mg, 0.88 mmol). The crude 
product was purified by column chromatography (silica gel, petrol:EtOAc, 1:0  3:1) to 
yield the title compound as a yellow oil (279 mg, 61%); Rf = 0.30 (petrol:EtOAc, 3:1; 
KMnO4); λmax (EtOH)/nm 276.5; IR (neat) νmax/cm
-1
 1611, 1589, 1532, 1508, 1355, 1208, 
1158, 1034; 
1
H NMR (500 MHz, CDCl3) δ 3.73 (6H, s, 2 × ArOCH3), 3.79 (6H, s, 
2 × ArOCH3), 4.55 (4H, s, 2 × ArCH2), 6.36 (2H, d, J = 2.4 Hz, H-3’), 6.40 (2H, dd, 
J = 8.4, 2.4 Hz, H-5’), 7.24 (2H, d, J = 8.4 Hz, H-6’), 7.34 (1H, ddd, J = 8.5, 7.3 and 
1.5 Hz, H-4), 7.52 (1H, dd, J = 8.2, 1.5 Hz, H-6), 7.60 – 7.54 (1H, m, H-5), 7.92 (1H, dd, 
J = 8.5, 1.6 Hz, H-3); 
13
C NMR (126 MHz, CDCl3)  47.3 (ArCH2), 55.2 (ArOCH3), 55.5 
(ArOCH3), 98.2 (C-3’), 104.1 (C-5’), 116.2 (C-1’), 124.5 (C-4), 125.8 (C-3), 126.5 (C-6), 
131.0 (C-6’), 134.2 (C-5), 142.7 (Cq Ar), 143.1 (Cq Ar), 158.6 (C-2’ or C-4’), 160.7 (C-2’ 
or C-4’); HRMS (ESI) calcd for C24H27N2O9S [M+H]
+
 519.1432, found 519.1409. 
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4-Cyanophenyl bis(2,4-dimethoxybenzyl)sulfamate, (71) 
 
Compound 71 was synthesised according to general procedure H, using the following 
reagents: 4-cyanophenyl 2-methyl-1H-imidazole-1-sulfonate (59) (300 mg, 1.14 mmol), 
trimethyloxonium tetrafluoroborate (169 mg, 1.14 mmol), DCM (11.5 mL), acetonitrile 
(5.7 mL) and bis(2,4-dimethoxybenzyl)amine (32) (362 mg, 1,14 mmol). The crude 
product was purified by column chromatography (silica gel, petrol:EtOAc, 1:0  3:1) to 
yield the title compound as a white solid (358 mg, 63%); Rf = 0.28 (petrol:EtOAc, 3:1; 
KMnO4); m.p. 113.0-115.0 °C; λmax (EtOH)/nm 277.0; IR (neat) νmax/cm
-1
 2229, 1606, 
1509, 1367, 1303, 1204, 1156, 1030; 
1
H NMR (500 MHz, CDCl3) δ 3.74 (6H, s, 
2 × ArOCH3), 3.81 (6H, s, 2 × ArOCH3), 4.47 (4H, s, 2 × ArCH2), 6.41 (2H, d, J = 2.4 Hz, 
H-3’), 6.44 (2H, dd, J = 8.3, 2.4 Hz, H-5’), 7.13 (2H, d, J = 8.8 Hz, H-2, 6), 7.24 (2H, d, 
J = 8.3 Hz, H-6’), 7.59 (2H, d, J = 8.8 Hz, H-3, 5); 13C NMR (126 MHz, CDCl3)  47.3 
(ArCH2), 55.3 (ArOCH3), 55.6 (ArOCH3), 98.4 (C-3’), 104.1 (C-5’), 110.1 (C-4’), 116.3 
(C-1’), 118.3 (CN), 122.7 (C-2, 6), 131.2 (C-6’), 133.8 (C-3, 5), 153.7 (C-1), 158.6 (C-2’ 
or C-4’), 160.9 (C-2’ or C-4’); HRMS (ESI) calcd for C25H27N2O7S [M+H]
+
 499.1533, 
found 499.1530. 
 
2-Cyanophenyl bis(2,4-dimethoxybenzyl)sulfamate, (72) 
 
Compound 72 was synthesised according to general procedure H, using the following 
reagents: 2-cyanophenyl 2-methyl-1H-imidazole-1-sulfonate (60) (300 mg, 1.14 mmol), 
trimethyloxonium tetrafluoroborate (169 mg, 1.14 mmol), DCM (11.5 mL), acetonitrile 
(5.7 mL) and bis(2,4-dimethoxybenzyl)amine (32) (362 mg, 1,14 mmol). The crude 
product was purified by column chromatography (silica gel, petrol:EtOAc, 1:0  3:1) to 
yield the title compound as a clear oil (341 mg, 60%); Rf = 0.26 (petrol:EtOAc, 3:1; 
KMnO4); λmax (EtOH)/nm 276.5; IR (neat) νmax/cm
-1
 2236, 1613, 1592, 1508, 1450, 1374, 
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1208, 1157, 1033; 
1
H NMR (500 MHz, CDCl3) δ 3.73 (6H, s, 2 × ArOCH3), 3.79 (6H, s, 
2 × ArOCH3), 4.61 (4H, s, 2 × ArCH2), 6.36 (2H, d, J = 2.3 Hz, H-3’), 6.40 (2H, dd, 
J = 8.4, 2.3 Hz, H-5’), 7.27 (2H, d, J = 8.4 Hz, H-6’), 7.30 (1H, ddd, J = 7.6, 7.6 and 
1.3 Hz, H-4), 7.53 – 7.50 (1H, m, H-6), 7.59 – 7.55 (1H, m, H-5), 7.61 (1H, dd, J = 7.6, 
1.6 Hz, H-3); 
13
C NMR (126 MHz, CDCl3)  47.4 (ArCH2), 55.2 (ArOCH3), 55.5 
(ArOCH3), 98.2 (C-3’), 104.1 (C-5’), 107.2 (C-2), 115.3 (ArCN), 116.3 (C-1’), 122.7 
(C-6), 126.3 (C-4), 131.1 (C-6’), 133.7 (C-3), 134.2 (C-5), 151.8 (C-1), 158.6 (C-2’ or 
C-4’), 160.8 (C-2’ or C-4’); HRMS (ESI) calcd for C25H30N3O7S [M+NH4]
+
 516.1799, 
found 516.1796. 
 
4-(Trifluoromethyl)phenyl bis(2,4-dimethoxybenzyl)sulfamate, (73) 
 
Compound 73 was synthesised according to general procedure H, using the following 
reagents: 4-(trifluoromethyl)phenyl 2-methyl-1H-imidazole-1-sulfonate (61) (350 mg, 
1.14 mmol), trimethyloxonium tetrafluoroborate (169 mg, 1.14 mmol), DCM (11.4 mL), 
acetonitrile (5.7 mL) and bis(2,4-dimethoxybenzyl)amine (32) (362 mg, 1.14 mmol). The 
crude product was purified by column chromatography (silica gel, petrol:EtOAc, 
1:0  8:2) to yield the title compound as a yellow oil (408 mg, 66%); Rf = 0.32 
(petrol:EtOAc, 8:2; KMnO4); λmax (EtOH)/nm 277.5; IR (neat) νmax/cm
-1
 1613, 1592, 1508, 
1373, 1323, 1208, 1157, 1121, 1036; 
1
H NMR (500 MHz, CDCl3) δ 3.74 (6H, s, 
2 × ArOCH3), 3.80 (6H, s, 2 × ArOCH3), 4.47 (4H, s, 2 × ArCH2), 6.40 (2H, d, J = 2.4 Hz, 
H-3’), 6.44 (2H, dd, J = 8.4, 2.4 Hz, H-5’), 7.15 (2H, d, J = 8.1 Hz, H-2, 6), 7.25 (2H, d, 
J = 8.4 Hz, H-6’), 7.55 (2H, d, J = 8.1 Hz, H-3, 5); 13C NMR (126 MHz, CDCl3)  47.2 
(ArCH2), 55.2 (ArOCH3), 55.5 (ArOCH3), 98.3 (C-3’), 104.1 (C-5’), 116.4 (C-1’), 122.2 
(C-2, 6), 123.9 (d, J = 272.0 Hz, ArCF3), 127.0 (q, J = 3.7 Hz, C-3, 5), 128.5 (d, 
J = 32.9 Hz, C-4), 131.2 (C-6’), 153.0 (C-1), 158.6 (C-2’ or C-4’), 160.9 (C-2’ or C-4’); 
19
F NMR (471 MHz, CDCl3)  -62.2 (CF3); HRMS (ESI) calcd for C25H27F3NO7S [M+H]
+
 
542.1450, found 542.1455. 
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4-Methoxyphenyl bis(4-methoxybenzyl)sulfamate, (74) 
 
Compound 74 was synthesised according to general procedure H, using the following 
reagents: 4-methoxyphenyl 2-methyl-1H-imidazole-1-sulfonate (48) (300 mg, 1.12 mmol), 
trimethyloxonium tetrafluoroborate (165 mg, 1.12 mmol), DCM (11.2 mL), acetonitrile 
(5.6 mL) and bis(4-methoxybenzyl)amine (31) (288 mg, 1.12 mmol). The crude product 
was purified by column chromatography (silica gel, petrol:EtOAc, 1:0  85:15) to yield 
the title compound as a clear oil (398 mg, 80%); Rf = 0.30 (petrol:EtOAc, 85:15; KMnO4); 
λmax (EtOH)/nm 274.5; IR (neat) νmax/cm
-1
 1612, 1502, 1367, 1247, 1165, 1031; 
1
H NMR 
(500 MHz, CDCl3) δ 3.80 (3H, s, ArOCH3), 3.82 (6H, s, 2 × ArOCH3), 4.29 (4H, s, 
2 × ArCH2), 6.83 (2H, d, J = 9.1 Hz, H-3, 5), 6.86 (4H, d, J = 8.7 Hz, H-3’, 5’), 7.05 (2H, 
d, J = 9.1 Hz, H-2, 6), 7.20 (4H, d, J = 8.7 Hz, H-2’, 6’); 13C NMR (126 MHz, CDCl3) 
 50.4 (ArCH2), 55.4 (ArOCH3), 55.7 (ArOCH3), 114.1 (C-3’, 5’), 114.7 (C-3, 5), 123.2 
(C-2, 6), 127.0 (C-1’), 130.5 (C-2’, 6’), 143.9 (C-1), 158.1 (C-2’ or C-4’), 159.6 (C-2’ or 
C-4’); HRMS (ESI) calcd for C25H30NO8S [M+H]
+
 504.1687, found 504.1677. 
 
2,6-Dimethylphenyl bis(4-methoxybenzyl)sulfamate, (75) 
 
Compound 75 was synthesised according to general procedure H, using the following 
reagents: 2,6-dimethylphenyl 2-methyl-1H-imidazole-1-sulfonate (51) (300 mg, 
1.13 mmol), trimethyloxonium tetrafluoroborate (167 mg, 1.13 mmol), DCM (11.3 mL), 
acetonitrile (5.7 mL) and bis(4-methoxybenzyl)amine (31) (290 mg, 1.13 mmol). The 
crude product was purified by column chromatography (silica gel, petrol:EtOAc, 
1:0  9:1) to yield the title compound as a clear oil (310 mg, 62%); Rf = 0.32 
(petrol:EtOAc, 9:1; KMnO4); λmax (EtOH)/nm 274.5; IR (neat) νmax/cm
-1
 1612, 1513, 1363, 
1247, 1175, 1032; 
1
H NMR (500 MHz, CDCl3) δ 2.42 (6H, s, 2 × ArCH3), 3.82 (6H, s, 
2 × ArOCH3), 4.46 (4H, s, 2 × ArCH2), 6.88 (4H, d, J = 8.7 Hz, H-3’, 5’), 7.07 (3H, s, H-3 
and H-4 and H-5), 7.27 (4H, d, J = 8.7 Hz, H-2’, 6’); 13C NMR (126 MHz, CDCl3)  17.7 
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(ArCH3), 50.3 (ArCH2), 55.4 (ArOCH3), 114.1 (C-3’, 5’), 126.7 (CH Ar), 127.1 (Cq Ar), 
129.5 (CH Ar), 130.3 (C-2’, 6’), 132.4 (Cq Ar), 147.9 (C-1), 159.6 (C-4’); HRMS (ESI) 
calcd for C24H31N2O5S [M+NH4]
+
 459.1948, found 459.1949. 
 
4-Chlorophenyl bis(4-methoxybenzyl)sulfamate, (76) 
 
Compound 76 was synthesised according to general procedure H, using the following 
reagents: 4-chlorophenyl 2-methyl-1H-imidazole-1-sulfonate (49) (300 mg, 1.10 mmol), 
trimethyloxonium tetrafluoroborate (163 mg, 1.10 mmol), DCM (11.0 mL), acetonitrile 
(5.5 mL) and bis(4-methoxybenzyl)amine (31) (283 mg, 1.10 mmol). The crude product 
was purified by column chromatography (silica gel, petrol:EtOAc, 1:0  9:1) to yield the 
title compound as a clear oil (399 mg, 81%); Rf = 0.33 (petrol:EtOAc, 9:1; KMnO4); 
λmax (EtOH)/nm 274.5; IR (neat) νmax/cm
-1
 1612, 1588, 1512, 1484, 1370, 1248, 1170, 
1032; 
1
H NMR (500 MHz, CDCl3) δ 3.82 (6H, s, 2 × ArOCH3), 4.30 (4H, s, 2 × ArCH2), 
6.88 (4H, d, J = 8.7 Hz, H-3’, 5’), 7.06 (2H, d, J = 8.9 Hz, H-2, 6), 7.20 (4H, d, J = 8.7 Hz, 
H-2’, 6’), 7.30 (2H, d, J = 8.9 Hz, H-3, 5); 13C NMR (126 MHz, CDCl3)  50.4 (ArCH2), 
55.4 (ArOCH3), 114.2 (C-3’, 5’), 123.5 (C-2, 6), 126.7 (Cq Ar), 129.9 (C-3, 5), 130.5 
(C-2’, 6’), 132.3 (Cq Ar), 148.9 (C-1), 159.7 (C-4’); HRMS (ESI) calcd for C22H26ClN2O5S 
[M+NH4]
+
 465.1245, found 465.1244. 
 
3-Chlorophenyl bis(4-methoxybenzyl)sulfamate, (77) 
 
Compound 77 was synthesised according to general procedure H, using the following 
reagents: 3-chlorophenyl 2-methyl-1H-imidazole-1-sulfonate (50) (300 mg, 1.10 mmol), 
trimethyloxonium tetrafluoroborate (163 mg, 1.10 mmol), DCM (11.0 mL), acetonitrile 
(5.5 mL) and bis(4-methoxybenzyl)amine (31) (283 mg, 1.10 mmol). The crude product 
was purified by column chromatography (silica gel, petrol:EtOAc, 1:0  9:1) to yield the 
title compound as a clear oil (355 mg, 72%); Rf = 0.32 (petrol:EtOAc, 9:1; KMnO4); 
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λmax (EtOH)/nm 274.5; IR (neat) νmax/cm
-1
 1611, 1586, 1512, 1371, 1248, 1167, 1032; 
1
H NMR (500 MHz, CDCl3) δ 3.83 (6H, s, 2 × ArOCH3), 4.32 (4H, s, 2 × ArCH2), 6.89 
(4H, d, J = 8.7 Hz, H-3’, 5’), 7.06 (1H, dd, J = 2.3, 2.1 Hz, H-2), 7.10 (1H, ddd, J = 7.9, 
2.3 and 1.4 Hz, H-4 or H-6), 7.22 (4H, d, J = 8.7 Hz, H-2’, 6’), 7.26 – 7.23 (1H, m, H-4 or 
H-6), 7.28 (1H, dd, J = 7.9, 7.9 Hz, H-5); 
13
C NMR (126 MHz, CDCl3)  50.4 (ArCH2), 
55.4 (ArOCH3), 114.2 (C-3’, 5’), 120.3 (C-4 or C-6), 122.6 (C-2), 126.7 (Cq Ar), 127.0 
(C-4 or C-6), 130.5 (C-5), 130.5 (C-2’, 6’), 135.0 (Cq Ar), 150.8 (C-1), 159.7 (C-4’); 
HRMS (ESI) calcd for C22H26ClN2O5S [M+NH4]
+
 465.1245, found 465.1244. 
 
2-Chlorophenyl bis(4-methoxybenzyl)sulfamate, (78) 
 
Compound 78 was synthesised according to general procedure H, using the following 
reagents: 2-chlorophenyl 2-methyl-1H-imidazole-1-sulfonate (52) (300 mg, 1.10 mmol), 
trimethyloxonium tetrafluoroborate (163 mg, 1.10 mmol), DCM (11.0 mL), acetonitrile 
(5.5 mL) and bis(4-methoxybenzyl)amine (31) (283 mg, 1.10 mmol). The crude product 
was purified by column chromatography (silica gel, petrol:EtOAc, 1:0  9:1) to yield the 
title compound as a clear oil (384 mg, 78%); Rf = 0.29 (petrol:EtOAc, 9:1; KMnO4); 
λmax (EtOH)/nm 274.0; IR (neat) νmax/cm
-1
 1612, 1586, 1514, 1359, 1166, 1054; 
1
H NMR 
(500 MHz, CDCl3) δ 3.81 (6H, s, 2 × ArOCH3), 4.42 (4H, s, 2 × ArCH2), 6.86 (4H, d, 
J = 8.7 Hz, H-3’, 5’), 7.24 – 7.19 (5H, m, H-2’, 6’ and H-5), 7.30 (1H, ddd, J = 8.2, 8.0 
and 1.6 Hz, H-4), 7.44 (1H, dd, J = 8.0, 1.6 Hz, H-6), 7.52 (1H, dd, J = 8.2, 1.6 Hz, H-3); 
13
C NMR (126 MHz, CDCl3)  50.6 (ArCH2), 55.4 (ArOCH3), 114.1 (C-3’, 5’), 123.6 
(C-6), 126.8 (Cq Ar), 127.2 (Cq Ar), 127.5 (C-4), 128.1 (C-5), 130.5 (C-2’, 6’), 130.9 
(C-3), 146.6 (C-1), 159.6 (C-4’); HRMS (ESI) calcd for C22H26ClN2O5S [M+NH4]
+
 
465.1245, found 465.1244. 
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4-Methoxyphenyl sulfamate, (79) 
 
Compound 79 was synthesised following two different procedures. 
1
st
 procedure: Compound 79 was synthesised according to general procedure D, using the 
following reagents: 4-methoxyphenyl bis(2,4-dimethoxybenzyl)sulfamate (62) (250 mg, 
0.50 mmol), DCM (4.5 mL) and TFA (0.5 mL). The crude product was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  65:35) to yield the title compound as an 
off-white solid (91 mg, 90%). 
2
nd
 procedure: Compound 79 was synthesised according to general procedure E, using the 
following reagents: 4-methoxyphenyl bis(4-methoxybenzyl)sulfamate (74) (250 mg, 
0.56 mmol), DCM (2.8 mL) and TFA (2.8 mL). The crude product was purified by column 
chromatography (silica gel, petrol:DCM, 1:0  0:1) to yield the title compound as an off-
white solid (107 mg, 93%); Rf = 0.33 (petrol:EtOAc, 65:35; KMnO4); m.p. 68.5-70.5 °C 
(lit. 70-72 °C)
264
; λmax (EtOH)/nm 275.0; IR (neat) νmax/cm
-1
 3376, 3275, 1595, 1542, 1499, 
1356, 1242, 1149, 1027; 
1
H NMR (500 MHz, DMSO-d6) 3.76 (3H, s, ArOCH3), 6.99 (2H, 
d, J = 9.1 Hz, H-3, 5), 7.20 (2H, d, J = 9.1 Hz, H-2, 6), 7.87 (2H, s, ArOSO2NH2); 
13
C NMR (126 MHz, DMSO-d6) δ 55.5 (ArOCH3), 114.6 (C-3, 5), 123.3 (C-2, 6), 143.6 
(C-1), 157.5 (C-4); LRMS (ES
-
) m/z 202.1 [M-H]
-
; IR, 
1
H NMR, 
13
C NMR and LRMS 
data were identical to literature data.
258, 264
 
 
2,6-Dimethylphenyl sulfamate, (80) 
 
Compound 80 was synthesised following two different procedures. 
1
st
 procedure: Compound 80 was synthesised according to general procedure D, using the 
following reagents: 2,6-dimethylphenyl bis(2,4-dimethoxybenzyl)sulfamate (63) (250 mg, 
0.50 mmol), DCM (4.5 mL) and TFA (0.5 mL). The crude product was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  8:2) to yield the title compound as a 
white solid (90 mg, 90%). 
2
nd
 procedure: Compound (80) was synthesised according to general procedure E, using 
the following reagents: 2,6-dimethylphenyl bis(4-methoxybenzyl)sulfamate (75) (200 mg, 
198 
0.45 mmol), DCM (2.3 mL) and TFA (2.3 mL). The crude product was purified by column 
chromatography (silica gel, petrol:DCM, 1:0  0:1) to yield the title compound as a white 
solid (84 mg, 92%); Rf = 0.28 (petrol:EtOAc, 8:2; KMnO4); m.p. 107.5-109.5 °C (lit. 
110 °C)
265
; λmax (EtOH)/nm 268.5; IR (neat) νmax/cm
-1
 3355, 3269, 1547, 1470, 1339, 1188, 
1143, 1090; 
1
H NMR (500 MHz, DMSO-d6) δ 2.32 (6H, s, 2 × CH3), 7.13 – 7.02 (3H, m, 
H-3 and H-4 and H-5), 8.04 (2H, s, ArOSO2NH2); 
13
C NMR (126 MHz, DMSO-d6) δ 17.1 
(CH3), 126.1 (CH Ar), 129.0 (CH Ar), 131.9 (C-2, 6), 147.9 (C-1); LRMS (ES
-
) m/z 
200.1 [M-H]
-
; HRMS (ESI) calcd for C8H10NO3S [M-H]
-
 200.0387, found 200.0383; IR, 
1
H NMR and HRMS data were identical to literature data.
266
 
 
4-Chlorophenyl sulfamate, (81) 
 
Compound 81 was synthesised following two different procedures. 
1
st
 procedure: Compound 81 was synthesised according to general procedure D, using the 
following reagents: 4-chlorophenyl bis(2,4-dimethoxybenzyl)sulfamate (64) (200 mg, 
0.39 mmol), DCM (5.5 mL) and TFA (0.4 mL). The crude product was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  8:2) to yield the title compound as a 
white solid (69 mg, 84%). 
2
nd
 procedure: Compound 81 was synthesised according to general procedure E, using the 
following reagents: 4-chlorophenyl bis(4-methoxybenzyl)sulfamate (76) (250 mg, 
0.56 mmol), DCM (2.8 mL) and TFA (2.8 mL). The crude product was purified by column 
chromatography (silica gel, petrol:DCM, 1:0  0:1) to yield the title compound as a white 
solid (105 mg, 90%); Rf = 0.30 (petrol:EtOAc, 8:2; KMnO4); m.p. 102.0-104.0 °C (lit. 
105 °C)
265
; λmax (EtOH)/nm 269.0, 274.5; IR (neat) νmax/cm
-1
 3388, 3277, 1531, 1485, 
1352, 1154, 1086; 
1
H NMR (500 MHz, DMSO-d6) δ 7.30 (2H, d, J = 8.8 Hz, H-2, 6), 7.53 
(2H, d, J = 8.8 Hz, H-3, 5), 8.07 (2H, s, ArOSO2NH2); 
13
C NMR (126 MHz, DMSO-d6) 
δ 124.1 (C-2, 6), 129.7 (C-3, 5), 130.9 (C-4), 148.9 (C-1); LRMS (ES-) m/z 206.1 
[M(
35
Cl)-H]
-
, 208.1 [M(
37
Cl)-H]
-
; HRMS (ESI) calcd for C6H5ClNO3S [M(
35
Cl)-H]
-
 
205.9684, found 205.9681; IR, 
1
H NMR and 
13
C NMR data were identical to literature 
data.
258
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3-Chlorophenyl sulfamate, (82) 
 
Compound 82 was synthesised following two different procedures. 
1
st
 procedure: Compound 82 was synthesised according to general procedure D, using the 
following reagents: 3-chlorophenyl bis(2,4-dimethoxybenzyl)sulfamate (65) (200 mg, 
0.39 mmol), DCM (5.5 mL) and TFA (0.4 mL). The crude product was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  8:2) to yield the title compound as a 
white solid (74 mg, 90%). 
2
nd
 procedure: Compound 82 was synthesised according to general procedure E, using the 
following reagents: 3-chlorophenyl bis(4-methoxybenzyl)sulfamate (77) (250 mg, 
0.56 mmol), DCM (2.8 mL) and TFA (2.8 mL). The crude product was purified by column 
chromatography (silica gel, petrol:DCM, 1:0  0:1) to yield the title compound as a white 
solid (100 mg, 86%); Rf = 0.29 (petrol:EtOAc, 8:2; KMnO4); m.p. 80.5-82.5 °C (lit. 
80 °C)
265
; λmax (EtOH)/nm 266.0, 273.0; IR (neat) νmax/cm
-1
 3378, 3277, 1585, 1466, 1375, 
1165, 1069; 
1
H NMR (500 MHz, DMSO-d6) δ 7.27 (1H, ddd, J = 8.3, 2.3 and 1.0 Hz, 
H-6), 7.37 (1H, dd, J = 2.3, 2.1 Hz, H-2), 7.42 (1H, ddd, J = 8.1, 2.1 and 1.1 Hz, H-4), 
7.53 – 7.46 (1H, m, H-5), 8.13 (2H, s, ArOSO2NH2); 
13
C NMR (126 MHz, DMSO-d6) δ 
121.1 (C-6), 122.3 (C-2), 126.7 (C-4), 131.2 (C-5), 133.5 (C-3), 150.7 (C-1); LRMS (ES
-
) 
m/z 206.0 [M(
35
Cl)-H]
-
, 208.1 [M(
37
Cl)-H]
-
; HRMS (ESI) calcd for C6H5ClNO3S 
[M(
35
Cl)-H]
-
 205.9684, found 205.9682; 
1
H NMR and 
13
C NMR data were identical to 
literature data.
267
 
 
2-Chlorophenyl sulfamate, (83) 
 
Compound 83 was synthesised following two different procedures. 
1
st
 procedure: Compound 83 was synthesised according to general procedure D, using the 
following reagents: 2-chlorophenyl bis(2,4-dimethoxybenzyl)sulfamate (66) (200 mg, 
0.39 mmol), DCM (3.5 mL) and TFA (0.4 mL). The crude product was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  8:2) to yield the title compound as an off-
white solid (66 mg, 81%). 
200 
2
nd
 procedure: Compound 83 was synthesised according to general procedure E, using the 
following reagents: 2-chlorophenyl bis(4-methoxybenzyl)sulfamate (78) (250 mg, 
0.56 mmol), DCM (2.8 mL) and TFA (2.8 mL). The crude product was purified by column 
chromatography (silica gel, petrol:DCM, 1:0  0:1) to yield the title compound as an off-
white solid (107 mg, 92%); Rf = 0.29 (petrol:EtOAc, 8:2; KMnO4); m.p. 63.0-65.0 °C 
(lit. 62.5-63.5 °C)
268
; λmax (EtOH)/nm 266.5; IR (neat) νmax/cm
-1
 3350, 3264, 1566, 1473, 
1377, 1179, 1059; 
1
H NMR (500 MHz, DMSO-d6) δ 7.33 (1H, ddd, J = 8.1, 7.7 and 
1.6 Hz, H-4 or H-5), 7.45 – 7.41 (1H, m, H-4 or H-5), 7.50 (1H, dd, J = 8.1, 1.6 Hz, H-6), 
7.60 (1H, dd, J = 8.0, 1.6 Hz, H-3), 8.26 (2H, s, ArOSO2NH2); 
13
C NMR (126 MHz, 
DMSO-d6) δ 123.8 (C-6), 126.4 (C-2), 127.7 (C-4 or C-5), 128.4 (C-4 or C-5), 130.6 (C-3), 
146.1 (C-1); LRMS (ES
-
) m/z 206.1 [M(
35
Cl)-H]
-
, 208.0 [M(
37
Cl)-H]
-
; HRMS (ESI) calcd 
for C6H5ClNO3S [M(
35
Cl)-H]
-
 205.9684, found 205.9684. 
 
2,6-Dichlorophenyl sulfamate, (84) 
 
Compound 84 was synthesised according to general procedure D, using the following 
reagents: 2,6-dichlorophenyl bis(2,4-dimethoxybenzyl)sulfamate (67) (250 mg, 
0.46 mmol), DCM (4.1 mL) and TFA (0.5 mL). The crude product was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  3:1) to yield the title compound as an off-
white solid (100 mg, 89%); Rf = 0.27 (petrol:EtOAc, 3:1; KMnO4); m.p. 103.5-105.5 °C; 
λmax (EtOH)/nm 269.5; IR (neat) νmax/cm
-1
 3352, 3280, 1576, 1544, 1441, 1373, 1227, 
1173, 1066; 
1
H NMR (500 MHz, DMSO-d6) 7.32 (1H, dd, J = 8.1, 8.1 Hz, H-4), 7.57 (2H, 
d, J = 8.1 Hz, H-3, 5), 8.40 (2H, s, ArOSO2NH2); 
13
C NMR (126 MHz, DMSO-d6) δ 128.2 
(C-2, 6), 129.4 (C-4), 129.5 (C-3, 5), 143.5 (C-1); HRMS (ESI) calcd for C6H4Cl2NO3S 
[M-H]
-
 239.9294, found 239.9291. 
 
4-Nitrophenyl sulfamate, (85) 
 
Compound 85 was synthesised according to general procedure D, using the following 
reagents: 4-nitrophenyl bis(2,4-dimethoxybenzyl)sulfamate (68) (250 mg, 0.48 mmol), 
DCM (4.3 mL) and TFA (0.5 mL). The crude product was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  7:3) to yield the title compound as a 
201 
yellow solid (84 mg, 80%); Rf = 0.30 (petrol:EtOAc, 7:3; KMnO4); m.p. 106.5-108.5 °C 
(lit. 107.2-11.8 °C)
269
; λmax (EtOH)/nm 268.5; IR (neat) νmax/cm
-1
 3420, 3294, 1612, 1587, 
1518, 1483, 1400, 1351, 1174, 1153, 1103; 
1
H NMR (500 MHz, DMSO-d6) δ 7.53 (2H, d, 
J = 9.2 Hz, H-2, 6), 8.35 (2H, d, J = 9.2 Hz, H-3, 5), 8.36 (s, 2H, ArOSO2NH2); 
13
C NMR 
(126 MHz, DMSO-d6) δ 122.9 (C-2, 6), 125.7 (C-3, 5), 145.3 (C-4), 154.8 (C-1); 
HRMS (ESI) calcd for C6H7N2O5S [M+H]
+
 219.0070, found 219.0065; IR, 
1
H NMR and 
13
C NMR data were identical to literature data.
258, 267
 
 
3-Nitrophenyl sulfamate, (86) 
 
Compound 86 was synthesised according to general procedure D, using the following 
reagents: 3-nitrophenyl bis(2,4-dimethoxybenzyl)sulfamate (69) (150 mg, 0.29 mmol), 
DCM (2.6 mL) and TFA (0.3 mL). The crude product was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  7:3) to yield the title compound as a pale 
orange solid (55 mg, 87%); Rf = 0.30 (petrol:EtOAc, 7:3; KMnO4); m.p. 116.0-118.0 °C; 
λmax (EtOH)/nm 257.0; IR (neat) νmax/cm
-1
 3412, 3306, 1526, 1375, 1345, 1175, 1077; 
1
H NMR (500 MHz, DMSO-d6) δ 7.76 – 7.73 (1H, m, H-6), 7.78 (1H, dd, J = 8.0, 8.0 Hz, 
H-5), 8.11 (1H, dd, J = 2.2, 2.2 Hz, H-2), 8.22 (1H, ddd, J = 8.0, 2.2 and 1.3 Hz, H-4), 8.26 
(s, 2H, ArOSO2NH2); 
13
C NMR (126 MHz, DMSO-d6) δ 117.4 (C-2), 121.6 (C-4), 129.3 
(C-6), 131.3 (C-5), 148.3 (C-1 or C-3), 150.3 (C-1 or C-3); HRMS (ESI) calcd for 
C6H7N2O5S [M+H]
+
 219.0070, found 219.0068; IR, 
1
H NMR and 
13
C NMR data were 
identical to literature data.
267
 
 
2-Nitrophenyl sulfamate, (87) 
 
Compound 87 was synthesised according to general procedure D, using the following 
reagents: 2-nitrophenyl bis(2,4-dimethoxybenzyl)sulfamate (70) (200 mg, 0.39 mmol), 
DCM (3.5 mL) and TFA (0.4 mL). The crude product was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  7:3) to yield the title compound as a pale 
orange solid (34 mg, 40%); Rf = 0.28 (petrol:EtOAc, 7:3; KMnO4); m.p. 98.0-100.0 °C (lit. 
102-103 °C)
91
; λmax (EtOH)/nm 247.5;  IR (neat) νmax/cm
-1
 3404, 3264, 1601, 1512, 1380, 
1356, 1176, 1087; 
1
H NMR (500 MHz, DMSO-d6) δ 7.58 – 7.54 (1H, m, H-4), 7.59 – 7.57 
202 
(1H, m, H-6), 7.82 (1H, ddd, J = 8.2, 7.4 and 1.7 Hz, H-5), 8.05 (1H, dd, J = 8.1, 1.7 Hz, 
H-3), 8.40 (2H, s, ArOSO2NH2); 
13
C NMR (126 MHz, DMSO-d6) δ 124.9 (C-6), 125.6 
(C-3), 127.6 (C-4), 134.7 (C-5), 141.7 (C-1 or C-2), 143.3 (C-1 or C-2); HRMS (ESI) 
calcd for C6H10N3O5S [M+NH4]
+
 236.0336, found 236.0338; 
1
H NMR data were identical 
to literature data.
91
 
 
4-Cyanophenyl sulfamate, (88) 
 
Compound 88 was synthesised according to general procedure D, using the following 
reagents: 4-cyanophenyl bis(2,4-dimethoxybenzyl)sulfamate (71) (200 mg, 0.40 mmol), 
DCM (3.6 mL) and TFA (0.4 mL). The crude product was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  65:35) to yield the title compound as a 
white solid (73 mg, 92%); Rf = 0.29 (petrol:EtOAc, 65:35; KMnO4); m.p. No clear m.p., 
decomposition range 130-145 °C (lit. 155 °C)
265
; λmax (EtOH)/nm 266.5; IR (neat) 
νmax/cm
-1
 2241, 1603, 1539, 1499, 1377, 1181, 1155; 
1
H NMR (500 MHz, DMSO-d6) 
δ 7.47 (2H, d, J = 8.7 Hz, H-2, 6), 7.98 (2H, d, J = 8.7 Hz, H-3, 5), 8.28 (2H, s, 
ArOSO2NH2); 
13
C NMR (126 MHz, DMSO-d6) δ 109.3 (C-4), 116.4 (ArCN), 123.1 (C-2, 
6), 134.4 (C-3, 5), 153.5 (C-1); LRMS (ES
+
) m/z 199.1 [M+H]
+
; HRMS (ESI) calcd for 
C7H7N2O3S [M+H]
+
 199.0172, found 199.0169; IR, 
1
H NMR and 
13
C NMR data were 
identical to literature data.
258
 
 
2-Cyanophenyl sulfamate, (89) 
 
Compound 89 was synthesised according to general procedure D, using the following 
reagents: 2-cyanophenyl bis(2,4-dimethoxybenzyl)sulfamate (72) (200 mg, 0.40 mmol), 
DCM (3.6 mL) and TFA (0.4 mL). The crude product was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  65:35) to yield the title compound as an 
off-white solid (68 mg, 86%); Rf = 0.30 (petrol:EtOAc, 65:35; KMnO4); m.p. 
82.0-84.0 °C; λmax (EtOH)/nm 281.0; IR (neat) νmax/cm
-1
 3366, 3243, 2247, 1602, 1558, 
1487, 1450, 1385, 1162, 1098; 
1
H NMR (500 MHz, DMSO-d6) δ 7.51 (1H, ddd, J = 7.6, 
7.6 and 1.0 Hz, H-4), 7.59 (1H, dd, J = 8.4, 1.0 Hz, H-6), 7.82 (1H, ddd, J = 8.4, 7.6 and 
1.7 Hz, H-5), 7.95 (1H, dd, J = 7.6, 1.7 Hz, H-3), 8.50 (2H, s, ArOSO2NH2); 
13
C NMR 
203 
(126 MHz, DMSO-d6) δ 106.6 (C-2), 115.3 (ArCN), 122.8 (C-6), 127.1 (C-4), 134.1 (C-3), 
135.0 (C-5), 151.1 (C-1); LRMS (ES
+
) m/z 199.1 [M+H]
+
; HRMS (ESI) calcd for 
C7H5N2O3S [M-H]
-
 197.0026, found 197.0027. 
 
4-(Trifluoromethyl)phenyl sulfamate, (90) 
 
Compound 90 was synthesised according to general procedure D, using the following 
reagents: 4-(trifluoromethyl)phenyl bis(2,4-dimethoxybenzyl)sulfamate (73) (250 mg, 
0.46 mmol), DCM (4.1 mL) and TFA (0.5 mL). The crude product was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  3:1) to yield the title compound as an off-
white solid (100 mg, 90%); Rf = 0.28 (petrol:EtOAc, 3:1; KMnO4); m.p. 102.5-104.5 °C 
(lit. 100-102 °C)
258
; λmax (EtOH)/nm 257.0; IR (neat) νmax/cm
-1
 3381, 3278, 1614, 1534, 
1510, 1351, 1320, 1158, 1126, 1066; 
1
H NMR (500 MHz, DMSO-d6) δ 7.50 (2H, d, 
J = 8.5 Hz, H-2, 6), 7.87 (2H, d, J = 8.5 Hz, H-3, 5), 8.21 (2H, s, ArOSO2NH2); 
13
C NMR 
(126 MHz, DMSO-d6) δ 123.0 (C-2, 6), 125.0 (CF3), 126.9 (C-4), 127.3 (q, J = 3.7 Hz, 
C-3, 5), 152.9 (C-1); 
19
F (471 MHz, DMSO)  -60.7 (CF3); LRMS (ES
-
) m/z 240.1 [M-H]
-
; 
HRMS (ESI) calcd for C7H5F3NO3S [M-H]
-
 239.9948, found 239.9939; IR, 
1
H NMR and 
13
C NMR data were identical to literature data.
258
 
 
4-(Benzyloxy)phenyl 2-methyl-1H-imidazole-1-sulfonate, (92) 
 
Compound 92 was synthesised according to general procedure B, using the following 
reagents: 1,1'-sulfonylbis(2-methyl-1H-imidazole) (19) (678 mg, 3.00 mmol), caesium 
carbonate (537 mg, 1.65 mmol), 4-(benzyloxy)phenol (300 mg, 1.50 mmol) and 
acetonitrile (20 mL). The crude yellow oil was purified by column chromatography (silica 
gel, petrol:EtOAc – 1:0  8:2) to yield the title compound as a clear oil (500 mg, 96%); 
Rf = 0.38 (petrol:EtOAc, 8:2; KMnO4); λmax (EtOH)/nm 273.0; IR (neat) νmax/cm
-1
 1595, 
1552, 1499, 1418, 1206, 1144, 1044; 
1
H NMR (500 MHz, CDCl3) δ 2.43 (3H, s, CH3), 
5.03 (2H, s, ArCH2), 6.86 – 6.78 (2H, m, H-2, 6 or H-3, 5), 6.88 (1H, d, J = 1.7 Hz, H-4’ 
or H-5’), 6.95 – 6.87 (2H, m, H-2, 6 or H-3, 5), 7.13 (1H, d, J = 1.7 Hz, H-4’ or H-5’), 
7.37 – 7.32 (1H, m, ArH), 7.39 (4H, d, J = 4.4 Hz, 4 × ArH); 13C NMR (126 MHz, CDCl3) 
 15.0 (CH3), 70.6 (ArCH2), 116.1 (C-2, 6 or C-3, 5), 120.5 (C-4’ or C-5’), 122.7 (C-2, 6 
204 
or C-3, 5), 127.6 (CH Ar), 128.0 (CH Ar), 128.4 (CH Ar), 128.8 (CH Ar), 136.2 (Cq Ar), 
142.6 (Cq Ar), 147.0 (Cq Ar), 158.5 (C-4); LRMS (ES
+
) m/z 345.2 [M+H]
+
; HRMS (ESI) 
calcd for C17H17N2O4S [M+H]
+
 345.0904, found 345.0904. 
 
4-(Benzyloxy)phenyl bis(2,4-dimethoxybenzyl)sulfamate, (93) 
 
Compound 93 was synthesised according to general procedure H, using the following 
reagents: 4-(benzyloxy)phenyl 2-methyl-1H-imidazole-1-sulfonate (92) (450 mg, 
1.31 mmol), trimethyloxonium tetrafluoroborate (193 mg, 1.31 mmol), DCM (13.0 mL), 
acetonitrile (6.5 mL) and bis(2,4-dimethoxybenzyl)amine (32) (416 mg, 1.31 mmol). The 
crude product was purified by column chromatography (silica gel, petrol:EtOAc, 
1:0  8:2) to yield the title compound as a clear oil (461 mg, 61%); Rf = 0.30 
(petrol:EtOAc, 8:2; KMnO4); λmax (EtOH)/nm 277.0; IR (neat) νmax/cm
-1
 1613, 1591, 1501, 
1369, 1208, 1155, 1035; 
1
H NMR (500 MHz, CDCl3) δ 3.72 (6H, s, 2 × ArOCH3), 3.79 
(6H, s, 2 × ArOCH3), 4.43 (4H, s, 2 × ArCH2), 5.02 (2H, s, ArCH2), 6.37 (2H, d, 
J = 2.3 Hz, H-3’), 6.42 (2H, dd, J = 8.4, 2.4 Hz, H-5’), 6.87 (2H, d, J = 9.1 Hz, H-2, 6 or 
H-3, 5), 7.00 (2H, d, J = 9.1 Hz, H-2, 6 or H-3, 5), 7.26 (2H, d, J = 8.4 Hz, H-6’), 7.36 – 
7.31 (1H, m, ArH), 7.44 – 7.36 (4H, m, 4 × ArH); 13C NMR (126 MHz, CDCl3)  47.0 
(ArCH2), 55.2 (ArOCH3), 55.5 (ArOCH3), 70.5 (ArCH2), 98.2 (C-3’), 104.0 (C-5’), 115.5 
(C-2, 6 or C-3, 5), 116.8 (C-1’), 123.2 (C-2, 6 or C-3, 5), 127.6 (CH Ar), 128.2 (CH Ar), 
128.8 (CH Ar), 131.1 (C-6’), 136.8 (Cq Ar), 144.1 (C-1), 157.1 (C-4), 158.5 (C-2’ or C-4’), 
160.6 (C-2’ or C-4’); HRMS (ESI) calcd for C31H34NO8S [M+H]
+
 580.2000, found 
580.1991. 
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4-Hydroxyphenyl bis(2,4-dimethoxybenzyl)sulfamate, (94) 
 
4-(Benzyloxy)phenyl bis(2,4-dimethoxybenzyl)sulfamate (93) (300 mg, 0.52 mmol) in 
MeOH (10.5 mL) was subjected to palladium-catalysed hydrogenation using an H-Cube

 
reactor and a 10% Pd/C CatCart. The reaction mixture was heated at 50 °C for 24 h. The 
crude product was purified by column chromatography (silica gel, petrol:EtOAc, 
1:0  65:35) to yield the title compound as a clear oil (215 mg, 85%); Rf = 0.31 
(petrol:EtOAc, 65:35; KMnO4); λmax (EtOH)/nm 277.0; IR (neat) νmax/cm
-1
 1613, 1592, 
1505, 1360, 1208, 1157, 1034; 
1
H NMR (500 MHz, CDCl3) δ 3.72 (6H, s, 2 × ArOCH3), 
3.79 (6H, s, 2 × ArOCH3), 4.43 (4H, s, 2 × ArCH2), 5.10 (1H, s, ArOH), 6.38 (2H, d, 
J = 2.4 Hz, H-3’), 6.42 (2H, dd, J = 8.4, 2.4 Hz, H-5’), 6.70 (2H, d, J = 9.0 Hz, H-3, 5), 
6.93 (2H, d, J = 9.0 Hz, H-2, 6), 7.25 (2H, d, J = 8.4 Hz, H-6’); 13C NMR (126 MHz, 
CDCl3)  47.0 (ArCH2), 55.2 (ArOCH3), 55.5 (ArOCH3), 98.2 (C-3’), 104.1 (C-5’), 116.0 
(C-1’), 116.8 (C-3, 5), 123.4 (C-2, 6), 131.0 (C-6’), 143.9 (C-1), 154.0 (C-4), 158.5 (C-2’ 
or C-4’), 160.7 (C-2’ or C-4’); LRMS (ES-) m/z 488.2 [M-H]-; HRMS (ESI) calcd for 
C24H28NO8S [M+H]
+
 490.1530, found 490.1527. 
 
4-Hydroxyphenyl sulfamate, (95) 
 
Compound 95 was synthesised according to general procedure D, using the following 
reagents: 4-hydroxyphenyl bis(2,4-dimethoxybenzyl)sulfamate (94) (150 mg, 0.31 mmol), 
DCM (2.8 mL) and TFA (0.3 mL). The crude product was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  1:1) to yield the title compound as a pale 
red solid (50 mg, 86%); Rf = 0.35 (petrol:EtOAc, 1:1; KMnO4); m.p. 138.0-140.0 °C; 
λmax (EtOH)/nm 277.5; IR (neat) νmax/cm
-1
 3371, 3232, 1601, 1551, 1504, 1364, 1150; 
1
H NMR (500 MHz, DMSO-d6) δ 6.78 (2H, d, J = 9.0 Hz, H-2, 6 or H-3, 5), 7.07 (2H, d, 
J = 9.0 Hz, H-2, 6 or H-3, 5), 7.88 (2H, brs, ArOSO2NH2), 9.41 (1H, brs, ArOH); 
13
C NMR (126 MHz, DMSO-d6) δ 115.7 (C-2, 6 or C-3, 5), 123.3 (C-2, 6 or C-3, 5), 142.4 
(C-1), 155.8 (C-4); LRMS (ES
-
) m/z 188.1 [M-H]
-
; HRMS (ESI) calcd for C6H6NO4S 
[M-H]
-
 188.0023, found 188.0023. 
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Methyl 3-(((2-methyl-1H-imidazol-1-yl)sulfonyl)oxy)benzoate, (97) 
 
Compound 97 was synthesised according to general procedure B, using the following 
reagents: 1,1'-sulfonylbis(2-methyl-1H-imidazole) (19) (149 mg, 0.66 mmol), caesium 
carbonate (118 mg, 0.36 mmol), methyl 3-hydroxybenzoate (50 mg, 0.33 mmol) and 
acetonitrile (5 mL). The crude yellow oil was purified by column chromatography (silica 
gel, petrol:EtOAc, 1:0  3:1) to yield the title compound as a clear oil (90 mg, 92%); 
Rf = 0.20 (petrol:EtOAc, 8:2; KMnO4); λmax (EtOH)/nm 272.0; IR (neat) νmax/cm
-1
 1727, 
1585, 1554, 1422, 1296, 1266, 1205, 1151, 1045; 
1
H NMR (500 MHz, CDCl3) δ 2.49 (3H, 
s, CH3), 3.92 (3H, s, ArCO2CH3), 6.89 (1H, d, J = 1.6 Hz, H-4’ or H-5’), 7.08 (1H, dd, 
J = 8.2, 2.4 Hz, H-4), 7.13 (1H, d, J = 1.6 Hz, H-4’ or H-5’), 7.45 (1H, dd, J = 8.2, 8.0 Hz, 
H-5), 7.66 (1H, dd, J = 2.4, 2.1 Hz, H-2), 8.04 (1H, d, J = 8.0 Hz, H-6); 
13
C NMR 
(126 MHz, CDCl3)  15.1 (CH3), 52.8 (ArCO2CH3), 120.4 (C-4’ or C-5’), 123.0 (C-2), 
125.9 (C-4), 128.2 (C-4’ or C-5’), 129.7 (C-6), 130.5 (C-5), 132.8 (C-1), 146.8 (C-3 or C-
2’), 149.0 (C-3 or C-2’), 165.2 (ArCO2Me); LRMS (ES
+
) m/z 297.0 [M+H]
+
; HRMS (ESI) 
calcd for C12H13N2O5S [M+H]
+
 297.0540, found 297.0545. 
 
Methyl 3-((N,N-bis(2,4-dimethoxybenzyl)sulfamoyl)oxy)benzoate, (98) 
 
Compound 98 was synthesised according to general procedure H, using the following 
reagents: methyl 3-(((2-methyl-1H-imidazol-1-yl)sulfonyl)oxy)benzoate (97) (750 mg, 
2.53 mmol), trimethyloxonium tetrafluoroborate (374 mg, 2.53 mmol), DCM (25.3 mL), 
acetonitrile (12.7 mL) and bis(2,4-dimethoxybenzyl)amine (32) (805 mg, 2.53 mmol). The 
crude product was purified by column chromatography (silica gel, petrol:EtOAc, 1:0  
3:1) to yield the title compound as a clear oil (845 mg, 64%); Rf = 0.30 (petrol:EtOAc, 8:2; 
KMnO4); λmax (EtOH)/nm 277.0; IR (neat) νmax/cm
-1
 1725, 1613, 1588, 1508, 1372, 1287, 
1267, 1208, 1157, 1035; 
1
H NMR (500 MHz, CDCl3) δ 3.74 (6H, s, 2 × ArOCH3), 3.80 
(6H, s, 2 × ArOCH3), 3.91 (3H, s, ArCO2CH3), 4.47 (4H, s, 2 × ArCH2), 6.39 (2H, d, 
J = 2.4 Hz, H-3’), 6.43 (2H, dd, J = 8.4, 2.4 Hz, H-5’), 7.26 (2H, d, J = 8.4 Hz, H-6’), 7.31 
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(1H, ddd, J = 8.1, 2.3 and 1.3 Hz, H-4), 7.37 (1H, dd, J = 8.1, 7.6 Hz, H-5), 7.65 (1H, dd, 
J = 2.3, 1.9 Hz, H-2), 7.89 (1H, ddd, J = 7.6, 1.9 and 1.3 Hz, H-6); 
13
C NMR (126 MHz, 
CDCl3)  47.1 (ArCH2), 52.4 (ArCO2CH3), 55.2 (ArOCH3), 55.5 (ArOCH3), 98.3 (C-3’), 
104.1 (C-5’), 116.6 (C-1’), 123.2 (C-2), 126.7 (C-4), 127.6 (C-6), 129.6 (C-5), 131.1 
(C-6’), 131.8 (C-1), 150.4 (C-3), 158.6 (C-2’ or C-4’), 160.8 (C-2’ or C-4’), 166.1 
(ArCO2Me); HRMS (ESI) calcd for C26H30NO9S [M+H]
+
 532.1636, found 532.1626. 
 
3-((N,N-bis(2,4-Dimethoxybenzyl)sulfamoyl)oxy)benzoic acid, (99) 
 
To methyl 3-((N,N-bis(2,4-dimethoxybenzyl)sulfamoyl)oxy)benzoate (98) in THF (5 mL) 
was added a 2 M aq. solution of lithium hydroxide (2.8 mL, 5.65 mmol). The resulting 
mixture was heated at 60 °C for 18 h. Upon completion, the mixture was acidified to pH 3 
using a 4 M aq. solution of HCl. The reaction was then diluted with water (20 mL) and 
extracted with EtOAc (3 × 25 mL). The pooled organic extracts were washed with water 
(30 mL) and brine (30 mL), dried over MgSO4 and concentrated in vacuo. The crude 
product was purified by column chromatography (silica gel, DCM:MeOH:AcOH, 
1:0:0  95:4.9:0.1) to yield the title compound as a clear oil (249 mg, 85%); Rf = 0.32 
(DCM:MeOH:AcOH, 95:4.9:0.1; KMnO4); λmax (EtOH)/nm 277.0; IR (neat) νmax/cm
-1
 
1696, 1613, 1587, 1508, 1371, 1291, 1266, 1208, 1157, 1034; 
1
H NMR (500 MHz, CDCl3) 
δ 3.76 (6H, s, 2 × ArOCH3), 3.81 (6H, s, 2 × ArOCH3), 4.49 (4H, s, 2 × ArCH2), 6.41 (2H, 
d, J = 2.4 Hz, H-3’), 6.44 (2H, dd, J = 8.4, 2.4 Hz, H-5’), 7.27 (2H, d, J = 8.4 Hz, H-6’), 
7.45 – 7.39 (2H, m, H-4 and H-5), 7.68 (1H, dd, J = 1.9, 1.9 Hz, H-2), 7.98 – 7.93 (1H, m, 
H-6); 
13
C NMR (126 MHz, CDCl3)  47.2 (ArCH2), 55.3 (ArOCH3), 55.5 (ArOCH3), 98.4 
(C-3’), 104.1 (C-5’), 116.6 (C-1’), 123.8 (C-2), 127.6 (C-4 or C-5), 128.1 (C-6), 129.8 
(C-4 or C-5), 130.9 (C-1), 131.2 (C-6’), 150.5 (C-3), 158.6 (C-2’ or C-4’), 160.8 (C-2’ or 
C-4’), 170.6 (ArCO2H); HRMS (ESI) calcd for C25H28NO9S [M+H]
+
 518.1479, found 
518.1474. 
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3-(Sulfamoyloxy)benzoic acid, (100) 
 
Compound 100 was synthesised according to general procedure D, using the following 
reagents: 3-((N,N-bis(2,4-dimethoxybenzyl)sulfamoyl)oxy)benzoic acid (99) (200 mg, 
0.39 mmol), DCM (3.5 mL) and TFA (0.4 mL). The crude product was purified by column 
chromatography (silica gel, DCM:MeOH:AcOH, 1:0:0  90:9.9:0.1) to yield the title 
compound as a white solid (75 mg, 89%); Rf = 0.28 (DCM:MeOH:AcOH, 90:9.9:0.1; 
KMnO4); m.p. 162.0-164.0 °C; λmax (EtOH)/nm 274.5; IR (neat) νmax/cm
-1
 3374, 3281, 
1681, 1587, 1451, 1366, 1302, 1166, 1101; 
1
H NMR (500 MHz, DMSO-d6) δ 7.52 (1H, 
ddd, J = 8.1, 2.5 and 1.0 Hz, H-4), 7.60 (1H, dd, J = 8.1, 7.8 Hz, H-5), 7.82 (1H, dd, 
J = 2.5, 2.0 Hz, H-2), 7.90 (1H, ddd, J = 7.8, 2.0 and 1.0 Hz, H-6), 8.09 (2H, s, 
ArOSO2NH2), 13.25 (1H, brs, ArCO2H); 
13
C NMR (126 MHz, DMSO-d6) δ 122.9 (C-2), 
126.9 (C-4), 127.4 (C-6), 130.2 (C-5), 132.6 (C-1), 150.1 (C-3), 166.4 (ArCO2H); LRMS 
(ES
-
) m/z 216.1 [M-H]
-
; HRMS (ESI) calcd for C7H6NO5S [M-H]
-
 215.9961, found 
215.9962. 
 
3-(Hydroxymethyl)phenyl bis(2,4-dimethoxybenzyl)sulfamate, (101) 
 
To methyl 3-((N,N-bis(2,4-dimethoxybenzyl)sulfamoyl)oxy)benzoate (98) (500 mg, 
0.94 mmol) in THF (8 mL), cooled at 0 °C, was added dropwise a lithium aluminium 
hydride solution (2.0 M in THF, 0.52 mL). The resulting solution was stirred at 0 °C for 
2 h. Upon completion, the reaction was quenched by addition of saturated aq. Rochelle’s 
salt (20 mL). The aqueous layer was extracted with EtOAc (3 × 30 mL). The pooled 
organic extracts were washed with water and brine (30 mL, respectively), dried over 
MgSO4 and concentrated in vacuo. The crude solid was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  1:1) to yield the title compound as a clear 
oil (400 mg, 84%); Rf = 0.35 (petrol:EtOAc, 1:1; KMnO4); λmax (EtOH)/nm 277.0; 
IR (neat) νmax/cm
-1
 1613, 1588, 1508, 1367, 1208, 1158, 1034; 
1
H NMR (500 MHz, 
CDCl3) δ 1.77 (1H, t, J = 6.1 Hz, ArCH2OH), 3.73 (6H, s, 2 × ArOCH3), 3.80 (6H, s, 
2 × ArOCH3), 4.46 (4H, s, 2 × ArCH2), 4.63 (2H, d, J = 6.1 Hz, ArCH2OH), 6.39 (2H, d, 
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J = 2.4 Hz, H-3’), 6.43 (2H, dd, J = 8.4, 2.4 Hz, H-5’), 6.99 (1H, s, H-2), 7.08 – 7.02 (1H, 
m, H-4 or H-6), 7.21 (1H, d, J = 7.7 Hz, H-4 or H-6), 7.26 (2H, d, J = 8.4 Hz, H-6’), 7.29 
(1H, dd, J = 7.8, 7.7 Hz, H-5); 
13
C NMR (126 MHz, CDCl3)  47.0 (ArCH2), 55.2 
(ArOCH3), 55.5 (ArOCH3), 64.8 (ArCH2OH), 98.3 (C-3’), 104.1 (C-5’), 116.8 (C-1’), 
120.3 (C-2), 121.1 (C-4 or C-6), 124.7 (C-4 or C-6), 129.7 (C-5), 131.1 (C-6’), 143.0 
(C-3), 150.7 (C-1), 158.6 (C-2’ or C-4’), 160.7 (C-2’ or C-4’); HRMS (ESI) calcd for 
C25H30NO8S [M+H]
+
 504.1687, found 504.1684. 
 
3-Formylphenyl bis(2,4-dimethoxybenzyl)sulfamate, (102) 
 
To 3-(hydroxymethyl)phenyl bis(2,4-dimethoxybenzyl)sulfamate (101) (300 mg, 
3.60 mmol) in DCM (10 mL) was added manganese oxide (518 mg, 5.96 mmol). The 
resulting solution was stirred at RT for 16 h. Upon completion, the heterogeneous mixture 
was filtered through Celite and washed with DCM (15 mL). The filtrate was concentrated 
in vacuo. The crude product was purified by column chromatography (silica gel, 
petrol:EtOAc, 1:0  7:3) to yield the title compound as a clear oil (266 mg, 89%); 
Rf = 0.30 (petrol:EtOAc, 7:3; KMnO4); λmax (EtOH)/nm 275.5; IR (neat) νmax/cm
-1
 1703, 
1616, 1588, 1507, 1361, 1208, 1173, 1031; 
1
H NMR (500 MHz, CDCl3) δ 3.75 (6H, s, 
2 × ArOCH3), 3.81 (6H, s, 2 × ArOCH3), 4.48 (4H, s, 2 × ArCH2), 6.40 (2H, d, J = 2.3 Hz, 
H-3’), 6.44 (2H, dd, J = 8.4, 2.3 Hz, H-5’), 7.26 (2H, d, J = 8.4 Hz, H-6’), 7.40 – 7.37 (1H, 
m, H-6), 7.41 (1H, dd, J = 1.7, 1.7 Hz, H-2), 7.47 (1H, dd, J = 7.8, 7.8 Hz, H-5), 7.72 (1H, 
ddd, J = 7.8, 1.7 and 1.2 Hz, H-4), 9.91 (1H, s, ArCHO); 
13
C NMR (126 MHz, CDCl3) 
 47.3 (ArCH2), 55.3 (ArOCH3), 55.5 (ArOCH3), 98.4 (C-3’), 104.2 (C-5’), 116.6 (C-1’), 
122.9 (C-2), 127.4 (C-4), 128.1 (C-6), 130.3 (C-5), 131.2 (C-6’), 137.9 (C-3), 151.1 (C-1), 
158.7 (C-2’ or C-4’), 160.9 (C-2’ or C-4’), 191.0 (ArCHO); HRMS (ESI) calcd for 
C25H28NO8S [M+H]
+
 502.1530, found 502.1519. 
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3-(Hydroxy(phenyl)methyl)phenyl bis(2,4-dimethoxybenzyl)sulfamate, (103) 
 
To methyl 3-formylphenyl bis(2,4-dimethoxybenzyl)sulfamate (102) (200 mg, 0.40 mmol) 
in THF (10 mL), cooled at 0 °C, was added dropwise a phenyl magnesium bromide 
solution (1.0 M in THF, 1.2 mL, 1.20 mmol). The resulting solution was stirred at 0 °C for 
3 h. Upon completion, the reaction was quenched by addition of a 1 M aq. HCl solution 
(4 mL) and diluted with water (10 mL). The aqueous layer was extracted with EtOAc 
(3 × 25 mL). The pooled organic extracts were washed with water and brine (30 mL, 
respectively), dried over MgSO4 and concentrated in vacuo. The crude solid was purified 
by column chromatography (silica gel, petrol:EtOAc, 1:0  7:3) to yield the title 
compound as a clear oil (203 mg, 88%); Rf = 0.25 (petrol:EtOAc – 7:3); λmax (EtOH)/nm 
277.0; IR (neat) νmax/cm
-1
 1613, 1588, 1508, 1368, 1208, 1157, 1034; 
1
H NMR (500 MHz, 
CDCl3) δ 2.25 (1H, d, J = 3.6 Hz, CHOH), 3.71 (6H, s, 2 × ArOCH3), 3.79 (6H, s, 
2 × ArOCH3), 4.42 (4H, s, 2 × ArCH2), 5.76 (1H, d, J = 3.0 Hz, CHOH), 6.38 (2H, d, 
J = 2.4 Hz, H-3’), 6.41 (2H, dd, J = 8.3, 2.4 Hz, H-5’), 7.08 – 7.02 (2H, m, 2 × ArH), 7.23 
– 7.19 (1H, m, ArH), 7.29 – 7.23 (4H, m, 4 × ArH), 7.33 (4H, d, J = 4.4 Hz, 4 × ArH); 
13
C NMR (126 MHz, CDCl3)  47.0 (ArCH2), 55.2 (ArOCH3), 55.5 (ArOCH3), 75.8 
(CHOH), 98.3 (C-3’), 104.1 (C-5’), 116.7 (C-1’), 120.0 (CH Ar), 121.1 (CH Ar), 124.5 
(CH Ar), 126.7 (CH Ar), 127.9 (CH Ar), 128.7 (CH Ar), 129.7 (CH Ar), 131.1 (C-6’), 
143.4 (Cq Ar), 145.9 (Cq Ar), 150.6 (C-1), 158.6 (C-2’ or C-4’), 160.7 (C-2’ or C-4’); 
HRMS (ESI) calcd for C31H32NO8S [M-H]
-
 578.1843, found 578.1857. 
 
3-Benzoylphenyl bis(2,4-dimethoxybenzyl)sulfamate, (104) 
 
To 3-(hydroxy(phenyl)methyl)phenyl bis(2,4-dimethoxybenzyl)sulfamate (103) (462 mg, 
0.80 mmol) in DCM (15 mL) was added manganese oxide (693 mg, 7.97 mmol). The 
resulting solution was stirred at RT for 16 h. Upon completion, the heterogeneous mixture 
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was filtered through Celite and washed with DCM (20 mL). The filtrate was concentrated 
in vacuo. The crude product was purified by column chromatography (silica gel, 
petrol:EtOAc, 1:0  7:3) to yield the title compound as a clear oil (386 mg, 84%); 
Rf = 0.33 (petrol:EtOAc – 7:3); λmax (EtOH)/nm 252.0; IR (neat) νmax/cm
-1
 1735, 1660, 
1612, 1588, 1507, 1455, 1371, 1275, 1208, 1158, 1036; 
1
H NMR (500 MHz, CDCl3) 
δ 3.72 (6H, s, 2 × ArOCH3), 3.78 (6H, s, 2 × ArOCH3), 4.47 (4H, s, 2 × ArCH2), 6.37 (2H, 
d, J = 2.4 Hz, H-3’), 6.40 (2H, dd, J = 8.3, 2.4 Hz, H-5’), 7.25 (2H, d, J = 8.3 Hz, H-6’), 
7.39 – 7.35 (1H, m, H-4 or H-6), 7.45 – 7.41 (2H, m, H-2 and H-5), 7.53 – 7.47 (2H, m, 
H-3”, 5”), 7.65 – 7.57 (1H, m, H-4”), 7.66 (1H, ddd, J = 7.7, 1.3 and 1.3 Hz, H-4 or H-6), 
7.78 (2H, dd, J = 8.3, 1.4 Hz, H-2”, 6”); 13C NMR (126 MHz, CDCl3)  47.2 (ArCH2), 
55.2 (ArOCH3), 55.5 (ArOCH3), 98.4 (C-3’), 104.1 (C-5’), 116.5 (C-1’), 123.6 (C-2), 
126.1 (C-4 or C-6), 128.0 (C-4 or C-6), 128.5 (C-3”, 5”), 129.7 (C-5), 130.2 (C-2”, 6”), 
131.1 (C-6’), 132.9 (C-4”), 137.2 (Cq Ar), 139.2 (Cq Ar), 150.3 (C-1), 158.6 (C-2’ or 
C-4’), 160.8 (C-2’ or C-4’), 195.4 (CO); HRMS (ESI) calcd for C31H32NO8S [M+H]
+
 
578.1843, found 578.1839. 
 
3-Benzoylphenyl sulfamate, (105) 
 
Compound 105 was synthesised according to general procedure D, using the following 
reagents: 3-benzoylphenyl bis(2,4-dimethoxybenzyl)sulfamate (104) (200 mg, 0.35 mmol), 
DCM (3.2 mL) and TFA (0.4 mL). The crude product was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  65:35) to yield the title compound as a 
pale orange solid (84 mg, 87%); Rf = 0.33 (petrol:EtOAc, 65:35; KMnO4); m.p. 
68.5-70.5 °C; λmax (EtOH)/nm 252.0; IR (neat) νmax/cm
-1
 3358, 3257, 1648, 1577, 1439, 
1365, 1282, 1169, 1158; 
1
H NMR (500 MHz, DMSO-d6) δ 7.62 – 7.55 (3H, m, 3 × ArH), 
7.63 (1H, dd, J = 2.0, 2.0 Hz, H-2), 7.67 (1H, dd, J = 7.8, 7.8 Hz, H-5), 7.74 – 7.69 (2H, m, 
2 × ArH), 7.82 – 7.75 (2H, m, 2 × ArH), 8.11 (2H, s, ArOSO2NH2); 
13
C NMR (126 MHz, 
DMSO-d6) δ 123.2 (C-2), 126.7 (CH Ar), 127.8 (CH Ar), 128.7 (CH Ar), 129.7 (CH Ar), 
130.3 (CH Ar), 133.0 (CH Ar), 136.5 (Cq Ar), 138.5 (Cq Ar), 149.9 (C-1), 194.6 (CO); 
LRMS (ES
-
) m/z 276.2 [M-H]
-
; HRMS (ESI) calcd for C13H12NO4S [M+H]
+
 278.0482, 
found 278.0482. 
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3-((tert-Butoxycarbonyl)amino)phenyl 2-methyl-1H-imidazole-1-sulfonate, (107) 
 
Compound 107 was synthesised according to general procedure B, using the following 
reagents: 1,1'-sulfonylbis(2-methyl-1H-imidazole) (19) (216 mg, 0.96 mmol), caesium 
carbonate (171 mg, 0.53 mmol), N-Boc-3-aminophenol (100 mg, 0.48 mmol) and 
acetonitrile (5 mL). The crude yellow oil was purified by column chromatography (silica 
gel, petrol:EtOAc, 1:0  8:2) to yield the title compound as a pale yellow solid (142 mg, 
84%); Rf = 0.30 (petrol:EtOAc, 8:2; KMnO4); m.p. 108.0-110.0 °C; λmax (EtOH)/nm 276.0; 
IR (neat) νmax/cm
-1
 1724, 1601, 1556, 1494, 1425, 1204, 1152, 1049; 
1
H NMR (500 MHz, 
CDCl3) δ 1.51 (9H, s, C(CH3)3), 2.48 (3H, s, CH3), 6.54 – 6.47 (1H, m, H-6), 6.57 (1H, s, 
ArNHBoc), 6.88 (1H, d, J = 1.7 Hz, H-4’ or H-5’), 7.18 – 7.10 (2H, m, H-4’ or H-5’ and 
H-2), 7.23 (1H, dd, J = 8.2, 7.9 Hz, H-5), 7.32 (1H, d, J = 7.9 Hz, H-4); 
13
C NMR 
(126 MHz, CDCl3)  15.1 (CH3), 28.4 (C(CH3)3), 81.5 (C(CH3)3), 111.6 (C-2), 115.3 
(C-6), 118.0 (C-4), 120.5 (C-4’ or C-5’), 128.0 (C-4’ or C-5’), 130.5 (C-5), 140.5 (C-3), 
146.9 (C-1 or C-2’), 149.5 (C-1 or C-2’), 152.2 (HNCO2); LRMS (ES
+
) m/z 354.6 [M+H]
+
; 
HRMS (ESI) calcd for C15H20N3O5S [M+H]
+
 354.1118, found 354.1124. 
 
3-((tert-Butoxycarbonyl)amino)phenyl bis(2,4-dimethoxybenzyl)sulfamate, (108) 
 
Compound 108 was synthesised according to general procedure H, using the following 
reagents: 3-((tert-butoxycarbonyl)amino)phenyl 2-methyl-1H-imidazole-1-sulfonate (107) 
(300 mg, 0.85 mmol), trimethyloxonium tetrafluoroborate (126 mg, 0.85 mmol), DCM 
(8.5 mL), acetonitrile (4.3 mL) and bis(2,4-dimethoxybenzyl)amine (32) (270 mg, 
0.85 mmol). The crude product was purified by column chromatography (silica gel, 
petrol:EtOAc – 1:0  3:1) to yield the title compound as a pale yellow oil (290 mg, 58%); 
Rf = 0.28 (petrol:EtOAc, 3:1; KMnO4); λmax (EtOH)/nm 277.0; IR (neat) νmax/cm
-1
 1727, 
1613, 1591, 1508, 1367, 1208, 1155, 1129, 1035; 
1
H NMR (500 MHz, CDCl3) δ 1.52 (9H, 
s, C(CH3)3), 3.71 (6H, s, 2 × ArOCH3), 3.80 (6H, s, 2 × ArOCH3), 4.45 (4H, s, 
2 × ArCH2), 6.37 (2H, d, J = 2.4 Hz, H-3’), 6.43 (2H, dd, J = 8.4, 2.4 Hz, H-5’), 6.79 (1H, 
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ddd, J = 8.1, 2.3 and 1.0 Hz, H-6), 7.03 (1H, dd, J = 2.4, 2.3 Hz, H-2), 7.20 (1H, dd, 
J = 8.4, 8.1 Hz, H-5), 7.26 (2H, d, J = 8.4 Hz, H-6’), 7.31 – 7.27 (1H, m, H-4); 13C NMR 
(126 MHz, CDCl3)  28.4 (C(CH3)3), 47.0 (ArCH2), 55.2 (ArOCH3), 55.5 (ArOCH3), 81.0 
(C(CH3)3), 98.2 (C-3’), 104.1 (C-5’), 112.2 (C-2), 116.2 (C-4 or C-6), 116.3 (C-4 or C-6), 
116.8 (C-1’), 129.9 (C-5), 131.1 (C-6’), 139.6 (C-3), 150.9 (C-1), 152.4 (HNCO2), 158.6 
(C-2’ or C-4’), 160.7 (C-2’ or C-4’); LRMS (ES-) m/z 587.4 [M-H]-; HRMS (ESI) calcd 
for C29H40N3O9S [M+NH4]
+
 606.2480, found 606.2476. 
 
3-((tert-Butoxycarbonyl)amino)phenyl bis(4-methoxybenzyl)sulfamate, (109) 
 
Compound 109 was synthesised according to general procedure H, using the following 
reagents: 3-((tert-butoxycarbonyl)amino)phenyl 2-methyl-1H-imidazole-1-sulfonate (107) 
(350 mg, 0.99 mmol), trimethyloxonium tetrafluoroborate (146 mg, 0.99 mmol), DCM 
(9.9 mL), acetonitrile (5.0 mL) and bis(4-methoxybenzyl)amine (31) (255 mg, 0.99 mmol). 
The crude product was purified by column chromatography (silica gel, petrol:EtOAc, 
1:0  85:15) to yield the title compound as a pale yellow oil (365 mg, 70%); Rf = 0.33 
(petrol:EtOAc, 85:15; KMnO4); λmax (EtOH)/nm 274.5; IR (neat) νmax/cm
-1
 1727, 1612, 
1513, 1367, 1246, 1156, 1032; 
1
H NMR (500 MHz, CDCl3) δ 1.52 (9H, s, C(CH3)3), 3.82 
(6H, s, 2 × ArOCH3), 4.32 (4H, s, 2 × ArCH2), 6.47 (1H, s, ArNHBoc), 6.86 (5H, d, 
J = 8.7 Hz, H-3’, 5’ and ArH), 7.20 (4H, d, J = 8.7 Hz, H-2’, 6’), 7.21 – 7.25 (3H, m, 
3 × ArH); 
13
C NMR (126 MHz, CDCl3)  28.4 (C(CH3)3), 50.4 (ArCH2), 55.4 (ArOCH3), 
112.2 (CH Ar), 114.1 (C-3’, 5’), 116.2 (CH Ar), 116.5 (CH Ar), 127.0 (C-1’), 130.0 
(CH Ar), 130.6 (C-2’, 6’), 139.8 (C-3), 150.8 (C-1), 152.4 (HNCO2), 159.6 (C-4’); 
LRMS (ES
-
) m/z 527.3 [M-H]
-
; HRMS (ESI) calcd for C27H36N3O7S [M+NH4]
+
 546.2268, 
found 546.2256. 
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3-Aminophenyl sulfamate, (110) 
 
Compound 110 was synthesised following two different procedures. 
1
st
 procedure: Compound 110 was synthesised according to general procedure D, using the 
following reagents: 3-((tert-butoxycarbonyl)amino)phenyl bis(2,4-dimethoxybenzyl) 
sulfamate (108) (150 mg, 0.25 mmol), DCM (2.3 mL) and TFA (0.3 mL). The crude 
product was purified by column chromatography (silica gel, DCM:MeOH, 1:0  96:4) to 
yield the title compound as a white solid (34 mg, 70%). 
2
nd
 procedure: Compound 110 was synthesised according to general procedure E, using the 
following reagents: 3-aminophenyl bis(4-methoxybenzyl)sulfamate (111) (200 mg, 
0.47 mmol), DCM (2.4 mL) and TFA (2.4 mL). The crude product was purified by column 
chromatography ( silica gel, DCM:MeOH, 1:0  96:4) to yield the title compound as a 
white solid (78 mg, 88%); Rf = 0.30 (DCM:MeOH, 96:4; ninhydrin); m.p. 95.0-97.0 °C; 
λmax (EtOH)/nm 238.5, 288.5; IR (neat) νmax/cm
-1
 3409, 3328, 1612, 1488, 1357, 1187, 
1126; 
1
H NMR (500 MHz, DMSO-d6) δ 5.34 (2H, s, ArNH2), 6.38 (1H, d, J = 8.1 Hz, H-4 
or H-6), 6.57 – 6.41 (2H, m, H-2 and H-4 or H-6), 7.03 (1H, dd, J = 8.1, 8.0 Hz, H-5), 7.84 
(2H, s, ArOSO2NH2); 
13
C NMR (126 MHz, DMSO-d6) δ 107.1 (CH Ar), 108.7 (CH Ar), 
111.9 (CH Ar), 129.6 (C-5), 150.2 (C-1 or C-3), 151.2 (C-1 or C-3); LRMS (ES
+
) m/z 
189.1 [M+H]
+
; HRMS (ESI) calcd for C6H9N2O3S [M+H]
+
 189.0328, found 189.0328. 
 
3-Aminophenyl bis(4-methoxybenzyl)sulfamate, (111) 
 
3-((tert-butoxycarbonyl)amino)phenyl bis(4-methoxybenzyl)sulfamate (109) (300 mg, 
0.57 mmol) was dissolved in a 10% TFA/DCM mixture (5 mL). The resulting solution was 
stirred at RT for 2 h. Upon completion, the solvent was removed in vacuo. The crude 
residue was dissolved in EtOAc (20 mL), washed with saturated aq. NaHCO3 (20 mL) and 
extracted with EtOAc (3 × 25 mL). The pooled organic extracts were washed with water 
(30 mL) and brine (30 mL), dried over MgSO4 and concentrated in vacuo. The crude 
product was purified by column chromatography (silica gel, petrol:EtOAc, 1:0  7:3) to 
yield the title compound as a pale yellow oil (230 mg, 94%); Rf = 0.28 (petrol:EtOAc, 7:3; 
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ninhydrin); λmax (EtOH)/nm 275.0, 281.5; IR (neat) νmax/cm
-1
 1611, 1585, 1512, 1491, 
1365, 1246, 1173, 1030; 
1
H NMR (500 MHz, CDCl3) δ 3.73 (2H, s, ArNH2), 3.82 (6H, s, 
2 × ArOCH3), 4.30 (4H, s, 2 × ArCH2), 6.46 (1H, dd, J = 2.3, 2.3 Hz, H-2), 6.53 (1H, ddd, 
J = 8.1, 2.3 and 0.8 Hz, H-4 or H-6), 6.56 (1H, ddd, J = 8.2, 2.3 and 0.8 Hz, H-4 or H-6), 
6.87 (4H, d, J = 8.7 Hz, H-3’, 5’), 7.09 (1H, dd, J = 8.2, 8.1 Hz, H-5), 7.20 (4H, d, 
J = 8.7 Hz, H-2’, 6’); 13C NMR (126 MHz, CDCl3)  50.4 (ArCH2), 55.4 (ArOCH3), 108.4 
(C-2), 111.5 (C-4 or C-6), 113.4 (C-4 or C-6), 114.1 (C-3’, 5’), 127.1 (C-1’), 130.3 (C-5), 
130.5 (C-2’, 6’), 148.0 (C-1 or C-3), 151.5 (C-1 or C-3), 159.6 (C-4’); LRMS (ES+) m/z 
429.4 [M+H]
+
; HRMS (ESI) calcd for C22H25N2O5S [M+H]
+
 429.1479, found 429.1476. 
 
1-(2,4-Dimethoxyphenyl)-N-methylmethanamine, (115) 
 
Compound 115 was synthesised according to general procedure F, using the following 
reagents: methylamine 8.03 M in EtOH (2.25 mL, 18.1 mmol), 2,4-dimethoxy 
benzaldehyde (3.0 g, 18.1 mmol), sodium borohydride (0.75 g, 19.9 mmol) and ethanol 
(9 mL). The crude product was purified by column chromatography (silica gel, 
DCM:MeOH:NH3, 1:0:0  90:9:1) to yield the title compound as a yellow liquid (0.82 g, 
25%); Rf = 0.22 (DCM:MeOH:NH3, 90:9:1; ninhydrin); λmax (EtOH)/nm 276.5; IR (neat) 
νmax/cm
-1
 1612, 1588, 1505, 1462, 1288, 1206, 1154, 1034; 
1
H NMR (500 MHz, CDCl3) 
δ 2.03 (1H, s, CH2NHCH3), 2.40 (3H, s, NHCH3), 3.68 (2H, s, ArCH2NH), 3.80 (3H, s, 
ArOCH3), 3.81 (3H, s, ArOCH3), 6.43 (1H, dd, J = 8.1, 2.4 Hz, H-5), 6.45 (1H, d, 
J = 2.4 Hz, H-3), 7.12 (1H, d, J = 8.1 Hz, H-6); 
13
C NMR (126 MHz, CDCl3)  35.8 
(NHCH3), 50.9 (ArCH2NH), 55.4 (ArOCH3), 55.5 (ArOCH3), 98.6 (C-3), 103.7 (C-5), 
120.7 (C-1), 130.7 (C-6), 158.8 (C-2 or C-4), 160.2 (C-2 or C-4); HRMS (ESI) calcd for 
C10H16NO2 [M+H]
+
 182.1176, found 182.1173; 
1
H NMR data were identical to literature 
data.
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1-(4-Methoxyphenyl)-N-methylmethanamine, (116) 
 
Compound 116 was synthesised according to general procedure F, using the following 
reagents: methylamine 8.03 M in EtOH (3.07 mL, 24.7 mmol), 4-methoxybenzaldehyde 
(3.0 mL, 3.36 g, 24.7 mmol), sodium borohydride (1.03 g, 27.1 mmol) and ethanol 
(12 mL). The crude product was purified by column chromatography (silica gel, 
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DCM:MeOH:NH3, 1:0:0  90:9:1) to yield the title compound as a clear liquid (0.90 g, 
24%); Rf = 0.24 (DCM:MeOH:NH3, 90:9:1; ninhydrin); λmax (EtOH)/nm 275.0; IR (neat) 
νmax/cm
-1
 1612, 1511, 1464, 1242, 1175, 1034; 
1
H NMR (500 MHz, CDCl3) δ 1.18 (1H, s, 
CH2NHCH3), 2.44 (3H, s, NHCH3), 3.68 (2H, s, ArCH2NH), 3.80 (3H, s, ArOCH3), 6.86 
(2H, d, J = 8.8 Hz, H-3, 5), 7.23 (2H, d, J = 8.8 Hz, H-2, 6); 
13
C NMR (126 MHz, CDCl3) 
 36.1 (NHCH3), 55.4 (ArOCH3), 55.7 (ArCH2NH), 113.9 (C-3, 5), 129.4 (C-2, 6), 132.6 
(C-1), 158.7 (C-4); 
1
H NMR and 
13
C NMR data were identical to literature data.
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N-(2,4-Dimethoxybenzyl)-2-methylpropan-1-amine, (117) 
 
Compound 117 was synthesised according to general procedure F, using the following 
reagents: isobutylamine (1.80 mL, 1.32 g, 18.1 mmol), 2,4-dimethoxybenzaldehyde (3.0 g, 
18.1 mmol), sodium borohydride (0.75 g, 19.9 mmol) and ethanol (9 mL). The crude 
product was purified by column chromatography (silica gel, EtOAc:MeOH, 1:0  95:5) to 
yield the title compound as a clear liquid (2.80 g, 69%); Rf = 0.25 (EtOAc:MeOH, 95:5; 
ninhydrin); λmax (EtOH)/nm 276.5; IR (neat) νmax/cm
-1
 1613, 1589, 1506, 1463, 1287, 
1207, 1153, 1037; 
1
H NMR (500 MHz, CDCl3) δ 0.89 (6H, d, J = 6.6 Hz, CH(CH3)2), 1.49 
(1H, s, CH2NHCH2), 1.81 – 1.72 (1H, m, CH(CH3)2), 2.38 (2H, d, J = 6.8 Hz, NHCH2CH), 
3.70 (2H, s, ArCH2NH), 3.80 (3H, s, ArOCH3), 3.81 (3H, s, ArOCH3), 6.43 (1H, dd, 
J = 8.1, 2.4 Hz, H-5), 6.45 (1H, d, J = 2.4 Hz, H-3), 7.13 (1H, d, J = 8.1 Hz, H-6); 
13
C NMR (126 MHz, CDCl3)  20.8 (CH(CH3)2), 28.4 (CH(CH3)2), 49.2 (ArCH2NH), 55.4 
(ArOCH3), 55.5 (ArOCH3), 57.4 (CHCH2NH), 98.6 (C-3), 103.7 (C-5), 121.4 (C-1), 130.4 
(C-6), 158.7 (C-2 or C-4), 160.0 (C-2 or C-4); HRMS (ESI) calcd for C13H22NO2 [M+H]
+
 
224.1645, found 224.1647. 
 
N-Benzyl-1-(2,4-dimethoxyphenyl)methanamine, (118) 
 
Compound 118 was synthesised according to general procedure F, using the following 
reagents: benzylamine (1.97 mL, 1.93 g, 18.1 mmol), 2,4-dimethoxybenzaldehyde (3.0 g, 
18.1 mmol), sodium borohydride (0.75 g, 19.9 mmol) and ethanol (9 mL). The crude 
product was purified by column chromatography (silica gel, petrol:EtOAc, 1:0  1:1) to 
yield the title compound as a clear oil (3.12 g, 67%); Rf = 0.33 (petrol:EtOAc, 1:1; 
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ninhydrin); λmax (EtOH)/nm 276.5; IR (neat) νmax/cm
-1
 1612, 1588, 1506, 1453, 1287, 
1207, 1155, 1034; 
1
H NMR (500 MHz, CDCl3) δ 1.82 (1H, s, CH2NHCH2), 3.75 (2H, s, 
ArCH2NH), 3.77 (2H, s, ArCH2NH), 3.81 (3H, s, ArOCH3), 3.81 (3H, s, ArOCH3), 6.44 
(1H, dd, J = 8.1, 2.4 Hz, H-5), 6.47 (1H, d, J = 2.4 Hz, H-3), 7.14 (1H, d, J = 8.1 Hz, H-6), 
7.26 – 7.21 (1H, m, H-4’), 7.38 – 7.29 (4H, m, 4 × ArH); 13C NMR (126 MHz, CDCl3) 
 48.5 (ArCH2), 53.1 (ArCH2), 55.4 (ArOCH3), 55.5 (ArOCH3), 98.7 (C-3), 103.7 (C-5), 
121.0 (Cq Ar), 126.9 (C-4’), 128.3 (CH Ar), 128.4 (CH Ar), 130.6 (C-5), 140.8 (Cq Ar), 
158.8 (C-2 or C-4), 160.2 (C-2 or C-4); HRMS (ESI) calcd for C16H20NO4 [M+H]
+
 
258.1489, found 258.1486. 
 
4-Bromophenyl 2,4-dimethoxybenzyl(methyl)sulfamate, (119) 
 
Compound 119 was synthesised according to general procedure A, using the following 
reagents: 1-((4-bromophenoxy)sulfonyl)-2,3-dimethyl-1H-imidazol-3-ium 
tetrafluoroborate (22) (600 mg, 1.43 mmol), 1-(2,4-dimethoxyphenyl)-N-
methylmethanamine (115) (260 mg, 1.43 mmol) and acetonitrile (11.5 mL). The crude 
product was purified by column chromatography (silica gel, petrol:EtOAc, 1:0  85:15) to 
yield the title compound as a clear oil (566 mg, 95%); Rf = 0.32 (petrol:EtOAc, 85:15; 
KMnO4); λmax (EtOH)/nm 277.0; IR (neat) νmax/cm
-1
 1613, 1589, 1509, 1481, 1372, 1197, 
1155, 1034; 
1
H NMR (500 MHz, CDCl3) δ 2.87 (3H, s, NCH3), 3.80 (3H, s, ArOCH3), 
3.82 (3H, s, ArOCH3), 4.40 (2H, s, ArCH2), 6.49 – 6.44 (2H, m, H-3’ and H-5’), 7.12 (2H, 
d, J = 8.9 Hz, H-2, 6), 7.21 (1H, d, J = 8.2 Hz, H-6’), 7.48 (2H, d, J = 8.9 Hz, H-3, 5); 
13
C NMR (126 MHz, CDCl3)  35.8 (NCH3), 49.3 (ArCH2), 55.5 (ArOCH3), 55.6 
(ArOCH3), 98.6 (C-3’), 104.5 (C-5’), 115.6 (C-1’), 120.0 (C-4), 123.8 (C-2, 6), 131.5 
(C-6’), 132.9 (C-3, 5), 149.5 (C-1), 158.8 (C-2’ or C-4’), 161.2 (C-2’ or C-4’); HRMS 
(ESI) calcd for C16H22BrN2O5S [M+NH4]
+
 433.0427, found 433.0422. 
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4-Bromophenyl 4-methoxybenzyl(methyl)sulfamate, (120) 
 
Compound 120 was synthesised according to general procedure A, using the following 
reagents: 1-((4-bromophenoxy)sulfonyl)-2,3-dimethyl-1H-imidazol-3-ium 
tetrafluoroborate (22) (600 mg, 1.43 mmol), 1-(4-methoxyphenyl)-N-methylmethanamine 
(116) (217 mg, 1.43 mmol) and acetonitrile (11.5 mL). The crude product was purified by 
column chromatography (silica gel, petrol:EtOAc, 1:0  85:15) to yield the title 
compound as a white solid (532 mg, 96%); Rf = 0.34 (petrol:EtOAc, 85:15; KMnO4); 
m.p. 65.0-67.0 °C; λmax (EtOH)/nm 274.0; IR (neat) νmax/cm
-1
 1613, 1585, 1512, 1483, 
1368, 1197, 1153; 
1
H NMR (500 MHz, CDCl3) δ 2.83 (3H, s, NCH3), 3.82 (3H, s, 
ArOCH3), 4.35 (2H, s, ArCH2), 6.89 (2H, d, J = 8.7 Hz, H-3’, 5’), 7.15 (2H, d, J = 8.9 Hz, 
H-2, 6), 7.23 (2H, d, J = 8.7 Hz, H-2’, 6’), 7.51 (2H, d, J = 8.9 Hz, H-3, 5); 13C NMR 
(126 MHz, CDCl3)  35.2 (NCH3), 54.8 (ArCH2), 55.5 (ArOCH3), 114.3 (C-3’, 5’), 120.2 
(C-4 or C-1’), 123.8 (C-2, 6), 126.8 (C-4 or C-1’), 130.1 (C-2’, 6’), 133.0 (C-3, 5), 149.4 
(C-1), 159.8 (C-4’); HRMS (ESI) calcd for C15H20BrN2O4S [M+NH4]
+
 403.0322, found 
403.0328. 
 
4-Bromophenyl 2,4-dimethoxybenzyl(isobutyl)sulfamate, (121) 
 
Compound 121 was synthesised according to general procedure A, using the following 
reagents: 1-((4-bromophenoxy)sulfonyl)-2,3-dimethyl-1H-imidazol-3-ium 
tetrafluoroborate (22) (600 mg, 1.43 mmol), N-(2,4-dimethoxybenzyl)-2-methylpropan-1-
amine (117) (321 mg, 1.43 mmol) and acetonitrile (11.5 mL). The crude product was 
purified by column chromatography (silica gel, petrol:EtOAc, 1:0  9:1) to yield the title 
compound as a clear oil (560 mg, 85%); Rf = 0.27 (petrol:EtOAc, 9:1; KMnO4); 
λmax (EtOH)/nm 277.0; IR (neat) νmax/cm
-1
 1613, 1588, 1509, 1482, 1368, 1197, 1154, 
1033; 
1
H NMR (500 MHz, CDCl3) δ 0.88 (6H, d, J = 6.7 Hz, CH(CH3)2), 2.02 – 1.89 (1H, 
m, CH(CH3)2), 3.04 (2H, d, J = 7.5 Hz, NCH2CH), 3.81 (3H, s, ArOCH3), 3.82 (3H, s, 
ArOCH3), 4.50 (2H, s, ArCH2), 6.49 – 6.43 (2H, m, H-3’ and H-5’), 7.01 (2H, d, 
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J = 8.9 Hz, H-2, 6), 7.33 (1H, d, J = 8.2 Hz, H-6’), 7.43 (2H, d, J = 8.9 Hz, H-3, 5); 
13
C NMR (126 MHz, CDCl3)  20.0 (CH(CH3)2), 27.0 (CH(CH3)2), 47.1 (ArCH2), 55.4 
(ArOCH3), 55.6 (ArOCH3), 56.5 (CH2CH), 98.4 (C-3’), 104.4 (C-5’), 116.2 (C-1’), 119.7 
(C-4), 123.7 (C-2, 6), 132.4 (C-6’), 132.7 (C-3, 5), 149.6 (C-1), 158.8 (C-2’ or C-4’), 161.1 
(C-2’ or C-4’); HRMS (ESI) calcd for C19H28BrN2O5S [M+NH4]
+
 475.0897, found 
475.0887. 
 
4-Bromophenyl benzyl(2,4-dimethoxybenzyl)sulfamate, (122) 
 
Compound 122 was synthesised according to general procedure A, using the following 
reagents: 1-((4-bromophenoxy)sulfonyl)-2,3-dimethyl-1H-imidazol-3-ium 
tetrafluoroborate (22) (600 mg, 1.43 mmol), N-benzyl-1-(2,4-
dimethoxyphenyl)methanamine (118) (369 mg, 1.43 mmol) and acetonitrile (11.5 mL). 
The crude product was purified by column chromatography (silica gel, petrol:EtOAc, 
1:0  85:15) to yield the title compound as a clear oil (629 mg, 89%); Rf = 0.33 
(petrol:EtOAc, 85:15; KMnO4); λmax (EtOH)/nm 277.0; IR (neat) νmax/cm
-1
 1613, 1588, 
1509, 1481, 1370, 1196, 1155, 1039; 
1
H NMR (500 MHz, CDCl3) δ 3.77 (3H, s, ArOCH3), 
3.82 (3H, s, ArOCH3), 4.39 (2H, s, ArCH2), 4.41 (2H, s, ArCH2), 6.42 (1H, d, J = 2.3 Hz, 
H-3’), 6.45 (1H, dd, J = 8.3, 2.3 Hz, H-5’), 6.91 (2H, d, J = 8.9 Hz, H-2, 6), 7.26 (1H, d, J 
= 8.3 Hz, H-6’), 7.35 – 7.28 (5H, m, 5 × ArH), 7.39 (2H, d, J = 8.9 Hz, H-3, 5); 13C NMR 
(126 MHz, CDCl3)  46.1 (ArCH2), 52.1 (ArCH2), 55.3 (ArOCH3), 55.6 (ArOCH3), 98.4 
(C-3’), 104.4 (C-5’), 115.8 (Cq Ar), 119.9 (Cq Ar), 123.9 (C-2, 6), 128.0 (CH Ar), 128.6 
(CH Ar), 128.7 (CH Ar), 132.4 (C-6’), 132.7 (C-3, 5), 135.8 (Cq Ar), 149.4 (C-1), 158.8 
(C-2’ or C-4’), 161.2 (C-2’ or C-4’); HRMS (ESI) calcd for C22H26BrN2O5S [M+NH4]
+
 
509.0740, found 509.0739. 
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[1,1'-Biphenyl]-4-yl 2,4-dimethoxybenzyl(methyl)sulfamate, (123) 
 
Compound 123 was synthesised according to general procedure C, using the following 
reagents: 4-bromophenyl 2,4-dimethoxybenzyl(methyl)sulfamate (119) (400 mg, 
0.96 mmol), potassium carbonate (398 mg, 2.88 mmol), phenyl boronic acid (176 mg, 
1.44 mmol), tetrakis(triphenylphosphine)palladium(0) (111 mg, 0.10 mmol) and 
acetonitrile (19 mL). The crude product was purified by column chromatography (silica 
gel, petrol:EtOAc, 1:0  85:15) to yield the title compound as a yellow oil (358 mg, 90%); 
Rf = 0.34 (petrol:EtOAc, 85:15); λmax (EtOH)/nm 251.0; IR (neat) νmax/cm
-1
 1613, 1591, 
1509, 1485, 1371, 1207, 1154, 1034; 
1
H NMR (500 MHz, CDCl3) δ 2.90 (3H, s, NCH3), 
3.80 (3H, s, ArOCH3), 3.81 (3H, s, ArOCH3), 4.43 (2H, s, ArCH2), 6.49 – 6.44 (2H, m, 
H-3” and H-5”), 7.25 (1H, d, J = 8.1 Hz, H-6”), 7.33 (2H, d, J = 8.7 Hz, H-3, 5), 7.39 – 
7.35 (1H, m, H-4’), 7.45 (2H, dd, J = 7.6, 7.6 Hz, H-3’, 5’), 7.61 – 7.54 (4H, m, H-2, 6 and 
H-2’, 6’); 13C NMR (126 MHz, CDCl3)  35.8 (NCH3), 49.2 (ArCH2), 55.5 (ArOCH3), 
55.5 (ArOCH3), 98.6 (C-3”), 104.5 (C-5”), 115.8 (C-1”), 122.3 (C-3, 5), 127.2 (C-2, 6 or 
C-2’, 6’), 127.7 (C-4’), 128.5 (C-2, 6 or C-2’, 6’), 129.0 (C-3’, 5’), 131.5 (C-6”), 139.9 
(C-1 or C-1’), 140.2 (C-1 or C-1’), 149.9 (C-4), 158.9 (C-2” or C-4”), 161.1 (C-2” or 
C-4”); HRMS (ESI) calcd for C22H27N2O5S [M+NH4]
+
 431.1635, found 431.1638. 
 
[1,1'-Biphenyl]-4-yl 4-methoxybenzyl(methyl)sulfamate, (124) 
 
Compound 124 was synthesised according to general procedure C, using the following 
reagents: 4-bromophenyl 4-methoxybenzyl(methyl)sulfamate (120) (400 mg, 1.04 mmol), 
potassium carbonate (429 mg, 3.11 mmol), phenyl boronic acid (189 mg, 1.55 mmol), 
tetrakis(triphenylphosphine)palladium(0) (120 mg, 0.10 mmol) and acetonitrile (20 mL). 
The crude product was purified by column chromatography (silica gel, petrol:EtOAc, 
1:0  85:15) to yield the title compound as a yellow solid (345 mg, 87%); Rf = 0.35 
(petrol:EtOAc, 85:15); m.p. 103.5-105.5 °C; λmax (EtOH)/nm 251.0; IR (neat) νmax/cm
-1
 
1609, 1594, 1512, 1485, 1460, 1373, 1180, 1151, 1032; 
1
H NMR (500 MHz, CDCl3) 
δ 2.86 (3H, s, NCH3), 3.81 (3H, s, ArOCH3), 4.38 (2H, s, ArCH2), 6.88 (2H, d, J = 8.6 Hz, 
221 
H-3”, 5”), 7.25 (2H, d, J = 8.6 Hz, H-2”, 6”), 7.40 – 7.33 (3H, m, H-4’ and H-3, 5), 7.45 
(2H, dd, J = 7.6, 7.6 Hz, H-3’, 5’), 7.57 (2H, dd, J = 7.6, 1.2 Hz, H-2’, 6’), 7.61 (2H, d, 
J = 8.8 Hz, H-2, 6); 
13
C NMR (126 MHz, CDCl3)  35.2 (NCH3), 54.8 (ArCH2), 55.4 
(ArOCH3), 114.2 (C-3”, 5”), 122.3 (C-3, 5), 127.0 (C-1”), 127.3 (C-2’, 6’), 127.7 (C-4’), 
128.6 (C-2, 6), 129.0 (C-3’, 5’), 130.1 (C-2”, 6”), 140.1 (C-1 or C-1’), 140.1 (C-1 or C-1’), 
149.8 (C-4), 159.7 (C-4”); HRMS (ESI) calcd for C21H25N2O4S [M+NH4]
+
 401.1530, 
found 401.1533. 
 
[1,1'-Biphenyl]-4-yl 2,4-dimethoxybenzyl(isobutyl)sulfamate, (125) 
 
Compound 125 was synthesised according to general procedure C, using the following 
reagents: 4-bromophenyl 2,4-dimethoxybenzyl(isobutyl)sulfamate (121) (400 mg, 
0.87 mmol), potassium carbonate (362 mg, 2.62 mmol), phenyl boronic acid (160 mg, 
1.31 mmol), tetrakis(triphenylphosphine)palladium(0) (101 mg, 0.09 mmol) and 
acetonitrile (17 mL). The crude product was purified by column chromatography (silica 
gel, petrol:EtOAc, 1:0  85:15) to yield the title compound as a clear oil (340 mg, 85%); 
Rf = 0.36 (petrol:EtOAc, 85:15); λmax (EtOH)/nm 252.0; IR (neat) νmax/cm
-1
 1613, 1592, 
1509, 1485, 1366, 1208, 1152, 1032; 
1
H NMR (500 MHz, CDCl3) δ 0.89 (6H, d, 
J = 6.7 Hz, CH(CH3)2), 2.02 – 1.92 (1H, m, CH(CH3)2), 3.09 (2H, d, J = 7.4 Hz, 
NCH2CH), 3.80 (3H, s, ArOCH3), 3.82 (3H, s, ArOCH3), 4.54 (2H, s, ArCH2), 6.46 (1H, d, 
J = 2.4 Hz, H-3”), 6.48 (1H, dd, J = 8.3, 2.4 Hz, H-5”), 7.23 (2H, d, J = 8.7 Hz, H-3, 5), 
7.37 – 7.32 (1H, m, H-4’), 7.39 (1H, d, J = 8.3 Hz, H-6”), 7.44 (2H, dd, J = 7.6, 7.6 Hz, 
H-3’, 5’), 7.58 – 7.51 (4H, m, H-2, 6 and H-2’, 6’); 13C NMR (126 MHz, CDCl3)  20.1 
(CH(CH3)2), 27.0 (CH(CH3)2), 47.1 (ArCH2), 55.4 (ArOCH3), 55.5 (ArOCH3), 56.5 
(CH2CH), 98.4 (C-3”), 104.4 (C-5”), 116.3 (C-1”), 122.2 (C-3, 5), 127.2 (C-2, 6 or C-2’, 
6’), 127.6 (C-6”), 128.4 (C-2, 6 or C-2’, 6’), 129.0 (C-3’, 5’), 132.3 (C-4’), 139.6 (C-1 or 
C-1’), 140.2 (C-1 or C-1’), 150.0 (C-4), 158.8 (C-2” or C-4”), 161.0 (C-2” or C-4”); 
HRMS (ESI) calcd for C25H29NO5Na [M+Na]
+
 478.1659, found 478.1653. 
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[1,1'-Biphenyl]-4-yl benzyl(2,4-dimethoxybenzyl)sulfamate, (126) 
 
Compound 126 was synthesised according to general procedure C, using the following 
reagents: 4-bromophenyl benzyl(2,4-dimethoxybenzyl)sulfamate (122) (400 mg, 
0.81 mmol), potassium carbonate (337 mg, 2.44 mmol), phenyl boronic acid (149 mg, 
1.22 mmol), tetrakis(triphenylphosphine)palladium(0) (94 mg, 0.08 mmol) and acetonitrile 
(16 mL). The crude product was purified by column chromatography (silica gel, 
petrol:EtOAc, 1:0  85:15) to yield the title compound as a pale yellow oil (350 mg, 
87%); Rf = 0.35 (petrol:EtOAc, 85:15); λmax (EtOH)/nm 251.5; IR (neat) νmax/cm
-1
 1613, 
1591, 1509, 1485, 1369, 1208, 1154, 1039; 
1
H NMR (500 MHz, CDCl3) δ 3.76 (3H, s, 
ArOCH3), 3.79 (3H, s, ArOCH3), 4.44 (2H, s, ArCH2), 4.45 (2H, s, ArCH2), 6.42 (1H, d, 
J = 2.3 Hz, H-3”), 6.45 (1H, dd, J = 8.4, 2.3 Hz, H-5”), 7.14 (2H, d, J = 8.3 Hz, H-3, 5), 
7.39 – 7.27 (7H, m, 5 × ArH and H-4’ and H-6”), 7.44 (2H, dd, J = 7.6, 7.6 Hz, H-3’, 5’), 
7.51 (2H, d, J = 8.3 Hz, H-2, 6), 7.55 (2H, d, J = 7.6 Hz, H-2’, 6’); 13C NMR (126 MHz, 
CDCl3)  46.0 (ArOCH3), 52.1 (ArOCH3), 55.3 (ArCH2), 55.5 (ArCH2), 98.4 (C-3”), 104.4 
(C-5”), 116.0 (C-1”), 122.3 (C-3, 5), 127.2 (C-2’, 6’), 127.6 (CH Ar), 127.9 (CH Ar), 
128.4 (CH Ar), 128.5 (C-2, 6), 128.7 (CH Ar), 129.0 (C-3’, 5’), 132.4 (C-6”), 136.0 
(Cq Ar), 139.7 (C-1 or C-1’), 140.2 (C-1 or C-1’), 149.8 (C-4), 158.8 (C-2” or C-4”), 161.1 
(C-2” or C-4”); HRMS (ESI) calcd for C28H31N2O5S [M+NH4]
+
 507.1948, found 
507.1947. 
 
[1,1'-Biphenyl]-4-yl methylsulfamate, (127) 
 
Compound 127 was synthesised following two different procedures. 
1
st
 procedure: Compound 127 was synthesised according to general procedure D, using the 
following reagents: [1,1'-biphenyl]-4-yl 2,4-dimethoxybenzyl(methyl)sulfamate (123) 
(250 mg, 0.60 mmol), DCM (5.4 mL) and TFA (0.6 mL). The crude product was purified 
by column chromatography (silica gel, petrol:EtOAc, 1:0  8:2) to yield the title 
compound as a pale yellow solid (151 mg, 95%). 
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2
nd
 procedure: Compound 127 was synthesised according to general procedure E, using the 
following reagents: [1,1'-biphenyl]-4-yl 4-methoxybenzyl(methyl)sulfamate (124) 
(250 mg, 0.65 mmol), DCM (3.3 mL) and TFA (3.3 mL). The crude product was purified 
by column chromatography (silica gel, petrol:DCM, 1:0  1:9) to yield the title compound 
as a pale yellow solid (165 mg, 96%); Rf = 0.30 (petrol:EtOAc, 8:2); m.p. 114.5-116.5 °C; 
λmax (EtOH)/nm 250.0; IR (neat) νmax/cm
-1
 3299, 1599, 1516, 1484, 1351, 1171, 1134, 
1085; 
1
H NMR (500 MHz, CDCl3) δ 2.75 (3H, d, J = 4.7 Hz, NHCH3), 7.42 – 7.34 (3H, m, 
H-3, 5 and H-4’), 7.48 (2H, dd, J = 7.7, 7.7 Hz, H-3’, 5’), 7.67 (2H, dd, J = 7.7, 1.1 Hz, 
H-2’, 6’), 7.75 (2H, d, J = 8.7 Hz, H-2, 6), 8.28 (1H, q, J = 4.7 Hz, NHCH3); 
13
C NMR 
(126 MHz, CDCl3)  29.2 (NHCH3), 122.5 (C-3, 5), 126.8 (C-2’, 6’), 127.7 (C-4’), 128.2 
(C-2, 6), 129.0 (C-3’, 5’), 138.8 (C-1 or C-1’), 139.1 (C-1 or C-1’), 149.3 (C-4); LRMS 
(ES
-
) m/z 304.2 [M+MeCN-H]
-
; HRMS (ESI) calcd for C13H12NO3S [M-H]
-
 262.0543, 
found 262.0537. 
 
[1,1'-Biphenyl]-4-yl isobutylsulfamate, (128) 
 
Compound 128 was synthesised according to general procedure D, using the following 
reagents: [1,1'-biphenyl]-4-yl 2,4-dimethoxybenzyl(isobutyl)sulfamate (125) (250 mg, 
0.55 mmol), DCM (5.0 mL) and TFA (0.6 mL). The crude product was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  8:2) to yield the title compound as a pale 
orange solid (156 mg, 93%); Rf = 0.34 (petrol:EtOAc, 8:2); m.p. 98.5-100.5 °C; λmax 
(EtOH)/nm 250.5; IR (neat) νmax/cm
-1
 3293, 1599, 1517, 1486, 1351, 1143, 1078; 
1
H NMR 
(500 MHz, DMSO-d6) δ 0.88 (6H, d, J = 6.6 Hz, CH(CH3)2), 1.81 – 1.70 (1H, m, 
CH(CH3)2), 2.92 (2H, dd, J = 6.6, 5.9 Hz, NHCH2CH), 7.41 – 7.34 (3H, m, H-3, 5 and 
H-4’), 7.48 (2H, dd, J = 7.7, 7.7 Hz, H-3’, 5’), 7.67 (2H, dd, J = 7.7, 1.1 Hz, H-2’, 6’), 7.75 
(2H, d, J = 8.7 Hz, H-2, 6), 8.43 (1H, t, J = 5.8 Hz, NHCH2); 
13
C NMR (126 MHz, 
DMSO-d6) δ 19.8 (CH(CH3)2), 28.0 (CH(CH3)2), 50.7 (ArCH2), 122.4 (C-3, 5), 126.7 
(C-2’, 6’), 127.7 (C-4’), 128.1 (C-2, 6), 129.0 (C-3’, 5’), 138.6 (C-1 or C-1’), 139.1 (C-1 or 
C-1’), 149.4 (C-4); LRMS (ES-) m/z 304.2 [M-H]-; HRMS (ESI) calcd for C16H18NO3S 
[M-H]
-
 304.1013, found 304.1004. 
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[1,1'-Biphenyl]-4-yl benzylsulfamate, (129) 
 
Compound 129 was synthesised according to general procedure D, using the following 
reagents: [1,1'-biphenyl]-4-yl benzyl(2,4-dimethoxybenzyl)sulfamate (126) (250 mg, 
0.51 mmol), DCM (4.5 mL) and TFA (0.5 mL). The crude product was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  8:2) to yield the title compound as a pale 
yellow solid (166 mg, 96%); Rf = 0.33 (petrol:EtOAc, 8:2); m.p. 113.0-115.0 °C; λmax 
(EtOH)/nm 251.5; IR (neat) νmax/cm
-1
 3274, 1599, 1518, 1485, 1454, 1448, 1348, 1153, 
1092, 1076; 
1
H NMR (500 MHz, DMSO-d6) δ 4.33 (2H, d, J = 6.0 Hz, ArCH2NH), 
7.31 - 7.28 (1H, m, ArH), 7.32 (2H, d, J = 8.7 Hz, H-3, 5), 7.38 – 7.34 (4H, m, 4 × ArH), 
7.41 – 7.37 (1H, m, H-4’), 7.48 (2H, dd, J = 7.7, 7.7 Hz, H-3’, 5’), 7.67 (2H, dd, J = 7.7, 
1.1 Hz, H-2’, 6’), 7.73 (2H, d, J = 8.8 Hz, H-2, 6), 8.98 (1H, t, J = 6.0 Hz, ArCH2NH); 
13
C NMR (126 MHz, DMSO-d6) δ 46.7 (ArCH2), 122.5 (C-3, 5), 126.8 (C-2’, 6’), 127.5 
(CH Ar), 127.8 (CH Ar), 128.1 (CH Ar), 128.4 (CH Ar), 129.0 (C-3’, 5’), 137.4 (Cq Ar), 
138.7 (Cq Ar), 139.1 (Cq Ar), 149.3 (C-4); LRMS (ES
-
) m/z 338.2 [M-H]
-
; HRMS (ESI) 
calcd for C19H16NO3S [M-H]
-
 338.0856, found 338.0843. 
 
3-Bromophenyl 2-methyl-1H-imidazole-1-sulfonate, (130) 
 
Compound 130 was synthesised according to general procedure B, using the following 
reagents: 1,1'-sulfonylbis(2-methyl-1H-imidazole) (19) (2.61 g, 11.6 mmol), caesium 
carbonate (2.07 g, 6.36 mmol), 3-bromophenol (12) (1.0 g, 5.78 mmol) and acetonitrile 
(20 mL). The crude yellow oil was purified by column chromatography (silica gel, 
petrol:EtOAc, 1:0  8:2) to yield the title compound as a pale yellow oil (1.39 g, 76%); 
Rf = 0.32 (petrol:EtOAc, 8:2; KMnO4); λmax (EtOH)/nm 270.5; IR (neat) νmax/cm
-1
 1581, 
1554, 1467, 1424, 1208, 1152, 890; 
1
H NMR (500 MHz, CDCl3) δ 2.51 (3H, s, CH3), 6.83 
(1H, ddd, J = 8.3, 2.4 and 0.9 Hz, H-6), 6.91 (1H, d, J = 1.8 Hz, H-4’ or H-5’), 7.13 (1H, d, 
J = 1.8 Hz, H-4’ or H-5’), 7.18 (1H, dd, J = 2.4, 1.7 Hz, H-2), 7.23 (1H, dd, J = 8.3, 
8.0 Hz, H-5), 7.50 (1H, ddd, J = 8.0, 1.7 and 0.9 Hz, H-4); 
13
C NMR (126 MHz, CDCl3) 
 15.1 (CH3), 120.3 (C-4’ or C-5’ or C-6), 120.5 (C-4’ or C-5’ or C-6), 123.2 (C-3), 125.4 
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(C-2), 128.2 (C-4’ or C-5’), 131.4 (C-5), 132.0 (C-4), 146.8 (C-1 or C-2’), 149.2 (C-1 or 
C-2’); LRMS (ES+) m/z 316.9 [M(79Br)+H]+, 319.1 [M(81Br)+H]+; HRMS (ESI) calcd for 
C10H10BrN2O3S [M(
79
Br)+H]
+
 316.9590, found 316.9597. 
 
1-((3-Bromophenoxy)sulfonyl)-2,3-dimethyl-1H-imidazol-3-ium tetrafluoroborate, 
(131) 
 
To 3-bromophenyl 2-methyl-1H-imidazole-1-sulfonate (130) (5.5 g, 17.4 mmol) in DCM 
(70 mL), cooled at 0 °C, was added trimethyloxonium tetrafluoroborate (2.57 g, 
17.4 mmol). The resulting solution was stirred at 0 °C for 1 h and allowed to warm to RT. 
Upon completion, the reaction was cooled in an ice bath. Cold petrol (120 mL) was added 
to the mixture, leading to the precipitation of 131. The white precipitate was filtered off, 
washed with cold petrol (60 mL) and dry under high vacuum. The white fluffy solid 
(6.20 g, 85%) was used in the next step without further purification; m.p. 149.5-151.5 °C; 
λmax (EtOH)/nm 265.5; IR (neat) νmax/cm
-1
 3159, 3103, 1594, 1580, 1447, 1229, 1214, 
1149, 1031, 906; 
1
H NMR (500 MHz, MeOD)  2.91 (3H, s, CH3), 4.86 (3H, s, NCH3), 
7.29 (1H, ddd, J = 8.5, 2.5 and 0.9 Hz, H-6), 7.45 (1H, dd, J = 8.5, 8.2 Hz, H-5), 7.66 (1H, 
dd, J = 2.5, 2.1 Hz, H-2), 7.72 – 7.68 (1H, m, H-4), 7.73 (1H, d, J = 2.4 Hz, H-4’ or H-5’), 
7.87 (1H, d, J = 2.4 Hz, H-4’ or H-5’); 13C NMR (126 MHz, MeOD)  11.9 (CH3), 36.8 
(NCH3), 121.5 (C-6), 122.4 (C-4’ or C-5’), 124.3 (C-3), 125.0 (C-4’ or C-5’), 126.2 (C-2), 
133.4 (C-5), 134.0 (C-4), 150.7 (C-1); 
19
F NMR (471 MHz, MeOD)  -154.4 (BF4
-
); 
LRMS (ES
+
) m/z 331.1 [M(
79
Br)-BF4]
+
, 333.2 [M(
81
Br)-BF4]
+
; HRMS (ESI) calcd for 
C11H12BrN2O3S [M(
79
Br)-BF4]
+
 330.9747, found 330.9751. 
 
3-Bromophenyl bis(2,4-dimethoxybenzyl)sulfamate, (132) 
 
To 1-((3-bromophenoxy)sulfonyl)-2,3-dimethyl-1H-imidazol-3-ium tetrafluoroborate 
(131) (3.0 g, 7.18 mmol) in acetonitrile (30 mL) was added a solution of bis(2,4-
dimethoxybenzyl)amine (32) (2.28 g, 7.18 mmol) in acetonitrile (25 mL). The reaction 
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mixture was heated at 82 °C for 24 h. Upon completion, the solvent was removed in vacuo 
to yield a crude product. The crude product was purified by column chromatography (silica 
gel, petrol:EtOAc, 1:0  8:2) to yield the title compound as a clear oil (2.81 g, 71%); 
Rf = 0.35 (petrol:EtOAc, 8:2; KMnO4); λmax (EtOH)/nm 276.5; IR (neat) νmax/cm
-1
 1612, 
1584, 1508, 1466, 1372, 1208, 1157, 1038, 879; 
1
H NMR (500 MHz, CDCl3) δ 3.75 (6H, 
s, 2 × ArOCH3), 3.81 (6H, s, 2 × ArOCH3), 4.45 (4H, s, 2 × ArCH2), 6.41 (2H, d, 
J = 2.4 Hz, H-3’), 6.45 (2H, dd, J = 8.4, 2.4 Hz, H-5’), 7.04 (1H, dd, J = 2.1, 2.1 Hz, H-2), 
7.09 (1H, ddd, J = 8.4, 2.3 and 1.1 Hz, H-6), 7.16 (1H, dd, J = 8.4, 8.1 Hz, H-5), 7.26 (2H, 
d, J = 8.4 Hz, H-6’), 7.36 – 7.31 (1H, m, H-4); 13C NMR (126 MHz, CDCl3)  47.3 
(ArCH2), 55.3 (ArOCH3), 55.5 (ArOCH3), 98.4 (C-3’), 104.2 (C-5’), 116.6 (C-1’), 120.8 
(C-6), 122.4 (C-3), 125.5 (C-2), 129.6 (C-4), 130.6 (C-5), 131.2 (C-6’), 150.9 (C-1), 158.6 
(C-2’ or C-4’), 160.8 (C-2’ or C-4’); HRMS (ESI) calcd for C24H27BrNO7S [M(
79
Br)+H]
+
 
552.0686, found 552.0675. 
 
Methyl 3'-((N,N-bis(2,4-dimethoxybenzyl)sulfamoyl)oxy)-[1,1'-biphenyl]-2-
carboxylate, (133) 
 
A solution of 3-bromophenyl bis(2,4-dimethoxybenzyl)sulfamate (132) (750 mg, 
1.36 mmol) in acetonitrile (15 mL) was sparged with nitrogen for 15 min. To this solution, 
potassium carbonate (563 mg, 4.07 mmol), 2-methoxycarbonylphenylboronic acid 
(293 mg, 1.63 mmol) and tetrakis(triphenylphosphine)palladium(0) (157 mg, 0.14 mmol) 
were added. The resulting mixture was heated at 120 °C for 20 min under microwave 
irradiation. Upon completion, the solvent was removed in vacuo. The crude residue was 
dissolved in a mixture of EtOAc and water (20 mL, respectively) and extracted with 
EtOAc (3 × 25 mL). The pooled organic extracts were washed with water (30 mL) and 
brine (30 mL), dried over MgSO4 and concentrated in vacuo. The crude product was 
purified by column chromatography (silica gel, petrol:EtOAc, 1:0  7:3) to yield the title 
compound as a yellow oil (580 mg, 75%); Rf = 0.32 (petrol:EtOAc, 7:3); λmax (EtOH)/nm 
277.5; IR (neat) νmax/cm
-1
 1724, 1611, 1587, 1507, 1454, 1370, 1290, 1264, 1208, 1156, 
1032, 886; 
1
H NMR (500 MHz, CDCl3) δ 3.61 (3H, s, ArCO2CH3), 3.68 (6H, s, 
2 × ArOCH3), 3.77 (6H, s, 2 × ArOCH3), 4.45 (4H, s, 2 × ArCH2), 6.34 (2H, d, J = 2.4 Hz, 
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H-3”), 6.43 (2H, dd, J = 8.4, 2.4 Hz, H-5”), 6.92 (1H, dd, J = 2.0, 2.0 Hz, H-2’), 
7.18 - 7.12 (2H, m, H-4’ and H-6’), 7.31 – 7.27 (3H, m, H-3 and H-6”), 7.33 (1H, dd, 
J = 7.9, 7.9 Hz, H-5’), 7.44 (1H, ddd, J = 7.6, 7.6 and 1.3 Hz, H-4 or H-5), 7.53 (1H, ddd, 
J = 7.5, 7.5 and 1.4 Hz, H-4 or H-5), 7.85 (1H, dd, J = 7.7, 1.4 Hz, H-6); 
13
C NMR 
(126 MHz, CDCl3)  47.1 (ArCH2), 52.2 (ArCO2CH3), 55.2 (ArOCH3), 55.5 (ArOCH3), 
98.3 (C-3”), 104.1 (C-5”), 116.8 (C-1”), 120.9 (C-4’ or C-6’), 122.2 (C-2’), 126.5 (C-4’ or 
C-6’), 127.7 (C-4 or C-5), 129.1 (C-5’), 130.1 (C-6), 130.8 (C-3), 130.9 (C-2), 131.1 
(C-6”), 131.4 (C-4 or C-5), 141.4 (C-1 or C-1’), 143.1 (C-1 or C-1’), 150.2 (C-3’), 158.6 
(C-2” or C-4”), 160.7 (C-2” or C-4”), 168.8 (ArCO2CH3); HRMS (ESI) calcd for 
C32H37N2O9S [M+H]
+
 625.2214, found 625.2211. 
 
3'-((N,N-Bis(2,4-dimethoxybenzyl)sulfamoyl)oxy)-[1,1'-biphenyl]-3-carboxylic acid, 
(134) 
 
Compound 134 was synthesised according to general procedure I, using the following 
reagents: 3-bromophenyl bis(2,4-dimethoxybenzyl)sulfamate (132) (750 mg, 1.36 mmol), 
dimethoxyethane (9.5 mL), 2 M aq. solution of sodium bicarbonate (1.36 mL, 2.72 mmol), 
3-carboxyphenylboronic acid pinacol ester (404 mg, 1.63 mmol) and 
[1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with DCM (55 mg, 
0.07 mmol). The crude product was purified by column chromatography (silica gel, 
petrol:EtOAc:AcOH, 1:0:0  50:49.5:0.5) to yield the title compound as a pale orange oil 
(637 mg, 79%); Rf = 0.32 (petrol:EtOAc:AcOH, 50:49.5:0.5); No λmax (EtOH)/nm; 
IR (neat) νmax/cm
-1
 2976, 1701, 1611, 1588, 1507, 1371, 1291, 1208, 1154, 1036, 827; 
1
H NMR (500 MHz, CDCl3) δ 3.71 (6H, s, 2 × ArOCH3), 3.76 (6H, s, 2 × ArOCH3), 4.48 
(4H, s, 2 × ArCH2), 6.37 (2H, d, J = 2.4 Hz, H-3”), 6.44 (2H, dd, J = 8.4, 2.4 Hz, H-5”), 
7.22 – 7.14 (2H, m, H-4’ and H-2’), 7.29 (2H, d, J = 8.4 Hz, H-6”), 7.40 (1H, d, 
J = 8.0 Hz, H-5’), 7.52 – 7.45 (1H, m, H-6’), 7.55 (1H, dd, J = 7.8, 7.8 Hz, H-5), 7.73 (1H, 
ddd, J = 7.8, 1.4 and 1.4 Hz, H-6), 8.11 (1H, ddd, J = 7.8, 1.4 and 1.4 Hz, H-4), 8.27 (1H, 
dd, J = 1.4, 1.4 Hz, H-2); 
13
C NMR (126 MHz, CDCl3)  47.1 (ArCH2), 55.2 (ArOCH3), 
55.5 (ArOCH3), 98.3 (C-3”), 104.1 (C-5”), 116.7 (C-1”), 120.8 (C-2’), 121.4 (C-4’), 125.2 
(C-6’), 128.9 (C-2), 129.2 (C-5), 129.5 (C-4), 130.1 (C-5’), 131.2 (C-6”), 132.6 (C-6), 
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140.5 (C-1 or C-1’), 141.6 (C-1 or C-1’), 151.0 (C-3’), 158.6 (C-2” or C-4”), 160.7 (C-2” 
or C-4”), 177.2 (ArCO2H); LRMS (ES
-
) m/z 592.3 [M-H]
-
; HRMS (ESI) calcd for 
C31H30NO9S [M-H]
-
 592.1647, found 592.1644. 
 
3'-((N,N-Bis(2,4-dimethoxybenzyl)sulfamoyl)oxy)-[1,1'-biphenyl]-4-carboxylic acid, 
(135) 
 
Compound 135 was synthesised according to general procedure I, using the following 
reagents: 3-bromophenyl bis(2,4-dimethoxybenzyl)sulfamate (132) (750 mg, 1.36 mmol), 
dimethoxyethane (9.5 mL), 2 M aq. solution of sodium bicarbonate (1.36 mL, 2.72 mmol), 
4-carboxyphenylboronic acid pinacol ester (404 mg, 1.63 mmol) and 
[1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with DCM (55 mg, 
0.07 mmol). The crude product was purified by column chromatography (silica gel, 
petrol:EtOAc:AcOH, 1:0:0  50:49.5:0.5) to yield the title compound as a pale orange oil 
(620 mg, 77%); Rf = 0.28 (petrol:EtOAc:AcOH, 50:49.5:0.5); λmax (EtOH)/nm 270.5; 
IR (neat) νmax/cm
-1
 2945, 1686, 1610, 1586, 1507, 1377, 1292, 1210, 1153; 
1
H NMR 
(500 MHz, CDCl3) δ 3.71 (6H, s, 2 × ArOCH3), 3.78 (6H, s, 2 × ArOCH3), 4.48 (4H, s, 
2 × ArCH2), 6.39 (2H, d, J = 2.4 Hz, H-3”), 6.45 (2H, dd, J = 8.4, 2.4 Hz, H-5”), 7.15 (1H, 
dd, J = 2.3, 2.0 Hz, H-2’), 7.20 (1H, ddd, J = 8.2, 2.3 and 1.0 Hz, H-4’), 7.30 (2H, d, 
J = 8.4 Hz, H-6”), 7.41 (1H, dd, J = 8.2, 7.9 Hz, H-5’), 7.50 – 7.46 (1H, m, H-6’), 7.59 
(1H, d, J = 8.5 Hz, H-2, 6), 8.17 (2H, d, J = 8.5 Hz, H-3, 5); 
13
C NMR (126 MHz, CDCl3) 
 47.1 (ArCH2), 55.2 (ArOCH3), 55.5 (ArOCH3), 98.4 (C-3”), 104.1 (C-5”), 116.7 (C-1”), 
120.9 (C-2’), 121.9 (C-4’), 125.3 (C-6’), 127.3 (C-2, 6), 128.6 (C-4), 130.1 (C-5’), 130.8 
(C-3, 5), 131.2 (C-6”), 141.5 (C-1 or C-1’), 145.2 (C-1 or C-1’), 151.0 (C-3), 158.6 (C-2” 
or C-4”), 160.8 (C-2” or C-4”), 177.4 (ArCO2H); LRMS (ES
-
) m/z 592.4 [M-H]
-
; HRMS 
(ESI) calcd for C31H30NO9S [M-H]
-
 592.1647, found 592.1644. 
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2'-Amino-[1,1'-biphenyl]-3-yl bis(2,4-dimethoxybenzyl)sulfamate, (136) 
 
Compound 136 was synthesised according to general procedure I, using the following 
reagents: 3-bromophenyl bis(2,4-dimethoxybenzyl)sulfamate (132) (900 mg, 1.63 mmol), 
dimethoxyethane (11.4 mL), 2 M aq. solution of sodium bicarbonate (1.63 mL, 
3.26 mmol), 2-aminophenylboronic acid pinacol ester (428 mg, 1.95 mmol) and 
[1,1′ bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with DCM (67 mg, 
0.08 mmol). The crude product was purified by column chromatography (silica gel, 
petrol:EtOAc, 1:0  7:3) to yield the title compound as a brown oil (755 mg, 82%); 
Rf = 0.31 (petrol:EtOAc, 7:3; ninhydrin); λmax (EtOH)/nm 225.5; IR (neat) νmax/cm
-1
 3442, 
3360, 1610, 1582, 1503, 1458, 1350, 1289, 1208, 1154; 
1
H NMR (500 MHz, CDCl3) 
δ 3.69 (6H, s, 2 × ArOCH3), 3.73 (2H, s, ArNH2), 3.77 (6H, s, 2 × ArOCH3), 4.46 (4H, s, 
2 × ArCH2), 6.36 (2H, d, J = 2.4 Hz, H-3”), 6.43 (2H, dd, J = 8.4, 2.4 Hz, H-5”), 6.75 (1H, 
dd, J = 7.9, 1.1 Hz, H-3’), 6.81 (1H, ddd, J = 7.5, 7.5 and 1.2 Hz, H-5’), 7.08 – 7.04 (2H, 
m, H-2 and H-6’), 7.18 – 7.11 (2H, m, H-4 and H-4’), 7.28 (2H, d, J = 8.4 Hz, H-6”), 7.34 
– 7.31 (1H, m, H-6), 7.38 (1H, dd, J = 7.7, 7.7 Hz, H-5); 13C NMR (126 MHz, CDCl3) 
 47.1 (ArCH2), 55.2 (ArOCH3), 55.5 (ArOCH3), 98.3 (C-3”), 104.1 (C-5”), 115.8 (C-3’), 
116.7 (C-1”), 118.7 (C-5’), 120.8 (C-4), 122.8 (C-2), 126.3 (C-2’), 127.2 (C-6), 129.0 
(C-4’), 130.0 (C-5), 130.5 (C-6’), 131.1 (C-6”), 141.2 (C-1 or C-1’), 143.6 (C-1 or C-1’), 
150.8 (C-3), 158.6 (C-2” or C-4”), 160.7 (C-2” or C-4”); LRMS (ES+) m/z 565.4 [M+H]+; 
HRMS (ESI) calcd for C30H33N2O7S [M+H]
+
 565.2003, found 565.1992. 
 
3'-Amino-[1,1'-biphenyl]-3-yl bis(2,4-dimethoxybenzyl)sulfamate, (137) 
 
Compound 137 was synthesised according to general procedure I, using the following 
reagents: 3-bromophenyl bis(2,4-dimethoxybenzyl)sulfamate (132) (900 mg, 1.63 mmol), 
dimethoxyethane (11.4 mL), 2 M aq. solution of sodium bicarbonate (1.63 mL, 
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3.26 mmol), 3-aminophenylboronic acid pinacol ester (428 mg, 1.95 mmol) and 
[1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with DCM (67 mg, 
0.08 mmol). The crude product was purified by column chromatography (silica gel, 
petrol:EtOAc, 1:0  6:4) to yield the title compound as a brown oil (709 mg, 77%); 
Rf = 0.30 (petrol:EtOAc, 6:4; ninhydrin); λmax (EtOH)/nm 221.5; IR (neat) νmax/cm
-1
 3465, 
3379, 1610, 1588, 1507, 1464, 1367, 1291, 1207, 1156, 1132, 1034, 845; 
1
H NMR 
(500 MHz, CDCl3) δ 3.68 (6H, s, 2 × ArOCH3), 3.79 (6H, s, 2 × ArOCH3), 4.45 (4H, s, 
2 × ArCH2), 6.39 (2H, d, J = 2.4 Hz, H-3”), 6.45 (2H, dd, J = 8.4, 2.4 Hz, H-5”), 6.69 (1H, 
ddd, J = 7.9, 2.3 and 1.0 Hz, H-4’), 6.77 (1H, dd, J = 2.3, 1.2 Hz, H-2’), 6.90 (1H, ddd, 
J = 7.8, 1.2 and 1.2 Hz, H-6’), 7.03 (1H, dd, J = 2.3, 2.1 Hz, H-2), 7.13 (1H, ddd, J = 8.0, 
2.3 and 1.1 Hz, H-4), 7.21 (1H, dd, J = 7.9, 7.8 Hz, H-5’), 7.30 (2H, d, J = 8.3 Hz, H-6”), 
7.33 (1H, dd, J = 8.0, 7.9 Hz, H-5), 7.44 – 7.40 (1H, m, H-6); 13C NMR (126 MHz, 
CDCl3)  47.1 (ArCH2), 55.2 (ArOCH3), 55.5 (ArOCH3), 98.4 (C-3”), 104.1 (C-5”), 113.9 
(C-2’), 114.6 (C-4’), 116.9 (C-1”), 117.6 (C-6’), 120.6 (C-2 or C-4), 120.8 (C-2 or C-4), 
125.1 (C-6), 129.7 (C-5 or C-5’), 129.8 (C-5 or C-5’), 131.2 (C-6”), 141.1 (C-1 or C-1’), 
143.0 (C-1 or C-1’), 147.0 (C-3’), 150.8 (C-3), 158.6 (C-2” or C-4”), 160.7 (C-2” or C-4”); 
LRMS (ES
+
) m/z 565.5 [M+H]
+
; HRMS (ESI) calcd for C30H33N2O7S [M+H]
+
 565.2003, 
found 565.2000. 
 
4'-Amino-[1,1'-biphenyl]-3-yl bis(2,4-dimethoxybenzyl)sulfamate, (138) 
 
Compound 138 was synthesised according to general procedure I, using the following 
reagents: 3-bromophenyl bis(2,4-dimethoxybenzyl)sulfamate (132) (500 mg, 0.90 mmol), 
dimethoxyethane (6.3 mL), 2 M aq. solution of sodium bicarbonate (0.91 mL, 1.81 mmol), 
4-aminobenzeneboronic acid pinacol ester (238 mg, 1.09 mmol) and 
[1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with DCM (37 mg, 
0.04 mmol). The crude product was purified by column chromatography (silica gel, 
petrol:EtOAc, 1:0  1:1) to yield the title compound as a brown oil (368 mg, 72%); 
Rf = 0.33 (petrol:EtOAc, 1:1; ninhydrin); λmax (EtOH)/nm 283.0; IR (neat) νmax/cm
-1
 3468, 
3380, 1610, 1587, 1507, 1364, 1290, 1207, 1156, 1130; 
1
H NMR (500 MHz, CDCl3) 
δ 3.70 (6H, s, 2 × ArOCH3), 3.75 (2H, s, ArNH2), 3.79 (6H, s, 2 × ArOCH3), 4.48 (4H, s, 
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2 × ArCH2), 6.38 (2H, d, J = 2.4 Hz, H-3”), 6.44 (2H, dd, J = 8.4, 2.4 Hz, H-5”), 6.74 (2H, 
d, J = 8.5 Hz, H-3’, 5’), 7.05 (1H, ddd, J = 8.3, 2.5 and 1.0 Hz, H-4), 7.14 (1H, dd, J = 2.5, 
2.1 Hz, H-2), 7.29 (2H, d, J = 8.4 Hz, H-6”), 7.31 (1H, dd, J = 8.3, 7.7 Hz, H-5), 7.33 (2H, 
d, J = 8.5 Hz, H-2’, 6’), 7.41 – 7.36 (1H, m, H-6); 13C NMR (126 MHz, CDCl3)  47.1 
(ArCH2), 55.2 (ArOCH3), 55.5 (ArOCH3), 98.3 (C-3”), 104.1 (C-5”), 115.4 (C-3’, 5’), 
116.8 (C-1”), 119.7 (C-2 or C-4), 119.8 (C-2 or C-4), 124.3 (C-6), 128.2 (C-2’, 6’), 129.7 
(C-5), 130.2 (C-4’), 131.2 (C-6”), 142.9 (C-1 or C-1’), 146.4 (C-1 or C-1’), 150.9 (C-3), 
158.6 (C-2” or C-4”), 160.7 (C-2” or C-4”); LRMS (ES+) m/z 565.4 [M+H]+; HRMS (ESI) 
calcd for C30H33N2O7S [M+H]
+
 565.2003, found 565.1998. 
 
Methyl 3'-(sulfamoyloxy)-[1,1'-biphenyl]-2-carboxylate, (139) 
 
Compound 139 was synthesised according to general procedure D, using the following 
reagents: methyl 3'-((N,N-bis(2,4-dimethoxybenzyl)sulfamoyl)oxy)-[1,1'-biphenyl]-2-
carboxylate (133) (250 mg, 0.41 mmol), DCM (3.7 mL) and TFA (0.4 mL). The crude 
product was purified by column chromatography (silica gel, petrol:EtOAc, 1:0  6:4) to 
yield the title compound as a pale yellow oil (112 mg, 88%); Rf = 0.34 (petrol:EtOAc, 6:4); 
λmax (EtOH)/nm 280.0; IR (neat) νmax/cm
-1
 3364, 3263, 1708, 1568, 1375, 1292, 1264, 
1190; 
1
H NMR (500 MHz, DMSO-d6) δ 3.61 (s, 3H, ArCO2CH3), 7.19 (dd, J = 2.0, 2.0 
Hz, 1H, H-2’), 7.31 – 7.24 (m, 2H, H-4’ and H-6’), 7.47 (dd, J = 7.7, 1.2 Hz, 1H, H-3), 
7.51 – 7.49 (m, 1H, H-5’), 7.55 – 7.51 (m, 1H, H-4 or H-5), 7.66 (ddd, J = 7.6, 7.6, 1.4 Hz, 
1H, H-4 or H-5), 7.77 (dd, J = 7.7, 1.4 Hz, 1H, H-6), 8.05 (s, 2H, ArOSO2NH2); 
13
C NMR 
(126 MHz, DMSO-d6) δ 52.1 (ArCO2CH3), 121.0 (C-4’ or C-6’), 121.8 (C-2’), 126.3 (C-4’ 
or C-6’), 127.9 (C-4 or C-5), 129.4 (C-6), 129.6 (C-5’), 130.6 (C-3), 130.7 (C-2), 131.6 
(C-4 or C-5), 139.9 (C-1 or C-1’), 142.0 (C-1 or C-1’), 149.9 (C-3’), 168.2 (ArCO2CH3); 
LRMS (ES
-
) m/z 306.1 [M-H]
-
; HRMS (ESI) calcd for C14H12NO5S [M-H]
-
 306.0442, 
found 306.0442. 
 
  
232 
3'-(Sulfamoyloxy)-[1,1'-biphenyl]-3-carboxylic acid, (140) 
 
Compound 140 was synthesised according to general procedure D, using the following 
reagents: 3'-((N,N-bis(2,4-dimethoxybenzyl)sulfamoyl)oxy)-[1,1'-biphenyl]-3-carboxylic 
acid (134) (250 mg, 0.42 mmol), DCM (3.8 mL) and TFA (0.5 mL). The crude product 
was purified by column chromatography (silica gel, petrol:EtOAc:AcOH, 
1:0:0  50:49.5:0.5) to yield the title compound as a pale pink solid (102 mg, 82%); 
Rf = 0.29 (petrol:EtOAc:AcOH, 50:49.5:0.5); m.p. 168.0-170.0 °C; λmax (EtOH)/nm 250.0; 
IR (neat) νmax/cm
-1
 3368, 3274, 1677, 1606, 1577, 1459, 1362, 1312; 
1
H NMR (500 MHz, 
DMSO-d6) δ 7.37 – 7.28 (1H, m, H-4’), 7.58 (1H, dd, J = 7.8, 7.8 Hz, H-5 or H-5’), 7.60 
(1H, dd, J = 2.0, 2.0 Hz, H-2’), 7.63 (1H, dd, J = 7.7, 7.7 Hz, H-5 or H-5’), 7.71 – 7.66 
(1H, m, H-6’), 7.95 (1H, ddd, J = 7.8, 1.4 and 1.4 Hz, H-4 or H-6), 7.98 (1H, ddd, J = 7.6, 
1.3 and 1.3 Hz, H-4 or H-6), 8.06 (2H, s, ArOSO2NH2), 8.21 (1H, dd, J = 1.8, 1.8 Hz, 
H-2), 13.13 (1H, s, ArCO2H); 
13
C NMR (126 MHz, DMSO-d6) δ 120.6 (C-2’), 121.8 
(C-4’), 125.0 (C-6’), 127.4 (C-2), 128.8 (C-4 or C-6), 129.5 (C-5 or C-5’), 130.5 (C-5 or 
C-5’), 131.3 (C-4 or C-6), 131.6 (C-3), 139.4 (C-1 or C-1’), 141.0 (C-1 or C-1’), 150.8 
(C-3’), 167.1 (ArCO2H); LRMS (ES
-
) m/z 292.1 [M-H]
-
; HRMS (ESI) calcd for 
C13H10NO5S [M-H]
-
 292.0285, found 292.0286. 
 
3'-(Sulfamoyloxy)-[1,1'-biphenyl]-4-carboxylic acid, (141) 
 
Compound 141 was synthesised according to general procedure D, using the following 
reagents: 3'-((N,N-bis(2,4-dimethoxybenzyl)sulfamoyl)oxy)-[1,1'-biphenyl]-4-carboxylic 
acid (135) (250 mg, 0.42 mmol), DCM (3.8 mL) and TFA (0.5 mL). The crude product 
was purified by column chromatography (silica gel, petrol:EtOAc:AcOH, 
1:0:0  50:49.5:0.5) to yield the title compound as an off-white solid (112 mg, 90%); 
Rf = 0.26 (petrol:EtOAc:AcOH, 50:49.5:0.5); m.p. 190.0-192.0 °C; λmax (EtOH)/nm 266.0; 
IR (neat) νmax/cm
-1
 3393, 3300, 1680, 1608, 1378, 1368, 1301, 1201, 1150, 912; 
1
H NMR 
(500 MHz, DMSO-d6) δ 7.34 (1H, ddd, J = 8.2, 2.3 and 1.3 Hz, H-4’), 7.59 (1H, dd, 
J = 8.2, 7.9 Hz, H-5’), 7.62 (1H, dd, J = 2.3, 1.3 Hz, H-2’), 7.71 (ddd, J = 7.7, 1.3 and 
1.3 Hz, 1H, H-6’), 7.82 (2H, d, J = 8.3 Hz, H-2, 6), 8.05 (2H, d, J = 8.3 Hz, H-3, 5), 8.06 
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(2H, s, ArOSO2NH2), 12.98 (brs, 1H, ArCO2H); 
13
C NMR (126 MHz, DMSO-d6) δ 120.7 
(C-2’), 122.1 (C-4’), 125.2 (C-6’), 127.0 (C-2, 6), 130.0 (C-3, 5), 130.1 (C-4), 130.5 
(C-5’), 140.8 (C-1 or C-1’), 143.1 (C-1 or C-1’), 150.7 (C-3’), 167.0 (ArCO2H); LRMS 
(ES
-
) m/z 292.1 [M-H]
-
; HRMS (ESI) calcd for C13H10NO5S [M-H]
-
 292.0285, found 
292.0277. 
 
2'-Amino-[1,1'-biphenyl]-3-yl sulfamate, (142) 
 
Compound 142 was synthesised according to general procedure D, using the following 
reagents: 2'-amino-[1,1'-biphenyl]-3-yl bis(2,4-dimethoxybenzyl)sulfamate (136) (330 mg, 
0.58 mmol), DCM (5.3 mL) and TFA (0.6 mL). The crude product was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  6:4) to yield the title compound as a 
brown solid (128 mg, 83%); Rf = 0.29 (petrol:EtOAc, 6:4; ninhydrin); m.p. 
101.5-103.5 °C; λmax (EtOH)/nm 225.0; IR (neat) νmax/cm
-1
 3358, 1611, 1474, 1357, 1186, 
1147; 
1
H NMR (500 MHz, DMSO-d6) δ 4.89 (2H, s, ArNH2), 6.64 (1H, ddd, J = 7.4, 7.4 
and 1.2 Hz, H-5’), 6.76 (1H, dd, J = 8.0, 1.2 Hz, H-3’), 7.01 (1H, dd, J = 7.6, 1.6 Hz, 
H-6’), 7.07 (1H, ddd, J = 8.4, 7.3 and 1.6 Hz, H-4’), 7.23 (1H, ddd, J = 8.2, 2.3 and 1.3 Hz, 
H-4), 7.40 – 7.33 (2H, m, H-2 and H-6), 7.53 (1H, dd, J = 8.2, 8.2 Hz, H-5), 7.98 (2H, s, 
ArOSO2NH2); 
13
C NMR (126 MHz, DMSO-d6) δ 115.3 (C-3’), 116.7 (C-5’), 120.8 (C-4), 
122.4 (C-2), 124.3 (C-2’), 127.0 (C-6), 128.6 (C-4’), 130.0 (C-5 or C-6’), 130.1 (C-5 or C-
6’), 141.4 (C-1 or C-1’), 145.1 (C-1 or C-1’), 150.2 (C-3); LRMS (ES-) m/z 263.2 [M-H]-; 
HRMS (ESI) calcd for C12H11N2O3S [M-H]
-
 263.0496, found 263.0497. 
 
3'-Amino-[1,1'-biphenyl]-3-yl sulfamate, (143) 
 
Compound 143 was synthesised according to general procedure D, using the following 
reagents: 3'-amino-[1,1'-biphenyl]-3-yl bis(2,4-dimethoxybenzyl)sulfamate (137) (150 mg, 
0.27 mmol), DCM (2.4 mL) and TFA (0.3 mL). The crude product was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  1:1) to yield the title compound as a 
brown solid (42 mg, 82%); Rf = 0.33 (petrol:EtOAc, 1:1; ninhydrin); m.p. 106.5-108.5 °C; 
λmax (EtOH)/nm 235.5; IR (neat) νmax/cm
-1
 3413, 3340, 3292, 3040, 1605, 1576, 1473, 
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1362, 1230, 1146; 
1
H NMR (500 MHz, DMSO-d6) δ 5.21 (2H, s, ArNH2), 6.59 (1H, ddd, 
J = 8.0, 2.3 and 1.0 Hz, H-4’), 6.81 – 6.76 (1H, m, H-6’), 6.84 (1H, dd, J = 2.0, 2.0 Hz, 
H-2’), 7.12 (1H, dd, J = 7.8, 7.8 Hz, H-5’), 7.28 – 7.19 (1H, m, H-4), 7.47 – 7.39 (1H, m, 
H-2), 7.54 – 7.47 (2H, m, H-5 and H-6), 8.02 (2H, s, ArOSO2NH2); 
13
C NMR (126 MHz, 
DMSO-d6) δ 112.0 (C-2’), 113.6 (C-4’), 114.3 (C-6), 120.1 (C-2), 120.8 (C-4), 124.6 
(C-6), 129.5 (C-5’), 130.0 (C-5), 139.7 (C-1 or C-1’), 142.9 (C-1 or C-1’), 149.2 (C-3 or 
C-3’), 150.5 (C-3 or C-3’); LRMS (ES-) m/z 263.2 [M-H]-; HRMS (ESI) calcd for 
C12H11N2O3S [M-H]
-
 263.0496, found 263.0498. 
 
4'-Amino-[1,1'-biphenyl]-3-yl sulfamate, (144) 
 
Compound 144 was synthesised according to general procedure D, using the following 
reagents: 4'-amino-[1,1'-biphenyl]-3-yl bis(2,4-dimethoxybenzyl)sulfamate (138) (110 mg, 
0.19 mmol), DCM (1.7 mL) and TFA (0.2 mL). The crude product was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  4:6) to yield the title compound as a pale 
brown solid (42 mg, 82%); Rf = 0.29 (petrol:EtOAc, 4:6; ninhydrin); m.p. 144.5-146.5 °C; 
λmax (EtOH)/nm 287.5; IR (neat) νmax/cm
-1
 3417, 3342, 2901, 1604, 1573, 1525, 1480, 
1363, 1149, 910; 
1
H NMR (500 MHz, DMSO-d6) δ 5.32 (2H, s, ArNH2), 6.65 (2H, d, J = 
8.4 Hz, H-3’, 5’), 7.11 (1H, ddd, J = 8.4, 2.3 and 1.0 Hz, H-4), 7.37 (2H, d, J = 8.5 Hz, H-
2’, 6’), 7.41 (1H, dd, J = 2.0, 2.0 Hz, H-2), 7.43 (1H, dd, J = 7.9, 7.9 Hz, H-5), 7.51 – 7.46 
(1H, m, H-6), 7.98 (2H, s, ArOSO2NH2); 
13
C NMR (126 MHz, DMSO-d6) δ 114.2 (C-3’, 
5’), 118.9 (C-2), 119.2 (C-4), 123.4 (C-6), 126.1 (Cq Ar), 127.3 (C-2’, 6’), 129.9 (C-5), 
142.6 (Cq Ar), 148.9 (Cq Ar), 150.7 (Cq Ar); LRMS (ES
-
) m/z 263.2 [M-H]
-
; HRMS (ESI) 
calcd for C12H11N2O3S [M-H]
-
 263.0496, found 263.0497 
 
3'-((N,N-Bis(2,4-dimethoxybenzyl)sulfamoyl)oxy)-[1,1'-biphenyl]-2-carboxylic acid, 
(145) 
 
To methyl 3'-((N,N-bis(2,4-dimethoxybenzyl)sulfamoyl)oxy)-[1,1'-biphenyl]-2-carboxylate 
(133) (300 mg, 0.49 mmol) in THF (5 mL) was added a 2M aq. solution of lithium 
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hydroxide (2.47 mL, 4.94 mmol). The resulting mixture was heated at 60 °C for 18 h. 
Upon completion, the mixture was acidified to pH 3 using a 4 M aq. solution of HCl. The 
reaction was then diluted with water (20 mL) and extracted with EtOAc (3 × 25 mL). The 
pooled organic extracts were washed with water (30 mL) and brine (30 mL), dried over 
MgSO4 and concentrated in vacuo. The crude product was purified by column 
chromatography (silica gel, petrol:EtOAc:AcOH, 1:0:0  50:49.5:0.5) to yield the title 
compound as a yellow oil (235 mg, 80%); Rf = 0.28 (petrol:EtOAc:AcOH, 50:49.5:0.5); 
λmax (EtOH)/nm 275.5; IR (neat) νmax/cm
-1
 2945, 1693, 1610, 1586, 1506, 1458, 1353, 
1292, 1209, 1177, 1154, 1037, 890; 
1
H NMR (500 MHz, CDCl3) δ 3.68 (6H, s, 
2 × ArOCH3), 3.73 (6H, s, 2 × ArOCH3), 4.41 (4H, s, 2 × ArCH2), 6.33 (2H, d, J = 2.4 Hz, 
H-3”), 6.41 (2H, dd, J = 8.3, 2.4 Hz, H-5”), 6.79 (1H, dd, J = 2.3, 2.0 Hz, H-2’), 7.13 (1H, 
ddd, J = 8.1, 2.3 and 1.0 Hz, H-4’ or H-6’), 7.19 – 7.15 (1H, m, H-4’ or H-6’), 7.27 (3H, d, 
J = 8.3 Hz, H-3 and H-6”), 7.32 (1H, dd, J = 8.1, 7.9 Hz, H-5’), 7.44 (1H, ddd, J = 7.6, 7.6 
and 1.3 Hz, H-4 or H-5), 7.56 (1H, ddd, J = 7.6, 7.5 and 1.5 Hz, H-4 or H-5), 7.94 (1H, dd, 
J = 7.8, 1.5 Hz, H-6); 
13
C NMR (126 MHz, CDCl3)  47.2 (ArCH2), 55.2 (ArOCH3), 55.5 
(ArOCH3), 98.4 (C-3”), 104.3 (C-5”), 116.8 (C-1”), 121.2 (C-4’ or C-6’), 122.3 (C-2’), 
126.7 (C-4’ or C-6’), 127.7 (C-4 or C-5), 129.2 (C-5’), 129.3 (C-2), 130.9 (C-3), 131.1 (C-
6”), 131.2 (C-6), 132.1 (C-4 or C-5), 142.3 (C-1 or C-1’), 143.0 (C-1 or C-1’), 150.1 (C-
3’), 158.4 (C-2” or C-4”), 160.7 (C-2” or C-4”), 171.2 (ArCO2H); LRMS (ES
-
) m/z 592.3 
[M-H]
-
; HRMS (ESI) calcd for C31H30NO9S [M-H]
-
 592.1647, found 592.1643. 
 
2'-Acetamido-[1,1'-biphenyl]-3-yl bis(2,4-dimethoxybenzyl)sulfamate, (146) 
 
Compound 146 was synthesised according to general procedure J, using the following 
reagents: 2'-amino-[1,1'-biphenyl]-3-yl bis(2,4-dimethoxybenzyl)sulfamate (136) (180 mg, 
0.32 mmol), triethylamine (65 mg, 89 µL, 0.64 mmol), acetic anhydride (39 mg, 36 µL, 
0.38 mmol) and DCM (3.2 mL). The crude product was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  1:1) to yield the title compound as a pale 
yellow oil (168 mg, 87%); Rf = 0.32 (petrol:EtOAc, 1:1); No λmax (EtOH)/nm; IR (neat) 
νmax/cm
-1
 1680, 1611, 1586, 1507, 1368, 1290, 1208, 1156, 1132, 1032, 887; 
1
H NMR 
(500 MHz, CDCl3) δ 2.03 (3H, s, CH3CO), 3.71 (6H, s, 2 × ArOCH3), 3.76 (6H, s, 
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2 × ArOCH3), 4.49 (4H, s, 2 × ArCH2), 6.38 (2H, d, J = 2.4 Hz, H-3”), 6.44 (2H, dd, 
J = 8.4, 2.4 Hz, H-5”), 7.00 (1H, dd, J = 2.0, 2.0 Hz, H-2), 7.25 – 7.12 (4H, m, 4 × ArH), 
7.28 (2H, d, J = 8.4 Hz, H-6”), 7.38 (1H, ddd, J = 8.5, 7.0 and 2.0 Hz, H-4’ or H-5’), 7.44 
(1H, dd, J = 7.9, 7.9 Hz, H-5), 8.28 (1H, d, J = 8.2 Hz, H-3’); 13C NMR (126 MHz, CDCl3) 
 24.7 (CH3CO), 47.3 (ArCH2), 55.3 (ArOCH3), 55.5 (ArOCH3), 98.4 (C-3”), 104.1 
(C-5”), 116.6 (C-1”), 121.7 (CH Ar), 122.0 (C-3’), 123.3 (C-2), 124.4 (CH Ar), 127.5 
(CH Ar), 128.9 (C-4’ or C-5’), 130.0 (CH Ar), 130.5 (C-5), 130.9 (Cq Ar), 131.1 (C-6”), 
134.9 (Cq Ar), 139.8 (Cq Ar), 150.7 (C-3), 158.6 (C-2” or C-4”), 160.8 (C-2” or C-4”), 
168.8 (COCH3); LRMS (ES
-
) m/z 605.3 [M-H]
-
; HRMS (ESI) calcd for C32H33N2O8S 
[M-H]
-
 605.1963, found 605.1965. 
 
3'-Acetamido-[1,1'-biphenyl]-3-yl bis(2,4-dimethoxybenzyl)sulfamate, (147) 
 
Compound 147 was synthesised according to general procedure J, using the following 
reagents: 3'-amino-[1,1'-biphenyl]-3-yl bis(2,4-dimethoxybenzyl)sulfamate (137) (180 mg, 
0.32 mmol), triethylamine (65 mg, 89 µL, 0.64 mmol), acetic anhydride (39 mg, 36 µL, 
0.38 mmol) and DCM (3.2 mL). The crude product was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  4:6) to yield the title compound as a pale 
yellow oil (172 mg, 89%); Rf = 0.29 (petrol:EtOAc, 4:6); λmax (EtOH)/nm 235.0; IR (neat) 
νmax/cm
-1
 1669, 1610, 1589, 1507, 1368, 1207, 1156, 1133, 1035; 
1
H NMR (500 MHz, 
CDCl3) δ 2.24 (3H, s, CH3CO), 3.67 (6H, s, 2 × ArOCH3), 3.81 (6H, s, 2 × ArOCH3), 4.43 
(4H, s, 2 × ArCH2), 6.39 (2H, d, J = 2.4 Hz, H-3”), 6.47 (2H, dd, J = 8.4, 2.4 Hz, H-5”), 
6.83 (1H, dd, J = 2.0, 2.0 Hz, H-2), 7.17 (1H, ddd, J = 8.2, 2.4 and 1.1 Hz, ArH), 7.25 – 
7.22 (2H, m, 2 × ArH), 7.32 (2H, d, J = 8.4 Hz, H-6”), 7.35 (1H, dd, J = 7.9, 7.9 Hz, H-5 
or H-5’), 7.39 (1H, dd, J = 7.8, 7.8 Hz, H-5 or H-5’), 7.45 – 7.41 (1H, m, H-6), 7.59 (1H, s, 
NHAc), 7.81 (1H, ddd, J = 8.3, 1.4 and 1.4 Hz, H-4’); 13C NMR (126 MHz, CDCl3)  24.8 
(CH3CO), 47.2 (ArCH2), 55.2 (ArOCH3), 55.6 (ArOCH3), 98.5 (C-3”), 104.2 (C-5”), 117.0 
(C-1”), 118.3 (CH Ar), 119.5 (C-4’), 120.5 (C-2), 121.3 (CH Ar), 123.0 (CH Ar), 125.1 
(C-6), 129.7 (C-5 or C-5’), 129.9 (C-5 or C-5’), 131.4 (C-6”), 138.6 (Cq Ar), 140.6 (Cq 
Ar), 142.1 (Cq Ar), 150.9 (C-3), 158.7 (C-2” or C-4”), 160.6 (C-2” or C-4”), 168.5 
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(COCH3); LRMS (ES
-
) m/z 605.4 [M-H]
-
; HRMS (ESI) calcd for C32H33N2O8S [M-H]
-
 
605.1963, found 605.1961. 
 
4'-Acetamido-[1,1'-biphenyl]-3-yl bis(2,4-dimethoxybenzyl)sulfamate, (148) 
 
Compound 148 was synthesised according to general procedure J, using the following 
reagents: 4'-amino-[1,1'-biphenyl]-3-yl bis(2,4-dimethoxybenzyl)sulfamate (138) (150 mg, 
0.27 mmol), triethylamine (54 mg, 74 µL, 0.53 mmol), acetic anhydride (33 mg, 30 µL, 
0.32 mmol) and DCM (2.7 mL). The crude product was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  2:8) to yield the title compound as an 
orange oil (142 mg, 88%); Rf = 0.34 (petrol:EtOAc, 2:8); λmax (EtOH)/nm 277.0; IR (neat) 
νmax/cm
-1
 1666, 1599, 1532, 1506, 1379, 1207, 1155, 1125, 1038, 893; 
1
H NMR 
(500 MHz, CDCl3) δ 2.20 (3H, s, CH3CO), 3.70 (6H, s, 2 × ArOCH3), 3.78 (6H, s, 
2 × ArOCH3), 4.47 (4H, s, 2 × ArCH2), 6.37 (2H, d, J = 2.4 Hz, H-3”), 6.43 (2H, dd, 
J = 8.4, 2.4 Hz, H-5”), 7.15 – 7.08 (2H, m, H-2 and H-4), 7.28 (2H, d, J = 8.4 Hz, H-6”), 
7.32 (1H, s, NHAc), 7.34 (1H, dd, J = 7.9, 7.9 Hz, H-5), 7.42 – 7.38 (1H, m, H-6), 7.44 
(2H, d, J = 8.5 Hz, H-2’, 6’), 7.57 (2H, d, J = 8.5 Hz, H-3’, 5’); 13C NMR (126 MHz, 
CDCl3)  24.8 (CH3CO), 47.1 (ArCH2), 55.2 (ArOCH3), 55.5 (ArOCH3), 98.3 (C-3”), 
104.1 (C-5”), 116.7 (C-1”), 120.1 (C-2’, 6’), 120.3 (C-2 or C-4), 120.6 (C-2 or C-4), 124.8 
(C-6), 127.8 (C-3’, 5’), 129.9 (C-5), 131.2 (C-6”), 135.8 (Cq Ar), 137.8 (Cq Ar), 142.2 
(Cq Ar), 150.9 (C-3), 158.6 (C-2” or C-4”), 160.7 (C-2” or C-4”), 168.4 (COCH3); LRMS 
(ES
-
) m/z 605.4 [M-H]
-
; HRMS (ESI) calcd for C32H33N2O8S [M-H]
-
 605.1963, found 
605.1961. 
 
3'-(Sulfamoyloxy)-[1,1'-biphenyl]-2-carboxylic acid, (149) 
 
Compound 149 was synthesised according to general procedure D, using the following 
reagents: 3'-((N,N-bis(2,4-dimethoxybenzyl)sulfamoyl)oxy)-[1,1'-biphenyl]-2-carboxylic 
acid (145) (200 mg, 0.34 mmol), DCM (3.1 mL) and TFA (0.4 mL). The crude product 
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was purified by column chromatography (silica gel, petrol:EtOAc:AcOH, 
1:0:0  50:49.5:0.5) to yield the title compound as a pale pink solid (88 mg, 89%); 
Rf = 0.26 (petrol:EtOAc:AcOH, 50:49.5:0.5); m.p. 162.0-164.0 °C; λmax (EtOH)/nm 280.0; 
IR (neat) νmax/cm
-1
 3370, 3269, 1697, 1477, 1346, 1311, 1200, 1180; 
1
H NMR (500 MHz, 
DMSO-d6) δ 7.25 (1H, dd, J = 2.0, 2.0 Hz, H-2’), 7.34 – 7.26 (2H, m, H-4’ and H-6’), 7.43 
(1H, dd, J = 7.8, 1.2 Hz, H-3), 7.54 – 7.46 (2H, m, 2 × ArH), 7.61 (1H, ddd, J = 7.6, 7.6 
and 1.4 Hz, H-4), 7.77 (1H, dd, J = 7.8, 1.4 Hz, H-6), 8.04 (2H, s, ArOSO2NH2), 12.83 
(1H, brs, ArCO2H); 
13
C NMR (126 MHz, DMSO-d6) δ 120.9 (C-4’ or C-6’), 122.0 (C-2’), 
126.6 (C-4’ or C-6’), 127.8 (CH Ar), 129.3 (CH Ar), 129.4 (CH Ar), 130.6 (CH Ar), 131.1 
(C-3), 132.1 (C-2), 139.7 (C-1 or C-1’), 142.4 (C-1 or C-1’), 149.9 (C-3’), 169.3 
(ArCO2H); LRMS (ES
-
) m/z 292.2 [M-H]
-
; HRMS (ESI) calcd for C13H10NO5S [M-H]
-
 
292.0285, found 292.0286. 
 
2'-Acetamido-[1,1'-biphenyl]-3-yl sulfamate, (150) 
 
Compound 150 was synthesised according to general procedure D, using the following 
reagents: 2'-acetamido-[1,1'-biphenyl]-3-yl bis(2,4-dimethoxybenzyl)sulfamate (146) 
(130 mg, 0.21 mmol), DCM (1.8 mL) and TFA (0.2 mL). The crude product was purified 
by column chromatography (silica gel, petrol:EtOAc, 1:0  4:6) to yield the title 
compound as a white solid (57 mg, 86%); Rf = 0.30 (petrol:EtOAc, 4:6); m.p. 
164.5-166.5 °C; No λmax (EtOH)/nm; IR (neat) νmax/cm
-1
 3297, 3038, 1616, 1589, 1382, 
1366, 1197, 1147, 892; 
1
H NMR (500 MHz, DMSO-d6) δ 1.90 (3H, s, CH3CO), 7.44 - 7.17 
(6H, m, 6 × ArH), 7.65 – 7.44 (2H, m, 2 × ArH), 8.00 (2H, s, ArOSO2NH2), 9.26 (1H, s, 
ArNHAc); 
13
C NMR (126 MHz, DMSO-d6) δ 23.1 (CH3CO), 121.1 (CH Ar), 122.4 (CH 
Ar), 125.9 (CH Ar), 127.0 (CH Ar), 128.1 (CH Ar), 129.8 (CH Ar), 130.2 (CH Ar), 134.9 
(Cq Ar), 135.1 (Cq Ar), 140.6 (Cq Ar), 150.0 (C-3), 168.8 (COCH3); LRMS (ES
+
) m/z 
307.2 [M+H]
+
; HRMS (ESI) calcd for C14H15N2O4S [M+H]
+
 307.0747, found 307.0750. 
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3'-Acetamido-[1,1'-biphenyl]-3-yl sulfamate, (151) 
 
Compound 151 was synthesised according to general procedure D, using the following 
reagents: 3'-acetamido-[1,1'-biphenyl]-3-yl bis(2,4-dimethoxybenzyl)sulfamate (147) 
(130 mg, 0.21 mmol), DCM (1.8 mL) and TFA (0.2 mL). The crude product was purified 
by column chromatography (silica gel, petrol:EtOAc, 1:0  3:7) to yield the title 
compound as a white solid (60 mg, 91%); Rf = 0.30 (petrol:EtOAc, 3:7); m.p. 
152.0-154.0 °C; λmax (EtOH)/nm 242.0; IR (neat) νmax/cm
-1
 3356, 3219, 1653, 1554, 1364, 
1186; 
1
H NMR (500 MHz, DMSO-d6) δ 2.07 (3H, s, CH3CO), 7.31 – 7.25 (1H, m, ArH), 
7.34 (1H, d, J = 7.7 Hz, ArH), 7.41 (1H, dd, J = 7.8, 7.8 Hz, H-5), 7.51 – 7.46 (1H, m, 
H-2), 7.64 – 7.53 (3H, m, 3 × ArH), 7.91 (1H, dd, J = 1.9, 1.9 Hz, H-2’), 8.05 (2H, s, 
ArOSO2NH2), 10.07 (1H, s, ArNHAc); 
13
C NMR (126 MHz, DMSO-d6) δ 24.0 (CH3CO), 
117.3 (C-2’), 118.6 (CH Ar), 120.3 (C-2), 121.3 (CH Ar), 121.5 (CH Ar), 124.8 (CH Ar), 
129.4 (C-5), 130.3 (CH Ar), 139.5 (Cq Ar), 140.0 (Cq Ar), 142.0 (Cq Ar), 150.7 (C-3), 
168.5 (COCH3); LRMS (ES
+
) m/z 307.2 [M+H]
+
; HRMS (ESI) calcd for C14H15N2O4S 
[M+H]
+
 307.0747, found 307.0753. 
 
4'-Acetamido-[1,1'-biphenyl]-3-yl sulfamate, (152) 
 
Compound 152 was synthesised according to general procedure D, using the following 
reagents: 4'-acetamido-[1,1'-biphenyl]-3-yl bis(2,4-dimethoxybenzyl)sulfamate (148) 
(120 mg, 0.20 mmol), DCM (1.8 mL) and TFA (0.2 mL). The crude product was purified 
by column chromatography (silica gel, petrol:EtOAc, 1:0  1:9) to yield the title 
compound as a pale orange solid (51 mg, 84%); Rf = 0.32 (petrol:EtOAc, 1:9); m.p. 
175.5-177.5 °C; λmax (EtOH)/nm 276.5; IR (neat) νmax/cm
-1
 3362, 3291, 2976, 1656, 1595, 
1528, 1358, 1182; 
1
H NMR (500 MHz, DMSO-d6) δ 2.07 (3H, s, CH3CO), 7.23 (1H, dd, 
J = 7.8, 2.5 Hz, H-4), 7.56 – 7.47 (2H, m, H-2 and H-5), 7.65 – 7.58 (3H, m, H-6 and 
H-2’, 6’), 7.69 (2H, d, J = 8.3 Hz, H-3’, 5’), 8.02 (2H, s, ArOSO2NH2), 10.06 (1H, s, 
ArNHAc); 
13
C NMR (126 MHz, DMSO-d6) δ 24.1 (CH3CO), 119.3 (C-3’, 5’), 119.9 
(C-2), 120.7 (C-4), 124.4 (C-6), 127.1 (C-2’, 6’), 130.2 (C-5), 133.4 (C-4’), 139.3 (C-1 or 
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C-1’), 141.6 (C-1 or C-1’), 150.7 (C-3), 168.4 (COCH3); LRMS (ES
+
) m/z 307.2 [M+H]
+
; 
HRMS (ESI) calcd for C14H13N2O4S [M-H]
-
 305.0602, found 305.0593. 
 
Sodium (3'-(sulfamoyloxy)-[1,1'-biphenyl]-2-yl)sulfamate, (154) 
 
To 2,2,2-trichloroethyl (3'-(sulfamoyloxy)-[1,1'-biphenyl]-2-yl)((2,2,2-trichloroethoxy) 
sulfonyl)sulfamate (167) (110 mg, 0.16 mmol) in MeOH (3.5 mL) were added 3.5 mL of 
acetate buffer pH 4.65 and zinc (210 mg, 3.20 mmol). The resulting reaction mixture was 
stirred at RT for 24 h, until LC-MS indicated completion of the deprotection. Upon 
completion, the heterogeneous mixture was filtered through Celite and washed with MeOH 
(10 mL). The filtrate was concentrated in vacuo to give a crude oil, which was dissolved in 
a mixture of MeOH (3.5 mL) and acetate buffer pH 4.65 (3.5 mL). Acetic acid was added 
to acidify the reaction mixture to pH 4.0. The resulting solution was heated at 40 °C for 12 
h. Upon completion, the solvents were removed in vacuo and the crude product was 
converted to the sodium salt by ion-exchange chromatography (DOWEX 50WX2 - Na
+
 
form). The crude product was purified by column chromatography (silica gel, 
EtOAc:MeOH, 1:0  93:7) to yield the title compound as a white solid (30 mg, 50%). 
Rf = 0.25 (EtOAc:MeOH, 93:7; KMnO4); m.p. 142.0-144.0 °C; λmax (EtOH)/nm 275.6; IR 
(neat) νmax/cm
-1
 3501, 3305, 3205, 3071, 2922, 1670, 1609, 1580, 1475, 1370, 1183, 1149, 
1039; 
1
H NMR (500 MHz, MeOD)  7.03 (1H, ddd, J = 7.4, 7.4 and 1.2 Hz, H-4), 7.18 
(1H, dd, J = 7.7, 1.7 Hz, H-3), 7.30 (1H, ddd, J = 8.5, 7.9 and 1.6 Hz, H-5), 7.35 (1H, ddd, 
J = 8.2, 2.3 and 1.1 Hz, H-4’ or H-6’), 7.42 (1H, ddd, J = 7.4, 1.3 and 1.3 Hz, H-4’ or H-
6’), 7.46 (1H, dd, J = 1.9, 1.9 Hz, H-2’), 7.54 (1H, dd, J = 7.9, 7.9 Hz, H-5’), 7.72 (1H, dd, 
J = 8.4, 1.2 Hz, H-6); 
13
C NMR (126 MHz, MeOD)  120.4 (C-6), 122.9 (C-4’ or C-6’), 
123.0 (C-4), 124.5 (C-2’), 128.8 (C-4’ or C-6’), 129.6 (C-5), 131.0 (C-3), 131.3 (C-5’), 
131.3 (C-1), 139.4 (C-2 or C-1’), 142.0 (C-2 or C-1’), 152.3 (C-3’); LRMS (ES-) m/z 343.2 
[M-Na]
-
; HRMS (ESI) calcd for C12H11N2O6S2 [M-Na]
-
 343.0064, found 343.0055 
 
2,2,2-Trichlroethyl chlorosulfate, (156) 
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To sulfuryl chloride (6.76 mL, 83.5 mmol) in Et2O (40 mL), cooled at -78 °C, was added 
dropwise over 35 min a solution of 2,2,2-trichloroethanol (155) (8.00 mL, 12.5 g, 
83.5 mmol) and pyridine (6.76 mL, 6.61 g, 83.5 mmol) in Et2O (40 mL). The resulting 
mixture was stirred at -78 °C for 1 h and for an additional 2 h at RT. The mixture was then 
filtered to remove the pyridinium hydrochloride salt by-product and concentrated in vacuo. 
The crude liquid was purified by distillation under reduced pressure using a Kügelrohr 
distillation apparatus to yield the title compound as a clear liquid (17.3 g, 83%); IR (neat) 
νmax/cm
-1
 1414, 1189, 985, 870; 
1
H NMR (500 MHz, CDCl3) δ 4.92 (s, 2H, CH2OSO3Cl); 
13
C NMR (126 MHz, CDCl3)  81.3 (CH2OSO3Cl), 91.4 (CH2CCl3); 
1
H NMR, 
13
C NMR 
and IR data were identical to literature data.
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2,2,2-Trichloroethyl 2-methyl-1H-imidazole-1-sulfonate, (157) 
 
To a suspension of 2-methylimidazole (10.4 g, 126 mmol) in THF (60 mL), cooled at 0 °C, 
was added dropwise a solution of 2,2,2-trichloroethyl chlorosulfate (156) (4.68 mL, 8.7 g, 
35.1 mmol) in THF (40 mL). The resulting solution was stirred at 0 °C for 1 h and allowed 
to warm to RT. After 16 h, the remaining 2-methylimidazole was filtered off and washed 
with THF (50 mL), and the filtrate was concentrated in vacuo. The crude residue was 
dissolved in EtOAc (80 mL), washed with water and brine (50 mL, respectively), dried 
over MgSO4 and concentrated in vacuo. The crude product was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  7:3) to yield the title compound as a 
white amorphous solid (9.75 g, 95%); Rf = 0.29 (petrol:EtOAc, 7:3; KMnO4); 
m.p. 64.5-66.5 °C (lit. 53.0-55.0 °C)
121
; IR (neat) νmax/cm
-1
 3167, 1556, 1420, 1197, 1182, 
1155, 980; 
1
H NMR (500 MHz, CDCl3) δ 2.68 (3H, s, CH3), 4.64 (2H, s, CH2CCl3), 6.95 
(1H, d, J = 1.8 Hz, H-4 or H-5), 7.32 (1H, d, J = 1.8 Hz, H-4 or H-5); 
13
C NMR (126 MHz, 
CDCl3)  15.1 (CH3), 80.1 (CH2CCl3), 91.9 (CH2CCl3), 120.3 (C-4 or C-5), 128.4 (C-4 or 
C-5), 146.6 (C-2); LRMS (ES
+
) m/z 293.1 [M(
35
Cl
35
Cl
35
Cl)+H]
+
, 295.1 
[M(
37
Cl
35
Cl
35
Cl)+H]
+
, 297.1 [M(
37
Cl
37
Cl
35
Cl)+H]
+
; 
1
H NMR, 
13
C NMR and LRMS data 
were identical to literature data.
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242 
2,3-Dimethyl-1-((2,2,2-trichloroethoxy)sulfonyl)-1H-imidazol-3-ium 
tetrafluoroborate, (158) 
 
To 2,2,2-trichloroethyl 2-methyl-1H-imidazole-1-sulfonate (157) (9.8 g, 33.4 mmol) in 
DCM (100 mL), cooled at 0 °C, was added trimethyloxonium tetrafluoroborate (4.94 g, 
33.4 mmol). The resulting solution was stirred at 0 °C for 1 h and allowed to warm to RT. 
After 20 h, the reaction was cooled in an ice bath. Cold petrol (120 mL) was added to the 
mixture, leading to the precipitation of 158. The white precipitate was filtered off, washed 
with cold petrol (60 mL) and dry under high vacuum. The white fluffy solid (11.4 g, 86%) 
was used in the next step without further purification; m.p. 118.5-120.5 °C; IR (neat) 
νmax/cm
-1
 3150, 1601, 1531, 1438, 1230, 1208, 1162, 1050, 1027, 973; 
1
H NMR 
(500 MHz, MeOD)  2.93 (3H, s, CH3), 3.94 (3H, s, NCH3), 5.34 (2H, s, CH2CCl3), 7.74 
(1H, d, J = 2.5 Hz, H-4 or H-5), 8.08 (1H, d, J = 2.5 Hz, H-4 or H-5); 
13
C NMR (126 MHz, 
MeOD)  11.8 (CH3), 36.6 (NCH3), 83.3 (CH2CCl3), 93.0 (CH2CCl3), 122.1 (C-4 or C-5), 
124.9 (C-4 or C-5), 150.0 (C-2); 
19
F NMR (471 MHz, MeOD)  -154.50 (BF4
-
); 
LRMS (ES
+
) m/z 307.1 [M(
35
Cl
35
Cl
35
Cl)+H]
+
, 309.1 [M(
37
Cl
35
Cl
35
Cl)+H]
+
, 311.1 
[M(
37
Cl
37
Cl
35
Cl)+H]
+
; 
1
H NMR, 
13
C NMR, 
19
F NMR and LRMS data were identical to 
literature data.
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3'-(((2,2,2-Trichloroethoxy)sulfonyl)amino)-[1,1'-biphenyl]-3-yl bis(2,4-dimethoxy 
benzyl)sulfamate, (160) 
 
Compound 160 was synthesised according to general procedure K, using the following 
reagents: 3'-amino-[1,1'-biphenyl]-3-yl bis(2,4-dimethoxybenzyl)sulfamate (137) (550 mg, 
0.97 mmol), 2,3-dimethyl-1-((2,2,2-trichloroethoxy)sulfonyl)-1H-imidazol-3-ium 
tetrafluoroborate (158) (1.16 g, 2.92 mmol) and THF (9.8 mL). The crude product was 
purified by column chromatography (silica gel, petrol:EtOAc, 1:0  65:35) to yield the 
title compound as a pale yellow oil (567 mg, 75%); Rf = 0.31 (petrol:EtOAc, 65:35); No 
λmax (EtOH)/nm; IR (neat) νmax/cm
-1
 3264, 1610, 1589, 15074, 1360, 1208, 1176, 1157; 
1
H NMR (500 MHz, CDCl3) δ 3.66 (6H, s, 2 × ArOCH3), 3.85 (6H, s, 2 × ArOCH3), 4.42 
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(4H, s, 2 × ArCH2), 4.70 (2H, s, CH2CCl3), 6.41 (2H, d, J = 2.4 Hz, H-3”), 6.51 (2H, dd, 
J = 8.4, 2.4 Hz, H-5”), 6.56 (1H, dd, J = 2.0, 2.0 Hz, H-2’), 7.01 (1H, dd, J = 2.0, 2.0 Hz, 
H-2), 7.26 (1H, ddd, J = 8.0, 2.0 and 1.1 Hz, ArH), 7.35 (2H, d, J = 8.4 Hz, H-6”), 
7.39 - 7.36 (2H, m, 2 × ArH), 7.46 – 7.41 (3H, m, 3 × ArH), 7.71 (1H, s, ArNHSO3); 
13
C NMR (126 MHz, CDCl3)  47.3 (ArCH2), 55.3 (ArOCH3), 55.8 (ArOCH3), 79.1 
(CH2CCl3), 93.2 (CH2CCl3), 98.7 (C-3”), 104.4 (C-5”), 117.3 (C-1”), 119.7 (C-2), 119.9 
(CH Ar), 120.4 (C-2’), 121.7 (CH Ar), 124.3 (CH Ar), 124.9 (CH Ar), 130.1 (CH Ar), 
130.2 (CH Ar), 131.6 (C-6”), 136.2 (C-3’), 141.1 (C-1 or C-1’), 141.2 (C-1 or C-1’), 150.9 
(C-3), 158.8 (C-2” or C-4”), 160.5 (C-2” or C-4”); HRMS (ESI) calcd for 
C32H37Cl3N3O10S2 [M(
35
Cl
35
Cl
35
Cl)+H]
+
 792.0980, found 792.0989. 
 
4'-(((2,2,2-Trichloroethoxy)sulfonyl)amino)-[1,1'-biphenyl]-3-yl bis(2,4-dimethoxy 
benzyl)sulfamate, (161) 
 
Compound 161 was synthesised according to general procedure K, using the following 
reagents: 4'-amino-[1,1'-biphenyl]-3-yl bis(2,4-dimethoxybenzyl)sulfamate (138) (550 mg, 
0.97 mmol), 2,3-dimethyl-1-((2,2,2-trichloroethoxy)sulfonyl)-1H-imidazol-3-ium 
tetrafluoroborate (158) (1.16 g, 2.92 mmol) and THF (9.8 mL). The crude product was 
purified by column chromatography (silica gel, petrol:EtOAc, 1:0  6:4) to yield the title 
compound as a yellow oil (620 mg, 82%); Rf = 0.32 (petrol:EtOAc, 6:4); λmax (EtOH)/nm 
272.5; IR (neat) νmax/cm
-1
 1611, 1588, 1507, 1367, 1208, 1178, 1132, 1038; 
1
H NMR 
(500 MHz, CDCl3) δ 3.71 (6H, s, 2 × ArOCH3), 3.78 (6H, s, 2 × ArOCH3), 4.47 (4H, s, 
2 × ArCH2), 4.68 (2H, s, CH2CCl3), 6.38 (2H, d, J = 2.4 Hz, H-3”), 6.44 (2H, dd, J = 8.4, 
2.4 Hz, H-5”), 7.14 – 7.10 (2H, m, H-2 and H-4), 7.28 (2H, d, J = 8.4 Hz, H-6”), 7.30 (2H, 
d, J = 8.6 Hz, H-3’, 5’), 7.38 – 7.34 (1H, m, H-5), 7.41 – 7.38 (1H, m, H-6), 7.48 (2H, d, 
J = 8.6 Hz, H-2’, 6’); 13C NMR (126 MHz, CDCl3)  47.1 (ArCH2), 55.3 (ArOCH3), 55.5 
(ArOCH3), 79.2 (CH2CCl3), 93.1 (CH2CCl3), 98.4 (C-3”), 104.1 (C-5”), 116.7 (C-1”), 
120.5 (C-2 or C-4), 121.1 (C-2 or C-4), 121.6 (C-3’, 5’), 124.9 (C-6), 128.4 (C-2’, 6’), 
130.1 (C-5), 131.2 (C-6”), 135.0 (C-4’), 137.7 (C-1 or C-1’), 141.5 (C-1 or C-1’), 151.0 
(C-3), 158.6 (C-2” or C-4”), 160.8 (C-2” or C-4”); HRMS (ESI) calcd for 
C32H34Cl3N2O10S2 [M(
35
Cl
35
Cl
35
Cl)+H]
+
 775.0715, found 775.0721. 
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2,2,2-Trichloroethyl (3'-(sulfamoyloxy)-[1,1'-biphenyl]-3-yl)sulfamate, (162) 
 
Compound 162 was synthesised according to general procedure D, using the following 
reagents: 3'-(((2,2,2-trichloroethoxy)sulfonyl)amino)-[1,1'-biphenyl]-3-yl bis(2,4-
dimethoxy benzyl)sulfamate (160) (550 mg, 0.71 mmol), DCM (6.4 mL) and TFA 
(0.7 mL). The crude product was purified by column chromatography (silica gel, 
petrol:EtOAc, 1:0  7:3) to yield the title compound as a pale orange oil (290 mg, 86%); 
Rf = 0.29 (petrol:EtOAc, 7:3); λmax (EtOH)/nm 248.0; IR (neat) νmax/cm
-1
 3281, 1606, 
1576, 1476, 1370, 1175, 1146, 1087, 1014; 
1
H NMR (500 MHz, CDCl3) δ 4.68 (2H, s, 
CH2CCl3), 5.12 (2H, s, ArOSO2NH2), 7.10 (1H, s, ArNHSO3), 7.30 – 7.26 (1H, m, ArH), 
7.35 - 7.31 (1H, m, ArH), 7.54 – 7.39 (6H, m, 6 × ArH); 13C NMR (126 MHz, CDCl3) 
 79.1 (CH2CCl3), 93.1 (CH2CCl3), 119.8 (CH Ar), 120.5 (CH Ar), 120.9 (CH Ar), 121.5 
(CH Ar), 124.8 (CH Ar), 126.1 (CH Ar), 130.4 (CH Ar), 130.5 (CH Ar), 136.1 (C-3’), 
141.2 (C-1 or C-1’), 142.2 (C-1 or C-1’), 150.6 (C-3); LRMS (ES-) m/z 473.1 
[M(
35
Cl
35
Cl
35
Cl)-H]
-
, 475.1 [M(
37
Cl
35
Cl
35
Cl)-H]
-
, 477.2 [M(
37
Cl
37
Cl
35
Cl)-H]
-
; HRMS 
(ESI) calcd for C14H12Cl3N2O6S2 [M(
35
Cl
35
Cl
35
Cl)-H]
-
 472.9208, found 472.9202. 
 
2,2,2-Trichloroethyl (3'-(sulfamoyloxy)-[1,1'-biphenyl]-4-yl)sulfamate, (163) 
 
Compound 163 was synthesised according to general procedure D, using the following 
reagents: 4'-(((2,2,2-trichloroethoxy)sulfonyl)amino)-[1,1'-biphenyl]-3-yl bis(2,4-
dimethoxy benzyl)sulfamate (161) (600 mg, 0.77 mmol), DCM (7.0 mL) and TFA 
(0.7 mL). The crude product was purified by column chromatography (silica gel, 
petrol:EtOAc, 1:0  65:35) to yield the title compound as a pale yellow oil (335 mg, 
91%); Rf = 0.28 (petrol:EtOAc, 65:35); λmax (EtOH)/nm 264.0; IR (neat) νmax/cm
-1
 3361, 
3265, 1605, 1574, 1522, 1483, 1427, 1363, 1170, 1145; 
1
H NMR (500 MHz, DMSO-d6) δ 
4.88 (2H, s, CH2CCl3), 7.26 (1H, ddd, J = 7.9, 2.3 and 1.0 Hz, H-4 or H-6), 7.34 (2H, d, 
J = 8.6 Hz, H-3’, 5’), 7.57 – 7.50 (2H, m, H-2 and H-5), 7.64 – 7.58 (1H, m, H-4 or H-6), 
7.70 (2H, d, J = 8.7 Hz, H-2’, 6’), 8.03 (2H, s, ArOSO2NH2), 11.15 (1H, s, ArNHSO3); 
13
C NMR (126 MHz, DMSO-d6) δ 77.8 (CH2CCl3), 93.5 (CH2CCl3), 120.1 (C-2), 120.3 
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(C-3’, 5’), 121.1 (C-4 or C-6), 124.6 (C-4 or C-6), 127.7 (C-2’, 6’), 130.3 (C-5), 135.1 
(C-1’ or C-4’), 136.5 (C-1’ or C-4’), 141.1 (C-1), 150.7 (C-3); LRMS (ES-) m/z 473.1 
[M(
35
Cl
35
Cl
35
Cl)-H]
-
, 475.1 [M(
37
Cl
35
Cl
35
Cl)-H]
-
, 477.1 [M(
37
Cl
37
Cl
35
Cl)-H]
-
; HRMS 
(ESI) calcd for C14H12Cl3N2O6S2 [M(
35
Cl
35
Cl
35
Cl)-H]
-
 472.9208, found 472.9198. 
 
Sodium (3'-(sulfamoyloxy)-[1,1'-biphenyl]-3-yl)sulfamate, (164) 
 
Compound 164 was synthesised according to general procedure M, using the following 
reagents: 2,2,2-trichloroethyl (3'-(sulfamoyloxy)-[1,1'-biphenyl]-3-yl)sulfamate (162) 
(200 mg, 0.42 mmol), MeOH (4.2 mL), acetate buffer pH 4.65 (4.2 mL) and zinc (275 mg, 
4.20 mmol). The crude product was converted to the sodium salt by ion-exchange 
chromatography (DOWEX 50WX2 - Na
+
 form). The crude product was purified by 
column chromatography (silica gel, EtOAc:MeOH, 1:0  93:7) to yield the title 
compound as a white solid (128 mg, 84%); Rf = 0.21 (EtOAc:MeOH, 93:7; KMnO4); 
m.p. 185.5-187.5 °C; λmax (EtOH)/nm 235.2; IR (neat) νmax/cm
-1
 3367, 3306, 3263, 1602, 
1576, 1468, 1423, 1360, 1239, 1199, 1176, 1151; 
1
H NMR (500 MHz, MeOD)  7.16 (2H, 
dd, J = 8.0, 2.1 Hz, 2 × ArH), 7.32 – 7.26 (2H, m, H-5 or H-5’ and ArH), 7.47 (1H, dd, 
J = 8.1, 8.1 Hz, H-5 or H-5’), 7.51 (1H, dd, J = 2.0 Hz, H-2 or H-2’), 7.60 – 7.55 (2H, m, 
2 × ArH); 
13
C NMR (126 MHz, MeOD)  117.2 (C-2 or C-2’), 118.2 (CH Ar), 120.5 
(CH Ar), 121.9 (CH Ar), 122.0 (CH Ar), 126.3 (CH Ar), 130.2 (C-5 or C-5’), 130.9 (C-5 
or C-5’), 141.7 (C-3), 143.7 (C-1 or C-1’), 144.6 (C-1 or C-1’), 152.4 (C-3’); LRMS (ES-) 
m/z 343.2 [M-Na]
-
; HRMS (ESI) calcd for C12H11N2O6S2 [M-Na]
-
 343.0064, found 
343.0052. 
 
Sodium (3'-(sulfamoyloxy)-[1,1'-biphenyl]-4-yl)sulfamate, (165) 
 
Compound 165 was synthesised according to general procedure M, using the following 
reagents: 2,2,2-trichloroethyl (3'-(sulfamoyloxy)-[1,1'-biphenyl]-4-yl)sulfamate (163) 
(100 mg, 0.21 mmol), MeOH (2.1 mL), acetate buffer pH 4.65 (2.1 mL) and zinc (137 mg, 
2.10 mmol). The crude product was converted to the sodium salt by ion-exchange 
chromatography (DOWEX 50WX2 - Na
+
 form). The crude product was purified by 
246 
column chromatography (silica gel, EtOAc:MeOH, 1:0  93:7) to yield the title 
compound as a white solid (62 mg, 80%); Rf = 0.21 (EtOAc:MeOH, 93:7; KMnO4); 
m.p. No clear m.p., decomposition range 185-195 °C; λmax (EtOH)/nm 280.5; IR (neat) 
νmax/cm
-1
 3362, 3254, 1607, 1586, 1573, 1523, 1480, 1365, 1195, 1183, 1154, 1064; 
1
H NMR (500 MHz, MeOD)  7.26 – 7.19 (1H, m, H-4’ or H-6’), 7.26 (2H, d, J = 8.6 Hz, 
H-3, 5), 7.44 (1H, dd, J = 8.2, 8.2 Hz, H-5’), 7.57 – 7.48 (4H, m, 4 × ArH); 13C NMR 
(126 MHz, MeOD)  118.8 (C-3, 5), 121.2 (CH Ar), 121.2 (CH Ar), 125.6 (CH Ar), 128.2 
(C-2, 6), 130.9 (C-5’), 133.4 (C-4), 143.2 (C-1 or C-1’), 144.3 (C-1 or C-1’), 152.5 (C-3’); 
LRMS (ES
-
) m/z 343.2 [M-Na]
-
; HRMS (ESI) calcd for C12H11N2O6S2 [M-Na]
-
 343.0064, 
found 343.0052. 
 
2'-(bis((2,2,2-trichloroethoxy)sulfonyl)amino)-[1,1'-biphenyl]-3-yl bis(2,4-dimethoxy 
benzyl)sulfamate, (166) 
 
Compound 166 was synthesised according to general procedure L, using the following 
reagents: 2'-amino-[1,1'-biphenyl]-3-yl bis(2,4-dimethoxybenzyl)sulfamate (136) (550 mg, 
0.97 mmol), 4-(dimethylamino)pyridine (262 mg, 2.14 mmol), triethylamine (543 µL, 394 
mg, 3.90 mmol), 2,2,2-trichloroethyl chlorosulfate (156) (519 µL, 966 mg, 3.90 mmol) and 
THF (10 + 5 mL). The crude product was purified by column chromatography (silica gel, 
petrol:EtOAc, 1:0  3:1) to yield the title compound as a pale yellow oil (673 mg, 70%); 
Rf = 0.30 (petrol:EtOAC, 3:1); λmax (EtOH)/nm 276.5; IR (neat) νmax/cm
-1
 1612, 1588, 
1508, 1425, 1369, 1185, 1156; 
1
H NMR (500 MHz, CDCl3) δ 3.71 (6H, s, 2 × ArOCH3), 
3.76 (6H, s, 2 × ArOCH3), 4.45 (2H, d, J = 11.4 Hz, CH2CCl3), 4.49 (4H, s, 2 × ArCH2), 
4.66 (2H, d, J = 11.4 Hz, CH2CCl3), 6.37 (2H, d, J = 2.4 Hz, H-3”), 6.43 (2H, dd, J = 8.3, 
2.4 Hz, H-5”), 7.18 (1H, dd, J = 1.4, 1.4 Hz, H-2), 7.24 (1H, ddd, J = 7.6, 2.6 and 2.6 Hz, 
H-4 or H-6), 7.29 (2H, d, J = 8.4 Hz, H-6”), 7.39 (1H, dd, J = 7.6, 1.7 Hz, H-3’), 
7.45 - 7.40 (2H, m, H-5 and H-4 or H-6), 7.56 – 7.51 (1H, m, H-4’ or H-5’), 7.62 – 7.57 
(1H, m, H-4’ or H-5’), 7.68 (1H, dd, J = 7.9, 1.3 Hz, H-6’); 13C NMR (126 MHz, CDCl3) 
 47.0 (ArCH2), 55.2 (ArOCH3), 55.5 (ArOCH3), 81.5 (CH2CCl3), 92.7 (CH2CCl3), 98.3 
(C-3”), 104.2 (C-5”), 116.6 (C-1”), 122.3 (C-4 or C-6), 123.4 (C-2), 127.4 (CH Ar), 129.6 
(CH Ar), 129.7 (CH Ar), 131.1 (C-6”), 131.5 (C-4’ or C-5’), 132.5 (C-3’), 132.7 (C-2’), 
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139.5 (C-1 or C-1’), 141.9 (C-1 or C-1’), 150.7 (C-3), 158.6 (C-2” or C-4”), 160.7 (C-2” or 
C-4”); HRMS (ESI) calcd for C34H38Cl6N3O13S3 [M(6 × 
35
Cl)+NH4]
+
 1001.9692, found 
1001.9675. 
 
2,2,2-Trichloroethyl (3'-(sulfamoyloxy)-[1,1'-biphenyl]-2-yl)((2,2,2-trichloroethoxy) 
sulfonyl)sulfamate, (167) 
 
Compound 167 was synthesised according to general procedure D, using the following 
reagents: 2'-(bis((2,2,2-trichloroethoxy)sulfonyl)amino)-[1,1'-biphenyl]-3-yl bis(2,4-
dimethoxybenzyl)sulfamate (166) (550 mg, 0.56 mmol), DCM (5.1 mL) and TFA 
(0.6 mL). The crude product was purified by column chromatography (silica gel, 
petrol:EtOAc, 1:0  8:2) to yield the title compound as a pale orange oil (344 mg, 90%); 
Rf = 0.29 (petrol:EtOAc, 8:2); λmax (EtOH)/nm 232.0; IR (neat) νmax/cm
-1
 3456, 3346, 
1545, 1473, 1424, 1388, 1189, 1152, 1093, 990; 
1
H NMR (500 MHz, CDCl3) δ 4.53 (2H, 
d, J = 11.4 Hz, CH2CCl3), 4.72 (2H, d, J = 11.4 Hz, CH2CCl3), 5.10 (2H, s, ArOSO2NH2), 
7.45 - 7.39 (2H, m, 2 × ArH), 7.47 (1H, dd, J = 7.6, 1.7 Hz, H-3’), 7.59 – 7.52 (3H, m, 
3 × ArH), 7.65 – 7.60 (1H, m, H-4’ or H-5’), 7.69 – 7.66 (1H, m, H-6’); 13C NMR 
(126 MHz, CDCl3)  81.6 (CH2CCl3), 92.6 (CH2CCl3), 122.6 (CH Ar), 122.8 (CH Ar), 
128.6 (CH Ar), 129.7 (C-6’), 130.0 (CH Ar), 130.5 (CH Ar), 131.8 (C-4’ or C-5’), 132.3 
(C-3’), 132.6 (C-2’), 139.7 (C-1 or C-1’), 141.6 (C-1 or C-1’), 150.1 (C-3); HRMS (ESI) 
calcd for C16H18Cl6N3O9S3 [M(6 × 
35
Cl)+NH4]
+
 701.8331, found 701.8334. 
 
3-(Benzyloxy)phenol, (170) 
 
To resorcinol (169) (7.4 g, 67.3 mmol) in acetonitrile (70 mL) were added potassium 
carbonate (2.32 g, 16.8 mmol) and benzyl bromide (2.0 mL, 2.88 g, 16.8 mmol). The 
resulting solution was heated at reflux for 24 h. Upon completion, the solvent was removed 
in vacuo to yield a crude product. The crude residue was dissolved in EtOAc (50 mL), 
washed with saturated aq. NaHCO3 (40 mL) and water (2 × 40 mL). The organic phase 
was dried over MgSO4 and concentrated in vacuo. The crude yellow solid was purified by 
column chromatography (silica gel, petrol:EtOAc, 1:0  85:15) to yield the title 
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compound as a pale yellow solid (2.43 g, 72%); Rf = 0.30 (petrol:EtOAc, 85:15; KMnO4); 
m.p. 47.5-49.5 °C (lit. 52 °C)
273
; λmax (EtOH)/nm 275.0; IR (neat) νmax/cm
-1
 3292, 1592, 
1497, 1487, 1462, 1451, 1378, 1277, 1142; 
1
H NMR (500 MHz, CDCl3) δ 4.74 (1H, s, 
ArOH), 5.04 (2H, s, ArCH2), 6.44 (1H, ddd, J = 8.2, 2.5 and 0.8 Hz, H-4 or H-6), 6.49 
(1H, dd, J = 2.5, 2.4 Hz, H-2), 6.58 (1H, ddd, J = 8.4, 2.4 and 0.8 Hz, H-4 or H-6), 7.14 
(1H, dd, J = 8.4, 8.2 Hz, H-5), 7.35 – 7.31 (1H, m, H-4’), 7.41 – 7.36 (2H, m, H-3’, 5’), 
7.45 – 7.41 (2H, m, H-2’, 6’); 13C NMR (126 MHz, CDCl3)  70.2 (ArCH2), 102.6 (C-2), 
107.5 (C-4 or C-6), 108.2 (C-4 or C-6), 127.6 (C-3’, 5’), 128.1 (C-4’), 128.7 (C-2’, 6’), 
130.3 (C-5), 137.0 (C-1’), 156.8 (C-1 or C-3), 160.3 (C-1 or C-3); LRMS (ES-) m/z 199.1 
[M-H]
-
; HRMS (ESI) calcd for C13H11O2 [M-H]
-
 199.0765, found 199.0763; 
1
H NMR, 
13
C NMR and IR data were identical to literature data.
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3-(Benzyloxy)phenyl 2-methyl-1H-imidazole-1-sulfonate, (171) 
 
Compound 171 was synthesised according to general procedure B, using the following 
reagents: 1,1'-sulfonylbis(2-methyl-1H-imidazole) (19) (2.26 g, 9.99 mmol), caesium 
carbonate (1.79 g, 5.49 mmol), 3-(benzyloxy)phenol (170) (1.0 g, 4.99 mmol) and 
acetonitrile (20 mL). The crude yellow oil was purified by column chromatography (silica 
gel, petrol:EtOAc, 1:0  3:1) to yield the title compound as a clear oil (1.64 g, 95%); 
Rf = 0.28 (petrol:EtOAc, 3:1; KMnO4); λmax (EtOH)/nm 271.5; IR (neat) νmax/cm
-1
 1608, 
1585, 1552, 1486, 1422, 1206, 1114; 
1
H NMR (500 MHz, CDCl3) δ 2.46 (3H, s, CH3), 
4.99 (2H, s, ArCH2), 6.52 – 6.47 (1H, m, H-4 or H-6), 6.55 (1H, dd, J = 2.3, 2.3 Hz, H-2), 
6.88 (1H, d, J = 1.7 Hz, H-4’ or H-5’), 6.97 – 6.93 (1H, m, H-4 or H-6), 7.13 (1H, d, 
J = 1.7 Hz, H-4’ or H-5’), 7.24 (1H, dd, J = 8.3, 8.3 Hz, H-5), 7.41 – 7.32 (5H, m, 5 × ArH 
(benzyl)); 
13
C NMR (126 MHz, CDCl3)  15.0 (CH3), 70.6 (ArCH2), 108.4 (C-2), 113.7 
(C-4 or C-6), 115.6 (C-4 or C-6), 120.5 (C-4’ or C-5’), 127.6 (CH Ar (benzyl)), 128.1 
(C-4’ or C-5’), 128.5 (CH Ar (benzyl)), 128.9 (CH Ar (benzyl)), 130.7 (C-5), 136.0 
(Cq (benzyl)), 146.9 (C-2’ or C-1), 149.8 (C-2’ or C-1), 160.0 (C-3); LRMS (ES
+
) m/z 
345.3 [M+H]
+
; HRMS (ESI) calcd for C17H17N2O4S [M+H]
+
 345.0904, found 345.0902. 
 
  
249 
3-(Benzyloxy)phenyl bis(2,4-dimethoxybenzyl)sulfamate, (172) 
 
Compound 172 was synthesised according to general procedure H, using the following 
reagents: 3-(benzyloxy)phenyl 2-methyl-1H-imidazole-1-sulfonate (171) (5.0 g, 
14.5 mmol), trimethyloxonium tetrafluoroborate (2.15 g, 14.5 mmol), DCM (145 mL), 
acetonitrile (73 mL) and bis(2,4-dimethoxybenzyl)amine (32) (4.62 g, 14.5 mmol). The 
crude product was purified by column chromatography (silica gel, petrol:EtOAc, 
1:0  3:1) to yield the title compound as a clear oil (4.63 g, 55%); Rf = 0.26 
(petrol:EtOAc, 3:1; KMnO4); λmax (EtOH)/nm 277.5; IR (neat) νmax/cm
-1
 1608, 1587, 1507, 
1454, 1370, 1207, 1120; 
1
H NMR (500 MHz, CDCl3) δ 3.72 (6H, s, 2 × ArOCH3), 3.78 
(6H, s, 2 × ArOCH3), 4.45 (4H, s, 2 × ArCH2), 4.95 (2H, s, ArCH2 (benzyl)), 6.39 (2H, d, 
J = 2.4 Hz, H-3’), 6.43 (2H, dd, J = 8.3, 2.4 Hz, H-5’), 6.67 (1H, dd, J = 2.5, 2.2 Hz, H-2), 
6.75 (1H, ddd, J = 8.1, 2.2 and 0.9 Hz, H-4 or H-6), 6.84 (1H, ddd, J = 8.4, 2.5 and 0.9 Hz, 
H-4 or H-6), 7.20 (1H, dd, J = 8.4, 8.1 Hz, H-5), 7.27 (2H, d, J = 8.3 Hz, H-6’), 7.36 – 7.31 
(1H, m, ArH (benzyl)), 7.45 – 7.37 (4H, m, 4 × ArH (benzyl)); 13C NMR (126 MHz, 
CDCl3)  47.0 (ArCH2), 55.2 (ArOCH3), 55.5 (ArOCH3), 70.3 (ArCH2 (benzyl)), 98.3 
(C-3’), 104.1 (C-5’), 108.6 (C-2), 113.5 (C-4 or C-6), 114.4 (C-4 or C-6), 116.7 (C-1’), 
127.7 (CH Ar (benzyl)), 128.2 (CH Ar (benzyl)), 128.7 (CH Ar (benzyl)), 130.0 (C-5), 
131.1 (C-6’), 136.6 (C-1”), 151.4 (C-1), 158.6 (C-2’ or C-4’), 159. 7 (C-3), 160.7 (C-2’ or 
C-4’); HRMS (ESI) calcd for C31H34NO8S [M+H]
+
 580.2000, found 580.1987. 
 
3-Hydroxyphenyl bis(2,4-dimethoxybenzyl)sulfamate, (173) 
 
Compound 173 was synthesised following two different procedures. 
1
st
 procedure: 3-(Benzyloxy)phenyl bis(2,4-dimethoxybenzyl)sulfamate (172) (4.0 g, 
6.90 mmol) in a mixture of MeOH (120 mL) and THF (30 mL) was subjected to 
palladium-catalysed hydrogenation using an H-Cube

 reactor and a 10% Pd/C CatCart. 
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The reaction was conducted at 50 °C for 24 h in full hydrogen mode. The crude product 
was purified by column chromatography (silica gel, petrol:EtOAc, 1:0  6:4) to yield the 
title compound as a pale yellow oil (2.53 g, 75%). 
2
nd
 procedure: To 3-hydroxyphenyl 2-methyl-1H-imidazole-1-sulfonate (174) (1.8 g, 
7.08 mmol) in a mixture of DCM (80 mL) and THF (10 mL), cooled at 0 °C, was added 
trimethyloxonium tetrafluoroborate (1.05 g, 7.08 mmol). The resulting solution was stirred 
at 0 °C for 3 h and allowed to warm to RT. After 6 h, the reaction was diluted with 
acetonitrile (25 mL) and bis(2,4-dimethoxybenzyl)amine (32) (2.25 g, 7.08 mmol) was 
added. The resulting reaction mixture was heated at 42 °C for 24 h. Upon completion, the 
solvent was removed in vacuo to yield a crude product. The crude product was purified by 
column chromatography (silica gel, petrol:EtOAc, 1:0  6:4) to yield the title compound 
as a clear oil (2.08 g, 60%); Rf = 0.28 (petrol:EtOAc, 6:4; KMnO4); λmax (EtOH)/nm 276.5; 
IR (neat) νmax/cm
-1
 3449, 1611, 1588, 1507, 1456, 1362, 1291, 1207, 1157, 1115, 1034; 
1
H NMR (500 MHz, CDCl3) δ 3.71 (6H, s, 2 × ArOCH3), 3.79 (6H, s, 2 × ArOCH3), 4.45 
(4H, s, 2 × ArCH2), 5.40 (1H, s, ArOH), 6.38 (2H, d, J = 2.4 Hz, H-3’), 6.43 (2H, dd, 
J = 8.4, 2.4 Hz, H-5’), 6.55 (1H, dd, J = 2.3, 2.3 Hz, H-2’), 6.71 – 6.64 (2H, m, H-4 and 
H-6), 7.13 (1H, dd, J = 8.2, 8.2 Hz, H-5), 7.26 (2H, d, J = 8.4 Hz, H-6’); 13C NMR 
(126 MHz, CDCl3)  47.1 (ArCH2), 55.2 (ArOCH3), 55.5 (ArOCH3), 98.3 (C-3’), 104.1 
(C-5’), 109.5 (C-2), 113.7 (C-4 or C-6), 114.0 (C-4 or C-6), 116.7 (C-1’), 130.2 (C-5), 
131.1 (C-6’), 151.3 (C-1), 156.6 (C-3), 158.6 (C-2’ or C-4’), 160.7 (C-2’ or C-4’); LRMS 
(ES
-
) m/z 488.4 [M-H]
-
; HRMS (ESI) calcd for C24H26NO8S [M-H]
-
 488.1385, found 
488.1374. 
 
3-Hydroxyphenyl 2-methyl-1H-imidazole-1-sulfonate, (174) 
 
To 1,1'-sulfonylbis(2-methyl-1H-imidazole) (19) (2.0 g, 8.84 mmol) and caesium 
carbonate (2.88 g, 8.84 mmol) in acetonitrile was added resorcinol (169) (4.87 g, 
44.2 mmol). The resulting mixture was heated at 120 °C for 15 min under microwave 
irradiation. After cooling, the mixture was concentrated in vacuo. The resulting residue 
was dissolved in a saturated aq. NH4Cl (20 mL) and the mixture extracted with EtOAc 
(3 × 20 mL). The pooled organic extracts were washed with water (2 × 20 mL) and brine 
(20 mL), dried over MgSO4 and concentrated in vacuo. The crude yellow solid was 
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purified by column chromatography (silica gel, petrol:EtOAc, 1:0  6:4) to yield the title 
compound as a pale yellow solid (1.80 g, 80%); Rf = 0.30 (petrol:EtOAc, 6:4; KMnO4); 
m.p. 122.0-124.0 °C; λmax (EtOH)/nm 274.0; IR (neat) νmax/cm
-1
 1618, 1585, 1556, 1463, 
1427, 1381, 1204, 1181, 1154; 
1
H NMR (500 MHz, CDCl3) δ 2.48 (3H, s, CH3), 6.16 (1H, 
dd, J = 2.4, 2.3 Hz, H-2), 6.67 (1H, ddd, J = 8.2, 2.4 and 0.9 Hz, H-4 or H-6), 6.89 – 6.82 
(2H, m, H-4 or H-6 and H-4’ or H-5’), 7.21 (1H, d, J = 1.8 Hz, H-4’ or H-5’), 7.26 (1H, d, 
J = 8.3 Hz, H-5), 9.43 (1H, s, ArOH); 
13
C NMR (126 MHz, CDCl3)  14.6 (CH3), 107.8 
(C-2), 113.2 (C-4 or C-6), 116.6 (C-4 or C-6), 120.9 (C-4’ or C-5’), 126.7 (C-4’ or C-5’), 
131.2 (C-5), 147.4 (C-1 or C-2’), 149.6 (C-1 or C-2’), 158.6 (C-3); LRMS (ES+) m/z 255.2 
[M+H]
+
; HRMS (ESI) calcd for C10H11N2O4S [M+H]
+
 255.0434, found 255.0439. 
 
3-(2-Nitrophenoxy)phenyl bis(2,4-dimethoxybenzyl)sulfamate, (178) 
 
Compound 178 was synthesised according to general procedure N, using the following 
reagents: 3-hydroxyphenyl bis(2,4-dimethoxybenzyl)sulfamate (173) (1.4 g, 2.86 mmol), 
potassium carbonate (474 mg, 3.43 mmol), 1-fluoro-2-nitrobenzene (603 µL, 807 mg, 
5.72 mmol) and N,N-dimethylformamide (20 mL). The crude brown oil was purified by 
column chromatography (silica gel, petrol:EtOAc, 1:0  3:1) to yield the title compound 
as a pale orange oil (1.40 g, 80%); Rf = 0.28 (petrol:EtOAc, 3:1); λmax (EtOH)/nm 276.0; 
IR (neat) νmax/cm
-1
 1611, 1588, 1527, 1507, 1476, 1350, 1251, 1207, 1157, 1112; 
1
H NMR 
(500 MHz, CDCl3) δ 3.72 (6H, s, 2 × ArOCH3), 3.78 (6H, s, 2 × ArOCH3), 4.43 (4H, s, 
2 × ArCH2), 6.37 (2H, d, J = 2.4 Hz, H-3”), 6.41 (2H, dd, J = 8.3, 2.4 Hz, H-5”), 6.66 (1H, 
dd, J = 2.3, 2.3 Hz, H-2), 6.90 (1H, dd, J = 8.0, 2.0 Hz, H-6’), 7.02 – 6.95 (2H, m, H-4 or 
H-6 and H-4’), 7.25 – 7.21 (3H, m, H-4 or H-6 and H-6”), 7.30 (1H, dd, J = 8.3, 8.3 Hz, 
H-5), 7.54 – 7.49 (1H, m, H-5’), 7.97 (1H, dd, J = 8.2, 1.6 Hz, H-3’); 13C NMR (126 MHz, 
CDCl3)  47.2 (ArCH2), 55.2 (ArOCH3), 55.5 (ArOCH3), 98.3 (C-3”), 104.1 (C-5”), 113.3 
(C-2), 116.5 (C-1”), 117.1 (C-6’), 118.2 (C-4 or C-6 or C-4’), 120.8 (C-4 or C-6 or C-4’), 
123.8 (C-4 or C-6), 126.0 (C-3’), 130.6 (C-5), 131.1 (C-6”), 134.4 (C-5’), 141.5 (C-2’), 
150.2 (C-1 or C-1’), 151.5 (C-1 or C-1’), 156.4 (C-3), 158.6 (C-2” or C-4”), 160.8 (C-2” or 
C-4”); HRMS (ESI) calcd for C30H34N3O10S [M+NH4]
+
 628.1959, found 628.1957. 
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3-(3-Nitrophenoxy)phenyl bis(2,4-dimethoxybenzyl)sulfamate, (179) 
 
Compound 179 was synthesised according to general procedure N, using the following 
reagents: 3-hydroxyphenyl bis(2,4-dimethoxybenzyl)sulfamate (173) (1.4 g, 2.86 mmol), 
potassium carbonate (474 mg, 3.43 mmol), 1-fluoro-3-nitrobenzene (609 µL, 807 mg, 
5.72 mmol) and N,N-dimethylformamide (20 mL). The crude brown oil was purified by 
column chromatography (silica gel, petrol:EtOAc, 1:0  3:1) to yield the title compound 
as a brown oil (1.31 g, 75%); Rf = 0.30 (petrol:EtOAc, 3:1); λmax (EtOH)/nm 273.5; 
IR (neat) νmax/cm
-1
 1611, 1588, 1529, 1507, 1479, 1349, 1248, 1208, 1157, 1113; 
1
H NMR 
(500 MHz, CDCl3) δ 3.72 (6H, s, 2 × ArOCH3), 3.78 (6H, s, 2 × ArOCH3), 4.45 (4H, s, 
2 × ArCH2), 6.37 (2H, d, J = 2.4 Hz, H-3”), 6.41 (2H, dd, J = 8.4, 2.4 Hz, H-5”), 6.73 (1H, 
dd, J = 2.3, 2.2 Hz, H-2), 6.91 (1H, ddd, J = 8.3, 2.3 and 0.9 Hz, H-4 or H-6), 6.97 (1H, 
ddd, J = 8.2, 2.2 and 0.9 Hz, H-4 or H-6), 7.25 (2H, d, J = 8.4 Hz, H-6”), 7.30 (1H, ddd, 
J = 8.2, 2.4 and 0.9 Hz, H-6’), 7.33 (1H, dd, J = 8.3, 8.2 Hz, H-5), 7.50 (1H, dd, J = 8.2, 
8.2 Hz, H-5’), 7.80 (1H, dd, J = 2.3, 2.3 Hz, H-2’), 7.97 (1H, ddd, J = 8.2, 2.1 and 0.9 Hz, 
H-4’); 13C NMR (126 MHz, CDCl3)  47.1 (ArCH2), 55.2 (ArOCH3), 55.5 (ArOCH3), 98.3 
(C-3”), 104.1 (C-5”), 113.4 (C-2’), 113.7 (C-2), 116.5 (C-1”), 117.5 (C-4 or C-6), 118.3 
(C-4 or C-6 or C-4’), 118.3 (C-4 or C-6 or C-4’), 124.4 (C-6’), 130.6 (C-5’), 130.8 (C-5), 
131.1 (C-6”), 149.4 (C-3’), 151. 7 (C-1), 156.4 (C-3 or C-1’), 157.9 (C-3 or C-1’), 158.6 
(C-2” or C-4”), 160.8 (C-2” or C-4”); HRMS (ESI) calcd for C30H34N3O10S [M+NH4]
+
 
628.1959, found 628.1956. 
 
3-(4-Nitrophenoxy)phenyl bis(2,4-dimethoxybenzyl)sulfamate, (180) 
 
Compound 180 was synthesised according to general procedure N, using the following 
reagents: 3-hydroxyphenyl bis(2,4-dimethoxybenzyl)sulfamate (173) (1.2 g, 2.45 mmol), 
potassium carbonate (407 mg, 2.94 mmol), 1-fluoro-4-nitrobenzene (692 mg, 4.90 mmol) 
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and N,N-dimethylformamide (20 mL). The crude brown oil was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  8:2) to yield the title compound as a 
yellow oil (1.28 g, 85%); Rf = 0.28 (petrol:EtOAc, 8:2); λmax (EtOH)/nm 282.5; IR (neat) 
νmax/cm
-1
 1611, 1585, 1507, 1478, 1371, 1342, 1250, 1207, 1157, 1111; 
1
H NMR 
(500 MHz, CDCl3) δ 3.72 (6H, s, 2 × ArOCH3), 3.77 (6H, s, 2 × ArOCH3), 4.44 (4H, s, 
2 × ArCH2), 6.37 (2H, d, J = 2.4 Hz, H-3”), 6.41 (2H, dd, J = 8.4, 2.4 Hz, H-5”), 6.73 (1H, 
dd, J = 2.3, 2.2 Hz, H-2), 6.96 (1H, ddd, J = 8.2, 2.3 and 0.9 Hz, H-4 or H-6), 7.00 (2H, d, 
J = 9.3 Hz, H-2’, 6’), 7.03 (1H, ddd, J = 8.3, 2.2 and 0.9 Hz, H-4 or H-6), 7.24 (2H, d, 
J = 8.4 Hz, H-6”), 7.36 (1H, dd, J = 8.3, 8.2 Hz, H-5), 8.21 (2H, d, J = 9.3 Hz, H-3’, 5’); 
13
C NMR (126 MHz, CDCl3)  47.1 (ArCH2), 55.3 (ArOCH3), 55.5 (ArOCH3), 98.3 
(C-3”), 104.1 (C-5”), 114.5 (C-2), 116.4 (C-1”), 117.5 (C-2’, 6’), 118.4 (C-4 or C-6), 119.1 
(C-4 or C-6), 126.1 (C-3’, 5’), 130.9 (C-5), 131.1 (C-6”), 143.1 (C-4’), 151.7 (C-1), 155.4 
(C-3), 158.6 (C-2” or C-4”), 160.8 (C-2” or C-4”), 162.7 (C-1’); HRMS (ESI) calcd for 
C30H31N2O10S [M+H]
+
 611.1691, found 611.1694. 
 
3-(2-Aminophenoxy)phenyl bis(2,4-dimethoxybenzyl)sulfamate, (181) 
 
Compound 181 was synthesised according to general procedure O, using the following 
reagents: 3-(2-nitrophenoxy)phenyl bis(2,4-dimethoxybenzyl)sulfamate (178) (1.20 g, 
1.96 mmol), MeOH (29.4 mL) and THF (9.8 mL). The crude brown oil was purified by 
column chromatography (silica gel, petrol:EtOAc, 1:0  7:3) to yield the title compound 
as a yellow oil (970 mg, 85%); Rf = 0.32 (petrol:EtOAc, 7:3); λmax (EtOH)/nm 277.8; IR 
(neat) νmax/cm
-1
 3467, 3378, 1611, 1587, 1505, 1479, 1369, 1243, 1207, 1156; 
1
H NMR 
(500 MHz, CDCl3) δ 3.71 (6H, s, 2 × ArOCH3), 3.79 (6H, s, 2 × ArOCH3), 4.44 (4H, s, 
2 × ArCH2), 6.37 (2H, d, J = 2.4 Hz, H-3”), 6.41 (2H, dd, J = 8.4, 2.4 Hz, H-5”), 
6.75 - 6.70 (2H, m, 2 × ArH), 6.89 – 6.79 (4H, m, 4 × ArH), 7.00 (1H, ddd, J = 7.7, 7.7 and 
1.4 Hz, H-4’), 7.22 (1H, dd, J = 8.3, 8.3 Hz, H-5), 7.24 (2H, d, J = 8.4 Hz, H-6”); 
13
C NMR (126 MHz, CDCl3)  47.0 (ArCH2), 55.2 (ArOCH3), 55.5 (ArOCH3), 98.3 
(C-3”), 104.1 (C-5”), 111.3 (C-2), 114.9 (CH Ar), 116.2 (CH Ar), 116.6 (C-1”), 116.8 
(CH Ar), 119.0 (CH Ar), 120.5 (CH Ar), 125.4 (C-4’), 130.2 (C-5), 131.0 (C-6”), 138.8 
(C-1’ or C-2’), 142.6 (C-1’ or C-2’), 151.5 (C-1), 158.4 (C-3), 158.5 (C-2” or C-4”), 160.7 
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(C-2” or C-4”); LRMS (ES+) m/z 581.4 [M+H]+; HRMS (ESI) calcd for C30H33N2O8S 
[M+H]
+
 581.1952, found 581.1947. 
 
3-(3-Aminophenoxy)phenyl bis(2,4-dimethoxybenzyl)sulfamate, (182) 
 
Compound 182 was synthesised according to general procedure O, using the following 
reagents: 3-(3-nitrophenoxy)phenyl bis(2,4-dimethoxybenzyl)sulfamate (179) (1.20 g, 
1.96 mmol), MeOH (29.4 mL) and THF (9.8 mL). The crude brown oil was purified by 
column chromatography (silica gel, petrol:EtOAc, 1:0  65:35) to yield the title 
compound as a brown oil (994 mg, 87%); Rf = 0.29 (petrol:EtOAc, 65:35); λmax (EtOH)/nm 
260.2; IR (neat) νmax/cm
-1
 3467, 3380, 1610, 1586, 1507, 1478, 1464, 1367, 1207, 1148, 
1110; 
1
H NMR (500 MHz, CDCl3) δ 3.71 (6H, s, 2 × ArOCH3), 3.78 (6H, s, 2 × ArOCH3), 
4.44 (4H, s, 2 × ArCH2), 6.32 (1H, dd, J = 2.3, 2.3 Hz, H-2’), 6.37 (2H, d, J = 2.4 Hz, 
H-3”), 6.40 – 6.37 (1H, m, H-4’ or H-6’), 6.41 (2H, dd, J = 8.4, 2.4 Hz, H-5”), 6.44 (1H, 
ddd, J = 8.1, 2.2 and 0.9 Hz, H-4’ or H-6’), 6.72 (1H, dd, J = 2.3, 2.3 Hz, H-2), 6.91 – 6.84 
(2H, m, H-4 and H-6), 7.10 (1H, dd, J = 8.1, 8.0 Hz, H-5’), 7.26 – 7.21 (3H, m, H-5 and 
H-6”); 13C NMR (126 MHz, CDCl3)  47.1 (ArCH2), 55.2 (ArOCH3), 55.5 (ArOCH3), 
98.3 (C-3”), 104.1 (C-5”), 105.8 (C-2’), 109.2 (C-4’ or C-6’), 110.7 (C-4’ or C-6’), 113.0 
(C-2), 116.6 (C-4 or C-6), 116.7 (C-4 or C-6), 116.9 (C-1”), 130.1 (C-5’), 130.6 (C-5), 
131.1 (C-6”), 148.1 (C-3’), 151.4 (C-1), 157.9 (C-3 or C-1’), 158.1 (C-3 or C-1’), 158.5 
(C-2” or C-4”), 160.7 (C-2” or C-4”); LRMS (ES+) m/z 581.5 [M+H]+; HRMS (ESI) calcd 
for C30H33N2O8S [M+H]
+
 581.1952, found 581.1947. 
 
3-(4-Aminophenoxy)phenyl bis(2,4-dimethoxybenzyl)sulfamate, (183) 
 
Compound 183 was synthesised according to general procedure O, using the following 
reagents: 3-(4-nitrophenoxy)phenyl bis(2,4-dimethoxybenzyl)sulfamate (180) (1.20 g, 
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1.96 mmol), MeOH (29.4 mL) and THF (9.8 mL). The crude brown oil was purified by 
column chromatography (silica gel, petrol:EtOAc, 1:0  55:45) to yield the title 
compound as a brown oil (982 mg, 86%); Rf = 0.31 (petrol:EtOAc, 55:45); λmax (EtOH)/nm 
264.5; IR (neat) νmax/cm
-1
 3453, 3378, 1611, 1588, 1506, 1478, 1366, 1247, 1205, 1157, 
1111, 1033; 
1
H NMR (500 MHz, CDCl3) δ 3.71 (6H, s, 2 × ArOCH3), 3.79 (6H, s, 
2 × ArOCH3), 4.43 (4H, s, 2 × ArCH2), 6.37 (2H, d, J = 2.4 Hz, H-3”), 6.41 (2H, dd, 
J = 8.3, 2.4 Hz, H-5”), 6.71 – 6.66 (3H, m, H-2 and H-2’, 6’), 6.77 (1H, ddd, J = 8.3, 2.4 
and 0.8 Hz, H-4 or H-6), 6.80 (1H, ddd, J = 8.2, 2.2  and 0.8 Hz, H-4 or H-6), 6.85 (2H, d, 
J = 8.7 Hz, H-3’, 5’), 7.19 (1H, dd, J = 8.3, 8.2 Hz, H-5), 7.23 (2H, d, J = 8.3 Hz, H-6”); 
13
C NMR (126 MHz, CDCl3)  47.0 (ArCH2), 55.2 (ArOCH3), 55.5 (ArOCH3), 98.3 
(C-3”), 104.1 (C-5”), 111.3 (C-2), 115.1 (C-4 or C-6), 115.6 (C-4 or C-6), 116.6 (C-2’, 6’), 
116.7 (C-1”), 121.3 (C-3’, 5’), 130.0 (C-5), 131.0 (C-6”), 142.8 (C-4’), 148.3 (C-1’), 151.4 
(C-1), 158.5 (C-2” or C-4”), 159. 8 (C-3), 160.7 (C-2” or C-4”); LRMS (ES+) m/z 581.5 
[M+H]
+
; HRMS (ESI) calcd for C30H33N2O8S [M+H]
+
 581.1952, found 581.1945. 
 
3-(2-Aminophenoxy)phenyl sulfamate, (184) 
 
Compound 184 was synthesised according to general procedure D, using the following 
reagents: 3-(2-aminophenoxy)phenyl bis(2,4-dimethoxybenzyl)sulfamate (181) (200 mg, 
0.34 mmol), DCM (3.1 mL) and TFA (0.4 mL). The crude product was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  7:3) to yield the title compound as a pale 
yellow solid (87 mg, 90%); Rf = 0.34 (petrol:EtOAc, 7:3); m.p. 91-5-93.5 °C; λmax 
(EtOH)/nm 277.2; IR (neat) νmax/cm
-1
 3482, 3390, 3345, 3263, 1622, 1604, 1586, 1503, 
1478, 1344; 
1
H NMR (500 MHz, DMSO-d6) δ 4.93 (2H, s, ArNH2), 6.57 (1H, ddd, J = 7.7, 
7.7 and 1.6 Hz, H-5’), 6.84 – 6.78 (3H, m, 3 × ArH), 6.85 (1H, dd, J = 8.0, 1.5 Hz, H-3’ or 
H-6’), 6.99 – 6.93 (2H, m, 2 × ArH), 7.40 – 7.34 (1H, m, H-5), 8.02 (2H, s, ArOSO2NH2); 
13
C NMR (126 MHz, DMSO-d6) δ 110.4 (C-2), 114.2 (C-3’ or C-6’), 115.7 (C-4 or C-6), 
116.0 (C-4 or C-6), 116.4 (C-5’), 120.9 (C-3’ or C-6’), 125.6 (C-4’), 130.4 (C-5), 140.6 
(C-1’ or C-2’), 140.7 (C-1’ or C-2’), 151.0 (C-1), 158.5 (C-3); LRMS (ES-) m/z 279.2 
[M-H]
-
; HRMS (ESI) calcd for C12H11N2O4S [M-H]
-
 279.0445, found 279.0436. 
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3-(3-Aminophenoxy)phenyl sulfamate, (185) 
 
Compound 185 was synthesised according to general procedure D, using the following 
reagents: 3-(3-aminophenoxy)phenyl bis(2,4-dimethoxybenzyl)sulfamate (182) (200 mg, 
0.34 mmol), DCM (3.1 mL) and TFA (0.4 mL). The crude product was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  65:35) to yield the title compound as a 
pale brown solid (80 mg, 82%); Rf = 0.31 (petrol:EtOAc, 65:35); m.p. 79.5-81.5 °C; 
λmax (EtOH)/nm 279.2; IR (neat) νmax/cm
-1
 3438, 3357, 3321, 1607, 1586, 1478, 1363, 
1250, 1181; 
1
H NMR (500 MHz, DMSO-d6) δ 5.26 (2H, s, ArNH2), 6.17 (1H, dd, J = 8.0, 
2.3 Hz, H-4’ or H-6’), 6.24 (1H, dd, J = 2.2, 2.2 Hz, H-2’), 6.37 (1H, dd, J = 8.1, 1.9 Hz, 
H-4’ or H-6’), 6.87 (1H, dd, J = 2.3, 2.3 Hz, H-2), 6.93 (1H, dd, J = 8.3, 2.3 Hz, H-4 or 
H-6), 7.06 – 6.97 (2H, m, H-4 or H-6 and H-5’), 7.42 (1H, dd, J = 8.2, 8.2 Hz, H-5’), 8.02 
(2H, s, ArOSO2NH2); 
13
C NMR (126 MHz, DMSO-d6) δ 104.2 (C-2’), 106.1 (C-4’ or 
C-6’), 109.9 (C-4’ or C-6’), 112.0 (C-2), 116.1 (C-4 or C-6), 116.4 (C-4 or C-6), 130.2 
(C-5’), 130.5 (C-5), 150.6 (C-1 or C-3’), 151.0 (C-1 or C-3’), 156.7 (C-3 or C-1’), 158.0 
(C-3 or C-1’); LRMS (ES-) m/z 279.2 [M-H]-; HRMS (ESI) calcd for C12H11N2O4S [M-H]
-
 
279.0445, found 279.0438. 
 
3-(4-Aminophenoxy)phenyl sulfamate, (186) 
 
Compound 186 was synthesised according to general procedure D, using the following 
reagents: 3-(4-aminophenoxy)phenyl bis(2,4-dimethoxybenzyl)sulfamate (183) (200 mg, 
0.34 mmol), DCM (3.1 mL) and TFA (0.4 mL). The crude product was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  6:4) to yield the title compound as a 
brown solid (63 mg, 65%); Rf = 0.30 (petrol:EtOAc, 6:4); m.p. 133.5-135.5 °C; 
λmax (EtOH)/nm 242.6; IR (neat) νmax/cm
-1
 3410, 3327, 3296, 1600, 1507, 1475, 1366, 
1249, 1173; 
1
H NMR (500 MHz, DMSO-d6) δ 5.04 (2H, s, ArNH2), 6.60 (2H, d, 
J = 8.8 Hz, H-2’, 6’), 6.74 (1H, dd, J = 2.3, 2.3 Hz, H-2), 6.85 – 6.76 (3H, m, H-4 or H-6 
and H-3’, 5’), 6.91 (1H, dd, J = 8.1, 2.3 Hz, H-4 or H-6), 7.36 (1H, dd, J = 8.2, 8.1 Hz, 
H-5), 7.99 (2H, s, ArOSO2NH2); 
13
C NMR (126 MHz, DMSO-d6) δ 110.2 (C-2), 114.3 
(C-4 or C-6), 114.9 (C-3’, 5’), 115.3 (C-4 or C-6), 121.1 (C-2’, 6’), 130.4 (C-5), 144.7 
(C-1’ or C-4’), 145.9 (C-1’ or C-4’), 151.0 (C-1), 159.9 (C-3); LRMS (ES-) m/z 279.2 
[M-H]
-
; HRMS (ESI) calcd for C12H11N2O4S [M-H]
-
: 279.0445; found 279.0437. 
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3-(2-Acetamidophenoxy)phenyl bis(2,4-dimethoxybenzyl)sulfamate, (187) 
 
Compound 187 was synthesised according to general procedure J, using the following 
reagents: 3-(2-aminophenoxy)phenyl bis(2,4-dimethoxybenzyl)sulfamate (181) (250 mg, 
0.43 mmol), triethylamine (87 mg, 120 µL, 0.86 mmol), acetic anhydride (53 mg, 49 µL, 
0.52 mmol) and DCM (4.3 mL). The crude product was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  6:4) to yield the title compound as a clear 
oil (233 mg, 87%); Rf = 0.30 (petrol:EtOAc, 6:4); λmax (EtOH)/nm 277.2; IR (neat) 
νmax/cm
-1
 1683, 1609, 1589, 1507, 1476, 1440, 1368, 1252, 1207, 1157, 1115, 1034; 
1
H NMR (500 MHz, CDCl3) δ 2.19 (3H, s, CH3CO), 3.71 (6H, s, 2 × ArOCH3), 3.78 (6H, 
s, 2 × ArOCH3), 4.46 (4H, s, 2 × ArCH2), 6.38 (2H, d, J = 2.4 Hz, H-3”), 6.41 (2H, dd, 
J = 8.4, 2.4 Hz, H-5”), 6.75 (1H, dd, J = 2.5, 2.3 Hz, H-2), 6.82 (1H, dd, J = 8.1, 1.5 Hz, 
H-6’), 6.85 (1H, ddd, J = 8.3, 2.5 and 0.9 Hz, H-4 or H-6), 6.93 (1H, ddd, J = 8.2, 2.3 and 
1.0 Hz, H-4 or H-6), 7.00 (1H, ddd, J = 7.8, 7.8 and 1.7 Hz, H-4’), 7.13 (1H, ddd, J = 7.7, 
7.7 and 1.4 Hz, H-5’), 7.25 (2H, d, J = 8.4 Hz, H-6”), 7.28 (1H, dd, J = 8.3, 8.2 Hz, H-5), 
7.69 (1H, s, ArNHAc), 8.44 (1H, dd, J = 8.2, 1.7 Hz, H-3’); 13C NMR (126 MHz, CDCl3) 
 25.0 (CH3CO), 47.1 (ArCH2), 55.2 (ArOCH3), 55.5 (ArOCH3), 98.3 (C-3”), 104.1 
(C-5”), 113.1 (C-2), 116.5 (C-4 or C-6), 116.6 (C-1”), 117.6 (C-4 or C-6), 117.7 (C-6’), 
121.2 (C-3’), 124.2 (C-4 or C-6), 124.5 (C-4’), 129.9 (C-2’), 130.5 (C-5), 131.1 (C-6”), 
145.2 (C-1’), 151.6 (C-1), 157.1 (C-3), 158.6 (C-2” or C-4”), 160.8 (C-2” or C-4”), 168.5 
(COCH3); LRMS (ES
-
) m/z 621.4 [M-H]
-
; HRMS (ESI) calcd for C32H33N2O9S [M-H]
-
 
621.1912, found 621.1893. 
 
3-(3-Acetamidophenoxy)phenyl bis(2,4-dimethoxybenzyl)sulfamate, (188) 
 
Compound 188 was synthesised according to general procedure J, using the following 
reagents: 3-(4-aminophenoxy)phenyl bis(2,4-dimethoxybenzyl)sulfamate (182) (250 mg, 
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0.43 mmol), triethylamine (87 mg, 120 µL, 0.86 mmol), acetic anhydride (53 mg, 49 µL, 
0.52 mmol) and DCM (4.3 mL). The crude product was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  45:55) to yield the title compound as a 
clear oil (236 mg, 88%); Rf = 0.27 (petrol:EtOAc, 45:55); λmax (EtOH)/nm 278.7; IR (neat) 
νmax/cm
-1
 1670, 1589, 1541, 1507, 1478, 1368, 1257, 1207, 1157, 1111; 
1
H NMR 
(500 MHz, CDCl3) δ 2.11 (3H, s, CH3CO), 3.70 (6H, s, 2 × ArOCH3), 3.78 (6H, s, 
2 × ArOCH3), 4.44 (4H, s, 2 × ArCH2), 6.37 (2H, d, J = 2.4 Hz, H-3”), 6.41 (2H, dd, 
J = 8.4, 2.4 Hz, H-5”), 6.70 (1H, dd, J = 2.4, 2.3 Hz, H-2), 6.75 – 6.71 (1H, m, H-6’), 6.86 
(1H, ddd, J = 8.2, 2.4 and 0.9 Hz, H-4 or H-6), 6.89 (1H, ddd, J = 8.3, 2.3 and 0.9 Hz, H-4 
or H-6), 7.10 (1H, dd, J = 2.4, 2.3 Hz, H-2’), 7.30 – 7.21 (4H, m, H-5 and H-5’ and H-6”), 
7.32 (1H, s, ArNHAc), 7.38 – 7.34 (1H, m, H-4’); 13C NMR (126 MHz, CDCl3)  24.7 
(CH3CO), 47.1 (ArCH2), 55.3 (ArOCH3), 55.5 (ArOCH3), 98.3 (C-3”), 104.1 (C-5”), 110.4 
(C-2’), 113.0 (C-2), 114.7 (C-6’), 115.1 (C-4’), 116.6 (C-1”), 117.0 (C-4 or C-6), 117.0 
(C-4 or C-6), 130.3 (C-5 or C-5’), 130.3 (C-5 or C-5’), 131.0 (C-6”), 139.5 (C-3’), 151.4 
(C-1), 157.3 (C-3 or C-1’), 157.8 (C-3 or C-1’), 158.5 (C-2” or C-4”), 160.7 (C-2” or 
C-4”), 168.4 (COCH3); LRMS (ES
-
) m/z 621.4 [M-H]
-
; HRMS (ESI) calcd for 
C32H33N2O9S [M-H]
-
 621.1912, found 621.1894. 
 
3-(4-Acetamidophenoxy)phenyl bis(2,4-dimethoxybenzyl)sulfamate, (189) 
 
Compound 189 was synthesised according to general procedure J, using the following 
reagents: 3-(4-aminophenoxy)phenyl bis(2,4-dimethoxybenzyl)sulfamate (183) (250 mg, 
0.43 mmol), triethylamine (87 mg, 120 µL, 0.86 mmol), acetic anhydride (53 mg, 49 µL, 
0.52 mmol) and DCM (4.3 mL). The crude product was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  35:65) to yield the title compound as a 
white solid (231 mg, 86%); Rf = 0.30 (petrol:EtOAc, 35:65); m.p. 49.5-51.5 °C; 
λmax (EtOH)/nm 251.0; IR (neat) νmax/cm
-1
 1667, 1611, 1589, 1505, 1478, 1368, 1249, 
1206, 1157; 
1
H NMR (500 MHz, CDCl3) δ 2.16 (3H, s, CH3CO), 3.70 (6H, s, 
2 × ArOCH3), 3.78 (6H, s, 2 × ArOCH3), 4.44 (4H, s, 2 × ArCH2), 6.36 (2H, d, J = 2.4 Hz, 
H-3”), 6.41 (2H, dd, J = 8.4, 2.4 Hz, H-5”), 6.70 (1H, dd, J = 2.3, 2.1 Hz, H-2), 6.82 (1H, 
dd, J = 8.3, 2.3 Hz, H-4 or H-6), 6.86 (1H, dd, J = 8.2, 2.1 Hz, H-4 or H-6), 6.95 (2H, d, 
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J = 8.9 Hz, H-2’, 6’), 7.25 – 7.20 (3H, m, H-5 and H-6”), 7.31 (1H, s, ArNHAc), 7.46 (2H, 
d, J = 8.9 Hz, H-3’, 5’); 13C NMR (126 MHz, CDCl3)  24.6 (CH3CO), 47.1 (ArCH2), 55.2 
(ArOCH3), 55.5 (ArOCH3), 98.3 (C-3”), 104.1 (C-5”), 112.3 (C-2), 116.2 (C-4 or C-6), 
116.5 (C-4 or C-6), 116.6 (C-1”), 120.0 (C-2’, 6’), 121.8 (C-3’, 5’), 130.2 (C-5), 131.0 
(C-6”), 134.0 (C-4’), 151.4 (C-1 or C-1’), 152.8 (C-1 or C-1’), 158.5 (C-3), 158.5 (C-2” or 
C-4”), 160.7 (C-2” or C-4”), 168.4 (COCH3); LRMS (ES
-
) m/z 621.5 [M-H]
-
; HRMS (ESI) 
calcd for C32H33N2O9S [M-H]
-
 621.1912, found 621.1892. 
 
3-(2-Acetamidophenoxy)phenyl sulfamate, (190) 
 
Compound 190 was synthesised according to general procedure D, using the following 
reagents: 3-(2-acetamidophenoxy)phenyl bis(2,4-dimethoxybenzyl)sulfamate (187) 
(200 mg, 0.32 mmol), DCM (2.9 mL) and TFA (0.3 mL). The crude product was purified 
by column chromatography (silica gel, petrol:EtOAc, 1:0  65:35) to yield the title 
compound as a white solid (88 mg, 85%); Rf = 0.29 (petrol:EtOAc, 65:35); m.p. 
142.0-144.0 °C; No λmax (EtOH)/nm; IR (neat) νmax/cm
-1
 3383, 3299, 1665, 1609, 1594, 
1539, 1477, 1453, 1366, 1254, 1190, 1123; 
1
H NMR (500 MHz, DMSO-d6) δ 2.00 (3H, s, 
CH3CO), 6.93 – 6.88 (2H, m, 2 × ArH), 6.99 (1H, dd, J = 7.8, 1.8 Hz, H-6’), 7.06 – 7.02 
(1H, m, ArH), 7.19 – 7.08 (2H, m, 2 × ArH), 7.43 (1H, dd, J = 8.5, 8.5 Hz, H-5), 7.94 (1H, 
d, J = 7.4 Hz, H-3’), 8.04 (2H, s, ArOSO2NH2), 9.48 (1H, s, ArNHAc); 
13
C NMR 
(126 MHz, DMSO-d6) δ 23.5 (CH3CO), 112.1 (CH Ar), 116.0 (CH Ar), 116.8 (CH Ar), 
119.4 (C-6’), 124.2 (CH Ar), 124.3 (CH Ar), 125.0 (CH Ar), 130.1 (C-2’), 130.6 (C-5), 
146.8 (C-1’), 151.0 (C-1), 157.6 (C-3), 168.7 (COCH3); LRMS (ES
-
) m/z 321.2 [M-H]
-
; 
HRMS (ESI) calcd for C14H13N2O5S [M-H]
-
 321.0551, found 321.0539. 
 
3-(3-Acetamidophenoxy)phenyl sulfamate, (191) 
 
Compound 191 was synthesised according to general procedure D, using the following 
reagents: 3-(3-acetamidophenoxy)phenyl bis(2,4-dimethoxybenzyl)sulfamate (188) 
(200 mg, 0.32 mmol), DCM (2.9 mL) and TFA (0.3 mL). The crude product was purified 
by column chromatography (silica gel, petrol:EtOAc, 1:0  1:1) to yield the title 
compound as a white solid (98 mg, 94%); Rf = 0.28 (petrol:EtOAc, 1:1); m.p. 
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134.0-136.0 °C; λmax (EtOH)/nm 275.0; IR (neat) νmax/cm
-1
 3361, 3290, 3215, 3085, 1651, 
1600, 1549, 1478, 1436, 1379, 1264, 1182; 
1
H NMR (500 MHz, DMSO-d6) δ 2.02 (3H, s, 
CH3CO), 6.76 – 6.71 (1H, m, H-6’), 6.91 (1H, dd, J = 2.3, 2.3 Hz, H-2), 6.96 (1H, ddd, 
J = 8.3, 2.4 and 0.9 Hz, H-4 or H-6), 7.05 (1H, ddd, J = 8.2, 2.2 and 0.9 Hz, H-4 or H-6), 
7.35 – 7.30 (2H, m, H-5 and H-4’), 7.43 (1H, dd, J = 1.6, 1.6 Hz, H-2’), 7.45 (1H, dd, 
J = 8.3, 8.3 Hz, H-5’), 8.03 (2H, s, ArOSO2NH2), 10.04 (1H, s, ArNHAc); 
13
C NMR 
(126 MHz, DMSO-d6) δ 24.0 (CH3CO), 109.5 (C-2’), 112.3 (C-2), 113.5 (C-6’), 114.4 
(C-4’), 116.3 (C-4 or C-6), 117.0 (C-4 or C-6), 130.2 (C-5 or C-5’), 130.8 (C-5 or C-5’), 
141.0 (C-3’), 151.1 (C-1), 156.0 (C-1’), 157.5 (C-3), 168.5 (COCH3); LRMS (ES
-
) m/z 
643.3 [2M-H]
-
; HRMS (ESI) calcd for C14H13N2O5S [M-H]
-
 321.0551, found 321.0541. 
 
3-(4-Acetamidophenoxy)phenyl sulfamate, (192) 
 
Compound 192 was synthesised according to general procedure D, using the following 
reagents: 3-(4-acetamidophenoxy)phenyl bis(2,4-dimethoxybenzyl)sulfamate (189) 
(200 mg, 0.32 mmol), DCM (2.9 mL) and TFA (0.3 mL). The crude product was purified 
by column chromatography (silica gel, petrol:EtOAc, 1:0  45:55) to yield the title 
compound as a white solid (96 mg, 92%); Rf = 0.29 (petrol:EtOAc, 45:55); m.p. 
108.0-110.0 °C; λmax (EtOH)/nm 250.8; IR (neat) νmax/cm
-1
 3309, 3178, 3076, 1635, 1596, 
1526, 1506, 1477, 1371, 1250, 1178, 1161; 
1
H NMR (500 MHz, DMSO-d6) δ 2.04 (3H, s, 
CH3CO), 6.84 (1H, dd, J = 2.4, 2.2 Hz, H-2), 6.91 (1H, ddd, J = 8.3, 2.4 and 0.9 Hz, H-4 
or H-6), 7.00 (1H, ddd, J = 8.2, 2.2 and 0.9 Hz, H-4 or H-6), 7.04 (2H, d, J = 9.0 Hz, 
H-2’, 6’), 7.42 (1H, dd, J = 8.3, 8.2 Hz, H-5), 7.62 (2H, d, J = 9.0 Hz, H-3’, 5’), 8.01 (2H, 
s, ArOSO2NH2), 9.99 (1H, s, ArNHAc); 
13
C NMR (126 MHz, DMSO-d6) δ 23.9 (CH3CO), 
111.4 (C-2), 115.5 (C-4 or C-6), 116.4 (C-4 or C-6), 119.9 (C-2’, 6’), 120.6 (C-3’, 5’), 
130.7 (C-5), 135.9 (C-4’), 150.5 (C-1 or C-1’), 151.0 (C-1 or C-1’), 158.4 (C-3), 168.1 
(COCH3); LRMS (ES
-
) m/z 321.2 [M-H]
-
; HRMS (ESI) calcd for C14H13N2O5S [M-H]
-
 
321.0551, found 321.0543. 
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3-(2-(((2,2,2-Trichloroethoxy)sulfonyl)amino)phenoxy)phenyl bis(2,4-dimethoxy 
benzyl) sulfamate, (193) 
 
Compound 193 was synthesised according to general procedure K, using the following 
reagents: 3-(2-aminophenoxy)phenyl bis(2,4-dimethoxybenzyl)sulfamate (181) (50 mg, 
0.09 mmol), 2,3-dimethyl-1-((2,2,2-trichloroethoxy)sulfonyl)-1H-imidazol-3-ium 
tetrafluoroborate (158) (102 mg, 0.26 mmol) and THF (1 mL). The crude product was 
purified by column chromatography (silica gel, petrol:EtOAc, 1:0  3:1) to yield the title 
compound as a clear oil (10 mg, 15%); Rf = 0.31 (petrol:EtOAc, 3:1); λmax (EtOH)/nm 
277.2; IR (neat) νmax/cm
-1
 1611, 1589, 1507, 1368, 1255, 1208, 1174, 1157, 1116, 1036; 
1
H NMR (500 MHz, CDCl3) δ 3.72 (6H, s, 2 × ArOCH3), 3.79 (6H, s, 2 × ArOCH3), 4.45 
(4H, s, 2 × ArCH2), 4.68 (2H, s, CH2CCl3), 6.39 (2H, d, J = 2.4 Hz, H-3”), 6.42 (2H, dd, 
J = 8.3, 2.4 Hz, H-5”), 6.67 (1H, dd, J = 2.3, 2.3 Hz, H-2), 6.83 (1H, dd, J = 8.1, 1.5 Hz, 
H-6’), 6.88 (1H, ddd, J = 8.3, 2.4 and 0.9 Hz, H-4 or H-6), 6.97 (1H, ddd, J = 8.3, 2.3 and 
0.9 Hz, H-4 or H-6), 7.09 (1H, ddd, J = 8.0, 7.6 and 1.7 Hz, H-4 or H-5), 7.14 (1H, ddd, 
J = 7.9, 1.5 and 1.5 Hz, H-4’ or H-5’), 7.24 (2H, d, J = 8.3 Hz, H-6”), 7.31 (1H, dd, 
J = 8.3, 8.3 Hz, H-5), 7.65 (1H, dd, J = 8.0, 1.6 Hz, H-3’); 13C NMR (126 MHz, CDCl3) 
 47.1 (ArCH2), 55.3 (ArOCH3), 55.6 (ArOCH3), 79.1 (CH2CCl3), 93.0 (CH2CCl3), 98.3 
(C-3”), 104.1 (C-5”), 113.3 (C-2), 116.6 (C-1”), 116.9 (C-4 or C-6), 117.6 (C-6’), 118.2 
(C-4 or C-6), 121.2 (C-3’), 124.4 (C-4’ or C-5’), 126.1 (C-4’ or C-5’), 126.8 (C-2’), 130.6 
(C-5), 131.1 (C-6”), 146.6 (C-1’), 151.6 (C-1), 156.1 (C-3), 158.6 (C-2” or C-4”), 160.7 
(C-2” or C-4”); LRMS (ES-) m/z 789.3 [M(35Cl35Cl35Cl)-H]-, 791.3 [M(37Cl35Cl35Cl)-H]-; 
HRMS (ESI) calcd for C32H32Cl3N2O11S2 [M(
35
Cl
35
Cl
35
Cl)-H]
-
 789.0519, found 789.0494. 
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3-(3-(((2,2,2-Trichloroethoxy)sulfonyl)amino)phenoxy)phenyl bis(2,4-dimethoxy 
benzyl) sulfamate, (194) 
 
Compound 194 was synthesised according to general procedure K, using the following 
reagents: 3-(3-aminophenoxy)phenyl bis(2,4-dimethoxybenzyl)sulfamate (182) (450 mg, 
0.77 mmol), 2,3-dimethyl-1-((2,2,2-trichloroethoxy)sulfonyl)-1H-imidazol-3-ium 
tetrafluoroborate (158) (919 mg, 2.32 mmol) and THF (7.7 mL). The crude product was 
purified by column chromatography (silica gel, petrol:EtOAc, 1:0  7:3) to yield the title 
compound as a yellow oil (480 mg, 78%); Rf = 0.31 (petrol:EtOAc, 7:3); λmax (EtOH)/nm 
277.4; IR (neat) νmax/cm
-1
 1611, 1590, 1507, 1478, 1367, 1266, 1208, 1175, 1149, 1112; 
1
H NMR (500 MHz, CDCl3) δ 3.71 (6H, s, 2 × ArOCH3), 3.79 (6H, s, 2 × ArOCH3), 4.44 
(4H, s, 2 × ArCH2), 4.62 (2H, s, CH2CCl3), 6.38 (2H, d, J = 2.4 Hz, H-3”), 6.42 (2H, dd, 
J = 8.3, 2.4 Hz, H-5”), 6.69 (1H, dd, J = 2.3, 2.3 Hz, H-2), 6.81 (1H, dd, J = 2.2, 2.2 Hz, 
H-2’), 6.85 – 6.82 (1H, m, H-6’), 6.90 – 6.86 (1H, m, H-4 or H-6), 6.91 (1H, ddd, J = 8.2, 
2.3 and 0.9 Hz, H-4 or H-6), 7.05 (1H, ddd, J = 8.2, 2.3 and 1.0 Hz, H-4’), 7.17 (1H, s, 
ArNHSO3), 7.24 (2H, d, J = 8.4 Hz, H-6”), 7.27 (1H, dd, J = 8.2, 8.2 Hz, H-5 or H-5’), 
7.32 (1H, dd, J = 8.1, 8.1 Hz, H-5 or H-5’); 13C NMR (126 MHz, CDCl3)  47.2 (ArCH2), 
55.3 (ArOCH3), 55.6 (ArOCH3), 79.0 (CH2CCl3), 93.1 (CH2CCl3), 98.4 (C-3”), 104.2 
(C-5”), 111.2 (C-2’), 113.3 (C-2), 115.7 (C-4’), 116.0 (C-6’), 116.6 (C-1”), 117.3 (C-4 or 
C-6), 117.5 (C-4 or C-6), 130.5 (C-5 or C-5’), 131.0 (C-5 or C-5’), 131.1 (C-6”), 137.0 
(C-3’), 151.4 (C-1), 157.1 (C-3 or C-1’), 157.9 (C-3 or C-1’), 158.5 (C-2” or C-4”), 160.7 
(C-2” or C-4”); LRMS (ES-) m/z 789.2 [M(35Cl35Cl35Cl)-H]-, 791.2 [M(37Cl35Cl35Cl)-H]-; 
HRMS (ESI) calcd for C32H32Cl3N2O11S2 [M(
35
Cl
35
Cl
35
Cl)-H]
-
 789.0519, found 789.0493. 
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3-(4-(((2,2,2-Trichloroethoxy)sulfonyl)amino)phenoxy)phenyl bis(2,4-dimethoxy 
benzyl) sulfamate, (195) 
 
Compound 195 was synthesised according to general procedure K, using the following 
reagents: 3-(4-aminophenoxy)phenyl bis(2,4-dimethoxybenzyl)sulfamate (183) (450 mg, 
0.77 mmol), 2,3-dimethyl-1-((2,2,2-trichloroethoxy)sulfonyl)-1H-imidazol-3-ium 
tetrafluoroborate (158) (919 mg, 2.32 mmol) and THF (7.7 mL). The crude product was 
purified by column chromatography (silica gel, petrol:EtOAc, 1:0  6:4) to yield the title 
compound as a yellow oil (553 mg, 90%); Rf = 0.32 (petrol:EtOAc, 65:35); 
1
H NMR 
(500 MHz, CDCl3) δ 3.71 (6H, s, 2 × ArOCH3), 3.79 (6H, s, 2 × ArOCH3), 4.44 (4H, s, 
2 × ArCH2), 4.65 (2H, s, CH2CCl3), 6.37 (2H, d, J = 2.4 Hz, H-3”), 6.41 (2H, dd, J = 8.4, 
2.4 Hz, H-5”), 6.71 (1H, dd, J = 2.4, 2.3 Hz, H-2), 6.85 (1H, ddd, J = 8.3, 2.4 and 0.9 Hz, 
H-4 or H-6), 6.87 (1H, s, ArNHSO3), 6.90 (1H, ddd, J = 8.2, 2.3 and 0.9 Hz, H-4 or H-6), 
6.99 (2H, d, J = 8.8 Hz, H-2’, 6’), 7.30 – 7.20 (5H, m, H-5 and H-3’, 5’ and H-6”); 
13
C NMR (126 MHz, CDCl3)  47.1 (ArCH2), 55.2 (ArOCH3), 55.5 (ArOCH3), 79.0 
(CH2CCl3), 93.2 (CH2CCl3), 98.3 (C-3”), 104.1 (C-5”), 112.9 (C-2), 116.5 (C-1”), 116.9 
(C-4 or C-6), 117.3 (C-4 or C-6), 119.9 (C-2’, 6’), 124.8 (C-3’, 5’), 130.4 (C-5), 130.6 
(C-4’), 131.0 (C-5), 151.5 (C-1), 155.3 (C-1’), 157.6 (C-3), 158.6 (C-2” or C-4”), 160.7 
(C-2” or C-4”); IR (neat) νmax/cm
-1
 1612, 1589, 1505, 1478, 1368, 1254, 1208, 1175, 1112, 
1037; λmax (EtOH)/nm 277.6; LRMS (ES
-
) m/z 789.3 [M(
35
Cl
35
Cl
35
Cl)-H]
-
, 791.3 
[M(
37
Cl
35
Cl
35
Cl)-H]
-
; HRMS (ESI) calcd for C32H32Cl3N2O11S2 [M(
35
Cl
35
Cl
35
Cl)-H]
-
 
789.0519, found 789.0497. 
 
2,2,2-Trichloroethyl (3-(3-(sulfamoyloxy)phenoxy)phenyl)sulfamate, (196) 
 
Compound 196 was synthesised according to general procedure D, using the following 
reagents: 3-(3-(((2,2,2-trichloroethoxy)sulfonyl)amino)phenoxy)phenyl bis(2,4-
dimethoxybenzyl) sulfamate (194) (450 mg, 0.57 mmol), DCM (5.2 mL) and TFA 
(0.6 mL). The crude product was purified by column chromatography (silica gel, 
petrol:EtOAc, 1:0  7:3) to yield the title compound as a clear brown oil (240 mg, 86%); 
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Rf = 0.33 (petrol:EtOAc, 7:3); λmax (EtOH)/nm 277.4; IR (neat) νmax/cm
-1
 3285, 1593, 
1478, 1363, 1257, 1181, 1146, 1112; 
1
H NMR (500 MHz, DMSO-d6) δ 4.85 (2H, s, 
CH2CCl3), 6.84 (1H, ddd, J = 8.2, 2.4 and 0.9 Hz, ArH), 6.94 – 6.91 (2H, m, H-2 and 
H-2’), 6.96 (1H, ddd, J = 8.2, 2.4 and 0.9 Hz, ArH), 7.09 – 7.02 (2H, m, 2 × ArH), 7.40 
(1H, dd, J = 8.2, 8.2 Hz, H-5 or H-5’), 7.46 (1H, dd, J = 8.2, 8.2 Hz, H-5 or H-5’), 8.04 
(2H, s, ArOSO2NH2), 11.16 (1H, s, ArNHSO3); 
13
C NMR (126 MHz, DMSO-d6) δ 77.8 
(CH2CCl3), 93.4 (CH2CCl3), 110.1 (C-2 or C-2’), 112.6 (C-2 or C-2’), 114.7 (CH Ar), 
115.0 (CH Ar), 116.4 (CH Ar), 117.4 (CH Ar), 130.9 (C-5 or C-5’), 130.9 (C-5 or C-5’), 
138.3 (C-3’), 151.1 (C-1), 156.5 (C-3 or C-1’), 157.0 (C-3 or C-1’); LRMS (ES-) m/z 489.1 
[M(
35
Cl
35
Cl
35
Cl)-H]
-
, 491.2 [M(
37
Cl
35
Cl
35
Cl)-H]
-
; HRMS (ESI) calcd for C14H12Cl3N2O7S2 
[M(
35
Cl
35
Cl
35
Cl)-H]
-
 488.9157, found 488.9152. 
 
2,2,2-Trichloroethyl (4-(3-(sulfamoyloxy)phenoxy)phenyl)sulfamate, (197) 
 
Compound 197 was synthesised according to general procedure D, using the following 
reagents: 3-(4-(((2,2,2-trichloroethoxy)sulfonyl)amino)phenoxy)phenyl bis(2,4-
dimethoxybenzyl) sulfamate (195) (500 mg, 0.63 mmol), DCM (5.7 mL) and TFA 
(0.7 mL). The crude product was purified by column chromatography (silica gel, 
petrol:EtOAc, 1:0  65:35) to yield the title compound as a clear brown oil (276 mg, 
89%); Rf = 0.30 (petrol:EtOAc, 6:4); λmax (EtOH)/nm 234.6; IR (neat) νmax/cm
-1
 3278, 
1596, 1504, 1478, 1364, 1252, 1171, 1111, 1012; 
1
H NMR (500 MHz, DMSO-d6) δ 4.86 
(2H, s, CH2CCl3),6.89 (1H, dd, J = 2.4, 2.3 Hz, H-2), 6.93 (1H, ddd, J = 8.3, 2.4 and 
1.0 Hz, H-4 or H-6), 7.04 (1H, ddd, J = 8.2, 2.3 and 1.0 Hz, H-4 or H-6), 7.11 (2H, d, 
J = 8.9 Hz, H-2’, 6’), 7.29 (2H, d, J = 8.9 Hz, H-3’, 5’), 7.45 (1H, dd, J = 8.3, 8.2 Hz, 
H-5), 8.03 (2H, s, ArOSO2NH2), 10.95 (1H, s, ArNHSO3); 
13
C NMR (126 MHz, 
DMSO-d6) δ 77.7 (CH2CCl3), 93.6 (CH2CCl3), 112.0 (C-2), 115.9 (C-4 or C-6), 117.0 (C-4 
or C-6), 120.2 (C-2’, 6’), 122.7 (C-3’, 5’), 130.8 (C-5), 132.5 (C-4’), 151.1 (C-1), 152.7 
(C-1’), 157.7 (C-3); LRMS (ES-) m/z 489.1 [M(35Cl35Cl35Cl)-H]-, 491.2 
[M(
37
Cl
35
Cl
35
Cl)-H]
-
; HRMS (ESI) calcd for C14H12Cl3N2O7S2 [M(
35
Cl
35
Cl
35
Cl)-H]
-
 
488.9157, found 488.9152. 
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Sodium (3-(3-(sulfamoyloxy)phenoxy)phenyl)sulfamate, (198) 
 
Compound 198 was synthesised according to general procedure M, using the following 
reagents: 2,2,2-trichloroethyl (3-(3-(sulfamoyloxy)phenoxy)phenyl)sulfamate (196) 
(150 mg, 0.31 mmol), MeOH (3.1 mL), acetate buffer pH 4.65 (3.1 mL) and zinc (200 mg, 
3.06 mmol). The crude product was converted to the sodium salt by ion-exchange 
chromatography (DOWEX 50WX2 - Na
+
 form). The crude product was purified by 
column chromatography (silica gel, EtOAc:MeOH, 1:0  93:7) to yield the title 
compound as a white solid (87 mg, 75%); Rf = 0.23 (EtOAc:MeOH, 93:7; KMnO4); 
m.p. 133.5-135.5 °C; λmax (EtOH)/nm 279.2; IR (neat) νmax/cm
-1
 3472, 3346, 3093, 1592, 
1478, 1368, 1185, 1150, 1045; 
1
H NMR (500 MHz, MeOD) δ 6.55 (1H, dd, J = 8.4, 
2.7 Hz, ArH), 6.99 – 6.89 (4H, m, 4 × ArH), 7.03 (1H, d, J = 7.7 Hz, ArH), 7.20 (1H, dd, 
J = 8.0, 8.0 Hz, H-5 or H-5’), 7.35 (1H, dd, J = 8.1, 8.1 Hz, H-5 or H-5’); 13C NMR 
(126 MHz, MeOD) δ 109.7 (CH Ar), 112.5 (CH Ar), 113.4 (CH Ar), 114.2 (CH Ar), 117.4 
(CH Ar), 117.7 (CH Ar), 130.9 (C-5 or C-5’), 131.3 (C-5 or C-5’), 144.9 (C-1), 152.9 
(C-3’), 158.1 (C-3 or C-1’), 160.0 (C-3 or C-1’); LRMS (ES-) m/z 359.2 [M-Na]-; HRMS 
(ESI) calcd for C12H11N2O7S2 [M-Na]
-
 359.0013, found 359.0000. 
 
Sodium (4-(3-(sulfamoyloxy)phenoxy)phenyl)sulfamate, (199) 
 
Compound 199 was synthesised according to general procedure M, using the following 
reagents: 2,2,2-trichloroethyl (4-(3-(sulfamoyloxy)phenoxy)phenyl)sulfamate (197) 
(150 mg, 0.31 mmol), MeOH (3.1 mL), acetate buffer pH 4.65 (3.1 mL) and zinc (200 mg, 
3.06 mmol). The crude product was converted to the sodium salt by ion-exchange 
chromatography (DOWEX 50WX2 - Na
+
 form). The crude product was purified by 
column chromatography (silica gel, EtOAc:MeOH, 1:0  93:7) to yield the title 
compound as a white solid (81 mg, 70%); Rf = 0.22 (EtOAc:MeOH, 93:7; KMnO4); 
m.p. 180.0-182.0 °C; λmax (EtOH)/nm 241.0; IR (neat) νmax/cm
-1
 3368, 3261, 3227, 3103, 
1600, 1508, 1479, 1363, 1207, 1169, 1159; 
1
H NMR (500 MHz, MeOD) δ 6.88 – 6.84 
(2H, m, H-2’ and H-4’ or H-6’), 6.94 (2H, d, J = 8.9 Hz, H-3, 5), 6.99 (2H, ddd, J = 8.1, 
2.0 and 1.0 Hz, H-4’ or H-6’), 7.23 (2H, d, J = 8.9 Hz, H-2, 3), 7.33 (1H, dd, J = 8.6, 
8.6 Hz, H-5’); 13C NMR (126 MHz, MeOD) δ 112.6 (C-2’), 116.4 (C-4’ or C-6’), 117.1 
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(C-4’ or C-6’), 120.9 (C-2, 6), 121.4 (C-3, 5), 131.2 (C-5), 139.7 (C-1), 151.5 (C-4 or 
C-3’), 152.9 (C-4 or C-3’), 161.0 (C-1’); LRMS (ES-) m/z 359.2 [M-Na]-; HRMS (ESI) 
calcd for C12H11N2O7S2 [M-Na]
-
 359.0013, found 358.9998. 
 
O,O-bis(2,2,2-Trichloroethyl) (2-(3-((N,N-bis(2,4-dimethoxybenzyl)sulfamoyl)oxy) 
phenoxy)phenyl)iminodisulfate, (200) 
 
Compound (200) was synthesised according to general procedure L, using the following 
reagents: 2'-amino-[1,1'-biphenyl]-3-yl bis(2,4-dimethoxybenzyl)sulfamate (181) (450 mg, 
0.77 mmol), 4-(dimethylamino)pyridine (208 mg, 1.70 mmol), triethylamine (432 µL, 
314 mg, 3.01 mmol), 2,2,2-trichloroethyl chlorosulfate (156) (413 µL, 769 mg, 3.01 mmol) 
and THF (8 + 4 mL). The crude product was purified by column chromatography (silica 
gel, petrol:EtOAc, 1:0  8:2) to yield the title compound as a pale yellow oil (428 mg, 
55%); Rf = 0.29 (petrol:EtOAC, 8:2); λmax (EtOH)/nm 277.6; IR (neat) νmax/cm
-1
 1612, 
1588, 1508, 1479, 1429, 1371, 1261, 1208, 1191, 1158, 1117, 1038, 1003; 
1
H NMR 
(500 MHz, CDCl3) δ 3.71 (6H, s, 2 × ArOCH3), 3.78 (6H, s, 2 × ArOCH3), 4.46 (4H, s, 
2 × ArCH2), 4.96 (2H, d, J = 11.3 Hz, CH2CCl3), 5.04 (2H, d, J = 11.3 Hz, CH2CCl3), 6.38 
(2H, d, J = 2.4 Hz, H-3”), 6.42 (2H, dd, J = 8.4, 2.4 Hz, H-5”), 6.90 (1H, dd, J = 8.4, 
1.3 Hz, H-6’), 6.94 (1H, dd, J = 2.3, 2.3 Hz, H-2), 7.01 (2H, dd, J = 8.3, 2.3 Hz, H-4 and 
H-6), 7.21 (1H, ddd, J = 7.8, 7.8 and 1.3 Hz, H-4’), 7.25 (2H, d, J = 8.4 Hz, H-6”), 7.33 
(1H, dd, J = 8.2, 8.2 Hz, H-5), 7.43 (1H, ddd, J = 8.5, 7.6 and 1.7 Hz, H-5’), 7.58 (1H, dd, 
J = 8.0, 1.6 Hz, H-3’); 13C NMR (126 MHz, CDCl3)  47.1 (ArCH2), 55.2 (ArOCH3), 55.5 
(ArOCH3), 81.6 (CH2CCl3), 92.7 (CH2CCl3), 98.3 (C-3”), 104.1 (C-5”), 114.4 (C-2), 116.4 
(C-1”), 118.1 (C-4 or C-6), 118.3 (C-4 or C-6), 118.9 (C-6’), 124.1 (C-4’), 124.6 (C-2’), 
130.9 (C-5), 131.0 (C-6”), 131.8 (C-5’), 133.0 (C-3’), 151.7 (C-1), 155.1 (C-3 or C-1’), 
155.7 (C-3 or C-1’), 158.5 (C-2” or C-4”), 160.8 (C-2” or C-4”); HRMS (ESI) calcd for 
C34H38Cl6N3O14S3 [M(6 × 
35
Cl)+NH4]
+
 1017.9642, found 1017.9658. 
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O,O-bis(2,2,2-Trichloroethyl) (2-(3-(sulfamoyloxy)phenoxy)phenyl)iminodisulfate, 
(201) 
 
Compound 201 was synthesised according to general procedure D, using the following 
reagents: O,O-bis(2,2,2-trichloroethyl) (2-(3-((N,N-bis(2,4-dimethoxybenzyl)sulfamoyl) 
oxy) phenoxy)phenyl)iminodisulfate (200) (350 mg, 0.35 mmol), DCM (3.2 mL) and TFA 
(0.4 mL). The crude product was purified by column chromatography (silica gel, 
petrol:EtOAc, 1:0  3:1) to yield the title compound as a clear brown oil (240 mg, 86%); 
Rf = 0.29 (petrol:EtOAc, 3:1); λmax (EtOH)/nm 277.2; IR (neat) νmax/cm
-1
 3398, 3295, 
1590, 1490, 1479, 1428, 1375, 1259, 1186, 1118; 
1
H NMR (500 MHz, DMSO-d6) δ 5.28 
(2H, d, J = 11.3 Hz, CH2CCl3), 5.36 (2H, d, J = 11.3 Hz, CH2CCl3), 7.10 – 7.04 (3H, m, 
H-2 and H-4 or H-6 and H-6’), 7.17 (1H, ddd, J = 8.3, 2.1 and 0.9 Hz, H-4 or H-6), 7.32 
(1H, ddd, J = 7.9, 7.9 and 1.3 Hz, H-4’), 7.61 – 7.51 (2H, m, H-5 and H-5’), 7.88 (1H, dd, 
J = 8.0, 1.6 Hz, H-3’), 8.10 (2H, s, ArOSO2NH2); 
13
C NMR (126 MHz, DMSO-d6) δ 80.7 
(CH2CCl3), 92.8 (CH2CCl3), 114.1 (C-2), 117.8 (C-4 or C-6 or C-6’), 118.4 (C-4 or C-6 or 
C-6’), 118.9 (C-4 or C-6), 124.0 (C-4’), 124.4 (C-2’), 131.2 (C-5), 132.2 (C-3’), 133.4 
(C-5’), 151.1 (C-1), 154.4 (C-3 or C-1’), 155.4 (C-3 or C-1’); HRMS (ESI) calcd for 
C16H13Cl6N2O10S3 [M(6 × 
35
Cl)-H]
-
 698.7869, found 698.7868. 
 
Sodium (2-(3-(sulfamoyloxy)phenoxy)phenyl)sulfamate, (202) 
 
To O,O-bis(2,2,2-trichloroethyl) (2-(3-(sulfamoyloxy)phenoxy)phenyl)iminodisulfate 
(201) (140 mg, 0.20 mmol) in MeOH (3.5 mL) were added 3.5 mL of acetate buffer pH 
4.65 and zinc (260 mg, 3.98 mmol). The resulting reaction mixture was stirred at RT for 24 
h, until LC-MS indicated completion of the deprotection. Upon completion, the 
heterogeneous mixture was filtered through Celite and washed with MeOH (10 mL). The 
filtrate was concentrated in vacuo to give a crude oil, which was dissolved in a mixture of 
MeOH (3.5 mL) and acetate buffer pH 4.65 (3.5 mL). Acetic acid was added to acidify the 
reaction mixture to pH 4.0. The resulting solution was heated at 40 °C for 12 h. Upon 
completion, the solvents were removed in vacuo and the crude product was converted to 
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the sodium salt by ion-exchange chromatography (DOWEX 50WX2 - Na
+
 form). The 
crude product was purified by column chromatography (silica gel, EtOAc:MeOH, 
1:0  93:7) to yield the title compound as an off-white solid (25 mg, 33%); Rf = 0.24 
(EtOAc:MeOH, 93:7; KMnO4); m.p. No clear m.p., decomposition range 160-170 °C; λmax 
(EtOH)/nm 270.6, 276.2; IR (neat) νmax/cm
-1
 3409, 3248, 2920, 1611, 1593, 1499, 1479, 
1380, 1226, 1195, 1118, 1059; 
1
H NMR (500 MHz, MeOD) δ 6.93 – 6.91 (2H, m, H-3 and 
H-4), 6.95 – 6.93 (1H, m, H-4’ or H-6’), 6.96 (1H, dd, J = 2.3, 2.3 Hz, H-2’), 7.04 (1H, 
ddd, J = 8.2, 2.2 and 0.9 Hz, H-4’ or H-6’), 7.13 (1H, ddd, J = 8.5, 6.2 and 2.6 Hz, H-5), 
7.36 (1H, dd, J = 8.2, 8.2 Hz, H-5’), 7.73 – 7.69 (1H, m, H-6); 13C NMR (126 MHz, 
MeOD) δ 112.9 (C-2’), 116.7 (C-4’ or C-6’), 117.9 (C-4’ or C-6’), 120.0 (C-6), 120.7 
(C-3), 122.8 (C-4), 126.0 (C-5), 131.4 (C-5’), 134.9 (C-1), 145.2 (C-2), 152.9 (C-3’), 159.8 
(C-1’); LRMS (ES-) m/z 359.2 [M-Na]-; HRMS (ESI) calcd for C12H11N2O7S2 [M-Na]
-
 
359.0013, found 358.9998. 
 
3-(2-Cyanophenoxy)phenyl bis(2,4-dimethoxybenzyl)sulfamate, (206) 
 
Compound 206 was synthesised according to general procedure N, using the following 
reagents: 3-hydroxyphenyl bis(2,4-dimethoxybenzyl)sulfamate (173) (1.0 g, 2.04 mmol), 
potassium carbonate (339 mg, 2.45 mmol), 2-fluorobenzonitrile (495 mg, 443 µL, 
4.08 mmol) and N,N-dimethylformamide (20 mL). The crude orange oil was purified by 
column chromatography (silica gel, petrol:EtOAc, 1:0  7:3) to yield the title compound 
as a pale yellow oil (975 mg, 81%); Rf = 0.31 (petrol:EtOAc, 7:3); λmax (EtOH)/nm 278.2, 
283.0; IR (neat) νmax/cm
-1
 2230, 1611, 1589, 1507, 1478, 1449, 1371, 1253, 1208, 1173, 
1157, 1034; 
1
H NMR (500 MHz, CDCl3) δ 3.73 (6H, s, 2 × ArOCH3), 3.78 (6H, s, 
2 × ArOCH3), 4.44 (4H, s, 2 × ArCH2), 6.39 (2H, d, J = 2.4 Hz, H-3”), 6.42 (2H, dd, 
J = 8.3, 2.4 Hz, H-5”), 6.64 (1H, dd, J = 2.3, 2.3 Hz, H-2), 6.84 (1H, dd, J = 8.5, 1.0 Hz, 
H-6’), 6.95 (1H, ddd, J = 8.2, 2.4 and 0.9 Hz, H-4 or H-6), 7.02 (1H, ddd, J = 8.3, 2.2 and 
0.9 Hz, H-4 or H-6), 7.16 (1H, ddd, J = 7.6, 7.6 and 1.0 Hz, H-4’), 7.25 (2H, d, J = 8.5 Hz, 
H-6”), 7.33 (1H, dd, J = 8.3, 8.3 Hz, H-5), 7.48 (1H, ddd, J = 8.6, 7.6 and 1.7 Hz, H-5’), 
7.68 (1H, dd, J = 7.7, 1.7 Hz, H-3’); 13C NMR (126 MHz, CDCl3)  47.2 (ArCH2), 55.3 
(ArOCH3), 55.5 (ArOCH3), 98.3 (C-3”), 104.0 (C-5”), 104.1 (C-5”), 114.2 (C-2), 115.9 
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(ArCN), 116.5 (C-1”), 117.1 (C-6’), 118.0 (C-4 or C-6), 118.8 (C-4 or C-6), 123.3 (C-4’), 
130.7 (C-5), 131.1 (C-6”), 134.1 (C-3’), 134.4 (C-5’), 151.5 (C-1), 155.6 (C-3), 158.6 
(C-2” or C-4”), 159.3 (C-1’), 160.8 (C-2” or C-4”); HRMS (ESI) calcd for C31H34N3O8S 
[M+NH4]
+
 608.2061, found 608.2056. 
 
3-(3-Cyanophenoxy)phenyl bis(2,4-dimethoxybenzyl)sulfamate, (207) 
 
Compound 207 was synthesised according to general procedure N, using the following 
reagents: 3-hydroxyphenyl bis(2,4-dimethoxybenzyl)sulfamate (173) (1.0 g, 2.04 mmol), 
potassium carbonate (339 mg, 2.45 mmol), 3-fluorobenzonitrile (495 mg, 437 µL, 4.08 
mmol) and N,N-dimethylformamide (20 mL). The crude orange oil was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  7:3) to yield the title compound as a 
yellow oil (740 mg, 61%); Rf = 0.30 (petrol:EtOAc, 7:3); λmax (EtOH)/nm 277.8; IR (neat) 
νmax/cm
-1
 2232, 1611, 1588, 1507, 1478, 1370, 1255, 1207, 1175, 1157, 1111, 1033; 
1
H 
NMR (500 MHz, CDCl3) δ 3.72 (6H, s, 2 × ArOCH3), 3.78 (6H, s, 2 × ArOCH3), 4.45 
(4H, s, 2 × ArCH2), 6.38 (2H, d, J = 2.4 Hz, H-3”), 6.42 (2H, dd, J = 8.3, 2.4 Hz, H-5”), 
6.72 (1H, dd, J = 2.3, 2.3 Hz, H-2), 6.88 (1H, ddd, J = 8.3, 2.3 and 0.9 Hz, H-4 or H-6), 
6.96 (1H, ddd, J = 8.2, 2.2 and 0.9 Hz, H-4 or H-6), 7.20 (1H, ddd, J = 8.0, 2.5 and 1.4 Hz, 
H-6’), 7.26 – 7.22 (3H, m, H-2’ and H-6”), 7.31 (1H, dd, J = 8.2, 8.2 Hz, H-5), 7.41 – 7.38 
(1H, m, H-4’), 7.45 – 7.41 (1H, m, H-5’); 13C NMR (126 MHz, CDCl3)  47.1 (ArCH2), 
55.2 (ArOCH3), 55.5 (ArOCH3), 98.3 (C-3”), 104.1 (C-5”), 113.7 (C-2), 113.9 (C-3’), 
116.5 (C-1”), 117.4 (C-4 or C-6), 118.1 (C-4 or C-6), 118.2 (ArCN), 121.7 (C-2’), 123.1 
(C-6’), 127.1 (C-4’), 130.7 (C-5 or C-5’), 130.9 (C-5 or C-5’), 131.1 (C-6”), 151.6 (C-1), 
156.4 (C-3 or C-1’), 157.5 (C-3 or C-1’), 158.6 (C-2” or C-4”), 160.8 (C-2” or C-4”); 
HRMS (ESI) calcd for C31H34N3O8S [M+NH4]
+
 608.2061, found 608.2058. 
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3-(4-Cyanophenoxy)phenyl bis(2,4-dimethoxybenzyl)sulfamate, (208) 
 
Compound 208 was synthesised according to general procedure N, using the following 
reagents: 3-hydroxyphenyl bis(2,4-dimethoxybenzyl)sulfamate (173) (1.0 g, 2.04 mmol), 
potassium carbonate (339 mg, 2.45 mmol), 4-fluorobenzonitrile (495 mg, 4.08 mmol) and 
N,N-dimethylformamide (20 mL). The crude orange oil was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  7:3) to yield the title compound as a pale 
yellow oil (870 mg, 72%); Rf = 0.31 (petrol:EtOAc, 7:3); λmax (EtOH)/nm 272.0; IR (neat) 
νmax/cm
-1
 2226, 1611, 1589, 1504, 1478, 1370, 1250, 1208, 1157, 1112, 1033; 
1
H NMR 
(500 MHz, CDCl3) δ 3.72 (6H, s, 2 × ArOCH3), 3.78 (6H, s, 2 × ArOCH3), 4.44 (4H, s, 
2 × ArCH2), 6.37 (2H, d, J = 2.4 Hz, H-3”), 6.42 (2H, dd, J = 8.4, 2.4 Hz, H-5”), 6.72 (1H, 
dd, J = 2.3, 2.3 Hz, H-2), 6.93 (1H, ddd, J = 8.2, 2.3 and 0.9 Hz, H-4 or H-6), 7.02 – 6.97 
(3H, m, H-4 or H-6 and H-2’, 6’), 7.24 (2H, d, J = 8.4 Hz, H-6”), 7.34 (1H, dd, J = 8.2, 
8.2 Hz, H-5), 7.61 (2H, d, J = 8.8 Hz, H-3’, 5’); 13C NMR (126 MHz, CDCl3)  47.1 
(ArCH2), 55.2 (ArOCH3), 55.5 (ArOCH3), 98.3 (C-3”), 104.1 (C-5”), 106.5 (C-4’), 114.4 
(C-2), 116.4 (C-1”), 118.2 (C-4 or C-6), 118.3 (C-2’, 6’), 118.8 (C-4 or C-6), 118.8 
(ArCN), 130.8 (C-5), 131.1 (C-6”), 134.3 (C-3’, 5’), 151.6 (C-1), 155.6 (C-3), 158.6 (C-2” 
or C-4”), 160.8 (C-2” or C-4”), 161.0 (C-1’); HRMS (ESI) calcd for C31H31N2O8S [M+H]
+
 
591.1796, found 591.1794. 
 
2-(3-((N,N-bis(2,4-Dimethoxybenzyl)sulfamoyl)oxy)phenoxy)benzoic acid, (209) 
 
To 3-(2-cyanophenoxy)phenyl bis(2,4-dimethoxybenzyl)sulfamate (206) (600 mg, 
1.02 mmol) in dioxane (5.1 mL) was added 2 M aq. solution of NaOH (5.1 mL, 
10.2 mmol). The resulting mixture was heated at 130 °C for 2 h under microwave 
irradiation. After cooling, the mixture was acidified to pH 1-2 with using a 4 M aq. 
solution of HCl and stirred at RT for 30 min. The reaction was then diluted with water 
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(20 mL) and extracted with EtOAc (3 × 25 mL). The pooled organic extracts were washed 
with water (30 mL) and brine (30 mL), dried over MgSO4 and concentrated in vacuo. The 
crude product was purified by column chromatography (silica gel, petrol:EtOAc:AcOH, 
1:0:0  50:49.7:0.3) to yield the title compound as a yellow oil (279 mg, 45%); Rf = 0.30 
(petrol:EtOAc:AcOH, 50:49.7:0.3); λmax (EtOH)/nm 278.0; IR (neat) νmax/cm
-1
 1697, 1605, 
1589, 1507, 1477, 1455, 1370, 1249, 1207, 1157; 
1
H NMR (500 MHz, CDCl3) δ 3.72 (6H, 
s, 2 × ArOCH3), 3.77 (6H, s, 2 × ArOCH3), 4.43 (4H, s, 2 × ArCH2), 6.37 (2H, d, 
J = 2.4 Hz, H-3”), 6.41 (2H, dd, J = 8.4, 2.4 Hz, H-5”), 6.67 (1H, dd, J = 2.3, 2.3 Hz, 
H-2’), 6.92 – 6.86 (2H, m, H-3 and H-4’ or H-6’), 7.00 (1H, ddd, J = 8.3, 2.3 and 0.9 Hz, 
H-4’ or H-6’), 7.26 – 7.22 (m, 3H, H-5 and H-6”), 7.31 (dd, J = 8.2, 8.2 Hz, 1H, H-5’), 
7.50 (1H, ddd, J = 8.3, 7.3 and 1.8 Hz, H-4), 8.15 (1H, dd, J = 7.9, 1.8 Hz, H-6); 
13
C NMR 
(126 MHz, CDCl3)  47.2 (ArCH2), 55.3 (ArOCH3), 55.5 (ArOCH3), 98.3 (C-3”), 104.2 
(C-5”), 113.7 (C-2’), 116.5 (C-1”), 117.3 (C-4’ or C-6’), 118.4 (C-4’ or C-6’), 119.1 (C-3), 
120.6 (C-1), 124.2 (C-5), 130.6 (C-5’), 131.1 (C-6”), 133.5 (C-6), 135.0 (C-4), 151.6 
(C-1), 156.2 (C-2 or C-1’), 156.6 (C-2 or C-1’), 158.5 (C-2” or C-4”), 160.8 (C-2” or 
C-4”), 167.1 (ArCO2H); LRMS (ES
-
) m/z 608.5 [M-H]
-
; HRMS (ESI) calcd for 
C31H30NO10S [M-H]
-
 608.1596, found 608.1578. 
 
3-(3-((N,N-bis(2,4-Dimethoxybenzyl)sulfamoyl)oxy)phenoxy)benzoic acid, (210) 
 
To 3-(3-cyanophenoxy)phenyl bis(2,4-dimethoxybenzyl)sulfamate (210) (600 mg, 
1.02 mmol) in dioxane (5.1 mL) was added 2 M aq. solution of NaOH (5.1 mL, 
10.2 mmol). The resulting mixture was heated at 130 °C for 2 h under microwave 
irradiation. After cooling, the mixture was acidified to pH 1-2 with using a 4 M aq. 
solution of HCl and stirred at RT for 30 min. The reaction was then diluted with water 
(20 mL) and extracted with EtOAc (3 × 25 mL). The pooled organic extracts were washed 
with water (30 mL) and brine (30 mL), dried over MgSO4 and concentrated in vacuo. The 
crude product was purified by column chromatography (silica gel, petrol:EtOAc:AcOH, 
1:0:0  50:49.7:0.3) to yield the title compound as a clear oil (495 mg, 80%); Rf = 0.31 
(petrol:EtOAc:AcOH, 50:49.7:0.3); λmax (EtOH)/nm 277.8; IR (neat) νmax/cm
-1
 1694, 1612, 
1585, 1507, 1479, 1451, 1371, 1249, 1207; 
1
H NMR (500 MHz, CDCl3) δ 3.71 (6H, s, 
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2 × ArOCH3), 3.77 (6H, s, 2 × ArOCH3), 4.43 (4H, s, 2 × ArCH2), 6.36 (2H, d, J = 2.4 Hz, 
H-3”), 6.40 (2H, dd, J = 8.4, 2.4 Hz, H-5”), 6.69 (1H, dd, J = 2.3, 2.3 Hz, H-2’), 6.88 (1H, 
ddd, J = 8.2, 2.4 and 1.0 Hz, H-4’ or H-6’), 6.93 (1H, ddd, J = 8.3, 2.2 and 0.9 Hz, H-4’ or 
H-6’), 7.25 – 7.20 (3H, m, H-4 and H-6”), 7.29 (1H, dd, J = 8.3, 8.3 Hz, H-5), 7.45 (1H, 
dd, J = 8.0, 8.0 Hz, H-5), 7.70 (1H, dd, J = 2.5, 1.5 Hz, H-2), 7.86 (1H, ddd, J = 7.8, 1.3 
and 1.3 Hz, H-6); 
13
C NMR (126 MHz, CDCl3)  47.1 (ArCH2), 55.2 (ArOCH3), 55.5 
(ArOCH3), 98.3 (C-3”), 104.1 (C-5”), 113.2 (C-2’), 116.6 (C-1”), 117.0 (C-4’ or C-6’), 
117.5 (C-4’ or C-6’), 120.3 (C-2), 124.3 (C-4), 125.4 (C-6), 130.2 (C-5), 130.5 (C-5’), 
131.1 (C-6”), 131.3 (C-1), 151.6 (C-3’), 157.1 (C-3 or C-1’), 157.4 (C-3 or C-1’), 158.6 
(C-2” or C-4”), 160.7 (C-2” or C-4”), 170.9 (ArCO2H); LRMS (ES
-
) m/z 608.5 [M-H]
-
; 
HRMS (ESI) calcd for C31H30NO10S [M-H]
-
 608.1596, found 608.1577. 
 
2-(3-(Sulfamoyloxy)phenoxy)benzoic acid, (212) 
 
Compound 212 was synthesised according to general procedure D, using the following 
reagents: 2-(3-((N,N-bis(2,4-dimethoxybenzyl)sulfamoyl)oxy)phenoxy)benzoic acid (209) 
(200 mg, 0.33 mmol), DCM (3.0 mL) and TFA (0.3 mL). The crude product was purified 
by column chromatography (silica gel, petrol:EtOAc:AcOH, 1:0:0  50:49.7:0.3) to yield 
the title compound as an off-white solid (91 mg, 90%); Rf = 0.30 (petrol:EtOAc:AcOH, 
50:49.7:0.3); m.p. 101.5-103.5 °C; λmax (EtOH)/nm 278.6; IR (neat) νmax/cm
-1
 3405, 3298, 
1681, 1602, 1573, 1478, 1448, 1385, 1263, 1252, 1190, 1112; 
1
H NMR (500 MHz, 
DMSO-d6) δ 6.82 (1H, dd, J = 2.4, 2.4 Hz, H-2’), 6.84 (1H, ddd, J = 8.3, 2.4 and 0.8 Hz, 
H-4’ or H-6’), 7.00 (1H, ddd, J = 8.3, 2.2 and 0.9 Hz, H-4’ or H-6’), 7.11 (1H, dd, J = 8.3, 
1.1 Hz, H-3), 7.32 (1H, ddd, J = 7.6, 7.6 and 1.1 Hz, H-5), 7.41 (dd, J = 8.2, 8.2 Hz, 1H, 
H-5’), 7.60 (1H, ddd, J = 8.2, 7.3 and 1.8 Hz, H-4), 7.86 (1H, dd, J = 7.8, 1.8 Hz, H-6), 
8.04 (2H, s, ArOSO2NH2), 12.85 (1H, s, ArCO2H); 
13
C NMR (126 MHz, DMSO-d6) 
δ 111.4 (C-2’), 115.3 (C-4’ or C-6’), 116.3 (C-4’ or C-6’), 121.5 (C-3), 124.6 (C-1), 124.7 
(C-5), 130.6 (C-5’), 131.5 (C-6), 133.7 (C-4), 151.0 (C-3’), 154.1 (C-2), 158.4 (C-1’), 
166.3 (ArCO2H); LRMS (ES
-
) m/z 308.2 [M-H]
-
; HRMS (ESI) calcd for C13H10NO6S 
[M-H]
-
 308.0234, found 308.0222. 
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3-(3-(Sulfamoyloxy)phenoxy)benzoic acid, (213) 
 
Compound 213 was synthesised according to general procedure D, using the following 
reagents: 3-(3-((N,N-bis(2,4-dimethoxybenzyl)sulfamoyl)oxy)phenoxy)benzoic acid (210) 
(200 mg, 0.33 mmol), DCM (3.0 mL) and TFA (0.3 mL). The crude product was purified 
by column chromatography (silica gel, petrol:EtOAc:AcOH, 1:0:0  50:49.7:0.3) to yield 
the title compound as an off-white solid (95 mg, 94%); Rf = 0.32 (petrol:EtOAc:AcOH, 
50:49.7:0.3); m.p. 132.0-134.0 °C; λmax (EtOH)/nm 275.4; IR (neat) νmax/cm
-1
 3369, 3265, 
1689, 1586, 1480, 1447, 1350, 1304, 1250, 1177, 1116; 
1
H NMR (500 MHz, DMSO-d6) 
δ 6.97 (1H, dd, J = 2.3, 2.3 Hz, H-2’), 7.01 (1H, ddd, J = 8.3, 2.4 and 0.9 Hz, H-4’ or 
H-6’), 7.10 (1H, ddd, J = 8.2, 2.3 and 0.9 Hz, H-4’ or H-6’), 7.35 (1H, ddd, J = 8.2, 2.7 and 
1.1 Hz, H-4), 7.49 (1H, dd, J = 8.2, 8.2 Hz, H-5 or H-5’), 7.52 (1H, dd, J = 2.6, 1.5 Hz, 
H-2), 7.55 (1H, dd, J = 7.9, 7.9 Hz, H-5 or H-5’), 7.76 (1H, ddd, J = 7.7, 1.3 and 1.3 Hz, 
H-6), 8.06 (2H, s, ArOSO2NH2), 13.09 (1H, s, ArCO2H); 
13
C NMR (126 MHz, DMSO-d6) 
δ 112.8 (C-2’), 116.8 (C-4’ or C-6’), 117.6 (C-4’ or C-6’), 119.0 (C-2), 123.4 (C-4), 124.8 
(C-6), 130.6 (C-5 or C-5’), 131.0 (C-5 or C-5’), 132.9 (C-1), 151.2 (C-3’), 156.2 (C-3 or 
C-1’), 157.1 (C-3 or C-1’), 166.6 (ArCO2H); LRMS (ES
-
) m/z 308.2 [M-H]
-
; HRMS (ESI) 
calcd for C13H10NO6S [M-H]
-
 308.0234, found 308.0225. 
 
4-(3-(Sulfamoyloxy)phenoxy)benzoic acid, (214) 
 
Compound 214 was synthesised according to general procedure D, using the following 
reagents: 4-(3-((N,N-bis(2,4-dimethoxybenzyl)sulfamoyl)oxy)phenoxy)benzoic acid (211) 
(200 mg, 0.33 mmol), DCM (3.0 mL) and TFA (0.3 mL). The crude product was purified 
by column chromatography (silica gel, petrol:EtOAc:AcOH, 1:0:0  50:49.7:0.3) to yield 
the title compound as an off-white solid (93 mg, 92%); Rf = 0.32 (petrol:EtOAc:AcOH, 
50:49.7:0.3); m.p. 173.5-175.5 °C; λmax (EtOH)/nm 252.2; IR (neat) νmax/cm
-1
 3368, 3286, 
1669, 1593, 1485, 1429, 1366, 1248, 1181; 
1
H NMR (500 MHz, DMSO-d6) δ 7.02 (1H, 
dd, J = 2.3, 2.3 Hz, H-2’), 7.09 (1H, ddd, J = 8.2, 2.4 and 0.9 Hz, H-4’ or H-6’), 7.16 - 7.10 
(3H, m, H-3, 5 and H-4’ or H-6’), 7.52 (1H, dd, J = 8.2, 8.2 Hz, H-5’), 7.97 (2H, d, 
J = 8.8 Hz, H-2, 6), 8.06 (2H, s, ArOSO2NH2), 12.79 (1H, s, ArCO2H); 
13
C NMR 
(126 MHz, DMSO-d6) δ 113.7 (C-2’), 117.7 (C-4’ or C-6’), 117.8 (C-3, 5), 118.3 (C-4’ or 
C-6’), 125.9 (C-1), 131.1 (C-5’), 131.7 (C-2, 6), 151.2 (C-3’), 156.1 (C-1’), 160.2 (C-4), 
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166.7 (ArCO2H); LRMS (ES
-
) m/z 308.2 [M-H]
-
; HRMS (ESI) calcd for C13H10NO6S 
[M-H]
-
 308.0234, found 308.0226. 
 
10.3. ERK5 Inhibitors - Experimental Procedures 
10.3.1. ERK5 and p38α Biological Assay Protocols 
The ERK5 biological assays were performed by Ms Ai Ching Wong at Cancer Research 
Technology Discovery research Laboratories, London, by Dr Pamela Lochhead at the 
Babraham Institute, Cambridge, by Ms Lan-Zhen Wang and Dr Noel Edwards at the Paul 
O’Gorman Building, Newcastle Cancer Centre, Newcastle upon Tyne. 
 
ERK5 IMAP
TM
 assay protocol 
Preparation of assay buffer (1x) 
The assay buffer was prepared using 0.01% Tween
®
-20 5x stock, supplied as part of 
IMAP
TM
 FP Progressive Binding System Kit (Molecular Devices R7436) and diluted to 1x 
using milliQ H2O. 1 µL of a 1 M DTT stock was added for every 1 mL of 1x assay buffer 
to give a final concentration of 1 mM DTT. 
Preparation of ERK5 working solution 
The final dilution was dependent on activity of the enzyme batches. The initial batch 
(08/08/08) was used at a 1 in 1 in 350 final dilution in assay buffer. A 1:175 dilution of 
ERK5 stock was performed in 1x assay buffer. For 1 plate, 13 μL of ERK5 stock was 
added to 2262 μL of 1x assay buffer. ERK5 was expressed and purified at CRT by Leon 
Pang and Sue Young. Aliquots were stored at -80 °C. Batch PO080808 was used at a stock 
concentration of 73.4 ng/μL. 
Preparation of ATP/substrate working solution 
For one plate, ATP disodium salt (90 µL, 20 mM) (Sigma A7699) and FAM-EGFR-
derived peptide (15 µL, 100 µM) (LVEPLTPSGEAPNQ(K-5FAM)-COOH) (Molecular 
Devices RP7129; reconstituted in milliQ H2O to a stock concentration of 100 µL; stored at 
-20 C) was added to 2295 µL of 1x assay buffer. 
  
275 
Preparation of IMAP
TM
 binding solution 
For one plate, 20.5 µL of IMAP
™
 binding reagent stock, 1476 µL of 1x binding buffer A 
(60%), and 984 µL of binding buffer B (40%) (IMAP™ FP Progressive screening express 
kit (Molecular Devices R8127) was added to 9819.5 µL of milliQ H2O. 
Assay procedure 
1 µL of inhibitor (in 60:40 H2O/DMSO) or control/blanks (60:40 H2O/DMSO) were dry-
spotted into the relevant wells of a 384-well assay plate using the MATRIX PlateMate

 
Plus. 5 µL of ERK5 working solution was added to test and control wells, and 5 µL of 1x 
assay buffer added to blanks; 4 µL of ATP/substrate working solution was added to all 
wells using a Matrix multichannel pipette. The plate was sealed using DMSO resistant 
clear seal and incubated for 2 h at 37 C. 1 µL of the kinase reaction mixture from the first 
plate was dry spotted into a second 384-well assay plate using the MATRIX PlateMate

 
Plus. 9 µL of assay buffer was added, followed by 30 µL of IMAP
™
 binding solution using 
a multichannel pipette. The plate was incubated at RT in darkness for 2 h. The assay plate 
was then read on an Analyst HT plate reader (Molecular Devices) using the settings 
described below: 
Measurement mode = Fluorescence polarisation; Method ID = ERK5; Integration time = 
100 ms; Excitation filter = Fluorescein 485-20; Emission filter = 530-25; Dichroic mirror = 
505 nm; Plate definition file = Corning 384 black fb; Z-height = 5.715 mm (middle); 
G-factor = 1; Attenuator = out; Detector counting = Smartread+; Sensitivity = 2. 
 
p38α LANCE assay 
Preparation of assay buffer (1x) 
1x assay buffer was prepared consisting of the following reagents; 250 mM 
tris(hydroxymethyl)aminomethane (Tris) pH 7.5, 25 mM MgCl2, 2.5 mM ethylene glycol 
tetraacetic acid (EGTA), 10 mM DTT and 0.05% Triton X100 in milliQ H2O (NB: 1x 
buffer final assay concentrations were 5x lower than stated above). 
Preparation of p38α/SAPK2 working solution 
The p38α/SAPK2 working solution was prepared using active N-terminal GST-tagged 
recombinant full length protein (Millipore 14-251) supplied as a 10 µg/4 µL stock. This 
was diluted to a 10 µg/40 µL (1 µM) concentration by addition of 156 µL of Tris/HCl (pH 
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7.5, 50 mM), NaCl (150 mM), EGTA (0.1 mM), Brij-35 surfactant (0.03%), glycerol 
(50%) and 0.1% 2-mercaptoethanol (0.1%). The final dilution was dependent on activity of 
the enzyme batches. The p38α concentration used in the assay was 1 nM. A 2x working 
stock solution (2 nM, 500 fold dilution of 1 µM stock) in 1x assay buffer was prepared. For 
one plate, 9.4 µL of p38α (1 µM) was added to 1870.6 µL of milliQ H2O.  
Preparation of ATP/substrate working solution 
For one plate, ATP disodium salt (17.5 µL, 200 mM stock), (Sigma A7699) and Ulight-
MBP Peptide (50 µL, 5 µM stock) (Perkin Elmer TRF0109), which were added to 400 µL 
of 5x assay buffer and 1532.5 µL of milliQ H2O. 
Preparation of EDTA/antibody detection reagent 
For one plate, 84 µL of ethylenediaminetetraacetic acid (EDTA) (0.5 M) (Sigma E4378-
100G) and 27 µL of Europium-anti-phospho-MBP antibody (0.625 µM) (Perkin Elmer) 
was added to 420 µL of LANCE detection buffer (1x) and 3669 of milliQ H2O. 
Assay procedure 
1 µL of compound (in 80:20 H2O/DMSO) or control/blank (80:20 H2O/DMSO) was dry-
spotted into the relevant wells of a 384-well assay plate using the MATRIX PlateMate

 
Plus. 5 µL of p38α working solution was added to test and control wells, and 5 µL of assay 
buffer added to blanks; 4 µL of ATP/substrate working solution was added to all wells 
using a Thermo Multidrop Combi or Matrix multichannel pipette. The plate was sealed 
using DMSO resistant clear seal and incubated for 1 h at 37 C. 10 µL of the 
EDTA/antibody working solution was added to all wells using a Thermo Multidrop Combi 
or Matrix multichannel pipette. The plate was incubated at RT in darkness for 2 h. The 
assay plate was then read on a PheraStar microplate reader using the settings described 
below: 
Pherastar: Measurement mode = TRF; Method ID = LANCE HTRF ERK5; Optic Module: 
337, 665, 620 nm. Focal Height = 6.0, Positioning delay, 0.1 sec, Number of flashes per 
well = 100, Integration start = 60 µs, Integration time = 200 µs, Simultaneous dual 
emission, Ratio multiplicator = 1000. 
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Hela cell-based densitometry assay protocol 
HeLa cells were serum starved overnight followed by treatment with ERK5 inhibitors for 
1 h. Cells were then stimulated with 100 ng/ml EGF for 10 min. The cells were harvested 
and lysed at 4 C for 5–10 min in Laemmli buffer containing Halt protease and phosphate 
inhibitors (Pierce). The lysates were boiled for 10 min at 100 C. Twenty microliters 
sample was run on 6% Tris–glycine gels and transferred to nitrocellulose. Western blotting 
was done with ERK5 antibody (Cell signalling #3372S). The IC50 was calculated from 
densitometry of top bands. 
 
Dual-luciferase reporter assay protocol 
HEK293T forward transfection 
HEK293T cells were seeded in 96-well luminescence (white) plates (1.68 × 10
4
/well in 
84 μL standard culture medium) and incubated overnight at 37 °C in a humidified 
atmosphere of 5% CO2 in air. Next day, transfection mixtures were prepared as shown in 
Table 10.1. Plasmid DNA mastermix containing MEF2D-Gal4 (0.25 µg/µL), Gal4-Luc 
(1.25 µg/µL) and Renilla luciferase (0.1 µg/µL) was prepared in sterile distilled water. 
Constitutively-active, EGFP-tagged MEK5 (EGFP-MEK5D; 0.5 µg/µL), an EGFP-tagged 
construct containing no MEK5D (EGFP-C3; 0.5µg/µL), and HA-tagged ERK5 with 
C-terminal truncation (HA-ERK5-ΔP493; 0.5 µg/µL) were diluted separately in sterile 
distilled water. Plasmid DNA and Lipofectamine 2000 (Invitrogen) were separately diluted 
in Opti-MEM growth media (reduced serum medium, Invitrogen), and incubated at room 
temperature for 5min. Plasmid DNA (Tube A) and Lipofectamine 2000 (Tube B) were 
then combined and incubated for 20 min at room temperature to complex. Cells were then 
transfected by addition of 16 µL of the respective transfection mixture: 3 wells with 
EGFP-C3-containing (control) and 21 wells with MEK5D-containing transfection mixture 
(final volume, 100µL). Cells were subsequently incubated for 4 h at 37 °C prior to addition 
of potential ERK5-inhibitory compounds. 
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Table 10.1: Transfection mixture volumes for the HEK293T luciferase assay. Volumes are 
sufficient for the 3 control (EGFP-C3) and 21 test (MEK5D) wells required for each 
potential ERK5 inhibitory compound tested. 
Condition Control 
MEK5D-activated 
ERK5 
Plasmid DNA Tube A Tube B Tube A Tube B 
Mastermix 1.6 µL - 11.0 µL - 
EGFP-C3 0.1 µL - - - 
EGFP-MEK5D - - 0.4 µL - 
HA-ERK5-ΔP493 0.5 µL - 3.7 µL - 
Opti-MEM 27 µL 27 µL 183 µL 183 µL 
Lipofectamine 2000 - 1.1 µL - 7.3 µL 
 
Addition of compounds to ERK5-transfected HEK293T cells 
Potential ERK5-inhibitory compounds were prepared as a 2X solution by addition of 2 μL 
compound (or DMSO as control) to 1 mL standard culture medium. Compounds were 
tested in triplicate at a concentration range of 0.003 μM, 0.01 μM, 0.03 μM, 0.1 μM, 
0.3 μM and 1 μM (or 0.03 μM, 0.1 μM, 0.3 μM, 1 μM, 3 μM and 10 μM for BIX02189) by 
addition of 100 μL 2X solution to 100 μL transfected cells (final DMSO, 0.1% v/v). Cells 
were incubated for 24 h at 37°C. 
Cell lysis and luciferase quantification 
After 24 h incubation in the absence (control) or presence of potential inhibitor, the culture 
medium was aspirated and cells lysed in 20 μL 1X passive lysis buffer (Dual-Luciferase 
Reporter Assay System, Promega) for a minimum of 15 min with agitation. Lysates were 
further processed immediately or stored at -80 °C. Cellular inhibition of ERK5 was 
quantified using the Dual-Luciferase Reporter Assay System (Promega). Luciferase assay 
buffer/Luciferase assay substrate and Stop and Glo assay buffer/Stop and Glo substrate 
were prepared according to the manufacturer’s instructions. Luciferase reagent 
(50 μL/well) was added immediately before luminescence detection using a FLUOstar 
Omega plate reader (BMG Labtech). Stop and Glo reagent (50 μL/well) was subsequently 
added, and the Renilla luciferase signal (transfection efficiency control) quantified. 
  
279 
Data analysis 
The ERK5-specific signalling activity was calculated by subtraction of the EGFP-C3 
luciferase signal from the EGFP-MEK5D-induced luminescence. Luminescence in the 
absence of potential ERK5 inhibitor (DMSO control) was taken as 100% ERK5 activity. 
IC50 values (the concentration of compound yielding 50% inhibition of ERK5 activity) 
were determined from point-to-point analyses using GraphPad Prism v.6. Unless stated 
otherwise, data are mean ± standard deviation of three independent experiments. 
 
10.3.2. Synthesis of ERK5 Inhibitors: General Procedures 
Except where water was included in the reaction mixture, all reactions were carried out 
under strict anhydrous conditions with glassware oven-dried and cooled under nitrogen. 
Temperatures quoted refer to bath temperatures. 
 
General procedure P: To a solution or a suspension of the appropriate carboxylic acid 
(1 mol equiv.) in THF (1 mL/mmol of carboxylic acid), cooled at 0 °C, were added thionyl 
chloride (1.5 mol equiv.) and N,N-dimethylformamide (0.1 mol equiv.). The resulting 
solution was stirred at 0 °C for 30 min and allowed to warm to RT. Upon completion, the 
solvent was removed in vacuo and the crude material used in the next step without further 
purification. 
 
General procedure Q: To a suspension of aluminium trichloride (2.5 mol equiv.) in DCM 
(1 mL/mmol of aluminium trichloride), cooled at 0 °C, was added the appropriate acyl 
chloride (2 mol equiv.), followed by methyl 1H-pyrrole-2-carboxylate (1 mol equiv.). The 
resulting solution was stirred at 0 °C for 30 min and allowed to warm to RT. After 20 h, 
the reaction mixture was cooled to 0 °C and quenched by cautious addition of 1 M aq. HCl 
(0.5 mL/mmol of aluminium trichloride). The resulting solution was stirred at RT for 2 h. 
The reaction was then diluted with water (20 mL) and extracted with DCM (3 × 50 mL). 
The combined organic extracts were washed with saturated aq. NaHCO3 and brine (50 mL, 
respectively), dried over MgSO4 and concentrated in vacuo. The crude product was 
purified by column chromatography. 
 
General procedure R: To the appropriate pyrrole ester (1 mol equiv.) in THF 
(8 mL/mmol of pyrrole ester) was added a 2 M aq. solution of lithium hydroxide (15 mol 
equiv.). The resulting mixture was heated at 67 °C for 18 h. Upon completion, the mixture 
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was acidified to pH 3 using a 4 M aq. solution of HCl. The reaction was then diluted with 
water (30 mL) and extracted with EtOAc (3 × 50 mL). The pooled organic extracts were 
washed with water and brine (50 mL, respectively), dried over MgSO4 and concentrated in 
vacuo. The crude material was used in the next step without further purification. 
 
General procedure S: To 1-methyl-4-piperidone (251) (1 mol equiv.) in MeOH 
(1 mL/mmol of piperidone) was added acetic acid (1.1 mol equiv.), followed by a solution 
of the appropriate amine (2 mol equiv.) in MeOH (0.5 mL/mmol of amine). The resulting 
solution was stirred at RT for 30 min and then cooled to 0 °C. Sodium cyanoborohydride 
(1.5 mol equiv.) was added in several portions. The resulting solution was stirred at 0 °C 
for 30 min and allowed to warm to RT. After 24 h, the reaction mixture was poured in 1 M 
aq. sodium hydroxide (20 mL) and stirred for 30 min. The reaction mixture was 
concentrated in vacuo. The crude product was then dissolved in water (30 mL) and 
extracted with EtOAc (3 × 50 mL). The combined organic extracts were washed with 
water and brine (50 mL, respectively), dried over MgSO4 and concentrated in vacuo. The 
crude product was purified by Kugelröhr distillation. 
 
General procedure T: To the appropriate carboxylic acid (1 mol equiv.) in DCM 
(10 mL/mmol of carboxylic acid), cooled at 0 °C, were added the appropriate amine (3 mol 
equiv.), 4-(dimethylamino)pyridine (0.1 mol equiv.) and N-(3-dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (2 mol equiv.). The resulting solution was stirred at 0 °C 
for 30 min and allowed to warm to RT. After 24 h, the reaction mixture was concentrated 
in vacuo. The crude residue was then dissolved in water (20 mL) and extracted with EtOAc 
(3 × 30 mL). The pooled organic extracts were washed with water and brine (50 mL, 
respectively), dried over MgSO4 and concentrated in vacuo. The crude product was 
purified by column chromatography. 
 
General procedure U: To the appropriate carboxylic acid (1 mol equiv.) in acetonitrile 
(5 mL/mmol of carboxylic acid) were added the appropriate amine (2.5 mol equiv.) and 
phosphorus trichloride (1 mol equiv.). The resulting mixture was heated at 150 °C for 
7 min under microwave irradiation. After cooling, the mixture was quenched by addition 
of 2 M aq. NaOH (10 mL/mmol of carboxylic acid). The resulting heterogeneous solution 
was stirred at RT until solubilisation of all the brown residues formed during the reaction. 
The mixture was extracted with EtOAc (3 × 20 mL), the pooled organic extracts were 
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washed with an acetate buffer pH = 4.65 (20 mL) and brine (20 mL), dried over MgSO4 
and concentrated in vacuo. The crude product was purified by column chromatography. 
 
General procedure V: The appropriate nitropyridine in MeOH (20 mL/mmol of 
nitropyridine) was subjected to palladium-catalysed hydrogenation using an H-Cube

 
reactor and a 10% Pd/C CatCart. The reaction mixture was conducted at 40 °C under a full 
pressure of hydrogen for 8 h. Upon completion, the solvent was removed in vacuo and the 
crude product was purified by column chromatography if required. 
 
General procedure W: The appropriate chloropyridine (1 mol equiv.) in dioxane 
(4.9 mL/mmol of chloropyridine) was sparged with nitrogen for 15 min. To this solution, 
potassium carbonate (3 mol equiv.), the appropriate boronic acid (1.1 mol equiv.) and 
tetrakis(triphenylphosphine)palladium(0) (0.1 mol equiv.) were added. The resulting 
mixture was heated at 100 °C for 48 h. Upon completion, the heterogeneous mixture was 
filtered through Celite and the solvent removed in vacuo. The crude residue was dissolved 
in a mixture of EtOAc and water (20 mL, respectively) and extracted with EtOAc 
(3 × 25 mL). The pooled organic extracts were washed with water (30 mL) and brine 
(30 mL), dried over MgSO4 and concentrated in vacuo. The crude product was purified by 
column chromatography. 
 
General procedure X: To the appropriate carboxylic acid (1 mol equiv.) in acetonitrile 
(10 mL/mmol of carboxylic acid) were added pyridine (1 mol equiv.) and cyanuric fluoride 
(0.4 mol equiv.). The reaction mixture was stirred at RT for 30 min before addition of the 
appropriate amine (2.5 mol equiv.). The resulting mixture was stirred at 40 °C for 24 h. 
Upon completion, the mixture was quenched by addition of saturated aq. NaHCO3 (15 mL) 
and extracted with EtOAc (3 × 20 mL). The pooled organic extracts were washed with an 
acetate buffer pH = 4.65 and brine (30 mL, respectively), dried over MgSO4 and 
concentrated in vacuo. The crude product was purified by column chromatography. 
 
General procedure Y: To the appropriate 1H-pyrrole-2-carboxylic acid (1 mol equiv.) in 
DCM (10 mL/mmol of carboxylic acid) were added triethylamine (2.5 mol equiv.), 
2-chloro-1-methylpyridinium iodide (1.1 mol equiv.) and the appropriate amine (1.25 mol 
equiv.). The resulting solution was stirred at 42 °C for 24 h. Upon completion, the solvent 
was removed in vacuo. The crude residue was dissolved in EtOAc (30 mL), washed with 
saturated aq. NaHCO3 (20 mL) and extracted with EtOAc (3 × 20 mL). The combined 
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organic extracts were washed with brine (30 mL), dried over MgSO4 and concentrated in 
vacuo. The crude product was purified by column chromatography. 
 
General procedure Z: Carbonyl diimidazole (CDI, 2 mol equiv.) was added to a solution 
of the relevant carboxylic acid (1 mol equiv.) in THF (2 mL/mmol) and the mixture heated 
to 70 C for 3 h. The relevant amine (2.5 mol equiv.) was added and the mixture was 
heated at 70 C for 2 h. The mixture was partitioned between EtOAc (20 mL) and saturated 
aq. NaHCO3 (20 mL). The aqueous layer was extracted with EtOAc (2 × 20 mL) The 
organic layers were combined, washed with brine (20 mL), dried over MgSO4 and the 
solvent removed in vacuo. The crude product was purified by column chromatography. 
 
General procedure A’: To the appropriate 3-alkyloxy-4-chloro-2-fluorobenzene (1 mol 
equiv.) in THF (3 mL/mmol of benzene), cooled at -78 °C, was added dropwise 
n-butyllithium (2.4 M in hexane, 1 mol equiv.). The resulting mixture was stirred at -78 °C 
for 30 min. Crushed solid carbon dioxide was added in one portion and the reaction 
allowed to warm to RT. After 1 h, the solvent was removed in vacuo and the crude residue 
dissolved in 2 M aq. NaOH (20 mL). The aqueous layer was washed with EtOAc (20 mL), 
then acidified to pH 1-2 using a 4 M aq. solution of HCl and extracted with EtOAc 
(3 × 25 mL). The pooled organic extracts were washed with water (30 mL) and brine 
(30 mL), dried over MgSO4 and concentrated in vacuo. The crude product was purified by 
column chromatography. 
 
General procedure B’: To 4-chloro-2-fluorophenol (349) (1 mol equiv.) in THF 
(5 mL/mmol of phenol), cooled at 0 °C, were added triphenylphosphine (1.5 mol equiv.) 
and the appropriate alcohol (1.3 mol equiv.). Diethyl azodicarboxylate (1.5 mol equiv.) 
was then added dropwise at 0 °C. The resulting orange solution was stirred at 0 °C for 
30 min and allowed to warm to RT. The reaction was left stirring for 24 h. Upon 
completion, the mixture was diluted with EtOAc (30 mL), washed with saturated aq. 
NaHCO3 and brine (20 mL, respectively), dried over MgSO4 and concentrated in vacuo. 
The crude orange solid was purified by column chromatography. 
 
General procedure C’: To a solution of 2-chloro-5-nitropyrimidine (414) (1 mol equiv.) 
in THF (5.0 mL/mmol of 2-chloro-5-nitropyrimidine), cooled at 0 °C, was added 
triethylamine (1.1 mol equiv.), followed by the appropriate amine. The resulting solution 
was stirred at 0 °C for 5 min and allowed to warm to RT. Upon completion, the solvent 
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was removed in vacuo. The crude residue was dissolved in EtOAc (20 mL), washed with 
water (20 mL) and extracted with EtOAc (3 × 25 mL). The combined organic extracts were 
washed with brine (30 mL), dried over MgSO4 and concentrated in vacuo. The crude 
product was purified by column chromatography. 
 
General procedure D’: The appropriate nitro-pyrimidine/pyridine in MeOH:THF (1:1) 
(20 mL/mmol of nitro-pyrimidine/pyridine) was subjected to palladium-catalysed 
hydrogenation using an H-Cube

 reactor and a 10% Pd/C CatCart. The reaction was 
conducted at 40 °C under a full pressure of hydrogen for 8 h. Upon completion, the 
solvents were removed in vacuo and the crude product was purified by column 
chromatography if required. 
 
General procedure E’: To a suspension of the appropriate Boc-protected amine in formic 
acid (4 mL/mmol of amine) was added a solution of formaldehyde in water (37 wt. %) 
(4 mol equiv.). The resulting mixture was heated at 95 °C for 3 h. Upon completion, the 
reaction was cooled in an ice bath and quenched by addition of 2 M aq. NaOH until the pH 
was alkaline and then extracted with EtOAc (3 × 20 mL). The pooled organic extracts were 
washed with water and brine (40 mL, respectively), dried over MgSO4 and concentrated in 
vacuo. The crude product was purified by column chromatography. 
 
General procedure F’: To the appropriate Boc-protected amine (1 mol equiv.) in DCM 
(5 mL/mmol of amine) were added trifluoroacetic acid (5 mL/mmol of amine) and 
triethylsilane (2.5 mol equiv.). The resulting mixture was stirred at RT for 2 h. Upon 
completion, the solvent was removed in vacuo. The crude residue was dissolved in EtOAc 
(30 mL), washed with saturated aq. NaHCO3 (20 mL) and extracted with EtOAc 
(3 × 20 mL). The pooled organic extracts were washed with brine (30 mL), dried over 
MgSO4 and concentrated in vacuo. The crude product was purified by column 
chromatography. 
 
General procedure G’: To a solution of 2-chloro-5-nitropyridine (459) (1 mol equiv.) in 
THF (5.0 mL/mmol of 2-chloro-5-nitropyridine), cooled at 0 °C, was added triethylamine 
(1.1 mol equiv.), followed by the appropriate amine. The resulting solution was stirred at 
67 °C overnight. Upon completion, the solvent was removed in vacuo. The crude residue 
was dissolved in EtOAc (20 mL), washed with water (20 mL) and extracted with EtOAc 
(3 × 25 mL). The combined organic extracts were washed with brine (30 mL), dried over 
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MgSO4 and concentrated in vacuo. The crude product was purified by column 
chromatography. 
 
10.3.3. ERK5 Inhibitors Synthetic Procedures 
Methyl 4-(2-bromo-6-fluorobenzoyl)-1H-pyrrole-2-carboxylate, (243) 
 
Compound 243 was synthesised according to general procedure P and Q, using the 
following reagents: 2-bromo-6-fluorobenzoic acid (241) (10.5 g, 47.9 mmol), thionyl 
chloride (5.22 mL, 8.56 g, 71.9 mmol), N,N-dimethylformamide (0.37 mL, 0.35 g, 
4.79 mmol), THF (48 mL), methyl 1H-pyrrole-2-carboxylate (3.0 g, 24.0 mmol), 
aluminum trichloride (8.0 g, 59.9 mmol) and DCM (60 mL). The crude product was 
purified by column chromatography (silica gel, petrol:EtOAc, 1:0  7:3) to yield the title 
compound as a white solid (7.51 g, 96%); Rf = 0.29 (petrol:EtOAc, 7:3); m.p. 143.0-145.0 
°C; λmax (EtOH)/nm 263.0; IR (neat) νmax/cm
-1
 3233, 3140, 2996, 1731, 1639, 1599, 1564, 
1442, 1393, 1283, 1230; 
1
H NMR (500 MHz, DMSO-d6) δ 3.79 (3H, s, CO2CH3), 6.99 
(1H, brs, H-3), 7.44 – 7.37 (1H, m, H-5’), 7.53 – 7.46 (2H, m, , H-5 and H-4’), 7.59 (1H, d, 
J = 7.8 Hz, H-3’), 12.89 (1H, s, NH-pyrrole); 13C NMR (126 MHz, DMSO-d6) δ 51.7 
(CO2CH3), 114.7 (C-3), 115.4 (d, J = 21.4 Hz, C-5’), 118.9 (d, J = 5.1 Hz, C-2’), 124.6 
(C-2 or C-4), 125.0 (C-2 or C-4), 128.8 (d, J = 3.2 Hz, C-3’), 129.7 (d, J = 22.6 Hz, C-1’), 
130.1 (C-5), 132.3 (d, J = 8.8 Hz, C-4’), 158.4 (d, J = 247.8 Hz, C-6’), 160.3 (CO2CH3), 
184.7 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -113.8 (ArF); LRMS (ES
+
) m/z 326.3 
[M(
79
Br)+H]
+
, 328.3 [M(
81
Br)+H]
+
; HRMS (ESI) calcd for C13H10BrFNO3 [M(
79
Br)+H]
+
 
325.9823, found 325.9823. 
 
4-(2-Bromo-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid, (244) 
 
Compound 244 was synthesised according to general procedure R, using the following 
reagents: methyl 4-(2-bromo-6-fluorobenzoyl)-1H-pyrrole-2-carboxylate (243) (7.50 g, 
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23.0 mmol), 2 M aq. lithium hydroxide (173 mL, 346 mmol) and THF (184 mL). The 
crude off-white solid (7.05 g, 98%) was used in the next step without further purification; 
Rf = 0.18 (petrol:EtOAc:AcOH, 50:49.7:0.3); m.p. 220.0-222.0 °C; λmax (EtOH)/nm 263.4; 
IR (neat) νmax/cm
-1
 3318, 2888, 1667, 1641, 1602, 1560, 1440, 1390, 1278; 
1
H NMR 
(500 MHz, DMSO-d6) δ 6.94 (1H, d, J = 2.0 Hz, H-3), 7.40 (1H, dd, J = 8.8, 8.8 Hz, H-5’), 
7.43 (1H, d, J = 2.0 Hz, H-5), 7.49 (1H, ddd, J = 8.8, 8.0 and 6.1 Hz, H-4’), 7.58 (1H, dd, 
J = 8.0, 0.9 Hz, H-3’), 12.70 (1H, s, NH-pyrrole), 12.94 (s, 1H, CO2H); 
13
C NMR 
(126 MHz, DMSO-d6) δ 114.3 (C-3), 115.4 (d, J = 21.4 Hz, C-5’), 119.0 (d, J = 5.2 Hz, 
C-2), 125.0 (C-2 or C-4), 125.9 (C-2 or C-4), 128.8 (d, J = 3.0 Hz, C-3’), 129.7 (C-5), 
129.9 (d, J = 22.7 Hz, C-1’), 132.2 (d, J = 8.7 Hz, C-4’), 158.4 (d, J = 248.1 Hz, C-6’), 
161.3 (CO2H), 184.7 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -113.84 (ArF); 
LRMS (ES
-
) m/z 310.1 [M(
79
Br)-H]
-
, 312.1 [M(
81
Br)-H]
-
; HRMS (ESI) calcd for 
C12H6BrFNO3 [M(
79
Br)-H]
-
 309.9521, found 309.9518. 
 
Methyl 4-(2-chloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxylate, (247) 
 
Compound 247 was synthesised according to general procedure Q, using the following 
reagents: 2-chloro-6-fluorobenzoyl chloride (245) (4.31 mL, 6.17 g, 33.0 mmol), methyl 
1H-pyrrole-2-carboxylate (2.0 g, 16.0 mmol), aluminum trichloride (5.33 g, 40.0 mmol) 
and DCM (40 mL). The crude product was purified by column chromatography (silica gel, 
petrol:EtOAc, 1:0  7:3) to yield the title compound as a white solid (4.31 g, 96%); 
Rf = 0.31 (petrol:EtOAc, 7:3); m.p. 145.5-147.5 °C; λmax (EtOH)/nm 262.6; IR (neat) 
νmax/cm
-1
 3225, 3007, , 1731, 1639, 1603, 1563, 1440, 1394, 1284, 1230;
1
H NMR 
(500 MHz, DMSO-d6) δ 3.79 (3H, s, CO2CH3), 7.00 (1H, d, J = 1.8, H-3), 7.38 (1H, dd, 
J = 8.8, 8.8 Hz, H-5’), 7.45 (1H, d, J = 8.1 Hz, H-3’), 7.54 (1H, d, J = 1.8 Hz, H-5), 7.57 
(1H, ddd, J = 8.8, 8.1 and 6.2 Hz, H-4’), 12.91 (1H, s, NH-pyrrole); 13C NMR (126 MHz, 
DMSO-d6) δ 51.7 (CO2CH3), 114.6 (C-3), 115.0 (d, J = 21.7 Hz, C-5’), 124.6 (C-2 or C-4), 
125.4 (C-2 or C-4), 125.9 (d, J = 3.0 Hz, C-3’), 127.8 (d, J = 22.9 Hz, C-1’), 130.2 (C-5), 
130.3 (d, J = 6.2 Hz, C-2’), 132.0 (d, J = 9.0 Hz, C-4’), 158.5 (d, J = 247.1 Hz, C-6’), 
160.3 (CO2CH3), 183.7 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -114.4 (ArF); 
LRMS (ES
+
) m/z 282.3 [M(
35
Cl)+H]
+
, 284.3 [M(
37
Cl)+H]
+
; HRMS (ESI) calcd for 
C13H10ClFNO3 [M(
35
Cl)+H]
+
 282.0328, found 282.0330. 
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Methyl 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylate, (248) 
 
Compound 248 was synthesised according to general procedure Q, using the following 
reagents: 3,6-dichloro-2-fluorobenzoyl chloride (246) (7.27 g, 32.0 mmol), methyl 1H-
pyrrole-2-carboxylate (2.0 g, 16.0 mmol), aluminum trichloride (5.33 g, 40.0 mmol) and 
DCM (40 mL). The crude product was purified by column chromatography (silica gel, 
petrol:EtOAc, 1:0  8:2) to yield the title compound as an off-white solid (4.91 g, 97%); 
Rf = 0.28 (petrol:EtOAc, 8:2); m.p. 135.5-137.5 °C; λmax (EtOH)/nm 281.4; IR (neat) 
νmax/cm
-1
 3286, 3231, 1690, 1656, 1594, 1560, 1447, 1388, 1283; 
1
H NMR (500 MHz, 
DMSO-d6) δ 3.80 (3H, s, CO2CH3), 7.09 (1H, d, J = 1.8 Hz, H-3), 7.49 (1H, dd, J = 8.8, 
1.4 Hz, H-5’), 7.67 (1H, d, J = 1.8 Hz, H-5), 7.76 (1H, dd, J = 8.8, 8.4 Hz, H-4’), 12.94 
(1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 51.7 (CO2CH3), 114.6 (C-3), 119.4 
(d, J = 17.8 Hz, C-3’), 124.8 (C-2 or C-4), 124.9 (C-2 or C-4), 126.8 (d, J = 3.7 Hz, C-5’), 
128.9 (d, J = 22.9 Hz, C-1’), 129.1 (d, J = 5.1 Hz, C-6’), 131.0 (C-5), 131.9 (C-4’), 153.8 
(d, J = 248.7 Hz, C-2’), 160.3 (CO2CH3), 182.5 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) 
δ -116.7 (ArF); LRMS (ES-) m/z 314.2 [M(35Cl35Cl)-H]-, 316.1 [M(35Cl37Cl)-H]-; HRMS 
(NSI) calcd for C13H9Cl2FNO3 [M(
35
Cl)+H]
+
 315.9938, found 315.9944. 
 
4-(2-Chloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid, (249) 
 
Compound 249 was synthesised according to general procedure R, using the following 
reagents: methyl 4-(2-chloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxylate (247) (2.70 g, 
9.59 mmol), 2 M aq. lithium hydroxide (72 mL, 144 mmol) and THF (77 mL). The crude 
white solid (2.43 g, 95%) was used in the next step without further purification; Rf = 0.19 
(petrol:EtOAc:AcOH, 50:49.7:0.3); m.p. 218.0-220.0 °C; λmax (EtOH)/nm 280.8; IR (neat) 
νmax/cm
-1
 3314, 1881, 1669, 1638, 1609, 1553, 1443, 1391, 1276, 1242; 
1
H NMR 
(500 MHz, DMSO-d6) δ 6.95 (1H, d, J = 2.0 Hz, H-3), 7.37 (1H, dd, J = 8.5, 8.5 Hz, H-5’), 
7.49 – 7.42 (2H, m, H-5 and H-3’), 7.56 (1H, ddd, J = 8.5, 8.3 and 6.2 Hz, H-4’), 12.71 
(1H, s, NH-pyrrole), 12.93 (1H, s, CO2H); 
13
C NMR (126 MHz, DMSO-d6) δ 114.2 (C-3), 
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115.0 (d, J = 21.5 Hz, C-5’), 125.3 (C-2 or C-4), 125.9 (d, J = 3.2 Hz, C-3’), 125.9 (C-2 or 
C-4), 127.9 (d, J = 23.0 Hz, C-1’), 129.8 (C-5), 130.4 (d, J = 6.1 Hz, C-2’), 131.9 (d, 
J = 9.1 Hz, C-4’), 158.6 (d, J = 247.1 Hz, C-6’), 161.3 (CO2H), 183.8 (ArCO); 
19
F NMR 
(471 MHz, DMSO-d6) δ -114.4 (ArF); LRMS (ES
-
) m/z 266.2 [M(
35
Cl)-H]
-
, 268.2 
[M(
37
Cl)-H]
-
; HRMS (ESI) calcd for C12H6ClFNO3 [M(
35
Cl)-H]
-
 266.0026, found 
266.0022. 
 
4-(3,6-Dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid, (250) 
 
Compound 250 was synthesised according to general procedure R, using the following 
reagents: methyl 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylate (248) (5.0 g, 
15.8 mmol), 2 M aq. lithium hydroxide (119 mL, 238 mmol) and THF (127 mL). The 
crude white solid (4.45 g, 93%) was used in the next step without further purification; 
Rf = 0.25 (petrol:EtOAc:AcOH, 50:49.7:0.3); m.p. 228.5-230.5 °C; λmax (EtOH)/nm 281.6; 
IR (neat) νmax/cm
-1
 3268, 3144, 3092, 1698, 1648, 1565, 1501, 1452, 1420, 1390, 1239; 
1
H NMR (500 MHz, DMSO-d6) δ 7.03 (1H, d, J = 2.0 Hz, H-3), 7.49 (1H, dd, J = 8.8, 
1.3 Hz, H-5’), 7.60 (1H, d, J = 2.0 Hz, H-5), 7.75 (1H, dd, J = 8.8, 8.4 Hz, H-4’), 12.75 
(1H, s, NH-pyrrole), 12.93 (1H, brs, CO2H); 
13
C NMR (126 MHz, DMSO-d6) δ 114.1 
(C-3), 119.3 (d, J = 18.2 Hz, C-3’), 124.8 (C-2 or C-4), 126.1 (C-2 or C-4), 126.8 (d, 
J = 3.8 Hz, C-5’), 128.9 (d, J = 23.3 Hz, C-1’), 129.1 (d, J = 5.5 Hz, C-6’), 130.6 (C-5), 
131.9 (C-4’), 153.8 (d, J = 248.6 Hz, C-2’), 161.3 (CO2H), 182.47 (ArCO); 
19
F NMR 
(471 MHz, DMSO-d6) δ -116.7 (ArF); LRMS (ES
-
) m/z 300.0 [M(
35
Cl
35
Cl)-H]
-
, 302.1 
[M(
35
Cl
37
Cl)-H]
-
; HRMS (NSI) calcd for C12H5Cl2FNO3 [M(
35
Cl
35
Cl)-H]
-
 299.9636, found 
299.9632. 
 
N,1-Dimethylpiperidin-4-amine, (252) 
 
Compound 252 was synthesised according to general procedure S, using the following 
reagents: 1-methyl-4-piperidone (1.54 mL, 1.5 g, 13.3 mmol), acetic acid (0.83 mL, 0.88 g, 
14.6 mmol), 2 M methylamine in EtOH (13.3 mL, 26.6 mmol) and EtOH (13.3 mL). The 
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crude yellow oil was purified by Kugelröhr distillation to yield the title compound as a 
clear liquid (150 mg, 9%); Rf = 0.22 (EtOAc:MeOH, 6:4); IR (neat) νmax/cm
-1
 3283, 2938, 
2851, 2791, 2738, 1659, 1467, 1450, 1370, 1277; 
1
H NMR (500 MHz, CDCl3) δ 
1.40 - 1.29 (2H, m, H-3axial and H-5axial), 1.89 – 1.82 (2H, m, H-3equ and H-5equ), 
2.00 - 1.92 (2H, m, H-2axial and H-6axial), 2.24 (3H, s, NCH3), 2.35 – 2.27 (1H, m, H-4), 
2.40 (3H, s, NHCH3), 2.83 – 2.74 (2H, m, H-2equ and H-6equ); 
13
C NMR (126 MHz, 
CDCl3) δ 32.5 (C-3 and C-5), 33.6 (NHCH3), 46.3 (NCH3), 54.7 (C-2 and C-6), 56.2 (C-4); 
LRMS (ES
+
) m/z 129.3 [M+H]
+
; HRMS (APCI) calcd for C7H17N2 [M+H]
+
 129.1386, 
found 129.1385. 
 
N-Ethyl-1-methylpiperidin-4-amine, (253) 
 
Compound 253 was synthesised according to general procedure S, using the following 
reagents: 1-methyl-4-piperidone (251) (1.54 mL, 1.5 g, 13.3 mmol), acetic acid (0.83 mL, 
0.88 g, 14.6 mmol), 2 M ethylamine in MeOH (13.3 mL, 26.6 mmol) and MeOH 
(13.3 mL). The crude yellow oil was purified by Kugelröhr distillation to yield the title 
compound as a clear liquid (450 mg, 24%); Rf = 0.20 (EtOAc:MeOH, 7:3); IR (neat) 
νmax/cm
-1
 3273, 2936, 2843, 2783, 2737, 2677, 1660, 1465, 1447, 1377, 1278; 
1
H NMR 
(500 MHz, CDCl3) δ 1.11 (3H, t, J = 7.1 Hz, CH2CH3), 1.45 – 1.33 (2H, m, H-3axial and 
H-5axial), 1.92 – 1.82 (2H, m, H-3equ and H-5equ), 2.01 – 1.91 (2H, m, H-2axial and H-6axial), 
2.26 (3H, s, NCH3), 2.44 (1H, tt, J = 10.3, 4.0 Hz, H-4), 2.67 (2H, q, J = 7.1 Hz, 
NCH2CH3), 2.86 – 2.75 (2H, m, H-2equ and H-6equ); 
13
C NMR (126 MHz, CDCl3) δ 15.8 
(NCH2CH3), 33.1 (C-3 and C-5), 41.1 (NCH2CH3), 46.4 (NCH3), 54.6 (C-4), 54.9 (C-2 and 
C-6); LRMS (ES
+
) m/z 143.3 [M+H]
+
; HRMS (NSI) calcd for C8H19N2 [M+H]
+
 143.1543, 
found 143.1539. 
 
N-Isopropyl-1-methylpiperidin-4-amine, (254) 
 
Compound 254 was synthesised according to general procedure S, using the following 
reagents: 1-methyl-4-piperidone (251) (1.54 mL, 1.5 g, 13.3 mmol), acetic acid (0.83 mL, 
0.88 g, 14.6 mmol), 2 M isopropylamine in MeOH (13.3 mL, 26.6 mmol) and MeOH 
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(13.3 mL). The crude yellow oil was purified by Kugelröhr distillation to yield the title 
compound as a clear liquid (825 mg, 40%); Rf = 0.23 (EtOAc:MeOH, 7:3); IR (neat) 
νmax/cm
-1
 3258, 2961, 2937, 2845, 2790, 2739, 2676, 1466, 1449, 1379, 1278; 
1
H NMR 
(500 MHz, CDCl3) δ 1.02 (6H, d, J = 6.2 Hz, NCH(CH3)2), 1.40 – 1.24 (2H, m, H-3axial 
and H-5axial), 1.90 – 1.78 (2H, m, H-3equ and H-5equ), 1.96 (2H, ddd, J = 11.8, 11.8 and 
2.6 Hz, H-2axial and H-6axial), 2.24 (3H, s, NCH3), 2.49 (1H, tt, J = 10.5, 4.0 Hz, H-4), 2.80 
(2H, ddd, J = 11.8, 3.7 and 3.7 Hz, H-2equ and H-6equ), 3.01 – 2.91 (1H, m, NCH(CH3)2); 
13
C NMR (126 MHz, CDCl3) δ 23.6 (NCH(CH3)2), 33.6 (C-3 and C-5), 44.7 (NCH(CH3)2), 
46.5 (NCH3), 51.4 (C-4), 55.2 (C-2 and C-6); LRMS (ES
+
) m/z 157.3 [M+H]
+
; 
HRMS (NSI) calcd for C9H21N2 [M+H]
+
 157.1699, found 157.1696. 
 
4-(2-Chloro-6-fluorobenzoyl)-N-methyl-N-(1-methylpiperidin-4-yl)-1H-pyrrole-2-
carboxamide, (255) 
 
Compound 255 was synthesised according to general procedure T, using the following 
reagents: 4-(2-chloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (249) (100 mg, 
0.37 mmol), N,1-dimethylpiperidin-4-amine (252) (144 mg, 1.12 mmol), 
4-(dimethylamino)pyridine (5 mg, 0.04 mmol), N-(3-dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (144 mg, 0.75 mmol) and DCM (3.7 mL). The product 
was purified by column chromatography (silica gel, DCM:MeOH, 1:0  92:8) to yield the 
title compound as an off-white solid (26 mg, 18%); Rf = 0.22 (DCM:MeOH, 92:8); 
m.p. 226.0-228.0 °C; λmax (EtOH)/nm 234.4, 285.2; IR (neat) νmax/cm
-1
 3158, 2940, 2908, 
2847, 2785, 1653, 1587, 1558, 1483, 1448, 1391, 1322, 1244;
1
H NMR (500 MHz, 
DMSO-d6, 100 °C) δ 1.65 – 1.52 (2H, m, H-3”equ and H-5”equ), 1.85 (2H, dddd, J = 12.1, 
12.1, 12.1 and 3.8 Hz, H-3”axial and H-5”axial), 1.95 (2H, ddd, J = 11.7, 11.7 and 2.3 Hz, 
H-2”axial and H-6”axial), 2.19 (3H, s, NCH3), 2.88 – 2.79 (2H, m, H-2”equ and H-6”equ), 3.00 
(3H, s, CONCH3), 4.17 (1H, tt, J = 11.7, 4.0 Hz, H-4”), 6.74 (1H, d, J = 1.5 Hz, H-3), 7.26 
(1H, d, J = 1.5 Hz, H-5), 7.30 (1H, dd, J = 8.7, 8.7 Hz, H-5’), 7.40 (1H, d, J = 8.2 Hz, 
H-3’), 7.53 (1H, ddd, J = 8.7, 8.2 and 6.2 Hz, H-4’), 11.91 (1H, s, NH-pyrrole); 13C NMR 
(126 MHz, DMSO-d6) δ 28.2 (C-3” and C-5”), 29.4 (CONCH3), 45.0 (NCH3), 52.9 (C-4”), 
54.2 (C-2” and C-6”), 110.1 (C-3), 114.2 (d, J = 22.2 Hz, C-5’), 124.5 (C-2 or C-4), 125.2 
(d, J = 3.3 Hz, C-3’), 127.2 (C-5), 127.4 (C-2 or C-4), 128.0 (d, J = 23.3 Hz, C-1’), 130.4 
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(d, J = 6.1 Hz, C-6’), 131.0 (d, J = 9.3 Hz, C-4’), 158.3 (d, J = 247.5 Hz, C-6’), 160.8 
(CON), 183.0 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -114.4 (ArF); LRMS (ES
-
) m/z 
376.0 [M(
35
Cl)-H]
-
, 378.0 [M(
37
Cl)-H]
-
; HRMS (NSI) calcd for C19H20ClFN3O2 
[M(
35
Cl)-H]
-
 376.1234, found 376.1230. 
 
4-(2-Chloro-6-fluorobenzoyl)-N-ethyl-N-(1-methylpiperidin-4-yl)-1H-pyrrole-2-
carboxamide, (256) 
 
Compound 256 was synthesised according to general procedure T, using the following 
reagents: 4-(2-chloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (249) (100 mg, 
0.37 mmol), N-ethyl-1-methylpiperidin-4-amine (253) (160 mg, 1.12 mmol), 
4-(dimethylamino)pyridine (5 mg, 0.04 mmol), N-(3-dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (144 mg, 0.75 mmol) and DCM (3.7 mL). The product 
was purified by column chromatography (silica gel, DCM:MeOH, 1:0  93:7) to yield the 
title compound as an off-white solid (30 mg, 20%); Rf = 0.22 (DCM:MeOH, 93:7); 
m.p. 208.0-210.0 °C; λmax (EtOH)/nm 285.8, 235.2; IR (neat) νmax/cm
-1
 3156, 2961, 2921, 
1849, 2787, 1651, 1579, 1556, 1444, 1386, 1379, 1278; 
1
H NMR (500 MHz, DMSO-d6, 
100 °C) δ 1.17 (3H, t, J = 7.0 Hz, CH3CH2N), 1.72 – 1.58 (2H, m, CH2 piperidine), 1.97 - 1.83 
(4H, m, CH2 piperidine), 2.19 (3H, s, NCH3), 2.90 – 2.76 (2H, m, CH2 piperidine), 3.46 (2H, q, 
J = 7.0 Hz, CH3CH2N), 4.07 (1H, m, H-4”), 6.67 (1H, d, J = 1.5 Hz, H-3), 7.26 (1H, d, 
J = 1.5 Hz, H-5), 7.31 (1H, dd, J = 8.7, 8.7 Hz, H-5’), 7.40 (1H, d, J = 8.1 Hz, H-3’), 7.54 
(1H, ddd, J = 8.7, 8.1 and 6.2 Hz, H-4’), 11.94 (1H, s, NH-pyrrole); 13C NMR (126 MHz, 
DMSO-d6) δ 45.8 (NCH3), 54.8 (NCH2-piperidine), 109.6 (C-3), 114.9 (d, J = 21.6 Hz, 
C-5’), 124.7 (C-2 or C-4), 125.8 (d, J = 3.1 Hz, C-3’), 127.7 (C-2 or C-4), 128.0 (d, 
J = 23.0 Hz, C-1’), 128.4 (C-5), 130.4 (d, J = 6.2 Hz, C-2’), 131.8 (d, J = 9.3 Hz, C-4’), 
158.6 (d, J = 246.7 Hz, C-6’), 160.7 (CON), 183.7 (ArCO) – C-3”, 5” C-4” and the 
carbons of the ethyl are not visualised; 
19
F NMR (471 MHz, DMSO-d6) δ -114.37 (ArF); 
LRMS (ES
+
) m/z 392.5 [M(
35
Cl)+H]
+
, 394.4 [M(
37
Cl)+H]
+
; HRMS (ESI) calcd for 
C20H24ClFN3O2 [M(
35
Cl)+H]
+
 392.1536, found 392.1531. 
 
4-(2-Bromo-6-fluorobenzoyl)-N-ethyl-N-(1-methylpiperidin-4-yl)-1H-pyrrole-2-
carboxamide, (257) 
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Compound 257 was synthesised according to general procedure T, using the following 
reagents: 4-(2-bromo-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (244) (100 mg, 
0.32 mmol), N-ethyl-1-methylpiperidin-4-amine (253) (137 mg, 0.96 mmol), 
4-(dimethylamino)pyridine (4 mg, 0.03 mmol), N-(3-dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (123 mg, 0.64 mmol) and DCM (3.2 mL). The product 
was purified by column chromatography (silica gel, DCM:MeOH, 1:0  93:7) to yield the 
title compound as an off-white solid (31 mg, 22%); Rf = 0.25 (DCM:MeOH, 93:7); 
m.p. 198.0-200.0 °C; λmax (EtOH)/nm 285.6, 234.6; IR (neat) νmax/cm
-1
 3162, 2959, 2922, 
2849, 2785, 1651, 1579, 1555, 1442, 1379, 1278; 
1
H NMR (500 MHz, DMSO-d6, 100 °C) 
δ 1.16 (3H, t, J = 7.0 Hz, NCH2CH3), 1.60 – 1.66 (2H, m, CH2 piperidine), 1.84 – 1.96 (4H, m, 
CH2 piperidine), 2.18 (3H, s, NCH3), 2.82 – 2.87 (2H, m, CH2 piperidine), 3.45 (2H, q, 
J = 7.0 Hz, NCH2CH3), 4.01 – 4.10 (1H, m, H-4”), 6.65 (1H, d, J = 1.5 Hz, H-3), 7.26 (1H, 
d, J = 1.5 Hz, H-5), 7.33 (1H, dd, J = 8.6, 8.6 Hz, H-5’), 7.46 (1H, ddd, J = 8.6, 8.0 and 
6.1 Hz, H-4’), 7.54 (1H, d, J = 8.0 Hz, H-3’), 11.88 (1H, s, NH-pyrrole); 13C NMR 
(126 MHz, DMSO-d6) δ 15.1 (NCH2CH3), 29.5 (C-3”, 5”), 37.4 (NCH2CH3), 45.1 (NCH3), 
54.4 (C-4”), 54.5 (C-2”, 6”), 109.7 (C-3), 115.3 (d, J = 21.7 Hz, C-5’), 119.1 (d, 
J = 5.3 Hz, C-2’), 124.4 (C-2 or C-4), 127.7 (C-2 or C-4), 128.3 (C-5), 128.8 (d, 
J = 3.0 Hz, C-3’), 129.9 (d, J = 22.6 Hz, C-1’), 132.1 (d, J = 8.9 Hz, C-4’), 158.5 (d, 
J = 247.9 Hz, C-6’), 160.7 (CON), 184.6 (ArCO); 19F NMR (471 MHz, DMSO-d6) 
δ -113.8 (ArF); LRMS (ES+) m/z 436.4 [M(79Br)+H]+, 438.4 [M(81Br)+H]+; HRMS (ESI) 
calcd for C20H24BrFN3O2 [M(
79
Br)+H]
+
 436.1030, found 436.1021. 
 
N-Methylpyridin-3-amine, (259) 
 
A microwave vial was charged with 3-bromopyridine (258) (610 µL, 1.0 g, 6.33 mmol), 
copper powder (20 mg, 0.32 mmol), water (1.17 mL) and 40% aq. methylamine (3.52 mL, 
31.7 mmol). The resulting solution was stirred at 100 °C for 20 h. Upon completion, the 
reaction mixture was diluted with water (15 mL) and extracted with EtOAc (3 × 25 mL). 
The pooled organic extracts were washed with brine (30 mL), dried over MgSO4 and 
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concentrated in vacuo. The crude green oil was purified by column chromatography (silica 
gel, EtOAc:MeOH, 1:0  97:3) to yield the title compound as a pale yellow liquid 
(548 mg, 80%); Rf = 0.32 (EtOAc:MeOH, 97:3); λmax (EtOH)/nm 250.8, 314.8; IR (neat) 
νmax/cm
-1
 3273, 3044, 2982, 2892, 2814, 1654, 1580, 1521, 1486, 1304, 1248; 
1
H NMR 
(500 MHz, DMSO-d6) δ 2.68 (3H, d, J = 5.1 Hz, NHCH3), 5.86 (1H, q, J = 5.1 Hz, 
NHCH3), 6.84 (1H, ddd, J = 8.3, 2.9 and 1.4 Hz, H-4), 7.07 (1H, dd, J = 8.3, 4.6 Hz, H-5), 
7.75 (1H, dd, J = 4.6, 1.4 Hz, H-6), 7.92 (1H, d, J = 2.9 Hz, H-2); 
13
C NMR (126 MHz, 
DMSO-d6) δ 29.3 (NHCH3), 116.9 (C-4), 123.6 (C-5), 135.0 (C-2), 136.6 (C-6), 145.8 
(C-3); LRMS (ES
+
) m/z 109.1 [M+H]
+
; HRMS (APCI) calcd for C6H9N2 [M+H]
+
 
109.0760, found 109.0758; 
1
H and 
13
C NMR data were identical to literature data.
205
 
 
N-Isopropylpyridin-3-amine, (260) 
 
A microwave vial was charged with 3-bromopyridine (258) (610 µL, 1.0 g, 6.33 mmol), 
copper powder (20 mg, 0.32 mmol), water (6.35 mL) and isopropylamine (2.72 mL, 
1.87 g, 31.7 mmol). The resulting solution was stirred at 100 °C for 72 h. Upon 
completion, the reaction mixture was diluted with water (15 mL) and extracted with EtOAc 
(3 × 25 mL). The pooled organic extracts were washed with brine (30 mL), dried over 
MgSO4 and concentrated in vacuo. The crude brawn oil was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  15:85) to yield the title compound as a 
yellow oil (190 mg, 22%); Rf = 0.29 (petrol:EtOAc, 15:85); λmax (EtOH)/nm 253.6, 316.2; 
IR (neat) νmax/cm
-1
 3264, 3102, 3039, 2964, 2926, 2871, 1589, 1578, 1529, 1483, 1317, 
1245; 
1
H NMR (500 MHz, DMSO-d6) δ 1.12 (6H, d, J = 6.3 Hz, CH(CH3)2), 3.54 (1H, 
dhept, J = 8.0, 6.3 Hz, NHCH(CH3)2), 5.63 (1H, d, J = 8.0 Hz, NHCH(CH3)2), 6.86 (1H, 
ddd, J = 8.3, 2.9 and 1.4 Hz, H-4), 7.04 (1H, dd, J = 8.3, 4.6 Hz, H-5), 7.70 (1H, dd, 
J = 4.6, 1.4 Hz, H-6), 7.92 (1H, d, J = 2.9 Hz, H-2); 
13
C NMR (126 MHz, DMSO-d6) δ 
22.3 (CH(CH3)2), 42.7 (CH(CH3)2), 117.5 (C-4), 123.6 (C-5), 135.7 (C-2), 136.3 (C-6), 
144.2 (C-3); LRMS (ES
+
) m/z 137.2 [M+H]
+
; HRMS (ESI) calcd for C8H13N2 [M+H]
+
 
137.1073, found 137.1070; 
1
H and 
13
C NMR data were identical to literature data.
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N-Ethylpyridin-3-amine, (263) 
 
To 3-aminopyridine (261) (1.0 g, 10.6 mmol) in 2,2,2-trifluoroethanol (15 mL) was added 
acetaldehyde (596 µL, 468 mg, 10.6 mmol). The resulting solution was stirred at RT for 
1 h. Once cooled at 0 °C, sodium borohydride was carefully added. The resulting mixture 
was allowed to warm to RT and then stirred for 1 h. Upon completion, the solvent was 
removed in vacuo. The crude residue was dissolved in EtOAc (30 mL), neutralised by 
washing with saturated aq. NH4Cl (20 mL), washed with water and brine (20 mL, 
respectively), dried over MgSO4 and concentrated in vacuo. The crude product was 
purified by column chromatography (silica gel, petrol:EtOAc, 1:0  2:8) to yield the title 
compound as a pale yellow oil (875 mg, 67%); Rf = 0.29 (petrol:EtOAc, 2:8); 
λmax (EtOH)/nm 252.0, 315.0; IR (neat) νmax/cm
-1 
3263, 3099, 3035, 2969, 2873, 1585, 
1522, 1478, 1319, 1303, 1244; 
1
H NMR (500 MHz, DMSO-d6) δ 1.16 (3H, t, J = 7.1 Hz, 
NHCH2CH3), 3.03 (2H, qd, J = 7.1, 5.5 Hz, NHCH2CH3), 5.75 (1H, t, J = 5.5 Hz, 
ArNHCH2), 6.86 (1H, ddd, J = 8.3, 2.9 and 1.4 Hz, H-4), 7.05 (1H, dd, J = 8.3, 4.6 Hz, 
H-5), 7.73 (1H, dd, J = 4.6, 1.4 Hz, H-6), 7.93 (1H, d, J = 2.9 Hz, H-2); 
13
C NMR 
(126 MHz, DMSO-d6) δ 14.2 (NHCH2CH3), 36.9 (NHCH2CH3), 117.2 (C-4), 123.6 (C-5), 
135.2 (C-2), 136.6 (C-6), 144.9 (C-3); LRMS (ES
+
) m/z 123.1 [M+H]
+
; HRMS (APCI) 
calcd for C7H11N2 [M+H]
+
 123.0917, found 123.0916; 
1
H NMR, 
13
C NMR and IR data 
were identical to literature data.
275, 276
 
 
4-(2-Bromo-6-fluorobenzoyl)-N-methyl-N-(pyridin-3-yl)-1H-pyrrole-2-carboxamide, 
(264) 
 
Compound 264 was synthesised according to general procedure U, using the following 
reagents: 4-(2-bromo-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (244) (100 mg, 
0.32 mmol), N-methylpyridin-3-amine (259) (87 mg, 0.80 mmol), phosphorus trichloride 
(28 µL, 44 mg, 0.32 mmol) and acetonitrile (1.60 mL). The crude product was purified by 
column chromatography (silica gel, petrol:EtOAc, 1:0  15:85) to yield the title 
compound as a white solid (80 mg, 62%); Rf = 0.29 (petrol:EtOAc, 15:85); 
m.p. 181.5-183.5 °C; No λmax (EtOH)/nm; IR (neat) νmax/cm
-1
 3207, 1662, 1608, 1551, 
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1483, 1438, 1397, 1347, 1298; 
1
H NMR (500 MHz, DMSO-d6) δ 3.35 (3H, s, NCH3), 5.02 
(1H, brs, H-3), 7.26 (1H, brs, H-5), 7.33 (1H, dd, J = 8.5, 8.5 Hz, H-5’), 7.44 (1H, ddd, 
J = 8.5, 8.0 and 6.1 Hz, H-4’), 7.49 (1H, dd, J = 8.1, 4.7 Hz, H-5”), 7.51 (1H, d, 
J = 8.0 Hz, H-3’), 7.87 (1H, ddd, J = 8.1, 2.6 and 1.6 Hz, H-4”), 8.59 – 8.50 (2H, m, H-2” 
and H-6”), 12.51 (1H, s, NH-pyrrole); 13C NMR (126 MHz, DMSO-d6) δ 38.0 (NCH3), 
113.0 (C-3), 115.2 (d, J = 21.5 Hz, C-5’), 118.8 (d, J = 5.0 Hz, C-2’), 124.3 (C-5”), 124.4 
(C-2 or C-4), 127.0 (C-2 or C-4), 128.1 (C-5), 128.7 (d, J = 3.2 Hz, C-3’), 129.6 (d, 
J = 22.6 Hz, C-2’), 132.0 (d, J = 8.6 Hz, C-4’), 135.4 (C-4”), 140.3 (C-3”), 148.8 (C-2” or 
C-6”), 148.9 (C-2” or C-6”), 158.2 (d, J = 247.8 Hz, C-6’), 159.9 (CON), 184.4 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -113.8 (ArF); LRMS (ES
+
) m/z 402.3 [M(
79
Br)+H]
+
, 
404.2 [M(
81
Br)+H]
+
; HRMS (ESI) calcd for C18H14BrFN3O2 [M(
79
Br)+H]
+
 402.0248, 
found 402.0247. 
 
4-(2-Bromo-6-fluorobenzoyl)-N-ethyl-N-(pyridin-3-yl)-1H-pyrrole-2-carboxamide, 
(265) 
 
Compound 265 was synthesised according to general procedure U, using the following 
reagents: 4-(2-bromo-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (244) (100 mg, 
0.32 mmol), N-ethylpyridin-3-amine (263) (98 mg, 0.80 mmol), phosphorus trichloride 
(28 µL, 44 mg, 0.32 mmol) and acetonitrile (1.60 mL). The crude product was purified by 
column chromatography (silica gel, petrol:EtOAc, 1:0  1:3) to yield the title compound 
as a white solid (67 mg, 50%); Rf = 0.32 (petrol:EtOAc, 1:3); m.p. 184.5-186.5 °C; 
No λmax (EtOH)/nm; IR (neat) νmax/cm
-1
 3196, 1663, 1601, 1549, 1445, 1431, 1307; 
1
H NMR (500 MHz, DMSO-d6) δ 1.10 (3H, t, J = 7.1 Hz, CH3CH2N), 3.81 (2H, q, 
J = 7.1 Hz, CH3CH2N), 5.02 (1H, brs, H-3), 7.25 (1H, brs, H-5), 7.32 (1H, dd, J = 8.6, 
8.6 Hz, H-5’), 7.54 – 7.40 (3H, m, H-3’ and H-4’ and H-5”), 7.84 (1H, d, J = 8.0 Hz, 
H-4”), 8.52 (1H, d, J = 2.2 Hz, H-2”), 8.59 (1H, d, J = 3.7 Hz, H-6”), 12.50 (1H, s, 
NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 12.6 (CH3CH2N), 44.6 (CH3CH2N), 112.9 
(C-3), 115.1 (d, J = 21.7 Hz, C-5’), 118.8 (d, J = 5.2 Hz, C-2’), 124.4 (C-2 or C-4 or C-5”), 
124.4 (C-2 or C-4 or C-5”), 127.1 (C-2 or C-4), 128.0 (C-5), 128.7 (d, J = 3.2 Hz, C-3’), 
129.5 (d, J = 22.4 Hz, C-1’), 132.0 (d, J = 8.7 Hz, C-4’), 136.4 (C-4”), 138.5 (C-3”), 149.1 
(C-2” or C-6”), 149.7 (C-2” or C-6”), 158.2 (d, J = 247.9 Hz, C-6’), 159.4 (CON), 184.4 
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(ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -113.8 (ArF); LRMS (ES
+
) m/z 416.3 
[M(
79
Br)+H]
+
, 418.3 [M(
81
Br)+H]
+
; HRMS (ESI) calcd for C19H16BrFN3O2 [M(
79
Br)+H]
+
 
416.0404, found 416.0401. 
 
4-(2-Bromo-6-fluorobenzoyl)-N-isopropyl-N-(pyridin-3-yl)-1H-pyrrole-2-
carboxamide, (266) 
 
Compound 266 was synthesised according to general procedure U, using the following 
reagents: 4-(2-bromo-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (244) (100 mg, 
0.32 mmol), N-isopropylpyridin-3-amine (260) (109 mg, 0.80 mmol), phosphorus 
trichloride (28 µL, 44 mg, 0.32 mmol) and acetonitrile (1.60 mL). The crude product was 
purified by column chromatography (amine silica gel, petrol:EtOAc, 1:0  7:3) to yield 
the title compound as an off-white solid (76 mg, 55%); Rf = 0.31 (petrol:EtOAc, 35:65); 
m.p. 196.5-198.5 °C; λmax (EtOH)/nm 236.6; IR (neat) νmax/cm
-1
 3221, 3099, 2975, 1664, 
1595, 1577, 1548, 1479, 1434, 1328, 1229, 1117; 
1
H NMR (500 MHz, DMSO-d6) δ 1.06 
(6H, d, J = 6.9 Hz, NCH(CH3)2), 4.58 (1H, s, H-3), 4.99 (1H, hept, J = 6.9 Hz, 
NCH(CH3)2), 7.24 (1H, s, H-5), 7.33 (1H, dd, J = 8.6, 8.6 Hz, H-5’), 7.55 – 7.40 (3H, m, 
H-3’ and H-4’ and H-5”), 7.80 (1H, ddd, J = 7.1, 2.2 and 2.2 Hz, H-4”), 8.47 (1H, d, 
J = 2.6 Hz, H-2”), 8.61 (1H, dd, J = 4.9, 1.6 Hz, H-6”), 12.46 (1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 20.5 (NCH(CH3)2), 46.5 (NCH(CH3)2), 112.7 (C-3), 
115.2 (d, J = 21.6 Hz, C-5’), 118.8 (d, J = 5.1 Hz, C-2’), 124.1 (C-5”), 124.4 (C-2 or C-4), 
127.3 (C-2 or C-4), 127.7 (C-5), 128.7 (d, J = 3.2 Hz, C-3’), 129.5 (d, J = 22.6 Hz, C-1’), 
132.0 (d, J = 8.7 Hz, C-4’), 134.7 (C-3”), 138.5 (C-4”), 149.6 (C-6”), 151.3 (C-2”), 157.2 
(d, J = 248.4 Hz, C-6’), 159.1 (CON), 184.4 (ArCO); 19F NMR (471 MHz, DMSO-d6) 
δ -113.9 (ArF); LRMS (ES+) m/z 430.0 [M(79Br)+H]+, 432.0 [M(81Br)+H]+; HRMS (NSI) 
calcd for C20H16BrFN3O2 [M(
79
Br)-H]
-
 428.0415, found 428.0410. 
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4-(2-Chloro-6-fluorobenzoyl)-N-methyl-N-(pyridin-3-yl)-1H-pyrrole-2-carboxamide, 
(267) 
 
Compound 267 was synthesised according to general procedure U, using the following 
reagents: 4-(2-chloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (249) (100 mg, 
0.37 mmol), N-methylpyridin-3-amine (259) (101 mg, 0.94 mmol), phosphorus trichloride 
(34 µL, 51 mg, 0.37 mmol) and acetonitrile (1.85 mL). The crude product was purified by 
column chromatography (silica gel, petrol:EtOAc, 1:0  15:85) to yield the title 
compound as an off-white solid (81 mg, 60%); Rf = 0.28 (petrol:EtOAc, 15:85); 
m.p. 155.0-157.0 °C; λmax (EtOH)/nm 234.4; IR (neat) νmax/cm
-1
 3200, 1658, 1607, 1549, 
1482, 1443, 1298; 
1
H NMR (500 MHz, DMSO-d6) δ 3.35 (3H, s, NCH3), 5.02 (1H, brs, 
H-3), 7.33 – 7.25 (2H, m, H-5 and H-5’), 7.37 (1H, d, J = 8.1 Hz, H-3’), 7.48 (1H, dd, 
J = 8.1, 4.8 Hz, H-5”), 7.52 (1H, ddd, J = 8.4, 8.1 and 6.2 Hz, H-4’), 7.87 (1H, ddd, 
J = 8.1, 2.7 and 1.6 Hz, H-4”), 8.59 – 8.53 (2H, m, H-2” and H-6”), 12.52 (1H, s, 
NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 38.0 (NCH3), 113.0 (C-3), 114.8 (d, 
J = 21.7 Hz, C-5’), 124.3 (C-5”), 124.7 (C-2 or C-4), 125.7 (d, J = 3.1 Hz, C-3’), 127.0 
(C-2 or C-4), 127.6 (d, J = 23.1 Hz, C-1’), 128.0 (C-5), 130.2 (d, J = 6.0 Hz, C-2’), 131.7 
(d, J = 9.2 Hz, C-4’), 135.4 (C-4”), 140.3 (C-3”), 148.8 (C-2” or C-6”), 148.9 (C-2” or 
C-6”), 158.3 (d, J = 246.9 Hz, C-6’), 159.9 (CON), 183.5 (ArCO); 19F NMR (471 MHz, 
DMSO-d6) δ -114.4 (ArF); LRMS (ES
+
) m/z 358.3 [M(
35
Cl)+H]
+
, 360.4 [M(
37
Cl)+H]
+
; 
HRMS (ESI) calcd for C18H14ClFN3O2 [M(
35
Cl)+H]
+
 358.0753, found 358.0751. 
 
4-(2-Chloro-6-fluorobenzoyl)-N-ethyl-N-(pyridin-3-yl)-1H-pyrrole-2-carboxamide, 
(268) 
 
Compound 268 was synthesised according to general procedure U, using the following 
reagents: 4-(2-chloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (249) (100 mg, 
0.37 mmol), N-ethylpyridin-3-amine (263) (114 mg, 0.94 mmol), phosphorus trichloride 
(34 µL, 51 mg, 0.37 mmol) and acetonitrile (1.85 mL). The crude product was purified by 
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column chromatography (silica gel, petrol:EtOAc, 1:0  1:3) to yield the title compound 
as a white solid (56 mg, 40%); Rf = 0.30 (petrol:EtOAc, 1:3); m.p. 186.0-188.0 °C; 
λmax (EtOH)/nm 234.6; IR (neat) νmax/cm
-1
 3197, 1664, 1603, 1581, 1575, 1549, 1448, 
1432, 1308; 
1
H NMR (500 MHz, DMSO-d6) δ 1.10 (3H, t, J = 7.1 Hz, CH3CH2N), 3.81 
(2H, q, J = 7.1 Hz, CH3CH2N), 4.88 (1H, brs, H-3), 7.34 – 7.26 (2H, m, H-5 and H-5’), 
7.37 (1H, d, J = 8.1 Hz, H-3’), 7.60 – 7.44 (2H, m, H-4 and H-5”), 7.84 (1H, d, J = 7.9 Hz, 
H-4”), 8.51 (1H, d, J = 1.9 Hz, H-2”), 8.59 (1H, d, J = 3.9 Hz, H-6”), 12.51 (1H, s, 
NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 12.6 (CH3CH2N), 44.6 (CH3CH2N), 112.9 
(C-3), 114.8 (d, J = 21.6 Hz, C-5’), 124.4 (C-5”), 124.7 (C-2 or C-4), 125.7 (d, J = 3.3 Hz, 
C-3’), 127.1 (C-2 or C-4), 127.6 (d, J = 22.8 Hz, C-1’), 128.0 (C-5), 130.2 (d, J = 5.9 Hz, 
C-2’), 131.7 (d, J = 9.1 Hz, C-4’), 136.4 (C-4”), 138.5 (C-3”), 149.1 (C-2” or C-6”), 149.7 
(C-2” or C-6”), 158.3 (d, J = 246.8 Hz, C-6’), 159.4 (CON), 183.5 (ArCO); 19F NMR 
(471 MHz, DMSO-d6) δ -114.4 (ArF); LRMS (ES
+
) m/z 372.3 [M(
35
Cl)+H]
+
, 374.4 
[M(
37
Cl)+H]
+
; HRMS (ESI) calcd for C19H16ClFN3O2 [M(
35
Cl)+H]
+
 372.0910, found 
372.0909. 
 
4-(2-Chloro-6-fluorobenzoyl)-N-isopropyl-N-(pyridin-3-yl)-1H-pyrrole-2-
carboxamide, (269) 
 
Compound 269 was synthesised according to general procedure U, using the following 
reagents: 4-(2-chloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (249) (100 mg, 
0.37 mmol), N-isopropylpyridin-3-amine (260) (128 mg, 0.94 mmol), phosphorus 
trichloride (34 µL, 51 mg, 0.37 mmol) and acetonitrile (1.85 mL). The crude product was 
purified by column chromatography (silica gel, petrol:EtOAc, 1:0  35:65) to yield the 
title compound as an off-white solid (72 mg, 50%); Rf = 0.31 (petrol:EtOAc, 35:65); 
m.p. 194.5-196.5 °C; λmax (EtOH)/nm 236.6 nm; IR (neat) νmax/cm
-1
 3219, 1663, 1597, 
1575, 1548, 1435, 1329; 
1
H NMR (500 MHz, DMSO-d6) δ 1.06 (6H, d, J = 6.9 Hz, 
(CH3)2CHN), 4.59 (1H, brs, H-3), 4.99 (1H, hept, J = 6.9 Hz, (CH3)2CHN), 7.27 (1H, brs, 
H-5), 7.30 (1H, dd, J = 9.1, 9.1 Hz, H-5’), 7.37 (1H, d, J = 8.1 Hz, H-3’), 7.57 – 7.45 (2H, 
m, H-4’ and H-5”), 7.80 (1H, ddd, J = 7.6, 2.1 and 2.1 Hz, H-4”), 8.47 (1H, d, J = 2.1 Hz, 
H-2”), 8.61 (1H, dd, J = 4.9, 2.1 Hz, H-6”), 12.47 (1H, s, NH-pyrrole); 13C NMR 
(126 MHz, DMSO-d6) δ 20.5 ((CH3)2CHN), 46.5 ((CH3)2CHN), 112.7 (C-3), 114.8 (d, 
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J = 21.6 Hz, C-3’), 124.1 (C-5”), 124.7 (C-2 or C-4), 125.7 (d, J = 3.2 Hz, C-3’), 127.3 
(C-2 or C-4), 127.5 (d, J = 22.1 Hz, C-1’), 127.7 (C-5), 130.2 (d, J = 6.1 Hz, C-2’), 131.7 
(d, J = 8.9 Hz, C-4’), 134.7 (C-3”), 138.5 (C-4”), 149.6 (C-6”), 151.3 (C-2”), 158.3 (d, 
J = 247.0 Hz, C-6’), 159.2 (CON), 183.5 (ArCO); 19F NMR (471 MHz, DMSO-d6) 
δ -114.5 (ArF); LRMS (ES+) m/z 386.4 [M(35Cl)+H]+, 388.4 [M(37Cl)+H]+; HRMS (ESI) 
calcd for C20H18ClFN3O2 [M(
35
Cl)+H]
+
 386.1066, found 386.1063. 
 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-methyl-N-(pyridin-3-yl)-1H-pyrrole-2-
carboxamide, (270) 
 
Compound 270 was synthesised according to general procedure U, using the following 
reagents: 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250) (100 mg, 
0.33 mmol), N-methylpyridin-3-amine (259) (89 mg, 0.83 mmol), phosphorus trichloride 
(29 µL, 45 mg, 0.33 mmol) and acetonitrile (1.65 mL). The crude product was purified by 
column chromatography (silica gel, petrol:EtOAc, 1:0  15:85) to yield the title 
compound as a pale yellow solid (55 mg, 42%); Rf = 0.28 (petrol:EtOAc, 15:85); 
m.p. 198.5-200.5 °C; λmax (EtOH)/nm 280.4; IR (neat) νmax/cm
-1
 3214, 1667, 1614, 1584, 
1557, 1448, 1385, 1298; 
1
H NMR (500 MHz, DMSO-d6) δ 3.35 (3H, s, NCH3), 5.05 (1H, 
brs, H-3), 7.43 (1H, d, J = 8.9 Hz, H-5’), 7.45 (1H, brs, H-5), 7.50 (1H, dd, J = 8.1, 4.7 Hz, 
H-5”), 7.72 (1H, dd, J = 8.9, 8.3 Hz, H-4’), 7.88 (1H, d, J = 8.1 Hz, H-4”), 8.65 – 8.45 
(2H, m, H-2” and H-6”), 12.60 (1H, s, NH-pyrrole); 13C NMR (126 MHz, DMSO-d6) δ 
38.0 (NCH3), 112.8 (C-3), 119.2 (d, J = 17.9 Hz, C-3’), 124.2 (C-2 or C-4), 124.3 (C-5”), 
126.7 (d, J = 3.8 Hz, C-5’), 127.2 (C-2 or C-4), 128.8 (d, J = 23.0 Hz, C-1), 128.9 (C-5), 
129.0 (d, J = 5.0 Hz, C-6’), 131.8 (C-4’), 135.4 (C-4”), 140.3 (C-3”), 148.8 (C-2” or C-6”), 
148.9 (C-2” or C-6”), 153.6 (d, J = 248.3 Hz, C-2’), 159.9 (ArCON), 182.2 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -116.7 (ArF); LRMS (ES
-
) m/z 390.2 [M(
35
Cl
35
Cl)-H]
-
, 
392.2 [M(
35
Cl
37
Cl)-H]
-
; HRMS (NSI) calcd for C18H11Cl2FN3O2 [M(
35
Cl
35
Cl)-H]
-
 
390.0218, found 390.0214. 
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4-(3,6-Dichloro-2-fluorobenzoyl)-N-ethyl-N-(pyridin-3-yl)-1H-pyrrole-2-carboxamide, 
(271) 
 
Compound 271 was synthesised according to general procedure U, using the following 
reagents: 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250) (100 mg, 
0.33 mmol), N-ethylpyridin-3-amine (263) (101 mg, 0.83 mmol), phosphorus trichloride 
(29 µL, 45 mg, 0.33 mmol) and acetonitrile (1.65 mL). The crude product was purified by 
column chromatography (silica gel, petrol:EtOAc, 1:0  35:65) to yield the title 
compound as a white solid (80 mg, 60%); Rf = 0.30 (petrol:EtOAc, 35:65); 
m.p. 169.5-171.5 °C; λmax (EtOH)/nm 280.0; IR (neat) νmax/cm
-1
 3244, 2986, 2938, 1657, 
1632, 1543, 1447, 1431, 1418, 1298, 1228; 
1
H NMR (500 MHz, DMSO-d6) δ 1.11 (3H, t, 
J = 7.3 Hz, NCH2CH3), 3.81 (2H, q, J = 7.1 Hz, NCH2CH3), 4.90 (1H, brs, H-3), 
7.47 - 7.35 (2H, m, H-5 and H-5’), 7.51 (1H, dd, J = 8.2, 4.5 Hz, H-5”), 7.72 (1H, dd, 
J = 8.4, 8.4 Hz, H-4’), 7.86 (1H, d, J = 8.2 Hz, H-4”), 8.53 (1H, brs, H-2”), 8.60 (1H, d, 
J = 4.5 Hz, H-6”), 12.59 (1H, s, NH-pyrrole); 13C NMR (126 MHz, DMSO-d6) δ 12.6 
(NCH2CH3), 44.6 (NCH2CH3), 112.7 (C-3), 119.2 (d, J = 18.1 Hz, C-3’), 124.2 (C-2 or 
C-4), 124.4 (C-5”), 126.7 (d, J = 3.7 Hz, C-5’), 127.3 (C-2 or C-4), 128.8 (d, J = 22.9 Hz, 
C-1’), 128.8 (C-5), 129.0 (d, J = 5.1 Hz, C-6’), 131.7 (C-4’), 136.4 (C-4”), 138.5 (C-3”), 
149.0 (C-6”), 149.7 (C-2”), 153.6 (d, J = 248.3 Hz, C-2’), 159.3 (ArCON), 182.2 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -116.8 (ArF); LRMS (ES
-
) m/z 404.2 [M(
35
Cl
35
Cl)-H]
-
, 
406.3 [M(
35
Cl
37
Cl)-H]
-
; HRMS (NSI) calcd for C19H13Cl2FN3O2 [M(
35
Cl
35
Cl)-H]
-
 
404.0374, found 404.0371. 
 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-isopropyl-N-(pyridin-3-yl)-1H-pyrrole-2-
carboxamide, (272) 
 
Compound 272 was synthesised according to general procedure U, using the following 
reagents: 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250) (100 mg, 
300 
0.33 mmol), N-isopropylpyridin-3-amine (260) (113 mg, 0.83 mmol), phosphorus 
trichloride (29 µL, 45 mg, 0.33 mmol) and acetonitrile (1.65 mL). The crude product was 
purified by column chromatography (silica gel, petrol:EtOAc, 1:0  45:55) to yield the 
title compound as an off-white solid (86 mg, 62%); Rf = 0.29 (petrol:EtOAc, 45:55); 
m.p. 181.5-183.5 °C; λmax (EtOH)/nm 280.0; IR (neat) νmax/cm
-1
 3244, 1656, 1609, 1580, 
1550, 1479, 1429, 1384, 1315, 1235; 
1
H NMR (500 MHz, DMSO-d6) δ 1.07 (6H, d, 
J = 6.8 Hz, NCH(CH3)2), 4.60 (1H, brs, H-3), 4.99 (1H, hept, J = 6.8 Hz, NCH(CH3)2), 
7.46 – 7.38 (2H, m, H-5 and H-5’), 7.51 (1H, dd, J = 8.1, 4.8 Hz, H-5”), 7.73 (1H, dd, 
J = 8.4, 8.4 Hz, H-4’), 7.82 (1H, dd, J = 8.1, 1.9 Hz, H-4”), 8.49 (1H, d, J = 1.9 Hz, H-2”), 
8.63 (1H, d, J = 4.8 Hz, H-6”), 12.56 (1H, s, NH-pyrrole); 13C NMR (126 MHz, 
DMSO-d6) δ 20.4 (NCH(CH3)2), 46.5 (NCH(CH3)2), 112.5 (C-3), 119.2 (d, J = 18.2 Hz, 
C-3’), 124.1 (C-5”), 124.2 (C-2 or C-4), 126.7 (d, J = 3.7 Hz, C-5’), 127.6 (C-2 or C-4), 
128.5 (C-5), 128.7 (d, J = 22.9 Hz, C-1’), 129.0 (d, J = 5.0 Hz, C-6’), 131.7 (C-4’), 134.8 
(C-3”), 138.6 (C-4”), 149.6 (C-6”), 151.3 (C-2”), 153.5 (d, J = 248.5 Hz, C-2’), 159.1 
(ArCON), 182.2 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -116.8 (ArF); LRMS (ES
-
) 
m/z 418.3 [M(
35
Cl
35
Cl)-H]
-
, 420.3 [M(
35
Cl
37
Cl)-H]
-
; HRMS (NSI) calcd for 
C20H15Cl2FN3O2 [M(
35
Cl
35
Cl)-H]
-
 418.0531, found 418.0526. 
 
2-Ethyl-3-nitropyridine, (274) 
 
Compound 274 was synthesised according to general procedure W, using the following 
reagents: 2-chloro-3-nitropyridine (273) (650 mg, 4.10 mmol), ethylboronic acid (333 mg, 
4.51 mmol), potassium carbonate (1.70 g, 12.3 mmol), tetrakis(triphenylphosphine) 
palladium(0) (474 mg, 0.41 mmol) and dioxane (20 mL). The crude product was purified 
by column chromatography (silica gel, petrol:EtOAc, 1:0  9:1) to yield the title 
compound as a clear yellow oil (350 mg, 56%); Rf = 0.30 (petrol:EtOAc, 9:1); 
λmax (EtOH)/nm 273.4; IR (neat) νmax/cm
-1
 3079, 2940, 2877, 1597, 1565, 1522, 1465, 
1431, 1346; 
1
H NMR (500 MHz, DMSO-d6) δ 1.27 (3H, t, J = 7.5 Hz, ArCH2CH3), 3.00 
(2H, q, J = 7.5 Hz, ArCH2CH3), 7.54 (1H, dd, J = 8.3, 4.7 Hz, H-5), 8.37 (1H, dd, J = 8.3, 
1.5 Hz, H-4), 8.82 (1H, dd, J = 4.7, 1.5 Hz, H-6); 
13
C NMR (126 MHz, DMSO-d6) δ 12.7 
(ArCH2CH3), 28.0 (ArCH2CH3), 122.4 (C-5), 132.6 (C-4), 145.7 (C-3), 152.9 (C-6), 156.1 
(C-2); LRMS (ES
+
) m/z 153.0 [M+H]
+
; HRMS (APCI) calcd for C7H9N2O2 [M+H]
+
 
153.0659, found 153.0658. 
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(E)-3-Nitro-2-(prop-1-en-1-yl)pyridine, (275) 
 
Compound 275 was synthesised according to general procedure W, using the following 
reagents: 2-chloro-3-nitropyridine (273) (650 mg, 4.10 mmol), allylboronic acid pinacol 
ester (851 µL, 758 mg, 4.51 mmol), potassium carbonate (1.70 g, 12.3 mmol), 
tetrakis(triphenylphosphine)palladium(0) (474 mg, 0.41 mmol) and dioxane (20 mL). The 
crude product was purified by column chromatography (silica gel, petrol:EtOAc, 
1:0  9:1) to yield the title compound as an orange liquid (355 mg, 53%); Rf = 0.29 
(petrol:EtOAc, 9:1); λmax (EtOH)/nm 233.2, 272.0; IR (neat) νmax/cm
-1
 3063, 2969, 2938, 
2914, 2851, 1645, 1590, 1559, 1518, 1446, 1424, 1342; 
1
H NMR (500 MHz, DMSO-d6) 
δ 1.95 (3H, dd, J = 6.9, 1.7 Hz, ArCH=CHCH3), 6.85 (1H, dq, J = 15.2, 1.7 Hz, 
ArCH=CHCH3), 7.13 (1H, dq, J = 15.2, 6.9 Hz, ArCH=CHCH3), 7.50 (1H, dd, J = 8.3, 
4.6 Hz, H-5), 8.33 (1H, dd, J = 8.3, 1.6 Hz, H-4), 8.79 (1H, dd, J = 4.6, 1.6 Hz, H-6); 
13
C NMR (126 MHz, DMSO-d6) δ 18.4 (ArCH=CHCH3), 122.6 (C-5), 124.4 
(ArCH=CHCH3), 132.8 (C-4), 137.0 (ArCH=CHCH3), 143.8 (C-3), 147.4 (C-2), 152.9 
(C-6); LRMS (ES
+
) m/z 165.2 [M+H]
+
; HRMS (APCI) calcd for C8H9N2O2 [M+H]
+
 
165.0659, found 165.0657. 
 
2-Ethoxy-3-nitropyridine, (276) 
 
To a suspension of 2-chloro-3-nitropyridine (273) (1.0 g, 6.31 mmol) in ethanol (15 mL) 
was added sodium ethoxide (1.29 g 18.9 mmol). The resulting solution was stirred at RT 
overnight. Upon completion, the solvent was removed in vacuo. The crude residue was 
dissolved in EtOAc (40 mL), washed with water and brine (20 mL, respectively), dried 
over MgSO4 and concentrated in vacuo. The crude brawn oil was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  9:1) to yield the title compound as an 
orange oil (661 mg, 62%); Rf = 0.31 (petrol:EtOAc, 9:1); λmax (EtOH)/nm 242.6, 309.0; 
IR (neat) νmax/cm
-1
 2985, 1601, 1569, 1522, 1437, 1345, 1304, 1246; 
1
H NMR (500 MHz, 
DMSO-d6) δ 1.35 (3H, t, J = 7.1 Hz, ArOCH2CH3), 4.50 (2H, q, J = 7.1 Hz, ArOCH2CH3), 
7.22 (1H, dd, J = 7.9, 4.9 Hz, H-5), 8.41 (1H, dd, J = 7.9, 1.8 Hz, H-4), 8.48 (1H, dd, 
J = 4.9, 1.8 Hz, H-6); 
13
C NMR (126 MHz, DMSO-d6) δ 14.2 (ArOCH2CH3), 63.1 
302 
(ArOCH2CH3), 117.1 (C-5), 135.2 (C-4), 151.8 (C-6), 155.1 (C-2); LRMS (ES
+
) m/z 169.0 
[M+H]
+
; HRMS (APCI) calcd for C7H9N2O3 [M+H]
+
 169.0608, found 169.0603. 
 
3-Nitro-2-(pyrrolidin-1-yl)pyridine, (277) 
 
To a suspension of 2-chloro-3-nitropyridine (273) (1.0 g, 6.31 mmol) in acetonitrile 
(15 mL) was added potassium carbonate (959 mg, 6.94 mmol) and pyrrolidine (579 µL, 
493 mg, 6.94 mmol). The resulting solution was stirred at RT overnight. Upon completion, 
the potassium carbonate was removed by filtration and the solvent removed in vacuo. The 
crude residue was dissolved in EtOAc (40 mL), washed with water and brine (20 mL, 
respectively), dried over MgSO4 and concentrated in vacuo. The crude orange oil was 
purified by column chromatography (silica gel, petrol:EtOAc, 1:0  9:1) to yield the title 
compound as a yellow oil (1.11 g, 83%); Rf = 0.33 (petrol:EtOAc, 9:1); λmax (EtOH)/nm 
235.2, 286.2; IR (neat) νmax/cm
-1
 2970, 2953, 2874, 1592, 1552, 1501, 1476, 1455, 1435, 
1347, 1335, 1322, 1247; 
1
H NMR (500 MHz, DMSO-d6) δ 1.90 (4H, t, J = 6.4 Hz, 
NCH2CH2), 3.29 (4H, t, J = 6.4 Hz, NCH2CH2), 6.78 (1H, dd, J = 8.2, 4.5 Hz, H-5), 8.18 
(1H, d, J = 8.2 Hz, H-4), 8.38 (1H, d, J = 4.5 Hz, H-6); 
13
C NMR (126 MHz, DMSO-d6) 
δ 24.9 (NCH2CH2), 49.1 (NCH2CH2), 111.4 (C-5), 131.2 (C-3), 134.9 (C-4), 149.7 (C-2), 
152.2 (C-6); LRMS (ES
+
) m/z 194.1 [M+H]
+
; HRMS (NSI) calcd for C9H12N3O2 [M+H]
+
 
194.0924, found 194.0925. 
 
2-Ethylpyridin-3-amine, (278) 
 
Compound 278 was synthesised according to general procedure V, using the following 
reagents: 2-ethyl-3-nitropyridine (274) (550 mg, 3.61 mmol) and methanol (73 mL). The 
crude product was purified by column chromatography (silica gel, petrol:EtOAc, 
1:0  15:85) to yield the title compound as a white solid (410 mg, 93%); Rf = 0.32 
(petrol:EtOAc, 15:85); m.p. 114.5-116.5 °C; λmax (EtOH)/nm 241.0, 300.0; IR (neat) 
νmax/cm
-1
 3657, 3393, 3150, 2981, 2889, 1647, 1580, 1448, 1380, 1238; 
1
H NMR 
(500 MHz, DMSO-d6) δ 1.16 (3H, t, J = 7.5 Hz, ArCH2CH3), 2.59 (2H, q, J = 7.5 Hz, 
ArCH2CH3), 4.99 (2H, brs, ArNH2), 6.90 – 6.86 (2H, m, H-4 and H-6), 7.70 (1H, dd, 
J = 3.7, 2.4 Hz, H-5); 
13
C NMR (126 MHz, DMSO-d6) δ 11.4 (ArCH2CH3), 25.6 
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(ArCH2CH3), 119.8 (C-4 or C-6), 121.5 (C-4 or C-6), 136.4 (C-5), 141.7 (C-3), 146.7 
(C-2); LRMS (ES
+
) m/z 123.0 [M+H]
+
; HRMS (NSI) calcd for C7H11N2 [M+H]
+
 123.0917, 
found 123.0917. 
 
2-Propylpyridin-3-amine, (279) 
 
Compound 279 was synthesised according to general procedure V, using the following 
reagents: (E)-3-nitro-2-(prop-1-en-1-yl)pyridine (275) (300 mg, 1.83 mmol) and methanol 
(37 mL). The crude product was purified by column chromatography (silica gel, 
petrol:EtOAc, 1:0  3:7) to yield the title compound as a yellow oil (225 mg, 90%); 
Rf = 0.32 (petrol:EtOAc, 3:7); λmax (EtOH)/nm 240.4, 300.4; IR (neat) νmax/cm
-1
 3335, 
3202, 2959, 2932, 2871, 1621, 1583, 1451, 1305, 1236; 
1
H NMR (500 MHz, DMSO-d6) δ 
0.92 (3H, t, J = 7.4 Hz, ArCH2CH2CH3), 1.64 (2H, tq, J = 7.6, 7.4 Hz, ArCH2CH2CH3), 
2.55 (2H, t, J = 7.6 Hz, ArCH2CH2CH3), 4.98 (2H, brs, ArNH2), 6.90 – 6.84 (2H, m, H-4 
and H-5), 7.69 (1H, dd, J = 4.0, 2.1 Hz, H-6); 
13
C NMR (126 MHz, DMSO-d6) δ 14.0 
(ArCH2CH2CH3), 20.0 (ArCH2CH2CH3), 34.6 (ArCH2CH2CH3), 120.0 (C-4 or C-5), 121.5 
(C-4 or C-5), 136.4 (C-6), 141.9 (C-2 or C-3), 145.8 (C-2 or C-3); LRMS (ES
+
) m/z 137.2 
[M+H]
+
; HRMS (NSI) calcd for C8H13N2 [M+H]
+
 137.1073, found 137.1067. 
 
2-Ethoxypyridin-3-amine, (280) 
 
Compound 280 was synthesised according to general procedure V, using the following 
reagents: 2-ethoxy-3-nitropyridine (273) (600 mg, 3.57 mmol) and methanol (72 mL). The 
crude product was purified by column chromatography (silica gel, petrol:EtOAc, 
1:0  85:15) to yield the title compound as a yellow oil (378 mg, 76%); Rf = 0.30 
(petrol:EtOAc, 15:85); λmax (EtOH)/nm 240.6, 294.4; IR (neat) νmax/cm
-1
 3464, 3332, 3217, 
2978, 2934, 2896, 1612, 1596, 1452, 1386, 1347, 1233; 
1
H NMR (500 MHz, DMSO-d6) 
δ 1.31 (3H, t, J = 7.0 Hz, ArOCH2CH3), 4.29 (2H, q, J = 7.0 Hz, ArOCH2CH3), 4.83 (2H, 
brs, ArNH2), 6.67 (1H, dd, J = 7.5, 4.9 Hz, H-5), 6.85 (1H, dd, J = 7.5, 1.7 Hz, H-4), 7.33 
(1H, dd, J = 4.9, 1.7 Hz, H-6); 
13
C NMR (126 MHz, DMSO-d6) δ 14.7 (ArOCH2CH3), 
60.5 (ArOCH2CH3), 117.2 (C-5), 118.6 (C-4), 132.4 (C-3), 132.4 (C-6), 151.5 (C-2); 
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LRMS (ES
+
) m/z 139.2 [M+H]
+
; HRMS (APCI) calcd for C7H11N2O [M+H]
+
 139.0866, 
found 139.0864. 
 
2-(Pyrrolidin-1-yl)pyridin-3-amine, (281) 
 
Compound 281 was synthesised according to general procedure V, using the following 
reagents: 3-nitro-2-(pyrrolidin-1-yl)pyridine (277) (1.0 g, 5.18 mmol) and methanol 
(103 mL). The crude product was purified by column chromatography (silica gel, 
petrol:EtOAc, 1:0  3:7) to yield the title compound as a purple oil (776 mg, 92%); 
Rf = 0.31 (petrol:EtOAc, 3:7); λmax (EtOH)/nm 254.6, 312.8; IR (neat) νmax/cm
-1
 3320, 
3213, 2945, 2865, 1587, 1444, 1346, 1229; 
1
H NMR (500 MHz, DMSO-d6) δ 1.85 – 1.77 
(4H, m, NCH2CH2), 3.32 – 3.24 (4H, m, NCH2CH2), 4.60 (2H, brs, ArNH2), 6.61 (1H, dd, 
J = 7.5, 4.7 Hz, H-5), 6.85 (1H, dd, J = 7.5, 1.6 Hz, H-4), 7.46 (1H, dd, J = 4.7, 1.6 Hz, 
H-6); 
13
C NMR (126 MHz, DMSO-d6) δ 24.4 (NCH2CH2), 48.3 (NCH2CH2), 116.4 (C-5), 
120.3 (C-4), 134.8 (C-6), 134.9 (C-3), 149.6 (C-2); LRMS (ES
+
) m/z 164.2 [M+H]
+
; 
HRMS (NSI) calcd for C9H14N3 [M+H]
+
 164.1182, found 164.1182. 
 
4-(2-Chloro-6-fluorobenzoyl)-N-(2-ethylpyridin-3-yl)-1H-pyrrole-2-carboxamide, 
(282) 
 
Compound 282 was synthesised according to general procedure U, using the following 
reagents: 4-(2-chloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (249) (100 mg, 
0.37 mmol), 2-ethylpyridin-3-amine (278) (114 mg, 0.94 mmol), phosphorus trichloride 
(34 µL, 51 mg, 0.37 mmol) and acetonitrile (1.85 mL). The crude product was purified by 
column chromatography (silica gel, petrol:EtOAc, 1:0  3:7) to yield the title compound 
as a white solid (45 mg, 35%); Rf = 0.29 (petrol:EtOAc, 3:7); m.p. 125.5-127.5 °C; 
λmax (EtOH)/nm 239.2, 286.0; IR (neat) νmax/cm
-1
 3234, 3126, 2970, 2936, 1634, 1558, 
1516, 1445, 1287, 1245; 
1
H NMR (500 MHz, DMSO-d6) δ 1.18 (3H, t, J = 7.5 Hz, 
ArCH2CH3), 2.77 (2H, q, J = 7.5 Hz, ArCH2CH3), 7.27 (1H, dd, J = 7.9, 4.9 Hz, H-5”), 
7.51 – 7.34 (4H, m, H-3, H-5, H-3’ and H-5’), 7.57 (1H, ddd, J = 8.3, 8.3 and 6.3 Hz, 
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H-4’), 7.68 (1H, d, J = 7.9 Hz, H-4”), 8.40 (1H, d, J = 4.9 Hz, H-6”), 9.90 (1H, s, 
CONHAr), 12.65 (1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 12.3 
(ArCH2CH3), 26.2 (ArCH2CH3), 111.2 (C-3), 115.0 (d, J = 21.6 Hz, C-5’), 121.3 (C-5”), 
125.3 (C-2 or C-4), 125.8 (d, J = 3.1 Hz, C-3’), 128.1 (d, J = 23.1 Hz, C-1’), 128.3 (C-2 or 
C-4), 129.2 (C-5), 130.5 (d, J = 6.0 Hz, C-2’), 131.2 (C-3”), 131.8 (d, J = 9.3 Hz, C-4’), 
134.8 (C-4”), 146.6 (C-6”), 158.4 (CONHAr or C-2”), 158.6 (d, J = 246.7 Hz, C-6’), 159.0 
(CONHAr or C-2”), 183.9 (ArCO); 19F NMR (471 MHz, DMSO-d6) δ -114.3 (ArF); 
LRMS (ES
-
) m/z 370.3 [M(
35
Cl)-H]
-
, 372.2 [M(
37
Cl)-H]
-
; HRMS (NSI) calcd for 
C19H14ClFN3O2 [M(
35
Cl)-H]
-
 370.0764, found 370.0762. 
 
4-(2-Chloro-6-fluorobenzoyl)-N-(2-propylpyridin-3-yl)-1H-pyrrole-2-carboxamide, 
(283) 
 
Compound 283 was synthesised according to general procedure U, using the following 
reagents: 4-(2-chloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (249) (100 mg, 
0.37 mmol), 2-propylpyridin-3-amine (279) (127 mg, 0.94 mmol), phosphorus trichloride 
(34 µL, 51 mg, 0.37 mmol) and acetonitrile (1.85 mL). The crude product was purified by 
column chromatography (silica gel, petrol:EtOAc, 1:0  4:6) to yield the title compound 
as a pale orange solid (35 mg, 24%); Rf = 0.29 (petrol:EtOAc, 4:6); m.p. 128.5-130.5 °C; 
λmax (EtOH)/nm 239.6, 286.6; IR (neat) νmax/cm
-1
 3312, 3196, 2969, 1644, 1628, 1609, 
1574, 1558, 1510, 1442, 1397, 1289, 1246; 
1
H NMR (500 MHz, DMSO-d6) δ 0.86 (3H, t, 
J = 7.4 Hz, ArCH2CH2CH3), 1.67 (2H, tq, J = 7.6, 7.4 Hz, ArCH2CH2CH3), 2.73 (2H, t, 
J = 7.6 Hz, ArCH2CH2CH3), 7.27 (1H, dd, J = 8.0, 4.7 Hz, H-5”), 7.43 – 7.36 (2H, m, H-5 
and H-5’), 7.50 – 7.43 (2H, m, H-3 and H-3’), 7.58 (1H, ddd, J = 8.3, 8.3 and 6.1 Hz, 
H-4’), 7.68 (1H, dd, J = 8.0, 1.8 Hz, H-4”), 8.40 (1H, dd, J = 4.7, 1.8 Hz, H-6”), 9.90 (1H, 
s, CONHAr), 12.64 (1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 13.9 
(ArCH2CH2CH3), 20.9 (ArCH2CH2CH3), 35.1 (ArCH2CH2CH3), 111.1 (C-3), 115.0 (d, 
J = 21.6 Hz, C-5’), 121.3 (C-5”), 125.2 (C-2 or C-4), 125.8 (d, J = 3.1 Hz, C-3’), 128.0 (d, 
J = 23.3 Hz, C-1’), 128.3 (C-2 or C-4), 129.2 (C-5), 130.4 (d, J = 6.0 Hz, C-2’), 131.4 
(C-3”), 131.8 (d, J = 9.0 Hz, C-4’), 134.8 (C-4”), 146.5 (C-6”), 157.4 (CONHAr or C-2”), 
158.6 (d, J = 246.3 Hz, C-6’), 159.0 (CONHAr or C-2”), 183.9 (ArCO); 19F NMR 
(471 MHz, DMSO-d6) δ -114.4 (ArF); LRMS (ES
-
) m/z 384.3 [M(
35
Cl)-H]
-
, 386.2 
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[M(
37
Cl)-H]
-
; HRMS (NSI) calcd for C20H18ClFN3O2 [M(
35
Cl)+H]
+
 386.1066, found 
386.1064. 
 
4-(2-Chloro-6-fluorobenzoyl)-N-(2-methoxypyridin-3-yl)-1H-pyrrole-2-carboxamide, 
(284) 
 
Compound 284 was synthesised according to general procedure X, using the following 
reagents: 4-(2-chloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (249) (100 mg, 
0.37 mmol), pyridine (31 µL, 30 mg, 0.37 mmol), cyanuric fluoride (13 µL, 20 mg, 
0.15 mmol), acetonitrile (3.7 mL) and 3-amino-2-methoxypyridine (116 mg, 0.94 mmol). 
The crude product was purified by column chromatography (amine silica gel, 
petrol:EtOAc, 1:0  3:7) to yield the title compound as a white solid (87 mg, 62%); 
Rf = 0.30 (amine silica, petrol:EtOAc, 3:7); m.p. 226.5-228.5 °C; λmax (EtOH)/nm 299.4; 
IR (neat) νmax/cm
-1
 3288, 1678, 1645, 1603, 1552, 1510, 1450, 1404, 1275; 
1
H NMR 
(500 MHz, DMSO-d6) δ 3.91 (3H, s, ArOCH3), 7.03 (1H, dd, J = 7.7, 4.9 Hz, H-5”), 7.39 
(1H, dd, J = 8.6, 8.6 Hz, H-5’), 7.49 – 7.42 (3H, m, H-3, H-5 and H-3’), 7.58 (1H, ddd, 
J = 8.6, 8.3 and 6.2 Hz, H-4’), 7.97 (1H, dd, J = 7.7, 1.8 Hz, H-4”), 8.00 (1H, dd, J = 4.9, 
1.8 Hz, H-6”), 9.62 (1H, s, CONHAr), 12.65 (1H, s, NH-pyrrole); 13C NMR (126 MHz, 
DMSO-d6) δ 53.4 (ArOCH3), 111.7 (C-3), 115.0 (d, J = 21.5 Hz, C-5’), 116.9 (C-5”), 
121.2 (C-2 or C-4), 125.3 (C-2 or C-4), 125.8 (d, J = 3.2 Hz, C-3’), 128.1 (d, J = 23.1 Hz, 
C-1’), 128.2 (C-3”), 129.1 (C-5), 130.4 (d, J = 6.1 Hz, C-2’), 131.8 (d, J = 9.0 Hz, C-4’), 
133.2 (C-4”), 142.6 (C-6”), 156.5 (CONHAr or C-2”), 158.6 (d, J = 246.9 Hz, C-6’), 158.7 
(CONHAr or C-2”), 183.9 (ArCO); 19F NMR (471 MHz, DMSO-d6) δ -114.4 (ArF); 
LRMS (ES
-
) m/z 372.2 [M(
35
Cl)-H]
-
, 374.2 [M(
37
Cl)-H]
-
; HRMS (NSI) calcd for 
C18H12ClFN3O3 [M(
35
Cl)-H]
-
 372.0557, found 372.0556. 
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4-(2-Chloro-6-fluorobenzoyl)-N-(2-ethoxypyridin-3-yl)-1H-pyrrole-2-carboxamide, 
(285) 
 
Compound 285 was synthesised according to general procedure X, using the following 
reagents: 4-(2-chloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (249) (100 mg, 
0.37 mmol), pyridine (31 µL, 30 mg, 0.37 mmol), cyanuric fluoride (13 µL, 20 mg, 
0.15 mmol), acetonitrile (3.7 mL) and 2-ethoxypyridin-3-amine (280) (129 mg, 
0.94 mmol). The crude product was purified by column chromatography (silica gel, 
petrol:EtOAc, 1:0  7:3) to yield the title compound as a brown solid (60 mg, 41%); 
Rf = 0.31 (petrol:EtOAc, 7:3); m.p. 181.0-183.0 °C; λmax (EtOH)/nm 299.4; IR (neat) 
νmax/cm
-1
 3428, 3232, 2987, 2937, 1653, 1605, 1558, 1532, 1486, 1438, 1344, 1285, 1230; 
1
H NMR (500 MHz, DMSO-d6) δ 1.33 (3H, t, J = 7.0 Hz, ArOCH2CH3), 4.38 (2H, q, 
J = 7.0 Hz, ArOCH2CH3), 7.00 (1H, dd, J = 7.6, 5.0 Hz, H-5”), 7.39 (1H, dd, J = 8.7, 
8.7 Hz, H-5’), 7.48 – 7.41 (3H, m, H-3, H-5 and H-3’), 7.57 (ddd, J = 8.7, 8.3 and 6.1 Hz, 
1H, H-4’), 8.01 – 7.90 (2H, m, H-4” and H-6”), 9.52 (1H, s, CONHAr), 12.66 (1H, s, 
NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 14.5 (ArOCH2CH3), 61.5 (ArOCH2CH3), 
111.5 (C-3), 114.9 (d, J = 21.5 Hz, C-5’), 116.6 (C-5”), 121.1 (C-2 or C-4), 125.2 (C-2 or 
C-4), 125.8 (d, J = 3.2 Hz, C-3’), 128.1 (d, J = 23.1 Hz, C-1’), 128.3 (C-3”), 129.3 (C-5), 
130.4 (d, J = 6.0 Hz, C-2’), 131.8 (d, J = 9.0 Hz, C-4’), 133.1 (C-4”), 142.6 (C-6”), 156.2 
(CONHAr or C-2”), 158.6 (d, J = 246.8 Hz, C-6’), 158.6 (CONHAr or C-2”), 183.9 
(ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -114.4 (ArF); LRMS (ES
-
) m/z 386.2 
[M(
35
Cl)-H]
-
, 388.3 [M(
37
Cl)-H]
-
; HRMS (NSI) calcd for C19H14ClFN3O3 [M(
35
Cl)-H]
-
 
386.0713, found 386.0709. 
 
4-(2-Chloro-6-fluorobenzoyl)-N-(2-(pyrrolidin-1-yl)pyridin-3-yl)-1H-pyrrole-2-
carboxamide, (286) 
 
Compound 286 was synthesised according to general procedure Y, using the following 
reagents: 4-(2-chloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (249) (100 mg, 
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0.37 mmol), triethylamine (131 µL, 95 mg, 0.94 mmol), 2-chloro-1-methylpyridinium 
iodide (105 mg, 0.41 mmol), 2-(pyrrolidin-1-yl)pyridin-3-amine (281) (76 mg, 0.56 mmol) 
and DCM (3.7 mL). The crude yellow solid was purified by column chromatography 
(silica gel, petrol:EtOAc, 1:0  3:7) to yield the title compound as a yellow solid (48 mg, 
31%); Rf = 0.31 (petrol:EtOAc, 3:7); m.p. 239.5-241.5 °C; λmax (EtOH)/nm 237.4; 
IR (neat) νmax/cm
-1
 3335, 3164, 3124, 2981, 2876, 1632, 1593, 1571, 1519, 1446, 1394, 
1281, 1244; 
1
H NMR (500 MHz, DMSO-d6) δ 1.81 (4H, t, J = 6.4 Hz, NCH2CH2), 3.44 
(4H, t, J = 6.4 Hz, NCH2CH2), 6.66 (2H, dd, J = 7.4, 4.8 Hz, H-5”), 7.41 – 7.30 (3H, m, 
H-5, H-5’ and H-4”), 7.42 (1H, s, H-3), 7.45 (2H, d, J = 8.2 Hz, H-3’), 7.57 (2H, ddd, 
J = 8.3, 8.2 and 6.0 Hz, H-4’), 8.01 (2H, dd, J = 4.8, 1.8 Hz, H-6”), 9.84 (1H, s, CONHAr), 
12.56 (1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 25.1 (NCH2CH2), 48.4 
(NCH2CH2), 110.7 (C-3), 112.3 (C-5”), 114.9 (d, J = 21.7 Hz, C-5’), 118.0 (C-2 or C-4), 
125.3 (C-2 or C-4), 125.8 (d, J = 3.3 Hz, C-3’), 128.1 (d, J = 23.1 Hz, C-1’), 128.7 (C-3”), 
129.1 (C-5), 130.4 (d, J = 6.2 Hz, C-2’), 131.8 (d, J = 9.0 Hz, C-4’), 137.9 (C-4”), 145.6 
(C-6”), 155.3 (C-2”), 158.6 (d, J = 246.8 Hz, C-6’), 159.2 (CONHAr), 183.8 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -114.3 (ArF); LRMS (ES
-
) m/z 411.3 [M(
35
Cl)-H]
-
, 
413.4 [M(
37
Cl)-H]
-
; HRMS (NSI) calcd for C21H17ClFN4O2 [M(
35
Cl)-H]
-
 411.1030, found 
411.1024. 
 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(2-methylpyridin-3-yl)-1H-pyrrole-2-
carboxamide, (287) 
 
Compound 287 was synthesised according to general procedure U, using the following 
reagents: 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250) (100 mg, 
0.33 mmol), 3-amino-2-methylpyridine (89 mg, 0.83 mmol), phosphorus trichloride 
(29 µL, 45 mg, 0.33 mmol) and acetonitrile (1.65 mL). The crude product was purified by 
column chromatography (silica gel, petrol:EtOAc, 1:0  0:1) to yield the title compound 
as a white solid (82 mg, 63%); Rf = 0.31 (EtOAc, 100%); m.p. 146.0-148.0 °C; 
λmax (EtOH)/nm 239.0, 286.2; IR (neat) νmax/cm
-1
 3127, 1636, 1594, 1558, 1518, 1447, 
1290, 1223; 
1
H NMR (500 MHz, DMSO-d6) δ 2.44 (3H, s, ArCH3), 7.27 (1H, dd, J = 7.9, 
4.7 Hz, H-5”), 7.50 (1H, s, H-3), 7.51 (1H, d, J = 9.1 Hz, H-5’), 7.59 (1H, s, H-5), 7.72 
(1H, dd, J = 7.9, 1.8 Hz, H-4”), 7.77 (1H, dd, J = 9.1, 8.3 Hz, H-4’), 8.34 (1H, dd, J = 4.7, 
309 
1.8 Hz, H-6”), 9.90 (1H, s, CONHAr), 12.74 (1H, s, NH-pyrrole); 13C NMR (126 MHz, 
DMSO-d6) δ 21.1 (ArCH3), 111.2 (C-3), 119.3 (d, J = 18.1 Hz, C-3’), 121.4 (C-5”), 124.8 
(C-2 or C-4), 126.9 (d, J = 3.8 Hz, C-5’), 128.5 (C-2 or C-4), 129.1 (d, J = 19.4 Hz, C-1’), 
129.2 (d, J = 8.6 Hz, C-6’), 130.1 (C-5), 131.8 (d, J = 8.3 Hz, C-4’), 133.9 (C-4”), 146.2 
(C-6”), 153.9 (d, J = 248.6 Hz, C-2’), 153.9 (C-2”), 158.6 (CONHAr), 182.6 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -116.7 (ArF); LRMS (ES
-
) m/z 390.3 [M(
35
Cl
35
Cl)-H]
-
, 
392.2 [M(
35
Cl
37
Cl)-H]
-
; HRMS (NSI) calcd for C18H11Cl2FN3O2 [M(
35
Cl
35
Cl)-H]
-
 
390.0218, found 390.0214. 
 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(2-ethylpyridin-3-yl)-1H-pyrrole-2-carboxamide, 
(288) 
 
Compound 288 was synthesised according to general procedure U, using the following 
reagents: 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250) (100 mg, 
0.33 mmol), 2-ethylpyridin-3-amine (278) (101 mg, 0.83 mmol), phosphorus trichloride 
(29 µL, 45 mg, 0.33 mmol) and acetonitrile (1.65 mL). The crude product was purified by 
column chromatography (silica gel, petrol:EtOAc, 1:0  35:65) to yield the title 
compound as an off-white solid (55 mg, 41%); Rf = 0.29 (petrol:EtOAc, 35:65); 
m.p. 122.5-124.5 °C; λmax (EtOH)/nm 238.2, 285.6; IR (neat) νmax/cm
-1
 3236, 2981, 2889, 
1635, 1594, 1558, 1518, 1448, 1393, 1287, 1240, 1225; 
1
H NMR (500 MHz, DMSO-d6) 
δ 1.18 (3H, t, J = 7.4 Hz, ArCH2CH3), 2.77 (2H, q, J = 7.4 Hz, ArCH2CH3), 7.28 (1H, dd, 
J = 7.9, 5.1 Hz, H-5”), 7.55 – 7.48 (2H, m, H-3 and H-5’), 7.59 (1H, s, H-5), 7.69 (1H, d, 
J = 7.9 Hz, H-4”), 7.77 (1H, dd, J = 8.3, 8.3 Hz, H-4’), 8.41 (1H, d, J = 5.1 Hz, H-6”), 9.91 
(1H, s, CONHAr), 12.72 (1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 12.3 
(ArCH2CH3), 26.2 (ArCH2CH3), 111.1 (C-3), 119.3 (d, J = 18.0 Hz, C-3’), 121.4 (C-5”), 
124.8 (C-2 or C-4), 126.9 (d, J = 3.8 Hz, C-5’), 128.5 (C-2 or C-4), 129.2 (d, J = 23.0 Hz, 
C-1’), 129.2 (d, J = 5.0 Hz, C-2’), 130.1 (C-5), 131.1 (C-3”), 131.8 (C-4’), 134.8 (C-4”), 
146.6 (C-6”), 153.9 (d, J = 248.4 Hz, C-2’), 158.4 (CONHAr or C-2”), 158.9 (CONHAr or 
C-2”), 182.6 (ArCO); 19F NMR (471 MHz, DMSO-d6) δ -116.7 (ArF); LRMS (ES
-
) m/z 
404.2 [M(
35
Cl
35
Cl)-H]
-
, 406.3 [M(
35
Cl
37
Cl)-H]
-
; HRMS (NSI) calcd for C19H15Cl2FN3O2 
[M(
35
Cl
35
Cl)+H]
+
 406.0520, found 406.0525. 
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4-(3,6-Dichloro-2-fluorobenzoyl)-N-(2-propylpyridin-3-yl)-1H-pyrrole-2-
carboxamide, (289) 
 
Compound 289 was synthesised according to general procedure U, using the following 
reagents: 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250) (100 mg, 
0.33 mmol), 2-propylpyridin-3-amine (279) (113 mg, 0.83 mmol), phosphorus trichloride 
(29 µL, 45 mg, 0.33 mmol) and acetonitrile (1.65 mL). The crude product was purified by 
column chromatography (silica gel, petrol:EtOAc, 1:0  45:55) to yield the title 
compound as a brown solid (45 mg, 32%); Rf = 0.30 (petrol:EtOAc, 45:55); m.p. 
131.5-133.5 °C; λmax (EtOH)/nm 238.8, 285.4; IR (neat) νmax/cm
-1
 3225, 3122, 2967, 2934, 
2872, 1634, 1594, 1558, 1519, 1448, 1424, 1392, 1287; 
1
H NMR (500 MHz, DMSO-d6) 
δ 0.87 (3H, t, J = 7.4 Hz, ArCH2CH2CH3), 1.67 (2H, tq, J = 7.6, 7.5 Hz, ArCH2CH2CH3), 
2.74 (2H, t, J = 7.6 Hz, ArCH2CH2CH3), 7.27 (1H, dd, J = 7.9, 4.7 Hz, H-5”), 7.49 (1H, s, 
H-3), 7.51 (1H, d, J = 9.0 Hz, H-5’), 7.58 (1H, s, H-5), 7.69 (1H, dd, J = 7.9, 1.7 Hz, 
H-4”), 7.77 (1H, dd, J = 8.3, 8.3 Hz, H-4’), 8.40 (1H, dd, J = 4.7, 1.7 Hz, H-6”), 9.90 (1H, 
s, CONHAr), 12.72 (1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 13.9 
(ArCH2CH2CH3), 20.9 (ArCH2CH2CH3), 35.1 (ArCH2CH2CH3), 111.1 (C-3), 119.3 (d, 
J = 18.1 Hz, C-3’), 121.3 (C-5”), 124.8 (C-2 or C-4), 126.9 (d, J = 3.8 Hz, C-5’), 128.5 
(C-2 or C-4), 129.2 (d, J = 22.4 Hz, C-1’), 129.2 (d, J = 5.3 Hz, C-6’), 130.1 (C-5), 131.4 
(C-3”), 131.8 (C-4’), 134.8 (C-4”), 146.6 (C-6”), 153.9 (d, J = 248.2 Hz, C-2’), 157.4 
(CONHAr or C-2”), 158.9 (CONHAr or C-2”), 182.6 (ArCO); 19F NMR (471 MHz, 
DMSO-d6) δ -116.6 (ArF); LRMS (ES
-
) m/z 418.2 [M(
35
Cl
35
Cl)-H]
-
, 420.2 
[M(
35
Cl
37
Cl)-H]
-
; HRMS (NSI) calcd for C20H17Cl2FN3O2 [M(
35
Cl
35
Cl)+H]
+
 420.0676, 
found 420.0673. 
 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(2-methoxypyridin-3-yl)-1H-pyrrole-2-
carboxamide, (290) 
 
311 
Compound 290 was synthesised according to general procedure X, using the following 
reagents: 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250) (100 mg, 
0.33 mmol), pyridine (27 µL, 26 mg, 0.33 mmol), cyanuric fluoride (11 µL, 18 mg, 
0.13 mmol), acetonitrile (3.3 mL) and 3-amino-2-methoxypyridine (103 mg, 0.83 mmol). 
The crude product was purified by column chromatography (silica gel, petrol:EtOAc, 
1:0  7:3) to yield the title compound as a pale yellow solid (36 mg, 27%); Rf = 0.32 
(petrol:EtOAc, 3:7); m.p. 185.5-187.5 °C; λmax (EtOH)/nm 298.6; IR (neat) νmax/cm
-1
 3213, 
1642, 1594, 1556, 1520, 1465, 1448, 1405, 1223; 
1
H NMR (500 MHz, DMSO-d6) δ 3.92 
(3H, s, ArOCH3), 7.03 (1H, dd, J = 7.6, 5.0 Hz, H-5”), 7.55 – 7.47 (2H, m, H-3 and H-5’), 
7.60 (1H, s, H-5), 7.78 (1H, dd, J = 8.4 Hz, H-4’), 7.98 (1H, dd, J = 7.6, 1.9 Hz, H-4”), 
8.00 (1H, dd, J = 5.0, 1.9 Hz, H-6”), 9.61 (1H, s, CONHAr), 12.72 (1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 53.4 (ArOCH3), 111.6 (C-3), 116.9 (C-5”), 119.3 (d, 
J = 18.0 Hz, C-3’), 121.1 (C-2 or C-4), 124.8 (C-2 or C-4), 126.9 (d, J = 3.7 Hz, C-5’), 
128.4 (C-3”), 129.2 (d, J = 22.9 Hz, C-1’), 129.2 (d, J = 5.2 Hz, C-6’), 129.9 (C-5), 131.8 
(C-4’), 133.2 (C-4”), 142.6 (C-6”), 153.9 (d, J = 248.8 Hz, C-1’), 156.5 (CONHAr or 
C-2”), 158.6 (CONHAr or C-2”), 182.6 (ArCO); 19F NMR (471 MHz, DMSO-d6) δ -116.7 
(ArF); LRMS (ES
-
) m/z 406.4 [M(
35
Cl
35
Cl)-H]
-
, 408.6 [M(
35
Cl
37
Cl)-H]
-
; HRMS (NSI) 
calcd for C18H11Cl2FN3O3 [M(
35
Cl
35
Cl)-H]
-
 406.0167, found 406.0162. 
 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(2-ethoxypyridin-3-yl)-1H-pyrrole-2-
carboxamide, (291) 
 
Compound 291 was synthesised according to general procedure X, using the following 
reagents: 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250) (100 mg, 
0.33 mmol), pyridine (27 µL, 26 mg, 0.33 mmol), cyanuric fluoride (11 µL, 18 mg, 
0.13 mmol), acetonitrile (3.3 mL) and 2-ethoxypyridin-3-amine (280) (114 mg, 
0.83 mmol). The crude product was purified by column chromatography (silica gel, 
petrol:EtOAc, 1:0  3:1) to yield the title compound as a pale brown solid (87 mg, 62%); 
Rf = 0.28 (petrol:EtOAc, 3:1); m.p. 180.5-182.5 °C; λmax (EtOH)/nm 299.4; IR (neat) 
νmax/cm
-1
 3661, 3423, 3239, 2981, 2889, 1656, 1531, 1444, 1379, 1275, 1229; 
1
H NMR 
(500 MHz, DMSO-d6) δ 1.34 (3H, t, J = 7.0 Hz, ArOCH2CH3), 4.39 (2H, q, J = 7.0 Hz, 
ArOCH2CH3), 7.00 (1H, dd, J = 7.5, 5.0 Hz, H-5”), 7.49 (1H, s, H-3), 7.51 (1H, dd, 
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J = 8.5, 1.3 Hz, H-5’), 7.59 (1H, s, H-5), 7.77 (1H, dd, J = 8.5, 8.4 Hz, H-4’), 8.04 – 7.89 
(2H, m, H-4” and H-6”), 9.52 (1H, s, CONHAr), 12.73 (1H, s, NH-pyrrole); 13C NMR 
(126 MHz, DMSO-d6) δ 14.5 (ArOCH2CH3), 61.5 (ArOCH2CH3), 111.4 (C-3), 116.6 
(C-5”), 119.3 (d, J = 18.0 Hz, C-3’), 121.1 (C-2 or C-4), 124.8 (C-2 or C-4), 126.9 (d, 
J = 3.8 Hz, C-5’), 128.5 (C-3”), 129.2 (d, J = 23.1 Hz, C-1’), 129.2 (d, J = 5.1 Hz, C-6’), 
130.1 (C-5), 131.8 (C-4’), 133.1 (C-4”), 142.6 (C-6”), 153.9 (d, J = 248.6 Hz, C-2’), 156.2 
(CONHAr or C-2”), 158.6 (CONHAr or C-2”), 182.6 (ArCO); 19F NMR (471 MHz, 
DMSO-d6) δ -116.6 (ArF); LRMS (ES
-
) m/z 420.2 [M(
35
Cl
35
Cl)-H]
-
, 422.2 
[M(
35
Cl
37
Cl)-H]
-
; HRMS (NSI) calcd for C19H13Cl2FN3O3 [M(
35
Cl
35
Cl)-H]
-
 420.0323, 
found 420.0320. 
 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(2-(pyrrolidin-1-yl)pyridin-3-yl)-1H-pyrrole-2-
carboxamide, (292) 
 
Compound 292 was synthesised according to general procedure Y, using the following 
reagents: 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250) (100 mg, 
0.33 mmol), triethylamine (115 µL, 84 mg, 0.83 mmol), 2-chloro-1-methylpyridinium 
iodide (93 mg, 0.36 mmol), 2-(pyrrolidin-1-yl)pyridin-3-amine (281) (67 mg, 0.41 mmol) 
and DCM (3.3 mL). The crude yellow solid was purified by column chromatography 
(silica gel, petrol:EtOAc, 1:0  4:6) to yield the title compound as a pale yellow solid (45 
mg, 30%); Rf = 0.30 (petrol:EtOAc, 4:6); m.p. 236.5-238.5 °C; λmax (EtOH)/nm 236.6; 
IR (neat) νmax/cm
-1
 3230, 2970, 2870, 1635, 1594, 1562, 1516, 1448, 1294, 1227; 
1
H NMR 
(500 MHz, DMSO-d6) δ 1.81 (4H, t, J = 6.5 Hz, NCH2CH2), 3.44 (4H, t, J = 6.5 Hz, 
NCH2CH2), 6.67 (1H, dd, J = 7.5, 4.8 Hz, H-5”), 7.38 (1H, dd, J = 7.5, 1.9 Hz, H-4”), 7.44 
(1H, s, H-3), 7.51 (1H, d, J = 9.2 Hz, H-5’), 7.53 (1H, s, H-5), 7.77 (1H, dd, J = 9.2, 
8.3 Hz, H-4’), 8.02 (1H, dd, J = 4.8, 1.9 Hz, H-6”), 9.84 (1H, s, CONHAr), 12.64 (1H, s, 
NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 25.1 (NCH2CH2), 48.4 (NCH2CH2), 110.6 
(C-3), 112.3 (C-5”), 117.9 (C-2 or C-4), 119.2 (C-3’), 124.8 (C-2 or C-4), 126.8 (d, 
J = 3.4 Hz, C-5’), 128.9 (C-3”), 129.2 (d, J = 23.0 Hz, C-1’), 129.2 (d, J = 5.0 Hz, C-6’), 
130.0 (C-5), 131.8 (C-4’), 137.9 (C-4”), 145.6 (C-6”), 153.9 (d, J = 248.3 Hz, C-2’), 155.3 
(CONHAr or C-2”), 159.1 (CONHAr or C-2”), 182.5 (ArCO); 19F NMR (471 MHz, 
DMSO-d6) δ -116.6 (ArF); LRMS (ES
+
) m/z 447.3 [M(
35
Cl
35
Cl)+H]
+
, 449.3 
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[M(
35
Cl
37
Cl)+H]
+
; HRMS (NSI) calcd for C21H16Cl2FN4O2 [M(
35
Cl
35
Cl)-H]
-
 445.0640, 
found 445.0636. 
 
4-Ethyl-3-nitropyridine, (294) 
 
Compound 294 was synthesised according to general procedure W, using the following 
reagents: 4-chloro-3-nitropyridine (293) (650 mg, 4.10 mmol), ethylboronic acid (333 mg, 
4.51 mmol), potassium carbonate (1.70 g, 12.3 mmol), tetrakis(triphenylphosphine) 
palladium(0) (474 mg, 0.41 mmol) and dioxane (20 mL). The crude product was purified 
by column chromatography (silica gel, petrol:EtOAc, 1:0  7:3) to yield the title 
compound as a clear yellow oil (312 mg, 50%); Rf = 0.30 (petrol:EtOAc, 7:3); 
λmax (EtOH)/nm 241.8; IR (neat) νmax/cm
-1
 2979, 2940, 2880, 1602, 1522, 1349, 1215; 
1
H NMR (500 MHz, DMSO-d6) δ 1.22 (3H, t, J = 7.5 Hz, ArCH2CH3), 2.88 (2H, q, 
J = 7.5 Hz, ArCH2CH3), 7.61 (1H, d, J = 5.1 Hz, H-5), 8.76 (1H, d, J = 5.1 Hz, H-6), 9.08 
(1H, s, H-2); 
13
C NMR (126 MHz, DMSO-d6) δ 13.7 (ArCH2CH3), 24.5 (ArCH2CH3), 
125.5 (C-5), 145.2 (C-2), 145.8 (C-3), 147.2 (C-4), 153.3 (C-6); LRMS (ES
+
) m/z 153.2 
[M+H]
+
; HRMS (ESI) calcd for C7H9N2O2 [M+H]
+
 153.0659, found 153.0656; 
1
H and 
13
C NMR data were identical to literature data.
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3-Nitro-4-vinylpyridine, (295) 
 
Compound 295 was synthesised according to general procedure W, using the following 
reagents: 4-chloro-3-nitropyridine (293) (650 mg, 4.10 mmol), vinylboronic acid pinacol 
ester (765 µL, 695 mg, 4.51 mmol), potassium carbonate (1.70 g, 12.3 mmol), 
tetrakis(triphenylphosphine)palladium(0) (474 mg, 0.41 mmol) and dioxane (20 mL). The 
crude product was purified by column chromatography (silica gel, petrol:EtOAc, 
1:0  8:2) to yield the title compound as a clear yellow liquid (254 mg, 41%); Rf = 0.33 
(petrol:EtOAc, 8:2); λmax (EtOH)/nm 234.2; IR (neat) νmax/cm
-1
 1597, 1541, 1519, 1407, 
1347, 1220; 
1
H NMR (500 MHz, DMSO-d6) δ 5.77 (1H, d, J = 11.1 Hz, ArCH=CH2), 6.21 
(1H, d, J = 17.3 Hz, ArCH=CH2), 7.09 (1H, dd, J = 17.3, 11.1 Hz, ArCH=CH2), 7.86 (1H, 
d, J = 5.2 Hz, H-5), 8.82 (1H, d, J = 5.2 Hz, H-6), 9.14 (1H, s, H-2); 
13
C NMR (126 MHz, 
DMSO-d6) δ 121.6 (C-5), 123.8 (ArCH=CH2), 129.7 (ArCH=CH2), 139.4 (C-4), 143.7 
314 
(C-3), 145.5 (C-2), 153.5 (C-6); LRMS (ES
+
) m/z 151.1 [M+H]
+
; HRMS (APCI) calcd for 
C7H7N2O2 [M+H]
+
 151.0502, found 151.0501. 
 
3-Nitro-4-(prop-1-en-1-yl)pyridine, (296) 
 
Compound 296 was synthesised according to general procedure W, using the following 
reagents: 4-chloro-3-nitropyridine (293) (650 mg, 4.10 mmol), allylboronic acid pinacol 
ester (851 µL, 758 mg, 4.51 mmol), potassium carbonate (1.70 g, 12.3 mmol), 
tetrakis(triphenylphosphine)palladium(0) (474 mg, 0.41 mmol) and dioxane (20 mL). The 
crude product was purified by column chromatography (silica gel, petrol:EtOAc, 
1:0  85:15) to yield the title compound as an orange solid (235 mg, 35%); Rf = 0.30 
(petrol:EtOAc, 7:3); m.p. 42.0-44.0 °C; λmax (EtOH)/nm 241.6; IR (neat) νmax/cm
-1
 2976, 
2944, 2920, 2865, 1648, 1598, 1541, 1519, 1353, 1227; 
1
H NMR (500 MHz, DMSO-d6) 
δ 1.95 (3H, d, J = 5.2 Hz, ArCH=CHCH3), 6.84 – 6.73 (2H, m, ArCH=CHCH3), 7.81 (1H, 
d, J = 5.3 Hz, H-5), 8.72 (1H, d, J = 5.3 Hz, H-6), 9.06 (1H, s, H-2); 
13
C NMR (126 MHz, 
DMSO-d6) δ 18.9 (ArCH=CHCH3), 121.3 (C-5), 123.0 (ArCH=CHCH3 or 
ArCH=CHCH3), 137.1 (ArCH=CHCH3 or ArCH=CHCH3), 139.2 (C-4), 143.4 (C-3), 
145.5 (C-6), 152.9 (C-2); LRMS (ES
+
) m/z 165.1 [M+H]
+
; HRMS (APCI) calcd for 
C8H9N2O2 [M+H]
+
 165.0659, found 165.0658. 
 
4-Methoxy-3-nitropyridine, (297) 
 
To a suspension of 4-chloro-3-nitropyridine (293) (1.0 g, 6.31 mmol) in ethanol (15 mL) 
was added sodium methoxide (1.02 g 18.9 mmol). The resulting solution was stirred at RT 
overnight. Upon completion, the solvent removed in vacuo. The crude residue was 
dissolved in EtOAc (40 mL), washed with water and brine (20 mL, respectively), dried 
over MgSO4 and concentrated in vacuo. The crude brawn oil was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  4:6) to yield the title compound as a 
yellow solid (815 mg, 84%); Rf = 0.28 (petrol:EtOAc, 4:6); m.p. 72.0-74.0 °C (lit. 
73.0-75.0 °C)
278
; λmax (EtOH)/nm 283.4; IR (neat) νmax/cm
-1
 3101, 3005, 2870, 1595, 1562, 
1511, 1438, 1353, 1311, 1285, 1247, 1202; 
1
H NMR (500 MHz, DMSO-d6) δ 4.02 (3H, s, 
ArOCH3), 7.45 (1H, d, J = 5.9 Hz, H-5), 8.69 (1H, d, J = 5.9 Hz, H-6), 8.98 (1H, s, H-2); 
13
C NMR (126 MHz, DMSO-d6) δ 57.2 (ArOCH3), 109.9 (C-5), 136.4 (C-3), 146.0 (C-2), 
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155.0 (C-6), 158.2 (C-4); LRMS (ES
+
) m/z 155.1 [M+H]
+
; HRMS (ESI) calcd for 
C6H7N2O3 [M+H]
+
 155.0451, found 155.0451; 
1
H and 
13
C NMR data were identical to 
literature data.
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4-Ethoxy-3-nitropyridine, (298) 
 
To a suspension of 4-chloro-3-nitropyridine (293) (1.0 g, 6.31 mmol) in ethanol (15 mL) 
was added sodium ethoxide (1.29 g 18.9 mmol). The resulting solution was stirred at RT 
overnight. Upon completion, the solvent removed in vacuo. The crude residue was 
dissolved in EtOAc (40 mL), washed with water and brine (20 mL, respectively), dried 
over MgSO4 and concentrated in vacuo. The crude brawn oil was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  4:6) to yield the title compound as a 
yellow solid (760 mg, 76%); Rf = 0.32 (petrol:EtOAc, 4:6); m.p. 46.5-48.5 °C; 
λmax (EtOH)/nm 242.2, 286.8; IR (neat) νmax/cm
-1
 3000, 2951, 1596, 1558, 1522, 1491, 
1468, 1353, 1318, 1287, 1240; 
1
H NMR (500 MHz, DMSO-d6) δ 1.37 (3H, t, J = 7.0 Hz, 
ArOCH2CH3), 4.33 (2H, q, J = 7.0 Hz, ArOCH2CH3), 7.43 (1H, d, J = 5.9 Hz, H-5), 8.66 
(1H, d, J = 5.9 Hz, H-6), 8.96 (1H, s, H-2); 
13
C NMR (126 MHz, DMSO-d6) δ 14.0 
(ArOCH2CH3), 65.8 (ArOCH2CH3), 110.3 (C-5), 136.6 (C-3), 146.0 (C-2), 154.8 (C-6), 
157.3 (C-4); LRMS (ES
+
) m/z 169.1 [M+H]
+
; HRMS (NSI) calcd for C7H9N2O3 [M+H]
+
 
169.0608, found 169.0608. 
 
3-Nitro-4-(pyrrolidin-1-yl)pyridine, (299) 
 
To a suspension of 4-chloro-3-nitropyridine (293) (1.0 g, 6.31 mmol) in acetonitrile 
(15 mL) was added potassium carbonate (959 mg, 6.94 mmol) and pyrrolidine (579 µL, 
493 mg, 6.94 mmol). The resulting solution was stirred at RT overnight. Upon completion, 
the potassium carbonate was removed by filtration and the solvent removed in vacuo. The 
crude residue was dissolved in EtOAc (40 mL), washed with water and brine (20 mL, 
respectively), dried over MgSO4 and concentrated in vacuo. The crude orange oil was 
purified by column chromatography (silica gel, petrol:EtOAc, 1:0  1:3) to yield the title 
compound as a yellow solid (1.22 g, 91%); Rf = 0.30 (petrol:EtOAc, 1:3); m.p. 
88.5-90.5 °C; λmax (EtOH)/nm 244.4; IR (neat) νmax/cm
-1
 2953, 2925, 2879, 2858, 1599, 
1531, 1507, 1496, 1386, 1341, 1243, 1204; 
1
H NMR (500 MHz, DMSO-d6) δ 1.98 – 1.85 
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(4H, m, NCH2CH2), 3.28 – 3.13 (4H, m, NCH2CH2), 6.94 (1H, d, J = 6.2 Hz, H-5), 8.23 
(1H, d, J = 6.2 Hz, H-6), 8.66 (1H, s, H-2); 
13
C NMR (126 MHz, DMSO-d6) δ 25.0 
(NCH2CH2), 50.0 (NCH2CH2), 110.8 (C-5), 134.1 (C-3), 145.1 (C-4), 146.9 (C-6), 150.8 
(C-2); LRMS (ES
+
) m/z 194.0 [M+H]
+
; HRMS (NSI) calcd for C9H12N3O2 [M+H]
+
 
194.0924, found 194.0925. 
 
4-Ethylpyridin-3-amine, (300) 
 
Compound 300 was synthesised following two different procedures: 
1
st
 procedure: Compound 300 was synthesised according to general procedure V, using the 
following reagents: 4-ethyl-3-nitropyridine (294) (250 mg, 1.64 mmol) and methanol 
(33 mL). The crude product was purified by column chromatography (amine silica gel, 
petrol:EtOAc, 1:0  3:7) to yield the title compound as a pale yellow solid (164 mg, 
82%). 
2
nd
 procedure: Compound 300 was synthesised according to general procedure V, using the 
following reagents: 3-nitro-4-vinylpyridine (295) (200 mg, 1.33 mmol) and methanol 
(27 mL). The crude product was purified by column chromatography (amine silica gel, 
petrol:EtOAc, 1:0  3:7) to yield the title compound as a pale yellow solid (130 mg, 
80%); Rf = 0.29 (amine silica, petrol:EtOAc, 3:7); m.p. 82.0-84.0 °C; λmax (EtOH)/nm 
242.0, 296.2; IR (neat) νmax/cm
-1
 3337, 3176, 2969, 2935, 2879, 1645, 1595, 1563, 1502, 
1462, 1417, 1377, 1320, 1289; 
1
H NMR (500 MHz, DMSO-d6) δ 1.12 (3H, t, J = 7.5 Hz, 
ArCH2CH3), 2.43 (2H, q, J = 7.5 Hz, ArCH2CH3), 5.05 (2H, brs, ArNH2), 6.89 (1H, d, 
J = 4.7 Hz, H-5), 7.69 (1H, d, J = 4.7 Hz, H-6), 7.89 (1H, s, H-2); 
13
C NMR (126 MHz, 
DMSO-d6) δ 12.1 (ArCH2CH3), 22.5 (ArCH2CH3), 122.4 (C-5), 133.8 (C-4), 136.2 (C-2), 
137.6 (C-6), 142.6 (C-3); LRMS (ES
+
) m/z 123.2 [M+H]
+
; HRMS (ESI) calcd for C7H11N2 
[M+H]
+
 123.0917, found 123.0917. 
 
4-Propylpyridin-3-amine, (301) 
 
Compound 301 was synthesised according to general procedure V, using the following 
reagents: 3-nitro-4-(prop-1-en-1-yl)pyridine (296) (180 mg, 1.10 mmol) and methanol 
(22 mL). The crude product was purified by column chromatography (amine silica gel, 
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petrol:EtOAc, 1:0  1:1) to yield the title compound as a yellow oil (130 mg, 87%); 
Rf = 0.29 (amine silica, petrol:EtOAc, 1:1); λmax (EtOH)/nm 242.2, 297.4; IR (neat) 
νmax/cm
-1
 3331, 3203, 2959, 2931, 2871, 1633, 1595, 1560, 1501, 1420, 1325, 1282; 
1
H NMR (500 MHz, DMSO-d6) δ 0.91 (3H, t, J = 7.3 Hz, ArCH2CH2CH3), 1.54 (2H, tq, 
J = 7.7, 7.3 Hz, ArCH2CH2CH3), 2.39 (2H, t, J = 7.7 Hz, ArCH2CH2CH3), 5.04 (2H, brs, 
ArNH2), 6.86 (1H, d, J = 4.7 Hz, H-5), 7.67 (1H, d, J = 4.7 Hz, H-6), 7.89 (1H, s, H-2); 
13
C NMR (126 MHz, DMSO-d6) δ 13.8 (ArCH2CH2CH3), 20.6 (ArCH2CH2CH3), 31.5 
(ArCH2CH2CH3), 123.4 (C-5), 132.2 (C-4), 136.5 (C-2), 137.4 (C-6), 142.7 (C-3); 
LRMS (ES
+
) m/z 137.2 [M+H]
+
; HRMS (NSI) calcd for C8H13N2 [M+H]
+
 137.1073, found 
137.1068. 
 
4-Methoxypyridin-3-amine, (302) 
 
Compound 302 was synthesised according to general procedure V, using the following 
reagents: 4-methoxy-3-nitropyridine (297) (700 mg, 4.54 mmol) and methanol (91 mL). 
The crude product was purified by column chromatography (amine silica gel, 
petrol:EtOAc, 1:0  3:7) to yield the title compound as an orange solid (515 mg, 91%); 
Rf = 0.19 (EtOAc, 100%); m.p. 78.5-80.5 °C (lit. 83.0-85.0 °C)
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; λmax (EtOH)/nm 246.8, 
285.2; IR (neat) νmax/cm
-1
 3404, 3338, 3171, 3096, 2934, 2843, 1645, 1575, 1511, 1427, 
1304, 1286, 1234; 
1
H NMR (500 MHz, DMSO-d6) δ 3.81 (3H, s, ArOCH3), 4.81 (2H, brs, 
ArNH2), 6.80 (1H, d, J = 5.3 Hz, H-5), 7.73 (1H, d, J = 5.3 Hz, H-6), 7.85 (1H, s, H-2); 
13
C NMR (126 MHz, DMSO-d6) δ 55.1 (ArOCH3), 105.9 (C-5), 134.2 (C-3), 135.2 (C-2), 
139.0 (C-6), 151.6 (C-4); LRMS (ES
+
) m/z 125.2 [M+H]
+
; HRMS (ESI) calcd for 
C6H9N2O [M+H]
+
 125.0709, found 125.0710; 
1
H NMR, 
13
C NMR and IR data were 
identical to literature data.
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4-Ethoxypyridin-3-amine, (303) 
 
Compound 303 was synthesised according to general procedure V, using the following 
reagents: 4-ethoxy-3-nitropyridine (298) (700 mg, 4.16 mmol) and methanol (83 mL). The 
crude product was purified by column chromatography (amine silica gel, petrol:EtOAc, 
1:0  3:7) to yield the title compound as an orange solid (535 mg, 93%); Rf = 0.21 
(EtOAc, 100%); m.p. 63.5-65.5 °C; λmax (EtOH)/nm 247.0, 286.6; IR (neat) νmax/cm
-1
 
318 
3410, 3321, 3298, 3182, 2982, 2940, 2896, 1617, 1575, 1513, 1487, 1433, 1397, 1303, 
1282, 1234, 1225; 
1
H NMR (500 MHz, DMSO-d6) δ 1.35 (3H, t, J = 7.0 Hz, 
ArOCH2CH3), 4.07 (2H, q, J = 7.0 Hz, ArOCH2CH3), 4.75 (2H, brs, ArNH2), 6.78 (1H, d, 
J = 5.4 Hz, H-5), 7.70 (1H, d, J = 5.4 Hz, H-6), 7.85 (1H, s, H-2); 
13
C NMR (126 MHz, 
DMSO-d6) δ 14.4 (ArOCH2CH3), 63.1 (ArOCH2CH3), 106.5 (C-5), 134.2 (C-3), 135.3 
(C-2), 138.9 (C-6), 150.7 (C-4); LRMS (ES
+
) m/z 139.2 [M+H]
+
; HRMS (NSI) calcd for 
C7H11N2O [M+H]
+
 139.0866, found 139.0866. 
 
4-(Pyrrolidin-1-yl)pyridin-3-amine, (304) 
 
Compound 304 was synthesised according to general procedure V, using the following 
reagents: 3-nitro-4-(pyrrolidin-1-yl)pyridine (299) (1.1 g, 5.69 mmol) and methanol 
(114 mL). The crude product was purified by column chromatography (amine silica gel, 
petrol:EtOAc – 1:0  0:1) to yield the title compound as an orange oil (900 mg, 97%); 
Rf = 0.31 (EtOAc:MeOH – 9:1); λmax (EtOH)/nm 271.0, 299.0; IR (neat) νmax/cm
-1
 3660, 
3312, 3179, 2981, 2884, 1579, 1506, 1359, 1262; 
1
H NMR (500 MHz, DMSO-d6) 
δ 1.92 -1.74 (4H, m, NCH2CH2), 3.30 – 3.10 (4H, m, NCH2CH2), 4.48 (2H, brs, ArNH2), 
6.53 (1H, d, J = 5.3 Hz, H-5), 7.64 (1H, d, J = 5.3 Hz, H-6), 7.79 (1H, s, H-2); 
13
C NMR 
(126 MHz, DMSO-d6) δ 24.3 (NCH2CH2), 48.8 (NCH2CH2), 109.9 (C-5), 134.9 (C-3), 
137.2 (C-2), 139.6 (C-6), 143.1 (C-4); LRMS (ES
+
) m/z 164.1 [M+H]
+
; HRMS (NSI) calcd 
for C9H14N3 [M+H]
+
 164.1182, found 164.1182. 
 
4-(2-Chloro-6-fluorobenzoyl)-N-(4-methylpyridin-3-yl)-1H-pyrrole-2-carboxamide, 
(305) 
 
Compound 305 was synthesised according to general procedure U, using the following 
reagents: 4-(2-chloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (249) (100 mg, 
0.37 mmol), 3-amino-4-methylpyridine (101 mg, 0.94 mmol), phosphorus trichloride 
(34 µL, 51 mg, 0.37 mmol) and acetonitrile (1.85 mL). The crude product was purified by 
column chromatography (silica gel, petrol:EtOAc, 1:0  0:1) to yield the title compound 
as an off-white solid (87 mg, 65%); Rf = 0.30 (EtOAc, 100%); m.p. 276.5-278.5 °C; 
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λmax (EtOH)/nm 238.6, 285.8; IR (neat) νmax/cm
-1
 3255, 1663, 1610, 1552, 1524, 1445, 
1420, 1309, 1297, 1225, 1147; 
1
H NMR (500 MHz, DMSO-d6) δ 2.24 (3H, s, ArCH3), 
7.31 (1H, d, J = 4.9 Hz, H-5”), 7.39 (1H, ddd, J = 8.6, 8.3 and 0.9 Hz, H-5’), 7.49 – 7.42 
(3H, m, H-3, H-5 and H-3’), 7.57 (1H, ddd, J = 8.6, 8.3 and 6.2 Hz, H-4’), 8.31 (1H, d, 
J = 4.9 Hz, H-6”), 8.45 (1H, s, H-2”), 9.95 (1H, s, CONHAr), 12.67 (1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 17.4 (ArCH3), 111.3 (C-3), 115.0 (d, J = 21.5 Hz, 
C-5’), 125.3 (C-2 or C-4), 125.3 (C-5”), 125.8 (d, J = 3.1 Hz, C-3’), 128.0 (d, J = 21.9 Hz, 
C-1’), 128.1 (C-2 or C-4), 129.1 (C-5), 130.4 (d, J = 6.1 Hz, C-3’), 131.8 (d, J = 8.9 Hz, 
C-4’), 132.8 (C-4”), 142.9 (C-3”), 146.7 (C-6”), 147.4 (C-2”), 158.6 (d, J = 246.7 Hz, 
C-6’), 158.8 (CONHAr), 183.9 (ArCO); 19F NMR (471 MHz, DMSO-d6) δ -114.3 (ArF); 
LRMS (ES
-
) m/z 356.0 [M(
35
Cl)-H]
-
, 358.2 [M(
37
Cl)-H]
-
; HRMS (NSI) calcd for 
C18H12ClFN3O2 [M(
35
Cl)-H]
-
 356.0603, found 356.0608. 
 
4-(2-Chloro-6-fluorobenzoyl)-N-(4-ethylpyridin-3-yl)-1H-pyrrole-2-carboxamide, 
(306) 
 
Compound 306 was synthesised according to general procedure U, using the following 
reagents: 4-(2-chloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (249) (100 mg, 
0.37 mmol), 4-ethylpyridin-3-amine (300) (114 mg, 0.94 mmol), phosphorus trichloride 
(34 µL, 51 mg, 0.37 mmol) and acetonitrile (1.85 mL). The crude product was purified by 
column chromatography (silica gel, petrol:EtOAc, 1:0  15:85) to yield the title 
compound as an off-white solid (85 mg, 61%); Rf = 0.30 (petrol:EtOAc, 15:85); 
m.p. 228.0-230.0 °C; λmax (EtOH)/nm 238.2, 285.8; IR (neat) νmax/cm
-1
 3278, 3122, 3092, 
2970, 2881, 1659, 1643, 1607, 1573, 1522, 1454, 1418, 1390, 1316, 1256, 1235; 
1
H NMR 
(500 MHz, DMSO-d6) δ 1.14 (3H, t, J = 7.5 Hz, ArCH2CH3), 2.62 (2H, q, J = 7.5 Hz, 
ArCH2CH3), 7.34 (1H, d, J = 5.0 Hz, H-5”), 7.39 (1H, dd, J = 9.0, 9.0 Hz, H-5’), 7.42 (1H, 
s, H-5), 7.46 (2H, d, J = 7.7 Hz, H-3 and H-3’), 7.57 (1H, ddd, J = 9.0, 7.7 and 6.2 Hz, 
H-4’), 8.38 (1H, d, J = 5.0 Hz, H-6”), 8.42 (1H, s, H-2”), 9.93 (1H, s, CONHAr), 12.66 
(1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 13.0 (ArCH2CH3), 23.2 
(ArCH2CH3), 111.2 (C-3), 115.0 (d, J = 21.4 Hz, C-5’), 123.3 (C-5”), 125.3 (C-2 or C-4), 
125.8 (d, J = 3.1 Hz, C-3’), 128.0 (d, J = 22.8 Hz, C-1’), 128.1 (C-2 or C-4), 129.2 (C-5), 
130.4 (d, J = 6.0 Hz, C-2’), 131.8 (d, J = 9.1 Hz, C-4’), 132.1 (C-3”), 147.3 (C-6”), 148.2 
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(C-2”), 148.6 (C-4”), 158.6 (d, J = 246.8 Hz, C-6’), 159.2 (CONHAr), 183.9 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -114.4 (ArF); LRMS (ES
-
) m/z 370.2 [M(
35
Cl)-H]
-
, 
372.2 [M(
37
Cl)-H]
-
; HRMS (NSI) calcd for C19H16ClFN3O2 [M(
35
Cl)+H]
+
 372.0910, found 
372.0906. 
 
4-(2-Chloro-6-fluorobenzoyl)-N-(4-propylpyridin-3-yl)-1H-pyrrole-2-carboxamide, 
(307) 
 
Compound 307 was synthesised according to general procedure U, using the following 
reagents: 4-(2-chloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (249) (60 mg, 
0.23 mmol), 4-propylpyridin-3-amine (301) (76 mg, 0.56 mmol), phosphorus trichloride 
(20 µL, 31 mg, 0.23 mmol) and acetonitrile (1.15 mL). The crude product was purified by 
column chromatography (silica gel, petrol:EtOAc, 1:0  1:3) to yield the title compound 
as an off-white solid (42 mg, 48%); Rf = 0.28 (petrol:EtOAc, 1:3); m.p. 195.5-197.5 °C; 
λmax (EtOH)/nm 238.4, 285.4; IR (neat) νmax/cm
-1
 3262, 2970, 2880, 1661, 1634, 1605, 
1566, 1520, 1452, 1419, 1387, 1314, 1289, 1231; 
1
H NMR (500 MHz, DMSO-d6) δ 0.86 
(3H, t, J = 7.3 Hz, ArCH2CH2CH3), 1.57 (2H, tq, J = 7.7, 7.3 Hz, ArCH2CH2CH3), 2.58 
(2H, t, J = 7.7 Hz, ArCH2CH2CH3), 7.32 (1H, d, J = 5.0 Hz, H-5”), 7.39 (1H, dd, J = 9.0, 
8.6 Hz, H-5’), 7.42 (1H, s, H-5), 7.49 – 7.44 (2H, m, H-3 and H-3’), 7.57 (1H, ddd, J = 9.0, 
8.3 and 6.1 Hz, H-4’), 8.36 (1H, d, J = 5.0 Hz, H-6”), 8.43 (1H, s, H-2”), 9.93 (1H, s, 
CONHAr), 12.66 (1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 13.8 
(ArCH2CH2CH3), 21.6 (ArCH2CH2CH3), 32.1 (ArCH2CH2CH3), 111.2 (C-3), 115.0 (d, 
J = 21.6 Hz, C-5’), 124.1 (C-5”), 125.3 (C-2 or C-4), 125.8 (d, J = 3.2 Hz, C-3’), 128.0 (d, 
J = 23.0 Hz, C-1’), 128.2 (C-2 or C-4), 129.2 (C-5), 130.4 (d, J = 6.1 Hz, C-2’), 131.8 (d, 
J = 9.0 Hz, C-4’), 132.3 (C-3”), 147.1 (C-4” or C-6”), 147.1 (C-4” or C-6”), 148.4 (C-2”), 
158.6 (d, J = 247.0 Hz, C-6’), 159.2 (CONHAr), 183.9 (ArCO); 19F NMR (471 MHz, 
DMSO-d6) δ -114.3 (ArF); LRMS (ES
-
) m/z 384.2 [M(
35
Cl)-H]
-
, 386.2 [M(
37
Cl)-H]
-
 
HRMS (NSI) calcd for C20H18ClFN3O2 [M(
35
Cl)+H]
+
 386.1066, found 386.1061. 
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4-(2-Chloro-6-fluorobenzoyl)-N-(4-methoxypyridin-3-yl)-1H-pyrrole-2-carboxamide, 
(308) 
 
Compound 308 was synthesised according to general procedure Y, using the following 
reagents: 4-(2-chloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (249) (100 mg, 
0.37 mmol), triethylamine (131 µL, 95 mg, 0.94 mmol), 2-chloro-1-methylpyridinium 
iodide (105 mg, 0.41 mmol), 4-methoxypyridin-3-amine (302) (58 mg, 0.47 mmol) and 
DCM (3.7 mL). The crude yellow solid was purified by column chromatography (amine 
silica gel, petrol:EtOAc, 1:0  15:85) to yield the title compound as an off-white solid 
(19 mg, 14%); Rf = 0.28 (amine silica, petrol:EtOAc, 15:85); m.p. No clear m.p., 
decomposition range 255-265 °C; λmax (EtOH)/nm 253.0, 290.0; IR (neat) νmax/cm
-1
 3244, 
2981, 2922, 2851, 1657, 1627, 1601, 1558, 1531, 1499, 1446, 1424, 1305, 1236; 
1
H NMR 
(500 MHz, DMSO-d6) δ 3.88 (3H, s, ArOCH3), 7.15 (1H, d, J = 5.7 Hz, H-5”), 7.39 (1H, 
dd, J = 8.6, 8.6 Hz, H-5’), 7.44 (2H, d, J = 2.8 Hz, H-3 and H-5), 7.46 (1H, d, J = 8.3 Hz, 
H-3’), 7.58 (1H, ddd, J = 8.6, 8.3 and 6.2 Hz, H-4’), 8.33 (1H, d, J = 5.7 Hz, H-6”), 8.52 
(1H, s, H-2”), 9.68 (1H, s, CONHAr), 12.63 (1H, s, NH-pyrrole); 13C NMR (126 MHz, 
DMSO-d6) δ 55.8 (ArOCH3), 107.4 (C-5”), 111.6 (C-3), 115.0 (d, J = 21.5 Hz, C-5’), 
122.9 (C-3”), 125.2 (C-2 or C-4), 125.8 (d, J = 3.1 Hz, C-3’), 128.1 (d, J = 23.2 Hz, C-1’), 
128.1 (C-2 or C-4), 128.9 (C-5), 130.4 (d, J = 6.1 Hz, C-2’), 131.8 (d, J = 9.0 Hz, C-4’), 
147.2 (C-2”), 148.3 (C-6”), 158.6 (d, J = 247.0 Hz, C-6’), 158.7 (CONHAr or C-4”), 158.8 
(CONHAr or C-4”), 183.9 (ArCO); 19F NMR (471 MHz, DMSO-d6) δ -114.4 (ArF); 
LRMS (ES
-
) m/z 372.2 [M(
35
Cl)-H]
-
, 374.2 [M(
37
Cl)-H]
-
; HRMS (NSI) calcd for 
C18H14ClFN3O3 [M(
35
Cl)+H]
+
 374.0702, found 374.0705. 
 
4-(2-Chloro-6-fluorobenzoyl)-N-(4-ethoxypyridin-3-yl)-1H-pyrrole-2-carboxamide, 
(309) 
 
To a solution of 4-(2-chloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (249) 
(100 mg, 0.37 mmol) in DCM (3.7 mL) was added 4-ethoxypyridin-3-amine (303) (65 mg, 
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0.47 mmol) followed by 2-chloro-1-methylpyridinium iodide (105 mg, 0.41 mmol). The 
resulting solution was stirred at 42 °C for 72 h. Upon completion, the solvent removed in 
vacuo. The crude residue was dissolved in EtOAc (30 mL), washed with saturated aq. 
NaHCO3 (20 mL) and extracted with EtOAc (2 × 20 mL). The pooled organic extracts 
were washed with brine (30 mL), dried over MgSO4 and concentrated in vacuo.  The crude 
yellow solid was purified by column chromatography (amine silica gel, petrol:EtOAc, 
1:0  1:9) to yield the title compound as a white solid (30 mg, 21%); Rf = 0.24 (amine 
silica, petrol:EtOAc, 1:9); m.p. 188.5-190.5 °C; λmax (EtOH)/nm 250.6, 291.0; IR (neat) 
νmax/cm
-1
 3298, 2996, 2982, 2948, 2908, 1670, 1644, 1603, 1537, 1501, 1447, 1430, 1320, 
1307, 1235, 1152; 
1
H NMR (500 MHz, DMSO-d6) δ 1.34 (3H, t, J = 7.0 Hz, 
ArOCH2CH3), 4.18 (2H, q, J = 7.0 Hz, ArOCH2CH3), 7.13 (1H, d, J = 5.6 Hz, H-5”), 7.39 
(1H, dd, J = 9.0, 8.5 Hz, H-5’), 7.42 (1H, s, H-5), 7.44 (1H, s, H-3), 7.46 (1H, d, J = 8.2 
Hz, H-3’), 7.57 (1H, ddd, J = 9.0, 8.2 and 6.1 Hz, H-4’), 8.30 (1H, d, J = 5.6 Hz, H-6”), 
8.52 (1H, s, H-2”), 9.62 (1H, s, CONHAr), 12.64 (1H, s, NH-pyrrole); 13C NMR 
(126 MHz, DMSO-d6) δ 14.2 (ArOCH2CH3), 64.0 (ArOCH2CH3), 108.0 (C-5”), 111.4 
(C-3), 114.9 (d, J = 21.5 Hz, C-5’), 123.0 (C-2 or C-4), 125.2 (C-3”), 125.8 (d, J = 3.3 Hz, 
C-3’), 128.1 (d, J = 23.0 Hz, C-1’), 128.3 (C-2 or C-4), 129.1 (C-5), 130.4 (d, J = 6.1 Hz, 
C-2’), 131.8 (d, J = 9.0 Hz, C-4’), 147.3 (C-2”), 148.2 (C-6”), 158.0 (CONHAr or C-4”), 
158.6 (d, J = 246.7 Hz, C-6’), 158.6 (CONHAr or C-4”), 183.9 (ArCO); 19F NMR 
(471 MHz, DMSO-d6) δ -114.4 (ArF); LRMS (ES
-
) m/z 386.2 [M(
35
Cl)-H]
-
, 388.2 
[M(
37
Cl)-H]
-
; HRMS (NSI) calcd for C19H14ClFN3O3 [M(
35
Cl)-H]
-
 386.0713, found 
386.0708. 
 
4-(2-Chloro-6-fluorobenzoyl)-N-(4-(pyrrolidin-1-yl)pyridin-3-yl)-1H-pyrrole-2-
carboxamide, (310) 
 
To a solution of 4-(2-chloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (249) 
(100 mg, 0.37 mmol) in DCM (3.7 mL) was added 4-(pyrrolidin-1-yl)pyridin-3-amine 
(304) (76 mg, 0.56 mmol) followed by 2-chloro-1-methylpyridinium iodide (105 mg, 
0.41 mmol). The resulting solution was stirred at 42 °C for 72 h. Upon completion, the 
solvent removed in vacuo. The crude residue was dissolved in EtOAc (30 mL), washed 
with saturated aq. NaHCO3 (20 mL) and extracted with EtOAc (2 × 20 mL). The pooled 
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organic extracts were washed with brine (30 mL), dried over MgSO4 and concentrated in 
vacuo.  The crude yellow solid was purified by column chromatography (amine silica gel, 
EtOAc:MeOH, 1:0  95:5) to yield the title compound as an off-white solid (35 mg, 
23%); Rf = 0.31 (amine silica, EtOAc:MeOH – 95:5); m.p. 182.0-184.0 °C; 
λmax (EtOH)/nm 237.0; IR (neat) νmax/cm
-1
 3178, 3094, 2976, 2878, 1644, 1595, 1567, 
1531, 1513, 1497, 1446, 1429, 1394, 1383, 1294, 1228; 
1
H NMR (500 MHz, DMSO-d6) 
δ 1.84 (4H, t, J = 6.6 Hz, NCH2CH2), 3.37 (4H, t, J = 6.6 Hz, NCH2CH2), 6.59 (1H, d, 
J = 5.8 Hz, H-5”), 7.35 (1H, s, H-5), 7.43 – 7.36 (2H, m, H-3 and H-5’), 7.46 (1H, d, 
J = 8.1 Hz, H-3’), 7.57 (1H, ddd, J = 8.3, 8.1 and 6.2 Hz, H-4’), 7.92 (1H, s, H-2”), 8.03 
(1H, d, J = 5.8 Hz, H-6”), 9.82 (1H, s, CONHAr), 12.57 (1H, s, NH-pyrrole); 13C NMR 
(126 MHz, DMSO-d6) δ 25.0 (NCH2CH2), 48.8 (NCH2CH2), 109.1 (C-5”), 110.7 (C-3), 
114.9 (d, J = 21.5 Hz, C-5’), 117.8 (C-3”), 125.3 (C-2 or C-4), 125.8 (d, J = 3.4 Hz, C-3’), 
128.0 (d, J = 23.2 Hz, C-1’), 128.7 (C-2 or C-4), 129.2 (C-5), 130.4 (d, J = 6.1 Hz, C-2’), 
131.8 (d, J = 9.2 Hz, C-4’), 147.9 (C-6”), 149.9 (C-4”), 151.0 (C-2”), 158.6 (d, 
J = 247.0 Hz, C-6’), 159.8 (CONHAr), 183.8 (ArCO); 19F NMR (471 MHz, DMSO-d6) 
δ -114.3 (ArF); LRMS (ES+) m/z 413.4 [M(35Cl)+H]+, 415.4 [M(37Cl)+H]+; HRMS (NSI) 
calcd for C21H19ClFN4O2 [M(
35
Cl)+H]
+
 413.1175, found 413.1170. 
 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(4-methylpyridin-3-yl)-1H-pyrrole-2-
carboxamide, (311) 
 
Compound 311 was synthesised according to general procedure U, using the following 
reagents: 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250) (100 mg, 
0.33 mmol), 3-amino-4-methylpyridine (89 mg, 0.83 mmol), phosphorus trichloride 
(29 µL, 45 mg, 0.33 mmol) and acetonitrile (1.65 mL). The crude product was purified by 
column chromatography (silica gel, petrol:EtOAc, 1:0  0:1) to yield the title compound 
as a pale yellow solid (81 mg, 62%); Rf = 0.33 (EtOAc, 100%); m.p. 224.0-226.0 °C; 
λmax (EtOH)/nm 284.2; IR (neat) νmax/cm
-1
 1663, 1634, 1596, 1564, 1520, 1448, 1419, 
1386, 1316, 1286; 
1
H NMR (500 MHz, DMSO-d6) δ 2.25 (3H, s, ArCH3), 7.32 (1H, d, 
J = 4.9 Hz, H-5”), 7.49 (1H, s, H-3), 7.52 (1H, dd, J = 8.8, 1.3 Hz, H-5’), 7.60 (1H, s, 
H-5), 7.78 (1H, dd, J = 8.8, 8.4 Hz, H-4’), 8.32 (1H, d, J = 4.9 Hz, H-6”), 8.46 (1H, s, 
H-2”), 9.95 (1H, s, CONHAr), 12.74 (1H, s, NH-pyrrole); 13C NMR (126 MHz, DMSO-d6) 
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δ 17.4 (ArCH3), 111.2 (C-3), 119.3 (d, J = 18.0 Hz, C-3’), 124.8 (C-2 or C-4), 125.3 
(C-5”), 126.9 (d, J = 3.8 Hz, C-5’), 128.4 (C-2 or C-4), 129.1 (d, J = 19.4 Hz, C-1’), 129.2 
(d, J = 8.9 Hz, C-6’), 130.1 (C-5), 131.8 (C-4’), 132.8 (C-4”), 142.9 (C-3”), 146.7 (C-6”), 
147.4 (C-2”), 153.9 (d, J = 248.5 Hz, C-2’), 158.8 (CONHAr), 182.6 (ArCO); 19F NMR 
(471 MHz, DMSO-d6) δ -116.7 (ArF); LRMS (ES
+
) m/z 392.1 [M(
35
Cl
35
Cl)+H]
+
, 394.1 
[M(
35
Cl
37
Cl)+H]
+
; HRMS (NSI) calcd for C18H13Cl2FN3O2 [M(
35
Cl
35
Cl)+H]
+
 392.0363, 
found 392.0369. 
 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(4-ethylpyridin-3-yl)-1H-pyrrole-2-carboxamide, 
(312) 
 
Compound 312 was synthesised according to general procedure U, using the following 
reagents: 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250) (100 mg, 
0.33 mmol), 2-ethylpyridin-3-amine (300) (101 mg, 0.83 mmol), phosphorus trichloride 
(29 µL, 45 mg, 0.33 mmol) and acetonitrile (1.65 mL). The crude product was purified by 
column chromatography (silica gel, petrol:EtOAc, 1:0  35:65) to yield the title 
compound as a white solid (65 mg, 48%); Rf = 0.30 (petrol:EtOAc, 2:8); 
m.p. 257.0-259.0 °C; λmax (EtOH)/nm 238.4, 285.0; IR (neat) νmax/cm
-1
 3254, 3117, 2971, 
2883, 1664, 1636, 1564, 1520, 1480, 1449, 1420, 1387, 1315, 1288; 
1
H NMR (500 MHz, 
DMSO-d6) δ 1.14 (3H, t, J = 7.5 Hz, ArCH2CH3), 2.62 (2H, q, J = 7.5 Hz, ArCH2CH3), 
7.35 (1H, d, J = 5.0 Hz, H-5”), 7.49 (1H, s, H-3), 7.52 (1H, dd, J = 8.9, 1.3 Hz, H-5’), 7.59 
(1H, s, H-5), 7.78 (1H, dd, J = 8.9, 8.4 Hz, H-4’), 8.38 (1H, d, J = 5.0 Hz, H-6”), 8.43 (1H, 
s, H-2”), 9.94 (1H, s, CONHAr), 12.73 (1H, s, NH-pyrrole); 13C NMR (126 MHz, 
DMSO-d6) δ 13.0 (ArCH2CH3), 23.2 (ArCH2CH3), 111.1 (C-3), 119.3 (d, J = 18.1 Hz, 
C-3’), 123.3 (C-5”), 124.8 (C-2 or C-4), 126.9 (d, J = 3.7 Hz, C-5’), 128.4 (C-2 or C-4), 
129.2 (d, J = 23.1 Hz, C-1’), 129.2 (d, J = 5.1 Hz, C-6’), 130.1 (C-5), 131.8 (C-4’), 132.0 
(C-3”), 147.3 (C-6”), 148.2 (C-2”), 148.6 (C-4”), 153.9 (d, J = 248.5 Hz, C-2’), 159.1 
(CONHAr), 182.6 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -116.7 (ArF); LRMS (ES
-
) 
m/z 404.2 [M(
35
Cl
35
Cl)-H]
-
, 406.2 [M(
35
Cl
37
Cl)-H]
-
; HRMS (NSI) calcd for 
C19H15Cl2FN3O2 [M(
35
Cl
35
Cl)+H]
+
 406.0520, found 406.0515. 
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4-(3,6-Dichloro-2-fluorobenzoyl)-N-(4-propylpyridin-3-yl)-1H-pyrrole-2-
carboxamide, (313) 
 
Compound 313 was synthesised according to general procedure U, using the following 
reagents: 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250) (60 mg, 
0.20 mmol), 4-propylpyridin-3-amine (301) (68 mg, 0.50 mmol), phosphorus trichloride 
(17 µL, 27 mg, 0.20 mmol) and acetonitrile (1.0 mL). The crude product was purified by 
column chromatography (silica gel, petrol:EtOAc, 1:0  3:7) to yield the title compound 
as an off-white solid (34 mg, 41%); Rf = 0.29 (petrol:EtOAc, 3:7); m.p. 250.0-252.0 °C; 
λmax (EtOH)/nm 237.8, 280.6; IR (neat) νmax/cm
-1
 3254, 2964, 2929, 2876, 1663, 1634, 
1597, 1565, 1518, 1448, 1419, 1387, 1313, 1226; 
1
H NMR (500 MHz, DMSO-d6) δ 0.86 
(3H, t, J = 7.3 Hz, ArCH2CH2CH3), 1.57 (2H, tq, J = 7.7, 7.3 Hz, ArCH2CH2CH3), 2.59 
(2H, t, J = 7.7 Hz, ArCH2CH2CH3), 7.32 (1H, d, J = 5.0 Hz, H-5”), 7.49 (1H, s, H-3), 7.52 
(1H, dd, J = 8.8, 1.4 Hz, H-5’), 7.59 (1H, s, H-5), 7.78 (1H, dd, J = 8.8, 8.4 Hz, H-4’), 8.37 
(1H, d, J = 5.0 Hz, H-6”), 8.44 (1H, s, H-2”), 9.93 (1H, s, CONHAr), 12.73 (1H, s, 
NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 13.8 (ArCH2CH2CH3), 21.6 
(ArCH2CH2CH3), 32.1 (ArCH2CH2CH3), 111.1 (C-3), 119.3 (d, J = 17.9 Hz, C-3’), 124.1 
(C-5”), 124.8 (C-2 or C-4), 126.9 (d, J = 3.8 Hz, C-5’), 128.4 (C-2 or C-4), 129.2 (d, 
J = 22.6 Hz, C-1’), 129.2 (d, J = 5.3 Hz, C-6’), 130.1 (C-5), 131.8 (C-4’), 132.2 (C-3”), 
147.1 (C-4” or C-6”), 147.1 (C-4” or C-6”), 148.4 (C-2”), 153.9 (d, J = 248.5 Hz, C-2’), 
159.1 (CONHAr), 182.6 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -116.7 (ArF); LRMS 
(ES
-
) m/z 418.3 [M(
35
Cl
35
Cl)-H]
-
, 420.3 [M(
35
Cl
37
Cl)-H]
-
; HRMS (NSI) calcd for 
C20H17Cl2FN3O2 [M(
35
Cl
35
Cl)+H]
+
 420.0676, found 420.0671. 
 
  
326 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(4-methoxypyridin-3-yl)-1H-pyrrole-2-
carboxamide, (314) 
 
Compound 314 was synthesised according to general procedure Y, using the following 
reagents: 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250) (150 mg, 
0.50 mmol), triethylamine (173 µL, 126 mg, 1.24 mmol), 2-chloro-1-methylpyridinium 
iodide (140 mg, 0.55 mmol), 4-methoxypyridin-3-amine (302) (77 mg, 0.62 mmol) and 
DCM (5 mL). The crude yellow solid was purified by column chromatography (amine 
silica gel, petrol:EtOAc, 1:0  15:85) to yield the title compound as a pale yellow solid 
(10 mg, 5%); Rf = 0.27 (amine silica, petrol:EtOAc, 15:85); m.p. 174.0-176.0 °C; 
λmax (EtOH)/nm 248.0, 289.0; IR (neat) νmax/cm
-1
 2981, 2889, 1649, 1595, 1558, 1530, 
1490, 1448, 1422, 1392, 1301, 1239; 
1
H NMR (500 MHz, DMSO-d6) δ 3.89 (3H, s, 
ArOCH3), 7.16 (1H, d, J = 5.6 Hz, H-5”), 7.48 (1H, s, H-3), 7.52 (1H, d, J = 8.7 Hz, H-5’), 
7.59 (1H, s, H-5), 7.78 (1H, dd, J = 8.7, 8.3 Hz, H-4’), 8.33 (1H, d, J = 5.6 Hz, H-6”), 8.53 
(1H, s, H-2”), 9.68 (1H, s, CONHAr), 12.71 (1H, s, NH-pyrrole); 13C NMR (126 MHz, 
DMSO-d6) δ 55.8 (ArOCH3), 107.4 (C-5”), 111.5 (C-3), 119.3 (d, J = 18.0 Hz, C-3’), 
122.9 (C-3”), 124.7 (C-2 or C-4), 126.9 (d, J = 3.7 Hz, C-5’), 128.4 (C-2 or C-4), 129.2 (d, 
J = 4.8 Hz, C-6’), 129.2 (d, J = 23.4 Hz, C-1’), 129.8 (C-5), 131.8 (C-4’), 147.2 (C-2”), 
148.4 (C-6”), 153.8 (d, J = 248.3 Hz, C-2’), 158.7 (CONHAr or C-4”), 158.8 (CONHAr or 
C-4”), 182.6 (ArCO); 19F NMR (471 MHz, DMSO-d6) δ -116.7 (ArF); LRMS (ES
-
) m/z 
406.2 [M(
35
Cl
35
Cl)-H]
-
, 408.2 [M(
35
Cl
37
Cl)-H]
-
; HRMS (NSI) calcd for C18H13Cl2FN3O3 
[M(
35
Cl
35
Cl)+H]
+
 408.0313, found 408.0309. 
 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(4-ethoxypyridin-3-yl)-1H-pyrrole-2-
carboxamide, (315) 
 
To a solution of 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250) 
(100 mg, 0.33 mmol) in DCM (3.3 mL) was added 4-ethoxypyridin-3-amine (303) (57 mg, 
327 
0.41 mmol) followed by 2-chloro-1-methylpyridinium iodide (93 mg, 0.36 mmol). The 
resulting solution was stirred at 42 °C for 72 h. Upon completion, the solvent removed in 
vacuo. The crude residue was dissolved in EtOAc (30 mL), washed with saturated aq. 
NaHCO3 (20 mL) and extracted with EtOAc (2 × 20 mL). The pooled organic extracts 
were washed with brine (30 mL), dried over MgSO4 and concentrated in vacuo.  The crude 
yellow solid was purified by column chromatography (amine silica gel, petrol:EtOAc, 
1:0  85:15) to yield the title compound as an off-white solid (18 mg, 13%); Rf = 0.29 
(amine silica, petrol:EtOAc, 1:9); m.p. 269.0-271.0 °C; λmax (EtOH)/nm 247.4, 290.0; 
IR (neat) νmax/cm
-1
 3426, 2919, 1679, 1652, 1594, 1532, 1489, 1450, 1430, 1321, 1307, 
1240; 
1
H NMR (500 MHz, DMSO-d6) δ 1.34 (3H, t, J = 6.9 Hz, ArOCH2CH3), 4.18 (2H, 
q, J = 6.9 Hz, ArOCH2CH3), 7.14 (1H, d, J = 5.7 Hz, H-5”), 7.47 (1H, s, H-3), 7.51 (1H, 
dd, J = 8.7, 1.3 Hz, H-5’), 7.58 (1H, s, H-5), 7.78 (1H, dd, J = 8.7, 8.4 Hz, H-4’), 8.30 (1H, 
d, J = 5.7 Hz, H-6”), 8.53 (1H, s, H-2”), 9.61 (1H, s, CONHAr), 12.71 (1H, s, 
NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 14.2 (ArOCH2CH3), 64.0 (ArOCH2CH3), 
108.0 (C-5”), 111.3 (C-3), 119.3 (d, J = 18.2 Hz. C-3’), 123.0 (C-3”), 124.7 (C-2 or C-4), 
126.9 (d, J = 3.7 Hz, C-5’), 128.5 (C-2 or C-4), 129.2 (d, J = 23.1 Hz, C-1’), 129.2 (d, 
J = 5.3 Hz, C-6’), 130.0 (C-5), 131.8 (C-4’), 147.3 (C-2”), 148.2 (C-6”), 153.8 (d, 
J = 248.1 Hz, C-2’), 158.0 (CONHAr or C-4”), 158.6 (CONHAr or C-4”), 182.6 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -116.7 (ArF); LRMS (ES
-
) m/z 420.2 [M(
35
Cl
35
Cl)-H]
-
, 
422.2 [M(
35
Cl
37
Cl)-H]
-
; HRMS (NSI) calcd for C19H15Cl2FN3O3 [M(
35
Cl
35
Cl)+H]
+
 
422.0469, found 422.0465. 
 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(4-(pyrrolidin-1-yl)pyridin-3-yl)-1H-pyrrole-2-
carboxamide, (316) 
 
To a solution of 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250) 
(100 mg, 0.33 mmol) in DCM (3.3 mL) was added 4-(pyrrolidin-1-yl)pyridin-3-amine 
(304) (67 mg, 0.41 mmol) followed by 2-chloro-1-methylpyridinium iodide (93 mg, 
0.36 mmol). The resulting solution was stirred at 42 °C overnight. Upon completion, the 
solvent removed in vacuo. The crude residue was dissolved in EtOAc (30 mL), washed 
with saturated aq. NaHCO3 (20 mL) and extracted with EtOAc (2 × 20 mL). The pooled 
organic extracts were washed with brine (30 mL), dried over MgSO4 and concentrated in 
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vacuo. The crude yellow solid was purified by column chromatography (amine silica gel, 
EtOAc:MeOH, 1:0  95:5) to yield the title compound as an off-white solid (50 mg, 
34%); Rf = 0.32 (amine silica, EtOAc:MeOH, 95:5); m.p. 242.0-244.0 °C; λmax (EtOH)/nm 
229.4; IR (neat) νmax/cm
-1
 3227, 2981, 2964, 2883, 2837, 1659, 1634, 1603, 1505, 1485, 
1428, 1386, 1320, 1245; 
1
H NMR (500 MHz, DMSO-d6) δ 1.84 (4H, t, J = 6.6 Hz, 
NCH2CH2), 3.37 (4H, t, J = 6.6 Hz, NCH2CH2), 6.59 (1H, d, J = 5.9 Hz, H-5”), 7.43 (1H, 
s, H-3), 7.51 (1H, dd, J = 8.7, 1.3 Hz, H-5’), 7.53 (1H, s, H-5), 7.77 (1H, dd, J = 8.7, 
8.3 Hz, H-4’), 7.93 (1H, s, H-2”), 8.03 (1H, d, J = 5.9 Hz, H-6”), 9.83 (1H, s, CONHAr), 
12.66 (1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 25.0 (NCH2CH2), 48.8 
(NCH2CH2), 109.1 (C-5”), 110.6 (C-3), 117.7 (C-3”), 119.3 (d, J = 18.2 Hz, C-3’), 124.8 
(C-2 or C-4), 126.8 (d, J = 3.7 Hz, C-5’), 128.9 (C-2 or C-4), 129.2 (d, J = 22.8 Hz, C-1’), 
129.2 (d, J = 5.3 Hz, C-6’), 130.1 (C-5), 131.8 (C-4’), 147.9 (C-6”), 149.9 (C-4”), 151.0 
(C-2”), 153.9 (d, J = 248.6 Hz, C-2’), 159.8 (CONHAr), 182.5 (ArCO); 19F NMR 
(471 MHz, DMSO-d6) δ -116.6 (ArF); LRMS (ES
-
) m/z 445.2 [M(
35
Cl
35
Cl)-H]
-
, 447.2 
[M(
35
Cl
37
Cl)-H]
-
; HRMS (NSI) calcd for C21H16Cl2FN4O2 [M(
35
Cl
35
Cl)-H]
-
 445.0640, 
found 445.0633. 
 
Methyl 4-(6-chloro-2-fluoro-3-methoxybenzoyl)-1H-pyrrole-2-carboxylate, (336) 
 
Compound 336 was synthesised according to general procedure P and Q, using the 
following reagents: 6-chloro-2-fluoro-3-methoxybenzoic acid (332) (10.0 g, 48.9 mmol), 
thionyl chloride (5.32 mL, 8.73 g, 73.3 mmol), N,N-dimethylformamide (0.38 mL, 0.36 g, 
4.89 mmol), THF (49 mL), methyl 1H-pyrrole-2-carboxylate (3.06 g, 24.4 mmol), 
aluminum trichloride (8.15 g, 61.1 mmol) and DCM (60 mL). The crude product was 
purified by column chromatography (silica gel, petrol:EtOAc, 1:0  7:3) to yield the title 
compound as a white solid (6.15 g, 81%); Rf = 0.29 (petrol:EtOAc, 7:3); m.p. 
124.0-126.0 °C; λmax (EtOH)/nm 282.0; IR (neat) νmax/cm
-1
 3287, 3238, 2957, 2843, 1730, 
1696, 1656, 1630, 1561, 1473, 1434, 1390, 1268; 
1
H NMR (500 MHz, DMSO-d6) δ 3.79 
(3H, s, OCH3), 3.89 (3H, s, OCH3), 7.00 (1H, s, H-3), 7.31 (1H, dd, J = 8.9, 8.9 Hz, H-4’), 
7.36 (1H, dd, J = 8.9, 1.3 Hz, H-5’), 7.54 (1H, s, H-5), 12.89 (1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 51.7 (OCH3), 56.5 (OCH3), 114.6 (C-3), 115.3 (d, 
J = 1.8 Hz, C-4’), 120.1 (d, J = 4.8 Hz, C-6’), 124.6 (C-2 or C4), 125.3 (C-2 or C4), 125.6 
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(d, J = 3.8 Hz, C-5’)), 128.1 (d, J = 19.8 Hz, C-1’), 130.2 (C-5), 146.4 (d, J = 10.5 Hz, 
C-3’), 147.9 (d, J = 247.4 Hz, C-2’), 160.3 (CO2Me), 183.4 (ArCO); 
19
F NMR (471 MHz, 
DMSO-d6) δ -136.2 (ArF); LRMS (ES
-
) m/z 310.2 [M(
35
Cl)-H]
-
, 312.2 [M(
37
Cl)-H]
-
; 
HRMS (NSI) calcd for C14H12ClFNO4 [M(
35
Cl)+H]
+
 312.0433, found 312.0434. 
 
Methyl 4-(2-chloro-6-fluoro-3-methoxybenzoyl)-1H-pyrrole-2-carboxylate, (337) 
 
Compound 337 was synthesised according to general procedure P and Q, using the 
following reagents: 2-chloro-6-fluoro-3-methoxybenzoic acid (333) (2.0 g, 9.78 mmol), 
thionyl chloride (1.06 mL, 14.7 mmol), N,N-dimethylformamide (76 μL, 0.98 mmol), THF 
(9.8 mL), aluminum trichloride (1.64 g, 12.2 mmol), methyl 1H-pyrrole-2-carboxylate 
(0.61 g, 4.90 mmol) and DCM (12.2 mL). The crude product was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  7:3) to yield the title compound as a 
white solid (906 mg, 60%); Rf = 0.30 (petrol:EtOAc, 7:3); m.p. 133.5-135.5 °C; 
λmax (EtOH)/nm 284.4; IR (neat) νmax/cm
-1
 3279, 1707, 1655, 1560; 
1
H NMR (500 MHz, 
DMSO-d6) δ 3.79 (3H, s, CO2CH3), 3.89 (3H, s, ArOCH3), 6.99 (1H, d, J = 1.8 Hz, H-3), 
7.31 – 7.24 (1H, m, H-5’), 7.39 – 7.31 (1H, m, H-4’), 7.52 (1H, d, J = 1.8 Hz, H-5), 12.87 
(1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 51.7 (CO2CH3), 56.7 (ArOCH3), 
113.8 (d, J = 8.5 Hz, C-5’), 114.6 (C-2), 115.2 (C-4’), 118.0 (d, J = 6.5 Hz, C-2’), 124.5 
(C-1), 125.3 (C-3), 128.7 (d, J = 24.4 Hz, C-1’), 130.1 (C-4), 151.5 (d, J = 2.3 Hz, C-3’), 
152.0 (d, J = 238.5 Hz, C-6’), 160.3 (CO2Me), 183.6 (ArCO); 
19
F NMR (471 MHz, 
DMSO) δ -125.9 (ArF); LRMS (ES+) m/z 312.2 [M(35Cl)+H]+ , 314.3 [M(37Cl)+H]+; 
HRMS (NSI) calcd for C14H12ClFNO4 [M(
35
Cl)+H]
+
 312.0433, found 312.0437. 
 
4-(6-Chloro-2-fluoro-3-methoxybenzoyl)-1H-pyrrole-2-carboxylic acid, (338) 
 
Compound 338 was synthesised according to general procedure R, using the following 
reagents: methyl 4-(6-chloro-2-fluoro-3-methoxybenzoyl)-1H-pyrrole-2-carboxylate (336) 
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(4.50 g, 14.4 mmol), 2 M aq. lithium hydroxide (108 mL, 216 mmol) and THF (115 mL). 
The crude off-white solid (4.15 g, 97%) was used in the next step without further 
purification; Rf = 0.19 (petrol:EtOAc:AcOH, 50:49.7:0.3); m.p. 161.0-163.0 °C; 
λmax (EtOH)/nm 230.4, 289.2; IR (neat) νmax/cm
-1
 3275, 3128, 1648, 1555, 1472, 1433, 
1386, 1271, 1230; 
1
H NMR (500 MHz, DMSO-d6) δ 3.89 (3H, s, ArOCH3), 6.95 (1H, s, 
H-3), 7.31 (1H, dd, J = 8.8, 8.8 Hz, H-4’), 7.36 (1H, d, J = 8.8 Hz, H-5’), 7.46 (1H, s, H-
5), 12.69 (1H, s, NH-pyrrole), 12.85 (1H, s, CO2H); 
13
C NMR (126 MHz, DMSO-d6) 
δ 56.5 (ArOCH3), 114.2 (C-3), 115.2 (d, J = 1.8 Hz, C-4’), 120.1 (d, J = 4.8 Hz, C-6’), 
125.2 (C-2 or C-4), 125.5 (d, J = 3.6 Hz, C-5’), 125.9 (C-2 or C-4), 128.3 (d, J = 19.7 Hz, 
C-1’), 129.8 (C-5), 146.4 (d, J = 10.5 Hz, C-3’), 147.9 (d, J = 247.5 Hz, C-2’), 161.3 
(CO2H), 183.4 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -136.2; LRMS (ES
-
) m/z 296.1 
[M(
35
Cl)-H]
-
, 298.1 [M(
37
Cl)-H]
-
; HRMS (NSI) calcd for C13H10ClFNO4 [M(
35
Cl)+H]
+
 
298.0278, found 298.0277. 
 
4-(2-Chloro-6-fluoro-3-methoxybenzoyl)-1H-pyrrole-2-carboxylic acid, (339) 
 
Compound 339 was synthesised according to general procedure R, using the following 
reagents: methyl 4-(2-chloro-6-fluoro-3-methoxybenzoyl)-1H-pyrrole-2-carboxylate (337) 
(333 mg, 1.07 mmol), 2 M aq. lithium hydroxide (8.0 mL, 16.0 mmol) and THF (8.6 mL). 
No purification required. The crude white solid (294 mg, 93 %) was used in the next step 
without further purification; Rf = 0.32 (petrol:EtOAc:AcOH, 50:49.7:0.3); 
m.p. 226.0-228.0 °C; λmax (EtOH)/nm 266.8; IR (neat) νmax/cm
-1
 3250, 2360, 1676, 1648;
 
1
H NMR (500 MHz, DMSO-d6) δ 3.88 (3H, s, ArOCH3), 6.92 (1H, s, H-3), 7.27 (1H, dd, 
J = 9.0, 5.0 Hz, H-5’), 7.33 (1H, dd, J = 9.0, 9.0 Hz, H-4’), 7.40 (1H, s, H-5), 12.60 (1H, s, 
NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 56.8 (ArOCH3), 113.7 (C-5’), 113.8 
(C-3), 115.0 (d, J = 22.7 Hz, C-4’), 118.1 (d, J = 6.6 Hz, C-1’), 125.1 (C-2 or C-4), 128.8 
(C-2 or C-4), 129.0 (C-5), 129.4 (C-2’), 151.5 (d, J = 2.4 Hz, C-3’), 153.4 – 150.7 (m, 
C-6’), 161.9 (CO2H), 183.7 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -141.4 (ArF); 
LRMS (ES
+
) m/z 298.2 [M(
35
Cl)+H]
+ 
, 300.3 [M(
37
Cl)+H]
+
; HRMS (NSI) calcd for 
C13H8ClFNO4 [M(
35
Cl)-H]
-
 296.0131, found 296.0129. 
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4-(6-Chloro-2-fluoro-3-methoxybenzoyl)-N-(1-methylpiperidin-4-yl)-1H-pyrrole-2-
carboxamide, (340) 
 
Compound 340 was synthesised according to general procedure Z, using the following 
reagents: 4-(6-chloro-2-fluoro-3-methoxybenzoyl)-1H-pyrrole-2-carboxylic acid (338) 
(100 mg, 0.34 mmol), carbonyl diimidazole (109 mg, 0.67 mmol), THF (1.68 mL) and 
N-methyl-4-aminopiperidine (96 mg, 0.84 mmol). The crude product was purified by 
column chromatography (amine silica gel, petrol:EtOAc, 1:0  0:1) to yield the title 
compound as a white solid (85 mg, 64 %); Rf = 0.23 (amine silica, EtOAc, 100%); 
m.p. 206.0-208.0 °C; λmax (EtOH)/nm 286.0; IR (neat) νmax/cm
-1
 3358, 3184, 1619, 1574, 
1540; 
1
H NMR (500 MHz, DMSO-d6) δ 1.52 (2H, tt, J = 12.9, 6.5 Hz, H-3”), 1.72 (2H, d, 
J = 10.7 Hz, H-3”), 1.91 (2H, t, J = 11.6 Hz, H-2”), 2.14 (3H, s, NCH3), 2.74 (2H, d, 
J = 11.0 Hz, H-2”), 3.75 – 3.54 (1H, m, H-4”), 3.89 (3H, s, ArOCH3), 7.19 (1H, s, H-3), 
7.40 – 7.26 (3H, m, H-5 and H-4’ and H-5’), 8.09 (1H, d, J = 8.2 Hz, CONH), 12.39 (1H, 
s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 31.6 (C-3”), 45.9 (NCH3), 46.0 (C-4”), 
54.5 (C-2”), 56.4 (ArOCH3), 110.0 (C-3), 115.0 (d, J = 1.8 Hz, C-4’), 120.2 (d, J = 4.9 Hz, 
C-6’), 124.9 (C-2 or C-4), 125.5 (d, J = 3.7 Hz, C-5’), 128.2 (C-5), 128.6 (d, J = 19.9 Hz, 
C-1’), 128.9 (C-2 or C-4), 146.4 (d, J = 10.6 Hz, C-3’), 147.9 (d, J = 246.8 Hz, C-2’), 
159.1 (CONH), 183.6 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -136.2 (ArF); 
LRMS (ES
+
) m/z 394.4 [M(
35
Cl)+H]
+ 
, 396.4 [M(
37
Cl)+H]
+
; HRMS (NSI) calcd for 
C19H22ClFN3O3 [M(
35
Cl)+H]
+
 394.1328, found 394.1322. 
 
4-(6-Chloro-2-fluoro-3-methoxybenzoyl)-N-(pyridin-3-yl)-1H-pyrrole-2-carboxamide, 
(341) 
 
Compound 341 was synthesised according to general procedure U, using the following 
reagents: 4-(6-chloro-2-fluoro-3-methoxybenzoyl)-1H-pyrrole-2-carboxylic acid (338) 
(100 mg, 0.34 mmol), 3-aminopyridine (79 mg, 0.84 mmol), phosphorus trichloride 
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(30 μL, 0.34 mmol) and acetonitrile (1.70 mL).  The crude product was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  0:1) to yield the title compound as a 
white solid (14 mg, 56%); Rf = 0.16 (EtOAc, 100%); m.p. 234.5-236.5 °C; λmax (EtOH)/nm 
293.2; IR (neat) νmax/cm
-1
 3294, 1661, 1639, 1603, 1555, 1537; 
1
H NMR (500 MHz, 
DMSO-d6) δ 3.90 (3H, s, ArOCH3), 7.33 (1H, dd, J = 9.1, 9.1 Hz, H-4’), 7.43 – 7.36 (2H, 
m, H-5’ and H-5”), 7.49 (2H, brs, H-3 and H-5), 8.13 (1H, d, J = 8.2 Hz, H-4”), 8.29 (1H, 
d, J = 4.8 Hz, H-6”), 8.89 (1H, s, H-2”), 10.24 (1H, s, CONHAr), 12.71 (1H, s, 
NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 56.5 (ArOCH3), 111.6 (C-3), 115.2 
(C-4’), 120.2 (d, J = 4.8 Hz, C-6’), 123.6 (C-5”), 125.2 (C-2 or C-4), 125.6 (d, J = 3.6 Hz, 
C-5’), 127.0 (C-4”), 128.2 (C-2 or C-4), 128.4 (d, J = 20.4 Hz, C-1’), 129.5 (C-5), 135.5 
(C-3”), 141.6 (C-2”), 144.4 (C-6”), 146.5 (d, J = 10.5 Hz, C-3’), 148.0 (d, J = 247.1 Hz, 
C-2’), 158.7 (CONHAr), 183.7 (ArCO); 19F NMR (471 MHz, DMSO-d6) δ -136.14 (ArF); 
LRMS (ES
+
) m/z 374.3 [M(
35
Cl)+H]
+ 
, 376.3 [M(
37
Cl)+H]
+
; HRMS (NSI) calcd for 
C18H14ClFN3O3 [M(
35
Cl)+H]
+
 374.0702, found 374.0701. 
 
4-(6-Chloro-2-fluoro-3-methoxybenzoyl)-N-(pyrimidin-5-yl)-1H-pyrrole-2-
carboxamide, (342) 
 
Compound 342 was synthesised according to general procedure U, using the following 
reagents: 4-(6-chloro-2-fluoro-3-methoxybenzoyl)-1H-pyrrole-2-carboxylic acid (338) 
(100 mg, 0.34 mmol), 5-aminopyrimidine (80 mg, 0.84 mmol), phosphorus trichloride 
(30 μL, 0.34 mmol) and acetonitrile (1.70 mL). The crude product was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  2:8) to yield the title compound as a 
white solid (21 mg, 17%); Rf = 0.62 (EtOAc, 100%); m.p. 162.5-164.5 °C; λmax (EtOH)/nm 
290.4; IR (neat) νmax/cm
-1
 3731, 3122, 2925, 1642, 1578, 1531; 
1
H NMR (500 MHz, 
DMSO-d6) δ 3.90 (3H, s, ArOCH3), 7.34 (1H, d, J = 8.7 Hz, H-4’), 7.38 (1H, s, H-5’), 7.51 
(2H, brs, H-3 and H-5), 8.91 (1H, s, H-2”), 9.12 (2H, s, H-4”, 6”), 10.43 (1H, s, CONHAr), 
12.80 (1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 56.5 (ArOCH3), 112.2 
(C-3), 115.2 (C-4’), 120.2 (d, J = 4.5 Hz, C-3’), 125.3 (C-2 or C-4), 125.6 (d, J = 3.7 Hz, 
C-5’), 127.7 (C-2 or C-4), 128.4 (d, J = 20.1 Hz, C-1’), 129.8 (C-5), 134.3 (C-5”), 146.5 
(d, J = 10.0 Hz, C-6’), 147.9 (C-4” and C-6”), 146.9 – 149.1 (m, C-2’), 153.2 (C-2’’), 
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158.9 (CONHAr), 183.7 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -136.1 (ArF); LRMS 
(ES
+
) m/z 375.3 [M(
35
Cl)+H]
+ 
, 377.3 [M(
37
Cl)+H]
+
; HRMS (NSI) calcd for 
C17H13ClFN4O3 [M(
35
Cl)+H]
+
 375.0655, found 375.0654. 
 
4-(2-Chloro-6-fluoro-3-methoxybenzoyl)-N-(1-methylpiperidin-4-yl)-1H-pyrrole-2-
carboxamide, (343) 
 
Compound 343 was synthesised according to general procedure Z, using the following 
reagents: 4-(2-chloro-6-fluoro-3-methoxybenzoyl)-1H-pyrrole-2-carboxylic acid (339) 
(60 mg, 0.20 mmol), carbonyl diimidazole (65 mg, 0.40 mmol), THF (1.0 mL) and 
N-methyl-4-aminopiperidine (58 mg, 0.50 mmol). The crude product was purified by 
column chromatography (silica gel, DCM:MeOH, 1:0  9:1) to yield the title compound 
as a white solid (40 mg, 51%); Rf = 0.10 (DCM:MeOH, 9:1); m.p. 232.0-234.0 °C; 
λmax (EtOH)/nm 288.8; IR (neat) νmax/cm
-1
 3206, 2943, 2848, 2791, 1663, 1631, 1572, 
1541; 
1
H NMR (500 MHz, DMSO-d6) δ 1.52 (2H, dd, J = 11.2, 4.3 Hz, H-3”), 1.73 (2H, d, 
J = 10.9 Hz, H-3”), 1.98 (2H, dd, J = 14.6, 9.0 Hz, H-2”), 2.18 (3H, s, NCH3), 2.64 – 2.93 
(2H, m, H-2”), 3.57 – 3.76 (1H, m, H-4”), 3.89 (3H, s, ArOCH3), 7.18 (1H, s, H-3), 
7.41 - 7.21 (3H, m, H-5 and H-4’ and H-5’), 8.10 (1H, d, J = 8.0 Hz, CONH), 12.37 (1H, s, 
NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 31.4 (C-3”), 45.8 (NCH3), 45.8 (C-4”), 
54.3 (C-2”), 56.7 (ArOCH3), 110.0 (C-3), 113.5 (d, J = 8.5 Hz, C-4’), 115.0 (d, 
J = 22.6 Hz, C-5’), 118.1 (d, J = 6.5 Hz, C-2’), 124.9 (C-2 or C-4), 128.0 (C-5), 128.9 (C-2 
or C-4), 129.1 (d, J = 24.6 Hz, C-1’), 151.4 (d, J = 2.4 Hz, C-3’), 152.0 (d, J = 239.1 Hz, 
C-6’), 159.1 (CONH), 183.8 (ArCO); 19F NMR (471 MHz, DMSO-d6) δ -125.82 (ArF); 
LRMS (ES
+
) m/z 394.3 [M(
35
Cl)+H]
+ 
, 396.3 [M(
37
Cl)+H]
+
; HRMS (NSI) calcd for 
C19H22ClFN3O3 [M(
35
Cl)+H]
+
 394.1328, found 394.1323. 
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4-(2-Chloro-6-fluoro-3-methoxybenzoyl)-N-(pyridin-3-yl)-1H-pyrrole-2-carboxamide, 
(344) 
 
Compound 344 was synthesised according to general procedure U, using the following 
reagents: 4-(2-chloro-6-fluoro-3-methoxybenzoyl)-1H-pyrrole-2-carboxylic acid (339) 
(100 mg, 0.34 mmol), 3-aminopyridine (79 mg, 0.84 mmol), phosphorus trichloride 
(30 μL, 0.34 mmol) and acetonitrile (1.70 mL). The crude product was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  0:1) to yield the title compound as a 
white solid (90 mg, 72%); Rf = 0.50 (EtOAc, 100%); m.p. 198.5-200.5 °C; λmax (EtOH)/nm 
293.0; IR (neat) νmax/cm
-1
 3238, 3123, 2967, 1638, 1601, 1536; 
1
H NMR (500 MHz, 
DMSO-d6) δ 3.90 (3H, s, ArOCH3), 7.42 – 7.16 (3H, m, H-4’, H-5’ and H-5”), 7.48 (2H, s, 
H-3 and H-5), 8.13 (1H, d, J = 8.4 Hz, H-4”), 8.29 (1H, d, J = 5.0 Hz, H-6”), 8.89 (1H, s, 
H-2”), 10.23 (1H, s, CONHAr), 12.69 (1H, s, NH-pyrrole); 13C NMR (126 MHz, 
DMSO-d6) δ 56.7 (ArOCH3), 111.6 (C-3), 113.6 (d, J = 8.5 Hz, C-4’), 115.1 (d, 
J = 23.1 Hz, C-5’), 118.1 (d, J = 6.3 Hz, C-2’), 123.6 (C-5”), 125.2 (C-2 or C-4), 127.0 
(C-4”), 128.1 (C-2 or C-4), 129.0 (d, J = 24.5 Hz, C-1’), 129.4 (C-5), 135.5 (C-3”), 141.6 
(C-2”), 144.4 (C-6”), 151.5 (d, J = 2.4 Hz, C-3’), 152.0 (d, J = 239.0 Hz, C-6’), 158.7 
(CONHAr), 183.8 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -125.7 (ArF); LRMS (ES
+
) 
m/z 374.3 [M(
35
Cl)+H]
+ 
, 376.3 [M(
37
Cl)+H]
+
; HRMS (NSI) calcd for C18H14ClFN3O3 
[M(
35
Cl)+H]
+
 374.0702, found 374.0703. 
 
4-(2-Chloro-6-fluoro-3-methoxybenzoyl)-N-(pyrimidin-5-yl)-1H-pyrrole-2-
carboxamide, (345) 
 
Compound 345 was synthesised according to general procedure U, using the following 
reagents: 4-(2-chloro-6-fluoro-3-methoxybenzoyl)-1H-pyrrole-2-carboxylic acid (339) 
(100 mg, 0.34 mmol), 5-aminopyrimidine (80 mg, 0.84 mmol), phosphorus trichloride 
(30 μL, 0.34 mmol) and acetonitrile (1.70 mL). The crude product was purified by column 
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chromatography (silica gel, petrol:EtOAc, 1:0  2:8) to yield the title compound as a 
white solid (28 mg, 22%); Rf = 0.62 (EtOAc, 100%); m.p. 147.0-149.0 °C; 
λmax (EtOH)/nm 291.4, IR (neat) νmax/cm
-1
 3733, 3239, 3123, 2981, 1637, 1583, 1529; 
1
H NMR (500 MHz, DMSO-d6) δ 3.90 (3H, s, ArOCH3), 7.30 (1H, dd, J = 9.0, 4.8 Hz, 
H-4’), 7.37 (1H, t, J = 9.0 Hz, H-5’), 7.44 – 7.50 (1H, m, H-3), 7.51 – 7.57 (1H, m, H-5), 
8.91 (1H, s, H-2”), 9.12 (2H, s, H-4”, 6”), 10.42 (1H, s, CONHAr), 12.79 (1H, s, 
NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 56.7 (ArOCH3), 112.2 (C-3), 113.7 (d, 
J = 8.3 Hz, C-4’), 115.1 (d, J = 22.8 Hz, C-5’), 118.1 (d, J = 6.6 Hz, C-2’), 125.3 (C-2 or 
C-4), 127.6 (C-2 or C-4), 128.9 (d, J = 24.5 Hz, C-1’), 129.7 (C-5), 134.3 (C-5”), 147.9 
(C-4”, 6”), 151.5 (d, J = 2.3 Hz, C-3’), 152.0 (d, J = 238.9 Hz, C-6’), 153.2 (C-2”), 158.8 
(CONHAr), 183.8 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -125.7 (s, ArF); LRMS 
(ES
+
) m/z 375.3 [M(
35
Cl)+H]
+ 
, 377.3 [M(
37
Cl)+H]
+
; HRMS (NSI) calcd for 
C17H13ClFN4O3 [M(
35
Cl)+H]
+
 375.0655, found 375.0655. 
 
1-Methyl-4-nitro-1H-pyrazole, (347) 
 
Dimethyl oxalate (10.4 g, 92.9 mmol) was added to 4-nitropyrazole (346) (7.0 g, 
61.9 mmol) and potassium tert-butoxide (11.0 g, 92.9 mmol) in N,N-dimethylformamide 
(100 mL). The resulting solution was stirred at 140 °C for 4 h. Upon completion, the 
solvent was removed in vacuo. The dark orange residue was dissolved in saturated aq. 
NaHCO3 (70 mL) and extracted with EtOAc (2 × 80 mL). The combined organic extracts 
were washed with brine (50 mL), dried over MgSO4 and concentrated in vacuo. The crude 
product was purified by column chromatography (silica gel, petrol:EtOAc, 1:0  65:35) to 
yield the title compound as a pale yellow solid (6.73 g, 85%); Rf = 0.40 (petrol:EtOAc, 
65:35); m.p. 91.5-93.5 °C; λmax (EtOH)/nm 271.8; IR (neat) νmax/cm
-1
 3111, 1552, 1527, 
1504, 1420, 1399, 1309; 
1
H NMR (500 MHz, DMSO-d6) δ 3.91 (3H, s, NCH3), 8.24 (1H, 
s, H-3), 8.85 (1H, s, H-5); 
13
C NMR (126 MHz, DMSO-d6) δ 39.6 (NCH3), 131.0 (C-5), 
134.8 (C-4), 135.5 (C-3); LRMS (ES
+
) m/z 128.1 [M+H]
+
; HRMS (APCI) calcd for 
C4H6N3O2 [M+H]
+
 128.0455, found 128.0451; 
1
H NMR and 
13
C NMR data were identical 
to literature data.
165
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1-Methyl-1H-pyrazol-4-amine, (348) 
 
Compound 348 was synthesised according to general procedure V, using the following 
reagents: 1-methyl-4-nitro-1H-pyrazole (347) (6.7 g, 5.27 mmol) and methanol (200 mL). 
The crude orange oil (5.07 g, 99%) was used in the next step without further purification; 
Rf = 0.12 (amine silica, EtOAc, 100%); λmax (EtOH)/nm 336.6; IR (neat) νmax/cm
-1
 3205, 
3109, 2940, 1655, 1591, 1520, 1439, 1403, 1376, 1349; 
1
H NMR (500 MHz, DMSO-d6) δ 
3.64 (3H, s, NCH3), 3.79 (2H, brs, ArNH2), 6.86 (1H, s, H-3), 6.97 (1H, s, H-5); 
13
C NMR 
(126 MHz, DMSO-d6) δ 38.4 (NCH3), 117.2 (C-5), 128.9 (C-3), 131.0 (C-4); LRMS (ES
+
) 
m/z 98.0 [M+H]
+
; HRMS (APCI) calcd for C4H8N3 [M+H]
+
 98.0713, found 98.0703. 
 
tert-Butyl(4-chloro-2-fluorophenoxy)dimethylsilane, (350) 
 
To 4-chloro-2-fluorophenol (349) (3.63 mL, 5.0 g, 34.1 mmol) and imidazole (2.79 g, 
40.9 mmol) in N,N-dimethylformamide (50 mL), cooled in an ice bath, was added tert-
butyldimethylsilyl chloride (6.17 g, 40.9 mmol) portionwise. Once dissolution of tert-
butyldimethylsilyl chloride was complete, the ice bath was removed and the reaction 
stirred at RT for 18 h. Upon completion, saturated aq. NaHCO3 (30 mL) was cautiously 
added and the mixture extracted with diethyl ether (3 × 50 mL). The combined organic 
extracts were washed with water (40 mL) and brine (40 mL), dried over MgSO4 and 
concentrated in vacuo to give the title compound as a clear liquid (8.21 g, 92%),which was 
used in the next step without further purification; Rf = 0.70 (petrol, 100%); λmax (EtOH)/nm 
275.0; IR (neat) νmax/cm
-1
 2955, 2931, 2888, 2859, 1605, 1580, 1494; 
1
H NMR (500 MHz, 
DMSO-d6) δ 0.18 (6H, s, Si(CH3)2), 0.95 (9H, s, C(CH3)3), 7.04 (1H, dd, J = 9.0, 9.0 Hz, 
H-6), 7.10 – 7.18 (1H, m, H-5), 7.43 (1H, dd, J = 10.7, 2.5 Hz, H-3); 13C NMR (126 MHz, 
DMSO-d6) δ -4.9 (Si(CH3)2), 18.0 (C(CH3)3), 25.3 (C(CH3)3), 117.0 (d, J = 22.6 Hz, C-3), 
123.2 (d, J = 2.3 Hz, C-6), 124.9 (d, J = 3.8 Hz, C-5), 125.1 (d, J = 9.1 Hz, C-4), 141.8 (d, 
J = 12.0 Hz, C-1), 153.3 (d, J = 246.3 Hz, C-2); 
19
F NMR (471 MHz, DMSO-d6) δ -129.2 
(ArF); LRMS (ES
+
) m/z 261.1 [M(
35
Cl)+H]
+
; HRMS (APCI) calcd for C12H19ClFOSi 
[M(
35
Cl)+H]
+
 260.0872, found 260.0868. 
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6-Chloro-2-fluoro-3-hydroxybenzoic acid, (351) 
 
Compound 351 was synthesised according to general procedure A’, using the following 
reagents: tert-butyl(4-chloro-2-fluorophenoxy)dimethylsilane (350) (6.0 g, 23.0 mmol), 
n-butyllithium (9.58 mL, 23.0 mmol) and THF (69 mL). The white solid (4.05 g, 92%) was 
used in the next step without further purification; Rf = 0.31 (petrol:EtOAc:AcOH, 
50:49.7:0.3; KMnO4); m.p. 134.0-136.0 °C; λmax (EtOH)/nm 284.8; IR (neat) νmax/cm
-1
 
3387, 1676, 1615, 1577, 1475, 1454, 1281; 
1
H NMR (500 MHz, DMSO-d6) δ 7.01 (1H, 
dd, J = 9.1, 8.8 Hz, H-4), 7.15 (1H, dd, J = 8.8, 1.5 Hz, H-5), 10.46 (1H, s, ArOH), 13.95 
(1H, s, ArCO2H); 
13
C NMR (126 MHz, DMSO-d6) δ 118.2 (d, J = 4.5 Hz, C-6), 119.0 (d, 
J = 3.7 Hz, C-4), 124.3 (d, J = 19.0 Hz, C-1), 125.3 (d, J = 3.6 Hz, C-5), 144.3 (d, 
J = 12.0 Hz, C-3), 147.4 (d, J = 246.5 Hz, C-2), 163.9 (ArCO2H); 
19
F NMR (471 MHz, 
DMSO-d6) δ -136.4 (ArF); LRMS (ES
-
) m/z 189.0 [M(
35
Cl)-H]
-
, 191.0 [M(
37
Cl)-H]
-
; 
HRMS (NSI) calcd for C7H3ClFO3 [M(
35
Cl)-H]
-
 188.9760, found 188.9757. 
 
Methyl 4-(6-chloro-2-fluoro-3-hydroxybenzoyl)-1H-pyrrole-2-carboxylate, (353) 
 
To a solution of 6-chloro-2-fluoro-3-hydroxybenzoic acid (351) (500 mg, 2.62 mmol) in 
THF (10 mL), cooled at 0 °C, was added thionyl chloride (286 μL, 468 mg, 3.94 mmol) 
and N,N-dimethylformamide (20 μL, 19 mg, 0.26 mmol). The resulting solution was 
stirred at 0 °C for 30 min and allowed to warm to RT. After 5 h, the solvent was removed 
in vacuo and crude residue dissolved in DCM (5 mL). The resulting solution was added to 
a suspension of aluminium trichloride (875 mg, 6.56 mmol) in DCM (10 mL), cooled at 
0 °C, followed by methyl 1H-pyrrole-2-carboxylate (328 mg, 2.62 mmol). The resulting 
solution was stirred at 0 °C for 30 min and allowed to warm to RT. After 20 h, the reaction 
mixture was cooled to 0 °C and quenched by cautious addition of 1 M aq. HCl (10 mL). 
The resulting solution was stirred at RT for 2 h. The reaction was then diluted with water 
(20 mL) and extracted with DCM (3 × 40 mL). The pooled organic extracts were washed 
with brine (50 mL), dried over MgSO4 and concentrated in vacuo. The crude yellow solid 
was purified by column chromatography (petrol:EtOAc, 1:0  55:45) to yield the title 
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compound as a white solid (351 mg, 45%); Rf = 0.30 (petrol:EtOAc, 55:45); 
m.p. 160.5-162.5 °C; λmax (EtOH)/nm 230.2, 282.8; IR (neat) νmax/cm
-1
 3212, 1700, 1646, 
1557, 1487, 1445, 1285; 
1
H NMR (500 MHz, DMSO-d6) δ 3.79 (3H, s, CO2CH3), 6.99 
(1H, s, H-3), 7.06 (1H, dd, J = 9.1, 8.8 Hz, H-4’), 7.19 (1H, dd, J = 8.8, 1.0 Hz, H-5’), 7.51 
(1H, s, H-5), 10.46 (1H, s, ArOH), 12.86 (1H, s, pyrrole-NH); 
13
C NMR (126 MHz, 
DMSO-d6) δ 51.7 (CO2CH3), 114.7 (C-3), 118.3 (d, J = 4.5 Hz, C-6’), 119.0 (d, J = 3.5 Hz, 
C-4’), 124.5 (C-2 or C-4), 125.4 (C-2 or C-4), 125.5 (d, J = 3.2 Hz, C-5’), 128.4 (d, 
J = 20.0 Hz, C-1’), 130.1 (C-5), 144.4 (d, J = 12.3 Hz, C-3’), 147.5 (d, J = 244.2 Hz, C-2’), 
160.3 (CO2CH3), 183.8 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -137.2 (ArF); 
LRMS (ES
+
) m/z 298.2 [M(
35
Cl)+H]
+
, 300.2 [M(
37
Cl)+H]
+
; HRMS (NSI) calcd for 
C13H10ClFNO4 [M(
35
Cl)+H]
+
 298.0277, found 298.0279. 
 
4-(6-Chloro-2-fluoro-3-hydroxybenzoyl)-1H-pyrrole-2-carboxylic acid, (354) 
 
Compound 354 was synthesised according to general procedure R, using the following 
reagents: methyl 4-(6-chloro-2-fluoro-3-hydroxybenzoyl)-1H-pyrrole-2-carboxylate (353) 
(140 mg, 0.47 mmol), 2 M aq. lithium hydroxide (3.5 mL, 7.05 mmol) and THF (3.8 mL). 
The crude white solid (124 mg, 93%) was used in the next step without further 
purification; Rf = 0.15 (petrol:EtOAc:AcOH, 50:49.7:0.3); m.p. 218.5-220.5 °C; 
λmax (EtOH)/nm 230.2, 282.8; IR (neat) νmax/cm
-1
 3346, 3113, 1689, 1627, 1578, 1558, 
1280; 
1
H NMR (500 MHz, DMSO-d6) δ 6.94 (1H, s, H-3), 7.06 (1H, dd, J = 9.1, 8.8 Hz, 
H-4’), 7.19 (1H, dd, J = 8.8, 1.2 Hz, H-5’), 7.43 (1H, s, H-5), 10.45 (1H, s, ArOH), 12.67 
(1H, s, NH-pyrrole), 12.90 (1H, s, CO2H); 
13
C NMR (126 MHz, DMSO-d6) δ 114.2 (C-3), 
118.3 (d, J = 4.6 Hz, C-6’), 118.9 (d, J = 3.4 Hz, C-4’), 125.3 (C-2 or C-4), 125.5 (d, 
J = 3.3 Hz, C-5’), 125.8 (C-2 or C-4), 128.6 (d, J = 20.0 Hz, C-1’), 129.6 (C-3), 144.3 (d, 
J = 12.1 Hz, C-3’), 147.5 (d, J = 244.1 Hz, C-2’), 161.3 (CO2H), 183.8 (ArCO); 
19
F NMR 
(471 MHz, DMSO-d6) δ -137.2 (ArF); LRMS (ES
-
) m/z 282.1 [M(
35
Cl)-H]
-
, 284.0 
[M(
37
Cl)-H]
-
; HRMS (ESI) calcd for C12H8ClFNO4 [M(
35
Cl)+H]
+
 284.0120, found 
284.0123. 
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4-(6-Chloro-2-fluoro-3-hydroxybenzoyl)-N-(pyridin-3-yl)-1H-pyrrole-2-carboxamide, 
(355) 
 
Compound 355 was synthesised according to general procedure U, using the following 
reagents: 4-(6-chloro-2-fluoro-3-hydroxybenzoyl)-1H-pyrrole-2-carboxylic acid (354) 
(100 mg, 0.35 mmol), 3-aminopyridine (83 mg, 0.88 mmol), phosphorus trichloride 
(32 µL, 48 mg, 0.35 mmol) and acetonitrile (1.75 mL). The crude product was purified by 
column chromatography (silica gel, DCM:MeOH, 1:0  95:5) to yield the title compound 
as a white solid (70 mg, 55%); Rf = 0.32 (EtOAc, 100%); No clear m.p., decomposition 
range 300-310 °C; λmax (EtOH)/nm 292.6; IR (neat) νmax/cm
-1
 3275, 1627, 1602, 1586, 
1557, 1535, 1421, 1281; 
1
H NMR (500 MHz, DMSO-d6) δ 7.05 (1H, dd, J = 9.1, 8.7 Hz, 
H-4’), 7.16 (1H, d, J = 8.7 Hz, H-5’), 7.38 (1H, dd, J = 8.3, 4.9 Hz, H-5”), 7.46 (2H, s, H-3 
and H-5), 8.11 – 8.17 (1H, m, H-4”), 8.29 (1H, dd, J = 4.9, 2.5 Hz, H-6”), 8.90 (1H, d, 
J = 2.5 Hz, H-2”), 10.32 (1H, s, CONHAr), 12.17 (2H, s, NH-pyrrole and ArOH); 
13
C NMR (126 MHz, DMSO-d6) δ 111.9 (C-3), 117.1 (d, J = 7.6 Hz, C-6’), 119.1 (d, 
J = 3.8 Hz, C-4’), 123.6 (C-5”), 125.3 (d, J = 3.2 Hz, C-5’), 125.4 (C-2 or C-4), 127.0 
(C-4”), 128.1 (C-2 or C-4), 128.6 (d, J = 20.0 Hz, C-1’), 129.2 (C-5), 135.6 (C-3”), 141.6 
(C-2”), 144.4 (C-6”), 145.8 (d, J = 10.3 Hz, C-3’), 147.9 (d, J = 243.4 Hz, C-2’), 158.8 
(CONHAr), 184.4 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -137.3 (ArF); LRMS (ES
-
) 
m/z 358.1 [M(
35
Cl)-H]
-
, 360.1 [M(
37
Cl)-H]
-
; HRMS (NSI) calcd for C17H12ClFN3O3 
[M(
35
Cl)+H]
+
 360.0546, found 360.0549. 
 
4-(6-Chloro-2-fluoro-3-hydroxybenzoyl)-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrole-2-
carboxamide, (356) 
 
Compound 356 was synthesised according to general procedure U, using the following 
reagents: 4-(6-chloro-2-fluoro-3-hydroxybenzoyl)-1H-pyrrole-2-carboxylic acid (254) 
(100 mg, 0.35 mmol), 1-methyl-1H-pyrazol-4-amine (348) (85 mg, 0.88 mmol), 
phosphorus trichloride (32 µL, 48 mg, 0.35 mmol) and acetonitrile (1.75 mL). The crude 
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product was purified by column chromatography (silica gel, DCM:MeOH, 1:0  96:4) to 
yield the title compound as a off-white solid (58 mg, 45%); Rf = 0.29 (DCM:MeOH, 95:5); 
No clear m.p., decomposition range 280-290 °C; λmax (EtOH)/nm 250.4; IR (neat) νmax/cm
-1
 
3330, 3186, 3123, 1622, 1595, 1569, 1543, 1396, 1368; 
1
H NMR (500 MHz, DMSO-d6) 
δ 3.81 (3H, s, NCH3), 7.07 (1H, dd, J = 9.0, 8.9 Hz, H-4’), 7.20 (1H, dd, J = 8.9, 1.4 Hz, 
H-5’), 7.27 (1H, s, H-3), 7.40 (1H, s, H-5), 7.49 (1H, s, H-5”), 7.94 (1H, s, H-3”), 10.24 
(1H, s, CONHAr), 10.48 (1H, s, ArOH), 12.54 (1H, s, NH-pyrrole); 
13
C NMR (126 MHz, 
DMSO-d6) δ 38.7 (NCH3), 110.4 (C-3), 118.3 (d, J = 4.6 Hz, C-6’), 118.9 (d, J = 3.6 Hz, 
C-4’), 121.2 (C-4”), 121.4 (C-3”), 125.2 (C-2 or C-4), 125.5 (d, J = 3.5 Hz, C-5’), 128.3 
(C-2 or C-4), 128.5 (C-5), 128.8 (d, J = 20.2 Hz, C-1’), 129.9 (C-5”), 144.4 (d, 
J = 12.0 Hz, C-3’), 147.5 (d, J = 243.9 Hz, C-2’), 156.8 (CONHAr), 184.1 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -137.1 (ArF); LRMS (ES
-
) m/z 361.1 [M(
35
Cl)-H]
-
, 
363.1 [M(
37
Cl)-H]
-
; HRMS (NSI) calcd for C16H13ClFN4O3 [M(
35
Cl)+H]
+
 363.0655 found 
363.0658. 
 
4-Chloro-1-ethoxy-2-fluorobenzene, (357) 
 
To 4-chloro-2-fluorophenol (349) (1.0 g, 6.82 mmol) in acetonitrile (20 mL) was added 
potassium carbonate (1.41 g) and iodoethane (658 μL, 1.28 g, 8.19 mmol) at RT. The 
resulting solution was stirred at 65 °C for 18 h. Upon completion, the potassium carbonate 
was filtered off and the reaction mixture concentrated in vacuo. The crude yellow oil was 
purified by column chromatography (silica gel, petrol, 100%) to yield the title compound 
as a clear liquid (980 mg, 82%); Rf = 0.28 (petrol, 100%; KMnO4); λmax (EtOH)/nm 277.4; 
IR (neat) νmax/cm
-1
 2984, 2934, 1583, 1495, 1476, 1264, 1205; 
1
H NMR (500 MHz, 
DMSO-d6) δ 1.33 (3H, t, J = 7.0 Hz, OCH2CH3), 4.10 (2H, q, J = 7.0 Hz, OCH2CH3), 
7.15 – 7.22 (2H, m, H-5 and H-6), 7.38 – 7.44 (1H, m, H-3); 13C NMR (126 MHz, 
DMSO-d6) δ 14.5 (OCH2CH3), 64.6 (OCH2CH3), 115.9 (d, J = 2.5 Hz, C-6), 116.5 (d, 
J = 21.7 Hz, C-3), 123.6 (d, J = 9.2 Hz, C-4), 124.6 (d, J = 3.7 Hz, C-5), 145.6 (d, 
J = 10.4 Hz, C-1), 151.5 (d, J = 247.6 Hz, C-2); 
19
F NMR (471 MHz, DMSO-d6) δ -131.8 
(ArF); HRMS (APCI) calcd for C8H9ClFO [M(
35
Cl)+H]
+
 175.0320, found 175.0318. 
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4-Chloro-2-fluoro-1-(2-methoxyethoxy)benzene, (358) 
 
Compound 358 was synthesised according to general procedure B’, using the following 
reagents: 4-chloro-2-fluorophenol (349) (363 μL, 500 mg, 3.41 mmol), triphenylphosphine 
(1.34 g, 5.12 mmol), 2-methoxyethanol (350 μL, 337 mg, 4.44 mmol), diethyl 
azodicarboxylate (806 μL, 891 mg, 5.12 mmol) and THF (17 mL). The crude product was 
purified by column chromatography (silica gel, petrol:EtOAc, 1:0  93:7) to yield the title 
compound as a clear liquid (670 mg, 96%); Rf = 0.29 (petrol:EtOAc, 93:7; KMnO4); 
λmax (EtOH)/nm 277.2; IR (neat) νmax/cm
-1
 2984, 2929, 2883, 2822, 1587, 1498, 1266, 
1205; 
1
H NMR (500 MHz, DMSO-d6) δ 3.30 (3H, s, CH2OCH3), 3.63 – 3.69 (2H, m, 
OCH2), 4.14 – 4.20 (2H, m, OCH2), 7.17 – 7.23 (2H, m, H-5 and H-6), 7.39 – 7.46 (1H, m, 
H-3); 
13
C NMR (126 MHz, DMSO-d6) δ 58.2 (CH2OCH3), 68.4 (OCH2), 70.1 (OCH2), 
116.1 (d, J = 2.4 Hz, C-6), 116.6 (d, J = 21.8 Hz, C-3), 123.9 (d, J = 9.1 Hz, C-4), 124.6 (d, 
J = 3.7 Hz, C-5), 145.6 (d, J = 10.3 Hz, C-1), 151.5 (d, J = 247.8 Hz, C-2); 
19
F NMR 
(471 MHz, DMSO-d6) δ -131.5 (ArF); HRMS (APCI) calcd for C9H11ClFO2 [M(
35
Cl)+H]
+
 
205.0426 found 205.0423. 
 
3-(4-Chloro-2-fluorophenoxy)oxetane, (359) 
 
To 4-chloro-2-fluorophenol (349) (254 μL, 350 mg, 2.39 mmol) in THF (12 mL), cooled at 
0 °C, was added triphenylphosphine (940 mg, 3.58) and 3-hydroxyoxetane (197 μL, 
230 mg). Diisopropryl azodicarboxylate (705 μL, 724 mg, 3.58 mmol) was then added 
dropwise at 0 °C. The resulting orange solution was stirred at 0 °C for 30 min and allowed 
to warm to RT before being reflux for 24 h. Upon completion, the mixture was diluted with 
EtOAc (30 mL), washed with saturated aq. NaHCO3 and brine (20 mL, respectively), dried 
over MgSO4 and concentrated in vacuo. The crude orange solid was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  93:7) to yield the title compound as a 
white solid (470 mg, 97%); Rf = 0.29 (petrol:EtOAc, 93:7; KMnO4); m.p. 89.0-91.0 °C; 
λmax (EtOH)/nm 275.8; IR (neat) νmax/cm
-1
 3073, 3045, 2990, 2955, 2884, 1587, 1495, 
1419, 1375, 1269; 
1
H NMR (500 MHz, DMSO-d6) δ 4.57 (2H, ddd, J = 7.4, 4.9 and 
1.0 Hz, ArOCHCH2O), 4.91 (2H, dd, J = 7.1, 7.1 Hz, ArOCHCH2O), 5.33 (1H, ddd, 
J = 10.8, 6.0 and 4.8 Hz, ArOCHCH2O), 6.87 (1H, dd, J = 9.0, 9.0 Hz, H-6), 7.14 – 7.22 
(1H, m, H-5), 7.49 (1H, dd, J = 11.2, 2.5 Hz, H-3); 
13
C NMR (126 MHz, DMSO-d6) δ 71.3 
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(ArOCHCH2O), 76.5 (ArOCHCH2O), 116.0 (d, J = 2.2 Hz, C-6), 117.0 (d, J = 21.6 Hz, 
C-3), 124.8 (d, J = 4.1 Hz, C-5), 124.8 (d, J = 8.7 Hz, C-4), 143.4 (d, J = 10.6 Hz, C-1), 
151.5 (d, J = 248.2 Hz, C-2); 
19
F NMR (471 MHz, DMSO-d6) δ -131.4 (ArF); HRMS 
(APCI) calcd for C9H9ClFO2 [M(
35
Cl)+H]
+
 203.0270, found 203.0269. 
 
3-(4-Chloro-2-fluorophenoxy)tetrahydrofuran, (360) 
 
Compound 360 was synthesised according to general procedure B’, using the following 
reagents: 4-chloro-2-fluorophenol (349) (508 μL, 700 mg, 4.78 mmol), triphenylphosphine 
(1.88 g, 7.16 mmol), 3-hydroxytetrahydrofuran (502 μL, 547 mg, 6.21 mmol), diethyl 
azodicarboxylate (1.13 mL, 1.25 g, 7.16 mmol) and THF (24 mL). The crude product was 
purified by column chromatography (silica gel, petrol:EtOAc, 1:0  92:8) to yield the title 
compound as a clear liquid (989 mg, 96%); Rf = 0.28 (petrol:EtOAc, 92:8; KMnO4); 
λmax (EtOH)/nm 277.4; IR (neat) νmax/cm
-1
 2976, 2951, 2866, 1584, 1494, 1265, 1204; 
1
H NMR (500 MHz, DMSO-d6) δ 1.97 (1H, dt, J = 12.7, 5.7 Hz, ArOCHCH2CH2), 2.21 
(1H, dtd, J = 12.7, 8.4 and 6.3 Hz, ArOCHCH2CH2), 3.75 (1H, td, J = 8.4, 4.5 Hz, OCH2), 
3.79 – 3.89 (3H, m, OCH2), 5.08 (1H, dddd, J = 6.2, 4.0, 2.0 and 2.0 Hz, ArOCH(CH2)2), 
7.15 – 7.23 (2H, m, H-5 and H-6), 7.40 – 7.47 (1H, m, H-3); 13C NMR (126 MHz, 
DMSO-d6) δ 32.3 (ArOCHCH2CH2), 66.4 (OCH2), 72.1 (OCH2), 78.9 (ArOCH), 116.8 (d, 
J = 21.8 Hz, C-3), 117.2 (d, J = 2.3 Hz, C-6), 124.2 (d, J = 9.3 Hz, C-4), 124.7 (d, 
J = 3.7 Hz, C-5), 144.2 (d, J = 10.3 Hz, C-1), 152.0 (d, J = 247.8 Hz, C-2); 
19
F NMR 
(471 MHz, DMSO-d6) δ -131.0 (ArF); HRMS (APCI) calcd for C10H11ClFO2 
[M(
35
Cl)+H]
+
 217.0426, found 217.0424. 
 
4-(4-Chloro-2-fluorophenoxy)tetrahydro-2H-pyran, (361) 
 
Compound 361 was synthesised according to general procedure B’, using the following 
reagents: 4-chloro-2-fluorophenol (349) (508 μL, 700 mg, 4.78 mmol), triphenylphosphine 
(1.88 g, 7.16 mmol), 4-hydroxytetrahydropyran (592 μL, 634 mg, 6.21 mmol), diethyl 
azodicarboxylate (1.13 mL, 1.25 g, 7.16 mmol) and THF (24 mL). The crude product was 
purified by column chromatography (silica gel, petrol:EtOAc, 1:0  93:7) to yield the title 
compound as a clear liquid (1.05 mg, 95%); Rf = 0.29 (petrol:EtOAc, 93:7; KMnO4); 
λmax (EtOH)/nm 277.4; IR (neat) νmax/cm
-1
 2956, 2934, 2852, 1583, 1493, 1266, 1203; 
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1
H NMR (500 MHz, DMSO-d6) δ 1.59 (2H, dddd, J = 13.1, 9.1, 9.1 and 4.1 Hz, H-3’, 
5’axial), 1.89 – 2.00 (2H, m, H-3’, 5’equ), 3.46 (2H, ddd, J = 13.1, 9.1 and 2.7 Hz, H-2’, 
6’axial), 3.84 (2H, ddd, J = 13.1, 4.1 and 4.1 Hz, H-2’, 6’equ), 4.58 (1H, tt, J = 8.5, 4.1 Hz, 
H-4’), 7.19 (1H, ddd, J = 8.9, 2.4 and 1.5 Hz, H-5), 7.29 (1H, dd, J = 9.0, 8.9 Hz, H-6), 
7.43 (1H, dd, J = 11.1, 2.4 Hz, H-3); 
13
C NMR (126 MHz, DMSO-d6) δ 31.6 (C-3’, 5’), 
64.4 (C-2’, 6’), 73.6 (C-4’), 116.9 (d, J = 22.2 Hz, C-3), 118.6 (d, J = 2.3 Hz, C-6), 124.4 
(d, J = 9.3 Hz, C-4), 124.7 (d, J = 3.7 Hz, C-5), 143.8 (d, J = 10.5 Hz, C-1), 152.5 (d, 
J = 247.7 Hz, C-2); 
19
F NMR (471 MHz, DMSO-d6) δ -130.5 (ArF); HRMS (APCI) calcd 
for C11H13ClFO2 [M(
35
Cl)+H]
+
 231.0583, found 231.0582. 
 
tert-Butyl 4-(4-chloro-2-fluorophenoxy)piperidine-1-carboxylate, (362) 
 
Compound 362 was synthesised according to general procedure B’, using the following 
reagents: 4-chloro-2-fluorophenol (349) (508 μL, 700 mg, 4.78 mmol), triphenylphosphine 
(1.88 g, 7.16 mmol), 1-Boc-4-hydroxypiperidine (1.25 g, 6.21 mmol), diethyl 
azodicarboxylate (1.13 mL, 1.25 g, 7.16 mmol) and THF (24 mL). The crude product was 
purified by column chromatography (silica gel, petrol:EtOAc, 1:0  95:5) to yield the title 
compound as an off-white solid (1.31 g, 83%); Rf = 0.31 (petrol:EtOAc, 95:5; KMnO4); 
m.p. 78.0-100.0 °C; λmax (EtOH)/nm 277.2; IR (neat) νmax/cm
-1
 3048, 2970, 2932, 2888, 
1676, 1604, 1583, 1500, 1420; 
1
H NMR (500 MHz, DMSO-d6) δ 1.40 (9H, s, C(CH3)3), 
1.52 (2H, dddd, J = 12.8, 8.6, 8.6 and 3.9 Hz, H-3’, 5’axial), 1.89 (2H, dddd, J = 12.8, 6.7, 
3.9 and 3.9 Hz, H-3’, 5’equ), 3.17 (2H, brs, H-2’, 6’equ), 3.64 (2H, ddd, J = 12.8, 6.7 and 
3.9 Hz, H-2’, 6’axial), 4.56 (1H, tt, J = 7.9, 3.9 Hz, H-4’), 7.19 (1H, ddd, J = 8.8, 2.5 and 
1.4 Hz, H-5), 7.29 (1H, dd, J = 8.9, 8.8 Hz, H-6), 7.43 (1H, dd, J = 11.1, 2.5 Hz, H-3); 
13
C NMR (126 MHz, DMSO-d6) δ 28.0 (C(CH3)3), 30.3 (C-3’, 5’), 40.1 (C-2’, 6’), 74.3 
(C-4’), 78.8 (OC(CH3)3), 116.9 (d, J = 22.2 Hz, C-3), 118.8 (d, J = 2.1 Hz, C-6), 124.6 (d, 
J = 9.3 Hz, C-4), 124.7 (d, J = 3.7 Hz, C-5), 143.8 (d, J = 10.4 Hz, C-1), 152.6 (d, 
J = 247.6 Hz, C-2), 153.9 (CO2N); 
19
F NMR (471 MHz, DMSO-d6) δ -130.4 (ArF); 
LRMS (ES
+
) m/z 330.2 [M(
35
Cl)+H]
+
, 332.2 [M(
37
Cl)+H]
+
; HRMS (NSI) calcd for 
C16H22ClFNO3 [M(
35
Cl)+H]
+
 330.1267, found 330.1269. 
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6-Chloro-3-ethoxy-2-fluorobenzoic acid, (363) 
 
Compound 363 was synthesised according to general procedure A’, using the following 
reagents: 4-chloro-1-ethoxy-2-fluorobenzene (357) (950 mg, 5.44 mmol), n-butyllithium 
(2.27 mL, 5.44 mmol) and THF (16.3 mL). The white solid (1.16 g, 97%) was used in the 
next step without further purification; Rf = 0.45 (petrol:EtOAc:AcOH, 50:49.7:0.3; 
KMnO4); m.p. 153.0-155.0 °C; λmax (EtOH)/nm 283.2; IR (neat) νmax/cm
-1
 2984, 2889, 
1701, 1613, 1578, 1486, 1466, 1454, 1291, 1266; 
1
H NMR (500 MHz, DMSO-d6) δ 1.34 
(3H, t, J = 7.0 Hz, OCH2CH3), 4.14 (2H, q, J = 7.0 Hz, OCH2CH3), 7.26 (1H, dd, J = 9.0, 
8.8 Hz, H-4), 7.30 (1H, dd, J = 9.0, 1.0 Hz, H-5), 14.07 (1H, s, ArCO2H); 
13
C NMR 
(126 MHz, DMSO-d6) δ 14.4 (OCH2CH3), 64.9 (OCH2CH3), 116.2 (d, J = 2.6 Hz, C-4), 
119.9 (d, J = 4.6 Hz, C-6), 124.1 (d, J = 19.1 Hz, C-1), 125.4 (d, J = 3.9 Hz, C-5), 145.6 (d, 
J = 10.3 Hz, C-3), 148.0 (d, J = 249.3 Hz, C-2), 163.7 (ArCO2H); 
19
F NMR (471 MHz, 
DMSO-d6) δ -135.0 (ArF); LRMS (ES
+
) m/z 219.1 [M(
35
Cl)+H]
+
, 221.1 [M(
37
Cl)+H]
+
; 
HRMS (NSI) calcd for C9H9ClFO3 [M(
35
Cl)+H]
+
 219.0219 found 219.0219. 
 
6-Chloro-2-fluoro-3-(2-methoxyethoxy)benzoic acid, (364) 
 
Compound 364 was synthesised according to general procedure A’, using the following 
reagents: 4-chloro-2-fluoro-1-(2-methoxyethoxy)benzene (358) (1.05 g, 5.13 mmol), 
n-butyllithium (2.14 mL, 5.13 mmol) and THF (15.4 mL). The off-white solid (1.07 g, 
84%) was used in the next step without further purification; Rf = 0.22 
(petrol:EtOAc:AcOH, 50:49.7:0.3; KMnO4); m.p. 126.0-128.0 °C; λmax (EtOH)/nm 282.6; 
IR (neat) νmax/cm
-1
 2928, 2879, 2831, 1717, 1611, 1577, 1480, 1452, 1256; 
1
H NMR 
(500 MHz, DMSO-d6) δ 3.30 (3H, s, CH3OCH2), 3.62 – 3.71 (2H, m, CH3OCH2), 
4.17 - 4.25 (2H, m, ArOCH2), 7.26 – 7.33 (2H, m, H-4 and H-5), 14.12 (1H, s, ArCO2H); 
13
C NMR (126 MHz, DMSO-d6) δ 58.2 (CH3OCH2), 68.7 (OCH2), 70.1 (OCH2), 116.4 (d, 
J = 1.9 Hz, C-4), 120.1 (d, J = 4.6 Hz, C-6), 124.2 (d, J = 19.1 Hz, C-1), 125.4 (d, 
J = 3.8 Hz, C-5), 145.6 (d, J = 10.4 Hz, C-3), 148.0 (d, J = 249.6 Hz, C-2), 163.6 
(ArCO2H); 
19
F NMR (471 MHz, DMSO-d6) δ -134.7 (ArF); LRMS (ES
-
) m/z 247.1 
[M(
35
Cl)-H]
-
, 249.1 [M(
37
Cl)-H]
-
; HRMS (NSI) calcd for C10H11ClFO4 [M(
35
Cl)+H]
+
 
249.0324, found 249.0329. 
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6-Chloro-2-fluoro-3-((tetrahydrofuran-3-yl)oxy)benzoic acid, (365) 
 
Compound 365 was synthesised according to general procedure A’, using the following 
reagents: 3-(4-chloro-2-fluorophenoxy)tetrahydrofuran (360) (980 mg, 4.52 mmol), 
n-butyllithium (1.88 mL, 4.52 mmol) and THF (13.6 mL). The white solid (1.02 g, 86%) 
was used in the next step without further purification; Rf = 0.30 (petrol:EtOAc:AcOH, 
50:49.7:0.3; KMnO4); m.p. 11.5-113.5 °C; λmax (EtOH)/nm 283.0; IR (neat) νmax/cm
-1
 
2949, 2891, 1720, 1613, 1574, 1472, 1245; 
1
H NMR (500 MHz, DMSO-d6) δ 1.98 (1H, dt, 
J = 12.6, 5.7 Hz, ArOCHCH2CH2), 2.23 (1H, dtd, J = 14.2, 8.2, 6.3 Hz, ArOCHCH2CH2), 
3.75 (1H, td, J = 8.4, 4.5 Hz, OCH2), 3.80 – 3.90 (3H, m, OCH2), 5.13 (1H, dddd, J = 5.9, 
3.8, 1.8 and 1.8 Hz, ArOCH), 7.27 (1H, dd, J = 9.1, 8.7 Hz, H-4), 7.32 (1H, d, J = 9.1 Hz, 
H-5), 14.13 (1H, s, ArCO2H); 
13
C NMR (126 MHz, DMSO-d6) δ 32.3 (ArOCHCH2CH2), 
66.4 (OCH2), 72.1 (OCH2), 79.2 (ArOCH), 117.4 (d, J = 1.8 Hz, C-4), 120.4 (d, 
J = 4.7 Hz, C-6), 124.4 (d, J = 18.9 Hz, C-1), 125.4 (d, J = 3.9 Hz, C-5), 144.2 (d, 
J = 10.4 Hz, C-3), 148.5 (d, J = 249.5 Hz, C-2), 163.6 (ArCO2H); 
19
F NMR (471 MHz, 
DMSO-d6) δ -134.3 (ArF); LRMS (ES
-
) m/z 259.1 [M(
35
Cl)-H]
-
, 261.1 [M(
37
Cl)-H]
-
; 
HRMS (NSI) calcd for C11H11ClFO4 [M(
35
Cl)+H]
+
 261.0324, found 261.0329. 
 
6-Chloro-2-fluoro-3-((tetrahydro-2H-pyran-4-yl)oxy)benzoic acid, (366) 
 
Compound 366 was synthesised according to general procedure A’, using the following 
reagents: 4-(4-chloro-2-fluorophenoxy)tetrahydro-2H-pyran (361) (1.05 g, 4.55 mmol), 
n-butyllithium (1.90 mL, 4.55 mmol) and THF (13.7 mL). The white solid (1.18 g, 94%) 
was used in the next step without further purification; Rf = 0.29 (petrol:EtOAc:AcOH, 
50:49.7:0.3; KMnO4); m.p. 159.5-161.5 °C; λmax (EtOH)/nm 282.4; IR (neat) νmax/cm
-1
 
2935, 2877, 1716, 1611, 1575, 1469, 1263; 
1
H NMR (500 MHz, DMSO-d6) δ 1.60 (2H, 
dddd, J = 13.0, 9.1, 9.1 and 4.0 Hz, H-3’, 5’axial), 1.90 – 2.01 (2H, m, H-3’, 5’equ), 3.46 
(2H, ddd, J = 13.0, 9.5, 2.7 Hz, H-2’, 6’axial), 3.84 (2H, ddd, J = 13.0, 4.0 and 4.0 Hz, H-2’, 
6’equ), 4.64 (1H, tt, J = 8.4, 4.0 Hz, H-4’), 7.30 (1H, dd, J = 9.0, 1.5 Hz, H-5), 7.38 (1H, dd, 
J = 9.0, 9.0 Hz, H-4), 14.11 (1H, s, ArCO2H); 
13
C NMR (126 MHz, DMSO-d6) δ 31.5 
(C-3’, 5’), 64.4 (C-2’, 6’), 73.8 (C-4’), 118.7 (d, J = 1.8 Hz, C-4), 120.6 (d, J = 4.7 Hz, 
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C-6), 124.5 (d, J = 19.4 Hz, C-1), 125.4 (d, J = 3.8 Hz, C-5), 143.9 (d, J = 10.5 Hz, C-3), 
148.9 (d, J = 249.4 Hz, C-2), 163.6 (ArCO2H); 
19
F NMR (471 MHz, DMSO-d6) δ -133.8 
(ArF); LRMS (ES
-
) m/z 273.1 [M(
35
Cl)-H]
-
, 275.1 [M(
37
Cl)-H]
-
; HRMS (APCI) calcd for 
C12H16NClFO4 [M(
35
Cl)+NH4]
+
 292.0746, found 292.0747. 
 
3-((1-(tert-Butoxycarbonyl)piperidin-4-yl)oxy)-6-chloro-2-fluorobenzoic acid, (367) 
 
Compound 367 was synthesised according to general procedure A’, using the following 
reagents: tert-butyl 4-(4-chloro-2-fluorophenoxy)piperidine-1-carboxylate (362) (1.25 g, 
3.79 mmol), n-butyllithium (1.58 mL, 3.79 mmol) and THF (11.4 mL). The white solid 
(1.30 g, 92%) was used in the next step without further purification; Rf = 0.32 
(petrol:EtOAc:AcOH, 50:49.7:0.3); m.p. 136.0-138.0 °C; λmax (EtOH)/nm 281.4; IR (neat) 
νmax/cm
-1
 2972, 2933, 2869, 1733, 1687, 1637, 1575, 1471, 1434, 1365, 1267, 1234; 
1
H NMR (500 MHz, DMSO-d6) δ 1.40 (9H, s, C(CH3)3), 1.54 (2H, dddd, J = 12.5, 8.6, 8.6 
and 3.9 Hz, H-3’, 5’axial), 1.86 – 1.94 (2H, m, H-3’, 5’equ), 3.08 – 3.23 (2H, m, H-2’, 6’equ), 
3.64 (2H, ddd, J = 12.5, 3.9 and 3.9 Hz, H-2’, 6’axial), 4.62 (1H, tt, J = 7.9, 3.9 Hz, H-4’), 
7.30 (1H, dd, J = 9.0, 1.3 Hz, H-5), 7.36 (1H, dd, J = 9.0, 8.9 Hz, H-4), 14.13 (1H, s, 
ArCO2H); 
13
C NMR (126 MHz, DMSO-d6) δ 28.1 (C(CH3)3), 30.2 (C-3’, 5’), 40.1 (C-2’, 
6’), 74.5 (C-4’), 78.8 (OC(CH3)3), 118.7 (C-4), 120.7 (d, J = 4.6 Hz, C-6), 125.4 (d, 
J = 3.9 Hz, C-5), 143.9 (d, J = 10.6 Hz, C-3), 149.0 (d, J = 249.4 Hz, C-2), 153.9 (CO2N), 
163.6 (ArCO2H); 
19
F NMR (471 MHz, DMSO-d6) δ -133.7 (ArF); LRMS (ES
-
) m/z 372.2 
[M(
35
Cl)-H]
-
, 374.2 [M(
37
Cl)-H]
-
; HRMS (NSI) calcd for C17H22ClFNO5 [M(
35
Cl)+H]
+
 
374.1165, found 374.1161. 
 
Methyl 4-(6-chloro-3-ethoxy-2-fluorobenzoyl)-1H-pyrrole-2-carboxylate, (368) 
 
To a solution of 6-chloro-3-ethoxy-2-fluorobenzoic acid (363) (1.14 g, 5.21 mmol) in THF 
(10 mL), cooled at 0 °C, was added thionyl chloride (567 μL, 931 mg, 7.82 mmol) and 
N,N-dimethylformamide (40 μL, 38 mg, 0.52 mmol). The resulting solution was stirred at 
0 °C for 30 min and allowed to warm to RT. After 5 h, the solvent was removed in vacuo 
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and the crude residue dissolved in DCM (5 mL). The resulting solution was added to a 
suspension of aluminium trichloride (869 mg, 6.52 mmol) in DCM (10 mL), cooled at 
0 °C, followed by methyl 1H-pyrrole-2-carboxylate (435 mg, 3.47 mmol). The resulting 
solution was stirred at 0 °C for 30 min and allowed to warm to RT. After 20 h, the reaction 
mixture was cooled to 0 °C and quenched by cautious addition of 1 M aq. HCl (10 mL). 
The resulting solution was stirred at RT for 2 h. The reaction was then diluted with water 
(20 mL) and extracted with DCM (3 × 40 mL). The pooled organic extracts were washed 
with saturated aq. NaHCO3 and brine (50 mL, respectively), dried over MgSO4 and 
concentrated in vacuo. The crude product was purified by column chromatography (silica 
gel, petrol:EtOAc, 1:0  7:3) to yield the title compound as a white solid (880 mg, 78%); 
Rf = 0.32 (petrol:EtOAc, 7:3); m.p. 119.0-121.0 °C; λmax (EtOH)/nm 230.6, 282.2; 
IR (neat) νmax/cm
-1
 3292, 3103, 2989, 2950, 1712, 1639, 1562, 1467, 1438, 1272, 1234, 
1196; 
1
H NMR (500 MHz, DMSO-d6) δ 1.35 (3H, t, J = 7.0 Hz, OCH2CH3), 3.79 (3H, s, 
CO2CH3), 4.15 (2H, q, J = 7.0 Hz, OCH2CH3), 7.00 (1H, s, H-3), 7.29 (1H, dd, J = 9.3, 
8.8 Hz, H-4’), 7.34 (1H, d, J = 9.3 Hz, H-5’), 7.54 (1H, s, H-5), 12.88 (1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 14.4 (OCH2CH3), 51.7 (CO2CH3), 64.9 (OCH2CH3), 
114.6 (C-3), 116.1 (d, J = 2.4 Hz, C-4’), 120.0 (d, J = 4.8 Hz, C-6’), 124.5 (C-2 or C-4), 
125.3 (C-2 or C-4), 125.5 (d, J = 3.7 Hz, C-5’), 128.2 (d, J = 20.0 Hz, C-1’), 130.2 (C-5), 
145.7 (d, J = 10.6 Hz, C-3’), 148.0 (d, J = 246.9 Hz, C-2’), 160.3 (CO2CH3), 183.5 
(ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -135.8 (ArF); LRMS (ES
+
) m/z 326.2 
[M(
35
Cl)+H]
+
, 328.2 [M(
37
Cl)+H]
+
; HRMS (NSI) calcd for C15H14ClFNO4 [M(
35
Cl)+H]
+
 
326.0590 found 326.0590. 
 
Methyl 4-(6-chloro-2-fluoro-3-(2-methoxyethoxy)benzoyl)-1H-pyrrole-2-carboxylate, 
(369) 
 
To a solution of 6-chloro-2-fluoro-3-(2-methoxyethoxy)benzoic acid (364) (1.05 g, 
4.22 mmol) in THF (10 mL), cooled at 0 °C, was added thionyl chloride (460 μL, 754 mg, 
6.33 mmol) and N,N-dimethylformamide (33 μL, 31 mg, 0.42 mmol). The resulting 
solution was stirred at 0 °C for 30 min and allowed to warm to RT. After 5 h, the solvent 
was removed in vacuo and the crude residue dissolved in DCM (5 mL). The resulting 
solution was added to a suspension of aluminium trichloride (1.13 g, 8.44 mmol) in DCM 
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(10 mL), cooled at 0 °C, followed by methyl 1H-pyrrole-2-carboxylate (349 mg, 
2.79 mmol). The resulting solution was stirred at 0 °C for 30 min and allowed to warm to 
RT. After 20 h, the reaction mixture was cooled to 0 °C and quenched by cautious addition 
of 1 M aq. HCl (10 mL). The resulting solution was stirred at RT for 2 h. The reaction was 
then diluted with water (20 mL) and extracted with DCM (3 × 40 mL). The pooled organic 
extracts were washed with saturated aq. NaHCO3 and brine (50 mL, respectively), dried 
over MgSO4 and concentrated in vacuo. The crude product was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  6:4) to yield the title compound as a 
yellow oil (718 mg, 72%); Rf = 0.29 (petrol:EtOAc, 6:4); λmax (EtOH)/nm 281.8; IR (neat) 
νmax/cm
-1
 3262, 3128, 2987, 2935, 2883, 1710, 1651, 1558, 1469, 1441, 1269, 1229; 
1
H NMR (500 MHz, DMSO-d6) δ 3.30 (3H, s, CH2OCH3), 3.68 (2H, dd, J = 5.1, 3.7 Hz, 
CH2O), 3.79 (3H, s, CO2CH3), 4.23 (2H, dd, J = 5.1, 3.7 Hz, CH2O), 7.00 (1H, s, H-3), 
7.27 – 7.41 (2H, m, H-4’ and H-5’), 7.55 (1H, s, H-5), 12.91 (1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 51.7 (CO2CH3), 58.2 (CH2OCH3), 68.6 (CH2O), 70.1 
(CH2O), 114.7 (C-3), 116.4 (C-4’), 120.3 (d, J = 4.8 Hz, C-6’), 124.6 (C-2 or C-4), 125.3 
(C-2 or C-4), 125.5 (d, J = 3.7 Hz, C-5’), 128.3 (d, J = 19.9 Hz, C-1’), 130.2 (C-5), 145.7 
(d, J = 10.6 Hz, C-3’), 148.1 (d, J = 247.2 Hz, C-2’), 160.3 (CO2CH3), 183.4 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -135.6 (ArF); LRMS (ES
+
) m/z 356.3 [M(
35
Cl)+H]
+
, 
358.3 [M(
37
Cl)+H]
+
; HRMS (NSI) calcd for C16H16ClFNO5 [M(
35
Cl)+H]
+
 356.0696, found 
356.0697. 
 
Methyl 4-(6-chloro-2-fluoro-3-((tetrahydrofuran-3-yl)oxy)benzoyl)-1H-pyrrole-2-
carboxylate, (370) 
 
To a solution of 6-chloro-2-fluoro-3-((tetrahydrofuran-3-yl)oxy)benzoic acid (365) (1.0 g, 
3.84 mmol) in THF (10 mL), cooled at 0 °C, was added thionyl chloride (417 μL, 685 mg, 
5.75 mmol) and N,N-dimethylformamide (30 μL, 28 mg, 0.38 mmol). The resulting 
solution was stirred at 0 °C for 30 min and allowed to warm to RT. After 5 h, the solvent 
was removed in vacuo and the crude residue dissolved in DCM (5 mL). The resulting 
solution was added to a suspension of aluminium trichloride (1.02 g, 7.67 mmol) in DCM 
(10 mL), cooled at 0 °C, followed by methyl 1H-pyrrole-2-carboxylate (317 mg, 
2.53 mmol). The resulting solution was stirred at 0 °C for 30 min and allowed to warm to 
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RT. After 20 h, the reaction mixture was cooled to 0 °C and quenched by cautious addition 
of 1 M aq. HCl (10 mL). The resulting solution was stirred at RT for 2 h. The reaction was 
then diluted with water (20 mL) and extracted with DCM (3 × 40 mL). The pooled organic 
extracts were washed with saturated aq. NaHCO3 and brine (50 mL, respectively), dried 
over MgSO4 and concentrated in vacuo. The crude product was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  6:4) to yield the title compound as a 
white solid (765 mg, 82%); Rf = 0.28 (petrol:EtOAc, 6:4); m.p. 87.5-89.5 °C; 
λmax (EtOH)/nm 230.4, 282.0; IR (neat) νmax/cm
-1
 3259, 3130, 2952, 2875, 1711, 1652, 
1559, 1466, 1439, 1389, 1272, 1229, 1198; 
1
H NMR (500 MHz, DMSO-d6) δ 2.03 (1H, dt, 
J = 11.5, 4.3 Hz, ArOCHCH2CH2), 2.25 (1H, dtd, J = 14.2, 8.2, 6.1 Hz, ArOCHCH2CH2), 
3.75 (1H, dt, J = 8.4, 4.2 Hz, OCH2), 3.79 (3H, s, CO2CH3), 3.82 – 3.91 (3H, m, OCH2), 
5.14 (1H, dddd, J = 6.1, 3.9, 1.9 and 1.9 Hz, ArOCH(CH2)2), 7.02 (1H, s, H-3), 7.30 (1H, 
dd, J = 9.2, 8.8 Hz, H-4’), 7.35 (1H, d, J = 9.2 Hz, H-5’), 7.54 – 7.59 (1H, m, H-5), 12.90 
(1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 32.3 (ArOCHCH2CH2), 51.7 
(CO2CH3), 66.4 (OCH2), 72.1 (OCH2), 79.1 (ArOCH), 114.6 (C-3), 117.2 (d, J = 2.1 Hz, 
C-4’), 120.5 (d, J = 4.9 Hz, C-6’), 124.6 (C-2 or C-4), 125.3 (C-2 or C-4), 125.5 (d, 
J = 3.8 Hz, C-5’), 128.5 (d, J = 20.1 Hz, C-1’), 130.4 (C-5), 144.4 (d, J = 10.6 Hz, C-3’), 
148.6 (d, J = 247.2 Hz, C-2’), 160.3 (CO2CH3), 183.4 (ArCO); 
19
F NMR (471 MHz, 
DMSO-d6) δ -135.21 (ArF); LRMS (ES
+
) m/z 368.3 [M(
35
Cl)+H]
+
, 370.3 [M(
37
Cl)+H]
+
; 
HRMS (NSI) calcd for C17H16ClFNO5 [M(
35
Cl)+H]
+
 368.0696, found 368.0700. 
 
Methyl 4-(6-chloro-2-fluoro-3-((tetrahydro-2H-pyran-4-yl)oxy)benzoyl)-1H-pyrrole-
2-carboxylate, (371) 
 
To a solution 6-chloro-2-fluoro-3-((tetrahydro-2H-pyran-4-yl)oxy)benzoic acid (366) 
(1.15 g, 4.19 mmol) in THF (10 mL), cooled at 0 °C, was added thionyl chloride (456 μL, 
747 mg, 6.28 mmol) and N,N-dimethylformamide (32 μL, 31 mg, 0.42 mmol). The 
resulting solution was stirred at 0 °C for 30 min and allowed to warm to RT. After 5 h, the 
solvent was removed in vacuo and the crude residue dissolved in DCM (5 mL). The 
resulting solution was added to a suspension of aluminium trichloride (1.12 g, 8.37 mmol) 
in DCM (10 mL), cooled at 0 °C, followed by methyl 1H-pyrrole-2-carboxylate (346 mg, 
2.76 mmol). The resulting solution was stirred at 0 °C for 30 min and allowed to warm to 
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RT. After 20 h, the reaction mixture was cooled to 0 °C and quenched by cautious addition 
of 1 M aq. HCl (10 mL). The resulting solution was stirred at RT for 2 h. The reaction was 
then diluted with water (20 mL) and extracted with DCM (3 × 40 mL). The pooled organic 
extracts were washed with saturated aq. NaHCO3 and brine (50 mL, respectively), dried 
over MgSO4 and concentrated in vacuo. The crude product was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  6:4) to yield the title compound as a 
white solid (852 mg, 81%); Rf = 0.30 (petrol:EtOAc, 6:4); m.p. 113.5-115.5 °C; 
λmax (EtOH)/nm 230.8, 282.2; IR (neat) νmax/cm
-1
 3260, 3126, 2953, 2855, 1709, 1651, 
1559, 1462, 1440, 1389, 1270; 
1
H NMR (500 MHz, DMSO-d6) δ 1.62 (2H, dddd, J = 13.0, 
9.1, 9.1 and 4.0 Hz, ArOCHCH2 axial), 1.99 (2H, dd, J = 13.0, 3.5 Hz, ArOCHCH2 equ), 3.47 
(2H, ddd, J = 13.0, 9.7 and 2.7 Hz, ArOCHCH2CH2 axial), 3.79 (3H, s, CO2CH3), 3.84 (2H, 
ddd, J = 13.0, 4.0, 4.0 Hz, ArOCHCH2CH2 equ), 4.66 (1H, tt, J = 8.4, 4.0 Hz, ArOCH), 
7.01 (1H, s, H-3), 7.33 (1H, dd, J = 9.0, 1.1 Hz, H-5’), 7.42 (1H, dd, J = 9.0, 9.0 Hz, H-4’), 
7.55 (1H, s, H-5), 12.88 (1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 31.6 
(ArOCHCH2), 51.7 (CO2CH3), 64.4 (ArOCHCH2CH2), 73.8 (ArOCH), 114.6 (C-3), 118.6 
(d, J = 1.7 Hz, C-4’), 120.7 (d, J = 4.9 Hz, C-6’), 124.6 (C-2 or C-4), 125.3 (C-2 or C-4), 
125.5 (d, J = 3.6 Hz, C-5’), 128.6 (d, J = 20.2 Hz, C-1’), 130.3 (C-5), 144.0 (d, 
J = 10.7 Hz, C-3’), 149.0 (d, J = 246.9 Hz, C-2’), 160.3 (CONHAr), 183.4 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -134.6 (ArF); LRMS (ES
+
) m/z 382.3 [M(
35
Cl)+H]
+
, 
384.2 [M(
37
Cl)+H]
+
; HRMS (NSI) calcd for C18H18ClFNO5 [M(
35
Cl)+H]
+
 382.0852, found 
382.0850. 
 
4-(6-Chloro-3-ethoxy-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid, (372) 
 
Compound 372 was synthesised according to general procedure R, using the following 
reagents: methyl 4-(6-chloro-3-ethoxy-2-fluorobenzoyl)-1H-pyrrole-2-carboxylate (368) 
(800 mg, 2.46 mmol), 2 M aq. lithium hydroxide (18.5 mL, 36.8 mmol) and THF 
(19.7 mL). The crude white solid (732 mg, 96%) was used in the next step without further 
purification; Rf = 0.26 (petrol:EtOAc:AcOH, 50:49.7:0.3); m.p. 163.5-165.5 °C; 
λmax (EtOH)/nm 230.8, 283.4; IR (neat) νmax/cm
-1
 3280, 3126, 2986, 2888, 1713, 1647, 
1554, 1466, 1442, 1282, 1268, 1232; 
1
H NMR (500 MHz, DMSO-d6) δ 1.35 (3H, t, 
J = 7.0 Hz, OCH2CH3), 4.15 (2H, q, J = 7.0 Hz, OCH2CH3), 6.95 (1H, s, H-3), 7.29 (1H, 
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dd, J = 9.2, 8.8 Hz, H-4’), 7.33 (1H, d, J = 9.2 Hz, H-5’), 7.45 (1H, s, H-5), 12.69 (1H, s, 
NH-pyrrole), 12.85 (1H, s, CO2H); 
13
C NMR (126 MHz, DMSO-d6) δ 14.5 (OCH2CH3), 
64.9 (OCH2CH3), 114.2 (C-3), 116.0 (C-4’), 120.0 (d, J = 4.8 Hz, C-6’), 125.2 (C-2 or 
C-4), 125.5 (d, J = 3.7 Hz, C-5’), 125.8 (C-2 or C-4), 128.3 (d, J = 20.0 Hz, C-1’), 129.8 
(C-5), 145.7 (d, J = 10.6 Hz, C-3’), 148.0 (d, J = 246.8 Hz, C-2’), 161.3 (CO2H), 183.5 
(ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -135.8 (ArF); LRMS (ES
-
) m/z 310.1 
[M(
35
Cl)-H]
-
, 312.1 [M(
37
Cl)-H]
-
; HRMS (NSI) calcd for C14H12ClFNO4 [M(
35
Cl)+H]
+
 
312.0433, found 312.0436. 
 
4-(6-Chloro-2-fluoro-3-(2-methoxyethoxy)benzoyl)-1H-pyrrole-2-carboxylic acid, 
(373) 
 
Compound 373 was synthesised according to general procedure R, using the following 
reagents: methyl 4-(6-chloro-2-fluoro-3-(2-methoxyethoxy)benzoyl)-1H-pyrrole-2-
carboxylate (369) (650 mg, 1.83 mmol), 2 M aq. lithium hydroxide (13.8 mL, 27.6 mmol) 
and THF (14.6 mL). The crude pale orange solid (593 mg, 95%) was used in the next step 
without further purification; Rf = 0.18 (petrol:EtOAc:AcOH, 50:49.7:0.3); m.p. 
100.0-102.0 °C; λmax (EtOH)/nm 230.4, 282.2; IR (neat) νmax/cm
-1
 3125, 2958, 2862, 1701, 
1688, 1650, 1559, 1464, 1437, 1268, 1226; 
1
H NMR (500 MHz, DMSO-d6) δ 3.30 (3H, s, 
CH3OCH2), 3.68 (2H, t, J = 4.2 Hz, OCH2), 4.23 (2H, t, J = 4.2 Hz, OCH2), 6.96 (1H, s, 
H-3), 7.28 – 7.37 (2H, m, H-4’ and H-5’), 7.47 (1H, s, H-5), 12.72 (1H, s, NH-pyrrole), 
12.95 (1H, s, CO2H); 
13
C NMR (126 MHz, DMSO-d6) δ 58.2 (CH3OCH2), 68.7 (OCH2), 
70.1 (OCH2), 114.2 (C-3), 116.3 (C-4’), 120.4 (d, J = 4.7 Hz, C-6’), 125.2 (C-2 or C-4), 
125.5 (d, J = 3.6 Hz, C-5’), 125.9 (C-2 or C-4), 128.4 (d, J = 20.0 Hz, C-1’), 129.9 (C-5), 
145.7 (d, J = 10.6 Hz, C-3’), 148.1 (d, J = 247.2 Hz, C-2’), 161.3 (CO2H), 183.5 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -135.5 (ArCO); LRMS (ES
-
) m/z 340.1 [M(
35
Cl)-H]
-
, 
342.1 [M(
37
Cl)-H]
-
; HRMS (NSI) calcd for C15H14ClFNO5 [M(
35
Cl)+H]
+
 342.0539, found 
342.0542. 
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4-(6-Chloro-2-fluoro-3-((tetrahydrofuran-3-yl)oxy)benzoyl)-1H-pyrrole-2-carboxylic 
acid, (374) 
 
Compound 374 was synthesised according to general procedure R, using the following 
reagents: methyl 4-(6-chloro-2-fluoro-3-((tetrahydrofuran-3-yl)oxy)benzoyl)-1H-pyrrole-
2-carboxylate (370) (650 mg, 1.77 mmol), 2 M aq. lithium hydroxide (13.3 mL, 
26.6 mmol) and THF (14.2 mL). The crude pale orange solid (600 mg, 96%) was used in 
the next step without further purification; Rf = 0.19 (petrol:EtOAc:AcOH, 50:49.7:0.3); 
m.p. 111.5-113.5 °C; λmax (EtOH)/nm 230.2, 282.4; IR (neat) νmax/cm
-1
 3127, 2987, 2933, 
2887, 1687, 1640, 1558, 1469, 1448, 1268, 1227, 1191; 
1
H NMR (500 MHz, DMSO-d6) 
δ 1.95 – 2.08 (1H, m, ArOCHCH2CH2), 2.24 (1H, dtd, J = 14.3, 8.3, 6.0 Hz, 
ArOCHCH2CH2), 3.75 (1H, td, J = 8.3, 4.5 Hz, OCH2), 3.81 – 3.91 (3H, m, OCH2), 5.13 
(1H, s, ArOCH), 6.98 (1H, s, H-3), 7.29 (1H, dd, J = 9.1, 8.8 Hz, H-4’), 7.34 (1H, d, 
J = 9.1 Hz, H-5’), 7.49 (1H, s, H-5), 12.72 (1H, s, NH-pyrrole), 12.94 (1H, s, CO2H); 
13
C NMR (126 MHz, DMSO-d6) δ 32.4 (ArOCHCH2CH2), 66.4 (OCH2), 72.1 (OCH2), 
79.2 (ArOCH), 114.3 (C-3), 117.2 (C-4’), 120.6 (d, J = 4.7 Hz, C-6’), 125.2 (C-2 or C-4), 
125.5 (d, J = 3.6 Hz, C-5’), 125.9 (C-2 or C-4), 128.7 (d, J = 20.1 Hz, C-1’), 130.0 (C-5), 
144.4 (d, J = 10.7 Hz, C-3’), 148.6 (d, J = 247.1 Hz, C-2’), 161.4 (CO2H), 183.5 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -135.2 (ArF); LRMS (ES
-
) m/z 352.1 [M(
35
Cl)-H]
-
, 
354.1 [M(
37
Cl)-H]
-
; HRMS (NSI) calcd for C16H14ClFNO5 [M(
35
Cl)+H]
+
 354.0539, found 
354.0543. 
 
4-(6-Chloro-2-fluoro-3-((tetrahydro-2H-pyran-4-yl)oxy)benzoyl)-1H-pyrrole-2-
carboxylic acid, (375) 
 
Compound 375 was synthesised according to general procedure R, using the following 
reagents: methyl 4-(6-chloro-2-fluoro-3-((tetrahydro-2H-pyran-4-yl)oxy)benzoyl)-1H-
pyrrole-2-carboxylate (371) (800 mg, 2.09 mmol), 2 M aq. lithium hydroxide (15.7 mL, 
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31.4 mmol) and THF (16.7 mL). The crude white solid (740 mg, 96%) was used in the 
next step without further purification; Rf = 0.21 (petrol:EtOAc:AcOH, 50:49.7:0.3); 
m.p. 111.5-113.5 °C; λmax (EtOH)/nm 230.6, 282.8; IR (neat) νmax/cm
-1
 3129, 2958, 2865, 
1698, 1689, 1649, 1559, 1463, 1435, 1268, 1225; 
1
H NMR (500 MHz, DMSO-d6) δ 1.62 
(2H, dddd, J = 13.1, 9.0, 9.0 and 4.1 Hz, ArOCHCH2), 1.92 – 2.03 (2H, m, ArOCHCH2), 
3.47 (2H, ddd, J = 13.1, 9.0 and 2.8 Hz, ArOCHCH2CH2O), 3.84 (2H, ddd, J = 13.1, 4.1 
and 4.1 Hz, ArOCHCH2CH2O), 4.65 (1H, tt, J = 9.0, 4.1 Hz, ArOCH), 6.96 (1H, s, H-3), 
7.32 (1H, dd, J = 9.0, 1.1 Hz, H-5’), 7.41 (1H, dd, J = 9.0, 9.0 Hz, H-4’), 7.47 (1H, s, H-5), 
12.69 (1H, s, NH-pyrrole), 12.91 (1H, s, CO2H); 
13
C NMR (126 MHz, DMSO-d6) δ 31.6 
(ArOCHCH2), 64.4 (ArOCHCH2CH2O), 73.8 (ArOCH), 114.2 (C-3), 118.5 (C-4’), 120.7 
(d, J = 4.9 Hz, C-6’), 125.2 (C-2 or C-4), 125.5 (d, J = 2.8 Hz, C-5’), 125.9 (C-2 or C-4), 
128.7 (d, J = 20.2 Hz, C-1’), 129.9 (C-5), 144.0 (d, J = 10.5 Hz, C-3’), 149.0 (d, 
J = 246.7 Hz, C-2’), 161.3 (CO2H), 183.5 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) 
δ -134.6 (ArF); LRMS (ES-) m/z 366.1 [M(35Cl)-H]-, 368.1 [M(37Cl)-H]-; HRMS (NSI) 
calcd for C17H16ClFNO5 [M(
35
Cl)+H]
+
 368.0696, found 368.0691. 
 
4-(6-Chloro-3-ethoxy-2-fluorobenzoyl)-N-(pyridin-3-yl)-1H-pyrrole-2-carboxamide, 
(376) 
 
Compound 376 was synthesised according to general procedure U, using the following 
reagents: 4-(6-chloro-3-ethoxy-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (372) 
(100 mg, 0.32 mmol), 3-aminopyridine (76 mg, 0.80 mmol), phosphorus trichloride 
(29 µL, 44 mg, 0.32 mmol) and acetonitrile (1.6 mL). The crude product was purified by 
column chromatography (silica gel, petrol:EtOAc, 1:0  1:9) to yield the title compound 
as an off-white solid (75 mg, 60%); Rf = 0.29 (petrol:EtOAc, 1:9); m.p. 146.0-148.0 °C; 
λmax (EtOH)/nm 293.4; IR (neat) νmax/cm
-1
 3123, 2976, 2958, 2932, 1633, 1598, 1555, 
1532, 1464, 1284, 1235; 
1
H NMR (500 MHz, DMSO-d6) δ 1.36 (3H, t, J = 7.0 Hz, 
OCH2CH3), 4.16 (2H, q, J = 7.0 Hz, OCH2CH3), 7.31 (1H, dd, J = 9.0, 8.8 Hz, H-4’), 
7.33 – 7.41 (2H, m, H-5’ and H-5”), 7.49 (2H, s, H-3 and H-5), 8.13 (1H, ddd, J = 8.5, 2.6 
and 1.5 Hz, H-4”), 8.30 (1H, dd, J = 4.7, 1.5 Hz, H-6”), 8.89 (1H, d, J = 2.6 Hz, H-2”), 
10.24 (1H, s, CONHAR), 12.71 (1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) 
δ 14.5 (OCH2CH3), 64.9 (OCH2CH3), 111.6 (C-3), 116.0 (d, J = 2.4 Hz, C-4’), 120.1 (d, 
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J = 4.9 Hz, C-6’), 123.6 (C-5”), 125.2 (C-2 or C-4), 125.6 (d, J = 3.6 Hz, C-5’), 127.0 
(C-4”), 128.1 (C-2 or C-4), 128.5 (d, J = 20.2 Hz, C-1’), 129.5 (C-5), 135.5 (C-3”), 141.6 
(C-2”), 144.4 (C-6”), 145.7 (d, J = 10.6 Hz, C-3’), 148.1 (d, J = 246.8 Hz, C-2’), 158.7 
(CONHAr), 183.7 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -135.7 (ArF); LRMS (ES
-
) 
m/z 386.1 [M(
35
Cl)-H]
-
, 388.2 [M(
37
Cl)-H]
-
; HRMS (NSI) calcd for C19H16ClFN3O3 
[M(
35
Cl)+H]
+
 388.0859, found 388.0860. 
 
4-(6-Chloro-2-fluoro-3-(2-methoxyethoxy)benzoyl)-N-(pyridin-3-yl)-1H-pyrrole-2-
carboxamide, (377) 
 
Compound 377 was synthesised according to general procedure U, using the following 
reagents: 4-(6-chloro-2-fluoro-3-(2-methoxyethoxy)benzoyl)-1H-pyrrole-2-carboxylic acid 
(373) (100 mg, 0.29 mmol), 3-aminopyridine (69 mg, 0.73 mmol), phosphorus trichloride 
(26 µL, 40 mg, 0.29 mmol) and acetonitrile (1.5 mL). The crude product was purified by 
column chromatography (silica gel, petrol:EtOAc, 1:0  5:95) to yield the title compound 
as a pale pink solid (80 mg, 66%); Rf = 0.29 (petrol:EtOAc, 5:95); m.p. 148.0-150.0 °C; 
λmax (EtOH)/nm 251.2, 293.4; IR (neat) νmax/cm
-1
 3122, 2933, 1637, 1598, 1554, 1534, 
1471, 1451, 1422, 1272; 
1
H NMR (500 MHz, DMSO-d6) δ 3.31 (3H, s, CH3OCH2), 3.69 
(2H, t, J = 4.3 Hz, CH3OCH2), 4.24 (2H, t, J = 4.3 Hz, CH2OAr), 7.34 (1H, dd, J = 9.0, 
9.0 Hz, H-4’), 7.36 (1H, d, J = 9.0 Hz, H-5’), 7.38 (1H, dd, J = 8.8, 4.4 Hz, H-5”), 7.48 
(1H, s, H-3), 7.50 (1H, s, H-5), 8.13 (1H, ddd, J = 8.8, 2.5 and 1.4 Hz, H-4”), 8.30 (1H, dd, 
J = 4.4, 1.4 Hz, H-6”), 8.89 (1H, d, J = 2.5, H-2”), 10.25 (1H, s, CONHAr), 12.72 (1H, s, 
NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 58.2 (CH3OCH2), 68.6 (OCH2), 70.1 
(OCH2), 111.7 (C-3), 116.2 (C-4’), 120.4 (d, J = 4.7 Hz, C-6’), 123.6 (C-5”), 125.2 (C-2 or 
C-4), 125.6 (d, J = 3.9 Hz, C-5’), 127.0 (C-4”), 128.1 (C-2 or C-4), 128.5 (d, J = 20.3 Hz, 
C-1’), 129.4 (C-5), 135.5 (C-3”), 141.6 (C-2”), 144.4 (C-6”), 145.7 (d, J = 10.8 Hz, C-3’), 
148.1 (d, J = 247.0 Hz, C-2’), 158.7 (CONHAr), 183.7 (ArCO); 19F NMR (471 MHz, 
DMSO-d6) δ -135.5 (ArF); LRMS (ES
-
) m/z 416.2 [M(
35
Cl)-H]
-
, 418.2 [M(
37
Cl)-H]
-
; 
HRMS (NSI) calcd for C20H18ClFN3O4 [M(
35
Cl)+H]
+
 418.0964, found 418.0953. 
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4-(6-Chloro-2-fluoro-3-((tetrahydrofuran-3-yl)oxy)benzoyl)-N-(pyridin-3-yl)-1H-
pyrrole-2-carboxamide, (378) 
 
Compound 378 was synthesised according to general procedure U, using the following 
reagents: 4-(6-chloro-2-fluoro-3-((tetrahydrofuran-3-yl)oxy)benzoyl)-1H-pyrrole-2-
carboxylic acid (374) (100 mg, 0.28 mmol), 3-aminopyridine (67 mg, 0.71 mmol), 
phosphorus trichloride (25 µL, 39 mg, 0.28 mmol) and acetonitrile (1.4 mL). The crude 
product was purified by column chromatography (silica gel, petrol:EtOAc, 1:0  5:95) to 
yield the title compound as a white solid (76 mg, 62%); Rf = 0.30 (petrol:EtOAc, 5:95); 
m.p. 150.5-152.5 °C; λmax (EtOH)/nm 250.8, 292.4; IR (neat) νmax/cm
-1
 3112, 2953, 2864, 
1636, 1596, 1553, 1531, 1464, 1420, 1271; 
1
H NMR (500 MHz, DMSO-d6) δ 2.02 (1H, dt, 
J = 12.7, 5.9 Hz, ArOCHCH2CH2), 2.26 (1H, dtd, J = 14.2, 8.2, 6.0 Hz, ArOCHCH2CH2), 
3.76 (1H, td, J = 8.4, 4.6 Hz, OCH2), 3.82 – 3.92 (3H, m, OCH2), 5.09 – 5.20 (1H, m, 
ArOCH), 7.31 (1H, dd, J = 9.7, 8.8 Hz, H-4’), 7.37 (1H, d, J = 9.7 Hz, H-5’), 7.40 (1H, dd, 
J = 8.4, 4.3 Hz, H-5”), 7.46 – 7.54 (2H, m, H-3 and H-5), 8.14 (1H, d, J = 8.4 Hz, H-4”), 
8.30 (1H, d, J = 4.3 Hz, H-6”), 8.90 (1H, s, H-2”), 10.26 (1H, s, CONHAr), 12.72 (1H, s, 
NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 32.3 (ArOCHCH2CH2), 66.4 (OCH2), 
72.1 (OCH2), 79.1 (ArOCH), 111.6 (C-3), 117.1 (C-4’), 120.7 (d, J = 4.9 Hz, C-6’), 123.6 
(C-5”), 125.2 (C-2 or C-4), 125.5 (d, J = 3.7 Hz, C-5’), 127.1 (C-4”), 128.2 (C-2 or C-4), 
128.8 (d, J = 20.2 Hz, C-1’), 129.7 (C-5), 135.5 (C-3”), 141.5 (C-2”), 144.3 (C-6”), 144.4 
(d, J = 9.6 Hz, C-3’), 148.6 (d, J = 246.9 Hz, C-2’), 158.7 (CONHAr), 183.6 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -135.1 (ArF); LRMS (ES
+
) m/z 428.2 [M(
35
Cl)+H]
+
, 
430.2 [M(
37
Cl)+H]
+
; HRMS (NSI) calcd for C21H18ClFN3O4 [M(
35
Cl)+H]
+
 430.0964, 
found 430.0957. 
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4-(6-Chloro-2-fluoro-3-((tetrahydro-2H-pyran-4-yl)oxy)benzoyl)-N-(pyridin-3-yl)-1H-
pyrrole-2-carboxamide, (379) 
 
Compound 379 was synthesised according to general procedure U, using the following 
reagents: 4-(6-chloro-2-fluoro-3-((tetrahydro-2H-pyran-4-yl)oxy)benzoyl)-1H-pyrrole-2-
carboxylic acid (375) (100 mg, 0.27 mmol), 3-aminopyridine (64 mg, 0.68 mmol), 
phosphorus trichloride (24 µL, 37 mg, 0.27 mmol) and acetonitrile (1.4 mL). The crude 
product was purified by column chromatography (silica gel, petrol:EtOAc, 1:0  5:95) to 
yield the title compound as a white solid (85 mg, 70%); Rf = 0.31 (petrol:EtOAc, 5:95); 
m.p. 133.5-135.5 °C; λmax (EtOH)/nm 251.2, 293.4; IR (neat) νmax/cm
-1
 3238, 3120, 2955, 
2923, 2852, 1635, 1596, 1553, 1531, 1462, 1420, 1271, 1227; 
1
H NMR (500 MHz, 
DMSO-d6) δ 1.63 (2H, dddd, J = 13.2, 8.9, 8.9 and 4.0 Hz, ArOCHCH2), 1.93 – 2.07 (2H, 
m, ArOCHCH2), 3.48 (2H, ddd, J = 13.2, 8.9 and 2.9 Hz, ArOCHCH2CH2O), 3.85 (2H, 
ddd, J = 13.2, 4.5 and 4.5 Hz, ArOCHCH2CH2O), 4.67 (1H, tt, J = 8.9, 4.0 Hz, ArOCH), 
7.35 (1H, d, J = 9.0 Hz, H-5’), 7.38 (1H, dd, J = 8.2, 4.7 Hz, H-5”), 7.43 (1H, dd, J = 9.0, 
8.9 Hz, H-4’), 7.50 (2H, s, H-3 and H-5), 8.13 (1H, d, J = 8.2 Hz, H-4”), 8.30 (1H, d, 
J = 4.7 Hz, H-6”), 8.89 (1H, s, H-2”), 10.25 (1H, s, CONHAr), 12.71 (1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 31.6 (ArOCHCH2), 64.4 (ArOCHCH2CH2O), 73.8 
(ArOCH), 111.6 (C-3), 118.5 (C-4’), 120.8 (d, J = 5.0 Hz, C-6’), 123.6 (C-5”), 125.2 (C-2 
or C-4), 125.5 (d, J = 3.3 Hz, C-5’), 127.0 (C-4”), 128.2 (C-2 or C-4), 128.8 (d, 
J = 20.3 Hz, C-1’), 129.6 (C-5), 135.5 (C-3”), 141.6 (C-2”), 144.0 (d, J = 10.7 Hz, C-3’), 
144.4 (C-6”), 149.0 (d, J = 246.8 Hz, C-2’), 158.7 (CONHAr), 183.6 (ArCO); 19F NMR 
(471 MHz, DMSO-d6) δ -134.5 (ArF); LRMS (ES
+
) m/z 444.3 [M(
35
Cl)+H]
+
, 446.3 
[M(
37
Cl)+H]
+
; HRMS (NSI) calcd for C22H20ClFN3O4 [M(
35
Cl)+H]
+
 444.1121, found 
444.1115. 
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4-(6-Chloro-3-ethoxy-2-fluorobenzoyl)-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrole-2-
carboxamide, (380) 
 
Compound 380 was synthesised according to general procedure U, using the following 
reagents: 4-(6-chloro-3-ethoxy-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (372) 
(100 mg, 0.32 mmol), 1-methyl-1H-pyrazol-4-amine (348) (78 mg, 0.80 mmol), 
phosphorus trichloride (29 µL, 44 mg, 0.32 mmol) and acetonitrile (1.6 mL). The crude 
product was purified by column chromatography (silica gel, petrol:EtOAc, 1:0  5:95) to 
yield the title compound as a white solid (78 mg, 62%); Rf = 0.30 (petrol:EtOAc, 5:95); 
m.p. 152.5-154.5 °C; λmax (EtOH)/nm 251.6; IR (neat) νmax/cm
-1
 3319, 3123, 2979, 2935, 
1619, 1593, 1571, 1464, 1268, 1243; 
1
H NMR (500 MHz, DMSO-d6) δ 1.36 (3H, t, 
J = 7.0 Hz, OCH2CH3), 3.81 (3H, s, NCH3), 4.16 (2H, q, J = 7.0 Hz, OCH2CH3), 
7.25 - 7.32 (2H, m, H-3 and H-4’), 7.35 (1H, dd, J = 9.0, 1.3 Hz, H-5’), 7.42 (1H, s, H-5), 
7.50 (1H, s, H-5”), 7.94 (1H, s, H-3”), 10.25 (1H, s, CONHAr), 12.57 (1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 14.5 (OCH2CH3), 38.7 (NCH3), 64.9 (OCH2CH3), 
110.3 (C-3), 115.9 (C-4’), 120.1 (d, J = 4.8 Hz, C-6’), 121.2 (C-2”), 121.4 (C-3”), 125.1 
(C-2 or C-4), 125.5 (d, J = 3.6 Hz, C-5’), 128.4 (C-2 or C-4), 128.6 (d, J = 20.2 Hz, C-1’), 
128.7 (C-5), 129.9 (C-5”), 145.7 (d, J = 10.7 Hz, C-3’), 148.0 (d, J = 246.7 Hz, C-2’), 
156.8 (CONHAr), 183.7 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -135.8 (ArF); 
LRMS (ES
-
) m/z 389.2 [M(
35
Cl)-H]
-
, 391.2 [M(
37
Cl)-H]
-
; HRMS (NSI) calcd for 
C18H17ClFN4O3 [M(
35
Cl)+H]
+
 391.0968 found 391.0968. 
 
4-(6-Chloro-2-fluoro-3-(2-methoxyethoxy)benzoyl)-N-(1-methyl-1H-pyrazol-4-yl)-1H-
pyrrole-2-carboxamide, (381) 
 
Compound 381 was synthesised according to general procedure U, using the following 
reagents: 4-(6-chloro-2-fluoro-3-(2-methoxyethoxy)benzoyl)-1H-pyrrole-2-carboxylic acid 
(373) (100 mg, 0.29 mmol), 1-methyl-1H-pyrazol-4-amine (348) (71 mg, 0.73 mmol), 
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phosphorus trichloride (26 µL, 40 mg, 0.29 mmol) and acetonitrile (1.5 mL). The crude 
product was purified by column chromatography (silica gel, petrol:EtOAc, 1:0  5:95) to 
yield the title compound as a pale pink solid (76 mg, 62%); Rf = 0.31 (petrol:EtOAc, 5:95); 
m.p. 241.0-243.0 °C; λmax (EtOH)/nm 251.0; IR (neat) νmax/cm
-1
 3344, 3121, 2935, 1622, 
1589, 1569, 1544, 1471, 1449, 1435, 1404, 1272, 1241; 
1
H NMR (500 MHz, DMSO-d6) 
δ 3.31 (3H, s, CH3OCH2), 3.64 – 3.72 (2H, m, CH3OCH2), 3.81 (3H, s, NCH3), 4.20 – 4.27 
(2H, m, CH2OAr), 7.28 (1H, s, H-3), 7.30 – 7.38 (2H, m, H-4’, 5’), 7.43 (1H, s, H-5), 7.50 
(1H, s, H-5”), 7.94 (1H, s, H-3”), 10.25 (1H, s, CONHAr), 12.57 (1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 38.7 (NCH3), 58.2 (CH3OCH2), 68.6 (OCH2), 70.1 
(OCH2), 110.3 (C-3), 116.1 (d, J = 2.3 Hz, C-4’), 120.4 (d, J = 4.9 Hz, C-6’), 121.2 (C-3”), 
121.4 (C-4”), 125.1 (C-2 or C-4), 125.5 (d, J = 3.6 Hz, C-5’), 128.4 (C-2 or C-4), 128.6 (d, 
J = 20.3 Hz, C-1’), 128.7 (C-5), 129.9 (C-5”), 145.7 (d, J = 10.5 Hz, C-3’), 148.1 (d, 
J = 247.0 Hz, C-2’), 156.8 (CONHAr), 183.6 (ArCO); 19F NMR (471 MHz, DMSO-d6) 
δ -135.5 (ArF); LRMS (ES-) m/z 419.2 [M(35Cl)-H]-, 421.2 [M(37Cl)-H]-; HRMS (NSI) 
calcd for C19H19ClFN4O4 [M(
35
Cl)+H]
+
 421.1073, found 421.1064. 
 
4-(6-Chloro-2-fluoro-3-((tetrahydrofuran-3-yl)oxy)benzoyl)-N-(1-methyl-1H-pyrazol-
4-yl)-1H-pyrrole-2-carboxamide, (382) 
 
Compound 382 was synthesised according to general procedure U, using the following 
reagents: 4-(6-chloro-2-fluoro-3-((tetrahydrofuran-3-yl)oxy)benzoyl)-1H-pyrrole-2-
carboxylic acid (374) (100 mg, 0.28 mmol), 1-methyl-1H-pyrazol-4-amine (348) (69 mg, 
0.71 mmol), phosphorus trichloride (25 µL, 39 mg, 0.28 mmol) and acetonitrile (1.4 mL). 
The crude product was purified by column chromatography (silica gel, petrol:EtOAc, 
1:0  5:95) to yield the title compound as a white solid (46 mg, 38%); Rf = 0.29 
(petrol:EtOAc, 5:95); m.p. 158.5-160.5 °C; λmax (EtOH)/nm 251.2; IR (neat) νmax/cm
-1
 
3187, 3123, 2954, 2866, 1631, 1591, 1568, 1545, 1465, 1435, 1407, 1271; 
1
H NMR 
(500 MHz, DMSO-d6) δ 2.02 (1H, dt, J = 12.7, 5.9 Hz, ArOCHCH2CH2), 2.26 (1H, dq, 
J = 12.7, 7.8 Hz, ArOCHCH2CH2), 3.76 (1H, td, J = 8.5, 4.7 Hz, OCH2), 3.81 (3H, s, 
NCH3), 3.83 – 3.93 (3H, m, OCH2), 5.15 (1H, s, ArOCH), 7.25 – 7.33 (2H, m, H-3 and 
H-4’), 7.36 (1H, d, J = 9.0 Hz, H-5’), 7.44 (1H, s, H-5), 7.50 (1H, s, H-5”), 7.94 (1H, s, 
H-3”), 10.25 (1H, s, CONHAr), 12.58 (1H, s, NH-pyrrole); 13C NMR (126 MHz, 
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DMSO-d6) δ 32.3 (ArOCHCH2CH2), 38.7 (NCH3), 66.4 (OCH2), 72.1 (OCH2), 79.1 
(ArOCH), 110.2 (C-3), 117.1 (C-4’), 120.7 (d, J = 4.9 Hz, C-6’), 121.2 (C-5”), 121.4 
(C-4”), 125.0 (C-2 or C-4), 125.5 (d, J = 3.4 Hz, C-5’), 128.5 (C-2 or C-4), 128.9 (d, 
J = 20.4 Hz, C-2’), 129.0 (C-5), 129.9 (C-3”), 144.3 (d, J = 10.8 Hz, C-3’), 148.6 (d, 
J = 247.0 Hz, C-2’), 156.8 (CONHAr), 183.6 (ArCO); 19F NMR (471 MHz, DMSO-d6) 
δ -135.1 (ArF); LRMS (ES-) m/z 431.2 [M(35Cl)-H]-, 433.2 [M(37Cl)-H]-; HRMS (NSI) 
calcd for C20H19ClFN4O4 [M(
35
Cl)+H]
+
 433.1073, found 433.1062. 
 
4-(6-Chloro-2-fluoro-3-((tetrahydro-2H-pyran-4-yl)oxy)benzoyl)-N-(1-methyl-1H-
pyrazol-4-yl)-1H-pyrrole-2-carboxamide, (383) 
 
Compound 383 was synthesised according to general procedure U, using the following 
reagents: 4-(6-chloro-2-fluoro-3-((tetrahydro-2H-pyran-4-yl)oxy)benzoyl)-1H-pyrrole-2-
carboxylic acid (375) (100 mg, 0.27 mmol), 1-methyl-1H-pyrazol-4-amine (348) (66 mg, 
0.68 mmol), phosphorus trichloride (24 µL, 37 mg, 0.27 mmol) and acetonitrile (1.4 mL). 
The crude product was purified by column chromatography (silica gel, petrol:EtOAc, 
1:0  5:95) to yield the title compound as a white solid (71 mg, 59%); Rf = 0.29 
(petrol:EtOAc, 5:95); m.p. 125.0-127.0 °C; λmax (EtOH)/nm 251.2; IR (neat) νmax/cm
-1
 
3192, 3122, 2955, 2924, 2853, 1630, 1590, 1567, 1544, 1462, 1433, 1407, 1270, 1232; 
1
H NMR (500 MHz, DMSO-d6) δ 1.63 (2H, dddd, J = 13.1, 9.0, 9.0 and 4.0 Hz, 
ArOCHCH2), 1.94 – 2.03 (2H, m, ArOCHCH2), 3.48 (2H, ddd, J = 13.1, 9.0 and 2.8 Hz, 
ArOCHCH2CH2O), 3.81 (3H, s, NCH3), 3.85 (2H, ddd, J = 13.1, 4.2 and 4.2 Hz, 
ArOCHCH2CH2O), 4.66 (1H, tt, J = 9.0, 4.2 Hz, ArOCH), 7.29 (1H, s, H-3), 7.34 (1H, d, 
J = 9.3 Hz, H-5’), 7.42 (1H, dd, J = 9.3, 8.7 Hz, H-4’), 7.43 (1H, s, H-5), 7.50 (1H, s, 
H-5”), 7.94 (1H, s, H-3”), 10.25 (1H, s, CONHAr), 12.56 (1H, s, NH-pyrrole); 13C NMR 
(126 MHz, DMSO-d6) δ 31.6 (ArOCHCH2), 64.4 (ArOCHCH2CH2O), 73.8 (ArOCH), 
110.3 (C-3), 118.4 (C-4’), 120.8 (d, J = 4.8 Hz, C-6’), 121.2 (C-4”), 121.4 (C-3”), 125.1 
(C-2 or C-4), 125.5 (d, J = 3.4 Hz, C-5’), 128.5 (C-2 or C-4), 128.8 (C-5), 128.9 (d, 
J = 20.7 Hz, C-1’), 129.9 (C-5”), 144.0 (d, J = 10.8 Hz, C-3’), 149.0 (d, J = 246.8 Hz, 
C-2’), 156.8 (CONHAr), 183.6 (ArCO); 19F NMR (471 MHz, DMSO-d6) δ -134.5 (ArF); 
LRMS (ES
+
) m/z 447.3 [M(
35
Cl)+H]
+
, 449.3 [M(
37
Cl)+H]
+
; HRMS (NSI) calcd for 
C21H21ClFN4O4 [M(
35
Cl)+H]
+
 447.1230, found 447.1224. 
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6-Chloro-2-fluoro-3-(oxetan-3-yloxy)benzoic acid, (384) 
 
Compound 384 was synthesised according to general procedure A’, using the following 
reagents: 3-(4-chloro-2-fluorophenoxy)oxetane (349) (500 mg, 2.47 mmol), n-butyllithium 
(1.03 mL, 2.47 mmol) and THF (7.4 mL). The white solid (570 mg, 94%) was used in the 
next step without further purification; Rf = 0.29 (petrol:EtOAc:AcOH, 50:49.7:0.3); 
m.p. 152.0-154.0 °C; λmax (EtOH)/nm 282.4; IR (neat) νmax/cm
-1
 2952, 2923, 2886, 1720, 
1614, 1577, 1472, 1253; 
1
H NMR (500 MHz, DMSO-d6) δ 4.58 (2H, dd, J = 7.4, 4.8 Hz, 
ArOCHCH2O), 4.85 – 4.96 (2H, m, ArOCHCH2O), 5.37 (1H, p, J = 5.4 Hz, 
ArOCHCH2O), 6.95 (1H, dd, J = 9.0, 8.9 Hz, H-4), 7.29 (1H, dd, J = 8.9, 1.5 Hz, H-5), 
14.17 (1H, s, ArCO2H); 
13
C NMR (126 MHz, DMSO-d6) δ 71.6 (ArOCHCH2O), 76.4 
(ArOCHCH2O), 116.3 (d, J = 1.9 Hz, C-4), 121.0 (d, J = 4.6 Hz, C-6), 124.5 (d, 
J = 19.0 Hz, C-1), 125.5 (d, J = 3.9 Hz, C-5), 143.5 (d, J = 10.7 Hz, C-3), 148.0 (d, 
J = 250.0 Hz, C-2), 163.5 (ArCO2H); 
19
F NMR (471 MHz, DMSO-d6) δ -134.6 (ArF); 
LRMS (ES
-
) m/z 245.1 [M(
35
Cl)-H]
-
, 247.1 [M(
37
Cl)-H]
-
; HRMS (NSI) calcd for 
C10H9ClFO4 [M(
35
Cl)+H]
+
 245.0022, found 245.0022. 
 
Methyl 4-(6-chloro-3-((1-chloro-3-hydroxypropan-2-yl)oxy)-2-fluorobenzoyl)-1H-
pyrrole-2-carboxylate, (385) 
 
To a solution 6-chloro-2-fluoro-3-(oxetan-3-yloxy)benzoic acid (384) (550 mg, 
2.23 mmol) in THF (5 mL), cooled at 0 °C, was added thionyl chloride (243 μL, 398 mg, 
3.03 mmol) and N,N-dimethylformamide (17 μL, 16 mg, 0.22 mmol). The resulting 
solution was stirred at 0 °C for 30 min and allowed to warm to RT. After 5 h, the solvent 
was removed in vacuo and the crude residue dissolved in DCM (3 mL). The resulting 
solution was added to a suspension of aluminium trichloride (594 mg, 4.46 mmol) in DCM 
(7 mL), cooled at 0 °C, followed by methyl 1H-pyrrole-2-carboxylate (184 mg, 
1.47 mmol). The resulting solution was stirred at 0 °C for 30 min and allowed to warm to 
RT. After 20 h, the reaction mixture was cooled to 0 °C and quenched by cautious addition 
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of 1 M aq. HCl (10 mL). The resulting solution was stirred at RT for 2 h. The reaction was 
then diluted with water (15 mL) and extracted with DCM (3 × 30 mL). The pooled organic 
extracts were washed with saturated aq. NaHCO3 and brine (40 mL, respectively), dried 
over MgSO4 and concentrated in vacuo. The crude product was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  35:65) to yield the title compound as a 
yellow oil (390 mg, 68%); Rf = 0.30 (petrol:EtOAc, 35:65); λmax (EtOH)/nm 230.2, 282.2; 
IR (neat) νmax/cm
-1
 3261, 3128, 2953, 2925, 2854, 1704, 1641, 1559, 1462, 1440, 1389, 
1270, 1229; 
1
H NMR (500 MHz, DMSO-d6) δ 3.68 (2H, dd, J = 5.4, 5.4 Hz, 
ArOCHCH2OH), 3.79 (3H, s, CO2CH3), 3.85 (1H, dd, J = 11.9, 5.6 Hz, ArOCHCH2Cl), 
3.94 (1H, dd, J = 11.9, 4.0 Hz, ArOCHCH2Cl), 4.60 – 4.68 (1H, m, ArOCH), 5.13 (1H, t, 
J = 5.6 Hz, ArOCHCH2OH), 7.01 (1H, s, H-3), 7.32 – 7.37 (1H, m, H-5’), 7.44 (1H, dd, 
J = 9.0, 9.0 Hz, H-4’), 7.51 – 7.58 (1H, s, H-5), 12.89 (1H, s, NH-pyrrole); 13C NMR 
(126 MHz, DMSO-d6) δ 43.8 (ArOCHCH2Cl), 51.7 (CO2CH3), 60.1 (ArOCHCH2OH), 
80.1 (ArOCH), 114.7 (C-3), 118.8 (C-4’), 121.2 (d, J = 4.8 Hz, C-6’), 124.6 (C-2 or C-4), 
125.3 (C-2 or C-4), 125.6 (d, J = 3.7 Hz, C-5’), 128.6 (d, J = 20.4 Hz, C-1’), 130.3 (C-5), 
144.9 (d, J = 10.7 Hz, C-3’), 148.9 (d, J = 247.6 Hz, C-2’), 160.3 (CO2CH3), 183.4 
(ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -133.9 (ArF); LRMS (ES
+
) m/z 390.2 
[M(
35
Cl)+H]
+
, 392.2 [M(
37
Cl)+H]
+
; HRMS (NSI) calcd for C16H15Cl2FNO5 [M(
35
Cl)+H]
+
 
390.0306, found 390.0306. 
 
4-(6-Chloro-2-fluoro-3-(oxetan-3-yloxy)benzoyl)-1H-pyrrole-2-carboxylic acid, (386) 
 
Compound 386 was synthesised according to general procedure R, using the following 
reagents: methyl 4-(6-chloro-3-((1-chloro-3-hydroxypropan-2-yl)oxy)-2-fluorobenzoyl)-
1H-pyrrole-2-carboxylate (385) (350 mg, 0.90 mmol), 2 M aq. lithium hydroxide (6.8 mL, 
13.6 mmol) and THF (7.2 mL). The reaction mixture was reflux for 72 h. The crude 
product was purified by column chromatography (silica gel, DCM:MeOH:AcOH, 
1:0:0  90:9.9:0.1) to yield the title compound as a white solid (225 mg, 74%); Rf = 0.34 
(DCM:MeOH:AcOH, 90:9.9:0.1); m.p. 94.5-96.5 °C; λmax (EtOH)/nm 230.0, 283.0; 
IR (neat) νmax/cm
-1
 3126, 2952, 2880, 1689, 1640, 1559, 1465, 1269, 1227; 
1
H NMR 
(500 MHz, DMSO-d6) δ 4.61 (2H, dd, J = 7.4, 4.9 Hz, ArOCHCH2O), 4.93 (2H, t, 
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J = 6.9 Hz, ArOCHCH2O), 5.39 (1H, p, J = 5.5 Hz, ArOCHCH2O), 6.94 – 7.02 (2H, m, 
H-3 and H-4’), 7.31 (1H, dd, J = 8.9, 1.2 Hz, H-5’), 7.49 (1H, s, H-5), 12.71 (1H, s, 
NH-pyrrole), 12.79 (1H, s, CO2H); 
13
C NMR (126 MHz, DMSO-d6) δ 71.5 
(ArOCHCH2O), 76.4 (ArOCHCH2O), 114.2 (C-3), 116.2 (C-4’), 121.1 (d, J = 4.7 Hz, 
C-6’), 125.1 (C-2 or C-4), 125.6 (d, J = 3.8 Hz, C-5’), 125.9 (C-2 or C-4), 128.7 (d, 
J = 19.8 Hz, C-1’), 130.0 (C-5), 143.6 (d, J = 11.0 Hz, C-3’), 148.1 (d, J = 247.4 Hz, C-2’), 
161.3 (CO2H), 183.2 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -135.4 (ArF); 
LRMS (ES
-
) m/z 338.0 [M(
35
Cl)-H]
-
, 340.0 [M(
37
Cl)-H]
-
; HRMS (NSI) calcd for 
C15H12ClFNO5 [M(
35
Cl)+H]
+
 340.0383 found 340.0385. 
 
4-(6-Chloro-3-((1-chloro-3-hydroxypropan-2-yl)oxy)-2-fluorobenzoyl)-N-(pyridin-3-
yl)-1H-pyrrole-2-carboxamide, (387) 
 
Compound 387 was synthesised according to general procedure U, using the following 
reagents: 4-(6-chloro-2-fluoro-3-(oxetan-3-yloxy)benzoyl)-1H-pyrrole-2-carboxylic acid 
(386) (50 mg, 0.15 mmol), 3-aminopyridine (35 mg, 0.37 mmol), phosphorus trichloride 
(13 µL, 20 mg, 0.15 mmol) and acetonitrile (0.8 mL). The crude product was purified by 
column chromatography (silica gel, petrol:EtOAc, 1:0  1:9) to yield the title compound 
as an off-white solid (15 mg, 23%); Rf = 0.26 (petrol:EtOAc, 1:9); m.p. 121.5-123.5 °C; 
λmax (EtOH)/nm 251.2, 293.2; IR (neat) νmax/cm
-1
 3225, 2956, 2922, 2852, 1635, 1600, 
1553, 1534, 1462, 1422, 1274, 1233; 
1
H NMR (500 MHz, DMSO-d6) δ 3.68 (2H, dd, 
J = 5.4, 5.4 Hz, ArOCHCH2OH), 3.86 (1H, dd, J = 11.9, 5.4 Hz, ArOCHCH2Cl), 3.95 (1H, 
dd, J = 11.9, 4.0 Hz, ArOCHCH2Cl), 4.65 (1H, p, J = 5.4 Hz, ArOCH), 5.14 (1H, t, 
J = 5.4 Hz, ArOCHCH2OH), 7.35 – 7.41 (2H, m, H-5’ and H-5”), 7.45 (1H, dd, J = 9.0, 
9.0 Hz, H-4’), 7.49 (1H, s, H-3), 7.50 (1H, s, H-5), 8.13 (1H, dd, J = 8.5, 2.6 Hz, H-4”), 
8.30 (1H, d, J = 4.0 Hz, H-6”), 8.89 (1H, d, J = 2.6 Hz, H-2”), 10.26 (1H, s, CONHAr), 
12.72 (1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 43.8 (ArOCHCH2Cl), 60.1 
(ArOCHCH2OH), 80.1 (ArOCH), 111.6 (C-3), 118.7 (C-4’), 121.3 (d, J = 5.0 Hz, C-6’), 
123.5 (C-5”), 125.1 (C-2 or C-4), 125.5 (d, J = 3.6 Hz, C-5’), 127.0 (C-4”), 128.2 (C-2 or 
C-4), 128.8 (d, J = 20.5 Hz, C-1’), 129.5 (C-5), 135.5 (C-3”), 141.6 (C-2”), 144.4 (C-6”), 
144.9 (d, J = 10.8 Hz, C-3’), 148.9 (d, J = 247.5 Hz, C-2’), 158.7 (CONHAr), 183.6 
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(ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -133.9 (ArF); LRMS (ES
-
) m/z 450.2 
[M(
35
Cl
35
Cl)-H]
-
, 452.2 [M(
37
Cl
35
Cl)-H]
-
; HRMS (NSI) calcd for C20H17Cl2FN3O4 
[M(
35
Cl
35
Cl)+H]
+
 452.0575, found 452.0570. 
 
4-(6-Chloro-3-((1,3-dichloropropan-2-yl)oxy)-2-fluorobenzoyl)-N-(pyridin-3-yl)-1H-
pyrrole-2-carboxamide, (388) 
 
Compound 388 was synthesised according to general procedure U, using the following 
reagents: 4-(6-chloro-2-fluoro-3-(oxetan-3-yloxy)benzoyl)-1H-pyrrole-2-carboxylic acid 
(386) (50 mg, 0.15 mmol), 3-aminopyridine (35 mg, 0.37 mmol), phosphorus trichloride 
(13 µL, 20 mg, 0.15 mmol) and acetonitrile (0.8 mL). The crude product was purified by 
column chromatography (silica gel, petrol:EtOAc, 1:0  4:6) to yield the title compound 
as a white solid (17 mg, 25%); Rf = 0.62 (petrol:EtOAc, 1:9); m.p. 182.5-184.5 °C; 
λmax (EtOH)/nm 252.8, 293.0; IR (neat) νmax/cm
-1
 3237, 3123, 2961, 1636, 1599, 1554, 
1533, 1462, 1423, 1276, 1234; 
1
H NMR (500 MHz, DMSO-d6) δ 3.97 (4H, qd, J = 12.0, 
4.9 Hz, ArOCH(CH2Cl)2), 4.99 (1H, p, J = 4.9 Hz, ArOCH), 7.36 – 7.44 (2H, m, H-5’ and 
H-5”), 7.48 – 7.56 (3H, m, H-3, H-5 and H-4’), 8.13 (1H, dd, J = 8.4, 1.8 Hz, H-4”), 8.30 
(1H, d, J = 3.9 Hz, H-6”), 8.89 (1H, s, H-2”), 10.26 (1H, s, CONHAr), 12.73 (1H, s, 
NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 43.7 (ArOCH(CH2Cl)2), 78.4 (ArOCH), 
111.5 (C-3), 119.3 (C-4’), 122.3 (d, J = 4.7 Hz, C-6’), 123.6 (C-5”), 125.1 (C-2 or C-4), 
125.7 (d, J = 3.6 Hz, C-5’), 127.0 (C-4”), 128.2 (C-2 or C-4), 129.0 (d, J = 20.6 Hz, C-1’), 
129.7 (C-5), 135.5 (C-3”), 141.6 (C-2”), 144.1 (d, J = 11.0 Hz, C-3’), 144.4 (C-6”), 149.1 
(d, J = 248.2 Hz, C-2’), 158.7 (CONHAr), 183.4 (ArCO); 19F NMR (471 MHz, DMSO-d6) 
δ -133.5 (ArF); LRMS (ES-) m/z 468.2 [M(35Cl35Cl35Cl)-H]-, 470.2 [M(37Cl35Cl35Cl)-H]-; 
HRMS (NSI) calcd for C20H16Cl3FN3O3 [M(
35
Cl
35
Cl
35
Cl)+H]
+
 470.0236, found 470.0230. 
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4-(6-Chloro-2-fluoro-3-(oxetan-3-yloxy)benzoyl)-N-(pyridin-3-yl)-1H-pyrrole-2-
carboxamide, (389) 
 
Compound 389 was synthesised according to general procedure Y, using the following 
reagents: 4-(6-chloro-2-fluoro-3-(oxetan-3-yloxy)benzoyl)-1H-pyrrole-2-carboxylic acid 
(386) (75 mg, 0.22 mmol), triethylamine (77 µL, 56 mg, 0.55 mmol), 2-chloro-1-
methylpyridinium iodide (62 mg, 0.24 mmol), 3-aminopyridine (26 mg, 0.28 mmol) and 
DCM (2.2 mL). The crude yellow solid was purified by column chromatography (silica 
gel, petrol:EtOAc, 1:0  1:9) to yield the title compound as a white solid (19 mg, 21%); 
Rf = 0.29 (petrol:EtOAc, 1:9); m.p. 148.5-150.5 °C; λmax (EtOH)/nm 250.8, 293.2; 
IR (neat) νmax/cm
-1
 3259, 3121, 2955, 2876, 1638, 1598, 1553, 1534, 1465, 1422, 1271, 
1233; 
1
H NMR (500 MHz, DMSO-d6) δ 4.61 (2H, dd, J = 7.6, 4.8 Hz, ArOCHCH2O), 4.95 
(2H, t, J = 6.8 Hz, ArOCHCH2O), 5.40 (1H, p, J = 5.5 Hz, ArOCHCH2O), 7.00 (1H, dd, 
J = 9.0, 9.0 Hz, H-4’), 7.34 (1H, dd, J = 9.0, 1.6 Hz, H-5’), 7.39 (1H, dd, J = 8.3, 4.7 Hz, 
H-5”), 7.47 – 7.57 (2H, m, H-3 and H-5), 8.13 (1H, d, J = 8.3, H-4”), 8.30 (1H, d, 
J = 4.7 Hz, H-6”), 8.89 (1H, s, H-2”), 10.25 (1H, s, CONHAr), 12.74 (1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 71.6 (ArOCHCH2O), 76.4 (ArOCHCH2O), 111.5 (C-3), 
116.1 (C-4’), 121.3 (d, J = 4.9 Hz, C-6’), 123.6 (C-5”), 125.1 (C-2 or C-4), 125.7 (d, 
J = 3.5 Hz, C-5’), 127.0 (C-4”), 128.2 (C-2 or C-4), 128.9 (d, J = 20.0 Hz, C-1’), 129.7 
(C-5), 135.5 (C-3”), 141.6 (C-2”), 143.6 (d, J = 11.0 Hz, C-3’), 144.4 (C-6”), 148.1 (d, 
J = 247.2 Hz, C-2’), 158.7 (CONHAr), 183.4 (ArCO); 19F NMR (471 MHz, DMSO-d6) 
δ -135.3 (ArF); LRMS (ES-) m/z 414.2 [M(35Cl)-H]-, 416.2 [M(37Cl)-H]-; HRMS (NSI) 
calcd for C20H16ClFN3O4 [M(
35
Cl)+H]
+
 416.0808, found 416.0803. 
 
  
365 
4-(6-Chloro-2-fluoro-3-(oxetan-3-yloxy)benzoyl)-N-(1-methyl-1H-pyrazol-4-yl)-1H-
pyrrole-2-carboxamide, (390) 
 
Compound 390 was synthesised according to general procedure Y, using the following 
reagents: 4-(6-chloro-2-fluoro-3-(oxetan-3-yloxy)benzoyl)-1H-pyrrole-2-carboxylic acid 
(386) (75 mg, 0.22 mmol), triethylamine (77 µL, 56 mg, 0.55 mmol), 2-chloro-1-
methylpyridinium iodide (62 mg, 0.24 mmol), 1-methyl-1H-pyrazol-4-amine (348) 
(27 mg, 0.28 mmol) and DCM (2.2 mL). The crude yellow solid was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  1:9) to yield the title compound as a 
white solid (25 mg, 27%); Rf = 0.30 (petrol:EtOAc, 5:95); m.p. 141.5-143.5 °C; 
λmax (EtOH)/nm 251.4; IR (neat) νmax/cm
-1
 3180, 3122, 2952, 2924, 2875, 1631, 1591, 
1566, 1545, 1464, 1434, 1407, 1270, 1234; 
1
H NMR (500 MHz, DMSO-d6) δ 3.81 (3H, s, 
NCH3), 4.61 (2H, dd, J = 7.4, 5.0 Hz, ArOCHCH2O), 4.94 (2H, t, J = 6.9 Hz, 
ArOCHCH2O), 5.40 (1H, p, J = 5.7 Hz, ArOCHCH2O), 6.99 (1H, dd, J = 9.0, 8.9 Hz, 
H-4’), 7.31 (1H, s, H-3), 7.33 (1H, dd, J = 8.9, 1.3 Hz, H-5’), 7.45 (1H, s, H-5), 7.50 (1H, 
s, H-5”), 7.94 (1H, s, H-3”), 10.26 (1H, s, CONHAr), 12.60 (1H, s, NH-pyrrole); 13C NMR 
(126 MHz, DMSO-d6) δ 38.7 (NCH3), 71.5 (ArOCHCH2O), 76.4 (ArOCHCH2O), 110.2 
(C-3), 116.1 (C-4’), 121.2 (C-4”), 121.3 (d, J = 4.8 Hz, C-6’), 121.4 (C-3”), 125.0 (C-2 or 
C-4), 125.6 (d, J = 3.7 Hz, C-5’), 128.5 (C-2 or C-4), 128.9 (d, J = 17.2 Hz, C-1’), 129.0 
(C-5), 129.9 (C-5”), 143.6 (d, J = 10.8 Hz, C-3’), 148.1 (d, J = 247.6 Hz, C-2’), 156.8 
(CONHAr), 183.4 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -135.3 (ArF); LRMS (ES
-
) 
m/z 417.3 [M(
35
Cl)-H]
-
, 419.3 [M(
37
Cl)-H]
-
; HRMS (NSI) calcd for C19H17ClFN4O4 
[M(
35
Cl)+H]
+
 419.0917, found 419.0912. 
 
(2-(4-Chloro-2-fluorophenoxy)ethyl)(methyl)sulfane, (391) 
 
Compound 391 was synthesised according to general procedure B’, using the following 
reagents: 4-chloro-2-fluorophenol (349) (508 μL, 700 mg, 4.78 mmol), triphenylphosphine 
(1.88 g, 7.16 mmol), 2-(methylthio)ethanol (540 μL, 572 mg, 6.21 mmol), diethyl 
azodicarboxylate (1.13 mL, 1.25 g, 7.16 mmol) and THF (24 mL). The crude product was 
purified by column chromatography (silica gel, petrol:EtOAc, 1:0  96:4) to yield the title 
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compound as a clear liquid (1.01 g, 95%); Rf = 0.40 (petrol:EtOAc, 95:5; KMnO4); 
λmax (EtOH)/nm 276.8; IR (neat) νmax/cm
-1
 2919, 1585, 1495, 1304, 1264, 1204, 1128; 
1
H NMR (500 MHz, DMSO-d6) δ 2.15 (3H, s, SCH3), 2.85 (2H, t, J = 6.5 Hz, CH2SCH3), 
4.22 (2H, t, J = 6.5 Hz, ArOCH2), 7.17 – 7.27 (2H, m, H-5 and H-6), 7.41 – 7.45 (1H, m, 
H-3); 
13
C NMR (126 MHz, DMSO-d6) δ 15.3 (CH2SCH3), 32.0 (CH2SCH3), 68.5 
(ArOCH2), 116.1 (C-6), 116.6 (d, J = 21.7 Hz, C-3), 124.0 (d, J = 9.2 Hz, C-4), 124.7 (d, 
J = 3.8 Hz, C-5), 145.3 (d, J = 10.3 Hz, C-1), 151.4 (d, J = 247.8 Hz, C-2); 
19
F NMR 
(471 MHz, DMSO-d6) δ -131.5 (ArF); HRMS (APCI) calcd for C9H11ClFOS [M(
35
Cl)+H]
+
 
221.0198, found 221.0198. 
 
6-Chloro-2-fluoro-3-(2-(methylthio)ethoxy)benzoic acid, (392) 
 
Compound 392 was synthesised according to general procedure A’, using the following 
reagents: (2-(4-chloro-2-fluorophenoxy)ethyl)(methyl)sulfane (391) (1.05 g, 4.76 mmol), 
n-butyllithium (1.98 mL, 4.76 mmol) and THF (14.3 mL). The off-white solid (1.11 g, 
88%) was used in the next step without further purification; Rf = 0.30 
(petrol:EtOAc:AcOH, 50:49.7:0.3; KMnO4); m.p. 98.0-100.0 °C; λmax (EtOH)/nm 282.6; 
IR (neat) νmax/cm
-1
 2945, 1696, 1611, 1572, 1476, 1461, 1445, 1262; 
1
H NMR (500 MHz, 
DMSO-d6) δ 2.15 (3H, s, SCH3), 2.86 (2H, t, J = 6.5 Hz, CH2SCH3), 4.26 (2H, t, 
J = 6.5 Hz, ArOCH2), 7.28 – 7.34 (2H, m, H-4 and H-5), 14.13 (1H, s, ArCO2H); 
13
C NMR (126 MHz, DMSO-d6) δ 15.3 (CH2SCH3), 31.9 (CH2SCH3), 68.7 (ArOCH2), 
116.4 (C-4), 120.2 (d, J = 4.6 Hz, C-6), 124.2 (d, J = 19.2 Hz, C-1), 125.4 (d, J = 3.9 Hz, 
C-5), 145.4 (d, J = 10.4 Hz, C-3), 148.0 (d, J = 249.5 Hz, C-2), 163.6 (ArCO2H); 
19
F NMR 
(471 MHz, DMSO-d6) δ -134.7 (ArF); LRMS (ES
+
) m/z 264.9 [M(
35
Cl)+H]
+
, 266.9 
[M(
37
Cl)+H]
+
; HRMS (NSI) calcd for C10H11ClFO3S [M(
35
Cl)+H]
+
 265.0096, found 
265.0099. 
 
6-Chloro-2-fluoro-3-(2-(methylsulfonyl)ethoxy)benzoic acid, (393) 
 
To 6-chloro-2-fluoro-3-(2-(methylthio)ethoxy)benzoic acid (392) (300 mg, 1.13 mmol) in 
MeOH (8 mL) was added a solution of OXONE
®
 (monopersulfate compound) (1.04 g, 
3.40 mmol) in water (4 mL). The resulting cloudy solution was stirred at RT for 24 h. The 
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reaction mixture was filtered through Celite and concentrated in vacuo. The white residue 
was dissolved in saturated aq. NH4Cl (20 mL) and extracted with EtOAc (3 × 20 mL). The 
pooled organic extracts were washed with water and brine (30 mL, respectively), dried 
over MgSO4 and concentrated in vacuo. The crude product was purified by column 
chromatography (silica gel, DCM:MeOH:AcOH, 1:0:0  90:9.9:0.1) to yield the title 
compound as a white solid (300 mg, 89%); Rf = 0.25 (DCM:MeOH:AcOH, 90:9.9:0.1; 
KMnO4); m.p. 180.0-182.0 °C; λmax (EtOH)/nm 251.2, 293.4; IR (neat) νmax/cm
-1
 3150, 
3100, 3040, 3011, 2983, 2927, 1744, 1618, 1579, 1482, 1468, 1267, 1235; 
1
H NMR 
(500 MHz, DMSO-d6) δ 3.08 (3H, s, CH3SO2CH2), 3.68 (2H, t, J = 5.6 Hz, CH3SO2CH2), 
4.46 (2H, t, J = 5.6 Hz, CH2OAr), 7.33 – 7.39 (2H, m, H-4 and H-5), 14.17 (1H, s, 
ArCO2H); 
13
C NMR (126 MHz, DMSO-d6) δ 42.3 (CH3SO2CH2), 53.1 (CH3SO2CH2), 
63.6 (CH2OAr), 116.5 (C-4), 120.9 (d, J = 4.5 Hz, C-6), 124.3 (d, J = 19.1 Hz, C-1), 125.6 
(d, J = 3.8 Hz, C-5), 144.8 (d, J = 10.5 Hz, C-3), 148.0 (d, J = 249.7 Hz, C-2), 163.5 
(ArCO2H); 
19
F NMR (471 MHz, DMSO-d6) δ -134.70 (ArF); LRMS (ES
-
) m/z 295.1 
[M(
35
Cl)-H]
-
, 297.0 [M(
37
Cl)-H]
-
; HRMS (NSI) calcd for C10H11ClFO5S [M(
35
Cl)+H]
+
 
296.9994, found 296.9996. 
 
Methyl 4-(6-chloro-2-fluoro-3-(2-(methylsulfonyl)ethoxy)benzoyl)-1H-pyrrole-2-
carboxylate, (394) 
 
To a solution 6-chloro-2-fluoro-3-(2-(methylsulfonyl)ethoxy)benzoic acid (393) (600 mg, 
2.02 mmol) in THF (5 mL), cooled at 0 °C, were added thionyl chloride (220 μL, 361 mg, 
3.03 mmol) and N,N-dimethylformamide (16 μL, 15 mg, 0.20 mmol). The resulting 
solution was stirred at 0 °C for 30 min and allowed to warm to RT. After 5 h, the solvent 
was removed in vacuo and the crude residue dissolved in DCM (3 mL). The resulting 
solution was added to a suspension of aluminium trichloride (674 mg, 5.06 mmol) in DCM 
(7 mL), cooled at 0 °C, followed by methyl 1H-pyrrole-2-carboxylate (167 mg, 
1.33 mmol). The resulting solution was stirred at 0 °C for 30 min and allowed to warm to 
RT. After 20 h, the reaction mixture was cooled to 0 °C and quenched by cautious addition 
of 1 M aq. HCl (10 mL). The resulting solution was stirred at RT for 2 h, diluted with 
water (15 mL) and extracted with DCM (3 × 30 mL). The pooled organic extracts were 
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washed with saturated aq. NaHCO3 and brine (40 mL, respectively), dried over MgSO4 and 
concentrated in vacuo. The crude product was purified by column chromatography (silica 
gel, petrol:EtOAc, 1:0  4:6) to yield the title compound as a white solid (370 mg, 69%); 
Rf = 0.29 (petrol:EtOAc, 4:6); m.p. 72.0-74.0 °C; λmax (EtOH)/nm 229.6, 282.0; IR (neat) 
νmax/cm
-1
 3274, 3126, 2952, 2929, 1708, 1651, 1559, 1461, 1441, 1390, 1272, 1230, 1199, 
1125; 
1
H NMR (500 MHz, DMSO-d6) δ 3.06 (3H, s, CH3SO2CH2), 3.68 (2H, t, J = 5.6 Hz, 
CH3SO2CH2), 3.79 (3H, s, CO2CH3), 4.49 (2H, t, J = 5.6 Hz, CH2OAr), 7.02 (1H, s, H-3), 
7.36 – 7.43 (2H, m, H-4’ and H-5’), 7.57 (1H, s, H-5), 12.89 (1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 42.2 (CH3SO2CH2), 51.7 (CO2CH3), 53.1 
(CH3SO2CH2), 63.5 (CH2OAr), 114.6 (C-3), 116.5 (C-4’), 121.0 (d, J = 4.7 Hz, C-6’), 
124.6 (C-2 or C-4), 125.2 (C-2 or C-4), 125.7 (d, J = 3.4 Hz, C-5’), 128.4 (d, J = 19.8 Hz, 
C-1’), 130.4 (C-5), 144.8 (d, J = 10.8 Hz, C-3’), 148.1 (d, J = 247.2 Hz, C-2’), 160.3 
(CO2CH3), 183.3 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -135.5 (ArF); LRMS (ES
-
) 
m/z 404.2 [M(
35
Cl)-H]
-
, 406.2 [M(
37
Cl)-H]
-
; HRMS (NSI) calcd for C16H16ClFNO6S 
[M(
35
Cl)+H]
+
 404.0365, found 404.0359. 
 
4-(6-Chloro-2-fluoro-3-(2-(methylsulfonyl)ethoxy)benzoyl)-1H-pyrrole-2-carboxylic 
acid, (395) 
 
To methyl 4-(6-chloro-2-fluoro-3-(2-(methylsulfonyl)ethoxy)benzoyl)-1H-pyrrole-2-
carboxylate (394) (300 mg, 0.74 mmol) in dioxane (6 mL) was added 4 M aq. HCl solution 
(6 mL) and the resulting solution was stirred for 70 h at 65 °C. Upon completion, the 
solvents were removed in vacuo to yield a yellow solid which was dissolved in saturated 
aq. NaHCO3 (20 mL). The aqueous layer was washed with EtOAc (20 mL), then acidified 
to pH 1-2 using a 4 M aq. solution of HCl and extracted with EtOAc (3 × 25 mL). The 
pooled organic extracts were washed with water (30 mL) and brine (30 mL), dried over 
MgSO4 and concentrated in vacuo. The off-white solid (240 mg, 83%) was used in the next 
step without further purification; Rf = 0.28 (DCM:MeOH:AcOH, 90:9.9:0.1); m.p. 
123.0-125.0 °C; λmax (EtOH)/nm 229.6, 282.6; IR (neat) νmax/cm
-1
 3248, 3127, 2989, 2933, 
1700, 1643, 1558, 1461, 1439, 1389, 1271, 1227; 
1
H NMR (500 MHz, DMSO-d6) δ 3.06 
(3H, s, CH3SO2CH2), 3.68 (2H, t, J = 5.6 Hz, CH3SO2CH2), 4.49 (2H, t, J = 5.6 Hz, 
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CH2OAr), 6.97 (1H, s, H-3), 7.36 – 7.43 (2H, m, H-4’ and H-5’), 7.46 – 7.51 (1H, m, H-5), 
12.69 (1H, s, NH-pyrrole), 12.90 (1H, s, CO2H); 
13
C NMR (126 MHz, DMSO-d6) δ 42.2 
(CH3SO2CH2), 53.1 (CH3SO2CH2), 63.5 (CH2OAr), 114.2 (C-3), 116.4 (C-4’), 121.1 (d, 
J = 4.8 Hz, C-6’), 125.1 (C-2 or C-4), 125.6 (d, J = 3.6 Hz, C-5’), 125.9 (C-2 or C-4), 
128.5 (d, J = 19.9 Hz, C-1’), 129.9 (C-3), 144.8 (d, J = 10.8 Hz, C-3’), 148.1 (d, 
J = 247.2 Hz, C-2’), 161.3 (CO2H), 183.2 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) 
δ -135.5 (ArF); LRMS (ES+) m/z 390.3 [M(35Cl)+H]+, 392.3 [M(37Cl)+H]+; HRMS (NSI) 
calcd for C15H14ClFNO6S [M(
35
Cl)+H]
+
 390.0209, found 390.0212. 
 
4-(6-Chloro-2-fluoro-3-(2-(methylsulfonyl)ethoxy)benzoyl)-N-(pyridin-3-yl)-1H-
pyrrole-2-carboxamide, (396) 
 
Compound 396 was synthesised according to general procedure U, using the following 
reagents: 4-(6-chloro-2-fluoro-3-(2-(methylsulfonyl)ethoxy)benzoyl)-1H-pyrrole-2-
carboxylic acid (395) (100 mg, 0.26 mmol), 3-aminopyridine (60 mg, 0.64 mmol), 
phosphorus trichloride (23 µL, 35 mg, 0.26 mmol) and acetonitrile (1.3 mL). The crude 
product was purified by column chromatography (silica gel, DCM:MeOH, 1:0  95:5) to 
yield the title compound as a white solid (48 mg, 40%); Rf = 0.32 (DCM:MeOH, 95:5); 
m.p. 238.0-240.0 °C; λmax (EtOH)/nm 255.6, 292.2; IR (neat) νmax/cm
-1
 3349, 3116, 2922, 
2852, 1639, 1589, 1571, 1537, 1426, 1397, 1304, 1286, 1231; 
1
H NMR (500 MHz, 
DMSO-d6) δ 2.97 (3H, s, CH3SO2CH2), 3.67 (2H, t, J = 7.0 Hz, CH3SO2CH2), 4.78 (2H, t, 
J = 7.0 Hz, CH2OAr), 7.09 (1H, dd, J = 9.0, 8.7 Hz, H-4’), 7.22 (1H, d, J = 8.7 Hz, H-5’), 
7.38 (1H, dd, J = 8.2, 4.7 Hz, H-5”), 7.54 (1H, s, H-3), 7.79 (1H, s, H-5), 8.12 (1H, d, 
J = 8.2 Hz, H-4”), 8.30 (1H, d, J = 4.7 Hz, H-6”), 8.86 (1H, s, H-2”), 10.30 (1H, s, 
CONHAr), 10.51 (1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 40.7 
(CH3SO2CH2), 43.2 (CH3SO2CH2), 54.0 (CH2OAr), 114.5 (C-3), 118.4 (d, J = 5.0 Hz, 
C-6’), 119.0 (d, J = 3.0 Hz, C-4’), 122.9 (C-2 or C-4), 123.5 (C-5”), 125.5 (d, J = 3.5 Hz, 
C-5’), 126.8 (C-2 or C-4), 127.4 (C-4”), 128.4 (d, J = 19.8 Hz, C-1’), 135.1 (C-5), 135.4 
(C-3”), 142.0 (C-2”), 144.4 (d, J = 11.9 Hz, C-3’), 144.5 (C-6”), 147.6 (d, J = 244.1 Hz, 
C-2’), 159.2 (CONHAr), 183.7 (ArCO); 19F NMR (471 MHz, DMSO-d6) δ -136.9 (ArF); 
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LRMS (ES
+
) m/z 466.3 [M(
35
Cl)+H]
+
, 468.3 [M(
37
Cl)+H]
+
; HRMS (NSI) calcd for 
C20H18ClFN3O5S [M(
35
Cl)+H]
+
 466.0634, found 466.0627. 
 
4-(6-Chloro-2-fluoro-3-(2-(methylsulfonyl)ethoxy)benzoyl)-N-(1-methyl-1H-pyrazol-
4-yl)-1H-pyrrole-2-carboxamide, (397) 
 
Compound 397 was synthesised according to general procedure U, using the following 
reagents: 4-(6-chloro-2-fluoro-3-(2-(methylsulfonyl)ethoxy)benzoyl)-1H-pyrrole-2-
carboxylic acid (395) (100 mg, 0.26 mmol), 1-methyl-1H-pyrazol-4-amine (348) (66 mg, 
0.68 mmol), phosphorus trichloride (23 µL, 35 mg, 0.26 mmol) and acetonitrile (1.3 mL). 
The crude product was purified by column chromatography (silica gel, DCM:MeOH, 
1:0  95:5) to yield the title compound as a white solid (41 mg, 35%); Rf = 0.33 
(DCM:MeOH, 95:5); m.p. 253.5-255.5 °C; λmax (EtOH)/nm 253.4; IR (neat) νmax/cm
-1
 
3373, 3119, 2923, 1657, 1619, 1555, 1539, 1492, 1393, 1374, 1303, 1254; 
1
H NMR 
(500 MHz, DMSO-d6) δ 2.98 (3H, s, CH3SO2CH2), 3.66 (2H, t, J = 7.1 Hz, CH3SO2CH2), 
3.81 (3H, s, NCH3), 4.77 (2H, t, J = 7.1 Hz, CH2OAr), 7.08 (1H, dd, J = 9.0, 9.0 Hz, H-4’), 
7.19 – 7.23 (1H, m, H-5’), 7.37 (1H, s, H-3), 7.49 (1H, s, H-5”), 7.74 (1H, s, H-5), 7.98 
(1H, s, H-3”), 10.32 (1H, s, CONHAr), 10.51 (1H, s, NH-pyrrole); 13C NMR (126 MHz, 
DMSO-d6) δ 38.6 (NCH3), 40.7 (CH3SO2CH2), 43.1 (CH3SO2CH2), 54.1 (CH2OAr), 113.3 
(C-3), 118.3 (d, J = 4.5 Hz, C-6’), 119.0 (d, J = 3.4 Hz, C-4’), 121.1 (C-4”), 121.6 (C-3”), 
122.9 (C-2 or C-4), 125.5 (d, J = 3.5 Hz, C-5’), 127.0 (C-2 or C-4), 128.4 (d, J = 20.0 Hz, 
C-1’), 130.0 (C-5”), 134.4 (C-5), 144.5 (d, J = 10.9 Hz, C-3’), 147.6 (d, J = 244.1 Hz, 
C-2’), 157.2 (CONHAr), 183.7 (ArCO); 19F NMR (471 MHz, DMSO-d6) δ -137.0 (ArF); 
LRMS (ES
+
) m/z 469.3 [M(
35
Cl)+H]
+
, 471.3 [M(
37
Cl)+H]
+
; HRMS (NSI) calcd for 
C19H19ClFN4O5S [M(
35
Cl)+H]
+
 469.0743, found 469.0737. 
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4-(2-Chloro-6-fluorobenzoyl)-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrole-2-
carboxamide, (398) 
 
Compound 398 was synthesised according to general procedure U, using the following 
reagents: 4-(2-chloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (249) (100 mg, 
0.37 mmol), 1-methyl-1H-pyrazol-4-amine (348) (91 mg, 0.94 mmol), phosphorus 
trichloride (34 µL, 51 mg, 0.37 mmol) and acetonitrile (1.85 mL). The crude product was 
purified by column chromatography (silica gel, petrol:EtOAc, 1:0  1:9) to yield the title 
compound as a white solid (80 mg, 62%); Rf = 0.32 (petrol:EtOAc, 1:9); m.p. 
218.5-220.5 °C; λmax (EtOH)/nm 257.0; IR (neat) νmax/cm
-1
 3346, 3164, 3126, 2973, 2928, 
2858, 1626, 1590, 1570, 1543, 1442, 1397, 1274, 1238; 
1
H NMR (500 MHz, DMSO-d6) 
δ 3.81 (3H, s, NCH3), 7.29 (1H, s, H-3), 7.39 (1H, dd, J = 8.7, 8.7 Hz, H-5’), 7.42 (1H, s, 
H-5), 7.46 (1H, d, J = 8.1 Hz, H-3’), 7.50 (1H, s, H-5”), 7.57 (1H, ddd, J = 8.7, 8.1 and 
6.4 Hz, H-4’), 7.94 (1H, s, H-3”), 10.25 (1H, s, CONHAr), 12.57 (1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 38.7 (NCH3), 110.3 (C-3), 114.9 (d, J = 21.5 Hz, C-5’), 
121.2 (C-4”), 121.4 (C-3”), 125.2 (C-2 or C-4), 125.8 (d, J = 3.1 Hz, C-3’), 128.1 (d, 
J = 23.1 Hz, C-1’), 128.5 (C-2 or C-4), 128.6 (C-5), 129.9 (C-5”), 130.5 (d, J = 6.1 Hz, 
C-2’), 131.8 (d, J = 9.0 Hz, C-4’), 156.8 (CONHAr), 158.6 (d, J = 247.0 Hz, C-6’), 183.9 
(ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -114.3 (ArF); LRMS (ES
+
) m/z 347.3 
[M(
35
Cl)+H]
+
, 349.3 [M(
37
Cl)+H]
+
; HRMS (NSI) calcd for C16H13ClFN4O2 [M(
35
Cl)+H]
+
 
347.0706, found 347.0707. 
 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(2-(methyl(1-methylpiperidin-4-yl)amino) 
pyrimidin-5-yl)-1H-pyrrole-2-carboxamide, (403) 
 
Compound 403 was synthesised according to general procedure Y, using the following 
reagents: 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250) (100 mg, 
0.33 mmol), triethylamine (115 µL, 84 mg, 0.83 mmol), 2-chloro-1-methylpyridinium 
iodide (93 mg, 0.36 mmol), N
2
-methyl-N
2
-(1-methylpiperidin-4-yl)pyrimidine-2,5-diamine 
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(419) (92 mg, 0.41 mmol) and DCM (3.3 mL). The crude yellow solid was purified by 
column chromatography (amine silica gel, DCM:MeOH, 1:0  97:3) to yield the title 
compound as a white solid (75 mg, 45%); Rf = 0.18 (amine silica, DCM:MeOH, 97:3); 
m.p. 178.5-180.5 °C; λmax (EtOH)/nm 284.4; IR (neat) νmax/cm
-1
 3175, 2981, 2954, 2890, 
2797, 1663, 1645, 1591, 1552, 1519, 1486, 1448, 1404, 1296; 
1
H NMR (500 MHz, 
DMSO-d6) δ 1.40 – 1.63 (2H, m, CH2CH2NMe), 1.80 (2H, dddd, J = 12.2, 12.2, 12.2 and 
3.7 Hz, CH2CH2NMe), 1.93 – 2.11 (2H, m, CH2CH2NMe), 2.21 (3H, s, NCH3), 2.88 (2H, 
d, J = 12.2 Hz, CH2CH2NMe), 2.96 (3H, s, NCH3), 4.52 (1H, tt, J = 12.3, 3.7 Hz, 
ArN(CH3)CH), 7.40 (1H, s, H-3), 7.52 (2H, dd, J = 8.8, 1.0 Hz, H-5’), 7.60 (1H, s, H-5), 
7.78 (1H, dd, J = 8.8, 8.4 Hz, H-4’), 8.57 (2H, s, H-4”, 6”), 10.01 (1H, s, CONHAr), 12.74 
(1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 28.2 (NCH3) , 28.8 
(CH2CH2NMe), 45.7 (NCH3), 51.7 (ArN(CH3)CH), 54.9 (CH2CH2NMe), 111.0 (C-3), 
119.3 (d, J = 18.1 Hz, C-3’), 122.9 (C-5”), 124.7 (C-2 or C-4), 126.9 (d, J = 3.8 Hz, C-5’), 
128.4 (C-2 or C-4), 129.2 (d, J = 22.8 Hz, C-1’), 129.2 (d, J = 5.1 Hz, C-6’), 129.8 (C-5), 
131.8 (C-4’), 151.3 (C-4”, 6”), 153.8 (d, J = 248.4 Hz, C-2’), 158.4 (CONHAr), 182.6 
(ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -116.7 (ArF); LRMS (ES
-
) m/z 503.3 
[M(
35
Cl
35
Cl)-H]
-
, 505.3 [M(
35
Cl
37
Cl)-H]
-
; HRMS (NSI) calcd for C23H24Cl2FN6O2 
[M(
35
Cl
35
Cl)+H]
+
 505.1316, found 505.1304. 
 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(2-(methyl(piperidin-4-yl)amino)pyrimidin-5-yl)-
1H-pyrrole-2-carboxamide, (404) 
 
Compound 404 was synthesised according to general procedure F’, using the following 
reagents: tert-butyl 4-((5-(4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-
carboxamido)pyrimidin-2-yl)(methyl)amino)piperidine-1-carboxylate (417) (100 mg, 
0.17 mmol), triethylsilane (68 µL, 49 mg, 0.42 mmol), TFA (0.85 mL) and DCM 
(0.85 mL). The crude yellow solid was purified by column chromatography (amine silica 
gel, DCM:MeOH, 1:0  95:5) to yield the title compound as a white solid (62 mg, 75%); 
Rf = 0.31 (amine silica, DCM:MeOH, 95:5); m.p. 182.5-184.5 °C; λmax (EtOH)/nm 290.2; 
IR (neat) νmax/cm
-1
 3166, 3126, 2981, 2955, 1667, 1647, 1593, 1557, 1519, 1484, 1449, 
1405, 1381, 1301; 
1
H NMR (500 MHz, DMSO-d6) δ 1.42 – 1.56 (2H, m, CH2CH2NH), 
1.62 (2H, dddd, J = 12.1, 12.1, 12.1 and 4.2 Hz, CH2CH2NH), 2.56 (2H, ddd, J = 12.1, 
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12.1 and 2.6 Hz, CH2CH2NH), 2.95 (3H, s, NCH3), 2.98 – 3.09 (2H, m, CH2CH2NH), 4.61 
(1H, tt, J = 12.1, 4.2 Hz, ArN(CH3)CH), 7.37 (1H, s, H-3), 7.51 (1H, dd, J = 8.8, 1.4 Hz, 
H-5’), 7.58 (1H, s, H-5), 7.77 (1H, dd, J = 8.8, 8.4 Hz, H-4’), 8.57 (2H, s, H-4”, 6”), 9.98 
(1H, s, CONHAr); 
13
C NMR (126 MHz, DMSO-d6) δ 28.8 (NCH3), 29.8 (CH2CH2NH), 
45.8 (CH2CH2NH), 52.4 (ArN(CH3)CH), 111.0 (C-3), 119.3 (d, J = 17.7 Hz, C-3’), 122.9 
(C-5”), 124.8 (C-2 or C-4), 126.9 (d, J = 3.9 Hz, C-5’), 128.7 (C-2 or C-4), 129.2 (d, 
J = 5.5 Hz, C-6’), 129.3 (d, J = 23.1 Hz, C-1’), 130.0 (C-5), 131.8 (C-4’), 151.3 (C-4”, 6”), 
153.8 (d, J = 248.3 Hz, C-2’), 158.3 (CONHAr or C-2”), 158.6 (CONHAr or C-2”), 182.5 
(ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -116.7 (ArF); LRMS (ES
-
) m/z 489.3 
[M(
35
Cl
35
Cl)-H]
-
, 491.3 [M(
35
Cl
37
Cl)-H]
-
; HRMS (NSI) calcd for C22H22Cl2FN6O2 
[M(
35
Cl
35
Cl)+H]
+
 491.1160, found 491.1151. 
 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(2-((4-methylpiperazin-1-yl)methyl)pyrimidin-5-
yl)-1H-pyrrole-2-carboxamide, (405) 
 
Compound 405 was synthesised according to general procedure E’, using the following 
reagents: tert-butyl 4-((5-(4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-
carboxamido)pyrimidin-2-yl)methyl)piperazine-1-carboxylate (439) (60 mg, 0.10 mmol), 
formic acid (0.5 mL) and formaldehyde (37 % wt. in water) (31 µL, 0.42 mmol). The crude 
yellow solid was purified by column chromatography (amine silica gel, DCM:MeOH, 
1:0  96:4) to yield the title compound as a white solid (36 mg, 71%); Rf = 0.30 (amine 
silica, DCM:MeOH, 96:4); m.p. 183.0-185.0 °C; λmax (EtOH)/nm 293.0; IR (neat) 
νmax/cm
-1
 2935, 2802, 1641, 1581, 1557, 1515, 1447, 1280; 
1
H NMR (500 MHz, 
DMSO-d6) δ 2.13 (3H, s, NCH3), 2.29 (4H, brs, NCH2 piperazine), 2.47 (4H, brs, NCH2 
piperazine), 3.64 (2H, s, ArCH2N), 7.50 (1H, s, H-3), 7.52 (1H, dd, J = 8.8, 1.4 Hz, H-5’), 
7.67 (1H, s, H-5), 7.79 (1H, dd, J = 8.8, 8.4 Hz, H-4’), 9.07 (2H, s, H-4”, 6”), 10.41 (1H, s, 
CONHAr), 12.85 (1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 45.7 (NCH3), 
52.5 (NCH2 piperazine), 54.7 (NCH2 piperazine), 63.9 (ArCH2N), 111.9 (C-3), 119.4 (d, 
J = 18.1 Hz, C-3’), 124.8 (C-2 or C-4), 126.9 (d, J = 3.8 Hz, C-5’), 128.0 (C-2 or C-4), 
129.1 (d, J = 23.2 Hz, C-1’), 129.2 (d, J = 5.4 Hz, C-6’), 130.5 (C-5), 131.9 (C-4’), 132.4 
(C-5”), 147.9 (C-4”, 6”), 153.8 (d, J = 248.7 Hz, C-2’), 158.7 (CONHAr), 161.4 (C-2”), 
182.6 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -116.7 (ArF); LRMS (ES
+
) m/z 491.4 
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[M(
35
Cl
35
Cl)+H]
+
, 493.4 [M(
35
Cl
37
Cl)+H]
+
; HRMS (NSI) calcd for C22H22Cl2FN6O2 
[M(
35
Cl
35
Cl)+H]
+
 491.1160, found 491.1154. 
 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(2-(piperazin-1-ylmethyl)pyrimidin-5-yl)-1H-
pyrrole-2-carboxamide, (406) 
 
Compound 406 was synthesised according to general procedure F’, using the following 
reagents: tert-butyl 4-((5-(4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxamido) 
pyrimidin-2-yl)methyl)piperazine-1-carboxylate (439) (60 mg, 0.10 mmol), triethylsilane 
(41 µL, 30 mg, 0.26 mmol), TFA (0.5 mL) and DCM (0.5 mL). The crude yellow solid 
was purified by column chromatography (amine silica gel, DCM:MeOH, 1:0  94:6) to 
yield the title compound as an off-white solid (35 mg, 70%); Rf = 0.29 (amine silica, 
DCM:MeOH, 94:6); m.p. 239.5-241.5 °C; λmax (EtOH)/nm 266.0, 293.2; IR (neat) 
νmax/cm
-1
 3069, 2932, 2812, 1639, 1581, 1558, 1510, 1444, 1389, 1268; 
1
H NMR 
(500 MHz, DMSO-d6) δ 2.41 (4H, brs, NCH2 piperazine), 2.70 (4H, t, J = 4.9 Hz, NCH2 
piperazine), 3.63 (2H, s, ArCH2N), 7.48 (1H, s, H-3), 7.52 (1H, dd, J = 8.7, 1.4 Hz, H-5’), 
7.66 (1H, s, H-5), 7.78 (1H, dd, J = 8.7, 8.4 Hz, H-4’), 9.08 (2H, s, H-4”, 6”), 10.41 (1H, s, 
CONHAr); 
13
C NMR (126 MHz, DMSO-d6) δ 45.3 (NCH2 piperazine), 53.6 (NCH2 piperazine), 
64.5 (ArCH2N), 112.0 (C-3), 119.3 (d, J = 17.9 Hz, C-3’), 124.9 (C-2 or C-4), 126.9 (d, 
J = 3.8 Hz, C-5’), 128.3 (C-2 or C-4), 129.2 (d, J = 23.1 Hz, C-1’), 129.2 (d, J = 5.1 Hz, 
C-6’), 130.7 (C-5), 131.9 (C-4’), 132.4 (C-5”), 147.8 (C-4”, 6”), 153.8 (d, J = 248.5 Hz, 
C-2’), 158.9 (CONHAr), 161.3 (C-2”), 182.5 (ArCO); 19F NMR (471 MHz, DMSO-d6) 
δ -116.7 (ArF); LRMS (ES+) m/z 473.3 [M(35Cl35Cl)+H]+, 475.3 [M(35Cl37Cl)+H]+; 
HRMS (NSI) calcd for C21H20Cl2FN6O2 [M(
35
Cl
35
Cl)+H]
+
 477.1003, found 477.0999. 
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4-(3,6-Dichloro-2-fluorobenzoyl)-N-(2-((1-methylpiperidin-4-yl)methyl)pyrimidin-5-
yl)-1H-pyrrole-2-carboxamide, (407) 
 
Compound 407 was synthesised according to general procedure E’, using the following 
reagents: tert-butyl 4-((5-(4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxamido) 
pyrimidin-2-yl)methyl)piperidine-1-carboxylate (429) (165 mg, 0.29 mmol), formic acid 
(1.45 mL) and formaldehyde (37 % wt. in water) (85 µL, 1.14 mmol). The crude yellow 
solid was purified by column chromatography (amine silica gel, DCM:MeOH, 1:0  97:3) 
to yield the title compound as a white solid (100 mg, 72%); Rf = 0.30 (amine silica, 
DCM:MeOH, 97:3); m.p. 146.5-148.5 °C; λmax (EtOH)/nm 266.0, 293.2; IR (neat) 
νmax/cm
-1
 2923, 2849, 2788, 1637, 1580, 1558, 1511, 1444, 1391, 1272; 
1
H NMR 
(500 MHz, DMSO-d6) δ 1.24 (2H, dddd, J = 12.3, 12.3, 12.3 and 3.6 Hz, CH2CH2NCH3), 
1.52 (2H, d, J = 12.3 Hz, CH2CH2NCH3), 1.80 (3H, dd, J = 12.3, 12.3 Hz, CH2CH2NCH3 
and ArCH2CH), 2.11 (3H, s, NCH3), 2.70 (2H, d, J = 12.3 Hz, CH2CH2NCH3), 2.75 (2H, 
d, J = 7.1 Hz, ArCH2CH), 7.48 (1H, s, H-3), 7.52 (1H, dd, J = 8.7, 1.3 Hz, H-5’), 7.65 (1H, 
s, H-5), 7.78 (1H, dd, J = 8.7, 8.4 Hz, H-4’), 9.02 (2H, s, H-4”, 6”), 10.35 (1H, s, 
CONHAr), 12.79 (1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 31.7 
(CH2CH2NCH3), 34.9 (ArCH2CH), 44.9 (ArCH2CH), 46.2 (NCH3), 55.3 (CH2CH2NMe), 
111.8 (C-3), 119.4 (d, J = 18.1 Hz, C-3’), 124.8 (C-2 or C-4), 126.9 (d, J = 3.9 Hz, C-5’), 
128.1 (C-2 or C-4), 129.2 (d, J = 23.3 Hz, C-1’), 129.2 (d, J = 5.0 Hz, C-6’), 130.5 (C-5), 
131.7 (C-4’), 131.9 (C-5”), 148.1 (C-4”, 6”), 153.9 (d, J = 248.7 Hz, C-2’), 158.7 
(CONHAr), 163.9 (C-2”), 182.6 (ArCO); 19F NMR (471 MHz, DMSO-d6) δ -116.6 (ArF); 
LRMS (ES
+
) m/z 477.3 [M(
35
Cl
35
Cl)+H]
+
, 479.3 [M(
35
Cl
37
Cl)+H]
+
; HRMS (NSI) calcd for 
C23H23Cl2FN5O2 [M(
35
Cl
35
Cl)+H]
+
 490.1207 found 490.1201. 
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4-(3,6-Dichloro-2-fluorobenzoyl)-N-(2-(piperidin-4-ylmethyl)pyrimidin-5-yl)-1H-
pyrrole-2-carboxamide, (408) 
 
Compound 408 was synthesised according to general procedure F’, using the following 
reagents: tert-butyl 4-((5-(4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxamido) 
pyrimidin-2-yl)methyl)piperidine-1-carboxylate (429) (165 mg, 0.29 mmol), triethylsilane 
(114 µL, 83 mg, 0.71 mmol), TFA (1.45 mL) and DCM (1.45 mL). The crude yellow solid 
was purified by column chromatography (amine silica gel, DCM:MeOH, 1:0  95:5) to 
yield the title compound as a white solid (86 mg, 63%); Rf = 0.31 (amine silica, 
DCM:MeOH, 95:5); m.p. No clear m.p. Decomposition range 265-275 °C; λmax (EtOH)/nm 
270.4, 293.0; IR (neat) νmax/cm
-1
 2919, 1639, 1588, 1561, 1509, 1495, 1443, 1390, 1270; 
1
H NMR (500 MHz, DMSO-d6) δ 1.14 (2H, dddd, J = 12.4, 12.4, 12.4 and 3.8 Hz, 
CH2CH2NH), 1.52 (2H, d, J = 11.1 Hz, CH2CH2NH), 1.96 (1H, ttt, J = 12.4, 7.4 and 
3.8 Hz, ArCH2CH), 2.40 – 2.49 (2H, m, CH2CH2NH), 2.74 (2H, d, J = 7.4 Hz, ArCH2CH), 
2.94 (2H, d, J = 12.4 Hz, CH2CH2NH), 7.39 (1H, s, H-3), 7.51 (1H, dd, J = 8.9, 1.4 Hz, 
H-5’), 7.60 (1H, s, H-5), 7.77 (1H, dd, J = 8.9, 8.4 Hz, H-4’), 9.03 (2H, s, H-4”, 6”), 10.31 
(1H, s, CONHAr); 
13
C NMR (126 MHz, DMSO-d6) δ 32.2 (CH2CH2NH), 35.6 
(ArCH2CH), 45.4 (ArCH2CH), 45.6 (CH2CH2NH), 112.1 (C-3), 119.3 (d, J = 18.1 Hz, 
C-3’), 125.0 (C-2 or C-4), 126.8 (d, J = 3.8 Hz, C-5’), 129.3 (d, J = 5.2 Hz, C-6’), 129.3 
(C-2 or C-4), 129.5 (d, J = 22.8 Hz, C-1’), 131.5 (C-5), 131.7 (C-4’), 131.8 (C-5”), 147.9 
(C-4”, 6”), 153.8 (d, J = 248.2 Hz, C-2’), 159.3 (CONHAr), 163.6 (C-2”), 182.2 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -116.6 (ArF); LRMS (ES
+
) m/z 476.3 [M(
35
Cl
35
Cl)+H]
+
, 
478.3 [M(
35
Cl
37
Cl)+H]
+
; HRMS (NSI) calcd for C22H21Cl2FN5O2 [M(
35
Cl
35
Cl)+H]
+
 
476.1051, found 476.1045. 
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4-(3,6-Dichloro-2-fluorobenzoyl)-N-(2-(morpholinomethyl)pyrimidin-5-yl)-1H-
pyrrole-2-carboxamide, (409) 
 
Compound 409 was synthesised according to general procedure Y, using the following 
reagents: 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250) (80 mg, 
0.26 mmol), triethylamine (92 µL, 67 mg, 0.66 mmol), 2-chloro-1-methylpyridinium 
iodide (74 mg, 0.29 mmol), 2-(morpholinomethyl)pyrimidin-5-amine (442) (64 mg, 
0.33 mmol) and DCM (2.6 mL). The crude yellow solid was purified by column 
chromatography (silica gel, DCM:MeOH, 1:0  95:5) to yield the title compound as a 
white solid (20 mg, 16%); Rf = 0.28 (DCM:MeOH, 97:3); m.p. 158.5-160.5 °C; 
λmax (EtOH)/nm 292.6; IR (neat) νmax/cm
-1
 3125, 2960, 2924, 2857, 2819, 1641, 1585, 
1557, 1517, 1447, 1392, 1272; 
1
H NMR (500 MHz, DMSO-d6) δ 2.43 – 2.49 (4H, m, 
NCH2 morpholine), 3.52 – 3.59 (4H, m, CH2O morpholine), 3.66 (2H, s, ArCH2N), 7.50 (1H, s, 
H-3), 7.51 – 7.55 (1H, m, H-5’), 7.68 (1H, s, H-5), 7.79 (1H, dd, J = 8.7, 8.4 Hz, H-4’), 
9.08 (2H, s, H-4”, 6”), 10.43 (1H, s, CONHAr), 12.87 (1H, s, NH-pyrrole); 13C NMR 
(126 MHz, DMSO-d6) δ 53.2 (NCH2 morpholine), 64.2 (ArCH2N), 66.2 (CH2O morpholine), 
111.9 (C-3), 119.4 (d, J = 17.9 Hz, C-3’), 124.9 (C-2 or C-4), 126.9 (d, J = 3.8 Hz, C-5’), 
128.0 (C-2 or C-4), 129.1 (d, J = 24.3 Hz, C-1’), 129.2 (d, J = 5.5 Hz, C-6’), 130.6 (C-5), 
131.9 (C-4’), 132.5 (C-5”), 147.9 (C-4”, 6”), 153.9 (d, J = 248.7 Hz, C-2’), 158.8 
(CONHAr), 161.1 (C-2”), 182.6 (ArCO); 19F NMR (471 MHz, DMSO-d6) δ -116.7 (ArF); 
LRMS (ES
+
) m/z 478.3 [M(
35
Cl
35
Cl)+H]
+
, 480.3 [M(
35
Cl
37
Cl)+H]
+
; HRMS (NSI) calcd for 
C21H19Cl2FN5O3 [M(
35
Cl
35
Cl)+H]
+
 478.0843, found 478.0838. 
 
4-(6-Chloro-2-fluoro-3-methoxybenzoyl)-N-(2-((4-methylpiperazin-1-yl)methyl) 
pyrimidin-5-yl)-1H-pyrrole-2-carboxamide, (410) 
 
Compound 410 was synthesised according to general procedure E’, using the following 
reagents: tert-butyl 4-((5-(4-(6-chloro-2-fluoro-3-methoxybenzoyl)-1H-pyrrole-2-
378 
carboxamido)pyrimidin-2-yl)methyl)piperazine-1-carboxylate (440) (50 mg, 0.09 mmol), 
formic acid (0.45 mL) and formaldehyde (37 % wt. in water) (26 µL, 0.35 mmol). The 
crude yellow solid was purified by column chromatography (amine silica gel, 
DCM:MeOH, 1:0  96:4) to yield the title compound as a white solid (31 mg, 76%); 
Rf = 0.26 (amine silica, DCM:MeOH, 96:4); m.p. 210.0-212.0 °C; λmax (EtOH)/nm 292.6; 
IR (neat) νmax/cm
-1
 2936, 2803, 1641, 1577, 1555, 1517, 1472, 1438, 1271; 
1
H NMR 
(500 MHz, DMSO-d6) δ 2.13 (3H, s, NCH3), 2.29 (4H, brs, NCH2 piperazine), 2.47 (4H, brs, 
NCH2 piperazine), 3.64 (2H, s, ArCH2N), 3.90 (3H, s, ArOCH3), 7.33 (1H, dd, J = 9.0, 9.0 Hz, 
H-4’), 7.39 (1H, dd, J = 9.0, 1.4 Hz, H-5’), 7.46 (1H, s, H-3), 7.54 (1H, s, H-5), 9.07 (2H, 
s, H-4”, 6”), 10.41 (1H, s, CONHAr), 12.79 (1H, s, NH-pyrrole); 13C NMR (126 MHz, 
DMSO-d6) δ 45.7 (NCH3), 52.5 (NCH2 piperazine), 54.7 (NCH2 piperazine), 56.5 (ArOCH3), 63.9 
(ArCH2N), 112.1 (C-3), 115.2 (C-4’), 120.2 (d, J = 5.0 Hz, C-6’), 125.2 (C-2 or C-4), 
125.6 (d, J = 3.3 Hz, C-5’), 127.7 (C-2 or C-4), 128.4 (d, J = 19.8 Hz, C-1’), 129.7 (C-5), 
132.4 (C-5”), 146.4 (d, J = 10.7 Hz, C-3’), 147.9 (C-4”, 6”), 147.9 (d, J = 247.4 Hz, C-2’), 
158.7 (CONHAr), 161.4 (C-2”), 183.7 (ArCO); 19F NMR (471 MHz, DMSO-d6) δ -136.1 
(ArF); LRMS (ES
+
) m/z 487.4 [M(
35
Cl)+H]
+
, 489.4 [M(
37
Cl)+H]
+
; HRMS (NSI) calcd for 
C23H25ClFN6O3 [M(
35
Cl)+H]
+
 487.1647, found 487.1655. 
 
4-(6-Chloro-2-fluoro-3-methoxybenzoyl)-N-(2-(piperazin-1-ylmethyl)pyrimidin-5-yl)-
1H-pyrrole-2-carboxamide, (411) 
 
Compound 411 was synthesised according to general procedure F’, using the following 
reagents: tert-butyl 4-((5-(4-(6-chloro-2-fluoro-3-methoxybenzoyl)-1H-pyrrole-2-
carboxamido)pyrimidin-2-yl)methyl)piperazine-1-carboxylate (440) (50 mg, 0.09 mmol), 
triethylsilane (35 µL, 25 mg, 0.22 mmol), TFA (0.45 mL) and DCM (0.45 mL). The crude 
yellow solid was purified by column chromatography (amine silica gel, DCM:MeOH, 
1:0  94:6) to yield the title compound as a white solid (30 mg, 73%); Rf = 0.27 (amine 
silica, DCM:MeOH, 94:6); m.p. 195.5-197.5 °C; λmax (EtOH)/nm 292.8; IR (neat) 
νmax/cm
-1
 2935, 2815, 1639, 1576, 1556, 1512, 1471, 1435, 1268; 
1
H NMR (500 MHz, 
DMSO-d6) δ 2.40 (4H, brs, NCH2 piperazine), 2.68 (4H, t, J = 4.8 Hz, NCH2 piperazine), 3.62 
(2H, s, ArCH2N), 3.90 (3H, s, ArOCH3), 7.33 (1H, dd, J = 9.1, 9.0 Hz, H-4’), 7.39 (1H, d, 
J = 9.1 Hz, H-5’), 7.45 (1H, s, H-3), 7.53 (1H, s, H-5), 9.07 (2H, s, H-4”, 6”), 10.41 (1H, s, 
379 
CONHAr); 
13
C NMR (126 MHz, DMSO-d6) δ 45.4 (NCH2 piperazine), 53.7 (NCH2 piperazine), 
56.5 (ArOCH3), 64.5 (ArCH2N), 112.1 (C-3), 115.2 (C-4’), 120.2 (d, J = 4.8 Hz, C-6’), 
125.3 (C-2 or C-4), 125.6 (C-5’), 127.9 (C-2 or C-4), 128.4 (d, J = 19.9 Hz, C-1’), 129.9 
(C-5), 132.4 (C-5”), 146.4 (d, J = 10.8 Hz, C-3’), 147.8 (C-4”, 6”), 147.9 (d, J = 246.9 Hz, 
C-2’), 158.9 (CONHAr), 161.3 (C-2”), 183.6 (ArCO); 19F NMR (471 MHz, DMSO-d6) 
δ -136.1 (ArF); LRMS (ES+) m/z 473.3 [M(35Cl)+H]+, 475.3 [M(37Cl)+H]+; HRMS (NSI) 
calcd for C22H23ClFN6O3 [M(
35
Cl)+H]
+
 473.1499, found 473.1491. 
 
4-(6-Chloro-2-fluoro-3-methoxybenzoyl)-N-(2-((1-methylpiperidin-4-yl)methyl) 
pyrimidin-5-yl)-1H-pyrrole-2-carboxamide, (412) 
 
Compound 412 was synthesised according to general procedure E’, using the following 
reagents: tert-butyl 4-((5-(4-(6-chloro-2-fluoro-3-methoxybenzoyl)-1H-pyrrole-2-
carboxamido)pyrimidin-2-yl)methyl)piperidine-1-carboxylate (430) (125 mg, 0.22 mmol), 
formic acid (1.1 mL) and formaldehyde (37 % wt. in water) (65 µL, 0.87 mmol). The crude 
yellow solid was purified by column chromatography (amine silica gel, DCM:MeOH, 
1:0  97:3) to yield the title compound as a white solid (76 mg, 72%); Rf = 0.26 (amine 
silica, DCM:MeOH, 97:3); m.p. 255.0-257.0 °C; λmax (EtOH)/nm 293.0; IR (neat) 
νmax/cm
-1
 2925, 2843, 2783, 1638, 1576, 1555, 1511, 1471, 1438, 1270; 
1
H NMR 
(500 MHz, DMSO-d6) δ 1.23 (2H, dddd, J = 12.4, 12.4, 12.4 and 3.6 Hz, CH2CH2NCH3), 
1.52 (2H, d, J = 12.4 Hz, CH2CH2NCH3), 1.74 – 1.84 (3H, m, CH2CH2NCH3 and 
ArCH2CH), 2.11 (3H, s, NCH3), 2.70 (2H, d, J = 12.4 Hz, CH2CH2NCH3), 2.74 (2H, d, 
J = 7.1 Hz, ArCH2CH), 3.90 (3H, s, ArOCH3), 7.33 (1H, dd, J = 9.0, 8.9 Hz, H-4’), 7.39 
(1H, dd, J = 9.0, 1.4 Hz, H-5’), 7.44 (1H, s, H-3), 7.52 (1H, s, H-5), 9.02 (2H, s, H-4”, 6”), 
10.35 (1H, s, CONHAr), 12.75 (1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) 
δ 31.7 (CH2CH2NCH3), 34.9 (ArCH2CH), 44.9 (ArCH2CH), 46.2 (NCH3), 55.3 
(CH2CH2NMe), 56.5 (ArOCH3), 112.0 (C-3), 115.2 (C-4’), 120.2 (d, J = 4.8 Hz, C-6’), 
125.2 (C-2 or C-4), 125.6 (d, J = 3.7 Hz, C-5’), 127.9 (C-2 or C-4), 128.4 (d, J = 19.9 Hz, 
C-1’), 129.7 (C-5), 131.7 (C-5”), 146.4 (d, J = 10.7 Hz, C-3’), 147.9 (d, J = 247.3 Hz, 
C-2’), 148.0 (C-4”, 6”), 158.8 (CONHAr), 163.9 (C-2”), 183.6 (ArCO); 19F NMR 
(471 MHz, DMSO-d6) δ -136.1 (ArF); LRMS (ES
+
) m/z 486.4 [M(
35
Cl)+H]
+
, 488.4 
380 
[M(
37
Cl)+H]
+
; HRMS (NSI) calcd for C24H26ClFN5O3 [M(
35
Cl)+H]
+
 486.1703, found 
463.1695. 
 
4-(6-Chloro-2-fluoro-3-methoxybenzoyl)-N-(2-(piperidin-4-ylmethyl)pyrimidin-5-yl)-
1H-pyrrole-2-carboxamide, (413) 
 
Compound 413 was synthesised according to general procedure F’, using the following 
reagents: tert-butyl 4-((5-(4-(6-chloro-2-fluoro-3-methoxybenzoyl)-1H-pyrrole-2-
carboxamido)pyrimidin-2-yl)methyl)piperidine-1-carboxylate (430) (125 mg, 0.22 mmol), 
triethylsilane (87 µL, 64 mg, 0.55 mmol), TFA (1.1 mL) and DCM (1.1 mL). The crude 
yellow solid was purified by column chromatography (amine silica gel, DCM:MeOH, 
1:0  95:5) to yield the title compound as a white solid (67 mg, 65%); Rf = 0.30 (amine 
silica, DCM:MeOH, 95:5); m.p. 234.5-236.5 °C; λmax (EtOH)/nm 296.0; IR (neat) 
νmax/cm
-1
 2924, 2842, 1640, 1576, 1510, 1471, 1439, 1390, 1270; 
1
H NMR (500 MHz, 
DMSO-d6) δ 1.13 (2H, dddd, J = 12.3, 12.3, 12.3 and 3.8 Hz, CH2CH2NH), 1.51 (2H, d, 
J = 12.3 Hz, CH2CH2NH), 1.96 (1H, ttt, J = 12.3, 7.2 and 3.9 Hz, ArCH2CH), 2.40 – 2.48 
(2H, m, CH2CH2NH), 2.73 (2H, d, J = 7.2 Hz, ArCH2CH), 2.93 (2H, d, J = 12.3 Hz, 
CH2CH2NH), 3.90 (3H, s, ArOCH3), 7.32 (1H, dd, J = 9.0, 9.0 Hz, H-4’), 7.35 – 7.42 (2H, 
m, H-3 and H-5’), 7.49 (1H, s, H-5), 9.02 (2H, s, H-4”, 6”), 10.32 (1H, s, CONHAr); 
13
C NMR (126 MHz, DMSO-d6) δ 32.3 (CH2CH2NH), 35.7 (ArCH2CH), 45.5 (ArCH2CH), 
45.7 (CH2CH2NH), 56.4 (ArOCH3), 112.1 (C-3), 115.0 (C-4’), 120.3 (d, J = 5.0 Hz, C-6’), 
125.3 (C-2 or C-4), 125.5 (C-5’), 128.6 (C-2 or C-4), 128.7 (d, J = 20.6 Hz, C-1’), 130.3 
(C-5), 131.8 (C-5”), 146.4 (d, J = 10.6 Hz, C-3’), 147.9 (d, J = 246.8 Hz, C-2’), 148.0 
(C-4”, 6”), 159.1 (CONHAr), 163.7 (C-2”), 183.4 (ArCO); 19F NMR (471 MHz, 
DMSO-d6) δ -136.13 (ArF); LRMS (ES
+
) m/z 472.4 [M(
35
Cl)+H]
+
, 474.3 [M(
37
Cl)+H]
+
; 
HRMS (NSI) calcd for C23H24ClFN5O3 [M(
35
Cl)+H]
+
 472.1546, found 472.1538. 
 
  
381 
tert-Butyl 4-(methyl(5-nitropyrimidin-2-yl)amino)piperidine-1-carboxylate, (415) 
 
Compound 415 was synthesised according to general procedure C’, using the following 
reagents: 2-chloro-5-nitropyrimidine (414) (600 mg, 3.76 mmol), triethylamine (580 µL, 
421 mg, 4.14 mmol), tert-butyl 4-(methylamino)piperidine-1-carboxylate (883 µL, 
887 mg, 4.14 mmol) and THF (18.8 mL). The crude product was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  15:85) to yield the title compound as a 
pale yellow solid (1.20 g, 94%); Rf = 0.28 (petrol:EtOAc, 15:85); m.p. 155.0-157.0 °C; 
λmax (EtOH)/nm 344.8; IR (neat) νmax/cm
-1
 2964, 2935, 2858, 1684, 1594, 1558, 1533, 
1415, 1323, 1295, 1241; 
1
H NMR (500 MHz, DMSO-d6) δ 1.41 (9H, s, C(CH3)3), 
1.75 - 1.60 (4H, m, H-3’, 5’), 2.83 (2H, brs, H-2’, 6’), 3.11 (3H, s, NCH3), 4.08 (2H, brs, 
H-2’, 6’), 4.85 (1H, tt, J = 11.6, 4.4 Hz, H-4’), 9.13 (2H, d, J = 3.0 Hz, H-4, 6); 13C NMR 
(126 MHz, DMSO-d6) δ 28.1 (C(CH3)3), 28.2 (C-3’, 5’), 29.9 (NCH3), 42.7 (C-2’, 6’), 53.5 
(C-4’), 78.8 (OC(CH3)3), 133.3 (C-5), 153.7 (CO2N), 154.7 (C-4 or C-6), 155.0 (C-4 or 
C-6), 161.2 (C-2); HRMS (ESI) calcd for C15H24N5O4 [M+H]
+
 338.1823, found 338.1824. 
 
tert-Butyl 4-((5-aminopyrimidin-2-yl)(methyl)amino)piperidine-1-carboxylate, (416) 
 
Compound 416 was synthesised according to general procedure D’, using the following 
reagents: tert-butyl 4-(methyl(5-nitropyrimidin-2-yl)amino)piperidine-1-carboxylate (415) 
(400 mg, 1.19 mmol), THF (12 mL) and methanol (12 mL). The orange solid (350 mg, 
96%) was used in the next step without further purification; Rf = 0.22 (EtOAc, 100%); 
m.p. 142.0-144.0 °C; λmax (EtOH)/nm 255.0; IR (neat) νmax/cm
-1
 3392, 3336, 3232, 3003, 
2970, 2951, 2864, 1669, 1543, 1475, 1427, 1408, 1364, 1244; 
1
H NMR (500 MHz, 
DMSO-d6) δ 1.40 (9H, s, C(CH3)3), 1.64 – 1.44 (4H, m, H-3’, 5’), 2.81 (2H, brs, H-2’, 6’), 
2.82 (3H, s, NCH3), 4.04 (2H, brs, H-2’, 6’), 4.46 (2H, brs, ArNH2), 4.54 (1H, tt, J = 10.4, 
5.5 Hz, H-4’), 7.88 (2H, s, H-4, 6); 13C NMR (126 MHz, DMSO-d6) δ 28.1 (C(CH3)3), 
28.5 (C-3’, 5’), 28.7 (NCH3), 43.2 (C-2’, 6’), 51.8 (C-4’), 78.6 (OC(CH3)3), 133.3 (C-5), 
144.4 (C-4, 6), 153.8 (CO2N), 155.7 (C-2); LRMS (ES
+
) m/z 308.4 [M+H]
+
; HRMS (NSI) 
calcd for C15H26N5O2 [M+H]
+
 308.2081, found 308.2080. 
 
382 
tert-Butyl 4-((5-(4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxamido) 
pyrimidin-2-yl)(methyl)amino)piperidine-1-carboxylate, (417) 
 
Compound 417 was synthesised according to general procedure Y, using the following 
reagents: 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250) (150 mg, 
0.50 mmol), triethylamine (173 µL, 126 mg, 1.24 mmol), 2-chloro-1-methylpyridinium 
iodide (140 mg, 0.55 mmol), tert-butyl 4-((5-aminopyrimidin-2-
yl)(methyl)amino)piperidine-1-carboxylate (416) (191 mg, 0.62 mmol) and DCM (5 mL). 
The crude yellow solid was purified by column chromatography (silica gel, petrol:EtOAc, 
1:0  6:4) to yield the title compound as a pale brawn solid (142 mg, 48%); Rf = 0.27 
(petrol:EtOAc, 6:4); m.p. 228.5-230.5 °C; λmax (EtOH)/nm 291.8; IR (neat) νmax/cm
-1
 3187, 
2973, 2936, 2863, 1655, 1637, 1500, 1447, 1403, 1365, 1284, 1240; 
1
H NMR (500 MHz, 
DMSO-d6) δ 1.41 (9H, s, C(CH3)3), 1.55 – 1.70 (4H, m, CH2CH2NBoc), 2.81 (2H, s, 
CH2CH2NBoc), 2.95 (3H, s, NCH3), 4.08 (2H, s, CH2CH2NBoc), 4.70 (1H, tt, J = 10.8, 
5.1 Hz, ArN(CH3)CH), 7.39 (1H, s, H-3), 7.52 (1H, dd, J = 8.8, 1.4 Hz, H-5’), 7.60 (1H, s, 
H-5), 7.78 (1H, dd, J = 8.8, 8.4 Hz, H-4’), 8.58 (2H, s, H-4”, 6”), 10.01 (1H, s, CONHAr), 
12.73 (1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 28.1 (CH2CH2NBoc), 28.5 
(C(CH3)3), 28.8 (NCH3), 42.9 (CH2CH2NBoc), 52.0 (ArN(CH3)CH), 78.7 (OC(CH3)3), 
111.0 (C-3), 119.3 (d, J = 18.1 Hz, C-3’), 123.0 (C-5”), 124.7 (C-2 or C-4), 126.9 (d, 
J = 3.9 Hz, C-5’), 128.4 (C-2 or C-4), 129.2 (d, J = 23.1 Hz, C-1’), 129.2 (d, J = 5.2 Hz, 
C-6’), 129.8 (C-5), 131.8 (C-4’), 151.3 (C-4”, 6”), 153.8 (C-2”), 153.8 (d, J = 248.5 Hz, 
C-2’), 158.3 (CONHAr or CO2N), 158.4 (CONHAr or CO2N), 182.6 (ArCO); 
19
F NMR 
(471 MHz, DMSO-d6) δ -116.7 (ArF); LRMS (ES
-
) m/z 589.3 [M(
35
Cl
35
Cl)-H]
-
, 591.3 
[M(
35
Cl
37
Cl)-H]
-
; HRMS (NSI) calcd for C27H30Cl2FN6O4 [M(
35
Cl
35
Cl)+H]
+
 591.1684, 
found 591.1680. 
 
N-Methyl-N-(1-methylpiperidin-4-yl)-5-nitropyrimidin-2-amine, (418) 
 
Compound 418 was synthesised according to general procedure E’, using the following 
reagents: tert-butyl 4-(methyl(5-nitropyrimidin-2-yl)amino)piperidine-1-carboxylate (415) 
383 
(600 mg, 1.78 mmol), formic acid (7.1 mL) and formaldehyde (37 % wt. in water) 
(529 µL, 7.11 mmol). The crude yellow solid (420 mg, 94%) was used in the next step 
without further purification; Rf = 0.31 (amine silica, petrol:EtOAc, 7:3); m.p. 
179.5-181.5 °C; λmax (EtOH)/nm 352.6; IR (neat) νmax/cm
-1
 2945, 2926, 2777, 2736, 1598, 
1542, 1480, 1412, 1330, 1297, 1277; 
1
H NMR (500 MHz, DMSO-d6) δ 1.55 – 1.64 (2H, 
m, H-3’, 5’equ), 1.85 (2H, dddd, J = 12.1, 12.1, 12.1 and 4.1 Hz, H-3’, 5’axial), 1.94 – 2.03 
(2H, m, H-2’, 6’), 2.19 (3H, s, NCH3), 2.82 – 2.92 (2H, m, H-2’, 6’), 3.12 (3H, s, NCH3), 
4.66 (1H, tt, J = 12.1, 4.1 Hz, H-4’), 9.12 (2H, s, H-4, 6); 13C NMR (126 MHz, DMSO-d6) 
δ 28.1 (C-3’, 5’), 29.9 (NCH3), 45.8 (NCH3), 53.4 (C-4’), 54.6 (C-2’, 6’), 133.2 (C-5), 
154.7 (C-4 or C-6), 155.0 (C-4 or C-6), 161.3 (C-2); LRMS (ES
+
) m/z 252.3 [M+H]
+
; 
HRMS (NSI) calcd for C11H18N5O2 [M+H]
+
 252.1455, found 252.1452. 
 
N
2
-Methyl-N
2
-(1-methylpiperidin-4-yl)pyrimidine-2,5-diamine, (419) 
 
Compound 419 was synthesised according to general procedure D’, using the following 
reagents: N-methyl-N-(1-methylpiperidin-4-yl)-5-nitropyrimidin-2-amine (418) (450 mg, 
1.79 mmol), THF (18 mL) and methanol (18 mL). The crude yellow solid (380 mg, 96%) 
was used in the next step without further purification; Rf = 0.32 (amine silica, 
DCM:MeOH, 98:2); m.p. 150.5-152.5 °C; λmax (EtOH)/nm 255.2; IR (neat) νmax/cm
-1
 3314, 
3151, 2933, 2852, 2792, 2735, 1547, 1481, 1465, 1403, 1373; 
1
H NMR (500 MHz, 
DMSO-d6) δ 1.41 – 1.51 (2H, m, H-3’, 5’equ), 1.72 (2H, dddd, J = 12.2, 12.2, 12.2 and 
3.9 Hz, H-3’, 5’axial), 1.93 (2H, ddd, J = 12.2, 12.2 and 2.3 Hz, H-2’, 6’axial), 2.16 (3H, s, 
NCH3), 2.79 – 2.83 (2H, m, H-2’, 6’equ), 2.83 (3H, s, NCH3), 4.34 (1H, tt, J = 12.3, 3.9 Hz, 
H-4’), 4.43 (2H, brs, ArNH2), 7.87 (2H, s, H-4, 6); 
13
C NMR (126 MHz, DMSO-d6) δ 28.4 
(C-3’, 5’), 28.8 (NCH3), 46.0 (NCH3), 51.6 (C-4’), 55.2 (C-2’, 6’), 133.1 (C-5), 144.4 
(C-4, 6), 155.9 (C-2); LRMS (ES
+
) m/z 222.3 [M+H]
+
; HRMS (NSI) calcd for C11H20N5 
[M+H]
+
 222.1713, found 222.1710. 
 
  
384 
N-(3-(Dimethylamino)-2-[[(dimethylamino)methylene]amino]prop-2-en-1-ylidene)-N-
methylmethanaminium hydrogen dihexafluorophosphate, (421) 
 
Phosphorus(V) oxychloride (7.52 mL, 12.4 g, 80.7 mmol) was added dropwise to 
N,N-dimethylformamide (16.1 mL), cooled to 10 °C. During the addition, the temperature 
of the solution was maintained between 10 and 15 °C with an ice bath. Once the addition 
was complete, the reaction was stirred at RT for 20 min. The resulting solution was cooled 
to 5 °C before powdered glycine hydrochloride (3.0 g, 26.9 mmol) was added in portions; 
the temperature of the reaction mixture was maintained below 10 °C during the addition. 
The resulting reaction mixture was heated at 80 ± 2 °C (internal temperature) for 4 h. Then 
the still hot, dark orange, solution was poured directly in a fine stream into water (43 mL), 
precooled to 5 °C. The temperature of the solution was kept below 20 °C with an acetone 
dry ice bath. 5 min after the transfer was complete, the reaction mixture was cooled to -
5 °C and treated from a plastic vessel with 60% aq. HPF6 (7.93 mL, 53.8 mmol). The thick 
precipitate, which formed upon addition of the acid, was filtered off and washed with cold 
EtOH (100 mL) until a pale yellow solid was obtained (5.24 g, 40%); m.p. 151.0-153.0 °C; 
λmax (EtOH)/nm 254.6; IR (neat) νmax/cm
-1
 1701, 1611, 1402, 1291; 
1
H NMR (500 MHz, 
DMSO-d6) δ 3.19 (9H, s, 3 × NCH3), 3.24 (3H, s, NCH3), 3.29 (6H, s, 2 × NCH3), 7.70 
(2H, s, 2 × CH), 8.07 (1H, d, J = 10.4 Hz, CHNH(CH3)2
+
), 10.74 (1H, d, J = 6.8 Hz, 
CHNH(CH3)2
+
); 
13
C NMR (126 MHz, DMSO-d6) δ 37.0 (NCH3), ca. 40 (overlapping with 
DMSO) (NCH3), 43.6 (NCH3), 48.8 (NCH3), 100.8 (Cq), 158.1 (CH), 160.7 
(CHNH(CH3)2
+
); 
19
F NMR (471 MHz, DMSO-d6) δ -70.9 (PF6
-
), -69.4 (PF6
-
); 
LRMS (ES
+
) m/z 197.3 [M-HP2F12
-
]
+
; HRMS (NSI) calcd for C10H21N4 [M-HP2F12
-
]
+
 
197.1761, found 197.1760. 
 
tert-Butyl 4-(cyanomethylene)piperidine-1-carboxylate, (423) 
 
To diethyl cyanomethylphosphonate (3.50 mL, 3.83 g, 21.6 mmol) in THF (60 mL), 
cooled at -78 °C, was added lithium bis(trimethylsilyl)amide (1.0 M solution in THF, 
21.6 mL, 21.6 mmol) and 1-Boc-4-piperidone (422) (3.92 g, 19.7 mmol) in THF (10 mL). 
The resulting solution was stirred at -78 °C for 1 h. Upon completion, the reaction mixture 
was quenched by the cautious addition saturated aq. NH4Cl (50 mL) and extracted with 
385 
EtOAc (3 × 60 mL). The pooled organic extracts were washed with water and brine 
(40 mL, respectively), dried over MgSO4 and concentrated in vacuo. The crude product 
was purified by column chromatography (silica gel, petrol:EtOAc, 1:0  8:2) to yield the 
title compound as a white solid (4.02 g, 92%); Rf = 0.33 (petrol:EtOAc, 8:2); 
m.p. 118.0-120.0 °C (lit. 117.0-119.0 °C)
282
; λmax (EtOH)/nm 230.4; IR (neat) νmax/cm
-1
 
3053, 2976, 2872, 2215, 1674, 1631, 1425, 1360; 
1
H NMR (500 MHz, DMSO-d6) δ 1.41 
(9H, s, C(CH3)3), 2.31 (2H, t, J = 5.7 Hz, CH2CH2NBoc), 2.44 (2H, t, J = 5.7 Hz, 
CH2CH2NBoc), 3.38 (2H, t, J = 5.9 Hz, CH2CH2NBoc), 3.43 (2H, t, J = 5.9 Hz, 
CH2CH2NBoc), 5.57 (1H, s, CHCN); 
13
C NMR (126 MHz, DMSO-d6) δ 28.0 (C(CH3)3), 
32.1 (CH2CH2NBoc), 34.0 (CH2CH2NBoc), 43.5 (CH2CH2NBoc), 44.0 (CH2CH2NBoc), 
79.2 (OC(CH3)3), 94.0 (CHCN), 116.8 (CHCN), 153.6 (C-4), 164.1 (CO2N); LRMS (ES
+
) 
m/z 223.3 [M+H]
+
; HRMS (ESI) calcd for C12H19N2O2 [M+H]
+
: 223.1441; found 
223.1436; 
1
H and 
13
C NMR data were identical to literature data.
282
 
 
tert-Butyl 4-(cyanomethyl)piperidine-1-carboxylate, (424) 
 
tert-Butyl 4-(cyanomethylene)piperidine-1-carboxylate (423) (4.0 g, 18.0 mmol) in EtOAc 
(360 mL) was subjected to palladium-catalysed hydrogenation using an H-Cube

 reactor 
and a 10% Pd/C CatCart under a full pressure of hydrogen. The reaction was conducted at 
RT for 24 h. The reaction mixture was concentrated in vacuo to afford a white solid 
(4.04 g, quantitative) which was used in the next step without further purification; 
Rf = 0.32 (petrol:EtOAc, 3:1); m.p. 74.0-76.0 °C; IR (neat) νmax/cm
-1
 2985, 2968, 2952, 
2935, 2922, 2853, 2240, 1684, 1419, 1365; 
1
H NMR (500 MHz, DMSO-d6) δ 1.07 (2H, 
dddd, J = 12.4, 12.4, 12.4 and 4.4 Hz, CH2CH2NBoc), 1.37 (9H, s, C(CH3)3), 1.65 (2H, d, 
J = 12.4 Hz, CH2CH2NBoc), 1.76 (1H, ttt, J = 12.4, 6.7 and 3.7 Hz, CHCH2CN), 2.48 (2H, 
d, J = 6.7 Hz, CHCH2CN), 2.68 (2H, brs, CH2CH2NBoc), 3.92 (2H, d, J = 9.8 Hz, 
CH2CH2NBoc); 
13
C NMR (126 MHz, DMSO-d6) δ 22.7 (CHCH2CN), 28.1 (C(CH3)3), 
30.6 (CH2CH2NBoc), 32.3 (CHCH2CN), 43.0 (CH2CH2NBoc), 78.6 (OC(CH3)3), 119.4 
(CHCH2CN), 153.8 (CO2N); LRMS (ES
+
) m/z 225.2 [M+H]
+
; HRMS (ESI) calcd for 
C12H24N3O2 [M+NH4]
+
: 242.1863; found 242.1857; 
1
H and 
13
C NMR data were identical 
to literature data.
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386 
tert-Butyl 4-(2-(acetoxyimino)-2-aminoethyl)piperidine-1-carboxylate, (425) 
 
To tert-butyl 4-(cyanomethyl)piperidine-1-carboxylate (424) (3.5 g, 15.6 mmol) in EtOH 
(35 mL) was added aqueous hydroxylamine (50% solution, 1.91 mL, 31.2 mmol) and the 
resulting solution stirred at 80 °C for 5 h. Once cooled to RT, the reaction solution was 
concentrated in vacuo to give tert-butyl 4-(2-amino-2-(hydroxyimino)ethyl)piperidine-1-
carboxylate as a white solid. To this solid, dissolved in dioxane (35 mL), were added acetic 
anhydride (2.95 mL, 3.19 g, 31.2 mmol) and triethylamine (2.18 mL, 1.58 g, 31.2 mmol). 
The resulting solution was stirred overnight at RT. Upon completion, the mixture was 
diluted with water (25 mL) and extracted with EtOAc (3 × 40 mL). The pooled organic 
extracts were washed with water and brine (50 mL, respectively), dried over MgSO4 and 
concentrated in vacuo. The crude product was purified by column chromatography (silica 
gel, petrol:EtOAc, 1:0  3:1) to yield the title compound as a white solid (3.67 g, 79%); 
Rf = 0.31 (petrol:EtOAc, 3:1); m.p. 149.5-151.5 °C; λmax (EtOH)/nm 274.2; IR (neat) 
νmax/cm
-1
 3461, 3436, 3331, 3302, 3264, 3174, 2978, 2929, 2908, 2845, 1738, 1679, 1631, 
1604, 1427; 
1
H NMR (500 MHz, DMSO-d6) δ 0.99 (2H, dddd, J = 12.6, 12.6, 12.6 and 4.2 
Hz, H-3, 5), 1.38 (9H, s, C(CH3)3), 1.62 (2H, d, J = 12.6 Hz, H-3, 5), 1.77 (1H, ttt, 
J = 12.6, 7.3 and 3.5 Hz, H-4), 1.95 (2H, d, J = 7.3 Hz, CH2CH), 2.02 (3H, s, CH3CO2), 
2.67 (2H, brs, H-2, 6), 3.90 (2H, d, J = 12.6 Hz, H-2, 6), 6.31 (2H, brs, NH2); 
13
C NMR 
(126 MHz, DMSO-d6) δ 19.8 (CH3CO2), 28.1 (C(CH3)3), 31.3 (C-3, 5), 33.4 (C-4), 36.9 
(CH2CH), 43.3 (C-2, 6), 78.4 (OC(CH3)3), 153.8 (CO2N), 157.4 (C(NH2)NO2CCH3), 168.4 
(CH3CO2); LRMS (ES
+
) m/z 300.4 [M+H]
+
; HRMS (NSI) calcd for C14H26N3O4 [M+H]
+
 
300.1918, found 300.1915. 
 
tert-Butyl 4-(2-amino-2-iminoethyl)piperidine-1-carboxylate acetate, (426) 
 
tert-Butyl 4-(2-(acetoxyimino)-2-aminoethyl)piperidine-1-carboxylate (425) (3.5 g, 
11.7 mmol) was dissolved in a EtOH:DCM (5:1) (84 mL), followed by addition of 
palladium on carbon (10 wt. %) (350 mg). The resulting heterogeneous solution was stirred 
under a hydrogen atmosphere at RT for 16 h. Upon completion, the reaction mixture was 
filtered through Celite and concentrated in vacuo to afford the title compound as an off-
white solid (3.32 g, 95%). The crude material was used in the next step without further 
purification; m.p. 176.0-178.0 °C; IR (neat) νmax/cm
-1
 2983, 2967, 2927, 2866, 1673, 1586, 
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1523, 1426, 1409; 
1
H NMR (500 MHz, DMSO-d6) δ 1.03 (2H, dddd, J = 12.5, 12.5, 12.5 
and 4.1 Hz, H-3, 5), 1.39 (9H, s, C(CH3)3), 1.59 (2H, d, J = 12.5 Hz, H-3, 5), 1.64 (3H, s, 
CH3CO2), 1.84 (1H, ttt, J = 12.5, 7.5 and 3.8 Hz, H-4), 2.20 (2H, d, J = 7.5 Hz, CH2CH), 
2.70 (2H, brs, H-2, 6), 3.92 (2H, d, J = 12.5 Hz, H-2, 6); 
13
C NMR (126 MHz, DMSO-d6) 
δ 25.0 (CH3CO2
-
), 28.1 (C(CH3)3), 31.0 (C-3, 5), 33.6 (C-4), 43.0 (C-2, 6), 78.6 
(OC(CH3)3), 153.8 (CO2N), 169.7 (C(NH2)NH2
+
), 176.3 (CH3CO2
-
); LRMS (ES
+
) m/z 
242.4 [M-AcO
-
]
+
; HRMS (NSI) calcd for C12H23N3O2 [M-AcO
-
]
+
 242.1863, found 
242.1859. 
 
tert-Butyl 4-((5-aminopyrimidin-2-yl)methyl)piperidine-1-carboxylate, (428) 
 
To a slurry of N-(3-(dimethylamino)-2-[[(dimethylamino)methylene]amino]prop-2-en-1-
ylidene)-N-methylmethanaminium hydrogen dihexafluorophosphate (421) (4.05 g, 
8.29 mmol) and tert-butyl 4-(2-amino-2-iminoethyl)piperidine-1-carboxylate acetate (426) 
(3.0 g, 9.95 mmol) in EtOH (20 mL) was added dropwise a solution of NaOMe in MeOH 
(1.61 g, 29.9 mmol, 25% w/v); the mixture was heated to reflux halfway through the 
addition. After refluxing for 150 min, the mixture was cooled to 0 °C, the inorganic 
precipitate was filtered off, washed with cold EtOH (2 ×20 mL) and the filtrate evaporated. 
The residue was dissolved in DCM (50 mL), washed with water (3 × 20 mL), dried over 
MgSO4, and concentrated in vacuo to give tert-butyl 4-((5-(((dimethylamino)methylene) 
amino)pyrimidin-2-yl)methyl)piperidine-1-carboxylate (427) as an orange oil. The oil was 
dissolved in dioxane (15 mL), treated with 5% aq. potassium carbonate (21 mL) and 
refluxed overnight. Once cooled to RT, the reaction mixture was extracted with EtOAc 
(3 × 40 mL). The pooled organic extracts were washed with water and brine (50 mL, 
respectively), dried over MgSO4 and concentrated in vacuo. The crude product was 
purified by column chromatography (amine silica gel, petrol:EtOAc, 1:0  4:6) to yield 
the title compound as an off-white solid (1.91 g, 79%); Rf = 0.32 (amine silica, 
petrol:EtOAc, 4:6); m.p. 133.5-135.5 °C; λmax (EtOH)/nm 246.6, 318.2; IR (neat) νmax/cm
-1
 
3457, 3342, 2970, 2944, 2916, 2863, 2842, 1663, 1618, 1547, 1443, 1424; 
1
H NMR 
(500 MHz, DMSO-d6) δ 1.02 (2H, dddd, J = 12.5, 12.5, 12.5 and 4.2 Hz, H-3’, 5’), 1.38 
(9H, s, C(CH3)3), 1.51 (2H, d, J = 12.5 Hz, H-3’, 5’), 1.92 (1H, ttt, J = 12.5, 7.2 and 
4.0 Hz, H-4’), 2.58 (2H, d, J = 7.2 Hz, ArCH2CH), 2.69 (2H, brs, H-2’, 6’), 3.88 (2H, brs, 
H-2’, 6’), 5.31 (2H, brs, ArNH2), 8.02 (2H, s, H-4, 6); 
13
C NMR (126 MHz, DMSO-d6) 
δ 28.1 (C(CH3)3), 31.6 (C-3’, 5’), 35.5 (C-4’), 43.5 (C-2’, 6’), 44.3 (ArCH2), 78.4 
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(OC(CH3)3), 140.4 (C-5), 141.8 (C-4, 6), 153.9 (CO2N), 156.6 (C-5); LRMS (ES
+
) m/z 
293.2 [M+H]
+
; HRMS (NSI) calcd for C15H25N4O2 [M+H]
+
 293.1972, found 293.1974. 
 
tert-Butyl 4-((5-(4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxamido) 
pyrimidin-2-yl)methyl)piperidine-1-carboxylate, (429) 
 
Compound 429 was synthesised according to general procedure Y, using the following 
reagents: 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250) (400 mg, 
1.32 mmol), triethylamine (461 µL, 335 mg, 3.31 mmol), 2-chloro-1-methylpyridinium 
iodide (372 mg, 1.46 mmol), tert-butyl 4-((5-aminopyrimidin-2-yl)methyl)piperidine-1-
carboxylate (428) (484 mg, 1.65 mmol) and DCM (13.2 mL). The crude yellow solid was 
purified by column chromatography (silica gel, petrol:EtOAc, 1:0  45:55) to yield the 
title compound as a white solid (386 mg, 51%); Rf = 0.31 (petrol:EtOAc, 45:55); 
m.p. 217.5-219.5 °C; λmax (EtOH)/nm 264.0; IR (neat) νmax/cm
-1
 3241, 2958, 2927, 2866, 
1649, 1584, 1555, 1514, 1445, 1425, 1392, 1274; 
1
H NMR (500 MHz, DMSO-d6) δ 1.09 
(2H, dddd, J = 12.5, 12.5, 12.5 and 4.0 Hz, CH2CH2NBoc), 1.38 (9H, s, C(CH3)3), 1.56 
(2H, d, J = 12.5 Hz, CH2CH2NBoc), 2.04 (1H, ttt, J = 12.5, 7.4 and 3.4 Hz, ArCH2CH), 
2.69 (2H, brs, CH2CH2NBoc), 2.77 (2H, d, J = 7.4 Hz, ArCH2CH), 3.90 (2H, d, 
J = 12.5 Hz, CH2CH2NBoc), 7.49 (1H, s, H-3), 7.52 (1H, dd, J = 8.6, 1.3 Hz, H-5’), 7.66 
(1H, s, H-5), 7.79 (1H, dd, J = 8.6, 8.4 Hz, H-4’), 9.03 (2H, s, H-4”, 6”), 10.36 (1H, s, 
CONHAr), 12.84 (1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 28.1 (C(CH3)3), 
31.5 (CH2CH2NBoc), 35.3 (ArCH2CH), 43.2 (CH2CH2NBoc), 44.7 (ArCH2CH), 78.4 
(OC(CH3)3), 111.8 (C-3), 119.4 (d, J = 18.1 Hz, C-3’), 124.8 (C-2 or C-4), 126.9 (d, 
J = 3.9 Hz, C-5’), 128.0 (C-2 or C-4), 129.1 (d, J = 22.3 Hz, C-1’), 129.2 (d, J = 4.7 Hz, 
C-6’), 130.5 (C-5), 131.7 (C-4’), 131.9 (C-5”), 148.1 (C-4”, 6”), 153.8 (d, J = 248.6 Hz, 
C--2’), 153.9 (CO2N), 158.7 (CONHAr), 163.7 (C-2”), 182.6 (ArCO); 
19
F NMR 
(471 MHz, DMSO-d6) δ -116.7 (ArF); LRMS (ES
-
) m/z 574.3 [M(
35
Cl
35
Cl)-H]
-
, 576.3 
[M(
35
Cl
37
Cl)-H]
-
; HRMS (NSI) calcd for C27H29Cl2FN5O4 [M(
35
Cl
35
Cl)+H]
+
 576.1575, 
found 576.1570. 
 
  
389 
tert-Butyl 4-((5-(4-(6-chloro-2-fluoro-3-methoxybenzoyl)-1H-pyrrole-2-carboxamido) 
pyrimidin-2-yl)methyl)piperidine-1-carboxylate, (430) 
 
Compound 430 was synthesised according to general procedure Y, using the following 
reagents: 4-(6-chloro-2-fluoro-3-methoxybenzoyl)-1H-pyrrole-2-carboxylic acid (338) 
(400 mg, 1.34 mmol), triethylamine (468 µL, 340 mg, 3.36 mmol), 2-chloro-1-
methylpyridinium iodide (378 mg, 1.48 mmol), tert-butyl 4-((5-aminopyrimidin-2-
yl)methyl)piperidine-1-carboxylate (428) (491 mg, 1.68 mmol) and DCM (13.4 mL). The 
crude yellow solid was purified by column chromatography (silica gel, petrol:EtOAc, 
1:0  4:6) to yield the title compound as a white solid (281 mg, 37%); Rf = 0.29 
(petrol:EtOAc, 4:6); m.p. 228.0-230.0 °C; λmax (EtOH)/nm 292.6; IR (neat) νmax/cm
-1
 3199, 
2127, 2970, 2928, 2855, 1652, 1637, 1577, 1554, 1514, 1473, 1425, 1392, 1272; 
1
H NMR 
(500 MHz, DMSO-d6) δ 1.09 (2H, dddd, J = 12.5, 12.5, 12.5 and 4.0 Hz, CH2CH2NBoc), 
1.38 (9H, s, C(CH3)3), 1.56 (2H, d, J = 12.5 Hz, CH2CH2NBoc), 2.04 (1H, ttt, J = 12.5, 7.1 
and 3.7 Hz, ArCH2CH), 2.67 (2H, brs, CH2CH2NBoc), 2.77 (2H, d, J = 7.1 Hz, 
ArCH2CH), 3.90 (5H, brs, CH2CH2NBoc and ArOCH3), 7.33 (1H, dd, J = 9.0, 8.9 Hz, 
H-4’), 7.39 (1H, dd, J = 9.0, 1.4 Hz, H-5’), 7.45 (1H, s, H-3), 7.53 (1H, s, H-5), 9.02 (2H, 
s, H-4”, 6”), 10.35 (1H, s, CONHAr), 12.77 (1H, s, NH-pyrrole); 13C NMR (126 MHz, 
DMSO-d6) δ 28.1 (C(CH3)3), 31.5 (CH2CH2NBoc), 35.3 (ArCH2CH), 43.5 (ArCH2CH), 
44.7 (CH2CH2NBoc), 56.5 (ArOCH3), 78.4 (OC(CH3)3), 111.9 (C-3), 115.2 (C-4’), 120.2 
(d, J = 4.8 Hz, C-6’), 125.2 (C-2 or C-4), 125.6 (d, J = 3.6 Hz, C-5’), 127.8 (C-2 or C-4), 
128.4 (d, J = 20.0 Hz, C-1’), 129.6 (C-5), 131.8 (C-5”), 146.4 (d, J = 10.3 Hz, C-3’), 147.9 
(d, J = 246.9 Hz, C-2’), 148.1 (C-4”, 6”), 153.9 (CO2N), 158.7 (CONHAr), 163.6 (C-2”), 
183.6 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -136.1 (ArF); LRMS (ES
-
) m/z 570.4 
[M(
35
Cl)-H]
-
, 572.4 [M(
37
Cl)-H]
-
; HRMS (NSI) calcd for C28H32ClFN5O5 [M(
35
Cl)+H]
+
 
572.2071, found 572.2063. 
 
  
390 
2,2-Diethoxyacetimidamide hydrochloride, (432) 
 
Sodium (8 mg, 0.36 mmol) was carefully added to MeOH (5 mL) at RT. Once 
effervescence had ceased, diethoxyacetonitrile (431) (1.0 mL, 929 mg, 7.19 mmol) was 
added and the resulting mixture stirred at RT for 16 h. Solid carbon dioxide was added and 
the solvent was removed in vacuo. The resulting oil was dissolved in Et2O (10 mL) and the 
sodium carbonate removed by filtration. The filtrate was concentrated in vacuo to afford 
methyl diethoxyacetimidate as a yellow oil which was used with no further purification. 
The oil was dissolved in MeOH (5 mL) and ammonium chloride (385 mg, 7.19 mmol) was 
added in one portion. The resulting solution was stirred at RT overnight before the solvent 
was concentrated in vacuo. The resulting oil was triturated with Et2O to afford 
diethoxyacetimidamide hydrochloride as an off-white solid (1.17 g, 89%). The compound 
was used in the next step without further purification; m.p. 58.0-60.0 °C (lit. 
81.0-82.0 °C)
284
; IR (neat) νmax/cm
-1
 3259, 3042, 2975, 1692, 1083; 
1
H NMR (500 MHz, 
DMSO-d6) δ 1.19 (6H, t, J = 7.0 Hz, OCH2CH3), 3.62 (4H, qd, J = 7.0, 3.0 Hz, OCH2CH3), 
5.29 (1H, s, CH(OEt)2), 9.05 (4H, s, NH2 and NH2
+
); 
13
C NMR (126 MHz, DMSO-d6) 
δ 14.9 (OCH2CH3), 63.1 (OCH2CH3), 95.7 (CH(OEt)2), 165.8 (C=NH(NH2)); LRMS (ES
+
) 
m/z 147.2 [M-Cl]
+
; HRMS (ESI) calcd for C6H15N2O2 [M-Cl]
+
 147.1128, found 147.1123; 
1
H NMR data were identical to literature data.
250
 
 
2-(Diethoxymethyl)pyrimidin-5-amine, (434) 
 
To a slurry of N-(3-(dimethylamino)-2-[[(dimethylamino)methylene]amino]prop-2-en-1-
ylidene)-N-methylmethanaminium hydrogen dihexafluorophosphate (421) (5.70 g, 
11.7 mmol) and 2,2-diethoxyacetimidamide hydrochloride (432) (2.56 g, 14.0 mmol) in 
EtOH (25 mL) was added dropwise a solution of NaOMe in MeOH (2.27 g, 42.0 mmol, 
25% w/v); the mixture was heated to reflux halfway through the addition. After refluxing 
for 150 min, the mixture was cooled to 0 °C, the inorganic precipitate was filtered off, 
washed with cold EtOH (3 × 20 mL) and the filtrate evaporated. The residue was dissolved 
in DCM (50 mL), washed with water (3 × 20 mL), dried over MgSO4, and concentrated in 
vacuo to give N'-(2-(diethoxymethyl)pyrimidin-5-yl)-N,N-dimethylformimidamide (433) 
as an orange oil. The oil was dissolved in dioxane (20 mL), treated with 5% aq. potassium 
391 
carbonate (30 mL) and refluxed overnight. Once cooled to RT, the reaction mixture was 
extracted with EtOAc (3 × 40 mL). The pooled organic extracts were washed with water 
and brine (50 mL, respectively), dried over MgSO4 and concentrated in vacuo. The crude 
product was purified by column chromatography (silica gel, DCM:MeOH, 1:0  95:5) to 
yield the title compound as an off-white solid (1.12 g, 49%); Rf = 0.25 (DCM:MeOH, 
95:5); m.p. 134.0-136.0 °C; λmax (EtOH)/nm 250.4, 315.4; IR (neat) νmax/cm
-1
 3358, 3324, 
3202, 2977, 2929, 2877, 1646, 1583, 1555, 1452; 
1
H NMR (500 MHz, DMSO-d6) δ 1.09 
(6H, t, J = 7.1 Hz, OCH2CH3), 3.49 (2H, dq, J = 9.7, 7.1 Hz, OCH2CH3), 3.61 (2H, dq, 
J = 9.7, 7.1 Hz, OCH2CH3), 5.27 (1H, s, ArCH(OEt)2), 5.60 (2H, brs, ArNH2), 8.07 (2H, s, 
H-4, 6); 
13
C NMR (126 MHz, DMSO-d6) δ 15.2 (OCH2CH3), 61.2 (OCH2CH3), 102.0 
(ArCH(OEt)2), 141.1 (C-4, 6), 142.1 (C-5), 153.5 (C-2); LRMS (ES
+
) m/z 198.2 [M+H]
+
; 
HRMS (NSI) calcd for C9H15N3O2Na [M+Na]
+
 220.1056, found 220.1052; 
1
H and 
13
C NMR data were identical to literature data.
247
 
 
Benzyl (2-(diethoxymethyl)pyrimidin-5-yl)carbamate, (435) 
 
To 2-(diethoxymethyl)pyrimidin-5-amine (434) (1.5 g, 7.60 mmol) in THF:H2O (1:1) 
(20 mL) was added potassium carbonate (2.1 g, 15.2 mmol) in one portion, followed by 
dropwise addition of benzyl chloroformate (2.17 mL, 2.6 g, 15.2 mmol) in THF (5 mL). 
The resulting reaction mixture was stirred at RT for 24 h. Upon completion, the mixture 
was diluted with water (20 mL) and extracted with EtOAc (3 × 40 mL). The pooled 
organic extracts were washed with water and brine (40 mL, respectively), dried over 
MgSO4 and concentrated in vacuo. The crude product was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  6:4) to yield the title compound as a clear 
oil (2.03 g, 80%); Rf = 0.32 (petrol:EtOAc, 6:4); λmax (EtOH)/nm 238.0; IR (neat) νmax/cm
-1
 
3227, 3032, 2975, 2933, 2882, 1728, 1586, 1525, 1224; 
1
H NMR (500 MHz, DMSO-d6) 
δ 1.11 (6H, t, J = 7.0 Hz, 2 × OCH2CH3), 3.54 (2H, dq, J = 9.6, 7.0 Hz, OCH2CH3), 3.65 
(2H, dq, J = 9.6, 7.0 Hz, OCH2CH3), 5.20 (2H, s, OCH2Ph), 5.42 (1H, s, ArCH(OEt)2), 
7.33 – 7.47 (5H, m, 5 × ArH), 8.88 (2H, s, H-4, 6), 10.26 (1H, s, ArNHCbz); 13C NMR 
(126 MHz, DMSO-d6) δ 15.2 (OCH2CH3), 61.6 (OCH2CH3), 66.5 (OCH2Ph), 101.7 
(ArCH(OEt)2), 128.2 (CH Ar), 128.5 (CH Ar), 133.7 (Cq Ar), 136.1 (Cq Ar), 146.2 (C-4, 
6), 153.4 (ArNHCO2Bn), 159.3 (C-2); LRMS (ES
-
) m/z 330.3 [M-H]
-
; HRMS (NSI) calcd 
for C17H21N3O4 [M+H]
+
: 332.1605 found 332.1600. 
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Benzyl (2-formylpyrimidin-5-yl)carbamate, (436) 
 
To benzyl (2-(diethoxymethyl)pyrimidin-5-yl)carbamate (435) (1.9 g, 5.73 mmol) in 
acetonitrile (20 mL) was added 1 M aq. HCl (3.5 mL) at RT. The resulting mixture was 
stirred at RT for 8 h. Upon completion, the solvents were removed under reduced pressure 
and the resulting white residue dissolved in saturated aq. NaHCO3 (20 mL). The aqueous 
layer was extracted with EtOAc (3 × 30 mL) and the pooled organic extracts were washed 
with water and brine (40 mL, respectively), dried over MgSO4 and concentrated in vacuo 
to afford the title compound as a white solid (1.31 g, 89%). The crude material was used in 
the next step without further purification; Rf = 0.31 (petrol:EtOAc, 1:1); m.p. 
166.5-168.5 °C; λmax (EtOH)/nm 283.4; IR (neat) νmax/cm
-1
 3217, 3062, 3033, 2964, 2876, 
1730, 1715, 1586, 1566, 1526; 
1
H NMR (500 MHz, DMSO-d6) δ 5.24 (2H, s, OCH2Ph), 
7.34 – 7.49 (5H, m, 5 × ArH), 9.10 (2H, s, H-4, 6), 9.89 (1H, s, ArCHO), 10.69 (1H, s, 
ArNHCbz); 
13
C NMR (126 MHz, DMSO-d6) δ 66.9 (OCH2Ph), 128.3 (CH Ar), 128.5 
(CH Ar), 135.8 (Cq Ar), 136.2 (Cq Ar), 146.0 (C-4, 6), 153.2 (C-2 or ArNHCO2Bn), 153.6 
(C-2 or ArNHCO2Bn), 190.4 (ArCHO); LRMS (ES
+
) m/z 258.2 [M+H]
+
; HRMS (NSI) 
calcd for C13H12N3O3 [M+H]
+
 258.0873, found 258.0875. 
 
tert-Butyl 4-((5-(((benzyloxy)carbonyl)amino)pyrimidin-2-yl)methyl)piperazine-1-
carboxylate, (437) 
 
To benzyl (2-formylpyrimidin-5-yl)carbamate (436) (900 mg, 3.50 mmol) in TFE (25 mL) 
was added tert-butyl piperazine-1-carboxylate (1.30 g, 7.00 mmol). The resulting solution 
was stirred at 38 °C for 1 h. Once cooled at 0 °C, sodium borohydride was carefully added. 
The resulting mixture was allowed to warm to RT and then stirred for 30 min. Upon 
completion, the solvent was removed in vacuo. The crude residue was dissolved in EtOAc 
(40 mL), neutralised by washing with saturated aq. NH4Cl (25 mL), washed with water and 
brine (20 mL, respectively), dried over MgSO4 and concentrated in vacuo. The crude 
product was purified by column chromatography (amine silica gel, petrol:EtOAc, 
1:0  4:6) to yield the title compound as a yellow solid (630 mg, 42%); Rf = 0.34 (amine 
silica, petrol:EtOAc, 4:6); λmax (EtOH)/nm 236.8 nm; IR (neat) νmax/cm
-1
 2974, 1684, 1591, 
1528, 1416; 
1
H NMR (500 MHz, DMSO-d6) δ 1.38 (9H, s, C(CH3)3), 2.35 – 2.45 (4H, m, 
CH2 piperazine), 3.28 (4H, s, CH2 piperazine), 3.65 (2H, s, ArCH2N), 5.19 (2H, s, OCH2Ph), 7.33 
393 
– 7.46 (5H, m, 5 × ArH), 8.83 (2H, s, H-4, 6), 10.17 (1H, s, ArNHCbz); 13C NMR 
(126 MHz, DMSO-d6) δ 28.0 (C(CH3)3), 43.1 (CH2 piperazine), 52.3 (CH2 piperazine), 63.6 
(ArCH2N), 66.4 (OCH2Ph), 78.7 (OC(CH3)3), 128.2 (CH Ar), 128.2 (CH Ar), 128.5 
(CH Ar), 132.7 (Cq Ar), 136.1 (Cq Ar), 146.3 (C-4, 6), 153.4 (
t
BuOCON or ArNHCO2Bn), 
153.8 (
t
BuOCON or ArNHCO2Bn), 160.4 (C-2); LRMS (ES
+
) m/z 428.5 [M+H]
+
; HRMS 
(NSI) calcd for C22H30N5O4 [M+H]
+
 428.2292, found 428.2288. 
 
tert-Butyl 4-((5-aminopyrimidin-2-yl)methyl)piperazine-1-carboxylate, (438) 
 
tert-Butyl 4-((5-(((benzyloxy)carbonyl)amino)pyrimidin-2-yl)methyl)piperazine-1-
carboxylate (437) (600 mg, 1.40 mmol) in EtOAc (28 mL) was subjected to palladium-
catalysed hydrogenation using an H-Cube

 reactor and a 10% Pd/C CatCart under a full 
pressure of hydrogen. The reaction was conducted at RT for 24 h. The reaction mixture 
was concentrated in vacuo to afford the title compound as a pale yellow solid (407 mg, 
99%) which was used in the next step without further purification; Rf = 0.26 (amine silica, 
DCM:MeOH, 97:3); m.p. 200.5-202.5 °C; λmax (EtOH)/nm 249.0, 318.0; IR (neat) 
νmax/cm
-1
 3381, 3323, 3197, 2972, 2929, 2894, 2863, 2811, 2775, 1673, 1589, 1554, 1453; 
1
H NMR (500 MHz, DMSO-d6) δ 1.37 (9H, s, C(CH3)3), 2.35 (4H, t, J = 5.0 Hz, 
CH2 piperazine), 3.26 (4H, brs, CH2 piperazine), 3.50 (2H, s, ArCH2N), 5.47 (2H, brs, ArNH2), 
8.05 (2H, s, H-4, 6); 
13
C NMR (126 MHz, DMSO-d6) δ 28.1 (C(CH3)3), 43.3 
(CH2 piperazine), 52.3 (CH2 piperazine), 63.8 (ArCH2N), 78.7 (OC(CH3)3), 141.1 (C-5), 141.5 
(C-4, 6), 153.8 (C-2 or CO2N), 154.1 (C-2 or CO2N); LRMS (ES
+
) m/z 294.3 [M+H]
+
; 
HRMS (NSI) calcd for C14H24N5O2 [M+H]
+
 294.1925, found 294.1926. 
 
tert-Butyl 4-((5-(4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxamido) 
pyrimidin-2-yl)methyl)piperazine-1-carboxylate, (439) 
 
Compound 439 was synthesised according to general procedure Y, using the following 
reagents: 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250) (200 mg, 
0.66 mmol), triethylamine (231 µL, 167 mg, 1.65 mmol), 2-chloro-1-methylpyridinium 
iodide (186 mg, 0.73 mmol), tert-butyl 4-((5-aminopyrimidin-2-yl)methyl)piperazine-1-
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carboxylate (438) (243 mg, 1.65 mmol) and DCM (6.6 mL). The crude yellow solid was 
purified by column chromatography (silica gel, petrol:EtOAc, 1:0  15:85) to yield the 
title compound as a white solid (160 mg, 42%); Rf = 0.32 (petrol:EtOAc, 15:85); 
m.p. 162.5-164.5 °C; λmax (EtOH)/nm 292.8; IR (neat) νmax/cm
-1
 2967, 2932, 2864, 2815, 
1652, 1585, 1555, 1516, 1447, 1423, 1392; 
1
H NMR (500 MHz, DMSO-d6) δ 1.38 (9H, s, 
C(CH3)3), 2.43 (4H, t, J = 5.1 Hz, CH2 piperazine), 3.29 (4H, brs, CH2 piperazine), 3.69 (2H, s, 
ArCH2N), 7.51 (1H, s, H-3), 7.53 (1H, dd, J = 8.9, 1.4 Hz, H-5’), 7.68 (1H, s, H-5), 7.79 
(1H, dd, J = 8.9, 8.4 Hz, H-4’), 9.08 (2H, s, H-4”, 6”), 10.43 (1H, s, CONHAr), 12.88 (1H, 
s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 28.1 (C(CH3)3), 43.2 (CH2 piperazine), 
52.3 (CH2 piperazine), 63.7 (ArCH2N), 78.7 (OC(CH3)3), 111.9 (C-3), 119.4 (d, J = 18.2 Hz, 
C-3’), 124.9 (C-2 or C-4), 126.9 (d, J = 3.9 Hz, C-5’), 128.0 (C-2 or C-4), 129.1 (d, 
J = 23.1 Hz, C-1’), 129.2 (d, J = 5.1 Hz, C-6’), 130.6 (C-5), 131.9 (C-4’), 132.5 (C-5”), 
147.9 (C-4”, 6”), 153.8 (CO2N), 153.9 (d, J = 248.5 Hz, C-2’), 158.7 (CONHAr), 161.1 
(C-2”), 182.6 (ArCO); 19F NMR (471 MHz, DMSO-d6) δ -116.7 (ArF); LRMS (ES
-
) m/z 
575.3 [M(
35
Cl
35
Cl)-H]
-
, 577.3 [M(
35
Cl
37
Cl)-H]
-
; HRMS (NSI) calcd for C26H28Cl2FN6O4 
[M(
35
Cl
35
Cl)+H]
+
 577.1528, found 577.1521. 
 
tert-Butyl 4-((5-(4-(6-chloro-2-fluoro-3-methoxybenzoyl)-1H-pyrrole-2-carboxamido) 
pyrimidin-2-yl)methyl)piperazine-1-carboxylate, (440) 
 
Compound 440 was synthesised according to general procedure Y, using the following 
reagents: 4-(6-chloro-2-fluoro-3-methoxybenzoyl)-1H-pyrrole-2-carboxylic acid (338) 
(200 mg, 0.67 mmol), triethylamine (234 µL, 170 mg, 1.68 mmol), 2-chloro-1-
methylpyridinium iodide (189 mg, 0.74 mmol), tert-butyl 4-((5-aminopyrimidin-2-
yl)methyl)piperazine-1-carboxylate (438) (246 mg, 0.84 mmol) and DCM (6.7 mL). The 
crude yellow solid was purified by column chromatography (silica gel, petrol:EtOAc, 
1:0  1:9) to yield the title compound as a white solid (121 mg, 31%); Rf = 0.29 
(petrol:EtOAc, 1:9); m.p. 169.0-171.0 °C; λmax (EtOH)/nm 293.0; IR (neat) νmax/cm
-1
 2958, 
2933, 2865, 2815, 1653, 1578, 1553, 1515, 1472, 1433, 1391; 
1
H NMR (500 MHz, 
DMSO-d6) δ 1.38 (9H, s, C(CH3)3), 2.43 (4H, t, J = 5.1 Hz, CH2 piperazine), 3.29 (4H, brs, 
CH2 piperazine), 3.68 (2H, s, ArCH2N), 3.90 (3H, s, ArOCH3), 7.33 (1H, dd, J = 9.0, 9.0 Hz, 
H-4’), 7.39 (1H, dd, J = 9.0, 1.4 Hz, H-5’), 7.46 (1H, s, H-3), 7.54 (1H, s, H-5), 9.08 (2H, 
395 
s, H-4”, 6”), 10.42 (1H, s, CONHAr), 12.81 (1H, s, NH-pyrrole); 13C NMR (126 MHz, 
DMSO-d6) δ 28.1 (C(CH3)3), 43.3 (CH2 piperazine), 52.3 (CH2 piperazine), 56.5 (ArOCH3), 63.7 
(ArCH2N), 78.7 (OC(CH3)3), 112.1 (C-3), 115.2 (C-4’), 120.2 (d, J = 4.6 Hz, C-6’), 125.3 
(C-2 or C-4), 125.6 (d, J = 3.7 Hz, C-5’), 127.7 (C-2 or C-4), 128.4 (d, J = 20.0 Hz, C-1’), 
129.8 (C-5), 132.5 (C-5”), 146.5 (d, J = 10.6 Hz, C-3’), 147.9 (C-4”, 6”), 147.9 (d, 
J = 247.1 Hz, C-2’), 153.8 (CO2N), 158.8 (CONHAr), 161.1 (C-2”), 183.7 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -136.2 (ArF); LRMS (ES
-
) m/z 571.3 [M(
35
Cl)-H]
-
, 
573.4 [M(
37
Cl)-H]
-
; HRMS (NSI) calcd for C27H31ClFN6O5 [M(
35
Cl)+H]
+
 573.2023, found 
573.2015. 
 
Benzyl (2-(morpholinomethyl)pyrimidin-5-yl)carbamate, (441) 
 
To benzyl (2-formylpyrimidin-5-yl)carbamate (436) (350 mg, 1.36 mmol) in TFE (10 mL) 
was added morpholine (238 µL, 237 mg, 2.72 mmol). The resulting solution was stirred at 
38 °C for 1 h. Once cooled at 0 °C, sodium borohydride was carefully added. The resulting 
mixture was allowed to warm to RT and then stirred for 30 min. Upon completion, the 
solvent was removed in vacuo. The crude residue was dissolved in EtOAc (30 mL), 
neutralised by washing with saturated aq. NH4Cl (20 mL), washed with water and brine 
(20 mL, respectively), dried over MgSO4 and concentrated in vacuo. The crude product 
was purified by column chromatography (amine silica gel, petrol:EtOAc, 1:0  3:7) to 
yield the title compound as a yellow solid (305 mg, 68%); Rf = 0.32 (amine silica, 
petrol:EtOAc, 3:7); m.p. 132.5-134.5 °C; λmax (EtOH)/nm 237.0; IR (neat) νmax/cm
-1
 3207, 
3144, 3063, 3005, 2960, 2868, 2812, 1729, 1589, 1531, 1452, 1228; 
1
H NMR (500 MHz, 
DMSO-d6) δ 2.40 – 2.47 (4H, m, NCH2 morpholine), 3.51 – 3.57 (4H, m, OCH2 morpholine), 3.62 
(2H, s, ArCH2N), 5.19 (2H, s, OCH2Ph), 7.32 – 7.46 (5H, m, 5 × ArH), 8.83 (2H, s, H-4, 
6), 10.17 (1H, s, ArNHCbz); 
13
C NMR (126 MHz, DMSO-d6) δ 53.1 (NCH2 morpholine), 64.1 
(ArCH2N), 66.1 (OCH2 morpholine), 66.4 (OCH2Ph), 128.2 (CH Ar), 128.2 (CH Ar), 128.5 
(CH Ar), 132.7 (Cq Ar), 136.1 (Cq Ar), 146.3 (C-4, 6), 153.4 (ArNHCO2Bn), 160.3 (C-2); 
LRMS (ES
+
) m/z 329.4 [M+H]
+
; HRMS (NSI) calcd for C17H21N4O3 [M+H]
+
 329.1608, 
found 329.1608. 
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2-(Morpholinomethyl)pyrimidin-5-amine, (442) 
 
Benzyl (2-(morpholinomethyl)pyrimidin-5-yl)carbamate (441) (275 mg, 0.84 mmol) in 
MeOH (17 mL) was subjected to palladium-catalysed hydrogenation using an H-Cube

 
reactor and a 10% Pd/C CatCart under a full pressure of hydrogen. The reaction was 
conducted at RT for 24 h. The reaction mixture was concentrated in vacuo to afford the 
title compound as a brown oil (158 mg, 97%) which was used in the next step without 
further purification; Rf = 0.34 (amine silica, EtOAc, 100%); λmax (EtOH)/nm 248.6, 317.0; 
IR (neat) νmax/cm
-1
 3298, 3189, 2920, 2854, 2815, 1660, 1627, 1581, 1449; 
1
H NMR 
(500 MHz, DMSO-d6) δ 2.29 – 2.45 (4H, m, NCH2 morpholine), 3.47 (2H, s, ArCH2N), 
3.49 - 3.62 (4H, m, OCH2 morpholine), 5.45 (2H, brs, ArNH2), 8.06 (2H, s, H-4, 6); 
13
C NMR 
(126 MHz, DMSO-d6) δ 53.1 (NCH2 morpholine), 64.2 (ArCH2N), 66.0 (OCH2 morpholine), 
141.1 (C-5), 141.5 (C-4, 6), 154.8 (C-2); LRMS (ES
+
) m/z 195.3 [M+H]
+
; HRMS (NSI) 
calcd for C9H15N4O [M+H]
+
 195.1240, found 195.1242. 
 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(6-(methyl(1-methylpiperidin-4-yl)amino)pyridin-
3-yl)-1H-pyrrole-2-carboxamide, (445) 
 
Compound 445 was synthesised according to general procedure E’, using the following 
reagents: tert-butyl 4-((5-(4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxamido) 
pyridin-2-yl)(methyl)amino)piperidine-1-carboxylate (465) (100 mg, 0.17 mmol), formic 
acid (0.85 mL) and formaldehyde (37 % wt. in water) (50 µL, 0.68 mmol). The crude 
yellow solid was purified by column chromatography (amine silica gel, DCM:MeOH, 
1:0  97:3) to yield the title compound as a white solid (63 mg, 74%); Rf = 0.32 (amine 
silica, DCM:MeOH, 97:3); m.p. 217.5-219.5 °C; λmax (EtOH)/nm 291.4; IR (neat) 
νmax/cm
-1
 3313, 2981, 2971, 2782, 1646, 1584, 1532, 1500, 1448, 1394, 1296, 1281, 1264; 
1
H NMR (500 MHz, DMSO-d6) δ 1.42 – 1.57 (2H, m, CH2CH2NMe), 1.75 (2H, dddd, 
J = 12.2, 12.2, 12.2 and 3.8 Hz, CH2CH2NMe), 1.99 (2H, ddd, J = 12.2, 12.2 and 2.5 Hz, 
CH2CH2NMe), 2.17 (3H, s, NCH3), 2.81 (3H, s, NCH3), 2.82 – 2.85 (2H, m, 
CH2CH2NMe), 4.34 (1H, tt, J = 12.2, 3.8 Hz, ArN(CH3)CH), 6.64 (1H, d, J = 9.1 Hz, 
H-5”), 7.41 (1H, s, H-3), 7.51 (1H, dd, J = 8.8, 1.4 Hz, H-5’), 7.56 (1H, s, H-5), 7.75 (1H, 
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dd, J = 9.1, 2.7 Hz, H-4”), 7.77 (1H, dd, J = 8.8, 8.5 Hz, H-4’), 8.35 (1H, d, J = 2.7 Hz, 
H-2”), 9.89 (1H, s, CONHAr), 12.66 (1H, s, NH-pyrrole); 13C NMR (126 MHz, DMSO-d6) 
δ 28.4 (CH2CH2NMe), 29.6 (NCH3), 46.0 (NCH3), 51.8 (ArN(CH3)CH), 55.1 
(CH2CH2NMe), 105.5 (C-5”), 110.6 (C-3), 119.3 (d, J = 18.1 Hz, C-3’), 124.5 (C-3”), 
124.7 (C-2 or C-4), 126.9 (d, J = 3.8 Hz, C-5’), 128.9 (C-2 or C-4), 129.2 (d, J = 5.5 Hz, 
C-6’), 129.2 (d, J = 23.1 Hz, C-1’), 129.7 (C-5), 131.3 (C-4’ or C-4”), 131.8 (C-4’ or 
C-4”), 140.4 (C-2”), 153.8 (d, J = 247.2 Hz, C-2’), 155.3 (C-6”), 158.2 (CONHAr), 182.6 
(ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -116.7 (ArF); LRMS (ES
-
) m/z 502.3 
[M(
35
Cl
35
Cl)-H]
-
, 504.3 [M(
35
Cl
37
Cl)-H]
-
; HRMS (NSI) calcd for C24H25Cl2FN5O2 
[M(
35
Cl
35
Cl)+H]
+
 504.1364, found 504.1352. 
 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(6-(methyl(piperidin-4-yl)amino)pyridin-3-yl)-
1H-pyrrole-2-carboxamide, (446) 
 
Compound 446 was synthesised according to general procedure F’, using the following 
reagents: tert-butyl 4-((5-(4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxamido) 
pyridin-2-yl)(methyl)amino)piperidine-1-carboxylate (465) (120 mg, 0.20 mmol), 
triethylsilane (81 µL, 59 mg, 0.51 mmol), TFA (1 mL) and DCM (1 mL). The crude 
yellow solid was purified by column chromatography (amine silica gel, DCM:MeOH, 
1:0  96:4) to yield the title compound as a white solid (77 mg, 77%); Rf = 0.31 (amine 
silica, DCM:MeOH, 96:4); m.p. 172.0-174.0 °C; λmax (EtOH)/nm 285.8; IR (neat) 
νmax/cm
-1
 3328, 2981, 2971, 1644, 1583, 1531, 1501, 1448, 1319, 1297, 1284; 
1
H NMR 
(500 MHz, DMSO-d6) δ 1.49 (2H, d, J = 9.7 Hz, CH2CH2NH), 1.59 (2H, dddd, J = 12.1, 
12.1, 12.1 and 4.1 Hz, CH2CH2NH), 2.57 (2H, ddd, J = 12.1, 12.1 and 2.7 Hz, 
CH2CH2NH), 2.81 (3H, s, NCH3), 3.01 (2H, d, J = 12.1 Hz, CH2CH2NH), 4.43 (1H, tt, 
J = 12.1, 4.1 Hz, ArN(CH3)CH), 6.64 (1H, d, J = 9.1 Hz, H-5”), 7.39 (1H, s, H-3), 7.51 
(1H, dd, J = 8.8, 1.3 Hz, H-5’), 7.55 (1H, s, H-5), 7.71 – 7.82 (2H, m, H-4’ and H-4”), 8.35 
(1H, d, J = 2.7 Hz, H-2”), 9.89 (1H, s, CONHAr); 13C NMR (126 MHz, DMSO-d6) δ 29.6 
(CH2CH2NH), 29.9 (NCH3), 45.8 (CH2CH2NH), 52.5 (ArN(CH3)CH), 105.5 (C-5”), 110.6 
(C-3), 119.3 (d, J = 18.1 Hz, C-3’), 124.5 (Cq Ar), 124.7 (Cq Ar), 126.8 (d, J = 3.8 Hz, 
C-5’), 129.2 (d, J = 4.9 Hz, C-6’), 129.3 (d, J = 27.0 Hz, C-1’), 129.9 (C-5), 131.3 (C-4’ or 
C-4”), 131.8 (C-4’ or C-4”), 140.4 (C-2”), 153.8 (d, J = 248.3 Hz, C-2’), 155.2 (C-3”), 
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158.3 (CONHAr), 182.5 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -116.7 (ArF); 
LRMS (ES
-
) m/z 488.3 [M(
35
Cl
35
Cl)-H]
-
, 490.3 [M(
35
Cl
37
Cl)-H]
-
; HRMS (NSI) calcd for 
C23H23Cl2FN5O2 [M(
35
Cl
35
Cl)+H]
+
 490.1207, found 490.1198. 
 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(6-((1-methylpiperidin-4-yl)oxy)pyridin-3-yl)-1H-
pyrrole-2-carboxamide, (447) 
 
Compound 447 was synthesised according to general procedure E’, using the following 
reagents: tert-butyl 4-((5-(4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxamido) 
pyridin-2-yl)oxy)piperidine-1-carboxylate (466) (100 mg, 0.17 mmol), formic acid 
(0.85 mL) and formaldehyde (37 % wt. in water) (52 µL, 0.69 mmol). The crude yellow 
solid was purified by column chromatography (amine silica gel, DCM:MeOH, 1:0  97:3) 
to yield the title compound as a white solid (60 mg, 71%); Rf = 0.28 (amine silica, 
DCM:MeOH, 97:3); m.p. 189.5-191.5 °C; λmax (EtOH)/nm 263.0; IR (neat) νmax/cm
-1
 3357, 
2981, 2971, 1670, 1635, 1588, 1528, 1485, 1450, 1289, 1275, 1231; 
1
H NMR (500 MHz, 
DMSO-d6) δ 1.64 (2H, dddd, J = 12.9, 9.3, 9.3 and 3.6 Hz, CH2CH2NMe), 1.89 – 2.00 
(2H, m, CH2CH2NMe), 2.14 (2H, dd, J = 12.9, 12.9 Hz, CH2CH2NMe), 2.17 (3H, s, 
NCH3), 2.63 (2H, ddd, J = 12.9, 4.5 and 4.5 Hz, CH2CH2NMe), 4.92 (1H, tt, J = 8.6, 
3.9 Hz, ArOCH), 6.79 (1H, d, J = 8.9 Hz, H-5”), 7.45 (1H, d, J = 1.9 Hz, H-3), 7.52 (1H, 
dd, J = 8.8, 1.4 Hz, H-5’), 7.59 (1H, d, J = 1.9 Hz, H-5), 7.78 (1H, dd, J = 8.8, 8.4 Hz, 
H-4’), 7.96 (1H, dd, J = 8.9, 2.7 Hz, H-4”), 8.43 (1H, d, J = 2.7 Hz, H-2”), 10.09 (1H, s, 
CONHAr), 12.72 (1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 30.7 
(CH2CH2NMe), 45.8 (NCH3), 52.8 (CH2CH2NMe), 70.2 (ArOCH), 110.8 (C-5”), 111.0 
(C-3), 119.3 (d, J = 18.2 Hz, C-3’), 124.7 (C-2 or C-4), 126.9 (d, J = 3.8 Hz, C-5’), 128.6 
(C-2 or C-4), 129.2 (d, J = 24.0 Hz, C-1’ and C-3”), 129.2 (d, J = 5.2 Hz, C-6’), 130.0 
(C-5), 131.8 (C-4’), 132.5 (C-4”), 138.6 (C-2”), 153.8 (d, J = 248.6 Hz, C-2’), 158.4 
(CONHAr or C-6”), 158.9 (CONHAr or C-6”), 182.6 (ArCO); 19F NMR (471 MHz, 
DMSO-d6) δ -116.7 (ArF); LRMS (ES
-
) m/z 489.3 [M(
35
Cl
35
Cl)-H]
-
, 491.2 
[M(
35
Cl
37
Cl)-H]
-
; HRMS (NSI) calcd for C23H22Cl2FN4O3 [M(
35
Cl
35
Cl)+H]
+
 491.1048, 
found 491.1038. 
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4-(3,6-Dichloro-2-fluorobenzoyl)-N-(6-(piperidin-4-yloxy)pyridin-3-yl)-1H-pyrrole-2-
carboxamide, (448) 
 
Compound 448 was synthesised according to general procedure F’, using the following 
reagents: tert-butyl 4-((5-(4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxamido) 
pyridin-2-yl)oxy)piperidine-1-carboxylate (466) (120 mg, 0.21 mmol), triethylsilane 
(83 µL, 30 mg, 0.52 mmol), TFA (1.1 mL) and DCM (1.1 mL). The crude yellow solid 
was purified by column chromatography (amine silica gel, DCM:MeOH, 1:0  96:4) to 
yield the title compound as a white solid (77 mg, 77%); Rf = 0.25 (amine silica, 
DCM:MeOH, 96:4); m.p. 212.0-214.0 °C; 
1
H NMR (500 MHz, DMSO-d6) δ 1.47 (2H, 
dddd, J = 12.9, 10.5, 10.2 and 4.0 Hz, CH2CH2NH), 1.84 – 2.00 (2H, m, CH2CH2NH), 
2.57 (2H, ddd, J = 12.9, 10.5 and 2.9 Hz, CH2CH2NH), 2.95 (2H, ddd, J = 12.9, 4.1 and 
4.1 Hz, CH2CH2NH), 4.99 (1H, tt, J = 9.2, 4.2 Hz, ArOCH), 6.78 (1H, d, J = 8.9 Hz, 
H-5”), 7.42 (1H, s, H-3), 7.51 (1H, dd, J = 8.8, 1.3 Hz, H-5’), 7.58 (1H, s, H-5), 7.77 (1H, 
dd, J = 8.8, 8.4 Hz, H-4’), 7.96 (1H, dd, J = 8.9, 2.8 Hz, H-4”), 8.42 (1H, d, J = 2.8 Hz, 
H-2”), 10.07 (1H, s, CONHAr); 13C NMR (126 MHz, DMSO-d6) δ 32.3 (CH2CH2NH), 
43.9 (CH2CH2NH), 71.4 (ArOCH), 110.7 (C-5”), 111.1 (C-3), 119.3 (d, J = 17.8 Hz, C-3’), 
124.8 (C-2 or C-4), 126.9 (d, J = 3.8 Hz, C-5’), 128.9 (C-2 or C-4), 129.2 (d, J = 5.4 Hz, 
C-6’), 129.3 (C-3”), 129.3 (d, J = 23.0 Hz, C-1’), 130.3 (C-5), 131.8 (C-4’), 132.4 (C-4”), 
138.6 (C-2”), 153.8 (d, J = 248.5 Hz, C-2’), 158.5 (CONHAr or C-6”), 158.9 (CONHAr or 
C-6”), 182.5 (ArCO); 19F NMR (471 MHz, DMSO-d6) δ -116.7 (ArF); IR (neat) νmax/cm
-1
 
3364, 3301, 2933, 2857, 1643, 1532, 1485, 1447, 1289, 1271, 1228; λmax (EtOH)/nm 
262.4; LRMS (ES
-
) m/z 473.3 [M(
35
Cl
35
Cl)-H]
-
, 475.3 [M(
35
Cl
37
Cl)-H]
-
; HRMS (ESI) 
calcd for C22H20Cl2FN4O3 [M(
35
Cl
35
Cl)+H]
+
 477.0891, found 477.0885. 
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4-(3,6-Dichloro-2-fluorobenzoyl)-N-(6-((4-methylpiperazin-1-yl)methyl)pyridin-3-yl)-
1H-pyrrole-2-carboxamide, (449) 
 
Compound 449 was synthesised according to general procedure E’, using the following 
reagents: tert-butyl 4-((5-(4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxamido) 
pyridin-2-yl)methyl)piperazine-1-carboxylate (476) (45 mg, 0.08 mmol), formic acid 
(0.4 mL) and formaldehyde (37 % wt. in water) (23 µL, 0.31 mmol). The crude yellow 
solid was purified by column chromatography (amine silica gel, DCM:MeOH, 1:0  95:5) 
to yield the title compound as a white solid (25 mg, 66%); Rf = 0.28 (amine silica, 
DCM:MeOH, 95:5); m.p. 161.5-163.5 °C; λmax (EtOH)/nm 296.0; IR (neat) νmax/cm
-1
 3215, 
2933, 2802, 1639, 1590, 1527, 1491, 1446, 1391; 
1
H NMR (500 MHz, DMSO-d6) δ 2.16 
(3H, s, NCH3), 2.22 – 2.49 (8H, m, NCH2 piperazine), 3.53 (2H, s, ArCH2N), 7.39 (1H, d, 
J = 8.5 Hz, H-5”), 7.47 – 7.55 (2H, m, H-3 and H-5’), 7.61 (1H, s, H-5), 7.78 (1H, dd, 
J = 8.8, 8.4 Hz, H-4’), 8.10 (1H, dd, J = 8.5, 2.5 Hz, H-4”), 8.79 (1H, d, J = 2.5 Hz, H-2”), 
10.22 (1H, s, CONHAr), 12.76 (1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) 
δ 45.7 (NCH3), 52.6 (NCH2 piperazine), 54.7 (NCH2 piperazine), 63.3 (ArCH2N), 111.4 (C-3), 
119.4 (d, J = 18.0 Hz), 122.6 (C-5”), 124.8 (C-2 or C-4), 126.9 (d, J = 3.7 Hz, C-5’), 127.6 
(C-4”), 128.5 (C-2 or C-4), 129.1 (d, J = 23.2 Hz, C-1’), 129.2 (d, J = 4.9 Hz, C-6’), 130.2 
(C-5), 131.9 (C-4’), 134.0 (C-3”), 140.7 (C-2”), 153.2 (C-6”), 153.9 (d, J = 248.5 Hz, 
C-2’), 158.6 (CONHAr), 182.6 (ArCO); 19F NMR (471 MHz, DMSO-d6) δ -116.7 (ArF); 
LRMS (ES
+
) m/z 490.4 [M(
35
Cl
35
Cl)+H]
+
, 492.5 [M(
35
Cl
37
Cl)+H]
+
; HRMS (NSI) calcd for 
C23H23Cl2FN5O2 [M(
35
Cl
35
Cl)+H]
+
 490.1207, found 490.1195. 
 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(6-(piperazin-1-ylmethyl)pyridin-3-yl)-1H-
pyrrole-2-carboxamide, (450) 
 
Compound 450 was synthesised according to general procedure F’, using the following 
reagents: tert-butyl 4-((5-(4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxamido) 
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pyridin-2-yl)methyl)piperazine-1-carboxylate (476) (50 mg, 0.09 mmol), triethylsilane 
(35 µL, 25 mg, 0.22 mmol), TFA (0.45 mL) and DCM (0.45 mL). The crude yellow solid 
was purified by column chromatography (amine silica gel, DCM:MeOH, 1:0  9:1) to 
yield the title compound as a white solid (30 mg, 73%); Rf = 0.25 (amine silica, 
DCM:MeOH, 9:1); m.p. 179.5-181.5 °C; λmax (EtOH)/nm 296.0; IR (neat) νmax/cm
-1
 3105, 
2921, 2812, 1637, 1589, 1525, 1490, 1445, 1389; 
1
H NMR (500 MHz, DMSO-d6) δ 2.33 
(4H, brs, NCH2 piperazine), 2.70 (4H, t, J = 4.8 Hz, NCH2 piperazine), 3.51 (2H, s, ArCH2N), 
7.40 (1H, d, J = 8.5 Hz, H-5”), 7.49 (1H, s, H-3), 7.52 (1H, dd, J = 8.8, 0.6 Hz, H-5’), 7.60 
(1H, s, H-5), 7.78 (1H, dd, J = 8.8, 8.3 Hz, H-4’), 8.09 (1H, dd, J = 8.5, 2.6 Hz, H-4”), 8.79 
(1H, d, J = 2.6 Hz, H-2”), 10.20 (1H, s, CONHAr); 13C NMR (126 MHz, DMSO-d6) 
δ 45.5 (NCH2 piperazine), 54.0 (NCH2 piperazine), 64.1 (ArCH2N), 111.4 (C-3), 119.3 (d, 
J = 17.9 Hz, C-3’), 122.6 (C-5”), 124.8 (C-2 or C-4), 126.9 (d, J = 3.7 Hz, C-5’), 127.5 
(C-4”), 128.7 (C-2 or C-4), 129.2 (d, J = 23.0 Hz, C-1’), 129.2 (d, J = 5.2 Hz, C-6’), 130.4 
(C-5), 131.8 (C-4’), 134.0 (C-3”), 140.6 (C-2”), 153.2 (C-6”), 154.8 (d, J = 248.8 Hz, 
C-2’), 158.7 (CONHAr), 182.5 (ArCO); 19F NMR (471 MHz, DMSO-d6) δ -116.6 (ArF); 
LRMS (ES
+
) m/z 476.5 [M(
35
Cl
35
Cl)+H]
+
, 478.5 [M(
35
Cl
37
Cl)+H]
+
; HRMS (NSI) calcd for 
C22H21Cl2FN5O2 [M(
35
Cl
35
Cl)+H]
+
 476.1051, found 476.1040. 
 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(6-((1-methylpiperidin-4-yl)methyl)pyridin-3-yl)-
1H-pyrrole-2-carboxamide, (451) 
 
Compound 451 was synthesised according to general procedure E’, using the following 
reagents: tert-butyl 4-((5-(4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxamido) 
pyridin-2-yl)methyl)piperidine-1-carboxylate (467) (100 mg, 0.17 mmol), formic acid 
(0.85 mL) and formaldehyde (37 % wt. in water) (52 µL, 0.69 mmol). The crude yellow 
solid was purified by column chromatography (amine silica gel, DCM:MeOH, 1:0  96:4) 
to yield the title compound as an off-white solid (64 mg, 75%); Rf = 0.26 (amine silica, 
DCM:MeOH, 96:4); m.p. 148.0-150.0 °C; λmax (EtOH)/nm 261.4, 296.0; IR (neat) 
νmax/cm
-1
 3286, 2926, 2846, 2788, 1646, 1592, 1525, 1493, 1447, 1392, 1282, 1237, 1224; 
1
H NMR (500 MHz, DMSO-d6) δ 1.11 – 1.31 (2H, m, CH2CH2NMe), 1.50 (2H, d, 
J = 12.0 Hz, CH2CH2NMe), 1.57 – 1.70 (1H, m, ArCH2CH), 1.77 (2H, dd, J = 12.0, 12.0 
Hz, CH2CH2NMe), 2.11 (3H, s, NCH3), 2.59 (2H, d, J = 7.0 Hz, ArCH2CH), 2.70 (2H, d, 
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J = 10.9 Hz, CH2CH2NMe), 7.20 (1H, d, J = 8.4 Hz, H-5”), 7.49 (1H, s, H-3), 7.52 (1H, d, 
J = 8.8 Hz, H-5’), 7.61 (1H, s, H-5), 7.78 (1H, dd, J = 8.8, 8.3 Hz, H-4’), 8.02 (1H, d, 
J = 8.4 Hz, H-4”), 8.78 (1H, s, H-2”), 10.17 (1H, s, CONHAr), 12.72 (1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 31.7 (CH2CH2NMe), 35.6 (ArCH2CH), 43.8 
(ArCH2CH), 46.2 (NCH3), 55.3 (CH2CH2NMe), 111.3 (C-3), 119.3 (d, J = 18.1 Hz, C-3’), 
123.0 (C-5”), 124.8 (C-2 or C-4), 126.9 (d, J = 3.7 Hz, C-5’), 127.4 (C-4”), 128.6 (C-2 or 
C-4), 129.2 (d, J = 23.0 Hz, C-1’), 129.2 (d, J = 5.0 Hz, C-3’), 130.2 (C-5), 131.8 (C-4’), 
133.1 (C-3”), 141.0 (C-2”), 153.9 (d, J = 248.9 Hz, C-2’), 155.1 (CONHAr or C-6”), 158.6 
(CONHAr or C-6”), 182.6 (ArCO); 19F NMR (471 MHz, DMSO-d6) δ -116.6 (ArF); 
LRMS (ES
-
) m/z 487.3 [M(
35
Cl
35
Cl)-H]
-
, 489.3 [M(
35
Cl
37
Cl)-H]
-
; HRMS (NSI) calcd for 
C24H24Cl2FN4O2 [M(
35
Cl
35
Cl)+H]
+
 489.1255, found 489.1243. 
 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(6-(piperidin-4-ylmethyl)pyridin-3-yl)-1H-
pyrrole-2-carboxamide, (452) 
 
Compound 452 was synthesised according to general procedure F’, using the following 
reagents: tert-butyl 4-((5-(4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxamido) 
pyridin-2-yl)methyl)piperidine-1-carboxylate (467) (120 mg, 0.21 mmol), triethylsilane 
(83 µL, 61 mg, 0.52 mmol), TFA (1.1 mL) and DCM (1.1 mL). The crude yellow solid 
was purified by column chromatography (amine silica gel, DCM:MeOH, 1:0  95:5) to 
yield the title compound as an off-white solid (69 mg, 70%); Rf = 0.24 (amine silica, 
DCM:MeOH, 95:5); m.p. 170.0-172.0 °C; λmax (EtOH)/nm 261.2, 295.8; IR (neat) 
νmax/cm
-1
 3112, 2921, 2851, 1642, 1592, 1526, 1490, 1447, 1392, 1286, 1239, 1225; 
1
H NMR (500 MHz, DMSO-d6) δ 1.00 – 1.17 (2H, m, CH2CH2NH), 1.39 – 1.54 (2H, m, 
CH2CH2NH), 1.68 – 1.88 (1H, m, ArCH2CH), 2.43 (2H, dd, J = 11.5, 11.5 Hz, 
CH2CH2NH), 2.58 (2H, d, J = 7.0 Hz, ArCH2CH), 2.91 (2H, ddd, J = 11.5, 3.4 and 3.4 Hz, 
CH2CH2NH), 7.19 (1H, d, J = 8.4 Hz, H-5”), 7.42 (1H, s, H-3), 7.51 (1H, d, J = 8.7 Hz, 
H-5’), 7.57 (1H, s, H-5), 7.77 (1H, dd, J = 8.7, 8.3 Hz, H-4’), 8.02 (1H, dd, J = 8.4, 2.8 Hz, 
H-4”), 8.78 (1H, d, J = 2.8 Hz, H-2”), 10.14 (1H, s, CONHAr); 13C NMR (126 MHz, 
DMSO-d6) δ 32.5 (CH2CH2NH), 36.5 (ArCH2CH), 44.4 (ArCH2CH), 45.8 (CH2CH2NH), 
111.5 (C-3), 119.3 (d, J = 18.3 Hz, C-3’), 123.0 (C-5”), 124.9 (C-2 or C-4), 126.8 (d, 
J = 4.1 Hz, C-5’), 127.3 (C-4”), 129.3 (d, J = 5.2 Hz, C-6’), 129.4 (d, J = 23.3 Hz, C-1’), 
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129.4 (C-2 or C-4), 130.9 (C-5), 131.7 (C-4’), 133.2 (C-3”), 141.0 (C-2”), 152.9 (d, 
J = 248.2 Hz, C-2’), 154.8 (CONHAr or C-6”), 159.0 (CONHAr or C-6”), 182.3 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -116.6 (ArF); LRMS (ES
-
) m/z 473.3 [M(
35
Cl
35
Cl)-H]
-
, 
475.3 [M(
35
Cl
37
Cl)-H]
-
; HRMS (NSI) calcd for C23H22Cl2FN4O2 [M(
35
Cl
35
Cl)+H]
+
 
475.1098, found 475.1090. 
 
4-(6-Chloro-2-fluoro-3-methoxybenzoyl)-N-(6-((4-methylpiperazin-1-yl)methyl) 
pyridin-3-yl)-1H-pyrrole-2-carboxamide, (453) 
 
Compound 453 was synthesised according to general procedure E’, using the following 
reagents: tert-butyl 4-((5-(4-(6-chloro-2-fluoro-3-methoxybenzoyl)-1H-pyrrole-2-
carboxamido)pyridin-2-yl)methyl)piperazine-1-carboxylate (477) (70 mg, 0.12 mmol), 
formic acid (0.6 mL) and formaldehyde (37 % wt. in water) (36 µL, 0.49 mmol). The crude 
yellow solid was purified by column chromatography (amine silica gel, DCM:MeOH, 
1:0  96:4) to yield the title compound as a white solid (45 mg, 76%); Rf = 0.27 (amine 
silica, DCM:MeOH, 96:4); m.p. 212.0-214.0 °C; λmax (EtOH)/nm 296.2; IR (neat) 
νmax/cm
-1
 2938, 2802, 1641, 1607, 1555, 1528, 1491, 1472, 1437, 1277; 
1
H NMR 
(500 MHz, DMSO-d6) δ 2.14 (3H, s, NCH3), 2.32 (4H, brs, NCH2 piperazine), 2.40 (4H, brs, 
NCH2 piperazine), 3.53 (2H, s, ArCH2N), 3.90 (3H, s, ArOCH3), 7.33 (1H, dd, J = 8.9, 8.9 Hz, 
H-4’), 7.39 (2H, d, J = 8.9 Hz, H-5’ and H-5”), 7.47 (1H, s, H-3), 7.48 (1H, s, H-5), 8.10 
(1H, dd, J = 8.9, 2.6 Hz, H-4”), 8.78 (1H, d, J = 2.6 Hz, H-2”), 10.22 (1H, s, CONHAr), 
12.69 (1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 45.7 (NCH3), 52.7 
(NCH2 piperazine), 54.7 (NCH2 piperazine), 56.5 (ArOCH3), 63.3 (ArCH2N), 111.5 (C-3), 115.1 
(C-4’), 120.2 (d, J = 4.9 Hz, C-6’), 122.6 (C-5”), 125.2 (C-2 or C-4), 125.6 (d, J = 3.8 Hz, 
C-5’), 127.6 (C-4”), 128.2 (C-2 or C-4), 128.4 (d, J = 19.9 Hz, C-1’), 129.4 (C-5), 134.0 
(C-3”), 140.6 (C-2”), 146.4 (d, J = 10.8 Hz, C-3’), 147.9 (d, J = 247.0 Hz, C-2’), 153.2 
(C-6”), 158.6 (CONHAr), 183.6 (ArCO); 19F NMR (471 MHz, DMSO-d6) δ -136.1 (ArF); 
LRMS (ES
+
) m/z 486.4 [M(
35
Cl)+H]
+
, 488.4 [M(
37
Cl)+H]
+
; HRMS (NSI) calcd for 
C24H26ClFN5O3 [M(
35
Cl)+H]
+
 486.1703, found 486.1695. 
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4-(6-Chloro-2-fluoro-3-methoxybenzoyl)-N-(6-(piperazin-1-ylmethyl)pyridin-3-yl)-
1H-pyrrole-2-carboxamide, (454) 
 
Compound 454 was synthesised according to general procedure E’, using the following 
reagents: tert-butyl 4-((5-(4-(6-chloro-2-fluoro-3-methoxybenzoyl)-1H-pyrrole-2-
carboxamido)pyridin-2-yl)methyl)piperazine-1-carboxylate (477) (70 mg, 0.12 mmol), 
triethylsilane (49 µL, 36 mg, 0.31 mmol), TFA (0.6 mL) and DCM (0.6 mL). The crude 
yellow solid was purified by column chromatography (amine silica gel, DCM:MeOH, 
1:0  94:6) to yield the title compound as a white solid (41 mg, 71%); Rf = 0.27 (amine 
silica, DCM:MeOH, 94:6); m.p. 234.5-236.5 °C; λmax (EtOH)/nm 296.0; IR (neat) 
νmax/cm
-1
 3110, 2935, 2812, 1639, 1525, 1490, 1471, 1435, 1270; 
1
H NMR (500 MHz, 
DMSO-d6) δ 2.33 (4H, brs, NCH2 piperazine), 2.70 (4H, t, J = 4.8 Hz, NCH2 piperazine), 3.50 
(2H, s, ArCH2N), 3.90 (3H, s, ArOCH3), 7.32 (1H, dd, J = 8.9, 8.6 Hz, H-4’), 7.38 (1H, dd, 
J = 8.6, 0.8 Hz, H-5’), 7.39 (1H, d, J = 8.4 Hz, H-5”), 7.46 (1H, s, H-3), 7.47 (1H, s, H-5), 
8.09 (1H, dd, J = 8.4, 2.6 Hz, H-4”), 8.79 (1H, d, J = 2.6 Hz, H-2”), 10.21 (1H, s, 
CONHAr); 
13
C NMR (126 MHz, DMSO-d6) δ 45.5 (NCH2 piperazine), 54.1 (NCH2 piperazine), 
56.5 (ArOCH3), 64.1 (ArCH2N), 111.5 (C-3), 115.1 (C-4’), 120.2 (d, J = 4.9 Hz, C-6’), 
122.6 (C-5”), 125.2 (C-2 or C-4), 125.6 (d, J = 3.8 Hz, C-5’), 127.5 (C-4”), 128.4 (C-2 or 
C-4), 128.5 (d, J = 20.3 Hz, C-1’), 129.6 (C-5), 134.0 (C-3”), 140.6 (C-2”), 146.4 (d, 
J = 10.7 Hz, C-3’), 147.9 (d, J = 247.0 Hz, C-2’), 153.1 (C-6”), 158.7 (CONHAr), 183.6 
(ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -136.1 (ArF); LRMS (ES
+
) m/z 472.4 
[M(
35
Cl)+H]
+
, 474.3 [M(
37
Cl)+H]
+
; HRMS (NSI) calcd for C23H24ClFN5O3 [M(
35
Cl)+H]
+
 
472.1546, found 472.1538. 
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4-(6-Chloro-2-fluoro-3-methoxybenzoyl)-N-(6-((1-methylpiperidin-4-
yl)methyl)pyridin-3-yl)-1H-pyrrole-2-carboxamide, (455) 
 
Compound 455 was synthesised according to general procedure E’, using the following 
reagents: tert-butyl 4-((5-(4-(6-chloro-2-fluoro-3-methoxybenzoyl)-1H-pyrrole-2-
carboxamido)pyridin-2-yl)methyl)piperidine-1-carboxylate (468) (90 mg, 0.16 mmol), 
formic acid (0.65 mL) and formaldehyde (37 % wt. in water) (47 µL, 0.63 mmol). The 
crude yellow solid was purified by column chromatography (amine silica gel, 
DCM:MeOH, 1:0  96:4) to yield the title compound as an off-white solid (54 mg, 71%); 
Rf = 0.27 (amine silica, DCM:MeOH, 96:4); m.p. 138.0-140.0 °C; λmax (EtOH)/nm 295.8; 
IR (neat) νmax/cm
-1
 2931, 2844, 2792, 1637, 1525, 1471, 1435, 1392; 
1
H NMR (500 MHz, 
DMSO-d6) δ 1.20 (2H, dddd, J = 12.1, 12.1, 12.1 and 4.1 Hz, CH2CH2NMe), 1.50 (2H, d, 
J = 12.1 Hz, CH2CH2NMe), 1.58 – 1.68 (1H, m, ArCH2CH), 1.77 (2H, dd, J = 10.8, 
10.8 Hz, CH2CH2NMe), 2.11 (3H, s, NCH3), 2.59 (2H, d, J = 7.1 Hz, ArCH2CH), 2.70 
(2H, d, J = 11.3 Hz, CH2CH2NMe), 3.90 (3H, s, ArOCH3), 7.20 (1H, d, J = 8.4 Hz, H-5”), 
7.32 (1H, dd, J = 9.6, 8.9 Hz, H-4’), 7.38 (1H, d, J = 9.6 Hz, H-5’), 7.45 (1H, s, H-3 or 
H-5), 7.47 (1H, s, H-3 or H-5), 8.01 (1H, dd, J = 8.4, 2.5 Hz, H-4”), 8.77 (1H, d, 
J = 2.5 Hz, H-2”), 10.16 (1H, s, CONHAr), 12.66 (1H, s, NH-pyrrole); 13C NMR 
(126 MHz, DMSO-d6) δ 31.8 (CH2CH2NMe), 35.7 (ArCH2CH), 43.8 (ArCH2CH), 46.2 
(NCH3), 55.4 (CH2CH2NMe), 56.5 (ArOCH3), 111.4 (C-3), 115.1 (C-4’), 120.2 (d, 
J = 4.9 Hz, C-6’), 123.0 (C-5”), 125.2 (C-2 or C-4), 125.6 (d, J = 3.6 Hz, C-5’), 127.4 
(C-4”), 128.3 (C-2 or C-4), 128.4 (d, J = 20.1 Hz, C-1’), 129.4 (C-5), 133.2 (C-3”), 141.0 
(C-2”), 146.4 (d, J = 10.5 Hz, C-3’), 148.0 (d, J = 247.0 Hz, C-2’), 155.1 (C-6”), 158.6 
(CONHAr), 183.6 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -136.1 (ArF); LRMS (ES
+
) 
m/z 485.5 [M(
35
Cl)+H]
+
, 487.5 [M(
37
Cl)+H]
+
; HRMS (NSI) calcd for C25H27ClFN4O3 
[M(
35
Cl)+H]
+
 485.1750, found 485.1736. 
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4-(6-Chloro-2-fluoro-3-methoxybenzoyl)-N-(6-(piperidin-4-ylmethyl)pyridin-3-yl)-
1H-pyrrole-2-carboxamide, (456) 
 
Compound 456 was synthesised according to general procedure F’, using the following 
reagents: tert-butyl 4-((5-(4-(6-chloro-2-fluoro-3-methoxybenzoyl)-1H-pyrrole-2-
carboxamido)pyridin-2-yl)methyl)piperidine-1-carboxylate (468) (90 mg, 0.16 mmol), 
triethylsilane (63 µL, 46 mg, 0.39 mmol), TFA (0.8 mL) and DCM (0.8 mL). The crude 
yellow solid was purified by column chromatography (amine silica gel, DCM:MeOH, 
1:0  95:5) to yield the title compound as an off-white solid (56 mg, 76%); Rf = 0.29 
(amine silica, DCM:MeOH, 95:5); m.p. 218.0-220.0 °C; λmax (EtOH)/nm 295.8; IR (neat) 
νmax/cm
-1
 3101, 2919, 2841, 1638, 1586, 1522, 1469, 1434, 1389; 
1
H NMR (500 MHz, 
DMSO-d6) δ 1.02 – 1.15 (2H, m, CH2CH2NH), 1.44 – 1.52 (2H, m, CH2CH2NH), 
1.71 - 1.85 (1H, m, ArCH2CH), 2.42 (2H, ddd, J = 12.1, 12.1 and 2.6 Hz, CH2CH2NH), 
2.58 (2H. d, J = 7.1 Hz, ArCH2CH), 2.90 (2H, ddd, J = 12.1, 3.4 and 3.4 Hz, CH2CH2NH), 
3.90 (3H, s, ArOCH3), 7.19 (1H, d, J = 8.4 Hz, H-5”), 7.31 (1H, dd, J = 9.0, 8.9 Hz, H-4’), 
7.38 (1H, dd, J = 9.0, 1.4 Hz, H-5’), 7.41 (1H, s, H-3 or H-5), 7.45 (1H, s, H-3 or H-5), 
8.02 (1H, dd, J = 8.4, 2.5 Hz, H-4”), 8.77 (1H, d, J = 2.5 Hz, H-2”), 10.15 (1H, s, 
CONHAr), 12.68 (1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 32.6 
(CH2CH2NH), 36.6 (ArCH2CH), 44.5 (ArCH2CH), 45.9 (CH2CH2NH), 56.5 (ArOCH3), 
111.6 (C-3), 115.0 (C-4’), 120.3 (d, J = 4.7 Hz, C-6’), 123.0 (C-5”), 125.3 (C-2 or C-4), 
125.5 (d, J = 3.7 Hz, C-5’), 127.3 (C-4”), 128.6 (d, J = 20.0 Hz, C-1’), 128.9 (C-2 or C-4), 
130.0 (C-5), 133.2 (C-3”), 141.0 (C-2”), 146.4 (d, J = 10.7 Hz, C-3’), 147.9 (d, 
J = 246.9 Hz, C-2’), 154.9 (C-6”), 158.9 (CONHAr), 183.5 (ArCO); 19F NMR (471 MHz, 
DMSO-d6) δ -136.1 (ArF); LRMS (ES
+
) m/z 471.5 [M(
35
Cl)+H]
+
, 473.5 [M(
37
Cl)+H]
+
; 
HRMS (NSI) calcd for C24H25ClFN4O3 [M(
35
Cl)+H]
+
 471.1594, found 471.1583. 
 
tert-Butyl 4-((5-nitropyridin-2-yl)methyl)piperidine-1-carboxylate, (458) 
 
To a degassed sample of tert-butyl 4-methylidenepiperidine-1-carboxylate (457) (750 mg, 
3.80 mmol) was added 9-BBN (0.5 M in THF) (7.60 mL, 3.80 mmol). The resulting 
407 
solution was sparged with nitrogen for 15 min and then reflux for 3 h. After cooling to RT, 
N,N-dimethylformamide (7 mL) and water (0.7 mL) were added and the resulting solution 
was sparged with nitrogen for 15 min. To the degassed mixture was added 2-chloro-5-
nitropyridine (1.20 g, 7.60 mmol), potassium carbonate (788 mg, 5.70 mmol) and 
[1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with DCM (233 mg, 
0.28 mmol). The resulting mixture was heated at 60 °C overnight. Upon completion, the 
heterogeneous mixture was filtered through Celite and the solvent was removed in vacuo. 
The crude residue was dissolved in a mixture of EtOAc and water (30 mL, respectively) 
and extracted with EtOAc (3 × 30 mL). The pooled organic extracts were washed with 
water (40 mL) and brine (40 mL), dried over MgSO4 and concentrated in vacuo. The crude 
product was purified by column chromatography (silica gel, petrol:EtOAc, 1:0  3:1) to 
yield the title compound as a yellow solid (485 mg, 40%); Rf = 0.31 (petrol:EtOAc, 3:1); 
m.p. 80.5-82.5 °C; λmax (EtOH)/nm 254.8, 278.4; IR (neat) νmax/cm
-1
 3044, 2972, 2922, 
2851, 1683, 1597, 1576, 1515, 1468, 1423, 1354, 1287, 1238; 
1
H NMR (500 MHz, 
DMSO-d6) δ 1.04 – 1.15 (2H, m, H-3’, 5’), 1.38 (9H, s, C(CH3)3), 1.48 – 1.56 (2H, m, 
H-3’, 5’), 1.91 – 2.03 (1H, m, H-4’), 2.66 (2H, brs, H-2’, 6’), 2.82 (2H, d, J = 7.1 Hz, 
ArCH2), 3.89 (2H, d, J = 13.2 Hz, H-2’, 6’), 7.56 (1H, d, J = 8.6 Hz, H-3), 8.50 (1H, dd, 
J = 8.6, 2.7 Hz, H-4), 9.29 (1H, d, J = 2.7 Hz, H-6); 
13
C NMR (126 MHz, DMSO-d6) 
δ 28.1 (C(CH3)3), 31.3 (C-3’, 5’), 35.8 (C-4’), 43.1 (C-2’, 6’), 44.0 (ArCH2), 78.4 
(OC(CH3)3), 124.2 (C-3), 131.6 (C-4), 142.6 (C-5), 144.2 (C-6), 153.8 (CO2N), 167.0 
(C-2); LRMS (ES
+
) m/z 320.3 [M+H]
+
; HRMS (NSI) calcd for C16H24N3O4 [M+H]
+
 
322.1761, found 322.1763. 
 
tert-Butyl 4-(methyl(5-nitropyridin-2-yl)amino)piperidine-1-carboxylate, (460) 
 
To 2-chloro-5-nitropyridine (459) (672 mg, 4.24 mmol) in THF (20 mL) was added 
triethylamine (650 µL, 472 mg, 4.67 mmol) and tert-butyl 4-(methylamino)piperidine-1-
carboxylate (995 µL, 1.0 g, 4.67 mmol) at RT. The resulting solution was stirred at reflux 
overnight. Upon completion, the solvent was removed in vacuo. The crude residue was 
dissolved in EtOAc (20 mL), washed with water (20 mL) and extracted with EtOAc 
(3 × 25 mL). The pooled organic extracts were washed with brine (30 mL), dried over 
MgSO4 and concentrated in vacuo. The crude yellow solid was purified by column 
chromatography (silica gel, petrol:EtOAc, 1:0  3:1) to yield the title compound as a 
yellow solid (1.07 g, 75%); Rf = 0.31 (petrol:EtOAc, 3:1); m.p. 158.5-160.5 °C; 
408 
λmax (EtOH)/nm 368.6; IR (neat) νmax/cm
-1
 2963, 2926, 1691, 1595, 1571, 1509, 1477, 
1410, 1334, 1295, 1241; 
1
H NMR (500 MHz, DMSO-d6) δ 1.41 (9H, s, C(CH3)3), 
1.55 - 1.74 (4H, m, H-3’, 5’), 2.84 (2H, brs, H-2’, 6’), 2.98 (3H, s, NCH3), 4.06 (2H, brs, 
H-2’, 6’), 4.79 (1H, brs, H-4’), 6.81 (1H, d, J = 9.7 Hz, H-3), 8.22 (1H, dd, J = 9.7, 2.9 Hz, 
H-4), 8.97 (1H, d, J = 2.9 Hz, H-6); 
13
C NMR (126 MHz, DMSO-d6) δ 28.1 (C(CH3)3), 
28.4 (C-3’, 5’), 30.3 (NCH3), 42.7 (C-2’, 6’), 78.8 (OC(CH3)3), 105.6 (C-3), 132.7 (C-4), 
134.1 (C-5), 146.0 (C-6), 153.7 (CO2N), 160.1 (C-2); HRMS (NSI) calcd for C16H25N4O4 
[M+H]
+
 337.1870, found 337.1871. 
 
tert-Butyl 4-((5-nitropyridin-2-yl)oxy)piperidine-1-carboxylate, (461) 
 
To a suspension of sodium hydride (60% dispersion in mineral oil, 246 mg, 6.15 mmol) in 
THF (20 mL), cooled in an ice bath, was added 1-Boc-4-hydroxypiperidine (1.24 g, 
6.15 mmol). The resulting solution was stirred at 0 °C for 10 min and allowed to warm to 
RT. After 1 h, the reaction mixture was cooled in an ice bath and 2-chloro-5-nitropyridine 
(459) (650 mg, 4.10 mmol) added in several portions. The resulting mixture was then 
stirred overnight at RT. Upon completion, the mixture was diluted with EtOAc (20 mL), 
quenched by the cautious addition of saturated aq. NaHCO3 (20 mL) and extracted with 
EtOAc (3 × 20 mL). The pooled organic extracts were washed with water and brine 
(40 mL, respectively), dried over MgSO4 and concentrated in vacuo. The crude product 
was purified by column chromatography (silica gel, petrol:EtOAc, 1:0  9:1) to yield the 
title compound as an off-white solid (1.03 g, 78%); Rf = 0.30 (petrol:EtOAc, 1:9); 
m.p. 109.5-111.5 °C; λmax (EtOH)/nm 295.0; IR (neat) νmax/cm
-1
 2961, 2924, 2873, 1675, 
1605, 1579, 1513, 1473, 1425, 1349, 1318, 1273; 
1
H NMR (500 MHz, DMSO-d6) δ 1.41 
(9H, s, C(CH3)3), 1.60 (2H, dddd, J = 12.9, 8.8, 8.8 and 4.0 Hz, H-3’, 5’axial), 2.03 – 1.90 
(2H, m, H-3’, 5’equ), 3.20 (2H, brs, H-2’, 6’axial), 3.69 (2H, ddd, J = 12.9, 4.6 and 4.6 Hz, 
H-2’, 6’equ), 5.32 (1H, tt, J = 8.8, 4.0 Hz, H-4’), 7.02 (1H, d, J = 9.1 Hz, H-3), 8.47 (1H, 
dd, J = 9.1, 2.9 Hz, H-4), 9.07 (1H, d, J = 2.9 Hz, H-6); 
13
C NMR (126 MHz, DMSO-d6) 
δ 28.0 (C(CH3)3), 30.2 (C-3’, 5’), 40.6 (C-2’, 6’) 72.3 (C-4’), 78.8 (OC(CH3)3), 111.8 
(C-3), 134.9 (C-4), 139.3 (C-5), 144.6 (C-6), 153.9 (CO2N), 165.9 (C-2); HRMS (NSI) 
calcd for C15H22N3O5 [M+H]
+
 324.1554, found 324.1553; 
1
H NMR data were identical to 
literature data.
285
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tert-Butyl 4-((5-aminopyridin-2-yl)(methyl)amino)piperidine-1-carboxylate, (462) 
 
Compound 462 was synthesised according to general procedure D’, using the following 
reagents: tert-butyl 4-(methyl(5-nitropyridin-2-yl)amino)piperidine-1-carboxylate (460) 
(750 mg, 2.23 mmol), THF (22.5 mL) and methanol (22.5 mL). The crude pale red solid 
(650 mg, 95%) was used in the next step without further purification; Rf = 0.32 (EtOAc, 
100%); m.p. 108.0-110.0 °C; λmax (EtOH)/nm 257.0; IR (neat) νmax/cm
-1
 3411, 3339, 3232, 
3004, 2945, 1673, 1562, 1494, 1412, 1290, 1270, 1243; 
1
H NMR (500 MHz, DMSO-d6) 
δ 1.40 (9H, s, C(CH3)3), 1.46 – 1.54 (4H, m, H-3’, 5’), 2.66 (3H, s, NCH3), 2.79 (2H, brs, 
H-2’, 6’), 4.03 (2H, brs, H-2’, 6’), 4.31 – 4.46 (3H, m, ArNH2 and H-4’), 6.46 (1H, d, 
J = 8.9 Hz, H-3), 6.91 (1H, dd, J = 8.9, 2.9 Hz, H-4), 7.58 (1H, d, J = 2.9 Hz, H-6); 
13
C NMR (126 MHz, DMSO-d6) δ 28.1 (C(CH3)3), 28.4 (C-3’, 5’), 29.9 (NCH3), 43.0 
(C-2’, 6’), 52.4 (C-4’), 78.5 (OC(CH3)3), 106.9 (C-3), 125.1 (C-4), 133.5 (C-6), 135.6 
(C-5), 151.6 (C-2), 153.8 (CO2N); LRMS (ES
+
) m/z 307.4 [M+H]
+
; HRMS (NSI) calcd for 
C16H27N4O2 [M+H]
+
 307.2129, found 307.2128. 
 
tert-Butyl 4-((5-aminopyridin-2-yl)oxy)piperidine-1-carboxylate, (463) 
 
Compound 463 was synthesised according to general procedure D’, using the following 
reagents: tert-butyl 4-((5-nitropyridin-2-yl)oxy)piperidine-1-carboxylate (461) (800 mg, 
2.47 mmol), THF (24.7 mL) and methanol (24.7 mL). The crude pale yellow solid 
(700 mg, 96%) was used in the next step without further purification; Rf = 0.29 (EtOAc, 
100%); m.p. 160.0-162.0 °C; λmax (EtOH)/nm 236.6, 313.8; IR (neat) νmax/cm
-1
 3384, 3335, 
2980, 2961, 2925, 2865, 1681, 1485, 1418, 1369, 1270, 1249, 1236; 
1
H NMR (500 MHz, 
DMSO-d6) δ 1.40 (9H, s, C(CH3)3), 1.46 (2H, dddd, J = 13.2, 9.2, 9.1 and 4.1 Hz, H-3’, 
5’axial), 1.87 (2H, ddd, J = 13.2, 5.8 and 3.3 Hz, H-3’, 5’equ), 3.12 (2H, brs, H-2’, 6’axial), 
3.66 (2H, ddd, J = 13.2, 4.9 and 4.9 Hz, H-2’, 6’equ), 4.74 (2H, brs, ArNH2), 4.93 (1H, tt, 
J = 8.3, 3.8 Hz, H-4’), 6.51 (1H, d, J = 8.6 Hz, H-3), 6.98 (1H, dd, J = 8.6, 2.9 Hz, H-4), 
7.48 (1H, d, J = 2.9 Hz, H-6); 
13
C NMR (126 MHz, DMSO-d6) δ 28.1 (C(CH3)3), 30.7 
(C-3’, 5’), 40.6 (C-2’, 6’), 69.3 (C-4’), 78.6 (OC(CH3)3), 110.9 (C-3), 126.3 (C-4), 131.1 
(C-6), 139.4 (C-5), 153.9 (C-2 or CO2N), 154.3 (C-2 or CO2N); LRMS (ES
+
) m/z 294.4 
[M+H]
+
; HRMS (ESI) calcd for C15H24N3O3 [M+H]
+
 294.1812, found 294.1811. 
410 
tert-Butyl 4-((5-aminopyridin-2-yl)methyl)piperidine-1-carboxylate, (464) 
 
Compound 464 was synthesised according to general procedure D’, using the following 
reagents: tert-butyl 4-((5-nitropyridin-2-yl)methyl)piperidine-1-carboxylate (458) (300 mg, 
0.93 mmol), THF (9.3 mL) and methanol (9.3 mL). The crude orange solid (261 mg, 96%) 
was used in the next step without further purification; Rf = 0.26 (amine silica, 
petrol:EtOAc, 1:1); m.p. 107.5-109.5 °C; λmax (EtOH)/nm 243.6, 307.4; IR (neat) νmax/cm
-1
 
3398, 3323, 3219, 2981, 2917, 2852, 1668, 1573, 1493, 1425, 1366; 
1
H NMR (500 MHz, 
DMSO-d6) δ 1.00 (2H, dddd, J = 12.3, 12.3, 12.3 and 4.3 Hz, H-3’, 5’), 1.38 (9H, s, 
C(CH3)3), 1.47 – 1.54 (2H, m, H-3’, 5’), 1.76 (1H, ttt, J = 12.3, 7.2 and 4.3 Hz, H-4’), 2.44 
(2H, d, J = 7.2 Hz, ArCH2CH), 2.64 (2H, brs, H-2’, 6’), 3.88 (2H, d, J = 13.1 Hz, H-2’, 6’), 
5.03 (2H, brs, ArNH2), 6.81 – 6.84 (2H, m, H-3 and H-4), 7.84 (1H, d, J = 1.7 Hz, H-6); 
13
C NMR (126 MHz, DMSO-d6) δ 28.1 (C(CH3)3), 31.5 (C-3’, 5’), 36.2 (C-4’), 42.9 (C-2’, 
6’), 43.3 (ArCH2), 78.3 (OC(CH3)3), 120.4 (C-3 or C-4), 123.0 (C-3 or C-4), 135.7 (C-6), 
142.5 (C-5), 146.8 (C-2), 153.8 (CO2N); LRMS (ES
+
) m/z 292.4 [M+H]
+
; HRMS (NSI) 
calcd for C16H26N3O2 [M+H]
+
 292.2020, found 292.2019. 
 
tert-Butyl 4-((5-(4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxamido)pyridin-
2-yl)(methyl)amino)piperidine-1-carboxylate, (465) 
 
Compound 465 was synthesised according to general procedure Y, using the following 
reagents: 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250) (300 mg, 
0.99 mmol), triethylamine (346 µL, 251 mg, 2.48 mmol), 2-chloro-1-methylpyridinium 
iodide (279 mg, 1.09 mmol), tert-butyl 4-((5-aminopyridin-2-yl)(methyl)amino)piperidine-
1-carboxylate (462) (380 mg, 1.24 mmol) and DCM (9.9 mL). The crude yellow solid was 
purified by column chromatography (silica gel, petrol:EtOAc, 1:0  1:1) to yield the title 
compound as a pale orange solid (285 mg, 49%); Rf = 0.31 (petrol:EtOAc, 1:1); 
m.p. 173.0-175.0 °C; λmax (EtOH)/nm 290.0; IR (neat) νmax/cm
-1
 3223, 2958, 2931, 2865, 
1656, 1638, 1527, 1494, 1448, 1421, 1393, 1365, 1291; 
1
H NMR (500 MHz, DMSO-d6) 
δ 1.41 (9H, s, C(CH3)3), 1.52 – 1.63 (4H, m, CH2CH2NBoc), 2.79 (3H, s, NCH3), 2.81 (2H, 
brs, CH2CH2NBoc), 4.06 (2H, brs, CH2CH2NBoc), 4.58 (1H, tt, J = 10.5, 5.9 Hz, 
411 
ArN(CH3)CH), 6.67 (1H, d, J = 9.1 Hz, H-3”), 7.41 (1H, s, H-3), 7.51 (1H, dd, J = 8.7, 
1.4 Hz, H-5’), 7.56 (1H, s, H-5), 7.71 – 7.83 (2H, m, H-4’ and H-4”), 8.36 (1H, d, 
J = 2.7 Hz, H-6”), 9.91 (1H, s, CONHAr), 12.67 (1H, s, NH-pyrrole); 13C NMR 
(126 MHz, DMSO-d6) δ 28.1 (C(CH3)3), 28.6 (CH2CH2NBoc), 29.6 (NCH3), 43.4 
(CH2CH2NBoc), 51.9 (ArN(CH3)CH), 78.6 (OC(CH3)3), 105.6 (C-3”), 110.6 (C-3), 119.3 
(d, J = 18.2 Hz, C-3’), 124.7 (C-2 or C-4 and C-5”), 126.9 (d, J = 3.3 Hz, C-5’), 128.9 (C-2 
or C-4), 129.2 (d, J = 5.2 Hz, C-6’), 129.2 (d, J = 23.0 Hz, C-1’), 129.6 (C-5), 131.4 (C-4’ 
or C-4”), 131.8 (C-4’ or C-4”), 140.4 (C-6”), 153.8 (CO2N or C-2”), 153.8 (d, 
J = 248.4 Hz, C-2’), 155.2 (CO2N or C-2”), 158.2 (CONHAr), 182.6 (ArCO); 
19
F NMR 
(471 MHz, DMSO-d6) δ -116.7; LRMS (ES
-
) m/z 588.3 [M(
35
Cl
35
Cl)-H]
-
, 590.3 
[M(
35
Cl
37
Cl)-H]
-
; HRMS (NSI) calcd for C28H31Cl2FN5O4 [M(
35
Cl
35
Cl)+H]
+
 590.1732, 
found 590.1725. 
 
tert-Butyl 4-((5-(4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxamido)pyridin-
2-yl)oxy)piperidine-1-carboxylate, (466) 
 
Compound 466 was synthesised according to general procedure Y, using the following 
reagents: 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250) (300 mg, 
0.99 mmol), triethylamine (346 µL, 251 mg, 2.48 mmol), 2-chloro-1-methylpyridinium 
iodide (279 mg, 1.09 mmol), tert-butyl 4-((5-aminopyridin-2-yl)oxy)piperidine-1-
carboxylate (463) (364 mg, 1.24 mmol) and DCM (9.9 mL). The crude yellow solid was 
purified by column chromatography (silica gel, petrol:EtOAc, 1:0  6:4) to yield the title 
compound as a pale orange solid (275 mg, 48%); Rf = 0.30 (petrol:EtOAc, 6:4); 
m.p. 226.5-228.5 °C; λmax (EtOH)/nm 261.6; IR (neat) νmax/cm
-1
 3166, 2980, 2936, 2857, 
1658, 1647, 1593, 1556, 1538, 1484, 1433, 1365, 1263;
1
H NMR (500 MHz, DMSO-d6) 
δ 1.41 (9H, s, C(CH3)3), 1.53 (2H, dddd, J = 13.0, 9.1, 9.0 and 4.0 Hz, CH2CH2NBoc), 
1.94 (2H, ddd, J = 13.0, 5.9 and 3.4 Hz, CH2CH2NBoc), 3.16 (2H, brs, CH2CH2NBoc), 
3.70 (2H, ddd, J = 13.0, 4.8 and 4.8 Hz, CH2CH2NBoc), 5.13 (1H, tt, J = 8.3, 3.8 Hz, 
ArOCH), 6.81 (1H, d, J = 8.9 Hz, H-3”), 7.45 (1H, s, H-3), 7.52 (1H, dd, J = 8.7, 1.3 Hz, 
H-5’), 7.59 (1H, s, H-5), 7.78 (1H, dd, J = 8.7, 8.5 Hz, H-4’), 7.98 (1H, dd, J = 8.9, 2.7 Hz, 
H-4”), 8.44 (1H, d, J = 2.7 Hz, H-6”), 10.10 (1H, s, CONHAr), 12.73 (1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 28.1 (C(CH3)3), 30.6 (CH2CH2NBoc), 40.7 
412 
(CH2CH2NBoc), 70.0 (ArOCH), 78.7 (OC(CH3)3), 110.8 (C-3”), 111.0 (C-3), 119.3 (d, 
J = 18.1 Hz, C-3’), 124.7 (C-2 or C-4), 126.9 (d, J = 3.4 Hz, C-5’), 128.6 (C-2 or C-4), 
129.2 (d, J = 23.3 Hz, C-1’), 129.2 (d, J = 5.3 Hz, C-6’), 129.5 (C-5”), 130.0 (C-5), 131.8 
(C-4’), 132.5 (C-4”), 138.6 (C-6”), 153.8 (d, J = 248.3 Hz, C-2’), 153.9 (CO2N), 158.4 
(CONHAr or C-2”), 158.7 (CONHAr or C-2”), 182.6 (ArCO); 19F NMR (471 MHz, 
DMSO-d6) δ -116.7 (ArF); LRMS (ES
-
) m/z 575.3 [M(
35
Cl
35
Cl)-H]
-
, 577.3 
[M(
35
Cl
37
Cl)-H]
-
; HRMS (NSI) calcd for C27H28Cl2FN4O5 [M(
35
Cl
35
Cl)+H]
+
 577.1415, 
found 577.1408. 
 
tert-Butyl 4-((5-(4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxamido)pyridin-
2-yl)methyl)piperidine-1-carboxylate, (467) 
 
Compound 467 was synthesised according to general procedure Y, using the following 
reagents: 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250) (250 mg, 
0.83 mmol), triethylamine (288 µL, 209 mg, 2.07 mmol), 2-chloro-1-methylpyridinium 
iodide (233 mg, 0.91 mmol), tert-butyl 4-((5-aminopyridin-2-yl)methyl)piperidine-1-
carboxylate (464) (301 mg, 1.03 mmol) and DCM (8.3 mL). The crude yellow solid was 
purified by column chromatography (silica gel, petrol:EtOAc, 1:0  1:1) to yield the title 
compound as an orange solid (201 mg, 42%); Rf = 0.29 (petrol:EtOAc, 1:1); m.p. 
132.0-134.0 °C; λmax (EtOH)/nm 295.6; IR (neat) νmax/cm
-1
 3238, 2926, 2853, 1651, 1592, 
1531, 1448, 1424, 1394, 1366; 
1
H NMR (500 MHz, DMSO-d6) δ 1.01 – 1.10 (2H, m, 
CH2CH2NBoc), 1.38 (9H, s, C(CH3)3), 1.53 (2H, dd, J = 12.6, 3.6 Hz, CH2CH2NBoc), 
1.83 – 1.90 (1H, m, ArCH2CH), 2.62 (2H, d, J = 7.1 Hz, ArCH2CH), 2.66 (2H, brs, 
CH2CH2NBoc), 3.90 (2H, d, J = 13.1 Hz, CH2CH2NBoc), 7.21 (1H, d, J = 8.4 Hz, H-3”), 
7.50 (1H, s, H-3), 7.52 (1H, dd, J = 8.8, 1.2 Hz, H-5’), 7.61 (1H, s, H-5), 7.78 (1H, dd, 
J = 8.8, 8.4 Hz, H-4’), 8.02 (1H, dd, J = 8.4, 2.5 Hz, H-4”), 8.78 (1H, d, J = 2.5 Hz, H-6”), 
10.18 (1H, s, CONHAr), 12.75 (1H, s, NH-pyrrole);
13
C NMR (126 MHz, DMSO-d6) 
δ 28.1 (C(CH3)3), 31.5 (CH2CH2NBoc), 36.0 (ArCH2CH), 43.6 (ArCH2CH), 43.9 
(CH2CH2NBoc), 78.4 (OC(CH3)3), 111.3 (C-3), 119.3 (d, J = 17.8 Hz, C-3’), 123.1 (C-3”), 
124.8 (C-2 or C-4), 126.9 (d, J = 3.7 Hz, C-5’), 127.5 (C-4”), 128.5 (C-2 or C-4), 129.1 (d, 
J = 22.8 Hz, C-1’), 129.2 (d, J = 5.4 Hz, C-6’), 130.2 (C-5), 131.9 (C-4’), 133.2 (C-5”), 
141.1 (C-6”), 153.8 (CO2N or C-2”), 153.9 (d, J = 248.6 Hz, C-2’), 154.8 (CO2N or C-2”), 
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158.5 (CONHAr), 182.6 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -116.7 (ArF); 
LRMS (ES
+
) m/z 573.4 [M(
35
Cl
35
Cl)+H]
+
, 575.4 [M(
35
Cl
37
Cl)+H]
+
; HRMS (NSI) calcd for 
C28H30Cl2FN4O4 [M(
35
Cl
35
Cl)+H]
+
 575.1623, found 575.1616. 
 
tert-Butyl 4-((5-(4-(6-chloro-2-fluoro-3-methoxybenzoyl)-1H-pyrrole-2-
carboxamido)pyridin-2-yl)methyl)piperidine-1-carboxylate, (468) 
 
Compound 468 was synthesised according to general procedure Y, using the following 
reagents: 4-(6-chloro-2-fluoro-3-methoxybenzoyl)-1H-pyrrole-2-carboxylic acid (338) 
(300 mg, 1.01 mmol), triethylamine (351 µL, 255 mg, 2.52 mmol), 2-chloro-1-
methylpyridinium iodide (283 mg, 1.11 mmol), tert-butyl 4-((5-aminopyridin-2-
yl)methyl)piperidine-1-carboxylate (464) (367 mg, 1.26 mmol) and DCM (10.1 mL). The 
crude yellow solid was purified by column chromatography (silica gel, petrol:EtOAc, 
1:0  45:55) to yield the title compound as a pale pink solid (222 mg, 39%); Rf = 0.28 
(petrol:EtOAc, 45:55); m.p. 227.5-229.5 °C; λmax (EtOH)/nm 296.0; IR (neat) νmax/cm
-1
 
3341, 3195, 2938, 2860, 1682, 1639, 1559, 1530, 1476, 1434; 
1
H NMR (500 MHz, 
DMSO-d6) δ 1.05 (2H, dddd, J = 12.5, 12.5, 12.5 and 4.3 Hz, CH2CH2NBoc), 1.38 (9H, s, 
C(CH3)3), 1.49 – 1.58 (2H, m, CH2CH2NBoc), 1.88 (1H, ttt, J = 12.5, 7.1 and 3.5 Hz, 
ArCH2CH), 2.61 (2H, d, J = 7.1 Hz, ArCH2CH), 2.65 (2H, s, CH2CH2NBoc), 3.85 (2H, s, 
CH2CH2NBoc), 3.90 (3H, s, ArOCH3), 7.21 (1H, d, J = 8.4 Hz, H-3”), 7.33 (1H, dd, 
J = 9.0, 8.9 Hz, H-4’), 7.39 (1H, dd, J = 8.9, 1.4 Hz, H-5’), 7.43 – 7.50 (2H, m, H-3 and 
H-5), 8.02 (1H, dd, J = 8.4, 2.5 Hz, H-4”), 8.78 (1H, d, J = 2.5 Hz, H-6”), 10.17 (1H, s, 
CONHAr), 12.68 (1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 28.1 (C(CH3)3), 
31.5 (CH2CH2NBoc), 36.0 (ArCH2CH), 42.9 (CH2CH2NBoc), 43.6 (ArCH2), 56.5 
(ArOCH3), 78.4 (OC(CH3)3), 111.4 (C-3), 115.1 (C-4’), 120.2 (d, J = 4.8 Hz, C-6’), 123.1 
(C-3”), 125.2 (C-2 or C-4), 125.6 (d, J = 3.6 Hz, C-5’), 127.4 (C-4”), 128.3 (C-2 or C-4), 
128.4 (d, J = 20.1 Hz, C-1’), 129.4 (C-5), 133.2 (C-5”), 141.1 (C-6”), 146.4 (d, 
J = 10.7 Hz, C-3’), 147.9 (d, J = 247.1 Hz, C-2’), 153.8 (CO2N or C-2”), 154.7 (CO2N or 
C-2”), 158.6 (CONHAr), 183.6 (ArCO); 19F NMR (471 MHz, DMSO-d6) δ -136.1 (ArF); 
LRMS (ES
-
) m/z 569.5 [M(
35
Cl)-H]
-
, 571.4 [M(
37
Cl)-H]
-
; HRMS (NSI) calcd for 
C29H33ClFN4O5 [M(
35
Cl)+H]
+
 571.2118, found 571.2113. 
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Diethyl 2-(5-nitropyridin-2-yl)malonate, (469) 
 
To a suspension of sodium hydride (60% dispersion in mineral oil, 4.04 g, 101 mmol) in 
THF (60 mL), cooled in an ice bath, was added diethyl malonate (8.08 g, 7.66 mL, 
50.5 mmol). The resulting solution was stirred at 0 °C for 10 min and allowed to warm to 
RT. After 1 h, the reaction mixture was cooled in an ice bath and a solution of 2-chloro-5-
nitropyridine (459) (8.0 g, 50.5 mmol) in THF (20 mL) added dropwise. The resulting 
mixture was then stirred overnight at RT. Upon completion, the mixture was diluted with 
EtOAc (40 mL), quenched by the cautious addition of 1 M aq. HCl (20 mL) and extracted 
with EtOAc (3 × 60 mL). The pooled organic extracts were washed with water and brine 
(40 mL, respectively), dried over MgSO4 and concentrated in vacuo. The crude product 
was purified by column chromatography (silica gel, petrol:EtOAc, 1:0  85:15) to yield 
the title compound as a yellow solid (9.05 g, 64%); Rf = 0.32 (petrol:EtOAc, 85:15); 
m.p. 86.5-88.5 °C (lit. 97.0-99.0 °C)
286
; λmax (EtOH)/nm 247.6, 272.4; IR (neat) νmax/cm
-1
 
3129, 3074, 2986, 2939, 1662, 1637, 1588, 1529, 1509, 1341; 
1
H NMR (500 MHz, 
DMSO-d6) δ 1.19 (6H, t, J = 7.1 Hz, OCH2CH3), 4.19 (4H, qd, J = 7.1, 1.9 Hz, OCH2CH3), 
5.41 (1H, s, ArCH(CO2Et)2), 7.77 (1H, d, J = 8.6 Hz, H-3), 8.64 (1H, dd, J = 8.6, 2.7 Hz, 
H-4), 9.33 (1H, d, J = 2.7 Hz, H-6); 
13
C NMR (126 MHz, DMSO-d6) δ 13.9 (OCH2CH3), 
59.2 (ArCH(CO2Et)2), 61.8 (OCH2CH3), 125.0 (C-3), 132.4 (C-4), 143.7 (C-5), 144.3 
(C-6), 158.9 (C-2), 166.5 (ArCH(CO2Et)2); LRMS (ES
+
) m/z 283.3 [M+H]
+
; HRMS (ESI) 
calcd for C12H15N2O6 [M+H]
+
 283.0925, found 283.0917. 
 
2-Methyl-5-nitropyridine, (470) 
 
To diethyl 2-(5-nitropyridin-2-yl)malonate (469) (8.0 g, 28.3 mmol) was added cold 20% 
aq. sulphuric acid (80 mL). The resulting solution was stirred at 100 °C for 2 h. Upon 
completion, the mixture was cooled in an ice bath, neutralised by the cautious addition of 
2 M aq. NaOH until pH 8-9 and extracted with DCM (3 × 100 mL). The pooled organic 
extracts were washed with water and brine (100 mL, respectively), dried over MgSO4 and 
concentrated in vacuo to give the title compound as a pale yellow solid (3.71 g, 95%). The 
crude material was used in the next step without further purification; Rf = 0.32 
(petrol:EtOAc, 9:1); m.p. 109.5-110.5 °C (lit. 110-111)
287
; λmax (EtOH)/nm 252.8, 276.4; 
IR (neat) νmax/cm
-1
 3039, 3019, 2950, 2854, 1600, 1572, 1512, 1469; 
1
H NMR (500 MHz, 
415 
DMSO-d6) δ 2.62 (3H, s, ArCH3), 7.57 (1H, d, J = 8.6 Hz, H-3), 8.48 (1H, dd, J = 8.6, 
2.8 Hz, H-4), 9.24 (1H, d, J = 2.8 Hz, H-6); 
13
C NMR (126 MHz, DMSO-d6) δ 24.3 
(ArCH3), 123.8 (C-3), 131.6 (C-4), 142.5 (C-5), 144.1 (C-6), 165.2 (C-2); LRMS (ES
+
) 
m/z 139.1 [M+H]
+
; HRMS (APCI) calcd for C6H7N2O2 [M+H]
+
 139.0502, found 
139.0500; 
1
H NMR, 
13
C NMR and IR data were identical to literature data.
288, 289
 
 
2-Methyl-5-nitropyridine 1-oxide, (471) 
 
To 2-methyl-5-nitropyridine (470) (2.0 g, 14.5 mmol) in DCM (50 mL), cooled in an ice 
bath, was added 3-chloroperbenzoic acid (74%, 5.06 g, 21.7 mmol) in portions. The 
resulting solution was stirred in an ice bath for 1 h and allowed to warm to RT. After 16 h, 
the reaction was quenched by addition of saturated aq. NaHCO3 (50 mL) and stirred for 
30 min. The aqueous layer was extracted with DCM (3 × 40 mL). The pooled organic 
extracts were washed with water (50 mL) and brine (50 mL), dried over MgSO4 and 
concentrated in vacuo. The crude product was purified by column chromatography (silica 
gel, petrol:EtOAc, 1:0  0:1) to yield the title compound as a yellow solid (2.15 g, 96%); 
Rf = 0.27 (EtOAc, 100%); m.p. 149.5-151.5 °C; λmax (EtOH)/nm 247.8, 278.2; IR (neat) 
νmax/cm
-1
 3126, 3102, 3036, 2920, 1564, 1519, 1491, 1350, 1285; 
1
H NMR (500 MHz, 
DMSO-d6) δ 2.44 (3H, s, ArCH3), 7.76 (1H, d, J = 8.7 Hz, H-3,), 8.05 (1H, dd, J = 8.7, 
2.2 Hz, H-4), 9.01 (1H, d, J = 2.2 Hz, H-6); 
13
C NMR (126 MHz, DMSO-d6) δ 17.4 
(ArCH3), 119.2 (C-4), 126.4 (C-3), 134.6 (C-6), 145.0 (C-5), 154.7 (C-2); LRMS (ES
+
) 
m/z 155.2 [M+H]
+
; HRMS (NSI) calcd for C6H7N2O3 [M+H]
+
 155.0451, found 155.0448. 
 
(5-Nitropyridin-2-yl)methanol, (472) 
 
To 2-methyl-5-nitropyridine 1-oxide (471) (1.0 g, 6.49 mmol) in DCM (20 mL), cooled in 
an ice bath, was added dropwise trifluoroacetic anhydride (1.80 mL, 2.73 g, 13.0 mmol). 
The resulting solution was stirred in an ice bath for 1 h and allowed to warm to RT. After 
16 h, the reaction was cooled in an ice bath, quenched by addition of MeOH (15 mL) and 
stirred for 8 h. The volatiles were concentrated in vacuo. The crude residue was dissolved 
in EtOAc (30 mL), washed with a saturated aq. NaHCO3 (30 mL) and extracted with 
EtOAc (2 × 35 mL). The pooled organic extracts were washed with water (40 mL) and 
brine (40 mL), dried over MgSO4 and concentrated in vacuo. The crude product was 
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purified by column chromatography (silica gel, petrol:EtOAc, 1:0  55:45) to yield the 
title compound as a yellow solid (500 mg, 50%); Rf = 0.31 (petrol:EtOAc, 55:45); 
m.p. 95.0-97.0 °C; λmax (EtOH)/nm 253.2, 276.2; IR (neat) νmax/cm
-1
 3161, 3040, 2917, 
2852, 1596, 1575, 1515, 1451, 1434, 1345; 
1
H NMR (500 MHz, DMSO-d6) δ 4.69 (2H, s, 
ArCH2OH), 5.77 (1H, brs, ArCH2OH), 7.75 (1H, d, J = 8.7 Hz, H-3), 8.61 (1H, dd, J = 8.7, 
2.7 Hz, H-4), 9.28 (1H, d, J = 2.7 Hz, H-6); 
13
C NMR (126 MHz, DMSO-d6) δ 64.0 
(ArCH2OH), 120.4 (C-3), 132.1 (C-4), 143.0 (C-5), 143.9 (C-6), 168.9 (C-2); LRMS (ES
+
) 
m/z 155.2 [M+H]
+
; HRMS (APCI) calcd for C6H7N2O3 [M+H]
+
 155.0451, found 
155.0450. 
 
5-Nitropicolinaldehyde, (473) 
 
To (5-nitropyridin-2-yl)methanol (472) (1.2 g, 7.79 mmol) in DCM (30 mL) was added 
manganese oxide (6.77 g, 77.9 mmol). The resulting solution was stirred at RT for 16 h. 
Upon completion, the heterogeneous mixture was filtered through Celite and washed with 
DCM (15 mL). The filtrate was concentrated in vacuo to give a yellow solid. The crude 
solid was purified by column chromatography (silica gel, petrol:EtOAc, 1:0  8:2) to 
yield the title compound as an orange solid (720 mg, 61%); Rf = 0.28 (petrol:EtOAc, 8:2); 
m.p. 65.0-67.0 °C (lit. 55 °C)
288
; λmax (EtOH)/nm 248.2, 273.6; IR (neat) νmax/cm
-1
 3102, 
2981, 2889, 2845, 1712, 1598, 1528, 1349; 
1
H NMR (500 MHz, DMSO-d6) δ 8.16 (1H, 
dd, J = 8.5, 0.7 Hz, H-3), 8.80 (1H, dd, J = 8.5, 2.5 Hz, H-4), 9.56 (1H, d, J = 2.5 Hz, H-6), 
10.08 (1H, d, J = 0.7 Hz, ArCHO); 
13
C NMR (126 MHz, DMSO-d6) δ 122.4 (C-3), 133.4 
(C-4), 145.3 (C-6), 146.1 (C-5), 155.2 (C-2), 192.0 (ArCHO); LRMS (ES
+
) m/z 153.2 
[M+H]
+
; HRMS (APCI) calcd for C6H5N2O3 [M+H]
+
 153.0295, found 153.0292; 
1
H and 
13
C NMR data were identical to literature data.
288
 
 
tert-Butyl 4-((5-nitropyridin-2-yl)methyl)piperazine-1-carboxylate, (474) 
 
To 5-nitropicolinaldehyde (473) (300 mg, 1.97 mmol) in TFE (10 mL) was added tert-
butyl piperazine-1-carboxylate (367 mg, 1.97 mmol). The resulting solution was stirred at 
38 °C for 1 h. Once cooled at 0 °C, sodium borohydride was carefully added. The resulting 
mixture was allowed to warm to RT and then stirred for 30 min. Upon completion, the 
solvent was removed in vacuo. The crude residue was dissolved in EtOAc (30 mL), 
neutralised by washing with saturated aq. NH4Cl (20 mL), washed with water and brine 
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(20 mL, respectively), dried over MgSO4 and concentrated in vacuo. The crude product 
was purified by column chromatography (silica gel, petrol:EtOAc, 1:0  1:1) to yield the 
title compound as a white solid (325 mg, 51%); Rf = 0.34 (petrol:EtOAc, 1:1); m.p. 
107.5-109.5 °C; λmax (EtOH)/nm 246.4, 305.4; IR (neat) νmax/cm
-1
 2981, 2941, 2881, 2820, 
1686, 1601, 1580, 1523, 1420, 1356, 1345; 
1
H NMR (500 MHz, DMSO-d6) δ 1.39 (9H, s, 
C(CH3)3), 2.40 (4H, t, J = 5.0 Hz, CH2 piperazine), 3.34 (4H, t, J = 5.0 Hz, CH2 piperazine), 3.76 
(2H, brs, ArCH2N), 7.75 (1H, d, J = 8.6 Hz, H-3), 8.57 (1H, dd, J = 8.6, 2.7 Hz, H-4), 9.29 
(1H, d, J = 2.7 Hz, H-6); 
13
C NMR (126 MHz, DMSO-d6) δ 28.1 (C(CH3)3), 43.0 
(CH2 piperazine), 52.5 (CH2 piperazine), 63.0 (ArCH2N), 78.8 (OC(CH3)3), 123.1 (C-3), 132.0 
(C-4), 143.2 (C-5), 144.1 (C-6), 153.8 (CO2N), 165.2 (C-2); LRMS (ES
-
) m/z 321.2 
[M-H]
-
; HRMS (NSI) calcd for C15H23N4O4 [M+H]
+
 323.1714, found 323.1712. 
 
tert-Butyl 4-((5-aminopyridin-2-yl)methyl)piperazine-1-carboxylate, (475) 
 
Compound 475 was synthesised according to general procedure D’, using the following 
reagents: tert-butyl 4-((5-nitropyridin-2-yl)methyl)piperazine-1-carboxylate (474) 
(300 mg, 0.93 mmol), THF (9.3 mL) and methanol (9.3 mL). The crude colourless oil 
(258 mg, 95%) was used in the next step without further purification; Rf = 0.32 (EtOAc, 
100%); λmax (EtOH)/nm 246.4, 305.4; IR (neat) νmax/cm
-1
 3410, 3327, 3204, 2980, 2925, 
2891, 2808, 2769, 1671, 1598, 1574, 1495, 1455, 1423; 
1
H NMR (500 MHz, DMSO-d6) 
δ 1.38 (9H, s, C(CH3)3), 2.29 (4H, t, J = 5.1 Hz, CH2 piperazine), 3.28 (4H, t, J = 5.1 Hz, 
CH2 piperazine), 3.39 (2H, s, ArCH2N), 5.18 (2H, brs, ArNH2), 6.88 (1H, dd, J = 8.3, 2.8 Hz, 
H-4), 7.03 (1H, d, J = 8.3 Hz, H-3), 7.83 (1H, d, J = 2.8 Hz, H-6); 
13
C NMR (126 MHz, 
DMSO-d6) δ 28.0 (C(CH3)3), 43.5 (CH2 piperazine), 52.4 (CH2 piperazine), 63.3 (ArCH2N), 78.7 
(OC(CH3)3), 120.4 (C-4), 123.1 (C-3), 135.2 (C-6), 143.5 (C-2 or C-5), 144.6 (C-2 or C-5), 
153.8 (CO2N); LRMS (ES
+
) m/z 293.5 [M+H]
+
; HRMS (NSI) calcd for C15H25N4O2 
[M+H]
+
 293.1972, found 293.1971. 
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tert-Butyl 4-((5-(4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxamido)pyridin-
2-yl)methyl)piperazine-1-carboxylate, (476) 
 
Compound 476 was synthesised according to general procedure Y, using the following 
reagents: 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250) (211 mg, 
0.70 mmol), triethylamine (243 µL, 177 mg, 1.75 mmol), 2-chloro-1-methylpyridinium 
iodide (196 mg, 0.77 mmol), tert-butyl 4-((5-aminopyridin-2-yl)methyl)piperazine-1-
carboxylate (475) (255 mg, 0.87 mmol) and DCM (7 mL). The crude yellow solid was 
purified by column chromatography (silica gel, petrol:EtOAc, 1:0  2:8) to yield the title 
compound as a pale orange solid (113 mg, 28%); Rf = 0.28 (petrol:EtOAc, 8:2); 
m.p. 147.0-149.0 °C; λmax (EtOH)/nm 295.8; IR (neat) νmax/cm
-1
 3238, 2964, 2932, 2871, 
2819, 1652, 1531, 1448, 1423, 1393; 
1
H NMR (500 MHz, DMSO-d6) δ 1.39 (9H, s, 
C(CH3)3), 2.32 – 2.42 (4H, m, CH2 piperazine), 3.33 (4H, brs, CH2 piperazine), 3.56 (2H, s, 
ArCH2N), 7.42 (1H, d, J = 8.5 Hz, H-3”), 7.48 – 7.54 (2H, m, H-3 and H-5’), 7.62 (1H, s, 
H-5), 7.78 (1H, dd, J = 8.7, 8.2 Hz, H-4’), 8.11 (1H, dd, J = 8.5, 2.6 Hz, H-4”), 8.80 (1H, 
d, J = 2.6 Hz, H-6”), 10.23 (1H, s, CONHAr), 12.77 (1H, s, NH-pyrrole); 13C NMR 
(126 MHz, DMSO-d6) δ 28.1 (C(CH3)3), 43.2 (CH2 piperazine), 52.5 (CH2 piperazine), 63.2 
(ArCH2N), 78.7 (OC(CH3)3), 111.4 (C-5), 119.3 (d, J = 18.0 Hz, C-3’), 122.7 (C-3”), 
124.8 (C-2 or C-4), 126.9 (d, J = 3.7 Hz, C-5’), 127.6 (C-4”), 128.5 (C-2 or C-4), 129.1 (d, 
J = 22.9 Hz, C-1’), 129.2 (d, J = 5.3 Hz, C-6’), 130.3 (C-5), 131.9 (C-4’), 134.1 (C-5”), 
140.7 (C-6”), 152.8 (CO2N or C-2”), 153.8 (CO2N or C-2”), 153.9 (d, J = 248.7 Hz, C-2’), 
158.6 (CONHAr), 182.6 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -116.7 (ArF); 
LRMS (ES
+
) m/z 576.5 [M(
35
Cl
35
Cl)+H]
+
, 578.5 [M(
35
Cl
37
Cl)+H]
+
; HRMS (NSI) calcd for 
C27H29Cl2FN5O4 [M(
35
Cl
35
Cl)+H]
+
 576.1575, found 576.1568. 
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tert-Butyl 4-((5-(4-(6-chloro-2-fluoro-3-methoxybenzoyl)-1H-pyrrole-2-carboxamido) 
pyridin-2-yl)methyl)piperazine-1-carboxylate, (477) 
 
Compound 477 was synthesised according to general procedure Y, using the following 
reagents: 4-(6-chloro-2-fluoro-3-methoxybenzoyl)-1H-pyrrole-2-carboxylic acid (338) 
(300 mg, 1.01 mmol), triethylamine (351 µL, 255 mg, 2.52 mmol), 2-chloro-1-
methylpyridinium iodide (283 mg, 1.11 mmol), tert-butyl 4-((5-aminopyridin-2-
yl)methyl)piperazine-1-carboxylate (475) (368 mg, 1.26 mmol) and DCM (10.1 mL). The 
crude yellow solid was purified by column chromatography (silica gel, petrol:EtOAc, 
1:0  15:85) to yield the title compound as a white solid (189 mg, 33%); Rf = 0.30 
(petrol:EtOAc, 15:85); m.p. 166.5-168.5 °C; λmax (EtOH)/nm 274.8; IR (neat) νmax/cm
-1
 
2956, 2933, 1653, 1553, 1527, 1472, 1432, 1391, 1271, 1240; 
1
H NMR (500 MHz, 
DMSO-d6) δ 1.38 (9H, s, C(CH3)3), 2.35 (4H, t, J = 4.9 Hz, CH2 piperazine), 3.31 (4H, brs, 
CH2 piperazine), 3.56 (2H, s, ArCH2N), 3.90 (3H, s, ArOCH3), 7.33 (1H, dd, J = 9.6, 8.9 Hz, 
H-4’), 7.39 (1H, d, J = 9.6 Hz, H-5’), 7.41 (1H, d, J = 8.5 Hz, H-3”), 7.47 (1H, s, H-3), 
7.49 (1H, s, H-5), 8.11 (1H, dd, J = 8.5, 2.6 Hz, H-4”), 8.79 (1H, d, J = 2.6 Hz, H-6”), 
10.23 (1H, s, CONHAr), 12.71 (1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) 
δ 28.1 (C(CH3)3), 42.9 (CH2 piperazine), 52.5 (CH2 piperazine), 56.5 (ArOCH3), 63.2 (ArCH2N), 
78.8 (OC(CH3)3), 111.5 (C-3), 115.2 (C-4’), 120.2 (d, J = 4.7 Hz, C-6’), 122.7 (C-3”), 
125.2 (C-2 or C-4), 125.6 (d, J = 3.8 Hz, C-5’), 127.6 (C-4”), 128.2 (C-2 or C-4), 128.4 (d, 
J = 20.1 Hz, C-1’), 129.5 (C-5), 134.1 (C-5”), 140.7 (C-6”), 146.5 (d, J = 10.8 Hz, C-3’), 
148.0 (d, J = 247.1 Hz, C-2’), 152.8 (CO2N or C-2”), 153.8 (CO2N or C-2”), 158.6 
(CONHAr), 183.7 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -136.2 (ArF); LRMS (ES
-
) 
m/z 570.4 [M(
35
Cl)-H]
-
, 572.4 [M(
37
Cl)-H]
-
; HRMS (NSI) calcd for C28H32ClFN5O5 
[M(
35
Cl)+H]
+
 572.2071, found 572.2062. 
 
  
420 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(2-((2-(dimethylamino)ethyl)amino)pyrimidin-5-
yl)-1H-pyrrole-2-carboxamide, (478) 
 
Compound 478 was synthesised according to general procedure Y, using the following 
reagents: 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250) (100 mg, 
0.33 mmol), triethylamine (115 µL, 84 mg, 0.83 mmol), 2-chloro-1-methylpyridinium 
iodide (93 mg, 0.36 mmol), N
2
-(2-(dimethylamino)ethyl)pyrimidine-2,5-diamine (518) 
(75 mg, 0.41 mmol) and DCM (3.3 mL). The crude yellow solid was purified by column 
chromatography (amine silica gel, DCM:MeOH, 1:0  96:4) to yield the title compound 
as a pale orange solid (17 mg, 11%); Rf = 0.26 (amine silica, DCM:MeOH, 96:4); 
m.p. 137.5-139.5 °C; λmax (EtOH)/nm 281.6; IR (neat) νmax/cm
-1
 3237, 1633, 1582, 1535, 
1510, 1445, 1423, 1390; 
1
H NMR (500 MHz, DMSO-d6) δ 2.16 (6H, s, CH2N(CH3)2), 2.39 
(2H, t, J = 6.8 Hz, CH2CH2NMe2), 3.30 – 3.39 (2H, m, NHCH2CH2), 6.86 (1H, t, 
J = 5.8 Hz, ArNHCH2), 7.39 (1H, s, H-3), 7.51 (1H, dd, J = 8.7, 1.2 Hz, H-5’), 7.59 (1H, s, 
H-5), 7.77 (1H, dd, J = 8.7, 8.4 Hz, H-4’), 8.49 (2H, s, H-4”, 6”), 9.95 (1H, s, CONHAr), 
12.71 (1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 39.0 (ArNHCH2), 45.3 
(CH2N(CH3)2), 58.1 (CH2CH2NMe2), 110.9 (C-3), 119.3 (d, J = 18.1 Hz, C-3’), 123.3 
(C-5”), 124.7 (C-2 or C-4), 126.9 (d, J = 3.8 Hz, C-5’), 128.5 (C-2 or C-4), 129.2 (d, 
J = 23.0 Hz, C-1’), 129.2 (d, J = 5.2 Hz, C-6’), 129.8 (C-5), 131.8 (C-4’), 151.6 (C-4”, 6”), 
153.8 (d, J = 248.5 Hz, C-2’), 158.4 (CONHAr or C-2”), 159.4 (CONHAr or C-2”), 182.6 
(ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -116.7 (ArF); LRMS (ES
+
) m/z 465.4 
[M(
35
Cl
35
Cl)+H]
+
, 467.4 [M(
35
Cl
37
Cl)+H]
+
; HRMS (NSI) calcd for C20H20Cl2FN6O2 
[M(
35
Cl
35
Cl)+H]
+
 465.1003, found 465.0995. 
 
  
421 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(6-((2-(diethylamino)ethyl)amino)pyridin-3-yl)-
1H-pyrrole-2-carboxamide, (479) 
 
Compound 479 was synthesised according to general procedure Y, using the following 
reagents: 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250) (150 mg, 
0.50 mmol), triethylamine (173 µL, 126 mg, 1.24 mmol), 2-chloro-1-methylpyridinium 
iodide (140 mg, 0.55 mmol), N
2
-(2-(diethylamino)ethyl)pyridine-2,5-diamine (519) 
(129 mg, 0.62 mmol) and DCM (5 mL). The crude product was purified by column 
chromatography (amine silica gel, DCM:MeOH, 1:0  97:3) to yield the title compound 
as a pink solid (66 mg, 27%); Rf = 0.36 (amine silica, DCM:MeOH, 97:3); m.p. 
200.0-202.0 °C; λmax (EtOH)/nm 279.4; IR (neat) νmax/cm
-1
 3413, 3314, 3236, 3115, 2965, 
2820, 1635, 1581, 1512, 1443; 
1
H NMR (500 MHz, DMSO-d6) δ 0.95 (6H, t, J = 7.1 Hz, 
CH2N(CH2CH3)2), 2.46 – 2.51 (4H, q, J = 7.1 Hz, CH2N(CH2CH3)2), 2.53 (2H, t, 
J = 7.0 Hz, CH2NEt2), 3.25 (2H, td, J = 7.0, 5.6 Hz, ArNHCH2), 6.17 (1H, t, J = 5.6 Hz, 
ArNHCH2), 6.47 (1H, d, J = 8.9 Hz, H-5”), 7.38 (1H, s, H-3), 7.50 (1H, dd, J = 8.9, 
1.2 Hz, H-5’), 7.54 (1H, s, H-5), 7.62 (1H, dd, J = 8.9, 2.7 Hz, H-4”), 7.76 (1H, dd, J = 8.9, 
8.3 Hz, H-4’), 8.21 (1H, d, J = 2.7 Hz, H-2”), 9.81 (1H, s, CONHAr), 12.61 (1H, s, 
NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 11.8 (CH2N(CH2CH3)2), 40.4 
(ArNHCH2), 46.6 (CH2N(CH2CH3)2), 51.7 (CH2NEt2), 107.4 (C-5”), 110.5 (C-3), 119.3 
(d, J = 18.2 Hz, C-1’), 124.4 (C-2 or C-4), 124.7 (C-3”), 126.9 (d, J = 3.5 Hz, C-5’), 129.0 
(C-2 or C-4), 129.2 (d, J = 5.0 Hz, C-6’), 129.2 (d, J = 22.9 Hz, C-3’), 129.6 (C-5), 131.2 
(C-4”), 131.8 (C-4’), 140.6 (C-2”), 153.8 (d, J = 248.4 Hz, C-2’), 155.9 (C-6”), 158.1 
(CONHAr), 182.6 (ArCO-pyrrole); 
19
F NMR (471 MHz, DMSO-d6) δ -116.7 (ArF); 
LRMS (ES
+
) m/z 492.4 [M(
35
Cl
35
Cl)+H]
+
, 494.4 [M(
37
Cl
35
Cl)+H]
+
; HRMS (NSI) calcd for 
C23H25Cl2FN5O2 [M(
35
Cl
35
Cl)+H]
+
 492.1264, found 492.1343. 
 
  
422 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(2-((2-(diethylamino)ethyl)amino)pyrimidin-5-yl)-
1H-pyrrole-2-carboxamide, (480) 
 
Compound 480 was synthesised according to general procedure Y, using the following 
reagents: 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250) (100 mg, 
0.33 mmol), triethylamine (115 µL, 84 mg, 0.83 mmol), 2-chloro-1-methylpyridinium 
iodide (93 mg, 0.36 mmol), N
2
-(2-(diethylamino)ethyl)pyrimidine-2,5-diamine (520) 
(87 mg, 0.41 mmol) and DCM (3.3 mL). The crude yellow solid was purified by column 
chromatography (amine silica gel, DCM:MeOH, 1:0  97:3) to yield the title compound 
as a pale orange solid (55 mg, 34%); Rf = 0.32 (amine silica, DCM:MeOH, 96:4); 
m.p. 160.0-162.0 °C; λmax (EtOH)/nm 282.6; IR (neat) νmax/cm
-1
 3317, 2970, 1637, 1514, 
1448, 1426, 1395, 1284; 
1
H NMR (500 MHz, DMSO-d6) δ 0.95 (6H, t, J = 7.1 Hz, 
N(CH2CH3)2), 2.52 – 2.47 (4H, m, N(CH2CH3)2), 2.54 (2H, t, J = 7.1 Hz, CH2NEt2), 
3.38 -3.26 (2H, m, ArNHCH2CH2), 6.81 (1H, t, J = 5.8 Hz, ArNHCH2), 7.38 (1H, s, H-3), 
7.51 (1H, dd, J = 8.8, 1.3 Hz, H-5’), 7.59 (1H, s, H-5), 7.78 (1H, dd, J = 8.8, 8.4 Hz, H-4’), 
8.48 (2H, s, H-4”, 6”), 9.94 (1H, s, CONHAr), 12.69 (1H, s, NH-pyrrole); 13C NMR 
(126 MHz, DMSO-d6) δ 11.9 (N(CH2CH3)2), ca. 40 (overlapping with DMSO) 
(ArNHCH2), 46.7 (N(CH2CH3)2), 51.5 (CH2NEt2), 110.9 (C-3), 119.3 (d, J = 18.3 Hz, 
C-3’), 123.3 (C-5”), 124.7 (C-2 or C-4), 126.9 (d, J = 3.9 Hz, C-5’), 128.5 (C-2 or C-4), 
129.2 (d, J = 23.4 Hz, C-1’), 129.2 (d, J = 5.0 Hz, C-6’), 129.8 (C-5), 131.8 (C-4’), 151.6 
(C-4”, 6”), 153.8 (d, J = 248.3 Hz, C-2’), 158.4 (CONHAr or C-2’), 159.5 (CONHAr or 
C-2’), 182.6 (ArCO); 19F NMR (471 MHz, DMSO-d6) δ -116.7 (ArF); LRMS (ES
-
) m/z 
491.3 [M(
35
Cl
35
Cl)-H]
-
, 493.3 [M(
35
Cl
37
Cl)-H]
-
; HRMS (NSI) calcd for C22H24Cl2FN6O2 
[M(
35
Cl
35
Cl)+H]
+
 493.1316, found 493.1306. 
 
  
423 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(6-((2-(pyrrolidin-1-yl)ethyl)amino)pyridin-3-yl)-
1H-pyrrole-2-carboxamide, (481) 
 
Compound 481 was synthesised according to general procedure Y, using the following 
reagents: 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250) (75 mg, 
0.25 mmol), triethylamine (87 µL, 63 mg, 0.62 mmol), 2-chloro-1-methylpyridinium 
iodide (70 mg, 0.27 mmol), N
2
-(2-(pyrrolidin-1-yl)ethyl)pyridine-2,5-diamine (521) 
(64 mg, 0.31 mmol) and DCM (5 mL). The crude product was purified by column 
chromatography (amine silica gel, DCM:MeOH, 1:0  97:3) to yield the title compound 
as a cream solid (24 mg, 20%); Rf = 0.18 (amine silica, DCM:MeOH, 97:3); 
m.p. 158.8-160.8 °C; λmax (EtOH)/nm 282.8; IR (neat) νmax/cm
-1
 2923, 2853, 1731, 1608, 
1534, 1511, 1483, 1405; 
1
H NMR (500 MHz, DMSO-d6) δ 1.68 (4H, p, J = 3.1 Hz, 
NCH2CH2 pyrrolidine), 2.47 (4H, p, J = 3.1 Hz, NCH2CH2 pyrrolidine), 2.57 (2H, t, J = 6.8 Hz, 
ArNHCH2CH2N), 3.25 – 3.38 (2H, m, ArNHCH2CH2N), 6.28 (1H, t, J = 5.7 Hz, 
ArNHCH2), 6.49 (1H, d, J = 8.9 Hz, H-5”), 7.39 (1H, s, H-3), 7.51 (1H, dd, J = 8.8, 
1.3 Hz, H-5’), 7.54 (1H, s, H-5), 7.62 (1H, dd, J = 8.9, 2.7 Hz, H-4”), 7.77 (1H, dd, J = 8.8, 
8.4 Hz, H-4’), 8.21 (1H, d, J = 2.7 Hz, H-2”), 9.82 (1H, s, CONHAr), 12.63 (1H, s, 
NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 23.1 (NCH2CH2 pyrrolidine), 40.2 
(ArNHCH2), 53.6 (NCH2CH2 pyrrolidine), 55.0 (ArNHCH2CH2N), 107.5 (C-5”), 110.5 (C-3), 
119.3 (d, J = 18.2 Hz, C-1’), 124.4 (C-2 or C-4), 124.7 (C-3”), 126.8 (d, J = 3.3 Hz, C-5’), 
129.0 (C-2 or C-4), 129.2 (d, J = 5.4 Hz, C-6’), 129.2 (d, J = 23.0 Hz, C-3’), 129.6 (C-5), 
131.2 (C-4”), 131.8 (C-4’), 140.5 (C-2”), 153.8 (d, J = 248.7 Hz, C-2’), 155.8 (C-6”), 
158.1 (CONHAr), 182.5 (ArCO-pyrrole); 
19
F NMR (471 MHz, DMSO-d6) δ -116.7 (ArF); 
LRMS (ES
+
) m/z 490.4 [M(
35
Cl
35
Cl)+H]
+
, 492.4 [M(
37
Cl
35
Cl)+H]
+
; HRMS (NSI) calcd for 
C23H23Cl2FN5O2 [M+H]
+
 490.1207, found 490.1193. 
 
  
424 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(2-((2-(pyrrolidin-1-yl)ethyl)amino)pyrimidin-5-
yl)-1H-pyrrole-2-carboxamide, (482) 
 
Compound 482 was synthesised according to general procedure Y, using the following 
reagents: 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250) (150 mg, 
0.50 mmol), triethylamine (173 µL, 126 mg, 1.24 mmol), 2-chloro-1-methylpyridinium 
iodide (140 mg, 0.55 mmol), N
2
-(2-(pyrrolidin-1-yl)ethyl)pyrimidine-2,5-diamine (522) 
(129 mg, 0.62 mmol) and DCM (5 mL). The crude yellow solid was purified by column 
chromatography (amine silica gel, DCM:MeOH, 1:0  96:4) to yield the title compound 
as an off-white solid (70 mg, 29%); Rf = 0.28 (amine silica, DCM:MeOH, 96:4); 
m.p. 140.0-142.0 °C; λmax (EtOH)/nm 282.4; IR (neat) νmax/cm
-1
 3285, 2960, 2801, 1634, 
1510, 1445, 1424, 1392; 
1
H NMR (500 MHz, DMSO-d6) δ 1.61 – 1.72 (4H, m, 
NCH2CH2 pyrrolidine), 2.42 – 2.49 (4H, m, NCH2CH2 pyrrolidine), 2.56 (2H, t, J = 6.9 Hz, 
ArNHCH2CH2N), 3.37 (2H, td, J = 6.9, 5.8 Hz, ArNHCH2CH2), 6.93 (1H, t, J = 5.8 Hz, 
ArNHCH2), 7.38 (1H, s, H-3), 7.51 (1H, dd, J = 8.8, 1.4 Hz, H-5’), 7.59 (1H, s, H-5), 7.78 
(1H, dd, J = 8.8, 8.4 Hz, H-4’), 8.48 (2H, s, H-4”, 6”), 9.94 (1H, s, CONHAr), 12.70 (1H, 
s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 23.1 (NCH2CH2 pyrrolidine), 40.1 
(ArNHCH2), 53.6 (NCH2CH2 pyrrolidine), 54.8 (ArNHCH2CH2N), 110.9 (C-3), 119.3 (d, 
J = 17.9 Hz, C-3’), 123.3 (C-5”), 124.7 (C-2 or C-4), 126.9 (d, J = 3.6 Hz, C-5’), 128.5 
(C-2 or C-4), 129.2 (d, J = 22.8 Hz, C-1’), 129.2 (d, J = 5.2 Hz, C-6’), 129.8 (C-5), 131.8 
(C-4’), 151.6 (C-4”, 6”), 153.8 (d, J = 248.8 Hz, C-2’), 158.4 (CONHAr or C-2”), 159.4 
(CONHAr or C-2”), 182.6 (ArCO); 19F NMR (471 MHz, DMSO-d6) δ -116.7 (ArF); 
LRMS (ES
+
) m/z 491.4 [M(
35
Cl
35
Cl)+H]
+
, 493.4 [M(
35
Cl
37
Cl)+H]
+
; HRMS (NSI) calcd for 
C22H22Cl2FN6O2 [M(
35
Cl
35
Cl)+H]
+
 491.1160, found 491.1149. 
 
  
425 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(6-((2-(piperidin-1-yl)ethyl)amino)pyridin-3-yl)-
1H-pyrrole-2-carboxamide, (483) 
 
Compound 483 was synthesised according to general procedure Y, using the following 
reagents: 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250) (150 mg, 
0.50 mmol), triethylamine (173 µL, 126 mg, 1.24 mmol), 2-chloro-1-methylpyridinium 
iodide (140 mg, 0.55 mmol), N
2
-(2-(piperidin-1-yl)ethyl)pyridine-2,5-diamine (523) 
(137 mg, 0.62 mmol) and DCM (5mL). The crude product was purified by column 
chromatography (amine silica gel, DCM:MeOH, 1:0  97:3) to yield the title compound 
as a grey solid (56 mg, 22%); Rf = 0.30 (amine silica, DCM:MeOH, 97:3); m.p. 
217.5-219.5 °C; λmax (EtOH)/nm 290.8; IR (neat) νmax/cm
-1
 3333, 3225, 3122, 2927, 2850, 
2768, 1632, 1583, 1516, 1445;
1
H NMR (500 MHz, DMSO-d6) δ 1.33 – 1.41 (2H, m, 
NCH2CH2CH2 piperidine), 1.45 – 1.53 (4H, m, NCH2CH2CH2 piperidine), 2.36 (4H, brs, 
NCH2CH2CH2 piperidine), 2.42 (2H, t, J = 6.8 Hz, ArNHCH2CH2N), 3.30 (2H, td, J = 6.8, 
5.6 Hz, ArNHCH2CH2N), 6.20 (1H, t, J = 5.6 Hz, ArNHCH2), 6.49 (1H, d, J = 8.9 Hz, 
H-5”), 7.40 (1H, s, H-3), 7.51 (1H, dd, J = 8.8, 1.3 Hz, H-5’), 7.55 (1H, s, H-5), 7.63 (1H, 
dd, J = 8.9, 2.7 Hz, H-4”), 7.77 (1H, dd, J = 8.8, 8.4 Hz, H-4’), 8.22 (1H, d, J = 2.7 Hz, 
H-2”), 9.82 (1H, s, CONHAr), 12.64 (1H, s, NH-pyrrole);13C NMR (126 MHz, DMSO-d6) 
δ 24.1 (NCH2CH2CH2 piperidine), 25.6 (NCH2CH2CH2 piperidine), 38.5 (ArNHCH2CH2N), 54.2 
(NCH2CH2CH2 piperidine), 57.9 (ArNHCH2CH2N), 107.4 (C-5”), 110.5 (C-3), 119.3 (d, 
J = 18.0 Hz, C-1’), 124.4 (C-2 or C-4), 124.68 (C-3”), 126.9 (d, J = 3.9 Hz, C-5’), 129.0 
(C-2 or C-4), 129.2 (d, J = 5.2 Hz, C-6’), 129.2 (d, J = 23.0 Hz, C-3’), 129.6 (C-5), 131.2 
(C-4”), 131.8 (C-4’), 140.6 (C-2”), 153.8 (d, J = 248.6 Hz, C-2’), 155.8 (C-6”), 158.1 
(CONHAr), 182.6 (ArCO-pyrrole); 
19
F NMR (471 MHz, DMSO-d6) δ -116. 7 (ArF); 
LRMS (ES
+
) m/z 504.4 [M(
35
Cl
35
Cl)+H]
+
, 506.4 [M(
37
Cl
35
Cl)+H]
+
; HRMS (NSI) calcd for 
C24H25Cl2FN5O2 [M(
35
Cl
35
Cl)+H]
+
 504.1364, found 504.1347. 
 
  
426 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(2-((2-(piperidin-1-yl)ethyl)amino)pyrimidin-5-
yl)-1H-pyrrole-2-carboxamide, (484) 
 
Compound 484 was synthesised according to general procedure Y, using the following 
reagents: 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250) (150 mg, 
0.50 mmol), triethylamine (173 µL, 126 mg, 1.24 mmol), 2-chloro-1-methylpyridinium 
iodide (140 mg, 0.55 mmol), N
2
-(2-(piperidin-1-yl)ethyl)pyrimidine-2,5-diamine (524) 
(137 mg, 0.62 mmol) and DCM (5 mL). The crude yellow solid was purified by column 
chromatography (amine silica gel, DCM:MeOH, 1:0  97:3) to yield the title compound 
as an off-white solid (102 mg, 41%); Rf = 0.32 (amine silica, DCM:MeOH, 97:3); 
m.p. 144.5-146.5 °C; λmax (EtOH)/nm 283.0; IR (neat) νmax/cm
-1
 3315, 3123, 2933, 2855, 
2806, 1636, 1510, 1445, 1429, 1394; 
1
H NMR (500 MHz, DMSO-d6) δ 1.32 – 1.40 (2H, 
m, NCH2CH2CH2 piperidine), 1.48 (4H, p, J = 5.6 Hz, NCH2CH2CH2 piperidine), 2.36 (4H, brs, 
NCH2CH2CH2 piperidine), 2.42 (2H, t, J = 6.9 Hz, ArNHCH2CH2N), 3.36 (2H, td, J = 6.9, 
5.7 Hz, ArNHCH2CH2), 6.83 (1H, t, J = 5.7 Hz, ArNHCH2), 7.39 (1H, s, H-3), 7.51 (1H, 
dd, J = 8.8, 1.4 Hz, H-5’), 7.59 (1H, s, H-5), 7.78 (1H, dd, J = 8.8, 8.4 Hz, H-4’), 8.48 (2H, 
s, H-4”, 6”), 9.95 (1H, s, CONHAr), 12.71 (1H, s, NH-pyrrole); 13C NMR (126 MHz, 
DMSO-d6) δ 24.1 (NCH2CH2CH2 piperidine), 25.6 (NCH2CH2CH2 piperidine), 38.5 (ArNHCH2), 
54.1 (NCH2CH2CH2 piperidine), 57.6 (ArNHCH2CH2N), 110.9 (C-3), 119.3 (d, J = 18.1 Hz, 
C-3’), 123.3 (C-5”), 124.7 (C-2 or C-4), 126.9 (d, J = 3.8 Hz, C-5’), 128.5 (C-2 or C-4), 
129.2 (d, J = 5.2 Hz, C-6’), 129.3 (d, J = 23.2 Hz, C-1’), 129.8 (C-5), 131.8 (C-4’), 151.6 
(C-4”, 6”), 153.8 (d, J = 248.6 Hz, C-2’), 158.4 (CONHAr or C-2”), 159.4 (CONHAr or 
C-2”), 182.6 (ArCO); 19F NMR (471 MHz, DMSO-d6) δ -116.7 (ArF); LRMS (ES
+
) m/z 
505.4 [M(
35
Cl
35
Cl)+H]
+
, 507.4 [M(
35
Cl
37
Cl)+H]
+
; HRMS (NSI) calcd for C23H24Cl2FN6O2 
[M(
35
Cl
35
Cl)+H]
+
 505.1316, found 505.1302. 
 
  
427 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(6-((2-morpholinoethyl)amino)pyridin-3-yl)-1H-
pyrrole-2-carboxamide, (485) 
 
Compound 485 was synthesised according to general procedure Y, using the following 
reagents: 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250) (150 mg, 
0.50 mmol), triethylamine (173 µL, 126 mg, 1.24 mmol), 2-chloro-1-methylpyridinium 
iodide (140 mg, 0.55 mmol), N
2
-(2-morpholinoethyl)pyridine-2,5-diamine (525) (138 mg, 
0.62 mmol) and DCM (5 mL). The crude product was purified by column chromatography 
(amine silica gel, DCM:MeOH, 1:0  97:3) to yield the title compound as a grey solid 
(36 mg, 14%); Rf = 0.29 (amine silica, DCM:MeOH, 97:3); m.p. 118.0-120.0°C; 
λmax (EtOH)/nm 283.0; IR (neat) νmax/cm
-1
 2921, 2852, 1633, 1590, 1504, 1445; 
1
H NMR 
(500 MHz, DMSO-d6) δ 2.40 (4H, t, J = 4.6 Hz, NCH2 morpholine), 2.46 (2H, t, J = 6.7 Hz, 
ArNHCH2CH2N), 3.34 (2H, m, ArNHCH2CH2), 3.58 (4H, t, J = 4.6 Hz, OCH2 morpholine), 
6.26 (1H, t, J = 5.6 Hz, ArNHCH2), 6.50 (1H, d, J = 8.9 Hz, H-5”), 7.40 (1H, s, H-3), 7.51 
(1H, d, J = 8.8 Hz, H-5’), 7.55 (1H, s, H-5), 7.63 (1H, dd, J = 8.9, 2.7 Hz, H-4”), 7.77 (1H, 
dd, J = 8.8, 8.4 Hz, H-4’), 8.22 (1H, d, J = 2.7 Hz, H-2”), 9.82 (1H, s, CONHAr), 12.63 
(1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 38.1 (ArNHCH2), 53.4 
(NCH2 morpholine), 57.5 (ArNHCH2CH2N), 66.2 (OCH2 morpholine), 107.5 (C-5”), 110.5 (C-3), 
119.3 (d, J = 18.1 Hz, C-1’), 124.5 (C-2 or C-4), 124.7 (C-3”), 126.9 (d, J = 3.8 Hz, C-5’), 
128.9 (C-2 or C-4), 129.2 (d, J = 5.2 Hz, C-6’), 129.2 (d, J = 23.0 Hz, C-3’), 129.6 (C-5), 
131.2 (C-4”), 131.8 (C-4’), 140.5 (C-2”), 153.8 (d, J = 248.6 Hz, C-2’), 155.8 (C-6”), 
158.1 (CONHAr), 182.6 (ArCO-pyrrole); 
19
F NMR (471 MHz, DMSO-d6) δ -116.7 (ArF); 
LRMS (ES
+
) m/z 506.3 [M(
35
Cl
35
Cl)+H]
+
, 508.4 [M(
37
Cl
35
Cl)+H]
+
; HRMS (NSI) calcd for 
C23H23Cl2FN5O3 [M+H]
+
 506.1156, found 506.1146. 
 
  
428 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(2-((2-morpholinoethyl)amino)pyrimidin-5-yl)-
1H-pyrrole-2-carboxamide, (486) 
 
Compound 486 was synthesised according to general procedure Y, using the following 
reagents: 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250) (150 mg, 
0.50 mmol), triethylamine (173 µL, 126 mg, 1.24 mmol), 2-chloro-1-methylpyridinium 
iodide (140 mg, 0.55 mmol), N
2
-(2-morpholinoethyl)pyrimidine-2,5-diamine (526) 
(139 mg, 0.62 mmol) and DCM (5 mL). The crude yellow solid was purified by column 
chromatography (amine silica gel, DCM:MeOH, 1:0  97:3) to yield the title compound 
as an off-white solid (91 mg, 36%); Rf = 0.30 (amine silica, DCM:MeOH, 97:3); 
m.p. 140.5-142.5 °C; λmax (EtOH)/nm 282.0; IR (neat) νmax/cm
-1
 3122, 2955, 2815, 1635, 
1510, 1445, 1424, 1392; 
1
H NMR (500 MHz, DMSO-d6) δ 2.40 (4H, brs, NCH2 morpholine), 
2.46 (2H, t, J = 6.8 Hz, ArNHCH2CH2N), 3.38 (2H, td, J = 6.8, 5.8 Hz, ArNHCH2CH2), 
3.56 (4H, t, J = 4.6 Hz, OCH2 morpholine), 6.90 (1H, t, J = 5.8 Hz, ArNHCH2), 7.39 (1H, s, H-
3), 7.51 (1H, dd, J = 8.8, 1.4 Hz, H-5’), 7.59 (1H, s, H-5), 7.77 (1H, dd, J = 8.8, 8.4 Hz, 
H-4’), 8.49 (2H, s, H-4”, 6”), 9.95 (1H, s, CONHAr), 12.71 (1H, s, NH-pyrrole); 13C NMR 
(126 MHz, DMSO-d6) δ 38.1 (ArNHCH2), 53.4 (NCH2 morpholine), 57.3 (ArNHCH2CH2N), 
66.2 (OCH2 morpholine), 110.9 (C-3), 119.3 (d, J = 18.0 Hz, C-3’), 123.4 (C-5”), 124.7 (C-2 
or C-4), 126.9 (d, J = 4.0 Hz, C-5’), 128.4 (C-2 or C-4), 129.2 (d, J = 22.9 Hz, C-1’), 129.2 
(d, J = 5.1 Hz, C-6’), 129.8 (C-5), 131.8 (C-4’), 151.6 (C-4”, 6”), 153.8 (d, J = 248.4 Hz, 
C-2’), 158.4 (CONHAr or C-2”), 159.4 (CONHAr or C-2”), 182.6 (ArCO); 19F NMR 
(471 MHz, DMSO-d6) δ -116.7 (ArF); LRMS (ES
+
) m/z 507.4 [M(
35
Cl
35
Cl)+H]
+
, 509.4 
[M(
35
Cl
37
Cl)+H]
+
; HRMS (NSI) calcd for C22H22Cl2FN6O3 [M(
35
Cl
35
Cl)+H]
+
 507.1109, 
found 507.1099. 
 
  
429 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(6-((2-(methylsulfonyl)ethyl)amino)pyridin-3-yl)-
1H-pyrrole-2-carboxamide, (491) 
 
Compound 491 was synthesised according to general procedure Y, using the following 
reagents: 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250) (150 mg, 
0.50 mmol), triethylamine (173 µL, 126 mg, 1.24 mmol), 2-chloro-1-methylpyridinium 
iodide (140 mg, 0.55 mmol), N
2
-(2-(methylsulfonyl)ethyl)pyridine-2,5-diamine (527) 
(133 mg, 0.62 mmol) and DCM (5 mL). The crude product was purified by column 
chromatography (amine silica gel, DCM:MeOH, 1:0  97:3) to yield the title compound 
as an off-white solid (43 mg, 17%); Rf = 0.31 (amine silica, DCM:MeOH, 97:3); 
m.p. 182.0-184.0 °C; λmax (EtOH)/nm 270.4; IR (neat) νmax/cm
-1
 3282, 3122, 2922, 2852, 
1631, 1501, 1446, 1391, 1276, 1122; 
1
H NMR (500 MHz, DMSO-d6) δ 3.01 (3H, s, 
SO2CH3), 3.36 (2H, t, J = 6.5 Hz, CH2SO2CH3), 3.66 (2H, td, J = 6.5, 5.9 Hz, ArNHCH2), 
6.54 (1H, d, J = 8.9 Hz, H-5”), 6.69 (1H, t, J = 5.9 Hz, ArNHCH2), 7.41 (1H, s, H-3), 7.51 
(1H, dd, J = 8.6, 1.5 Hz, H-5’), 7.56 (1H, s, H-5), 7.68 (1H, dd, J = 8.9, 2.8 Hz, H-4”), 7.77 
(1H, dd, J = 8.6, 8.3 Hz, H-4’), 8.30 (1H, d, J = 2.8 Hz, H-2”), 9.87 (1H, s, CONHAr), 
12.65 (1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 35.0 (ArNHCH2), 41.1 
(SO2CH3), 53.2 (CH2SO2CH3), 108.2 (C-5”), 110.6 (C-3), 119.3 (d, J = 18.0 Hz, C-1’), 
124.7 (C-2 or C-4), 125.2 (C-3”), 126.9 (d, J = 3.8 Hz, C-5’), 128.9 (C-2 or C-4), 129.2 (d, 
J = 5.0 Hz, C-6’), 129.2 (d, J = 22.9 Hz, C-3’), 129.7 (C-5), 131.3 (C-4”), 131.8 (C-4’), 
140.3 (C-2”), 153.8 (d, J = 248.6 Hz, C-2’), 154.9 (C-6”), 158.2 (CONHAr), 182.6 
(ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -116.7 (ArF); LRMS (ES
-
) m/z 497.2 
[M(
35
Cl
35
Cl)-H]
-
, 499.2 [M(
37
Cl
35
Cl)-H]
-
; HRMS (NSI) calcd for C20H18Cl2FN4O4S 
[M(
35
Cl
35
Cl)+H]
+
 499.0404, found 499.0389. 
 
  
430 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(2-((2-(methylsulfonyl)ethyl)amino)pyrimidin-5-
yl)-1H-pyrrole-2-carboxamide, (492) 
 
Compound 492 was synthesised according to general procedure Y, using the following 
reagents: 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250) (100 mg, 
0.33 mmol), triethylamine (115 µL, 84 mg, 0.83 mmol), 2-chloro-1-methylpyridinium 
iodide (93 mg, 0.36 mmol), N
2
-(2-(methylsulfonyl)ethyl)pyrimidine-2,5-diamine (528) 
(89 mg, 0.41 mmol) and DCM (3.3 mL). The crude yellow solid was purified by column 
chromatography (amine silica gel, DCM:MeOH, 1:0  97:3) to yield the title compound 
as a white solid (74 mg, 45%); Rf = 0.31 (amine silica, DCM:MeOH, 97:3); m.p. 
258.5-260.5 °C; λmax (EtOH)/nm 281.4; IR (neat) νmax/cm
-1
 3382, 3345, 2896, 1658, 1591, 
1522, 1455, 1401;
1
H NMR (500 MHz, DMSO-d6) δ 3.02 (3H, s, SO2CH3), 3.37 (2H, t, 
J = 6.9 Hz, CH2SO2CH3), 3.69 (2H, td, J = 6.9, 5.9 Hz, ArNHCH2CH2), 7.27 (1H, t, 
J = 5.9 Hz, ArNHCH2), 7.40 (1H, s, H-3), 7.52 (1H, dd, J = 8.7, 1.2 Hz, H-5’), 7.60 (1H, s, 
H-5), 7.78 (1H, dd, J = 8.7, 8.4 Hz, H-4’), 8.56 (2H, s, H-4”, 6”), 10.01 (1H, s, CONHAr), 
12.73 (1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 35.1 (ArNHCH2), 41.0 
(SO2CH3), 52.9 (CH2SO2CH3), 111.0 (C-3), 119.3 (d, J = 18.1 Hz, C-3’), 124.2 (C-5”), 
124.7 (C-2 or C-4), 126.9 (d, J = 3.7 Hz, C-5’), 128.4 (C-2 or C-4), 129.2 (d, J = 23.0 Hz, 
C-1’), 129.2 (d, J = 5.2 Hz, C-6’), 129.9 (C-5), 131.8 (C-4’), 151.5 (C-4”, 6”), 153.8 (d, 
J = 248.6 Hz, C-2’), 158.4 (CONHAr or C-2”), 158.9 (CONHAr or C-2”), 182.6 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -116.7 (ArF); LRMS (ES
+
) m/z 500.3 [M(
35
Cl
35
Cl)+H]
+
, 
502.3 [M(
35
Cl
37
Cl)+H]
+
; HRMS (NSI) calcd for C19H17Cl2FN5O4S [M(
35
Cl
35
Cl)+H]
+
 
500.0357, found 500.0343. 
 
  
431 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(6-(2-(methylsulfonyl)ethoxy)pyridin-3-yl)-1H-
pyrrole-2-carboxamide, (493) 
 
Compound 493 was synthesised according to general procedure Y, using the following 
reagents: 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250) (150 mg, 
0.50 mmol), triethylamine (173 µL, 126 mg, 1.24 mmol), 2-chloro-1-methylpyridinium 
iodide (140 mg, 0.55 mmol), 6-(2-(methylsulfonyl)ethoxy)pyridin-3-amine (506) (134 mg, 
0.62 mmol) and DCM (5mL). The crude product was purified by column chromatography 
(silica gel, petrol:EtOAc, 1:0  35:65) to yield the title compound as an off-white solid 
(60 mg, 24%); Rf = 0.32; (silica, petrol:EtOAc, 35:65); m.p. 173.0-175.0 °C; 
λmax (EtOH)/nm 261.0; IR (neat) νmax/cm
-1
 3334, 3218, 3123, 1627, 1590, 1560, 1528, 
1485, 1446; 
1
H NMR (500 MHz, DMSO-d6) δ 3.06 (3H, s, SO2CH3), 3.62 (2H, t, 
J = 5.8 Hz, CH2SO2CH3), 4.61 (2H, t, J = 5.8 Hz, ArOCH2), 6.90 (1H, d, J = 8.9 Hz, 
H-5”), 7.47 (1H, s, H-3), 7.52 (1H, d, J = 8.7 Hz, H-5’), 7.61 (1H, s, H-5), 7.78 (1H, dd, 
J = 8.7, 8.3 Hz, H-4’), 8.03 (1H, dd, J = 8.9, 2.7 Hz, H-4”), 8.50 (1H, d, J = 2.7 Hz, H-2”), 
10.14 (1H, s, CONHAr), 12.74 (1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) 
δ 42.1 (SO2CH3), 53.2 (CH2SO2CH3), 59.4 (ArOCH2), 110.4 (C-5”), 111.1 (C-3), 119.3 (d, 
J = 18.2 Hz, C-1’), 124.7 (C-2 or C-4), 126.9 (d, J = 3.8 Hz, C-5’), 128.5 (C-2 or C-4), 
129.2 (d, J = 23.2 Hz, C-3’), 129.2 (d, J = 5.1 Hz, C-6’), 130.0 (C-5), 130.1 (C-3”), 131.8 
(C-4”), 132.5 (C-4’), 138.5 (C-2”), 153.8 (d, J = 248.4 Hz, C-2’), 158.4 (CONHAr or 
C-6”), 158.5 (CONHAr or C-6”), 182.6 (ArCO-pyrrole); 19F NMR (471 MHz, DMSO-d6) 
δ -116.7 (ArF); LRMS (ES+) m/z 500.3 [M(35Cl35Cl)+H]+, 502.3 [M(37Cl35Cl)+H]+; HRMS 
(NSI) calcd for C20H17Cl2FN3O5S [M+H]
+
 500.0245, found 500.0236. 
 
  
432 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(6-(2-methoxyethoxy)pyridin-3-yl)-1H-pyrrole-2-
carboxamide, (494) 
 
Compound 494 was synthesised according to general procedure Y, using the following 
reagents: 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250) (150 mg, 
0.50 mmol), triethylamine (173 µL, 126 mg, 1.24 mmol), 2-chloro-1-methylpyridinium 
iodide (140 mg, 0.55 mmol), 6-(2-methoxyethoxy)pyridin-3-amine (501) (104 mg, 
0.62 mmol) and DCM (5 mL). The crude yellow solid was purified by column 
chromatography (amine silica gel, DCM:MeOH, 1:0  97:3) to yield the title compound 
as an off-white solid (114 mg, 51%); Rf = 0.32 (petrol:EtOAc, 6:4); m.p. 215.0-217.0 °C; 
λmax (EtOH)/nm 261.0; IR (neat) νmax/cm
-1
 3316, 3173, 3124, 2981, 2926, 1665, 1643, 
1612, 1592, 1556, 1537, 1485, 1446, 1438; 
1
H NMR (500 MHz, DMSO-d6) δ 3.29 (3H, s, 
CH2OCH3), 3.60 – 3.68 (2H, m, CH2CH2OMe), 4.29 – 4.38 (2H, m, ArOCH2CH2), 6.85 
(1H, d, J = 8.9 Hz, H-5”), 7.46 (1H, s, H-3), 7.49 – 7.56 (1H, m, H-5’), 7.60 (1H, s, H-5), 
7.78 (1H, dd, J = 8.4, 8.4 Hz, H-4’), 7.99 (1H, dd, J = 8.9, 2.7 Hz, H-4”), 8.45 (1H, d, 
J = 2.7 Hz, H-2”), 10.10 (1H, s, CONHAr), 12.73 (1H, s, NH-pyrrole); 13C NMR 
(126 MHz, DMSO-d6) δ 58.1 (CH2OCH3), 64.6 (ArOCH2), 70.3 (CH2OMe), 110.3 (C-5”), 
111.0 (C-3), 119.3 (d, J = 17.9 Hz, C-1’), 124.7 (C-2 or C-4), 126.9 (d, J = 3.9 Hz, C-5’), 
128.6 (C-2 or C-4), 129.2 (d, J = 22.9 Hz, C-3’), 129.2 (d, J = 5.2 Hz, C-6’), 129.6 (C-3”), 
129.9 (C-5), 131.8 (C-4’), 132.4 (C-4”), 138.5 (C-2”), 153.8 (d, J = 248.6 Hz, C-2’), 158.4 
(C-6”), 159.4 (CONHAr), 182.6 (ArCO); 19F NMR (471 MHz, DMSO-d6) δ -116.7 (ArF); 
LRMS (ES
+
) m/z 452.3 [M(
35
Cl
35
Cl)+H]
+
, 454.3 [M(
35
Cl
37
Cl)+H]
+
; HRMS (NSI) calcd for 
C20H17Cl2FN3O4 [M(
35
Cl
35
Cl)+H]
+
 452.0575, found 452.0574. 
 
  
433 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(6-(2-hydroxyethoxy)pyridin-3-yl)-1H-pyrrole-2-
carboxamide, (495) 
 
Compound 495 was synthesised according to general procedure Y, using the following 
reagents: 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250) (150 mg, 
0.50 mmol), triethylamine (173 µL, 126 mg, 1.24 mmol), 2-chloro-1-methylpyridinium 
iodide (140 mg, 0.55 mmol), 2-((5-aminopyridin-2-yl)oxy)ethanol (502) (96 mg, 
0.62 mmol) and DCM (5 mL). The crude yellow solid was purified by column 
chromatography (amine silica gel, DCM:MeOH, 1:0  97:3) to yield the title compound 
as a pale orange solid (43 mg, 20%); Rf = 0.34 (petrol:EtOAc, 2:8); m.p. 127.0-129.0 °C; 
λmax (EtOH)/nm 261.8; IR (neat) νmax/cm
-1
 3239, 3123, 2925, 1632, 1591, 1557, 1529, 
1486, 1446, 1392; 
1
H NMR (500 MHz, DMSO-d6) δ 3.70 (2H, dt, J = 5.4, 5.0 Hz, 
CH2CH2OH), 4.24 (2H, t, J = 5.0 Hz, ArOCH2CH2), 4.81 (1H, t, J = 5.4 Hz, CH2OH), 6.83 
(1H, d, J = 8.8 Hz, H-5”), 7.45 (1H, s, H-3), 7.52 (1H, d, J = 8.7 Hz, H-5’), 7.60 (1H, s, 
H-5), 7.78 (1H, dd, J = 8.7, 8.3 Hz, H-4’), 7.99 (1H, dd, J = 8.8, 2.3 Hz, H-4”), 8.44 (1H, 
d, J = 2.3 Hz, H-2”), 10.09 (1H, s, CONHAr), 12.73 (1H, s, NH-pyrrole); 13C NMR 
(126 MHz, DMSO-d6) δ 59.4 (CH2OH), 67.3 (ArOCH2), 110.3 (C-5”), 111.0 (C-3’), 119.3 
(d, J = 18.1 Hz, C-1’), 124.7 (C-2 or C-4), 126.9 (d, J = 3.5 Hz, C-5’), 128.6 (C-2 or C-4), 
129.2 (d, J = 23.0 Hz, C-3’), 129.2 (d, J = 5.2 Hz, C-6’), 129.4 (C-3”), 129.9 (C-5), 131.8 
(C-4’), 132.4 (C-4”), 138.6 (C-2”), 153.8 (d, J = 248.3 Hz, C-2’), 158.4 (C-6”), 159.6 
(CONHAr), 182.6 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -116.7 (ArF); LRMS (ES
+
) 
m/z 438.3 [M(
35
Cl
35
Cl)+H]
+
, 440.3 [M(
35
Cl
37
Cl)+H]
+
; HRMS (NSI) calcd for 
C19H15Cl2FN3O4 [M(
35
Cl
35
Cl)+H]
+
 438.0418, found 438.0418. 
 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(6-(oxetan-3-yloxy)pyridin-3-yl)-1H-pyrrole-2-
carboxamide, (496) 
 
Compound 496 was synthesised according to general procedure Y, using the following 
reagents: 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250) (150 mg, 
434 
0.50 mmol), triethylamine (173 µL, 126 mg, 1.24 mmol), 2-chloro-1-methylpyridinium 
iodide (140 mg, 0.55 mmol), 6-(oxetan-3-yloxy)pyridin-3-amine (503) (103 mg, 
0.62 mmol) and DCM (5 mL). The crude yellow solid was purified by column 
chromatography (amine silica gel, DCM:MeOH, 1:0  97:3) to yield the title compound 
as an off-white solid (63 mg, 28%); Rf = 0.29 (petrol:EtOAc, 6:4); m.p. 248.5-250.5 °C; 
λmax (EtOH)/nm 260.6; IR (neat) νmax/cm
-1
 3344, 3207, 3125, 3061, 2952, 2875, 1625, 
1589, 1560, 1527, 1486, 1446, 1277, 1230; 
1
H NMR (500 MHz, DMSO-d6) δ 4.55 (2H, 
dd, J = 7.4, 5.1 Hz, CHCH2O), 4.89 (2H, t, J = 6.8 Hz, CHCH2O), 5.53 (1H, p, J = 5.8 Hz, 
ArOCH), 6.92 (1H, d, J = 8.9 Hz, H-5”), 7.46 (1H, s, H-3), 7.49 – 7.54 (1H, m, H-5’), 7.60 
(1H, s, H-5), 7.78 (1H, dd, J = 8.4, 8.4 Hz, H-4’), 8.02 (1H, dd, J = 8.9, 2.6 Hz, H-4”), 8.43 
(1H, d, J = 2.6 Hz, H-2”), 10.12 (1H, s, CONHAr), 12.74 (1H, s, NH-pyrrole); 13C NMR 
(126 MHz, DMSO-d6) δ 68.8 (ArOCH), 77.0 (CHCH2O), 110.3 (C-5”), 111.1 (C-3), 119.3 
(d, J = 17.9 Hz, C-1’), 124.7 (C-2 or C-4), 126.9 (d, J = 3.8 Hz, C-5’), 128.5 (C-2 or C-4), 
129.2 (d, J = 22.9 Hz, C-3’), 129.2 (d, J = 5.1 Hz, C-6’), 130.0 (C-5), 130.2 (C-3”), 131.8 
(C-4’), 132.6 (C-4”), 138.5 (C-2”), 153.8 (d, J = 248.5 Hz, C-2’), 158.0 (C-6”), 158.4 
(CONHAr), 182.6 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -116.7 (ArF); LRMS (ES
+
) 
m/z 450.3 [M(
35
Cl
35
Cl)+H]
+
, 452.3 [M(
35
Cl
37
Cl)+H]
+
; HRMS (NSI) calcd for 
C20H15Cl2FN3O4 [M(
35
Cl
35
Cl)+H]
+
 450.0418, found 450.0418. 
 
2-(2-Methoxyethoxy)-5-nitropyridine, (498) 
 
To a suspension of sodium hydride (60% dispersion in mineral oil, 189 mg, 4.73 mmol) in 
THF (16 mL), cooled in an ice bath, was added 2-methoxyethanol (373 μL, 360 mg, 
4.73 mmol). The resulting solution was stirred at 0 °C for 10 min and allowed to warm to 
RT. After 1 h, the reaction mixture was cooled in an ice bath and 2-chloro-5-nitropyridine 
(459) (500 mg, 3.15 mmol) added in portions. The resulting mixture was then stirred 
overnight at RT. Upon completion, the mixture was diluted with EtOAc (20 mL), 
quenched by the cautious addition of saturated aq. NaHCO3 (20 mL) and extracted with 
EtOAc (3 × 20 mL). The pooled organic extracts were washed with water and brine 
(40 mL, respectively), dried over MgSO4 and concentrated in vacuo. The crude product 
was purified by column chromatography (silica gel, petrol:EtOAc, 1:0  9:1) to yield the 
title compound as a white solid (430 mg, 69%); Rf = 0.29 (petrol:EtOAc, 9:1); m.p. 
65.5-67.5 °C; λmax (EtOH)/nm 294.4; IR (neat) νmax/cm
-1
 3078, 3057, 2989, 2937, 2901, 
2849, 2816, 1598, 1575, 1503, 1477, 1345, 1310, 1295, 1273; 
1
H NMR (500 MHz, 
435 
DMSO-d6) δ 3.29 (3H, s, CH2OCH3), 3.65 – 3.71 (2H, m, CH2CH2OMe), 4.48 – 4.55 (2H, 
m, ArOCH2CH2), 7.06 (1H, d, J = 9.1 Hz, H-3), 8.47 (1H, dd, J = 9.1, 2.9 Hz, H-4), 9.07 
(1H, d, J = 2.9 Hz, H-6); 
13
C NMR (126 MHz, DMSO-d6) δ 58.1 (ArOCH2), 66.4 
(CH2OCH3), 69.8 (CH2OMe), 111.4 (C-3), 134.7 (C-4), 139.5 (C-5), 144.5 (C-6), 166.5 
(C-2); LRMS (ES
+
) m/z 199.2 [M+H]
+
; HRMS (NSI) calcd for C8H11N2O4 [M+H]
+
 
199.0713, found 199.0714. 
 
2-((5-Nitropyridin-2-yl)oxy)ethanol, (499) 
 
To a suspension of sodium hydride (60% dispersion in mineral oil, 189 mg, 4.73 mmol) in 
THF (16 mL), cooled in an ice bath, was added ethylene glycol (264 μL, 294 mg, 
4.73 mmol). The resulting solution was stirred at 0 °C for 10 min and allowed to warm to 
RT. After 1 h, the reaction mixture was cooled in an ice bath and 2-chloro-5-nitropyridine 
(459) (500 mg, 3.15 mmol) added in portions. The resulting mixture was then stirred 
overnight at RT. Upon completion, the mixture was diluted with EtOAc (20 mL), 
quenched by the cautious addition of saturated aq. NaHCO3 (20 mL) and extracted with 
EtOAc (3 × 20 mL). The pooled organic extracts were washed with water and brine 
(40 mL, respectively), dried over MgSO4 and concentrated in vacuo. The crude product 
was purified by column chromatography (silica gel, petrol:EtOAc, 1:0  6:4) to yield the 
title compound as a pale yellow solid (240 mg, 41%); Rf = 0.32 (petrol:EtOAc, 6:4); 
m.p. 113.0-115.0 °C; λmax (EtOH)/nm 294.2; IR (neat) νmax/cm
-1
 3231, 3078, 2947, 2878, 
1602, 1575, 15313, 1477, 1341, 1308, 1276; 
1
H NMR (500 MHz, DMSO-d6) δ 3.74 (2H, 
td, J = 5.5, 5.1 Hz, CH2CH2OH), 4.41 (2H, t, J = 5.1 Hz, ArOCH2CH2), 4.92 (1H, t, 
J = 5.5 Hz, CH2OH), 7.03 (1H, d, J = 9.1 Hz, H-3), 8.47 (1H, dd, J = 9.1, 2.9 Hz, H-4), 
9.07 (1H, d, J = 2.9 Hz, H-6); 
13
C NMR (126 MHz, DMSO-d6) δ 59.0 (CH2OH), 69.1 
(ArOCH2), 111.4 (C-3), 134.6 (C-4), 139.3 (C-5), 144.6 (C-6), 166.8 (C-2); LRMS (ES
+
) 
m/z 185.2 [M+H]
+
; HRMS (NSI) calcd for C7H9N2O4 [M+H]
+
 185.0557, found 185.0556. 
 
5-Nitro-2-(oxetan-3-yloxy)pyridine, (500) 
 
To a suspension of sodium hydride (60% dispersion in mineral oil, 189 mg, 4.73 mmol) in 
THF (16 mL), cooled in an ice bath, was added 3-hydroxyoxetane (300 μL, 350 mg, 
4.73 mmol). The resulting solution was stirred at 0 °C for 10 min and allowed to warm to 
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RT. After 1 h, the reaction mixture was cooled in an ice bath and 2-chloro-5-nitropyridine 
(459) (500 mg, 3.15 mmol) added in portions. The resulting mixture was then stirred 
overnight at RT. Upon completion, the mixture was diluted with EtOAc (20 mL), 
quenched by the cautious addition of saturated aq. NaHCO3 (20 mL) and extracted with 
EtOAc (3 × 20 mL). The pooled organic extracts were washed with water and brine 
(40 mL, respectively), dried over MgSO4 and concentrated in vacuo. The crude product 
was purified by column chromatography (silica gel, petrol:EtOAc, 1:0  85:15) to yield 
the title compound as a white solid (530 mg, 86%); Rf = 0.30 (petrol:EtOAc, 85:15); 
m.p. 108.0-110.0 °C; λmax (EtOH)/nm 290.2; IR (neat) νmax/cm
-1
 3091, 3007, 2974, 2951, 
2933, 2886, 1599, 1573, 1515, 1467, 1397, 1342, 1301, 1265; 
1
H NMR (500 MHz, 
DMSO-d6) δ 4.60 (2H, ddd, J = 7.6, 4.9 and 1.0 Hz, CHCH2O), 4.92 (2H, ddd, J = 7.2, 6.2 
and 1.0 Hz, CHCH2O), 5.69 (1H, tt, J = 6.2, 4.9 Hz, ArOCH), 7.14 (1H, d, J = 9.1 Hz, 
H-3), 8.53 (1H, dd, J = 9.1, 2.9 Hz, H-4), 9.03 (1H, d, J = 2.9 Hz, H-6); 
13
C NMR 
(126 MHz, DMSO-d6) δ 70.5 (ArOCH), 76.5 (CHCH2O), 111.5 (C-3), 135.1 (C-4), 140.0 
(C-5), 144.5 (C-6), 165.1 (C-2); LRMS (ES
+
) m/z 197.2 [M+H]
+
; HRMS (NSI) calcd for 
C8H9N2O4 [M+H]
+
 197.0557, found 197.0555. 
 
6-(2-Methoxyethoxy)pyridin-3-amine, (501) 
 
Compound 501 was synthesised according to general procedure D’, using the following 
reagents: 2-(2-methoxyethoxy)-5-nitropyridine (498) (400 mg, 2.02 mmol), THF (20 mL) 
and methanol (20 mL). The crude brown oil (325 mg, 96%) was used in the next step 
without further purification; Rf = 0.28 (petrol:EtOAc, 1:1); λmax (EtOH)/nm 235.8, 312.4; 
IR (neat) νmax/cm
-1
 3416, 3340, 3222, 2930, 2886, 2818, 1628, 1577, 1486, 1416, 1269, 
1246; 
1
H NMR (500 MHz, DMSO-d6) δ 3.27 (3H, s, CH2OCH3), 3.56 – 3.61 (2H, m, 
CH2CH2OMe), 4.16 – 4.23 (2H, m, ArOCH2CH2), 4.74 (2H, brs, ArNH2), 6.54 (1H, d, 
J = 8.7 Hz, H-3), 7.00 (1H, dd, J = 8.7, 2.9 Hz, H-4), 7.48 (1H, d, J = 2.9 Hz, H-6); 
13
C NMR (126 MHz, DMSO-d6) δ 58.0 (CH2OCH3), 64.0 (ArOCH2), 70.5 (CH2OMe), 
110.2 (C-3), 126.3 (C-4), 130.9 (C-6), 139.4 (C-5), 155.1 (C-2); LRMS (ES
+
) m/z 169.2 
[M+H]
+
; HRMS (NSI) calcd for C8H13N2O2 [M+H]
+
 169.0972, found 169.0968. 
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2-((5-Aminopyridin-2-yl)oxy)ethanol, (502) 
 
Compound 502 was synthesised according to general procedure D’, using the following 
reagents: 2-((5-nitropyridin-2-yl)oxy)ethanol (499) (200 mg, 1.09 mmol), THF (10.9 mL) 
and methanol (10.9 mL). The crude off-white solid (159 mg, 95%) was used in the next 
step without further purification; Rf = 0.35 (EtOAc, 100%); m.p. 60.5-62.5 °C; 
λmax (EtOH)/nm 236.0, 312.8; IR (neat) νmax/cm
-1
 3428, 3310, 3202, 2920, 2869, 1624, 
1573, 1491, 1458, 1419, 1386, 1274, 1238; 
1
H NMR (500 MHz, DMSO-d6) δ 3.64 (2H, s, 
CH2CH2OH), 4.10 (2H, t, J = 5.3 Hz, ArOCH2CH2), 4.74 (3H, brs, ArNH2 and CH2OH), 
6.53 (1H, d, J = 8.7 Hz, H-3), 7.00 (1H, dd, J = 8.7, 2.9 Hz, H-4), 7.48 (1H, d, J = 2.9 Hz, 
H-6); 
13
C NMR (126 MHz, DMSO-d6) δ 59.7 (CH2OH), 66.8 (ArOCH2), 110.2 (C-3), 
126.3 (C-4), 131.0 (C-6), 139.3 (C-5), 155.4 (C-2); LRMS (ES
+
) m/z 155.1 [M+H]
+
; 
HRMS (NSI) calcd for C7H11N2O2 [M+H]
+
 155.0815, found 155.0812. 
 
6-(Oxetan-3-yloxy)pyridin-3-amine, (503) 
 
Compound 503 was synthesised according to general procedure D’, using the following 
reagents: 5-nitro-2-(oxetan-3-yloxy)pyridine (500) (500 mg, 2.55 mmol), THF (26 mL) 
and methanol (26 mL). The crude yellow solid (394 mg, 93%) was used in the next step 
without further purification; Rf = 0.28 (petrol:EtOAc, 1:1); m.p. 84.0-86.0 °C; 
λmax (EtOH)/nm 236.4, 312.0; IR (neat) νmax/cm
-1
 3366. 3314, 2947, 2878, 1646, 1610, 
1577, 1482, 1423, 1249; 
1
H NMR (500 MHz, DMSO-d6) δ 4.43 – 4.54 (2H, m, CHCH2O), 
4.80 (2H, brs, ArNH2), 4.82 (2H, t, J = 6.9 Hz, CHCH2O), 5.38 (1H, p, J = 5.7 Hz, 
ArOCH), 6.60 (1H, d, J = 8.7 Hz, H-3), 7.02 (1H, dd, J = 8.7, 2.9 Hz, H-4), 7.42 (1H, d, 
J = 2.9 Hz, H-6); 
13
C NMR (126 MHz, DMSO-d6) δ 68.2 (ArOCH), 77.3 (CHCH2O), 
110.2 (C-3), 126.4 (C-4), 131.0 (C-6), 140.0 (C-5), 153.7 (C-2); LRMS (ES
+
) m/z 167.2 
[M+H]
+
; HRMS (NSI) calcd for C8H11N2O2 [M+H]
+
 167.0815, found 167.0812. 
 
2-(2-(Methylthio)ethoxy)-5-nitropyridine, (504) 
 
To a suspension of sodium hydride (60% dispersion in mineral oil, 136 mg, 5.68 mmol) in 
THF (20 mL), cooled in an ice bath, was added 2-(methylthio)ethanol (523 mg, 493 µL, 
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5.68 mmol). The resulting solution was stirred at 0 °C for 10 min and allowed to warm to 
room temperature. After 1 h, the reaction mixture was cooled in an ice bath and 2-chloro-
5-nitropyridine (459) (600 mg, 3.78 mmol) added in portions. The resulting mixture was 
then stirred overnight at room temperature. Upon completion, the mixture was diluted with 
EtOAc (20 mL), quenched by the cautious addition of sat. aq. NaHCO3 (20 mL) and 
extracted with EtOAc (3 × 20 mL). The pooled organic extracts were washed with water 
and brine (40 mL, respectively), dried over MgSO4 and concentrated in vacuo. The crude 
product was purified by column chromatography (silica gel, petrol:EtOAc, 1:0  95:5) to 
yield the title compound as an off-white solid (715 mg, 88%); Rf = 0.45 (petrol:EtOAc, 
9:1); m.p. 43.0-45.0 °C; λmax (EtOH)/nm 292.2; IR (neat) νmax/cm
-1
 2976, 2916, 1604, 
1576, 1506, 1482, 1451, 1400; 
1
H NMR (500 MHz, DMSO-d6) δ 2.14 (3H, s, CH2SCH3), 
2.88 (2H, t, J = 6.7 Hz, CH2SCH3), 4.56 (2H, t, J = 6.7 Hz, ArOCH2), 7.04 (1H, d, 
J = 9.2 Hz, H-3), 8.48 (1H, dd, J = 9.2, 2.9 Hz, H-4), 9.08 (1H, d, J = 2.9 Hz, H-6); 
13
C NMR (126 MHz, DMSO-d6) δ 15.1 (CH2SCH3), 31.7 (CH2SCH3), 66.1 (ArOCH2), 
111.4 (C-3), 134.8 (C-4), 139.5 (C-5), 144.6 (C-6), 166.3 (C-2); HRMS (NSI) calcd for 
C8H11N2O3S [M+H]
+
: 215.0485; found 215.0486. 
 
2-(2-(Methylsulfonyl)ethoxy)-5-nitropyridine, (505) 
 
To 2-(2-(methylthio)ethoxy)-5-nitropyridine (504) (138 mg, 0.64 mmol) in MeOH (5 mL) 
was added a solution of OXONE
® (monopersulfate compound) (396 mg, 1.29 mmol) in 
water (5 mL). The resulting cloudy solution was stirred at room temperature for 24 h. The 
reaction mixture was filtered through Celite and concentrated in vacuo. The white residue 
was dissolved in sat. aq. NH4Cl (20 mL) and extracted with EtOAc (3 × 20 mL). The 
pooled organic extracts were washed with water and brine (30 mL, respectively), dried 
over MgSO4 and concentrated in vacuo. The crude product was purified by column 
chromatography (silica gel, DCM:MeOH, 1:0  97:3) to yield the title compound as a 
grey solid (91 mg, 57%); Rf = 0.75 (DCM:MeOH, 95:5); m.p. 99.5-101.5 °C; 
λmax (EtOH)/nm 287.6; IR (neat) νmax/cm
-1
 3030, 2989, 2937, 1602, 1576, 1509, 1483, 
1457, 1421; 
1
H NMR (500 MHz, DMSO-d6) δ 3.07 (3H, s, CH2SO2CH3), 3.69 (2H, t, 
J = 5.8 Hz, CH2SO2CH3), 4.77 (2H, t, J = 5.8 Hz, ArOCH2), 7.11 (1H, d, J = 9.1 Hz, H-3), 
8.52 (1H, dd, J = 9.1, 2.9 Hz, H-4), 9.11 (1H, d, J = 2.9 Hz, H-6); 
13
C NMR (126 MHz, 
DMSO-d6) δ 42.0 (CH2SO2CH3), 52.8 (CH2SO2CH3), 61.0 (ArOCH2), 111.5 (C-3), 135.0 
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(C-4), 139.9 (C-5), 144.5 (C-6), 165.6 (C-2); LRMS (ES
+
) m/z 247.2 [M+H]
+
; HRMS 
(NSI) calcd for C8H11N2O5S [M+H]
+
 247.0383, found 247.0384. 
 
6-(2-(Methylsulfonyl)ethoxy)pyridin-3-amine, (506) 
 
Compound 506 was synthesised according to general procedure 3, using the following 
reagents: 2-(2-(methylsulfonyl)ethoxy)-5-nitropyridine (505) (379 mg, 1.54 mmol), 10% 
Pd/C (38 mg) and MeOH (15 mL). The brown solid (342 mg, 95%) was used in the next 
step without further purification; Rf = 0.66 (amine silica, EtOAc 100%); m.p. 
102.0-104.0 °C; λmax (EtOH)/nm 312.4, 235.6; IR (neat) νmax/cm
-1
 3413, 3347, 3243, 3016, 
2958, 2915, 1907, 1640, 1609, 1580, 1487, 1422; 
1
H NMR (500 MHz, DMSO-d6) δ 3.03 
(3H, s, CH2SO2CH3), 3.54 (2H, t, J = 5.9 Hz, CH2SO2CH3), 4.46 (2H, t, J = 5.9 Hz, 
ArOCH2), 4.82 (2H, brs, ArNH2), 6.59 (1H, d, J = 8.7 Hz, H-3), 7.03 (1H, dd, J = 8.7, 
3.0 Hz, H-4), 7.51 (1H, d, J = 3.0 Hz, H-6); 
13
C NMR (126 MHz, DMSO-d6) δ 42.1 
(CH2SO2CH3), 53.4 (CH2SO2CH3), 59.0 (ArOCH2), 110.3 (C-3), 126.3 (C-4), 130.9 (C-6), 
140.1 (C-5), 154.2 (C-2); LRMS (ES
+
) m/z 217.2 [M+H]
+
; HRMS (NSI) calcd for 
C8H13N2O3S [M+H]
+
 217.0641; found 217.0641. 
 
N
1
, N
1
-Dimethyl-N
2
-(5-nitropyrimidin-2-yl)ethane-1,2-diamine, (507) 
 
Compound 507 was synthesised according to general procedure C’, using the following 
reagents: 2-chloro-5-nitropyrimidine (414) (250 mg, 1.57 mmol), triethylamine (240 µL, 
174 mg, 1.72 mmol), N,N-dimethylethylenediamine (189 µL, 152 mg, 1.72 mmol) and 
THF (7.9 mL). The crude product was purified by column chromatography (amine silica 
gel, petrol:EtOAc, 1:0  1:1) to yield the title compound as a pale yellow solid (245 mg, 
74%); Rf = 0.29 (amine silica, petrol:EtOAc, 1:1); m.p. 144.5-146.5 °C; λmax (EtOH)/nm 
332.8; IR (neat) νmax/cm
-1
 3253, 2971, 2941, 2859, 2827, 2772, 1573, 1550, 1496, 1473, 
1459, 1443, 1319, 1289, 1274, 1255; 
1
H NMR (500 MHz, DMSO-d6) δ 2.16 (6H, s, 
CH2N(CH3)2), 2.42 (2H, t, J = 6.7 Hz, CH2CH2NMe2), 3.48 (2H, td, J = 6.7, 5.8 Hz, 
ArNHCH2CH2), 8.68 (1H, t, J = 5.8 Hz, ArNHCH2), 9.01 (1H, d, J = 3.4 Hz, H-4 or H-6), 
9.09 (1H, d, J = 3.4 Hz, H-4 or H-6); 
13
C NMR (126 MHz, DMSO-d6) δ ca. 40 
(overlapping with DMSO) (ArNHCH2) 45.2 (CH2N(CH3)2), 57.6 (CH2N(CH3)2), 133.6 
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(C-5), 155.2 (C-4 or C-6), 155.4 (C-4 or C-6), 162.7 (C-2); LRMS (ES
+
) m/z 212.2 
[M+H]
+
; HRMS (NSI) calcd for C8H14N5O2 [M+H]
+
 212.1142, found 212.1143. 
 
N,N-Diethyl-N’-(5-nitropyridin-2-yl)ethane-1,2-diamine, (508) 
 
Compound 508 was synthesised according to general procedure G’, using the following 
reagents: 2-chloro-5-nitropyridine (459) (400 mg, 2.52 mmol), triethylamine (387 µL, 
281 mg, 2.78 mmol), N,N-diethylethylenediamine (390 µL, 323 mg, 2.78 mmol) and THF 
(10 mL). The crude product was purified by column chromatography (amine silica gel, 
petrol:EtOAc, 1:0  3:1) to yield the title compound as a yellow oil (356 mg, 59%); 
Rf = 0.14 (amine silica, petrol:EtOAc, 8:2); λmax (EtOH)/nm 360.4; IR (neat) νmax/cm
-1
 
3367, 2967, 2812, 1599, 1576, 1526, 1497, 1468; 
1
H NMR (500 MHz, DMSO-d6) δ 0.95 
(6H, t, J = 7.1 Hz, CH2N(CH2CH3)2), 2.50 (4H, q, J = 7.1 Hz, CH2N(CH2CH3)2), 2.57 (2H, 
t, J = 6.8 Hz, CH2NEt2), 3.46 (2H, brs, ArNHCH2), 6.58 (1H, d, J = 9.4 Hz, H-3), 
7.95 - 8.14 (2H, m, H-4 and ArNHCH2), 8.90 (1H, d, J = 2.9 Hz, H-6); 
13
C NMR 
(126 MHz, DMSO-d6) δ 11.8 (CH2N(CH2CH3)2), 38.8 (ArNHCH2), 46.6 
(CH2N(CH2CH3)2), 51.2 (CH2NEt2), 108.6 (C-3), 131.5 (C-4), 134.1 (C-5), 146.9 (C-6), 
161.4 (C-2); LRMS (ES
-
) m/z 237.2 [M-H]
-
; HRMS (NSI) calcd for C11H19N4O2 [M+H]
+
 
239.1503, found 239.1498. 
 
N
1
, N
1
-Diethyl-N
2
-(5-nitropyrimidin-2-yl)ethane-1,2-diamine, (509) 
 
Compound 509 was synthesised according to general procedure C’, using the following 
reagents: 2-chloro-5-nitropyrimidine (414) (250 mg, 1.57 mmol), triethylamine (240 µL, 
174 mg, 1.72 mmol), N,N-diethylethylenediamine (242 µL, 200 mg, 1.72 mmol) and THF 
(7.9 mL). The crude product was purified by column chromatography (amine silica gel, 
petrol:EtOAc, 1:0  8:2) to yield the title compound as a yellow solid (350 mg, 93%); 
Rf = 0.29 (amine silica, petrol:EtOAc, 8:2); m.p. 70.0-72.0 °C; λmax (EtOH)/nm 334.6; 
IR (neat) νmax/cm
-1
 3364, 2965, 2934, 2900, 2875, 2805, 1599, 1556, 1471, 1337, 1285; 
1
H NMR (500 MHz, DMSO-d6) δ 0.95 (6H, t, J = 7.1 Hz, N(CH2CH3)2), 2.50 (4H, q, 
J = 7.1 Hz, N(CH2CH3)2), 2.58 (2H, t, J = 7.0 Hz, CH2NEt2), 3.46 (2H, td, J = 7.0, 5.9 Hz, 
ArNHCH2CH2), 8.64 (1H, t, J = 5.9 Hz, ArNHCH2), 9.02 (1H, d, J = 3.4 Hz, H-4 or H-6), 
9.10 (1H, d, J = 3.4 Hz, H-4 or H-6); 
13
C NMR (126 MHz, DMSO-d6) δ 11.9 
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(N(CH2CH3)2), ca. 40 (overlapping with DMSO) (ArNHCH2), 46.6 (N(CH2CH3)2), 51.0 
(CH2NEt2), 133.5 (C-5), 155.1 (C-4 or C-6), 155.4 (C-4 or C-6), 162.8 (C-2); LRMS (ES
+
) 
m/z 240.3 [M+H]
+
; HRMS (NSI) calcd for C10H18N5O2 [M+H]
+
 240.1455, found 
240.1455. 
 
5-Nitro-N-(2-(pyrrolidin-1-yl)ethyl)pyridin-2-amine, (510) 
 
Compound 510 was synthesised according to general procedure G’, using the following 
reagents: 2-chloro-5-nitropyridine (459) (400 mg, 2.52 mmol), triethylamine (387 µL, 
281 mg, 2.78 mmol), 1-(2-aminoethyl)pyrrolidine (286 µL, 317mg, 2.78 mmol) and THF 
(10 mL). The crude product was purified by column chromatography (amine silica gel, 
petrol:EtOAc, 1:0  3:7) to yield the title compound as a yellow solid (377 mg, 63%); 
Rf = 0.32 (amine silica, petrol:EtOAc, 3:7); m.p. 78.5-80.5 °C; λmax (EtOH)/nm 359.4; 
IR (neat) νmax/cm
-1
 3236, 3178, 2925, 2809, 1606, 1547, 1476, 1405; 
1
H NMR (500 MHz, 
DMSO-d6) δ 1.63 – 1.72 (4H, m, J = 3.7 Hz, NCH2CH2 pyrrolidine), 2.43 – 2.49 (4H, m, 
NCH2CH2 pyrrolidine), 2.59 (2H, t, J = 6.6 Hz, ArNHCH2CH2N), 3.51 (2H, brs, ArNHCH2), 
6.60 (1H, d, J = 9.4 Hz, H-3), 7.83 – 8.32 (2H, m, H-4 & ArNH), 8.90 (1H, d, J = 2.4 Hz, 
H-6); 
13
C NMR (126 MHz, DMSO-d6) δ 23.1 (NCH2CH2 pyrrolidine), 40.5 (ArNHCH2), 53.6 
(NCH2CH2 pyrrolidine), 54.5 (ArNHCH2CH2N), 108.6 (C-3), 131.6 (C-4), 134.1 (C-5), 146.9 
(C-6), 161.3 (C-2); LRMS (ES
+
) m/z 257.2 [M+H]
+
; HRMS (NSI) calcd for C11H17N4O2 
[M+H]
+
 237.1346, found 237.1339. 
 
5-Nitro-N-(2-(pyrrolidin-1-yl)ethyl)pyrimidin-2-amine, (511) 
 
Compound 511 was synthesised according to general procedure C’, using the following 
reagents: 2-chloro-5-nitropyrimidine (414) (350 mg, 2.19 mmol), triethylamine (336 µL, 
244 mg, 2.41 mmol), 1-(2-aminoethyl)pyrrolidine (306 µL, 276 mg, 2.41 mmol) and THF 
(11 mL). The crude product was purified by column chromatography (amine silica gel, 
petrol:EtOAc, 1:0  3:1) to yield the title compound as a pale yellow solid (454 mg, 
87%); Rf = 0.26 (amine silica, petrol:EtOAc, 3:1); m.p. 138.5-140.5 °C; λmax (EtOH)/nm 
331.8; IR (neat) νmax/cm
-1
 3255, 2950, 2806, 1574, 1550, 1497, 1464, 1322; 
1
H NMR 
(500 MHz, DMSO-d6) δ 1.63 – 1.69 (4H, m, NCH2CH2 pyrrolidine), 2.44 – 2.49 (4H, m, 
NCH2CH2 pyrrolidine), 2.60 (2H, t, J = 6.8 Hz, NHCH2CH2N), 3.51 (2H, td, J = 6.8, 5.9 Hz, 
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NHCH2CH2N), 8.73 (1H, t, J = 5.9 Hz, ArNHCH2), 9.01 (1H, d, J = 3.3 Hz, H-4 or H-6), 
9.09 (1H, d, J = 3.3 Hz, H-4 or H-6); 
13
C NMR (126 MHz, DMSO-d6) δ 23.1 
(NCH2CH2 pyrrolidine), 40.5 (ArNHCH2), 53.6 (NCH2CH2 pyrrolidine), 54.2 (NHCH2CH2N), 
133.6 (C-5), 155.2 (C-4 or C-6), 155.3 (C-4 or C-6), 162.7 (C-2); LRMS (ES
+
) m/z 238.3 
[M+H]
+
; HRMS (NSI) calcd for C10H16N5O2 [M+H]
+
 238.1299, found 238.1298. 
 
N-Piperidine-N’-(5-nitropyridin-2-yl)ethane-1,2-diamine, (512) 
 
Compound 512 was synthesised according to general procedure G’, using the following 
reagents: 2-chloro-5-nitropyridine (459) (152 mg, 0.96 mmol), triethylamine (147 µL, 
106 mg, 1.05 mmol), 1-(2-aminoethyl)piperidine (150 µL, 135 mg, 1.05 mmol) and THF 
(5 mL). The crude product was purified by column chromatography (amine silica gel, 
petrol:EtOAc, 1:0  3:1) to yield the title compound as a brown oil (230 mg, 96%); 
Rf = 0.15 (amine silica, petrol:EtOAc, 8:2); λmax (EtOH)/nm 359.6; IR (neat) νmax/cm
-1
 
3237, 3177, 3043, 2925, 2856, 2812, 2791, 2764, 1608, 1589, 1545, 1497, 1471, 1408; 
1
H NMR (500 MHz, DMSO-d6) δ 1.31 – 1.42 (2H, m, NCH2CH2CH2 piperidine), 1.48 (4H, p, 
J = 5.6 Hz, NCH2CH2CH2 piperidine), 2.30 – 2.40 (4H, m, NCH2CH2CH2 piperidine), 2.44 (2H, 
t, J = 6.7 Hz, ArNHCH2CH2N), 3.49 (2H, brs, ArNHCH2CH2N), 6.59 (1H, d, J = 9.4 Hz, 
H-3), 7.95 – 8.15 (2H, m, H-4 and ArNHCH2), 8.90 (1H, d, J = 2.9 Hz, H-6); 
13
C NMR 
(126 MHz, DMSO-d6) δ 24.0 (NCH2CH2CH2 piperidine), 25.5 (NCH2CH2CH2 piperidine), 38.8 
(ArNHCH2CH2N), 54.1 (NCH2CH2CH2 piperidine), 57.4 (ArNHCH2CH2N), 108.6 (C-3), 
131.5 (C-4), 134.1 (C-), 146.9 (C-6), 161.3 (C-2); LRMS (ES
+
) m/z 251.2 [M+H]
+
; 
HRMS (NSI) calcd for C12H19N4O2 [M+H]
+
 251.1503, found 251.1496. 
 
5-Nitro-N-(2-(piperidin-1-yl)ethyl)pyrimidin-2-amine, (513) 
 
Compound 513 was synthesised according to general procedure C’, using the following 
reagents: 2-chloro-5-nitropyrimidine (414) (350 mg, 2.19 mmol), triethylamine (336 µL, 
244 mg, 2.41 mmol), 1-(2-aminoethyl)piperidine (344 µL, 309 mg, 2.41 mmol) and THF 
(11 mL). The crude product was purified by column chromatography (amine silica gel, 
petrol:EtOAc, 1:0  8:2) to yield the title compound as a pale yellow solid (510 mg, 
93%); Rf = 0.29 (amine silica, petrol:EtOAc, 8:2); m.p. 97.5-99.5 °C; λmax (EtOH)/nm 
332.0; IR (neat) νmax/cm
-1
 3263, 2968, 2921, 2912, 1595, 1575, 1553, 1328, 1152; 
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1
H NMR (500 MHz, DMSO-d6) δ 1.31 – 1.40 (2H, m, NCH2CH2CH2 piperidine), 1.42 – 1.51 
(4H, m, NCH2CH2CH2 piperidine), 2.36 (4H, brs, NCH2CH2CH2 piperidine), 2.45 (2H, t, 
J = 6.8 Hz, CH2CH2N), 3.49 (2H, td, J = 6.8, 5.5 Hz, ArNHCH2CH2), 8.65 (1H, t, 
J = 5.5 Hz, ArNHCH2), 9.01 (1H, d, J = 3.3 Hz, H-4 or H-6), 9.08 (1H, d, J = 3.3 Hz, H-4 
or H-6); 
13
C NMR (126 MHz, DMSO-d6) δ 24.0 (NCH2CH2CH2 piperidine), 25.5 
(NCH2CH2CH2 piperidine), 38.9 (ArNHCH2), 54.0 (NCH2CH2CH2 piperidine), 57.1 (CH2CH2N), 
133.6 (C-5), 155.1 (C-4 or C-6), 155.3 (C-4 or C-6), 162.7 (C-2); LRMS (ES
+
) m/z 252.4 
[M+H]
+
; HRMS (NSI) calcd for C11H18N5O2 [M+H]
+
 252.1455, found 252.1454. 
 
N-(2-Morpholinoethyl)-5-nitropyridin-2-amine, (514) 
 
Compound 514 was synthesised according to general procedure G’, using the following 
reagents: 2-chloro-5-nitropyridine (459) (400 mg, 2.52 mmol), triethylamine (387 µL, 
281 mg, 2.78 mmol), 4-(2-aminoethyl)morpholine (358 µL, 361 mg, 2.78 mmol) and THF 
(10 mL). The crude product was purified by column chromatography (amine silica gel, 
petrol:EtOAc, 1:0  1:1) to yield the title compound as a yellow oil (416 mg, 65%); 
Rf = 0.26 (amine silica, petrol:EtOAc, 1:1); λmax (EtOH)/nm 359.4; IR (neat) νmax/cm
-1
 
3361, 2937, 2854, 2810, 1599, 1576, 1527, 1495, 1467; 
1
H NMR (500 MHz, DMSO-d6) 
δ 2.40 (4H, t, J = 4.7 Hz, NCH2 morpholine), 2.47 (2H, t, J = 6.6 Hz, ArNHCH2CH2N), 3.51 
(2H, brs, ArNHCH2CH2), 3.56 (4H, t, J = 4.7 Hz, OCH2 morpholine), 6.59 (1H, d, J = 9.4 Hz, 
H-3), 8.07 (2H, brs, H-4 and ArNHCH2), 8.89 (1H, d, J = 2.8 Hz, H-6); 
13
C NMR 
(126 MHz, DMSO-d6) δ 37.9 (ArNHCH2), 53.3 (NCH2 morpholine), 57.0 (ArNHCH2CH2N), 
66.1 (OCH2 morpholine), 108.6 (C-3), 131.6 (C-4), 134.2 (C-5), 146.8 (C-6), 161.3 (C-2); 
LRMS (ES
+
) m/z 253.2 [M+H]
+
; HRMS (NSI) calcd for C11H17N4O3 [M+H]
+
 253.1295, 
found 253.1289. 
 
N-(2-Morpholinoethyl)-5-nitropyrimidin-2-amine, (515) 
 
Compound 515 was synthesised according to general procedure C’, using the following 
reagents: 2-chloro-5-nitropyrimidine (414) (350 mg, 2.19 mmol), triethylamine (336 µL, 
244 mg, 2.41 mmol), 4-(2-aminoethyl)morpholine (317 µL, 314 mg, 2.41 mmol) and THF 
(11 mL). The crude product was purified by column chromatography (amine silica gel, 
petrol:EtOAc, 1:0  65:35) to yield the title compound as a pale yellow solid (504 mg, 
444 
91%); Rf = 0.29 (amine silica, petrol:EtOAc, 65:35); m.p. 125.0-127.0 °C; λmax (EtOH)/nm 
332.2; IR (neat) νmax/cm
-1
 3220, 3066, 2926, 2876, 2863, 2831, 1593, 1556, 1495, 1327; 
1
H NMR (500 MHz, DMSO-d6) δ 2.36 – 2.43 (4H, m, NCH2 morpholine), 2.48 (2H, t, 
J = 6.7 Hz, NHCH2CH2N), 3.49 – 3.57 (6H, m, NHCH2CH2N and OCH2 morpholine), 8.68 
(1H, t, J = 6.0 Hz, ArNHCH2), 9.02 (1H, d, J = 3.3 Hz, H-4 or H-6), 9.08 (1H, d, 
J = 3.3 Hz, H-4 or H-6); 
13
C NMR (126 MHz, DMSO-d6) δ 38.5 (ArNHCH2), 53.3 
(NCH2 morpholine), 56.8 (CH2CH2N), 66.2 (OCH2 morpholine), 133.6 (C-5), 155.2 (C-4 or C-6), 
155.3 (C-4 or C-6), 162.8 (C-2); LRMS (ES
+
) m/z 254.3 [M+H]
+
; HRMS (NSI) calcd for 
C10H16N5O3 [M+H]
+
 254.1248, found 254.1246. 
 
N-(2-(Methylsulfonyl)ethyl)-5-nitropyridin-2-amine, (516) 
 
Compound 516 was synthesised according to general procedure G’, using the following 
reagents: 2-chloro-5-nitropyridine (459) (400 mg, 2.52 mmol), triethylamine (915 µL, 
664 mg, 6.56 mmol), 2-aminoethyl methyl sulfone hydrochloride (524 mg, 3.28 mmol) and 
THF (15 mL). The crude product was purified by recrystallization from DCM to yield the 
title compound as a yellow solid (391 mg, 63%); Rf = 0.5 (amine silica, EtOAc, 100%); 
m.p. 242.0-244.0 °C; λmax (EtOH)/nm 347.0; IR (neat) νmax/cm
-1
 3359, 2993, 1599, 1578, 
1522, 1492, 1463, 1410; 
1
H NMR (500 MHz, DMSO-d6) δ 3.03 (3H, s, SO2CH3), 3.42 
(2H, t, J = 6.7 Hz, CH2SO2CH3), 3.81 (2H, td, J = 6.7, 6.4 Hz, ArNHCH2), 6.64 (1H, d, 
J = 8.2 Hz, H-3), 8.15 (1H, d, J = 8.2 Hz, H-4), 8.34 (1H, brs, ArNHCH2), 8.95 (1H, d, 
J = 2.8 Hz, H-6); 
13
C NMR (126 MHz, DMSO-d6) δ 34.8 (ArNHCH2), 41.0 (SO2CH3), 
52.5 (CH2SO2CH3), 109.0 (C-4), 132.0 (C-3), 134.9 (C-5), 146.5 (C-6), 160.9 (C-2); 
LRMS (ES
+
) m/z 246.2 [M+H]
+
; HRMS (NSI) calcd for C8H12N3O4S [M+H]
+
 246.0543, 
found 246.0538. 
 
N-(2-(Methylsulfonyl)ethyl)-5-nitropyrimidin-2-amine, (517) 
 
Compound 517 was synthesised according to general procedure C’, using the following 
reagents: 2-chloro-5-nitropyrimidine (414) (350 mg, 2.19 mmol), triethylamine (672 µL, 
488 mg, 4.82 mmol), 4-aminoethyl methylsulfone hydrochloride (385 mg, 2.41 mmol) and 
THF (11 mL). The crude product was purified by recrystallisation from DCM to yield the 
title compound as an off-white solid (250 mg, 46%); Rf = 0.29 (amine silica, petrol:EtOAc, 
445 
7:3); m.p. 204.0-206.0 °C; λmax (EtOH)/nm 322.2; IR (neat) νmax/cm
-1
 3325, 3298, 1593, 
1562, 1498, 1340, 1275; 
1
H NMR (500 MHz, DMSO-d6) δ 3.04 (3H, s, CH2SO2CH3), 3.42 
(2H, t, J = 6.9 Hz, CH2SO2CH3), 3.81 (2H, td, J = 6.9, 5.9 Hz, ArNHCH2CH2), 8.90 (1H, t, 
J = 5.9 Hz, ArNHCH2), 9.07 (1H, d, J = 3.3 Hz, H-4 or H-6), 9.15 (1H, d, J = 3.3 Hz, H-4 
or H-6); 
13
C NMR (126 MHz, DMSO-d6) δ 35.3 (ArNHCH2), 40.9 (SO2CH3), 52.3 
(CH2SO2), 134.3 (C-5), 155.3 (C-4 and C-6), 162.6 (C-2); LRMS (ES
-
) m/z 245.2 [M-H]
-
; 
HRMS (NSI) calcd for C7H11N4O4S [M+H]
+
 247.0496, found 247.0495. 
 
N
2
-(2-(Dimethylamino)ethyl)pyrimidine-2,5-diamine, (518) 
 
Compound 518 was synthesised according to general procedure D’, using the following 
reagents: N
1
,N
1
-dimethyl-N
2
-(5-nitropyrimidin-2-yl)ethane-1,2-diamine (507) (200 mg, 
0.95 mmol), THF (9.5 mL) and methanol (9.5 mL). The orange solid (165 mg, 96%) was 
used in the next step without further purification; Rf = 0.20 (amine silica, DCM:MeOH, 
8:2); m.p. 97.5-99.5 °C; λmax (EtOH)/nm 249.6; IR (neat) νmax/cm
-1
 3391, 3262, 3127, 
3010, 2910, 2818, 1613, 1573, 1530, 1447, 1422, 1366, 1340; 
1
H NMR (500 MHz, 
DMSO-d6) δ 2.14 (6H, s, CH2N(CH3)2), 2.34 (2H, t, J = 6.8 Hz, CH2CH2NMe2), 3.23 (2H, 
td, J = 6.8, 5.7 Hz, ArNHCH2CH2), 4.39 (2H, brs, ArNH2), 5.88 (1H, t, J = 5.7 Hz, 
ArNHCH2), 7.79 (2H, s, H-4, 6); 
13
C NMR (126 MHz, DMSO-d6) δ 39.3 (ArNHCH2), 
45.3 (CH2N(CH3)2), 58.4 (CH2N(CH3)2), 133.6 (C-5), 144.6 (C-4, 6), 156.4 (C-2); 
LRMS (ES
+
) m/z 182.3 [M+H]
+
; HRMS (NSI) calcd for C8H16N5 [M+H]
+
 182.1400, found 
182.1398. 
 
N
2
-(2-(Diethylamino)ethyl)pyridine-2,5-diamine, (519) 
 
Compound 519 was synthesised according to general procedure V, using the following 
reagents: N,N-diethyl-N’-(5-nitropyridin-2-yl)ethane-1,2-diamine (508) (320 mg, 
1.34 mmol) and MeOH (27 mL). The crude red oil (275 mg, 98%) was used in the next 
step without further purification; Rf = 0.62 (amine silica, DCM:MeOH, 97:3); 
λmax (EtOH)/nm 252.6, 336.6; IR (neat) νmax/cm
-1
 3315, 2966, 2933, 2814, 1607, 1574, 
1499; 
1
H NMR (500 MHz, DMSO-d6) δ 0.94 (6H, t, J = 7.1 Hz, CH2N(CH2CH3)2), 2.47 
(4H, q, J = 7.1 Hz, CH2N(CH2CH3)2), 2.50 (2H, t, J = 6.8 Hz, CH2NEt2), 3.13 (2H, td, 
J = 6.8, 5.6 Hz, ArNHCH2), 4.27 (2H, brs, ArNH2), 5.26 (1H, t, J = 5.6 Hz, ArNHCH2), 
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6.29 (1H, d, J = 8.6 Hz, H-3), 6.81 (1H, dd, J = 8.6, 2.8 Hz, H-4), 7.45 (1H, d, J = 2.8 Hz, 
H-6); 
13
C NMR (126 MHz, DMSO-d6) δ 11.8 (CH2N(CH2CH3)2), 39.6 (ArNHCH2), 46.6 
(CH2N(CH2CH3)2), 51.9 (CH2NEt2), 108.1 (C-3), 125.3 (C-4), 133.3 (C-6), 135.3 (C-5), 
151.8 (C-2); LRMS (ES
+
) m/z 209.2 [M+H]
+
; HRMS (NSI) calcd for C11H21N4 [M+H]
+
 
209.1761, found 209.1757. 
 
N
2
-(2-(Diethylamino)ethyl)pyrimidine-2,5-diamine, (520) 
 
Compound 520 was synthesised according to general procedure D’, using the following 
reagents: N
1
,N
1
-diethyl-N
2
-(5-nitropyrimidin-2-yl)ethane-1,2-diamine (509) (300 mg, 
1.25 mmol), THF (12.5 mL) and methanol (12.5 mL). The orange oil (249 mg, 95%) was 
used in the next step without further purification; Rf = 0.34 (amine silica, EtOAc – 100%); 
λmax (EtOH)/nm 250.2; IR (neat) νmax/cm
-1
 3308, 3218, 2968, 2934, 2872, 2810, 1678, 
1610, 1560, 1500, 1443; 
1
H NMR (500 MHz, DMSO-d6) δ 0.94 (6H, t, J = 7.1 Hz, 
N(CH2CH3)2), 2.55 – 2.41 (6H, m, N(CH2CH3)2 and CH2NEt2), 3.20 (2H, td, J = 7.0, 
5.9 Hz, ArNHCH2CH2), 4.39 (2H, brs, ArNH2), 5.84 (1H, t, J = 5.9 Hz, ArNHCH2), 7.79 
(2H, s, H-4, 6); 
13
C NMR (126 MHz, DMSO-d6) δ 11.9 (N(CH2CH3)2), ca. 40 (overlapping 
with DMSO) (ArNHCH2), 46.6 (N(CH2CH3)2), 51.7 (CH2NEt2), 133.6 (C-5), 144.6 (C-4, 
6), 156.5 (C-2); LRMS (ES
+
) m/z 210.3 [M+H]
+
; HRMS (NSI) calcd for C10H20N5 [M+H]
+
 
210.1713, found 210.1714. 
 
N
2
-(2-(Pyrrolidin-1-yl)ethyl)pyridine-2,5-diamine, (521) 
 
Compound 521 was synthesised according to general procedure V, using the following 
reagents: 5-nitro-N-(2-(pyrrolidin-1-yl)ethyl)pyridin-2-amine (510) (338 mg, 1.43 mmol), 
10% Pd/C (34 mg) and MeOH (15 mL). The crude red oil (274 mg, 93%) was used in the 
next step without further purification; Rf = 0.69 (amine silica, DCM:MeOH, 97:3); 
λmax (EtOH)/nm 254.6, 339.4; IR (neat) νmax/cm
-1
 3317, 2958, 2929, 2875, 2797, 1615, 
1576, 1498, 1419; 
1
H NMR (500 MHz, DMSO-d6) δ 1.65 (4H, p, J = 3.1 Hz, 
NCH2CH2 pyrrolidine), 2.41 (4H, m, NCH2CH2 pyrrolidine), 2.51 (2H, t, J = 6.8 Hz, 
ArNHCH2CH2N), 3.18 (2H, td, J = 6.8, 5.8 Hz, ArNHCH2), 4.23 (2H, brs, ArNH2), 5.34 
(1H, t, J = 5.8 Hz, ArNHCH2), 6.28 (1H, d, J = 8.7 Hz, H-3), 6.79 (1H, dd, J = 8.7, 2.8 Hz, 
H-4), 7.43 (1H, d, J = 2.8 Hz, H-6); 
13
C NMR (126 MHz, DMSO-d6) δ 23.1 
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(NCH2CH2 pyrrolidine), 40.9 (ArNHCH2), 53.7 (NCH2CH2 pyrrolidine), 55.3 (ArNHCH2CH2N), 
108.1 (C-3), 125.4 (C-4), 133.2 (C-6), 135.2 (C-5), 151.8 (C-2); LRMS (ES
+
) m/z 207.2 
[M+H]
+
; HRMS (NSI) calcd for C11H19N4 [M+H]
+
 207.1604, found 207.1601. 
 
N
2
-(2-(Pyrrolidin-1-yl)ethyl)pyrimidine-2,5-diamine, (522) 
 
Compound 522 was synthesised according to general procedure D’, using the following 
reagents: 5-nitro-N-(2-(pyrrolidin-1-yl)ethyl)pyrimidin-2-amine (511) (430 mg, 
1.81 mmol), THF (18.1 mL) and methanol (18.1 mL). The pale brown solid (346 mg, 92%) 
was used in the next step without further purification; Rf = 0.34 (amine silica, EtOAc, 
100%); m.p. 113.0-115.0 °C; λmax (EtOH)/nm 249.6; IR (neat) νmax/cm
-1
 3389, 3277, 3135, 
2957, 2909, 2798, 1613, 1573, 1531, 1445; 
1
H NMR (500 MHz, DMSO-d6) δ 1.62 – 1.70 
(4H, m, NCH2CH2 pyrrolidine), 2.39 – 2.46 (4H, m, NCH2CH2 pyrrolidine), 2.51 (2H, t, 
J = 6.9 Hz, NHCH2CH2N), 3.26 (2H, td, J = 6.9, 5.8 Hz, NHCH2CH2N), 4.38 (2H, brs, 
ArNH2), 5.94 (1H, t, J = 5.8 Hz, ArNHCH2), 7.79 (2H, s, H-4, 6); 
13
C NMR (126 MHz, 
DMSO-d6) δ 23.1 (NCH2CH2 pyrrolidine), 40.4 (ArNHCH2), 53.6 (NCH2CH2 pyrrolidine), 55.1 
(NHCH2CH2N), 133.6 (C-5), 144.6 (C-4, 6), 156.4 (C-2); LRMS (ES
+
) m/z 208.3 [M+H]
+
; 
HRMS (NSI) calcd for C10H18N5 [M+H]
+
 208.1557, found 208.1554. 
 
N
2
-(2-(Piperidin-1-yl)ethyl)pyridine-2,5-diamine, (523) 
 
Compound 523 was synthesised according to general procedure V, using the following 
reagents: N-piperidine-N’-(5-nitropyridin-2-yl)ethane-1,2-diamine (512) (371 mg, 
1.48 mmol), 10% Pd/C (37 mg) and MeOH (15 mL). The crude brown oil (317 mg, 97%) 
was used in the next step without further purification; Rf = 0.53 (amine silica, 
DCM:MeOH, 97:3); λmax (EtOH)/nm 250.6, 338.8; IR (neat) νmax/cm
-1
 3310, 2928, 2850, 
1603, 1574, 1497, 1469; 
1
H NMR (500 MHz, DMSO-d6) δ 1.37 (2H, m, 
NCH2CH2CH2 piperidine), 1.48 (4H, m, NCH2CH2CH2 piperidine), 2.32 (4H, brs, 
NCH2CH2CH2 piperidine), 2.37 (2H, t, J = 6.7 Hz, ArNHCH2CH2N), 3.17 (2H, td, J = 6.7, 
5.5 Hz, ArNHCH2CH2N), 4.25 (2H, brs, ArNH2), 5.27 (1H, t, J = 5.5 Hz, ArNHCH2), 6.29 
(1H, d, J = 8.6 Hz, H-3), 6.80 (1H, dd, J = 8.6, 2.8 Hz, H-4), 7.44 (1H, d, J = 2.8 Hz, H-6); 
13
C NMR (126 MHz, DMSO-d6) δ 24.1 (NCH2CH2CH2 piperidine), 25.6 
(NCH2CH2CH2 piperidine), 38.9 (ArNHCH2CH2N), 54.2 (NCH2CH2CH2 piperidine), 58.0 
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(ArNHCH2CH2N), 108.0 (C-3), 125.3 (C-4), 133.2 (C-6), 135.3 (C-5), 151.8 (C-2); 
LRMS (ES
+
) m/z 221.3 [M+H]
+
; HRMS (NSI) calcd for C12H21N4 [M+H]
+
 221.1761, 
found 221.1757. 
 
N
2
-(2-(Piperidin-1-yl)ethyl)pyrimidine-2,5-diamine, (524) 
 
Compound 524 was synthesised according to general procedure D’, using the following 
reagents: 5-nitro-N-(2-(piperidin-1-yl)ethyl)pyrimidin-2-amine (513) (480 mg, 
1.91 mmol), THF (19.1 mL) and methanol (19.1 mL). The pale yellow solid (385 mg, 
91%) was used in the next step without further purification; Rf = 0.28 (amine silica, 
EtOAc, 100%); m.p. 125.5-127.5 °C; λmax (EtOH)/nm 249.8; IR (neat) νmax/cm
-1
 3384, 
3277, 3157, 2935, 2801, 1613, 1573, 1532, 1447, 1429; 
1
H NMR (500 MHz, DMSO-d6) 
δ 1.33 – 1.40 (2H, m, NCH2CH2CH2 piperidine), 1.44 – 1.51 (4H, m, NCH2CH2CH2 piperidine), 
2.33 (4H, brs, NCH2CH2CH2 piperidine), 2.37 (2H, t, J = 6.9 Hz, CH2CH2N), 3.25 (2H, td, 
J = 6.9, 5.7 Hz, ArNHCH2CH2), 4.39 (2H, brs, ArNH2), 5.86 (1H, t, J = 5.7 Hz, 
ArNHCH2), 7.79 (2H, s, H-4, 6); 
13
C NMR (126 MHz, DMSO-d6) δ 24.1 
(NCH2CH2CH2 piperidine), 25.6 (NCH2CH2CH2 piperidine), 38.7 (ArNHCH2), 54.1 
(NCH2CH2CH2 piperidine), 57.9 (CH2CH2N), 133.6 (C-5), 144.6 (C-4, 6), 156.4 (C-2); 
LRMS (ES
+
) m/z 222.3 [M+H]
+
; HRMS (NSI) calcd for C11H20N5 [M+H]
+
 222.1713, 
found 222.1710. 
 
N
2
-(2-Morpholinoethyl)pyridine-2,5-diamine, (525) 
 
Compound 525 was synthesised according to general procedure V, using the following 
reagents: N-(2-morpholinoethyl)-5-nitropyridin-2-amine (514) (409 mg, 1.62 mmol), 10% 
Pd/C (40 mg) and MeOH (15 mL). The crude brown red (342 mg, 95%) was used in the 
next step without further purification; Rf = 0.56 (amine silica, DCM:MeOH, 97:3); 
λmax (EtOH)/nm 254.6, 339.4; IR (neat) νmax/cm
-1
 3317, 2958, 2929, 2875, 2797, 1615, 
1576, 1498, 1419; 
1
H NMR (500 MHz, DMSO-d6) δ 2.37 (4H, brs, NCH2 morpholine), 2.42 
(2H, t, J = 6.7 Hz, ArNHCH2CH2N), 3.21 (2H, td, J = 6.7, 5.7 Hz, ArNHCH2CH2), 3.57 
(4H, t, J = 4.6 Hz, OCH2 morpholine), 4.26 (2H, brs, ArNH2), 5.33 (1H, t, J = 5.7 Hz, 
ArNHCH2), 6.30 (1H, d, J = 8.6 Hz, H-3), 6.81 (1H, dd, J = 8.6, 2.8 Hz, H-4), 7.45 (1H, d, 
J = 2.8 Hz, H-5); 
13
C NMR (126 MHz, DMSO-d6) δ 38.7 (ArNHCH2), 53.4 
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(NCH2 morpholine), 57.8 (ArNHCH2CH2N), 66.2 (OCH2 morpholine), 108.1 (C-3), 125.3 (C-4), 
133.2 (C-5), 135.3 (C-6), 151.7 (C-2); LRMS (ES
+
) m/z  207.2 [M+H]
+
; HRMS (NSI) 
calcd for C11H19N4O [M+H]
+
 223.1553, found 223.1550. 
 
N
2
-(2-Morpholinoethyl)pyrimidine-2,5-diamine, (526) 
 
Compound 526 was synthesised according to general procedure D’, using the following 
reagents: N-(2-morpholinoethyl)-5-nitropyrimidin-2-amine (515) (480 mg, 1.89 mmol), 
THF (18.9 mL) and methanol (18.9 mL). The pale yellow solid (394 mg, 93%) was used in 
the next step without further purification; Rf = 0.42 (amine silica, EtOAc, 100%); 
m.p. 98.5-100.5 °C; λmax (EtOH)/nm 249.8; IR (neat) νmax/cm
-1
 3404, 3276, 2963, 2932, 
2918, 2818, 1613, 1574, 1527, 1454, 1424; 
1
H NMR (500 MHz, DMSO-d6) δ 2.34 – 2.39 
(4H, m, NCH2 morpholine), 2.41 (2H, t, J = 6.8 Hz, NHCH2CH2N), 3.27 (2H, td, J = 6.8, 
5.8 Hz, NHCH2CH2N), 3.55 (4H, t, J = 4.7 Hz, OCH2 morpholine), 4.39 (2H, brs, ArNH2), 
5.93 (1H, t, J = 5.8 Hz, ArNHCH2), 7.79 (2H, s, H-4, 6); 
13
C NMR (126 MHz, DMSO-d6) 
δ 38.3 (ArNHCH2), 53.4 (NCH2 morpholine), 57.6 (CH2CH2N), 66.2 (OCH2 morpholine), 133.6 
(C-5), 144.6 (C-4, 6), 156.4 (C-2); LRMS (ES
+
) m/z 224.4 [M+H]
+
; HRMS (NSI) calcd for 
C10H18N5O [M+H]
+
 224.1506, found 224.1504. 
 
N
2
-(2-(Methylsulfonyl)ethyl)pyridine-2,5-diamine, (527) 
 
Compound 527 was synthesised according to general procedure V, using the following 
reagents: N-(2-(methylsulfonyl)ethyl)-5-nitropyridin-2-amine (516) (350 mg, 1.43 mmol) 
and MeOH (30 mL). The crude red oil (293 mg, 95%) was used in the next step without 
further purification; Rf = 0.63 (amine silica, DCM:MeOH, 97:3); λmax (EtOH)/nm 251.4, 
333.2; IR (neat) νmax/cm
-1
 3341, 3017, 2923, 2096, 1994, 1615, 1578, 1498, 1405; 
1
H NMR (500 MHz, DMSO-d6) δ 2.98 (3H, s, SO2CH3), 3.29 (2H, t, J = 6.8 Hz, 
CH2SO2CH3), 3.55 (2H, dt, J = 6.8, 6.0 Hz, ArNHCH2), 4.36 (2H, brs, ArNH2), 5.84 (1H, 
t, J = 6.0 Hz, ArNHCH2), 6.33 (1H, d, J = 8.6 Hz, H-3), 6.84 (1H, dd, J = 8.6, 2.8 Hz, 
H-4), 7.49 (1H, d, J = 2.8 Hz, H-6); 
13
C NMR (126 MHz, DMSO-d6) δ 35.6 (ArNHCH2), 
41.2 (SO2CH3), 53.5 (CH2SO2CH3), 109.0 (C-3), 125.5 (C-4), 132.9 (C-6), 136.0 (C-5), 
150.7 (C-2); LRMS (ES
+
) m/z 216.4 [M+H]
+
; HRMS (NSI) calcd for C8H14N3O2S [M+H]
+
 
216.0801, found 216.0798. 
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N
2
-(2-(Methylsulfonyl)ethyl)pyrimidine-2,5-diamine, (528) 
 
Compound 528 was synthesised according to general procedure D’, using the following 
reagents: N-(2-(methylsulfonyl)ethyl)-5-nitropyrimidin-2-amine (517) (200 mg, 
0.81 mmol), THF (8.1 mL) and methanol (8.1 mL). The crude product was purified by 
column chromatography (amine silica gel, DCM:MeOH, 1:0  98:2) to yield the title 
compound as a pale yellow solid (97 mg, 55%); Rf = 0.28 (amine silica, DCM:MeOH, 
98:2); m.p. 128.5-130.5 °C; λmax (EtOH)/nm 248.6; IR (neat) νmax/cm
-1
 3377, 3260, 2997, 
2981, 1617, 1581, 1539, 1463, 1445, 1434, 1278, 1129, 1115; 
1
H NMR (500 MHz, 
DMSO-d6) δ 2.99 (s, 3H, CH2SO2CH3), 3.30 (t, J = 6.9 Hz, 2H, CH2SO2CH3), 3.58 (td, 
J = 6.9, 6.0 Hz, 2H, ArNHCH2CH2), 4.50 (brs, 2H, ArNH2), 6.37 (t, J = 6.0 Hz, 1H, 
ArNHCH2), 7.83 (s, 2H, H-4, 6); 
13
C NMR (126 MHz, DMSO-d6) δ 35.4 (ArNHCH2), 
41.0 (SO2CH3), 53.3 (CH2SO2), 134.4 (C-5), 144.5 (C-4, 6), 155.6 (C-2); LRMS (ES
+
) m/z 
217.2 [M+H]
+
; HRMS (NSI) calcd for C7H13N4O2S [M+H]
+
 217.0754, found 217.0751. 
 
4-(6-Chloro-2-fluoro-3-methoxybenzoyl)-N-(2-(morpholinomethyl)pyrimidin-5-yl)-
1H-pyrrole-2-carboxamide, (529) 
 
Compound 529 was synthesised according to general procedure Y, using the following 
reagents: 4-(6-chloro-2-fluoro-3-methoxybenzoyl)-1H-pyrrole-2-carboxylic acid (250) 
(80 mg, 0.27 mmol), triethylamine (94 µL, 68 mg, 0.67 mmol), 2-chloro-1-
methylpyridinium iodide (76 mg, 0.30 mmol), 2-(morpholinomethyl)pyrimidin-5-amine 
(442) (65 mg, 0.34 mmol) and DCM (2.7 mL). The crude yellow solid was purified by 
column chromatography (silica gel, DCM:MeOH, 1:0  94:6) to yield the title compound 
as a white solid (21 mg, 17%); Rf = 0.29 (DCM:MeOH, 94:6); m.p. 140.5-142.5 °C; 
λmax (EtOH)/nm 292.6; IR (neat) νmax/cm
-1
 3125, 2933, 2855, 1641, 1578, 1555, 1519, 
1473, 1438, 1272; 
1
H NMR (500 MHz, DMSO-d6) δ 2.47 (4H, t, J = 4.7 Hz, NCH2 
morpholine), 3.56 (4H, t, J = 4.7 Hz, CH2O morpholine), 3.66 (2H, s, ArCH2N), 3.90 (3H, s, 
ArOCH3), 7.33 (1H, dd, J = 9.0, 9.0 Hz, H-4’), 7.39 (1H, dd, J = 9.0, 1.4 Hz, H-5’), 7.46 
(1H, s, H-3), 7.55 (1H, s, H-5), 9.08 (2H, s, H-4”, 6”), 10.42 (1H, s, CONHAr), 12.81 (1H, 
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s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 53.2 (NCH2 morpholine), 56.5 (ArOCH3), 
64.2 (ArCH2N), 66.2 (CH2O morpholine), 112.1 (C-3), 115.2 (C-4’), 120.2 (d, J = 4.8 Hz, 
C-6’), 125.3 (C-2 or C-4), 125.6 (d, J = 3.7 Hz, C-5’), 127.7 (C-2 or C-4), 128.4 (d, 
J = 19.9 Hz, C-1’), 129.7 (C-5), 132.5 (C-5”), 146.5 (d, J = 10.6 Hz, C-3’), 147.9 (C-4”, 
6”), 147.9 (d, J = 247.2 Hz, C-2’), 158.8 (CONHAr), 161.1 (C-2”), 183.7 (ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -136.2 (ArF); LRMS (ES
+
) m/z 474.4 [M(
35
Cl)+H]
+
, 
476.4 [M(
37
Cl)+H]
+
; HRMS (NSI) calcd for C22H22ClFN5O4 [M(
35
Cl)+H]
+
 474.1339, 
found 474.1331. 
 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(6-(morpholinomethyl)pyridin-3-yl)-1H-pyrrole-
2-carboxamide, (530) 
 
Compound 530 was synthesised according to general procedure Y, using the following 
reagents: 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250) (100 mg, 
0.33 mmol), triethylamine (115 µL, 84 mg, 0.83 mmol), 2-chloro-1-methylpyridinium 
iodide (93 mg, 0.36 mmol), 6-(morpholinomethyl)pyridin-3-amine (543) (80 mg, 
0.41 mmol) and DCM (3.3 mL). The crude yellow solid was purified by column 
chromatography (amine silica gel, DCM:MeOH, 1:0  97:3) to yield the title compound 
as a white solid (70 mg, 44%); Rf = 0.34 (amine silica, DCM:MeOH, 97:3); 
m.p. 245.0-247.0 °C; λmax (EtOH)/nm 295.6; IR (neat) νmax/cm
-1
 3243, 3119, 2956, 2917, 
2854, 2814, 1639, 1590, 1526, 1492, 1446; 
1
H NMR (500 MHz, DMSO-d6) δ 2.40 (4H, t, 
J = 4.7 Hz, NCH2 morpholine), 3.55 (2H, s, ArCH2N), 3.58 (4H, t, J = 4.7 Hz, CH2O morpholine), 
7.42 (1H, d, J = 8.5 Hz, H-5”), 7.49 – 7.54 (2H, m, H-3 and H-5’), 7.62 (1H, s, H-5), 7.78 
(1H, dd, J = 8.7, 8.4 Hz, H-4’), 8.11 (1H, dd, J = 8.5, 2.4 Hz, H-4”), 8.80 (1H, d, 
J = 2.4 Hz, H-2”), 10.22 (1H, s, CONHAr), 12.75 (1H, s, NH-pyrrole); 13C NMR 
(126 MHz, DMSO-d6) δ 53.3 (NCH2 morpholine), 63.7 (ArCH2N), 66.2 (CH2O morpholine), 
111.4 (C-3), 119.4 (d, J = 18.2 Hz, C-3’), 122.7 (C-5”), 124.8 (C-2 or C-4), 126.9 (d, 
J = 3.7 Hz, C-5’), 127.6 (C-4”), 128.5 (C-2 or C-4), 129.1 (d, J = 23.1 Hz, C-1’), 129.2 (d, 
J = 5.0 Hz, C-6’), 130.2 (C-5), 131.9 (C-4’), 134.1 (C-3”), 140.7 (C-2”), 152.8 (C-6”), 
153.9 (d, J = 248.6 Hz, C-2’), 158.6 (CONHAr), 182.6 (ArCO); 19F NMR (471 MHz, 
DMSO-d6) δ -116.6 (ArF); LRMS (ES
+
) m/z 477.4 [M(
35
Cl
35
Cl)+H]
+
, 479.4 
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[M(
35
Cl
37
Cl)+H]
+
; HRMS (NSI) calcd for C22H20Cl2FN4O3 [M(
35
Cl
35
Cl)+H]
+
 477.0891, 
found 477.0880. 
 
4-(6-Chloro-2-fluoro-3-methoxybenzoyl)-N-(6-(morpholinomethyl)pyridin-3-yl)-1H-
pyrrole-2-carboxamide, (531) 
 
Compound 531 was synthesised according to general procedure Y, using the following 
reagents: 4-(6-chloro-2-fluoro-3-methoxybenzoyl)-1H-pyrrole-2-carboxylic acid (250) 
(100 mg, 0.34 mmol), triethylamine (117 µL, 85 mg, 0.84 mmol), 2-chloro-1-
methylpyridinium iodide (94 mg, 0.37 mmol), 6-(morpholinomethyl)pyridin-3-amine (543) 
(81 mg, 0.42 mmol) and DCM (3.4 mL). The crude yellow solid was purified by column 
chromatography (amine silica gel, DCM:MeOH, 1:0  97:3) to yield the title compound 
as a white solid (45 mg, 28%); Rf = 0.32 (amine silica, DCM:MeOH, 97:3); 
m.p. 219.0-221.0 °C; λmax (EtOH)/nm 295.8; IR (neat) νmax/cm
-1
 3228, 2931, 2854, 2799, 
1655, 1639, 1554, 1534, 1473, 1437, 1400; 
1
H NMR (500 MHz, DMSO-d6) δ 2.40 (4H, t, 
J = 4.5 Hz, NCH2 morpholine), 3.54 (2H, s, ArCH2N), 3.58 (4H, t, J = 4.5 Hz, CH2O morpholine), 
3.90 (3H, s, ArOCH3), 7.33 (1H, dd, J = 9.0, 8.9 Hz, H-4’), 7.39 (1H, dd, J = 9.0, 0.9 Hz, 
H-5’), 7.42 (1H, d, J = 8.5 Hz, H-5”), 7.47 (1H, s, H-3 or H-5), 7.48 (1H, s, H-3 or H-5), 
8.10 (1H, dd, J = 8.5, 2.5 Hz, H-4”), 8.80 (1H, d, J = 2.5 Hz, H-2”), 10.22 (1H, s, 
CONHAr), 12.68 (1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 53.3 
(NCH2 morpholine), 56.5 (ArOCH3), 63.7 (ArCH2N), 66.2 (CH2O morpholine), 111.5 (C-3), 115.2 
(C-4’), 120.2 (d, J = 4.9 Hz, C-6’), 122.7 (C-5”), 125.2 (C-2 or C-4), 125.6 (d, J = 3.5 Hz, 
C-5’), 127.6 (C-4”), 128.2 (C-2 or C-4), 128.4 (d, J = 20.0 Hz, C-1’), 129.4 (C-5), 134.1 
(C-3”), 140.7 (C-2”), 146.4 (d, J = 10.5 Hz, C-3’), 148.0 (d, J = 247.2 Hz, C-2’), 152.7 
(C-6”), 158.6 (CONHAr), 183.7 (ArCO); 19F NMR (471 MHz, DMSO-d6) δ -136.1 (ArF); 
LRMS (ES
+
) m/z 473.5 [M(
35
Cl)+H]
+
, 475.4 [M(
37
Cl)+H]
+
; HRMS (NSI) calcd for 
C23H23ClFN4O4 [M(
35
Cl)+H]
+
 473.1386, found 473.1377. 
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4-(3,6-Dichloro-2-fluorobenzoyl)-N-(6-((dimethylamino)methyl)pyridin-3-yl)-1H-
pyrrole-2-carboxamide, (532) 
 
Compound 532 was synthesised according to general procedure Y, using the following 
reagents: 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250) (150 mg, 
0.50 mmol), triethylamine (173 µL, 126 mg, 1.24 mmol), 2-chloro-1-methylpyridinium 
iodide (140 mg, 0.55 mmol), 6-((dimethylamino)methyl)pyridin-3-amine (544) (94 mg, 
0.62 mmol) and DCM (5 mL). The crude yellow solid was purified by column 
chromatography (amine silica gel, DCM:MeOH, 1:0  97:3) to yield the title compound 
as a white solid (17 mg, 8%); Rf = 0.28 (amine silica, DCM:MeOH, 97:3); 
m.p. 136.5-138.5 °C; λmax (EtOH)/nm 294.6; IR (neat) νmax/cm
-1
 3179, 3118, 2924, 2855, 
2776, 1637, 1590, 1555, 1526, 1491, 1446, 1391; 
1
H NMR (500 MHz, DMSO-d6) δ 2.18 
(6H, s, CH2N(CH3)2), 3.49 (2H, s, ArCH2N), 7.40 (1H, d, J = 8.5 Hz, H-5”), 7.48 – 7.54 
(2H, m, H-3 and H-5’), 7.62 (1H, s, H-5), 7.78 (1H, dd, J = 8.4, 8.4 Hz, H-4’), 8.11 (1H, 
dd, J = 8.5, 2.5 Hz, H-4”), 8.79 (1H, d, J = 2.5 Hz, H-2”), 10.22 (1H, s, CONHAr), 12.76 
(1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 45.1 (CH2N(CH3)2), 64.6 
(ArCH2N), 111.4 (C-3), 119.3 (d, J = 18.1 Hz, C-1’), 122.5 (C-5”), 124.7 (C-2 or C-4), 
126.9 (d, J = 3.8 Hz, C-5’), 127.6 (C-4”), 128.5 (C-2 or C-4), 129.1 (d, J = 22.3 Hz, C-3’), 
129.2 (d, J = 5.6 Hz, C-6’), 130.1 (C-5), 131.8 (C-4’), 134.0 (C-3”), 140.6 (C-2”), 153.6 
(C-6”), 153.8 (d, J = 248.7 Hz, C-2’), 158.6 (CONHAr), 182.6 (ArCO); 19F NMR 
(471 MHz, DMSO-d6) δ -116.7 (ArF); LRMS (ES
+
) m/z 435.3 [M(
35
Cl
35
Cl)+H]
+
, 437.3 
[M(
35
Cl
37
Cl)+H]
+
; HRMS (NSI) calcd for C20H18Cl2FN4O2 [M(
35
Cl
35
Cl)+H]
+
 435.0785, 
found 435.0785. 
 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(6-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-
pyrrole-2-carboxamide, (533) 
 
Compound 533 was synthesised according to general procedure Y, using the following 
reagents: 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250) (150 mg, 
454 
0.50 mmol), triethylamine (173 µL, 126 mg, 1.24 mmol), 2-chloro-1-methylpyridinium 
iodide (140 mg, 0.55 mmol), 6-(piperidin-1-ylmethyl)pyridin-3-amine (545) (119 mg, 
0.62 mmol) and DCM (5 mL). The crude yellow solid was purified by column 
chromatography (amine silica gel, DCM:MeOH, 1:0  97:3) to yield the title compound 
as a white solid (64 mg, 27%); Rf = 0.29 (amine silica, DCM:MeOH, 97:3); m.p. 
242.5-244.5 °C; λmax (EtOH)/nm 295.4; IR (neat) νmax/cm
-1
 3278, 3116, 2934, 2852, 2803, 
1663, 1640, 1545, 1529, 1446, 1299; 
1
H NMR (500 MHz, DMSO-d6) δ 1.33 – 1.44 (2H, 
m, NCH2CH2CH2), 1.44 – 1.58 (4H, m, NCH2CH2CH2), 2.37 (4H, brs, NCH2CH2CH2), 
3.51 (2H, s, ArCH2N), 7.40 (1H, d, J = 8.5 Hz, H-5”), 7.48 – 7.55 (2H, m, H-3 and H-5’), 
7.62 (1H, s, H-5), 7.78 (1H, dd, J = 8.4, 8.4 Hz, H-4’), 8.09 (1H, dd, J = 8.5, 2.5 Hz, H-4”), 
8.79 (1H, d, J = 2.5 Hz, H-2”), 10.22 (1H, s, CONHAr), 12.76 (1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 23.8 (NCH2CH2CH2), 25.5 (NCH2CH2CH2), 54.0 
(NCH2CH2CH2), 64.0 (ArCH2N), 111.3 (C-3), 119.3 (d, J = 18.3 Hz, C-1’), 122.4 (C-5”), 
124.7 (C-2 or C-4), 126.9 (d, J = 3.6 Hz, C-5’), 127.6 (C-4”), 128.4 (C-2 or C-4), 129.1 (d, 
J = 22.7 Hz, C-3’), 129.2 (d, J = 5.2 Hz, C-6’), 130.1 (C-5), 131.8 (C-4’), 133.9 (C-3”), 
140.6 (C-2”), 153.5 (C-6”), 153.8 (d, J = 248.6 Hz, C-2’), 158.5 (CONHAr), 182.6 
(ArCO); 
19
F NMR (471 MHz, DMSO-d6) δ -116.6 (ArF); LRMS (ES
+
) m/z 475.3 
[M(
35
Cl
35
Cl)+H]
+
, 477.3 [M(
35
Cl
37
Cl)+H]
+
; HRMS (NSI) calcd for C23H22Cl2FN4O2 
[M(
35
Cl
35
Cl)+H]
+
 475.1098, found 475.1085. 
 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(6-(((2-methoxyethyl)(methyl)amino)methyl) 
pyridin-3-yl)-1H-pyrrole-2-carboxamide, (534) 
 
Compound 534 was synthesised according to general procedure Y, using the following 
reagents: 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250) (150 mg, 
0.50 mmol), triethylamine (173 µL, 126 mg, 1.24 mmol), 2-chloro-1-methylpyridinium 
iodide (140 mg, 0.55 mmol), 6-(((2-methoxyethyl)(methyl)amino)methyl)pyridin-3-amine 
(534) (121 mg, 0.62 mmol) and DCM (5 mL). The crude yellow solid was purified by 
column chromatography (amine silica gel, DCM:MeOH, 1:0  97:3) to yield the title 
compound as a white solid (42 mg, 18%); Rf = 0.30 (amine silica, DCM:MeOH, 97:3); 
m.p. 188.5-190.5 °C; λmax (EtOH)/nm 295.0; IR (neat) νmax/cm
-1
 3283, 3113, 2924, 1638, 
1590, 1526, 1491, 1446, 1392, 1286; 
1
H NMR (500 MHz, DMSO-d6) δ 2.20 (3H, s, 
455 
NCH3), 2.56 (2H, t, J = 5.9 Hz, NCH2CH2OMe), 3.23 (3H, s, CH2OCH3), 3.45 (2H, t, 
J = 5.9 Hz, NCH2CH2OMe), 3.59 (2H, s, ArCH2N), 7.41 (1H, d, J = 8.5 Hz, H-5”), 
7.48 - 7.54 (2H, m, H-3 and H-5’), 7.62 (1H, s, H-5), 7.78 (1H, dd, J = 8.4, 8.4 Hz, H-4’), 
8.10 (1H, dd, J = 8.5, 2.6 Hz, H-4”), 8.79 (1H, d, J = 2.6 Hz, H-2”), 10.21 (1H, s, 
CONHAr), 12.76 (1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 42.6 (NCH3), 
56.0 (NCH2CH2OMe), 58.0 (CH2OCH3), 63.0 (ArCH2N), 70.3 (NCH2CH2OMe), 111.4 
(C-3), 119.3 (d, J = 18.2 Hz, C-1’), 122.5 (C-5”), 124.8 (C-2 or C-4), 126.9 (d, J = 3.8 Hz, 
C-5’), 127.6 (C-4”), 128.5 (C-2 or C-4), 129.2 (d, J = 22.7 Hz, C-3’), 129.2 (d, J = 5.2 Hz, 
C-6’), 130.1 (C-5), 131.8 (C-4’), 133.9 (C-3”), 140.6 (C-2”), 153.8 (d, J = 248.6 Hz, C-2’), 
154.0 (C-6”), 158.6 (CONHAr), 182.6 (ArCO); 19F NMR (471 MHz, DMSO-d6) δ -116.6 
(ArF); LRMS (ES
+
) m/z 479.3 [M(
35
Cl
35
Cl)+H]
+
, 481.3 [M(
35
Cl
37
Cl)+H]
+
; HRMS (NSI) 
calcd for C22H22Cl2FN4O3 [M(
35
Cl
35
Cl)+H]
+
 479.0148, found 479.0135. 
 
N-(6-((bis(2-methoxyethyl)amino)methyl)pyridin-3-yl)-4-(3,6-dichloro-2-
fluorobenzoyl)-1H-pyrrole-2-carboxamide, (535) 
 
Compound 535 was synthesised according to general procedure Y, using the following 
reagents: 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250) (150 mg, 
0.50 mmol), triethylamine (173 µL, 126 mg, 1.24 mmol), 2-chloro-1-methylpyridinium 
iodide (140 mg, 0.55 mmol), 6-((bis(2-methoxyethyl)amino)methyl)pyridin-3-amine (247) 
(149 mg, 0.62 mmol) and DCM (5 mL). The crude yellow solid was purified by column 
chromatography (amine silica gel, DCM:MeOH, 1:0  97:3) to yield the title compound 
as a white solid (53 mg, 20%); Rf = 0.34 (amine silica, DCM:MeOH, 97:3); m.p. 
165.0-167.0 °C; λmax (EtOH)/nm 295.4; IR (neat) νmax/cm
-1
 3178, 3114, 2924, 2873, 2818, 
1636, 1589, 1554, 1525, 1490, 1445, 1391; 
1
H NMR (500 MHz, DMSO-d6) δ 2.68 (4H, t, 
J = 6.0 Hz, N(CH2CH2OMe)2), 3.21 (6H, s, N(CH2CH2OCH3)2), 3.40 (4H, t, J = 6.0 Hz, 
N(CH2CH2OMe)2), 3.73 (2H, s, ArCH2N), 7.44 (1H, d, J = 8.5 Hz, H-5”), 7.48 – 7.56 (2H, 
m, H-3 and H-5’), 7.62 (1H, s, H-5), 7.78 (1H, dd, J = 8.4, 8.4 Hz, H-4’), 8.08 (1H, dd, 
J = 8.5, 2.6 Hz, H-4”), 8.78 (1H, d, J = 2.6 Hz, H-2”), 10.20 (1H, s, CONHAr), 12.75 (1H, 
s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) δ 53.4 (N(CH2CH2OMe)2), 58.0 
(N(CH2CH2OCH3)2), 60.2 (ArCH2N), 70.6 (N(CH2CH2OMe)2), 111.3 (C-3), 119.3 (d, 
J = 18.0 Hz, C-1’), 122.3 (C-5”), 124.7 (C-2 or C-4), 126.9 (d, J = 3.8 Hz, C-5’), 127.6 
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(C-4”), 128.5 (C-2 or C-4), 129.1 (d, J = 22.9 Hz, C-3’), 129.2 (d, J = 5.2 Hz, C-6’), 130.1 
(C-5), 131.8 (C-4’), 133.8 (C-3”), 140.5 (C-2”), 153.8 (d, J = 248.5 Hz, C-2’), 154.7 
(C-6”), 158.5 (CONHAr), 182.6 (ArCO); 19F NMR (471 MHz, DMSO-d6) δ -116.6 (ArF); 
LRMS (ES
+
) m/z 523.3 [M(
35
Cl
35
Cl)+H]
+
, 525.4 [M(
35
Cl
37
Cl)+H]
+
; HRMS (NSI) calcd for 
C24H26Cl2FN4O4 [M(
35
Cl
35
Cl)+H]
+
 523.1310, found 523.1294. 
 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(6-((4-hydroxypiperidin-1-yl)methyl)pyridin-3-
yl)-1H-pyrrole-2-carboxamide, (536) 
 
Compound 536 was synthesised according to general procedure Y, using the following 
reagents: 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (250) (150 mg, 
0.50 mmol), triethylamine (173 µL, 126 mg, 1.24 mmol), 2-chloro-1-methylpyridinium 
iodide (140 mg, 0.55 mmol), 1-((5-aminopyridin-2-yl)methyl)piperidin-4-ol (548) 
(129 mg, 0.62 mmol) and DCM (5 mL). The crude yellow solid was purified by column 
chromatography (amine silica gel, DCM:MeOH, 1:0  97:3) to yield the title compound 
as a white solid (57 mg, 23%); Rf = 0.28 (amine silica, DCM:MeOH, 97:3); m.p. 
148.5-150.5 °C; λmax (EtOH)/nm 295.4; IR (neat) νmax/cm
-1
 3219, 2925, 2853, 1637, 1591, 
1555, 1527, 1492, 1446; 
1
H NMR (500 MHz, DMSO-d6) δ 1.40 (2H, dddd, J = 13.1, 9.7, 
9.7 and 3.7 Hz, CH2CHOH), 1.71 (2H, ddd, J = 13.1, 3.6 and 3.6 Hz, CH2CHOH), 
2.02 - 2.17 (2H, m, NCH2CH2), 2.69 (2H, dd, J = 13.1, 5.6 Hz, NCH2CH2), 3.40 – 3.49 
(1H, m, CH2CHOH), 3.53 (2H, s, ArCH2N), 4.47 – 4.62 (1H, m, CH2CHOH), 7.40 (1H, d, 
J = 8.5 Hz, H-5”), 7.47 – 7.56 (2H, m, H-3 and H-5’), 7.62 (1H, s, H-5), 7.78 (1H, dd, 
J = 8.4, 8.4 Hz, H-4’), 8.10 (1H, dd, J = 8.5, 2.5 Hz, H-4”), 8.79 (1H, d, J = 2.5 Hz, H-2”), 
10.22 (1H, s, CONHAr), 12.76 (1H, s, NH-pyrrole); 
13
C NMR (126 MHz, DMSO-d6) 
δ 34.4 (CH2CHOH), 51.0 (NCH2CH2), 63.3 (ArCH2N), 66.1 (CH2CHOH), 111.3 (C-3), 
119.3 (d, J = 18.1 Hz, C-1’), 122.5 (C-5”), 124.7 (C-2 or C-4), 126.9 (d, J = 3.7 Hz, C-5’), 
127.6 (C-4”), 128.4 (C-2 or C-4), 129.0 (d, J = 22.8 Hz, C-3’), 129.2 (d, J = 5.5 Hz, C-6’), 
130.1 (C-5), 131.8 (C-4’), 133.9 (C-6”), 140.6 (C-2”), 153.6 (C-6”), 153.8 (d, 
J = 248.7 Hz, C-2’), 158.5 (CONHAr), 182.6 (ArCO); 19F NMR (471 MHz, DMSO-d6) 
δ -116.6 (ArF); LRMS (ES+) m/z 491.3 [M(35Cl35Cl)+H]+, 493.3 [M(35Cl37Cl)+H]+; 
HRMS (NSI) calcd for C23H22Cl2FN4O3 [M(
35
Cl
35
Cl)+H]
+
 491.1048, found 491.1038. 
 
457 
4-((5-Nitropyridin-2-yl)methyl)morpholine, (537) 
 
To 5-nitropicolinaldehyde (473) (300 mg, 1.97 mmol) in 2,2,2-trifluoroethanol (10 mL) 
was added morpholine (173 µL, 172 mg, 1.97 mmol). The resulting solution was stirred at 
38 °C for 1 h. Once cooled at 0 °C, sodium borohydride was carefully added. The resulting 
mixture was allowed to warm to RT and then stirred for 30 min. Upon completion, the 
solvent was removed in vacuo. The crude residue was dissolved in EtOAc (30 mL), 
neutralised by washing with saturated aq. NH4Cl (20 mL), washed with water and brine 
(20 mL, respectively), dried over MgSO4 and concentrated in vacuo. The crude product 
was purified by column chromatography (silica gel, petrol:EtOAc, 1:0  1:1) to yield the 
title compound as a pale yellow solid (301 mg, 68%); Rf = 0.22 (petrol:EtOAc, 1:1); 
m.p. 73.5-75.5 °C; λmax (EtOH)/nm 249.8, 274.0; IR (neat) νmax/cm
-1
 3043, 2980, 2862, 
2851, 2810, 1598, 1577, 1516, 1355, 1342, 1333; 
1
H NMR (500 MHz, DMSO-d6) 
δ 2.40 - 2.47 (4H, m, NCH2 morpholine), 3.60 (4H, t, J = 4.7 Hz, OCH2 morpholine), 3.74 (2H, s, 
ArCH2N), 7.76 (1H, d, J = 8.6 Hz, H-3), 8.57 (1H, dd, J = 8.6, 2.7 Hz, H-4), 9.29 (1H, d, 
J = 2.7 Hz, H-6); 
13
C NMR (126 MHz, DMSO-d6) δ 53.2 (NCH2 morpholine), 63.4 (ArCH2N), 
66.2 (OCH2 morpholine), 123.1 (C-3), 131.9 (C-4), 143.2 (C-5), 144.1 (C-6), 165.1 (C-2); 
LRMS (ES
+
) m/z 224.3 [M+H]
+
; HRMS (NSI) calcd for C10H14N3O3 [M+H]
+
 224.1030, 
found 224.1025. 
 
N,N-Dimethyl-1-(5-nitropyridin-2-yl)methanamine, (538) 
 
To 5-nitropicolinaldehyde (473) (200 mg, 1.31 mmol) in 1,2-dichloroethane (4 mL) was 
added dimethylamine (2.0 M solution in THF, 723 μL, 1.46 mmol). The resulting solution 
was stirred at RT for 5 min before sodium triacetoxyborohydride (418 mg, 1.97 mmol) was 
added in several portions. The resulting reaction mixture was stirred at RT for 16 h. Upon 
completion, the reaction was diluted with DCM (10 mL), quenched by addition of 
saturated aq. NaHCO3 (10 mL) and stirred for 1 h. The layers were separated and the 
aqueous phase extracted with DCM (3 × 20 mL). The combined organic extracts were 
washed with water and brine (40 mL, respectively), dried over MgSO4 and concentrated in 
vacuo. The crude yellow oil was purified by column chromatography (amine silica gel, 
petrol:EtOAc, 1:0  9:1) to yield the title compound as a yellow liquid (150 mg, 63%); 
Rf = 0.30 (amine silica, petrol:EtOAc, 9:1); λmax (EtOH)/nm 248.0, 277.0; IR (neat) 
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νmax/cm
-1
 3054, 3027, 2972, 2944, 2859, 2821, 2775, 1639, 1597, 1576, 1519, 1469, 1345; 
1
H NMR (500 MHz, DMSO-d6) δ 2.22 (6H, s, CH2N(CH3)2), 3.66 (2H, s, ArCH2N), 7.72 
(1H, d, J = 8.6 Hz, H-3), 8.57 (1H, dd, J = 8.6, 2.7 Hz, H-4), 9.28 (1H, d, J = 2.7 Hz, H-6); 
13
C NMR (126 MHz, DMSO-d6) δ 45.2 (CH2N(CH3)2), 64.5 (ArCH2N), 123.0 (C-3), 131.9 
(C-4), 143.1 (C-5), 144.0 (C-6), 165.9 (C-2); LRMS (ES
+
) m/z 182.2 [M+H]
+
; HRMS 
(NSI) calcd for C8H12N3O2 [M+H]
+
 182.0924, found 182.0922. 
 
5-Nitro-2-(piperidin-1-ylmethyl)pyridine, (539) 
 
To 5-nitropicolinaldehyde (473) (300 mg, 1.97 mmol) in 1,2-dichloroethane (6 mL) was 
added piperidine (214 μL, 185 mg, 2.17 mmol). The resulting solution was stirred at RT 
for 5 min before sodium triacetoxyborohydride (627 mg, 2.96 mmol) was added 
portionwise. The resulting reaction mixture was stirred at RT for 16 h. Upon completion, 
the reaction was diluted with DCM (10 mL), quenched by addition of saturated aq. 
NaHCO3 (10 mL) and stirred for 1 h. The layers were separated and the aqueous phase 
extracted with DCM (3 × 20 mL). The combined organic extracts were washed with water 
and brine (40 mL, respectively), dried over MgSO4 and concentrated in vacuo. The crude 
yellow oil was purified by column chromatography (amine silica gel, petrol:EtOAc, 
1:0  95:5) to yield the title compound as a yellow solid (258 mg, 59%); Rf = 0.28 (amine 
silica, petrol:EtOAc, 95:5); m.p. 50.0-52.0 °C; λmax (EtOH)/nm 250.6, 274.4; IR (neat) 
νmax/cm
-1
 2930, 2848, 2791, 2751, 1596, 1576, 1515, 1465, 1352, 1338; 
1
H NMR 
(500 MHz, DMSO-d6) δ 1.39 - 1.43 (2H, m, H-4’), 1.51 – 1.55 (4H, m, H-3’, 5’), 
2.33 - 2.44 (4H, m, H-2’, 6’), 3.69 (2H, brs, ArCH2N), 7.73 (1H, d, J = 8.6 Hz, H-3), 8.56 
(1H, dd, J = 8.6, 2.7 Hz, H-4), 9.28 (1H, d, J = 2.7 Hz, H-6); 
13
C NMR (126 MHz, 
DMSO-d6) δ 23.7 (C-4’), 25.6 (C-3’, 5’), 54.1 (C-2’, 6’), 64.0 (ArCH2N), 122.8 (C-3), 
131.8 (C-4), 143.1 (C-5), 144.0 (C-6), 166.0 (C-2); LRMS (ES
+
) m/z 222.2 [M+H]
+
; 
HRMS (NSI) calcd for C11H16N3O2 [M+H]
+
 222.1237, found 222.1235. 
 
2-Methoxy-N-methyl-N-((5-nitropyridin-2-yl)methyl)ethanamine, (540) 
 
To 5-nitropicolinaldehyde (473) (300 mg, 1.97 mmol) in 1,2-dichloroethane (6 mL) was 
added (2-methoxyethyl)methylamine (236 μL, 193 mg, 2.17 mmol). The resulting solution 
was stirred at RT for 5 min before sodium triacetoxyborohydride (627 mg, 2.96 mmol) was 
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added portionwise. The resulting reaction mixture was stirred at RT for 16 h. Upon 
completion, the reaction was diluted with DCM (10 mL), quenched by addition of 
saturated aq. NaHCO3 (10 mL) and stirred for 1 h. The layers were separated and the 
aqueous phase extracted with DCM (3 × 20 mL). The combined organic extracts were 
washed with water and brine (40 mL, respectively), dried over MgSO4 and concentrated in 
vacuo. The crude yellow oil was purified by column chromatography (amine silica gel, 
petrol:EtOAc, 1:0  9:1) to yield the title compound as a yellow liquid (308 mg, 69%); 
Rf = 0.29 (amine silica, petrol:EtOAc, 9:1); λmax (EtOH)/nm 249.0, 277.2; IR (neat) 
νmax/cm
-1
 3071, 2930, 2816, 1638, 1596, 1576, 1520, 1449, 1345; 
1
H NMR (500 MHz, 
DMSO-d6) δ 2.24 (3H, s, NCH3), 2.61 (2H, t, J = 5.8 Hz, NCH2CH2OMe), 3.23 (3H, s, 
CH2OCH3), 3.47 (2H, t, J = 5.8 Hz, NCH2CH2OMe), 3.79 (2H, s, ArCH2N), 7.75 (1H, d, 
J = 8.6 Hz, H-3), 8.57 (1H, dd, J = 8.6, 2.7 Hz, H-4), 9.28 (1H, d, J = 2.7 Hz, H-6); 
13
C NMR (126 MHz, DMSO-d6) δ 42.7 (NCH3), 56.2 (NCH2CH2OMe), 58.0 (CH2OCH3), 
63.0 (ArCH2N), 70.2 (NCH2CH2OMe), 122.9 (C-3), 131.8 (C-4), 143.1 (C-5), 143.9 (C-6), 
166.5 (C-2); LRMS (ES
+
) m/z 226.2 [M+H]
+
; HRMS (NSI) calcd for C10H16N3O3 [M+H]
+
 
226.1186, found 226.1187. 
 
2-Methoxy-N-(2-methoxyethyl)-N-((5-nitropyridin-2-yl)methyl)ethanamine, (541) 
 
To 5-nitropicolinaldehyde (473) (300 mg, 1.97 mmol) in 1,2-dichloroethane (6 mL) was 
added bis(2-methoxyethyl) amine (320 μL, 289 mg, 2.17 mmol). The resulting solution 
was stirred at RT for 5 min before sodium triacetoxyborohydride (627 mg, 2.96 mmol) was 
added in several portions. The resulting reaction mixture was stirred at RT for 16 h. Upon 
completion, the reaction was diluted with DCM (10 mL), quenched by addition of 
saturated aq. NaHCO3 (10 mL) and stirred for 1 h. The layers were separated and the 
aqueous phase extracted with DCM (3 × 20 mL). The combined organic extracts were 
washed with water and brine (40 mL, respectively), dried over MgSO4 and concentrated in 
vacuo. The crude yellow oil was purified by column chromatography (amine silica gel, 
petrol:EtOAc, 1:0  9:1) to yield the title compound as a yellow liquid (419 mg, 79%); 
Rf = 0.36 (amine silica, petrol:EtOAc, 9:1); λmax (EtOH)/nm 294.6; IR (neat) νmax/cm
-1
 
2979, 2925, 2875, 2817, 1595, 1577, 1519, 1457, 1345; 
1
H NMR (500 MHz, DMSO-d6) 
δ 2.72 (4H, t, J = 5.8 Hz, N(CH2CH2OMe)2), 3.19 (6H, s, N(CH2CH2OCH3)2), 3.41 (4H, t, 
J = 5.8 Hz, N(CH2CH2OMe)2), 3.94 (2H, s, ArCH2N), 7.81 (1H, d, J = 8.7 Hz, H-3), 8.57 
(1H, dd, J = 8.7, 2.6 Hz, H-4), 9.27 (1H, d, J = 2.6 Hz, H-6); 
13
C NMR (126 MHz, 
460 
DMSO-d6) δ 53.8 (N(CH2CH2OMe)2), 58.0 (N(CH2CH2OCH3)2), 60.5 (ArCH2N), 70.6 
(N(CH2CH2OMe)2), 122.7 (C-3), 131.7 (C-4), 143.0 (C-5), 143.9 (C-6), 167.6 (C-2); 
LRMS (ES
+
) m/z 270.5 [M+H]
+
; HRMS (NSI) calcd for C12H20N3O4 [M+H]
+
 238.1186, 
found 238.1187. 
 
1-((5-Nitropyridin-2-yl)methyl)piperidin-4-ol, (542) 
 
To 5-nitropicolinaldehyde (473) (300 mg, 1.97 mmol) in 1,2-dichloroethane (6 mL) was 
added 4-hydroxypiperidine (219 mg, 2.17 mmol). The resulting solution was stirred at RT 
for 5 min before sodium triacetoxyborohydride (627 mg, 2.96 mmol) was added 
portionwise. The resulting reaction mixture was stirred at RT for 16 h. Upon completion, 
the reaction was diluted with DCM (10 mL), quenched by addition of saturated aq. 
NaHCO3 (10 mL) and stirred for 1 h. The layers were separated and the aqueous phase 
extracted with DCM (3 × 20 mL). The combined organic extracts were washed with water 
and brine (40 mL, respectively), dried over MgSO4 and concentrated in vacuo. The crude 
yellow oil was purified by column chromatography (amine silica gel, petrol:EtOAc, 1:0  
3:7) to yield the title compound as a yellow solid (351 mg, 75%); Rf = 0.34 (amine silica, 
petrol:EtOAc, 7:3); m.p. 92.5-94.5 °C; λmax (EtOH)/nm 250.8, 274.6; IR (neat) νmax/cm
-1
 
3242, 3042, 2954, 2921, 2852, 1595, 1572, 1515, 1466, 1352, 1320; 
1
H NMR (500 MHz, 
DMSO-d6) δ 1.37 – 1.48 (2H, m, H-3’, 5’axial), 1.72 (2H, dddd, J = 12.3, 4.9, 2.6 and 2.6 
Hz, H-3’, 5’equ), 2.15 (2H, ddd, J = 12.3, 10.5 and 2.6 Hz, H-2’, 6’axial), 2.69 (2H, ddd, J = 
10.5, 4.3 and 4.3 Hz, H-2’, 6’equ), 3.47 (1H, ddd, J = 8.6, 4.3 and 4.2 Hz, H-4’), 3.70 (2H, 
s, ArCH2N), 4.57 (1H, d, J = 4.2 Hz, CHOH), 7.73 (1H, d, J = 8.6 Hz, H-3), 8.56 (1H, dd, 
J = 8.6, 2.7 Hz, H-4), 9.27 (1H, d, J = 2.7 Hz, H-6); 
13
C NMR (126 MHz, DMSO-d6) 
δ 34.4 (C-3’, 5’), 51.1 (C-2’, 6’), 63.2 (ArCH2N), 65.9 (C-4’), 122.8 (C-3), 131.9 (C-4), 
143.1 (C-5), 144.0 (C-6), 166.0 (C-2); LRMS (ES
+
) m/z 238.2 [M+H]
+
; HRMS (NSI) calcd 
for C11H16N3O3 [M+H]
+
 238.1186, found 238.1187. 
 
6-(Morpholinomethyl)pyridin-3-amine, (543) 
 
Compound 543 was synthesised according to general procedure D’, using the following 
reagents: 4-((5-nitropyridin-2-yl)methyl)morpholine (537) (300 mg, 1.34 mmol), THF 
(13.4 mL) and methanol (13.4 mL). The crude off-white solid (234 mg, 90%) was used in 
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the next step without further purification; Rf = 0.20 (amine silica, DCM:MeOH, 98:2); 
m.p. 86.5-88.5 °C; λmax (EtOH)/nm 246.4, 305.0; IR (neat) νmax/cm
-1
 3411, 3316, 3175, 
2959, 2918, 2878, 2857, 2806, 2761, 1646, 1599, 1568, 1495; 
1
H NMR (500 MHz, 
DMSO-d6) δ 2.30 – 2.37 (4H, m, NCH2 morpholine), 3.37 (2H, s, ArCH2N), 3.51 – 3.58 (4H, 
m, OCH2 morpholine), 5.16 (2H, brs, ArNH2), 6.88 (1H, dd, J = 8.3, 2.8 Hz, H-4), 7.03 (1H, d, 
J = 8.3 Hz, H-3), 7.84 (1H, d, J = 2.8 Hz, H-6); 
13
C NMR (126 MHz, DMSO-d6) δ 53.2 
(NCH2 morpholine), 63.8 (ArCH2N), 66.2 (OCH2 morpholine), 120.4 (C-4), 123.1 (C-3), 135.2 
(C-6), 143.4 (C-2 or C-5), 144.6 (C-2 or C-5); LRMS (ES
+
) m/z 194.2 [M+H]
+
; HRMS 
(NSI) calcd for C10H16N3O [M+H]
+
 194.1288, found 194.1284. 
 
6-((Dimethylamino)methyl)pyridin-3-amine, (544) 
 
Compound 544 was synthesised according to general procedure D’, using the following 
reagents: N,N-dimethyl-1-(5-nitropyridin-2-yl)methanamine (538) (200 mg, 1.10 mmol), 
THF (11 mL) and methanol (11 mL). The crude yellow oil (155 mg, 93%) was used in the 
next step without further purification; Rf = 0.24 (amine silica, EtOAc, 100%); 
λmax (EtOH)/nm 247.2, 306.2; IR (neat) νmax/cm
-1
 3321, 3190, 2972, 2939, 2858, 2817, 
2773, 1630, 1597, 1572, 1491, 1454; 
1
H NMR (500 MHz, DMSO-d6) δ 2.11 (6H, s, 
CH2N(CH3)2), 3.30 (2H, s, ArCH2N), 5.15 (2H, brs, ArNH2), 6.88 (1H, dd, J = 8.3, 2.7 Hz, 
H-4), 7.01 (1H, d, J = 8.3 Hz, H-5), 7.82 (1H, d, J = 2.7 Hz, H-2); 
13
C NMR (126 MHz, 
DMSO-d6) δ 45.0 (CH2N(CH3)2), 64.7 (ArCH2N), 120.5 (C-4), 122.9 (C-5), 135.0 (C-2), 
143.3 (C-3 or C-6), 145.7 (C-3 or C-6); LRMS (ES
+
) m/z 152.2 [M+H]
+
; HRMS (NSI) 
calcd for C8H14N3 [M+H]
+
 152.1179, found 152.1182. 
 
6-(Piperidin-1-ylmethyl)pyridin-3-amine, (545) 
 
Compound 545 was synthesised according to general procedure D’, using the following 
reagents: 5-nitro-2-(piperidin-1-ylmethyl)pyridine (539) (230 mg, 1.04 mmol), THF 
(10.4 mL) and methanol (10.4 mL). The yellow oil (190 mg, 95%) was used in the next 
step without further purification; Rf = 0.33 (amine silica, EtOAc, 100%); λmax (EtOH)/nm 
247.2, 305.8; IR (neat) νmax/cm
-1
 3317, 3190, 2927, 2852, 2787, 2750, 1626, 1591, 1571, 
1490; 
1
H NMR (500 MHz, DMSO-d6) δ 1.31 – 1.41 (2H, m, H-4’), 1.41 – 1.50 (4H, m, 
H-3’, 5’), 2.29 (4H, brs, H-2’, 6’), 3.33 (2H, s, ArCH2N), 5.13 (2H, brs, ArNH2), 6.88 (1H, 
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dd, J = 8.3, 2.7 Hz, H-4), 7.01 (1H, d, J = 8.3 Hz, H-5), 7.83 (1H, d, J = 2.7 Hz, H-2); 
13
C NMR (126 MHz, DMSO-d6) δ 24.0 (C-4’), 25.6 (C-3’, 5’), 53.9 (C-2’, 6’), 64.2 
(ArCH2N), 120.4 (C-4), 122.8 (C-5), 135.1 (C-2), 143.2 (C-3 or C-6), 145.5 (C-3 or C-6); 
LRMS (ES
+
) m/z 192.3 [M+H]
+
; HRMS (NSI) calcd for C11H18N3 [M+H]
+
 192.1495, 
found 192.1493. 
 
6-(((2-Methoxyethyl)(methyl)amino)methyl)pyridin-3-amine, (546) 
 
Compound 546 was synthesised according to general procedure D’, using the following 
reagents: 2-methoxy-N-methyl-N-((5-nitropyridin-2-yl)methyl)ethanamine (540) (280 mg, 
1.24 mmol), THF (12.4 mL) and methanol (12.4 mL). The crude orange oil (231 mg, 95%) 
was used in the next step without further purification; Rf = 0.42 (amine silica, EtOAc, 
100%); λmax (EtOH)/nm 246.6, 306.0; IR (neat) νmax/cm
-1
 3328, 3200, 2930, 2876, 2838, 
2810, 1629, 1596, 1572, 1491; 
1
H NMR (500 MHz, DMSO-d6) δ 2.18 (3H, s, NCH3), 2.55 
(2H, t, J = 5.9 Hz, NCH2CH2OMe), 3.22 (3H, s, CH2OCH3), 3.43 (2H, t, J = 5.9 Hz, 
NCH2CH2OMe), 3.48 (2H, s, ArCH2N), 5.19 (2H, brs, ArNH2), 6.89 (1H, dd, J = 8.3, 
2.7 Hz, H-4), 7.04 (1H, d, J = 8.3 Hz, H-5), 7.84 (1H, d, J = 2.7 Hz, H-2); 
13
C NMR 
(126 MHz, DMSO-d6) δ 42.2 (NCH3), 55.6 (NCH2CH2OMe), 57.9 (CH2OCH3), 62.7 
(ArCH2N), 70.0 (NCH2CH2OMe), 120.4 (C-4), 123.2 (C-5), 135.1 (C-2), 143.5 (C-3 or 
C-6), 144.9 (C-3 or C-6); LRMS (ES
+
) m/z 196.3 [M+H]
+
; HRMS (NSI) calcd for 
C10H18N3O [M+H]
+
 196.1444, found 196.1444. 
 
6-((bis(2-Methoxyethyl)amino)methyl)pyridin-3-amine, (547) 
 
Compound 547 was synthesised according to general procedure D’, using the following 
reagents: 2-methoxy-N-(2-methoxyethyl)-N-((5-nitropyridin-2-yl)methyl)ethanamine (547) 
(390 mg, 1.45 mmol), THF (14.5 mL) and methanol (14.5 mL). The yellow oil (330 mg, 
95%) was used in the next step without further purification; Rf = 0.30 (amine silica, 
petrol:EtOAc, 3:7); λmax (EtOH)/nm 245.0, 305.0; IR (neat) νmax/cm
-1
 3339, 3205, 2978, 
2924, 2876, 2816, 1630, 1597, 1572, 1491; 
1
H NMR (500 MHz, DMSO-d6) δ 2.61 (4H, t, 
J = 6.2 Hz, N(CH2CH2OMe)2), 3.19 (6H, s, N(CH2CH2OCH3)2), 3.36 (4H, t, J = 6.2 Hz, 
N(CH2CH2OMe)2), 3.55 (2H, brs, ArCH2N), 5.13 (2H, brs, ArNH2), 6.89 (1H, dd, J = 8.3, 
2.7 Hz, H-4), 7.05 (1H, d, J = 8.3 Hz, H-5), 7.82 (1H, d, J = 2.7 Hz, H-2); 
13
C NMR 
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(126 MHz, DMSO-d6) δ 53.2 (N(CH2CH2OMe)2), 58.0 (N(CH2CH2OCH3)2), 60.1 
(ArCH2N), 70.6 (N(CH2CH2OMe)2), 120.5 (C-4), 122.9 (C-5), 135.0 (C-2), 143.2 (C-3 or 
C-6), 146.3 (C-3 or C-6); LRMS (ES
+
) m/z 240.3 [M+H]
+
; HRMS (NSI) calcd for 
C12H22N3O2 [M+H]
+
 240.1707, found 240.1706. 
 
1-((5-Aminopyridin-2-yl)methyl)piperidin-4-ol, (548) 
 
Compound 548 was synthesised according to general procedure D’, using the following 
reagents: 1-((5-nitropyridin-2-yl)methyl)piperidin-4-ol (542) (340 mg, 1.43 mmol), THF 
(14.3 mL) and methanol (14.3 mL). The white solid (285 mg, 96%) was used in the next 
step without further purification; Rf = 0.28 (amine silica, EtOAc, 100%); m.p. 
206.5-208.5 °C; λmax (EtOH)/nm 246.2, 304.4; IR (neat) νmax/cm
-1
 3383, 3312, 3192, 3101, 
2951, 2937, 2884, 2827, 1637, 1597, 1573, 1500; 
1
H NMR (500 MHz, DMSO-d6) 
δ 1.29 - 1.40 (2H, m, H-3’, 5’), 1.62 – 1.72 (2H, m, H-3’, 5’), 1.99 (2H, t, J = 10.1 Hz, 
H-2’, 6’), 2.57 – 2.70 (2H, m, H-2’, 6’), 3.34 (2H, s, ArCH2N), 3.42 (1H, brs, H-4’), 4.53 
(1H, s, CHOH), 5.14 (2H, brs, ArNH2), 6.88 (1H, dd, J = 8.3, 2.7 Hz, H-4), 7.01 (1H, d, 
J = 8.3 Hz, H-3), 7.82 (1H, d, J = 2.7 Hz, H-6); 
13
C NMR (126 MHz, DMSO-d6) δ 34.5 
(C-3’, 5’), 51.0 (C-2’, 6’), 63.5 (ArCH2N), 66.5 (C-4’), 120.5 (C-4), 122.9 (C-3), 135.1 
(C-6), 143.3 (C-2 or C-5), 145.6 (C-2 or C-5); LRMS (ES
+
) m/z 208.3 [M+H]
+
; 
HRMS (NSI) calcd for C11H18N3O [M+H]
+
 208.1444, found 208.1444. 
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